*********** PTASSAMj00 ******** FILEIN user.vek ../../CSA/PIK_SPRITE/ ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 1 3 # 1 A 49 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 86 HIS A 41 HIS^? 12.51 O2 EDO A 103 A 250 ALA A 22 ALA~? 8.81 C2 EDO A 103 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 2 3 # 2 A 49 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 86 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 250 ALA A 72 ALA~? 7.55 O2 EDO A 103 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -25.31 -91.48 -27.77 -25.23 -92.69 -26.88 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 3 3 # 3 A 49 ASP B 27 ASP~? 12.32 O1 CIT B 103 A 86 HIS B 41 HIS^? 11.37 O1 CIT B 103 A 250 ALA B 22 ALA~? 8.36 O1 CIT B 103 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -8.49 -83.66 -0.03 -7.52 -84.08 -1.05 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 4 3 # 4 A 49 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 86 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 250 ALA B 72 ALA~? 6.61 O5 CIT B 103 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -3.15 -72.37 -7.72 -2.41 -71.95 -8.98 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 5 3 # 5 A 49 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 86 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 250 ALA C 72 ALA~? 6.17 O6 CIT C 104 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -48.37 -76.06 -28.58 -48.03 -76.66 -27.22 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 6 3 # 6 A 49 ASP D 27 ASP~? 12.70 O1 CIT D 103 A 86 HIS D 41 HIS^? 12.20 O1 CIT D 103 A 250 ALA D 22 ALA~? 7.88 O1 CIT D 103 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -51.90 -57.58 -1.45 -50.39 -57.48 -1.80 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 7 3 # 7 A 49 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 86 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 250 ALA D 72 ALA~? 6.22 O5 CIT D 103 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -49.69 -46.08 -9.74 -48.67 -45.48 -10.72 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 8 3 # 8 A 49 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 86 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 250 ALA A 30 ALA~? 11.67 O2 EDO A 103 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -27.26 -79.69 -27.43 -26.16 -78.86 -26.86 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 9 3 # 9 A 49 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 86 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 250 ALA E 22 ALA~? 8.49 O1 CIT E 104 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 10 3 # 10 A 49 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 86 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 250 ALA E 72 ALA~? 6.00 O6 CIT E 104 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -43.51 -80.10 -45.58 -44.16 -79.64 -46.88 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 11 3 # 11 A 49 ASP F 27 ASP~? 14.00 O1 CIT F 104 A 86 HIS F 41 HIS^? 12.43 O1 CIT F 104 A 250 ALA F 22 ALA~? 7.57 O1 CIT F 104 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -24.19 -81.70 -72.40 -24.12 -80.23 -71.87 ULMN 3 2wwt_o00 INTRACELLULAR SUBTILISIN PROTEASE user 12 3 # 12 A 49 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 86 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 250 ALA F 72 ALA~? 6.22 O6 CIT F 104 coo 18.89 -28.09 25.11 19.05 -26.61 23.60 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 21.50 -24.76 21.11 19.82 -23.58 21.50 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 16.40 -19.57 19.82 17.00 -20.87 19.22 -13.05 -80.52 -63.67 -12.49 -79.66 -62.58 2wwt_o00 source 2WWT INTRACELLULAR SUBTILISIN PROTEASE : 12 hits 2wwt_o00 naa= 3 ULMN 4 1am5_c05 PEPSIN user 1 4 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 75 TYR A 54 TYR.? 12.54 C1 EDO A 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -7.18 8.92 145.10 -8.77 8.81 143.59 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -12.30 10.35 145.24 -10.75 8.55 145.88 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo -13.30 2.78 144.49 -12.77 1.96 147.02 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo -8.20 12.64 138.30 -8.86 10.97 139.38 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 1am5_c05 source 1am5 PEPSIN : 1 hits 1am5_c05 naa= 4 ULMN 4 1apt_c06 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 1 4 # 1 E 33 ASP A 46 ASP.? 9.57 O6 CIT B 103 E 36 SER A 51 SER.? 9.93 O6 CIT B 103 E 75 TYR A 54 TYR.? 12.54 C1 EDO A 103 E 213 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 26.30 12.96 16.78 25.46 12.99 18.72 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 28.33 15.15 21.27 28.70 13.12 19.97 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 26.74 7.85 22.76 28.93 8.53 21.17 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 20.15 16.04 19.79 21.65 14.49 19.86 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 4 1apt_c06 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 2 4 # 2 E 33 ASP B 46 ASP.? 11.17 O1 EDO A 103 E 36 SER B 51 SER.? 11.29 O1 EDO A 103 E 75 TYR B 54 TYR.? 11.82 O7 CIT B 103 E 213 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 26.30 12.96 16.78 25.46 12.99 18.72 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 28.33 15.15 21.27 28.70 13.12 19.97 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 26.74 7.85 22.76 28.93 8.53 21.17 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 20.15 16.04 19.79 21.65 14.49 19.86 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 4 1apt_c06 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 3 4 # 3 E 33 ASP C 46 ASP.? 10.22 O6 CIT D 103 E 36 SER C 51 SER.? 10.55 O6 CIT D 103 E 75 TYR C 54 TYR.? 11.88 O3 CIT C 104 E 213 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 26.30 12.96 16.78 25.46 12.99 18.72 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 28.33 15.15 21.27 28.70 13.12 19.97 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 26.74 7.85 22.76 28.93 8.53 21.17 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 20.15 16.04 19.79 21.65 14.49 19.86 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 4 1apt_c06 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 4 4 # 4 E 33 ASP D 46 ASP.? 10.10 O7 CIT C 104 E 36 SER D 51 SER.? 10.41 O7 CIT C 104 E 75 TYR D 54 TYR.? 11.66 C4 CIT D 103 E 213 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 26.30 12.96 16.78 25.46 12.99 18.72 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 28.33 15.15 21.27 28.70 13.12 19.97 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 26.74 7.85 22.76 28.93 8.53 21.17 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 20.15 16.04 19.79 21.65 14.49 19.86 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 4 1apt_c06 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 5 4 # 5 E 33 ASP E 46 ASP.? 9.98 C4 CIT F 104 E 36 SER E 51 SER.? 10.11 C4 CIT F 104 E 75 TYR E 54 TYR.? 6.56 O1 EDO F 103 E 213 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 26.30 12.96 16.78 25.46 12.99 18.72 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 28.33 15.15 21.27 28.70 13.12 19.97 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 26.74 7.85 22.76 28.93 8.53 21.17 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 20.15 16.04 19.79 21.65 14.49 19.86 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 4 1apt_c06 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 6 4 # 6 E 33 ASP F 46 ASP.? 6.64 O2 EDO F 103 E 36 SER F 51 SER.? -5.94 O2 EDO F 103s E 75 TYR F 54 TYR.? 5.10 C2 EDO F 103 E 213 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 26.30 12.96 16.78 25.46 12.99 18.72 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 28.33 15.15 21.27 28.70 13.12 19.97 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 26.74 7.85 22.76 28.93 8.53 21.17 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 20.15 16.04 19.79 21.65 14.49 19.86 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 1apt_c06 source 1apt ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET (LYSTA IS : 6 hits 1apt_c06 naa= 4 ULMN 4 1b8f_c00 HISTIDINE AMMONIA-LYASE user 1 4 # 1 A 142 ALA A 15 ALA~? 15.06 C1 EDO A 103 A 144 GLY A 14 GLY~? 18.08 C2 EDO E 103 A 280 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 414 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 8.90 -17.98 11.65 7.53 -18.34 11.16 -7.92 -83.12 -38.44 -6.92 -83.81 -37.59 coo 11.65 -18.01 12.88 11.72 -18.24 12.53 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 coo -3.84 22.59 11.63 -6.55 23.25 11.72 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 7.29 -23.46 8.78 9.26 -22.73 8.47 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 1b8f_c00 source 1b8f HISTIDINE AMMONIA-LYASE : 1 hits 1b8f_c00 naa= 4 ULMN 4 1bbs_c08 RENIN user 1 4 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 75 TYR A 54 TYR.? 12.54 C1 EDO A 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 61.19 45.85 78.73 62.86 45.48 77.48 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 66.00 46.17 80.29 64.31 47.92 79.91 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 65.68 50.76 74.77 64.63 51.40 77.28 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 63.61 40.10 74.06 64.05 42.07 74.70 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 1bbs_c08 source 1bbs RENIN : 1 hits 1bbs_c08 naa= 4 ULMN 4 1bbs_c09 RENIN user 1 4 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 75 TYR A 54 TYR.? 12.54 C1 EDO A 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 61.19 45.85 78.73 62.86 45.48 77.48 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 66.00 46.17 80.29 64.31 47.92 79.91 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 65.68 50.76 74.77 64.63 51.40 77.28 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 63.61 40.10 74.06 64.05 42.07 74.70 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 1bbs_c09 source 1bbs RENIN : 1 hits 1bbs_c09 naa= 4 ULMN 4 1bvz_c06 ALPHA-AMYLASE II user 1 4 # 1 A 244 HIS A 41 HIS^? 12.51 O2 EDO A 103 A 325 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 354 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 421 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 38.32 48.73 66.97 37.08 50.15 66.21 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 31.05 49.37 64.51 31.97 51.11 63.85 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 29.07 50.42 58.36 29.02 52.18 59.49 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 30.82 59.76 58.47 31.12 59.02 60.40 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 1bvz_c06 source 1bvz ALPHA-AMYLASE II : 1 hits 1bvz_c06 naa= 4 ULMN 4 1bvz_c07 ALPHA-AMYLASE II user 1 4 # 1 B 244 HIS A 41 HIS^? 12.51 O2 EDO A 103 B 325 ASP A 27 ASP~? 13.11 O2 EDO A 103 B 354 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 421 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 18.86 7.90 56.29 20.11 7.10 54.89 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 25.90 8.19 53.87 25.36 6.97 52.29 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 27.87 10.66 47.95 27.82 8.60 48.27 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 26.02 1.87 43.38 25.90 1.97 45.49 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 1bvz_c07 source 1bvz ALPHA-AMYLASE II : 1 hits 1bvz_c07 naa= 4 ULMN 4 1c17_c11 ATP SYNTHASE SUBUNIT C user 1 4 # 1 A 61 ASP C 69 ASP~? 11.49 O6 CIT C 104 M 206 SER E 87 SER~? 10.44 O7 CIT E 104 M 210 ARG E 18 ARG~? 11.85 O4 CIT C 104 M 214 ASN C 90 ASN~? 14.00 O3 CIT C 104 coo 2.15 -17.14 -6.89 2.91 -15.59 -8.10 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -2.55 -23.32 19.81 -3.48 -21.59 18.38 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 coo 1.98 -17.11 17.69 1.79 -15.15 15.33 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo 8.13 -16.73 20.92 6.75 -15.93 19.51 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 1c17_c11 source 1c17 ATP SYNTHASE SUBUNIT C : 1 hits 1c17_c11 naa= 4 ULMN 4 1d8c_c00 MALATE SYNTHASE G user 1 4 # 1 A 270 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 272 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 338 ARG E 18 ARG~? 11.85 O4 CIT C 104 A 631 ASP A 27 ASP~? 13.11 O2 EDO A 103 coo 15.32 0.58 -16.16 13.76 -0.65 -16.82 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 11.90 -5.17 -18.46 9.90 -4.77 -17.84 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 11.94 -3.39 -13.78 10.23 -1.14 -15.20 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo 8.71 2.50 -20.96 7.71 1.86 -19.18 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 1d8c_c00 source 1d8c MALATE SYNTHASE G : 1 hits 1d8c_c00 naa= 4 ULMN 4 1ddj_c02 PLASMINOGEN user 1 4 # 1 C 603 HIS A 41 HIS^? 12.51 O2 EDO A 103 C 646 ASP A 27 ASP~? 13.11 O2 EDO A 103 C 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 C 741 ALA A 22 ALA~? 8.81 C2 EDO A 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 16.06 55.72 54.73 15.97 56.49 56.70 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 9.38 49.29 65.28 9.01 50.03 65.31 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 coo 13.55 54.01 62.74 13.86 55.50 62.79 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 ULMN 4 1ddj_c02 PLASMINOGEN user 2 4 # 2 C 603 HIS D 41 HIS^? 12.20 O1 CIT D 103 C 646 ASP D 27 ASP~? 12.70 O1 CIT D 103 C 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 C 741 ALA D 22 ALA~? 7.88 O1 CIT D 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 16.06 55.72 54.73 15.97 56.49 56.70 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 9.38 49.29 65.28 9.01 50.03 65.31 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 coo 13.55 54.01 62.74 13.86 55.50 62.79 -51.90 -57.58 -1.45 -50.39 -57.48 -1.80 ULMN 4 1ddj_c02 PLASMINOGEN user 3 4 # 3 C 603 HIS F 41 HIS^? 12.43 O1 CIT F 104 C 646 ASP F 27 ASP~? 14.00 O1 CIT F 104 C 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s C 741 ALA F 22 ALA~? 7.57 O1 CIT F 104 coo 15.33 59.81 59.60 13.98 60.99 60.69 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 16.06 55.72 54.73 15.97 56.49 56.70 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 9.38 49.29 65.28 9.01 50.03 65.31 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 coo 13.55 54.01 62.74 13.86 55.50 62.79 -24.19 -81.70 -72.40 -24.12 -80.23 -71.87 1ddj_c02 source 1ddj PLASMINOGEN : 3 hits 1ddj_c02 naa= 4 ULMN 4 1ddj_c03 PLASMINOGEN user 1 4 # 1 D 603 HIS A 41 HIS^? 12.51 O2 EDO A 103 D 646 ASP A 27 ASP~? 13.11 O2 EDO A 103 D 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 D 741 ALA A 22 ALA~? 8.81 C2 EDO A 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 coo -29.58 40.72 40.37 -30.29 39.69 41.25 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 ULMN 4 1ddj_c03 PLASMINOGEN user 2 4 # 2 D 603 HIS B 41 HIS^? 11.37 O1 CIT B 103 D 646 ASP B 27 ASP~? 12.32 O1 CIT B 103 D 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 D 741 ALA B 22 ALA~? 8.36 O1 CIT B 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 coo -29.58 40.72 40.37 -30.29 39.69 41.25 -8.49 -83.66 -0.03 -7.52 -84.08 -1.05 ULMN 4 1ddj_c03 PLASMINOGEN user 3 4 # 3 D 603 HIS C 41 HIS^? 12.16 O1 CIT C 104 D 646 ASP C 27 ASP~? 13.15 O1 CIT C 104 D 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s D 741 ALA C 22 ALA~? 8.59 C2 CIT C 104 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 coo -29.58 40.72 40.37 -30.29 39.69 41.25 -44.35 -64.88 -36.60 -43.33 -65.13 -35.53 ULMN 4 1ddj_c03 PLASMINOGEN user 4 4 # 4 D 603 HIS D 41 HIS^? 12.20 O1 CIT D 103 D 646 ASP D 27 ASP~? 12.70 O1 CIT D 103 D 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 D 741 ALA D 22 ALA~? 7.88 O1 CIT D 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 coo -29.58 40.72 40.37 -30.29 39.69 41.25 -51.90 -57.58 -1.45 -50.39 -57.48 -1.80 ULMN 4 1ddj_c03 PLASMINOGEN user 5 4 # 5 D 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s D 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 D 739 GLY E 81 GLY~? -3.27 O5 CIT E 104s D 741 ALA E 22 ALA~? 8.49 O1 CIT E 104 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 coo -29.58 40.72 40.37 -30.29 39.69 41.25 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 ULMN 4 1ddj_c03 PLASMINOGEN user 6 4 # 6 D 603 HIS F 41 HIS^? 12.43 O1 CIT F 104 D 646 ASP F 27 ASP~? 14.00 O1 CIT F 104 D 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s D 741 ALA F 22 ALA~? 7.57 O1 CIT F 104 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 coo -29.58 40.72 40.37 -30.29 39.69 41.25 -24.19 -81.70 -72.40 -24.12 -80.23 -71.87 1ddj_c03 source 1ddj PLASMINOGEN : 6 hits 1ddj_c03 naa= 4 ULMN 4 1djo_c00 GLUTAMINASE-ASPARAGINASE user 1 4 # 1 A1020 THR A 61 THR^? 12.85 O2 EDO A 103 A1034 TYR A 3 TYR.? 14.44 O2 EDO A 103 A1100 THR A 37 THR^? 15.29 O2 EDO A 103 B3294 GLU B 38 GLU^? 16.05 O1 CIT B 103 coo 40.94 131.25 89.60 39.24 130.12 90.27 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 35.38 132.08 89.27 36.78 129.74 88.76 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 43.56 124.16 89.51 42.17 124.73 91.05 -27.88 -79.13 -19.84 -28.01 -79.96 -17.89 coo 33.89 125.64 85.55 35.54 126.95 85.33 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 ULMN 4 1djo_c00 GLUTAMINASE-ASPARAGINASE user 2 4 # 2 A1020 THR A 61 THR^? 12.85 O2 EDO A 103 A1034 TYR A 3 TYR.? 14.44 O2 EDO A 103 A1100 THR A 63 THR.? 16.99 O2 EDO A 103 B3294 GLU A 101 GLU^? 18.10 O2 EDO A 103 coo 40.94 131.25 89.60 39.24 130.12 90.27 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 35.38 132.08 89.27 36.78 129.74 88.76 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 43.56 124.16 89.51 42.17 124.73 91.05 -29.11 -84.83 -15.99 -31.15 -84.10 -15.93 coo 33.89 125.64 85.55 35.54 126.95 85.33 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 ULMN 4 1djo_c00 GLUTAMINASE-ASPARAGINASE user 3 4 # 3 A1020 THR B 61 THR^? 13.51 O2 CIT B 103 A1034 TYR B 3 TYR.? 14.53 O2 CIT B 103 A1100 THR B 37 THR^? 15.70 O1 CIT B 103 B3294 GLU A 38 GLU^? 15.90 O2 EDO A 103 coo 40.94 131.25 89.60 39.24 130.12 90.27 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 35.38 132.08 89.27 36.78 129.74 88.76 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 43.56 124.16 89.51 42.17 124.73 91.05 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 coo 33.89 125.64 85.55 35.54 126.95 85.33 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 ULMN 4 1djo_c00 GLUTAMINASE-ASPARAGINASE user 4 4 # 4 A1020 THR B 61 THR^? 13.51 O2 CIT B 103 A1034 TYR B 3 TYR.? 14.53 O2 CIT B 103 A1100 THR B 63 THR.? 17.42 O2 CIT B 103 B3294 GLU B 101 GLU^? 17.79 O2 CIT B 103 coo 40.94 131.25 89.60 39.24 130.12 90.27 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 35.38 132.08 89.27 36.78 129.74 88.76 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 43.56 124.16 89.51 42.17 124.73 91.05 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 coo 33.89 125.64 85.55 35.54 126.95 85.33 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 ULMN 4 1djo_c00 GLUTAMINASE-ASPARAGINASE user 5 4 # 5 A1020 THR C 61 THR^? 13.10 O1 CIT C 104 A1034 TYR C 3 TYR.? 14.43 O1 CIT C 104 A1100 THR C 63 THR.? 16.93 O1 CIT C 104 B3294 GLU C 101 GLU^? 17.42 O2 CIT C 104 coo 40.94 131.25 89.60 39.24 130.12 90.27 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo 35.38 132.08 89.27 36.78 129.74 88.76 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 coo 43.56 124.16 89.51 42.17 124.73 91.05 -59.58 -71.81 -21.66 -61.47 -72.44 -22.48 coo 33.89 125.64 85.55 35.54 126.95 85.33 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 ULMN 4 1djo_c00 GLUTAMINASE-ASPARAGINASE user 6 4 # 6 A1020 THR D 61 THR^? 13.17 O2 CIT D 103 A1034 TYR D 3 TYR.? 14.21 O2 CIT D 103 A1100 THR D 63 THR.? 16.75 O2 CIT D 103 B3294 GLU D 101 GLU^? 17.58 O6 CIT D 103 coo 40.94 131.25 89.60 39.24 130.12 90.27 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo 35.38 132.08 89.27 36.78 129.74 88.76 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 43.56 124.16 89.51 42.17 124.73 91.05 -57.12 -48.47 -21.28 -59.10 -47.58 -21.26 coo 33.89 125.64 85.55 35.54 126.95 85.33 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 ULMN 4 1djo_c00 GLUTAMINASE-ASPARAGINASE user 7 4 # 7 A1020 THR E 61 THR^? 11.76 O1 EDO E 103 A1034 TYR E 3 TYR.? 13.85 O2 EDO E 103 A1100 THR E 63 THR.? 15.89 O2 CIT E 104 B3294 GLU E 101 GLU^? 17.69 O2 CIT E 104 coo 40.94 131.25 89.60 39.24 130.12 90.27 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo 35.38 132.08 89.27 36.78 129.74 88.76 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 43.56 124.16 89.51 42.17 124.73 91.05 -39.67 -90.87 -53.60 -40.19 -92.33 -52.07 coo 33.89 125.64 85.55 35.54 126.95 85.33 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 1djo_c00 source 1djo GLUTAMINASE-ASPARAGINASE : 7 hits 1djo_c00 naa= 4 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 1 4 # 1 A1294 GLU A 38 GLU^? 15.90 O2 EDO A 103 B3020 THR B 61 THR^? 13.51 O2 CIT B 103 B3034 TYR B 3 TYR.? 14.53 O2 CIT B 103 B3100 THR B 37 THR^? 15.70 O1 CIT B 103 coo 42.18 93.40 84.96 40.44 92.19 85.03 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 35.69 87.89 89.88 37.41 89.09 90.33 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 40.98 87.08 88.86 39.63 89.46 88.41 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 33.09 94.86 90.18 34.63 94.22 91.55 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 2 4 # 2 A1294 GLU A 101 GLU^? 18.10 O2 EDO A 103 B3020 THR A 61 THR^? 12.85 O2 EDO A 103 B3034 TYR A 3 TYR.? 14.44 O2 EDO A 103 B3100 THR A 63 THR.? 16.99 O2 EDO A 103 coo 42.18 93.40 84.96 40.44 92.19 85.03 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 35.69 87.89 89.88 37.41 89.09 90.33 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 40.98 87.08 88.86 39.63 89.46 88.41 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 33.09 94.86 90.18 34.63 94.22 91.55 -29.11 -84.83 -15.99 -31.15 -84.10 -15.93 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 3 4 # 3 A1294 GLU B 38 GLU^? 16.05 O1 CIT B 103 B3020 THR A 61 THR^? 12.85 O2 EDO A 103 B3034 TYR A 3 TYR.? 14.44 O2 EDO A 103 B3100 THR A 37 THR^? 15.29 O2 EDO A 103 coo 42.18 93.40 84.96 40.44 92.19 85.03 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 35.69 87.89 89.88 37.41 89.09 90.33 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 40.98 87.08 88.86 39.63 89.46 88.41 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 33.09 94.86 90.18 34.63 94.22 91.55 -27.88 -79.13 -19.84 -28.01 -79.96 -17.89 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 4 4 # 4 A1294 GLU B 101 GLU^? 17.79 O2 CIT B 103 B3020 THR B 61 THR^? 13.51 O2 CIT B 103 B3034 TYR B 3 TYR.? 14.53 O2 CIT B 103 B3100 THR B 63 THR.? 17.42 O2 CIT B 103 coo 42.18 93.40 84.96 40.44 92.19 85.03 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 35.69 87.89 89.88 37.41 89.09 90.33 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 40.98 87.08 88.86 39.63 89.46 88.41 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 33.09 94.86 90.18 34.63 94.22 91.55 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 5 4 # 5 A1294 GLU C 38 GLU^? 15.02 O1 CIT C 104 B3020 THR D 61 THR^? 13.17 O2 CIT D 103 B3034 TYR D 3 TYR.? 14.21 O2 CIT D 103 B3100 THR D 37 THR^? 15.68 O2 CIT D 103 coo 42.18 93.40 84.96 40.44 92.19 85.03 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 35.69 87.89 89.88 37.41 89.09 90.33 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo 40.98 87.08 88.86 39.63 89.46 88.41 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 33.09 94.86 90.18 34.63 94.22 91.55 -60.31 -53.03 -17.12 -60.51 -52.85 -19.30 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 6 4 # 6 A1294 GLU C 101 GLU^? 17.42 O2 CIT C 104 B3020 THR C 61 THR^? 13.10 O1 CIT C 104 B3034 TYR C 3 TYR.? 14.43 O1 CIT C 104 B3100 THR C 63 THR.? 16.93 O1 CIT C 104 coo 42.18 93.40 84.96 40.44 92.19 85.03 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 35.69 87.89 89.88 37.41 89.09 90.33 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo 40.98 87.08 88.86 39.63 89.46 88.41 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 coo 33.09 94.86 90.18 34.63 94.22 91.55 -59.58 -71.81 -21.66 -61.47 -72.44 -22.48 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 7 4 # 7 A1294 GLU D 38 GLU^? 15.43 O2 CIT D 103 B3020 THR C 61 THR^? 13.10 O1 CIT C 104 B3034 TYR C 3 TYR.? 14.43 O1 CIT C 104 B3100 THR C 37 THR^? 15.86 O1 CIT C 104 coo 42.18 93.40 84.96 40.44 92.19 85.03 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 35.69 87.89 89.88 37.41 89.09 90.33 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo 40.98 87.08 88.86 39.63 89.46 88.41 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 coo 33.09 94.86 90.18 34.63 94.22 91.55 -59.71 -66.76 -26.49 -61.02 -66.76 -24.80 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 8 4 # 8 A1294 GLU D 101 GLU^? 17.58 O6 CIT D 103 B3020 THR D 61 THR^? 13.17 O2 CIT D 103 B3034 TYR D 3 TYR.? 14.21 O2 CIT D 103 B3100 THR D 63 THR.? 16.75 O2 CIT D 103 coo 42.18 93.40 84.96 40.44 92.19 85.03 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 35.69 87.89 89.88 37.41 89.09 90.33 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo 40.98 87.08 88.86 39.63 89.46 88.41 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 33.09 94.86 90.18 34.63 94.22 91.55 -57.12 -48.47 -21.28 -59.10 -47.58 -21.26 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 9 4 # 9 A1294 GLU E 38 GLU^? 8.47 O1 EDO E 103 B3020 THR F 61 THR^? 11.09 O2 EDO E 103 B3034 TYR F 3 TYR.? 7.56 O2 EDO E 103 B3100 THR F 37 THR^? 14.28 O2 EDO E 103 coo 42.18 93.40 84.96 40.44 92.19 85.03 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 35.69 87.89 89.88 37.41 89.09 90.33 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo 40.98 87.08 88.86 39.63 89.46 88.41 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 coo 33.09 94.86 90.18 34.63 94.22 91.55 -20.68 -92.02 -57.87 -20.13 -91.87 -55.81 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 10 4 # 10 A1294 GLU E 101 GLU^? 17.69 O2 CIT E 104 B3020 THR E 61 THR^? 11.76 O1 EDO E 103 B3034 TYR E 3 TYR.? 13.85 O2 EDO E 103 B3100 THR E 63 THR.? 15.89 O2 CIT E 104 coo 42.18 93.40 84.96 40.44 92.19 85.03 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 35.69 87.89 89.88 37.41 89.09 90.33 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo 40.98 87.08 88.86 39.63 89.46 88.41 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 33.09 94.86 90.18 34.63 94.22 91.55 -39.67 -90.87 -53.60 -40.19 -92.33 -52.07 ULMN 4 1djo_c01 GLUTAMINASE-ASPARAGINASE user 11 4 # 11 A1294 GLU F 101 GLU^? 10.35 O2 EDO E 103 B3020 THR F 61 THR^? 11.09 O2 EDO E 103 B3034 TYR F 3 TYR.? 7.56 O2 EDO E 103 B3100 THR F 63 THR.? 14.48 O2 EDO E 103 coo 42.18 93.40 84.96 40.44 92.19 85.03 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 35.69 87.89 89.88 37.41 89.09 90.33 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo 40.98 87.08 88.86 39.63 89.46 88.41 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 coo 33.09 94.86 90.18 34.63 94.22 91.55 -16.31 -89.00 -52.99 -15.86 -90.98 -53.79 1djo_c01 source 1djo GLUTAMINASE-ASPARAGINASE : 11 hits 1djo_c01 naa= 4 ULMN 4 1dl2_c00 CLASS I ALPHA-1,2-MANNOSIDASE user 1 4 # 1 A 132 GLU A 38 GLU^? 15.90 O2 EDO A 103 A 136 ARG A 40 ARG^? 16.77 O2 EDO A 103 A 275 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 435 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo -6.23 53.40 -2.33 -7.38 55.09 -1.77 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo -4.99 57.22 1.82 -7.93 56.43 2.21 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -12.63 61.87 -10.13 -11.95 60.35 -8.79 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo -13.69 65.25 -3.58 -13.46 63.85 -2.01 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 1dl2_c00 source 1dl2 CLASS I ALPHA-1,2-MANNOSIDASE : 1 hits 1dl2_c00 naa= 4 ULMN 4 1dub_c00 2-ENOYL-COA HYDRATASE user 1 4 # 1 A 98 ALA A 30 ALA~? 11.67 O2 EDO A 103 A 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 A 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 58.27 102.60 178.19 59.43 101.66 178.07 -27.26 -79.69 -27.43 -26.16 -78.86 -26.86 coo 59.27 103.88 173.55 59.11 104.69 173.45 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 61.78 103.61 169.93 62.63 102.26 171.29 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 65.46 104.88 175.81 64.47 105.72 174.12 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 1dub_c00 source 1dub 2-ENOYL-COA HYDRATASE : 1 hits 1dub_c00 naa= 4 ULMN 4 1dub_c01 2-ENOYL-COA HYDRATASE user 1 4 # 1 B 98 ALA A 30 ALA~? 11.67 O2 EDO A 103 B 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 B 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 93.67 115.22 150.99 93.63 113.90 150.22 -27.26 -79.69 -27.43 -26.16 -78.86 -26.86 coo 88.87 114.43 152.30 88.45 115.15 152.32 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 85.20 111.99 152.05 86.60 110.89 150.91 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 88.14 113.46 145.73 86.79 113.92 147.30 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 1dub_c01 source 1dub 2-ENOYL-COA HYDRATASE : 1 hits 1dub_c01 naa= 4 ULMN 4 1dub_c02 2-ENOYL-COA HYDRATASE user 1 4 # 1 C 98 ALA A 30 ALA~? 11.67 O2 EDO A 103 C 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 C 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 C 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 53.00 102.79 132.36 53.08 101.42 133.06 -27.26 -79.69 -27.43 -26.16 -78.86 -26.86 coo 56.28 104.55 135.84 56.09 105.34 136.05 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 58.46 103.90 139.48 57.57 102.00 139.16 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 51.71 102.03 140.09 53.02 103.62 140.54 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 1dub_c02 source 1dub 2-ENOYL-COA HYDRATASE : 1 hits 1dub_c02 naa= 4 ULMN 4 1dub_c03 2-ENOYL-COA HYDRATASE user 1 4 # 1 D 98 ALA A 30 ALA~? 11.67 O2 EDO A 103 D 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 D 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 D 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 88.91 81.99 128.63 88.96 83.34 129.32 -27.26 -79.69 -27.43 -26.16 -78.86 -26.86 coo 86.19 80.64 132.77 86.38 79.85 132.93 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 84.75 81.24 136.88 85.62 83.14 136.43 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 91.47 83.05 136.24 90.35 81.38 136.84 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 1dub_c03 source 1dub 2-ENOYL-COA HYDRATASE : 1 hits 1dub_c03 naa= 4 ULMN 4 1dub_c04 2-ENOYL-COA HYDRATASE user 1 4 # 1 E 98 ALA A 30 ALA~? 11.67 O2 EDO A 103 E 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 E 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 E 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 91.93 82.37 174.92 90.77 83.36 175.00 -27.26 -79.69 -27.43 -26.16 -78.86 -26.86 coo 90.07 81.07 170.50 90.23 80.26 170.38 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 87.05 81.30 167.53 86.38 82.74 168.94 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 84.40 80.02 173.80 85.08 79.06 172.03 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 1dub_c04 source 1dub 2-ENOYL-COA HYDRATASE : 1 hits 1dub_c04 naa= 4 ULMN 4 1dub_c05 2-ENOYL-COA HYDRATASE user 1 4 # 1 F 98 ALA A 30 ALA~? 11.67 O2 EDO A 103 F 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 F 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 F 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 52.21 69.79 154.56 52.11 71.07 153.72 -27.26 -79.69 -27.43 -26.16 -78.86 -26.86 coo 57.12 70.68 155.10 57.52 69.95 155.02 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 60.62 73.13 154.21 59.05 74.26 153.35 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 56.75 71.71 148.46 58.44 71.01 149.54 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 1dub_c05 source 1dub 2-ENOYL-COA HYDRATASE : 1 hits 1dub_c05 naa= 4 ULMN 4 1eag_c05 PEPTIDE INHIBITOR user 1 4 # 1 A 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 35 SER A 51 SER.? 9.93 O6 CIT B 103 A 84 TYR A 54 TYR.? 12.54 C1 EDO A 103 A 218 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 47.22 22.34 8.57 45.16 22.02 9.13 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 43.58 20.85 5.15 44.62 23.01 5.76 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 40.49 26.39 8.83 42.48 26.82 6.92 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 44.05 16.99 12.67 44.05 18.89 11.74 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 4 1eag_c05 PEPTIDE INHIBITOR user 2 4 # 2 A 32 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 35 SER B 51 SER.? 11.29 O1 EDO A 103 A 84 TYR B 54 TYR.? 11.82 O7 CIT B 103 A 218 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 47.22 22.34 8.57 45.16 22.02 9.13 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 43.58 20.85 5.15 44.62 23.01 5.76 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 40.49 26.39 8.83 42.48 26.82 6.92 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 44.05 16.99 12.67 44.05 18.89 11.74 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 4 1eag_c05 PEPTIDE INHIBITOR user 3 4 # 3 A 32 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 35 SER C 51 SER.? 10.55 O6 CIT D 103 A 84 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 218 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 47.22 22.34 8.57 45.16 22.02 9.13 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 43.58 20.85 5.15 44.62 23.01 5.76 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 40.49 26.39 8.83 42.48 26.82 6.92 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 44.05 16.99 12.67 44.05 18.89 11.74 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 4 1eag_c05 PEPTIDE INHIBITOR user 4 4 # 4 A 32 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 35 SER D 51 SER.? 10.41 O7 CIT C 104 A 84 TYR D 54 TYR.? 11.66 C4 CIT D 103 A 218 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 47.22 22.34 8.57 45.16 22.02 9.13 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 43.58 20.85 5.15 44.62 23.01 5.76 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 40.49 26.39 8.83 42.48 26.82 6.92 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 44.05 16.99 12.67 44.05 18.89 11.74 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 4 1eag_c05 PEPTIDE INHIBITOR user 5 4 # 5 A 32 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 35 SER E 51 SER.? 10.11 C4 CIT F 104 A 84 TYR E 54 TYR.? 6.56 O1 EDO F 103 A 218 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 47.22 22.34 8.57 45.16 22.02 9.13 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 43.58 20.85 5.15 44.62 23.01 5.76 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 40.49 26.39 8.83 42.48 26.82 6.92 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 44.05 16.99 12.67 44.05 18.89 11.74 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 4 1eag_c05 PEPTIDE INHIBITOR user 6 4 # 6 A 32 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 35 SER F 51 SER.? -5.94 O2 EDO F 103s A 84 TYR F 54 TYR.? 5.10 C2 EDO F 103 A 218 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 47.22 22.34 8.57 45.16 22.02 9.13 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 43.58 20.85 5.15 44.62 23.01 5.76 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 40.49 26.39 8.83 42.48 26.82 6.92 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 44.05 16.99 12.67 44.05 18.89 11.74 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 1eag_c05 source 1eag PEPTIDE INHIBITOR : 6 hits 1eag_c05 naa= 4 ULMN 4 1fr2_c01 COLICIN E9 user 1 4 # 1 B 5 ARG F 79 ARG~? 14.02 O1 CIT F 104 B 100 GLU F 32 GLU~? 16.06 O1 CIT F 104 B 102 HIS F 74 HIS~? 11.52 O1 CIT F 104 B 103 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 7.07 18.80 36.78 9.58 17.30 35.86 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 coo 8.48 7.22 38.94 10.30 7.64 39.97 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 12.42 9.76 31.50 14.31 10.36 30.81 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 9.40 15.10 30.15 7.50 15.55 30.93 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 1fr2_c01 source 1fr2 COLICIN E9 : 1 hits 1fr2_c01 naa= 4 ULMN 4 1hpl_c00 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 1 4 # 1 A 77 PHE A 62 PHE^? 8.30 O2 EDO A 103 A 153 LEU A 59 LEU^? 10.77 O2 EDO A 103 A 176 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 263 HIS A 4 HIS.? -4.40 O2 EDO A 103s coo 49.46 51.93 11.85 50.12 53.23 14.23 -25.47 -86.10 -20.36 -24.36 -86.13 -22.89 coo 48.47 51.01 3.83 49.10 52.90 2.99 -17.38 -80.52 -20.70 -17.58 -81.04 -18.55 coo 40.04 48.33 9.02 39.08 50.19 9.48 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 43.45 51.20 11.32 44.32 50.94 9.50 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 ULMN 4 1hpl_c00 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 2 4 # 2 A 77 PHE B 62 PHE^? 8.69 O2 CIT B 103 A 153 LEU B 59 LEU^? 10.90 O2 CIT B 103 A 176 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 263 HIS B 4 HIS.? -4.11 O2 CIT B 103s coo 49.46 51.93 11.85 50.12 53.23 14.23 -10.74 -71.50 -12.21 -9.68 -73.15 -10.21 coo 48.47 51.01 3.83 49.10 52.90 2.99 -14.93 -80.44 -13.27 -15.13 -79.38 -15.15 coo 40.04 48.33 9.02 39.08 50.19 9.48 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 43.45 51.20 11.32 44.32 50.94 9.50 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 ULMN 4 1hpl_c00 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 3 4 # 3 A 77 PHE C 62 PHE^? 8.35 O1 CIT C 104 A 153 LEU C 59 LEU^? 10.89 O1 CIT C 104 A 176 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 263 HIS C 4 HIS.? -4.06 O2 CIT C 104s coo 49.46 51.93 11.85 50.12 53.23 14.23 -54.36 -71.13 -24.12 -52.54 -70.86 -26.21 coo 48.47 51.01 3.83 49.10 52.90 2.99 -50.97 -61.87 -23.60 -52.03 -62.27 -21.69 coo 40.04 48.33 9.02 39.08 50.19 9.48 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 43.45 51.20 11.32 44.32 50.94 9.50 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 ULMN 4 1hpl_c00 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 4 4 # 4 A 77 PHE D 62 PHE^? 8.07 O2 CIT D 103 A 153 LEU D 59 LEU^? 10.68 O2 CIT D 103 A 176 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 263 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 49.46 51.93 11.85 50.12 53.23 14.23 -53.64 -50.09 -16.77 -52.89 -50.72 -14.19 coo 48.47 51.01 3.83 49.10 52.90 2.99 -52.26 -59.76 -16.21 -51.85 -59.33 -18.29 coo 40.04 48.33 9.02 39.08 50.19 9.48 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 43.45 51.20 11.32 44.32 50.94 9.50 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 ULMN 4 1hpl_c00 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 5 4 # 5 A 77 PHE E 62 PHE^? 7.96 O2 CIT E 104 A 153 LEU E 59 LEU^? 9.06 O2 EDO E 103 A 176 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 263 HIS E 4 HIS.? -4.01 O2 CIT E 104s coo 49.46 51.93 11.85 50.12 53.23 14.23 -38.83 -85.80 -50.65 -38.38 -84.14 -48.46 coo 48.47 51.01 3.83 49.10 52.90 2.99 -29.71 -82.47 -50.91 -29.82 -82.98 -52.96 coo 40.04 48.33 9.02 39.08 50.19 9.48 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 43.45 51.20 11.32 44.32 50.94 9.50 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 ULMN 4 1hpl_c00 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 6 4 # 6 A 77 PHE F 58 PHE^? 5.07 O2 CIT F 104 A 153 LEU F 59 LEU^? 10.61 O2 CIT F 104 A 176 ASP F 27 ASP~? 14.00 O1 CIT F 104 A 263 HIS F 41 HIS^? 12.43 O1 CIT F 104 coo 49.46 51.93 11.85 50.12 53.23 14.23 -25.99 -81.08 -63.91 -23.68 -79.69 -64.67 coo 48.47 51.01 3.83 49.10 52.90 2.99 -26.99 -83.61 -58.38 -26.66 -84.07 -56.20 coo 40.04 48.33 9.02 39.08 50.19 9.48 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 43.45 51.20 11.32 44.32 50.94 9.50 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 ULMN 4 1hpl_c00 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 7 4 # 7 A 77 PHE F 62 PHE^? 8.18 O2 CIT F 104 A 153 LEU F 59 LEU^? 10.61 O2 CIT F 104 A 176 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 263 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 49.46 51.93 11.85 50.12 53.23 14.23 -17.45 -85.24 -57.40 -17.81 -84.27 -59.96 coo 48.47 51.01 3.83 49.10 52.90 2.99 -26.99 -83.61 -58.38 -26.66 -84.07 -56.20 coo 40.04 48.33 9.02 39.08 50.19 9.48 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 43.45 51.20 11.32 44.32 50.94 9.50 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 1hpl_c00 source 1hpl LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROL HYDROLAS: 7 hits 1hpl_c00 naa= 4 ULMN 4 1hpl_c01 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 1 4 # 1 B 77 PHE A 62 PHE^? 8.30 O2 EDO A 103 B 153 LEU A 59 LEU^? 10.77 O2 EDO A 103 B 176 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 263 HIS A 4 HIS.? -4.40 O2 EDO A 103s coo 29.53 52.84 46.76 28.82 54.35 44.53 -25.47 -86.10 -20.36 -24.36 -86.13 -22.89 coo 30.35 52.10 54.81 29.94 54.08 55.45 -17.38 -80.52 -20.70 -17.58 -81.04 -18.55 coo 38.97 49.40 49.54 39.78 51.32 48.96 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 35.23 51.95 47.14 34.55 51.97 49.04 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 ULMN 4 1hpl_c01 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 2 4 # 2 B 77 PHE B 62 PHE^? 8.69 O2 CIT B 103 B 153 LEU B 59 LEU^? 10.90 O2 CIT B 103 B 176 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 263 HIS B 4 HIS.? -4.11 O2 CIT B 103s coo 29.53 52.84 46.76 28.82 54.35 44.53 -10.74 -71.50 -12.21 -9.68 -73.15 -10.21 coo 30.35 52.10 54.81 29.94 54.08 55.45 -14.93 -80.44 -13.27 -15.13 -79.38 -15.15 coo 38.97 49.40 49.54 39.78 51.32 48.96 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 35.23 51.95 47.14 34.55 51.97 49.04 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 ULMN 4 1hpl_c01 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 3 4 # 3 B 77 PHE C 62 PHE^? 8.35 O1 CIT C 104 B 153 LEU C 59 LEU^? 10.89 O1 CIT C 104 B 176 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 263 HIS C 4 HIS.? -4.06 O2 CIT C 104s coo 29.53 52.84 46.76 28.82 54.35 44.53 -54.36 -71.13 -24.12 -52.54 -70.86 -26.21 coo 30.35 52.10 54.81 29.94 54.08 55.45 -50.97 -61.87 -23.60 -52.03 -62.27 -21.69 coo 38.97 49.40 49.54 39.78 51.32 48.96 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 35.23 51.95 47.14 34.55 51.97 49.04 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 ULMN 4 1hpl_c01 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 4 4 # 4 B 77 PHE D 62 PHE^? 8.07 O2 CIT D 103 B 153 LEU D 59 LEU^? 10.68 O2 CIT D 103 B 176 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 263 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 29.53 52.84 46.76 28.82 54.35 44.53 -53.64 -50.09 -16.77 -52.89 -50.72 -14.19 coo 30.35 52.10 54.81 29.94 54.08 55.45 -52.26 -59.76 -16.21 -51.85 -59.33 -18.29 coo 38.97 49.40 49.54 39.78 51.32 48.96 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 35.23 51.95 47.14 34.55 51.97 49.04 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 ULMN 4 1hpl_c01 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 5 4 # 5 B 77 PHE E 62 PHE^? 7.96 O2 CIT E 104 B 153 LEU E 59 LEU^? 9.06 O2 EDO E 103 B 176 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 263 HIS E 4 HIS.? -4.01 O2 CIT E 104s coo 29.53 52.84 46.76 28.82 54.35 44.53 -38.83 -85.80 -50.65 -38.38 -84.14 -48.46 coo 30.35 52.10 54.81 29.94 54.08 55.45 -29.71 -82.47 -50.91 -29.82 -82.98 -52.96 coo 38.97 49.40 49.54 39.78 51.32 48.96 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 35.23 51.95 47.14 34.55 51.97 49.04 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 ULMN 4 1hpl_c01 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 6 4 # 6 B 77 PHE F 58 PHE^? 5.07 O2 CIT F 104 B 153 LEU F 59 LEU^? 10.61 O2 CIT F 104 B 176 ASP F 27 ASP~? 14.00 O1 CIT F 104 B 263 HIS F 41 HIS^? 12.43 O1 CIT F 104 coo 29.53 52.84 46.76 28.82 54.35 44.53 -25.99 -81.08 -63.91 -23.68 -79.69 -64.67 coo 30.35 52.10 54.81 29.94 54.08 55.45 -26.99 -83.61 -58.38 -26.66 -84.07 -56.20 coo 38.97 49.40 49.54 39.78 51.32 48.96 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 35.23 51.95 47.14 34.55 51.97 49.04 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 ULMN 4 1hpl_c01 LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROuser 7 4 # 7 B 77 PHE F 62 PHE^? 8.18 O2 CIT F 104 B 153 LEU F 59 LEU^? 10.61 O2 CIT F 104 B 176 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 263 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 29.53 52.84 46.76 28.82 54.35 44.53 -17.45 -85.24 -57.40 -17.81 -84.27 -59.96 coo 30.35 52.10 54.81 29.94 54.08 55.45 -26.99 -83.61 -58.38 -26.66 -84.07 -56.20 coo 38.97 49.40 49.54 39.78 51.32 48.96 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 35.23 51.95 47.14 34.55 51.97 49.04 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 1hpl_c01 source 1hpl LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROL HYDROLAS: 7 hits 1hpl_c01 naa= 4 ULMN 4 1hzd_c00 AU-BINDING PROTEIN-ENOYL-COA HYDRATAuser 1 4 # 1 A 141 ALA B 92 ALA~? 4.16 O3 CIT B 103 A 186 GLY B 94 GLY.? 8.02 O3 CIT B 103 A 189 GLU B 9 GLU.? 11.84 O3 CIT B 103 A 209 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 37.84 0.78 41.05 36.64 1.72 41.12 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 35.09 -2.80 36.98 35.21 -3.54 37.30 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 31.14 -3.99 35.34 30.92 -2.18 36.39 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 29.51 -1.57 42.43 30.35 -3.27 41.49 0.63 -96.18 -5.96 0.64 -98.22 -6.51 1hzd_c00 source 1hzd AU-BINDING PROTEIN-ENOYL-COA HYDRATASE : 1 hits 1hzd_c00 naa= 4 ULMN 4 1hzd_c01 AU-BINDING PROTEIN-ENOYL-COA HYDRATAuser 1 4 # 1 B 141 ALA B 92 ALA~? 4.16 O3 CIT B 103 B 186 GLY B 94 GLY.? 8.02 O3 CIT B 103 B 189 GLU B 9 GLU.? 11.84 O3 CIT B 103 B 209 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo -8.13 -16.22 36.72 -8.40 -15.53 35.38 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo -1.96 -15.64 35.87 -1.68 -16.38 36.08 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 1.43 -14.98 33.07 -0.42 -14.67 32.13 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo -4.08 -18.59 28.97 -2.63 -18.97 30.46 0.63 -96.18 -5.96 0.64 -98.22 -6.51 1hzd_c01 source 1hzd AU-BINDING PROTEIN-ENOYL-COA HYDRATASE : 1 hits 1hzd_c01 naa= 4 ULMN 4 1hzd_c02 AU-BINDING PROTEIN-ENOYL-COA HYDRATAuser 1 4 # 1 C 141 ALA B 92 ALA~? 4.16 O3 CIT B 103 C 186 GLY B 94 GLY.? 8.02 O3 CIT B 103 C 189 GLU B 9 GLU.? 11.84 O3 CIT B 103 C 209 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 24.08 -22.10 -0.34 24.67 -20.69 -0.31 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 21.75 -21.33 5.24 22.01 -22.00 5.60 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 21.57 -18.82 8.95 22.63 -17.75 7.49 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 28.83 -17.90 5.95 27.84 -19.51 6.89 0.63 -96.18 -5.96 0.64 -98.22 -6.51 1hzd_c02 source 1hzd AU-BINDING PROTEIN-ENOYL-COA HYDRATASE : 1 hits 1hzd_c02 naa= 4 ULMN 4 1hzd_c03 AU-BINDING PROTEIN-ENOYL-COA HYDRATAuser 1 4 # 1 D 141 ALA B 92 ALA~? 4.16 O3 CIT B 103 D 186 GLY B 94 GLY.? 8.02 O3 CIT B 103 D 189 GLU B 9 GLU.? 11.84 O3 CIT B 103 D 209 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo -9.83 -0.92 -1.27 -9.83 -1.74 0.02 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo -5.10 2.47 0.73 -5.35 3.21 0.47 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo -2.98 4.12 3.98 -4.11 2.53 4.76 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo -9.98 2.96 6.77 -8.83 4.39 5.71 0.63 -96.18 -5.96 0.64 -98.22 -6.51 1hzd_c03 source 1hzd AU-BINDING PROTEIN-ENOYL-COA HYDRATASE : 1 hits 1hzd_c03 naa= 4 ULMN 4 1hzd_c04 AU-BINDING PROTEIN-ENOYL-COA HYDRATAuser 1 4 # 1 E 141 ALA B 92 ALA~? 4.16 O3 CIT B 103 E 186 GLY B 94 GLY.? 8.02 O3 CIT B 103 E 189 GLU B 9 GLU.? 11.84 O3 CIT B 103 E 209 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 2.89 21.88 40.63 4.19 21.12 40.89 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 2.61 20.08 34.75 2.44 20.78 34.37 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 4.93 18.46 31.25 6.09 18.34 33.00 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 10.22 22.22 35.51 8.60 22.81 34.29 0.63 -96.18 -5.96 0.64 -98.22 -6.51 1hzd_c04 source 1hzd AU-BINDING PROTEIN-ENOYL-COA HYDRATASE : 1 hits 1hzd_c04 naa= 4 ULMN 4 1hzd_c05 AU-BINDING PROTEIN-ENOYL-COA HYDRATAuser 1 4 # 1 F 141 ALA B 92 ALA~? 4.16 O3 CIT B 103 F 186 GLY B 94 GLY.? 8.02 O3 CIT B 103 F 189 GLU B 9 GLU.? 11.84 O3 CIT B 103 F 209 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 35.74 16.95 4.24 35.51 15.47 3.99 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 30.48 17.59 7.15 30.10 18.21 6.83 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 26.45 15.67 7.87 27.70 14.18 7.03 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 28.20 13.18 0.91 27.61 14.93 1.92 0.63 -96.18 -5.96 0.64 -98.22 -6.51 1hzd_c05 source 1hzd AU-BINDING PROTEIN-ENOYL-COA HYDRATASE : 1 hits 1hzd_c05 naa= 4 ULMN 4 1i8t_c02 UDP-GALACTOPYRANOSE MUTASE user 1 4 # 1 A 170 ARG D 53 ARG.? 12.25 O4 CIT D 103 A 278 ARG C 89 ARG.? 16.36 O3 CIT C 104 A 298 GLU C 11 GLU.? 13.80 O2 EDO C 103 A 348 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo -23.99 -12.72 0.77 -26.03 -13.46 2.92 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo -18.98 -3.88 -14.05 -18.01 -5.56 -11.69 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo -18.09 -5.55 -18.88 -17.66 -5.99 -16.85 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo -11.04 -13.38 -5.15 -13.10 -12.92 -5.14 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 1i8t_c02 source 1i8t UDP-GALACTOPYRANOSE MUTASE : 1 hits 1i8t_c02 naa= 4 ULMN 4 1iec_c02 CAPSID PROTEIN P40: ASSEMBLIN PROTEAuser 1 4 # 1 B 363 HIS C 74 HIS~? 12.10 O1 CIT C 104 B 457 ALA C 70 ALA~? 12.51 O1 CIT C 104 B 465 ARG C 79 ARG~? -3.25 O5 CIT E 104s B 466 ARG E 79 ARG~? -3.12 O5 CIT C 104s coo 66.07 12.30 58.15 65.21 10.91 59.48 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 69.52 5.37 56.42 70.10 6.70 55.92 -53.57 -78.01 -28.80 -55.09 -77.85 -28.87 coo 58.20 13.10 62.35 56.97 11.67 59.94 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo 59.04 4.50 63.99 59.56 4.71 60.96 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 ULMN 4 1iec_c02 CAPSID PROTEIN P40: ASSEMBLIN PROTEAuser 2 4 # 2 B 363 HIS E 74 HIS~? 12.16 O1 CIT E 104 B 457 ALA E 70 ALA~? 12.37 O2 CIT E 104 B 465 ARG E 79 ARG~? -3.12 O5 CIT C 104s B 466 ARG C 79 ARG~? -3.25 O5 CIT E 104s coo 66.07 12.30 58.15 65.21 10.91 59.48 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 69.52 5.37 56.42 70.10 6.70 55.92 -45.75 -85.11 -45.81 -45.60 -86.59 -45.87 coo 58.20 13.10 62.35 56.97 11.67 59.94 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo 59.04 4.50 63.99 59.56 4.71 60.96 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 1iec_c02 source 1iec CAPSID PROTEIN P40: ASSEMBLIN PROTEASE : 2 hits 1iec_c02 naa= 4 ULMN 4 1kim_c01 THYMIDINE KINASE user 1 4 # 1 B 59 GLY F 81 GLY~? -3.66 O5 CIT F 104s B 83 GLU F 21 GLU~? 14.58 O1 CIT F 104 B 163 ARG F 18 ARG~? 15.26 O3 CIT F 104 B 222 ARG F 79 ARG~? 14.02 O1 CIT F 104 coo 12.62 99.24 38.96 12.68 98.60 38.52 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 coo 14.40 90.04 44.78 14.76 92.05 44.57 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 17.43 90.38 41.69 17.76 92.72 39.75 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 coo 13.56 96.78 47.94 12.87 95.13 45.44 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 1kim_c01 source 1kim THYMIDINE KINASE : 1 hits 1kim_c01 naa= 4 ULMN 4 1l7d_c01 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 1 4 # 1 B 527 ARG A 45 ARG.? 18.60 O6 CIT B 103 B 532 GLN A 49 GLN.? 13.04 O6 CIT B 103 B 535 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 538 SER A 51 SER.? 9.93 O6 CIT B 103 coo 8.19 9.59 -28.92 8.45 9.38 -31.97 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 coo 0.23 9.51 -23.71 0.03 10.44 -21.81 3.77 -77.85 -19.84 4.25 -77.72 -21.93 coo 1.34 4.82 -26.96 3.28 4.18 -26.41 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 3.49 1.61 -23.72 2.22 3.16 -22.32 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 ULMN 4 1l7d_c01 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 2 4 # 2 B 527 ARG E 45 ARG.? 12.04 O2 EDO E 103 B 532 GLN E 49 GLN.? 12.99 O4 CIT F 104 B 535 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 538 SER E 51 SER.? 10.11 C4 CIT F 104 coo 8.19 9.59 -28.92 8.45 9.38 -31.97 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 coo 0.23 9.51 -23.71 0.03 10.44 -21.81 -14.41 -68.37 -56.14 -13.58 -67.15 -54.61 coo 1.34 4.82 -26.96 3.28 4.18 -26.41 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 3.49 1.61 -23.72 2.22 3.16 -22.32 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 ULMN 4 1l7d_c01 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 3 4 # 3 B 527 ARG F 45 ARG.? 16.99 O2 EDO F 103 B 532 GLN F 49 GLN.? 10.68 O2 EDO F 103 B 535 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 538 SER F 51 SER.? -5.94 O2 EDO F 103s coo 8.19 9.59 -28.92 8.45 9.38 -31.97 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 coo 0.23 9.51 -23.71 0.03 10.44 -21.81 -44.03 -70.98 -57.45 -45.61 -70.07 -58.56 coo 1.34 4.82 -26.96 3.28 4.18 -26.41 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 3.49 1.61 -23.72 2.22 3.16 -22.32 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 1l7d_c01 source 1l7d NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE, SUBU: 3 hits 1l7d_c01 naa= 4 ULMN 4 1l7d_c02 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 1 4 # 1 C 927 ARG A 45 ARG.? 18.60 O6 CIT B 103 C 932 GLN A 49 GLN.? 13.04 O6 CIT B 103 C 935 ASP A 46 ASP.? 9.57 O6 CIT B 103 C 938 SER A 51 SER.? 9.93 O6 CIT B 103 coo 1.74 -6.46 15.39 2.55 -4.22 13.45 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 coo 2.39 -8.41 25.36 1.15 -9.40 26.79 3.77 -77.85 -19.84 4.25 -77.72 -21.93 coo 4.51 -3.25 22.25 3.50 -2.74 20.47 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 0.91 -0.11 23.31 0.17 -1.93 24.76 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 ULMN 4 1l7d_c02 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 2 4 # 2 C 927 ARG B 45 ARG.? 19.51 O2 EDO A 103 C 932 GLN B 49 GLN.? 13.56 O1 EDO A 103 C 935 ASP B 46 ASP.? 11.17 O1 EDO A 103 C 938 SER B 51 SER.? 11.29 O1 EDO A 103 coo 1.74 -6.46 15.39 2.55 -4.22 13.45 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 coo 2.39 -8.41 25.36 1.15 -9.40 26.79 -15.66-100.57 -21.23 -16.63-100.94 -19.40 coo 4.51 -3.25 22.25 3.50 -2.74 20.47 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 0.91 -0.11 23.31 0.17 -1.93 24.76 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 ULMN 4 1l7d_c02 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 3 4 # 3 C 927 ARG C 45 ARG.? 18.33 O6 CIT D 103 C 932 GLN C 49 GLN.? 12.61 O3 CIT D 103 C 935 ASP C 46 ASP.? 10.22 O6 CIT D 103 C 938 SER C 51 SER.? 10.55 O6 CIT D 103 coo 1.74 -6.46 15.39 2.55 -4.22 13.45 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 coo 2.39 -8.41 25.36 1.15 -9.40 26.79 -36.24 -47.79 -16.21 -35.91 -47.13 -18.17 coo 4.51 -3.25 22.25 3.50 -2.74 20.47 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 0.91 -0.11 23.31 0.17 -1.93 24.76 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 ULMN 4 1l7d_c02 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 4 4 # 4 C 927 ARG E 45 ARG.? 12.04 O2 EDO E 103 C 932 GLN E 49 GLN.? 12.99 O4 CIT F 104 C 935 ASP E 46 ASP.? 9.98 C4 CIT F 104 C 938 SER E 51 SER.? 10.11 C4 CIT F 104 coo 1.74 -6.46 15.39 2.55 -4.22 13.45 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 coo 2.39 -8.41 25.36 1.15 -9.40 26.79 -14.41 -68.37 -56.14 -13.58 -67.15 -54.61 coo 4.51 -3.25 22.25 3.50 -2.74 20.47 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 0.91 -0.11 23.31 0.17 -1.93 24.76 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 ULMN 4 1l7d_c02 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 5 4 # 5 C 927 ARG F 45 ARG.? 16.99 O2 EDO F 103 C 932 GLN F 49 GLN.? 10.68 O2 EDO F 103 C 935 ASP F 46 ASP.? 6.64 O2 EDO F 103 C 938 SER F 51 SER.? -5.94 O2 EDO F 103s coo 1.74 -6.46 15.39 2.55 -4.22 13.45 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 coo 2.39 -8.41 25.36 1.15 -9.40 26.79 -44.03 -70.98 -57.45 -45.61 -70.07 -58.56 coo 4.51 -3.25 22.25 3.50 -2.74 20.47 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 0.91 -0.11 23.31 0.17 -1.93 24.76 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 1l7d_c02 source 1l7d NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE, SUBU: 5 hits 1l7d_c02 naa= 4 ULMN 4 1l7d_c03 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 1 4 # 1 D1327 ARG A 45 ARG.? 18.60 O6 CIT B 103 D1332 GLN A 49 GLN.? 13.04 O6 CIT B 103 D1335 ASP A 46 ASP.? 9.57 O6 CIT B 103 D1338 SER A 51 SER.? 9.93 O6 CIT B 103 coo -22.62 30.03 57.43 -19.58 30.46 57.46 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 coo -27.46 22.07 54.10 -27.67 20.09 54.90 3.77 -77.85 -19.84 4.25 -77.72 -21.93 coo -25.80 27.06 50.51 -24.16 28.17 51.26 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -21.87 25.29 48.40 -22.55 24.92 50.69 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 ULMN 4 1l7d_c03 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 2 4 # 2 D1327 ARG C 45 ARG.? 18.33 O6 CIT D 103 D1332 GLN C 49 GLN.? 12.61 O3 CIT D 103 D1335 ASP C 46 ASP.? 10.22 O6 CIT D 103 D1338 SER C 51 SER.? 10.55 O6 CIT D 103 coo -22.62 30.03 57.43 -19.58 30.46 57.46 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 coo -27.46 22.07 54.10 -27.67 20.09 54.90 -36.24 -47.79 -16.21 -35.91 -47.13 -18.17 coo -25.80 27.06 50.51 -24.16 28.17 51.26 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -21.87 25.29 48.40 -22.55 24.92 50.69 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 ULMN 4 1l7d_c03 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 3 4 # 3 D1327 ARG E 45 ARG.? 12.04 O2 EDO E 103 D1332 GLN E 49 GLN.? 12.99 O4 CIT F 104 D1335 ASP E 46 ASP.? 9.98 C4 CIT F 104 D1338 SER E 51 SER.? 10.11 C4 CIT F 104 coo -22.62 30.03 57.43 -19.58 30.46 57.46 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 coo -27.46 22.07 54.10 -27.67 20.09 54.90 -14.41 -68.37 -56.14 -13.58 -67.15 -54.61 coo -25.80 27.06 50.51 -24.16 28.17 51.26 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -21.87 25.29 48.40 -22.55 24.92 50.69 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 ULMN 4 1l7d_c03 NICOTINAMIDE NUCLEOTIDE TRANSHYDROGEuser 4 4 # 4 D1327 ARG F 45 ARG.? 16.99 O2 EDO F 103 D1332 GLN F 49 GLN.? 10.68 O2 EDO F 103 D1335 ASP F 46 ASP.? 6.64 O2 EDO F 103 D1338 SER F 51 SER.? -5.94 O2 EDO F 103s coo -22.62 30.03 57.43 -19.58 30.46 57.46 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 coo -27.46 22.07 54.10 -27.67 20.09 54.90 -44.03 -70.98 -57.45 -45.61 -70.07 -58.56 coo -25.80 27.06 50.51 -24.16 28.17 51.26 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -21.87 25.29 48.40 -22.55 24.92 50.69 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 1l7d_c03 source 1l7d NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE, SUBU: 4 hits 1l7d_c03 naa= 4 ULMN 4 1m53_c02 ISOMALTULOSE SYNTHASE user 1 4 # 1 A 145 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 241 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 295 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 369 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 5.03 36.88 76.44 6.25 36.30 78.05 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 11.74 38.14 80.19 10.63 36.40 80.65 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 16.11 33.72 80.99 14.10 33.54 81.63 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 12.19 31.08 87.29 11.13 32.66 86.38 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 1m53_c02 source 1m53 ISOMALTULOSE SYNTHASE : 1 hits 1m53_c02 naa= 4 ULMN 4 1mpp_c05 PEPSIN (RENIN) (E.C.3.4.23.23) user 1 4 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 75 TYR A 54 TYR.? 12.54 C1 EDO A 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 20.97 14.47 32.28 19.66 15.96 31.62 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 16.04 14.72 33.82 17.27 13.71 31.95 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 15.29 15.16 26.38 15.79 12.61 27.66 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 20.65 22.00 33.80 20.06 20.56 32.39 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 4 1mpp_c05 PEPSIN (RENIN) (E.C.3.4.23.23) user 2 4 # 2 32 ASP C 46 ASP.? 10.22 O6 CIT D 103 35 SER C 51 SER.? 10.55 O6 CIT D 103 75 TYR C 54 TYR.? 11.88 O3 CIT C 104 215 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 20.97 14.47 32.28 19.66 15.96 31.62 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 16.04 14.72 33.82 17.27 13.71 31.95 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 15.29 15.16 26.38 15.79 12.61 27.66 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 20.65 22.00 33.80 20.06 20.56 32.39 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 1mpp_c05 source 1mpp PEPSIN (RENIN) (E.C.3.4.23.23) : 2 hits 1mpp_c05 naa= 4 ULMN 4 1pix_c00 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 1 4 # 1 A 151 VAL C 102 VAL^? 16.13 O2 CIT D 103 A 194 GLY D 42 GLY^? 14.38 C1 CIT D 103 A 417 ILE A 25 ILE~? 7.68 C2 EDO E 103 A 457 ALA E 24 ALA~? 10.19 C1 EDO E 103 coo 60.43 93.31 8.03 62.16 94.30 8.93 -55.86 -67.26 -13.11 -55.18 -65.88 -14.70 coo 59.34 89.99 13.88 59.24 89.18 13.73 -52.42 -66.59 -9.79 -51.76 -66.17 -10.02 coo 39.61 128.90 22.54 40.04 128.24 23.80 -22.24 -81.29 -36.07 -22.27 -82.20 -37.12 coo 43.27 124.32 20.47 43.79 125.29 21.53 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 1pix_c00 source 1pix GLUTACONYL-COA DECARBOXYLASE A SUBUNIT : 1 hits 1pix_c00 naa= 4 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 1 4 # 1 A 457 ALA A 22 ALA~? 8.81 C2 EDO A 103 A 458 ALA A 24 ALA~? 12.06 C2 EDO E 103 B 193 ALA A 80 ALA~? 7.00 C2 EDO A 103 B 194 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 43.27 124.32 20.47 43.79 125.29 21.53 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 coo 39.57 123.53 20.89 38.42 124.25 20.20 -20.53 -76.91 -34.66 -20.26 -76.22 -36.01 coo 47.95 129.15 20.31 47.81 128.95 18.79 -20.19 -86.09 -35.24 -20.75 -85.14 -34.17 coo 50.40 126.23 20.48 50.46 127.00 20.75 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 2 4 # 2 A 457 ALA A 70 ALA~? 12.31 O2 EDO A 103 A 458 ALA A 72 ALA~? 7.55 O2 EDO A 103 B 193 ALA A 67 ALA~? 12.65 O2 EDO A 103 B 194 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo 43.27 124.32 20.47 43.79 125.29 21.53 -30.35 -90.25 -25.71 -31.25 -89.23 -25.08 coo 39.57 123.53 20.89 38.42 124.25 20.20 -25.31 -91.48 -27.77 -25.23 -92.69 -26.88 coo 47.95 129.15 20.31 47.81 128.95 18.79 -29.87 -88.33 -21.07 -29.62 -87.09 -20.21 coo 50.40 126.23 20.48 50.46 127.00 20.75 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 3 4 # 3 A 457 ALA B 22 ALA~? 8.36 O1 CIT B 103 A 458 ALA B 24 ALA~? 13.47 O1 CIT B 103 B 193 ALA B 80 ALA~? 6.55 O1 CIT B 103 B 194 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 43.27 124.32 20.47 43.79 125.29 21.53 -8.49 -83.66 -0.03 -7.52 -84.08 -1.05 coo 39.57 123.53 20.89 38.42 124.25 20.20 -13.42 -82.15 1.65 -13.47 -82.92 2.96 coo 47.95 129.15 20.31 47.81 128.95 18.79 -4.95 -80.68 -0.86 -6.33 -80.07 -1.20 coo 50.40 126.23 20.48 50.46 127.00 20.75 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 4 4 # 4 A 457 ALA B 70 ALA~? 12.64 O1 CIT B 103 A 458 ALA B 72 ALA~? 6.61 O5 CIT B 103 B 193 ALA B 67 ALA~? 13.32 O2 CIT B 103 B 194 GLY B 35 GLY.? 14.63 O1 CIT B 103 coo 43.27 124.32 20.47 43.79 125.29 21.53 -5.62 -67.50 -7.22 -6.87 -66.61 -7.10 coo 39.57 123.53 20.89 38.42 124.25 20.20 -3.15 -72.37 -7.72 -2.41 -71.95 -8.98 coo 47.95 129.15 20.31 47.81 128.95 18.79 -9.08 -66.99 -10.93 -10.52 -67.16 -11.45 coo 50.40 126.23 20.48 50.46 127.00 20.75 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 5 4 # 5 A 457 ALA C 22 ALA~? 8.59 C2 CIT C 104 A 458 ALA C 24 ALA~? 13.64 O1 EDO C 103 B 193 ALA C 80 ALA~? 6.86 O1 CIT C 104 B 194 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 43.27 124.32 20.47 43.79 125.29 21.53 -44.35 -64.88 -36.60 -43.33 -65.13 -35.53 coo 39.57 123.53 20.89 38.42 124.25 20.20 -48.96 -62.61 -38.35 -48.38 -62.01 -39.66 coo 47.95 129.15 20.31 47.81 128.95 18.79 -44.02 -69.49 -35.47 -45.39 -69.01 -34.93 coo 50.40 126.23 20.48 50.46 127.00 20.75 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 6 4 # 6 A 457 ALA C 70 ALA~? 12.51 O1 CIT C 104 A 458 ALA C 72 ALA~? 6.17 O6 CIT C 104 B 193 ALA C 67 ALA~? 13.02 O1 CIT C 104 B 194 GLY C 35 GLY.? 14.42 O1 CIT C 104 coo 43.27 124.32 20.47 43.79 125.29 21.53 -53.57 -78.01 -28.80 -55.09 -77.85 -28.87 coo 39.57 123.53 20.89 38.42 124.25 20.20 -48.37 -76.06 -28.58 -48.03 -76.66 -27.22 coo 47.95 129.15 20.31 47.81 128.95 18.79 -56.44 -75.71 -25.21 -57.34 -74.53 -24.80 coo 50.40 126.23 20.48 50.46 127.00 20.75 -59.78 -72.68 -26.82 -59.58 -72.16 -27.37 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 7 4 # 7 A 457 ALA C 86 ALA~? 9.98 O4 CIT C 104 A 458 ALA E 86 ALA~? 9.46 O2 EDO C 103 B 193 ALA E 15 ALA~? 10.03 O2 EDO C 103 B 194 GLY E 14 GLY~? 13.52 O2 EDO C 103 coo 43.27 124.32 20.47 43.79 125.29 21.53 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 39.57 123.53 20.89 38.42 124.25 20.20 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 47.95 129.15 20.31 47.81 128.95 18.79 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo 50.40 126.23 20.48 50.46 127.00 20.75 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 8 4 # 8 A 457 ALA D 22 ALA~? 7.88 O1 CIT D 103 A 458 ALA D 24 ALA~? 13.47 O1 CIT D 103 B 193 ALA D 80 ALA~? 6.01 O1 CIT D 103 B 194 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 43.27 124.32 20.47 43.79 125.29 21.53 -51.90 -57.58 -1.45 -50.39 -57.48 -1.80 coo 39.57 123.53 20.89 38.42 124.25 20.20 -57.08 -59.15 -2.14 -57.28 -59.76 -0.76 coo 47.95 129.15 20.31 47.81 128.95 18.79 -50.09 -53.10 -1.75 -51.22 -53.48 -2.77 coo 50.40 126.23 20.48 50.46 127.00 20.75 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 9 4 # 9 A 457 ALA D 70 ALA~? 12.47 O2 CIT D 103 A 458 ALA D 72 ALA~? 6.22 O5 CIT D 103 B 193 ALA D 67 ALA~? 12.76 O2 CIT D 103 B 194 GLY D 35 GLY.? 14.30 O2 CIT D 103 coo 43.27 124.32 20.47 43.79 125.29 21.53 -53.82 -43.25 -11.93 -55.23 -43.15 -12.59 coo 39.57 123.53 20.89 38.42 124.25 20.20 -49.69 -46.08 -9.74 -48.67 -45.48 -10.72 coo 47.95 129.15 20.31 47.81 128.95 18.79 -55.09 -45.19 -16.51 -55.94 -46.20 -17.30 coo 50.40 126.23 20.48 50.46 127.00 20.75 -59.28 -47.39 -16.68 -59.38 -47.87 -16.04 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 10 4 # 10 A 457 ALA E 22 ALA~? 8.49 O1 CIT E 104 A 458 ALA E 24 ALA~? 10.19 C1 EDO E 103 B 193 ALA E 80 ALA~? 6.56 O1 CIT E 104 B 194 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 43.27 124.32 20.47 43.79 125.29 21.53 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 coo 39.57 123.53 20.89 38.42 124.25 20.20 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 coo 47.95 129.15 20.31 47.81 128.95 18.79 -37.12 -76.28 -38.33 -36.63 -77.60 -38.82 coo 50.40 126.23 20.48 50.46 127.00 20.75 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 11 4 # 11 A 457 ALA E 70 ALA~? 12.37 O2 CIT E 104 A 458 ALA E 72 ALA~? 6.00 O6 CIT E 104 B 193 ALA E 67 ALA~? 12.61 O2 CIT E 104 B 194 GLY E 35 GLY.? 14.13 O2 CIT E 104 coo 43.27 124.32 20.47 43.79 125.29 21.53 -45.75 -85.11 -45.81 -45.60 -86.59 -45.87 coo 39.57 123.53 20.89 38.42 124.25 20.20 -43.51 -80.10 -45.58 -44.16 -79.64 -46.88 coo 47.95 129.15 20.31 47.81 128.95 18.79 -43.44 -87.76 -49.60 -42.32 -88.68 -50.03 coo 50.40 126.23 20.48 50.46 127.00 20.75 -40.51 -91.26 -48.44 -40.06 -91.01 -47.82 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 12 4 # 12 A 457 ALA E 86 ALA~? 9.46 O2 EDO C 103 A 458 ALA C 86 ALA~? 9.98 O4 CIT C 104 B 193 ALA C 15 ALA~? 8.64 C1 EDO C 103 B 194 GLY C 14 GLY~? 3.87 C1 EDO C 103 coo 43.27 124.32 20.47 43.79 125.29 21.53 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 39.57 123.53 20.89 38.42 124.25 20.20 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 47.95 129.15 20.31 47.81 128.95 18.79 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo 50.40 126.23 20.48 50.46 127.00 20.75 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 13 4 # 13 A 457 ALA F 22 ALA~? 7.57 O1 CIT F 104 A 458 ALA F 24 ALA~? 13.16 O1 CIT F 104 B 193 ALA F 80 ALA~? 5.70 O1 CIT F 104 B 194 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 43.27 124.32 20.47 43.79 125.29 21.53 -24.19 -81.70 -72.40 -24.12 -80.23 -71.87 coo 39.57 123.53 20.89 38.42 124.25 20.20 -25.76 -87.10 -72.06 -26.27 -87.27 -73.51 coo 47.95 129.15 20.31 47.81 128.95 18.79 -19.77 -80.17 -71.91 -20.13 -81.28 -70.95 coo 50.40 126.23 20.48 50.46 127.00 20.75 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 14 4 # 14 A 457 ALA F 70 ALA~? 12.64 O2 CIT F 104 A 458 ALA F 72 ALA~? 6.22 O6 CIT F 104 B 193 ALA F 67 ALA~? 12.75 O2 CIT F 104 B 194 GLY F 35 GLY.? 14.32 O2 CIT F 104 coo 43.27 124.32 20.47 43.79 125.29 21.53 -10.34 -85.12 -62.01 -10.33 -86.57 -61.57 coo 39.57 123.53 20.89 38.42 124.25 20.20 -13.05 -80.52 -63.67 -12.49 -79.66 -62.58 coo 47.95 129.15 20.31 47.81 128.95 18.79 -12.62 -86.76 -57.61 -13.72 -87.50 -56.90 coo 50.40 126.23 20.48 50.46 127.00 20.75 -14.95 -90.79 -57.80 -15.39 -90.89 -58.42 1pix_c02 source 1pix GLUTACONYL-COA DECARBOXYLASE A SUBUNIT : 14 hits 1pix_c02 naa= 4 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 1 4 # 1 A 193 ALA A 67 ALA~? 12.65 O2 EDO A 103 A 194 GLY A 35 GLY.? 14.47 O2 EDO A 103 B 457 ALA A 70 ALA~? 12.31 O2 EDO A 103 B 458 ALA A 72 ALA~? 7.55 O2 EDO A 103 coo 61.89 87.20 13.50 62.59 88.00 12.38 -29.87 -88.33 -21.07 -29.62 -87.09 -20.21 coo 59.34 89.99 13.88 59.24 89.18 13.73 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 coo 65.50 91.13 17.77 64.65 89.88 18.00 -30.35 -90.25 -25.71 -31.25 -89.23 -25.08 coo 68.56 91.15 20.03 69.95 90.68 19.64 -25.31 -91.48 -27.77 -25.23 -92.69 -26.88 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 2 4 # 2 A 193 ALA A 80 ALA~? 7.00 C2 EDO A 103 A 194 GLY A 81 GLY~? 4.93 C2 EDO A 103 B 457 ALA A 22 ALA~? 8.81 C2 EDO A 103 B 458 ALA A 24 ALA~? 12.06 C2 EDO E 103 coo 61.89 87.20 13.50 62.59 88.00 12.38 -20.19 -86.09 -35.24 -20.75 -85.14 -34.17 coo 59.34 89.99 13.88 59.24 89.18 13.73 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 coo 65.50 91.13 17.77 64.65 89.88 18.00 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 coo 68.56 91.15 20.03 69.95 90.68 19.64 -20.53 -76.91 -34.66 -20.26 -76.22 -36.01 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 3 4 # 3 A 193 ALA B 67 ALA~? 13.32 O2 CIT B 103 A 194 GLY B 35 GLY.? 14.63 O1 CIT B 103 B 457 ALA B 70 ALA~? 12.64 O1 CIT B 103 B 458 ALA B 72 ALA~? 6.61 O5 CIT B 103 coo 61.89 87.20 13.50 62.59 88.00 12.38 -9.08 -66.99 -10.93 -10.52 -67.16 -11.45 coo 59.34 89.99 13.88 59.24 89.18 13.73 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 coo 65.50 91.13 17.77 64.65 89.88 18.00 -5.62 -67.50 -7.22 -6.87 -66.61 -7.10 coo 68.56 91.15 20.03 69.95 90.68 19.64 -3.15 -72.37 -7.72 -2.41 -71.95 -8.98 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 4 4 # 4 A 193 ALA C 15 ALA~? 8.64 C1 EDO C 103 A 194 GLY C 14 GLY~? 3.87 C1 EDO C 103 B 457 ALA E 86 ALA~? 9.46 O2 EDO C 103 B 458 ALA C 86 ALA~? 9.98 O4 CIT C 104 coo 61.89 87.20 13.50 62.59 88.00 12.38 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo 59.34 89.99 13.88 59.24 89.18 13.73 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo 65.50 91.13 17.77 64.65 89.88 18.00 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 68.56 91.15 20.03 69.95 90.68 19.64 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 5 4 # 5 A 193 ALA C 67 ALA~? 13.02 O1 CIT C 104 A 194 GLY C 35 GLY.? 14.42 O1 CIT C 104 B 457 ALA C 70 ALA~? 12.51 O1 CIT C 104 B 458 ALA C 72 ALA~? 6.17 O6 CIT C 104 coo 61.89 87.20 13.50 62.59 88.00 12.38 -56.44 -75.71 -25.21 -57.34 -74.53 -24.80 coo 59.34 89.99 13.88 59.24 89.18 13.73 -59.78 -72.68 -26.82 -59.58 -72.16 -27.37 coo 65.50 91.13 17.77 64.65 89.88 18.00 -53.57 -78.01 -28.80 -55.09 -77.85 -28.87 coo 68.56 91.15 20.03 69.95 90.68 19.64 -48.37 -76.06 -28.58 -48.03 -76.66 -27.22 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 6 4 # 6 A 193 ALA D 67 ALA~? 12.76 O2 CIT D 103 A 194 GLY D 35 GLY.? 14.30 O2 CIT D 103 B 457 ALA D 70 ALA~? 12.47 O2 CIT D 103 B 458 ALA D 72 ALA~? 6.22 O5 CIT D 103 coo 61.89 87.20 13.50 62.59 88.00 12.38 -55.09 -45.19 -16.51 -55.94 -46.20 -17.30 coo 59.34 89.99 13.88 59.24 89.18 13.73 -59.28 -47.39 -16.68 -59.38 -47.87 -16.04 coo 65.50 91.13 17.77 64.65 89.88 18.00 -53.82 -43.25 -11.93 -55.23 -43.15 -12.59 coo 68.56 91.15 20.03 69.95 90.68 19.64 -49.69 -46.08 -9.74 -48.67 -45.48 -10.72 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 7 4 # 7 A 193 ALA D 80 ALA~? 6.01 O1 CIT D 103 A 194 GLY D 81 GLY~? 3.79 O7 CIT D 103 B 457 ALA D 22 ALA~? 7.88 O1 CIT D 103 B 458 ALA D 24 ALA~? 13.47 O1 CIT D 103 coo 61.89 87.20 13.50 62.59 88.00 12.38 -50.09 -53.10 -1.75 -51.22 -53.48 -2.77 coo 59.34 89.99 13.88 59.24 89.18 13.73 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 coo 65.50 91.13 17.77 64.65 89.88 18.00 -51.90 -57.58 -1.45 -50.39 -57.48 -1.80 coo 68.56 91.15 20.03 69.95 90.68 19.64 -57.08 -59.15 -2.14 -57.28 -59.76 -0.76 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 8 4 # 8 A 193 ALA E 15 ALA~? 10.03 O2 EDO C 103 A 194 GLY E 14 GLY~? 13.52 O2 EDO C 103 B 457 ALA C 86 ALA~? 9.98 O4 CIT C 104 B 458 ALA E 86 ALA~? 9.46 O2 EDO C 103 coo 61.89 87.20 13.50 62.59 88.00 12.38 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo 59.34 89.99 13.88 59.24 89.18 13.73 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 coo 65.50 91.13 17.77 64.65 89.88 18.00 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 68.56 91.15 20.03 69.95 90.68 19.64 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 9 4 # 9 A 193 ALA E 67 ALA~? 12.61 O2 CIT E 104 A 194 GLY E 35 GLY.? 14.13 O2 CIT E 104 B 457 ALA E 70 ALA~? 12.37 O2 CIT E 104 B 458 ALA E 72 ALA~? 6.00 O6 CIT E 104 coo 61.89 87.20 13.50 62.59 88.00 12.38 -43.44 -87.76 -49.60 -42.32 -88.68 -50.03 coo 59.34 89.99 13.88 59.24 89.18 13.73 -40.51 -91.26 -48.44 -40.06 -91.01 -47.82 coo 65.50 91.13 17.77 64.65 89.88 18.00 -45.75 -85.11 -45.81 -45.60 -86.59 -45.87 coo 68.56 91.15 20.03 69.95 90.68 19.64 -43.51 -80.10 -45.58 -44.16 -79.64 -46.88 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 10 4 # 10 A 193 ALA F 67 ALA~? 12.75 O2 CIT F 104 A 194 GLY F 35 GLY.? 14.32 O2 CIT F 104 B 457 ALA F 70 ALA~? 12.64 O2 CIT F 104 B 458 ALA F 72 ALA~? 6.22 O6 CIT F 104 coo 61.89 87.20 13.50 62.59 88.00 12.38 -12.62 -86.76 -57.61 -13.72 -87.50 -56.90 coo 59.34 89.99 13.88 59.24 89.18 13.73 -14.95 -90.79 -57.80 -15.39 -90.89 -58.42 coo 65.50 91.13 17.77 64.65 89.88 18.00 -10.34 -85.12 -62.01 -10.33 -86.57 -61.57 coo 68.56 91.15 20.03 69.95 90.68 19.64 -13.05 -80.52 -63.67 -12.49 -79.66 -62.58 1pix_c03 source 1pix GLUTACONYL-COA DECARBOXYLASE A SUBUNIT : 10 hits 1pix_c03 naa= 4 ULMN 4 1pya_c01 PYRUVOYL-DEPENDENT HISTIDINE DECARBOuser 1 4 # 1 A 81 SER D 51 SER.? 10.41 O7 CIT C 104 B 195 PHE D 47 PHE.? 11.25 O2 CIT C 104 B 197 GLU D 48 GLU.? -3.37 O7 CIT C 104s C 62 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo 33.85 117.83 62.00 33.48 115.65 62.93 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 34.74 126.89 58.64 35.76 127.46 56.11 -47.67 -75.88 -18.20 -50.04 -75.67 -16.72 coo 29.77 125.13 60.32 30.09 123.64 58.88 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 34.01 116.98 69.72 34.94 114.70 68.46 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 1pya_c01 source 1pya PYRUVOYL-DEPENDENT HISTIDINE DECARBOXYLASE : 1 hits 1pya_c01 naa= 4 ULMN 4 1qho_c03 ALPHA-AMYLASE user 1 4 # 1 A 132 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 228 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 256 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 329 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 30.47 73.42 20.05 31.26 72.46 21.74 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 28.46 69.88 26.74 30.40 70.70 26.53 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 30.54 71.65 32.58 31.73 72.26 30.92 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 37.87 70.12 31.80 36.61 69.74 30.15 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 1qho_c03 source 1qho ALPHA-AMYLASE : 1 hits 1qho_c03 naa= 4 ULMN 4 1r1j_c00 NEPRILYSIN user 1 4 # 1 A 584 GLU E 38 GLU^? 8.47 O1 EDO E 103 A 650 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 711 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 717 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 29.33 48.80 29.17 29.00 46.74 29.48 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 38.62 44.38 31.99 36.86 43.62 32.96 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 31.96 38.97 33.59 30.29 39.94 32.77 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 36.26 41.03 36.49 33.98 42.25 34.87 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 1r1j_c00 source 1r1j NEPRILYSIN : 1 hits 1r1j_c00 naa= 4 ULMN 4 1rne_c05 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 1 4 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 75 TYR A 54 TYR.? 12.54 C1 EDO A 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 11.85 17.24 72.81 11.09 15.37 72.36 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 12.20 12.71 75.45 13.69 13.84 74.03 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 15.08 11.29 68.68 16.45 12.70 70.65 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 5.22 15.03 71.43 7.19 14.88 70.83 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 4 1rne_c05 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 2 4 # 2 32 ASP B 46 ASP.? 11.17 O1 EDO A 103 35 SER B 51 SER.? 11.29 O1 EDO A 103 75 TYR B 54 TYR.? 11.82 O7 CIT B 103 215 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.85 17.24 72.81 11.09 15.37 72.36 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 12.20 12.71 75.45 13.69 13.84 74.03 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 15.08 11.29 68.68 16.45 12.70 70.65 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 5.22 15.03 71.43 7.19 14.88 70.83 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 4 1rne_c05 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 3 4 # 3 32 ASP C 46 ASP.? 10.22 O6 CIT D 103 35 SER C 51 SER.? 10.55 O6 CIT D 103 75 TYR C 54 TYR.? 11.88 O3 CIT C 104 215 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 11.85 17.24 72.81 11.09 15.37 72.36 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 12.20 12.71 75.45 13.69 13.84 74.03 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 15.08 11.29 68.68 16.45 12.70 70.65 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 5.22 15.03 71.43 7.19 14.88 70.83 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 4 1rne_c05 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 4 4 # 4 32 ASP D 46 ASP.? 10.10 O7 CIT C 104 35 SER D 51 SER.? 10.41 O7 CIT C 104 75 TYR D 54 TYR.? 11.66 C4 CIT D 103 215 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 11.85 17.24 72.81 11.09 15.37 72.36 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 12.20 12.71 75.45 13.69 13.84 74.03 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 15.08 11.29 68.68 16.45 12.70 70.65 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 5.22 15.03 71.43 7.19 14.88 70.83 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 4 1rne_c05 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 5 4 # 5 32 ASP E 46 ASP.? 9.98 C4 CIT F 104 35 SER E 51 SER.? 10.11 C4 CIT F 104 75 TYR E 54 TYR.? 6.56 O1 EDO F 103 215 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 11.85 17.24 72.81 11.09 15.37 72.36 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 12.20 12.71 75.45 13.69 13.84 74.03 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 15.08 11.29 68.68 16.45 12.70 70.65 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 5.22 15.03 71.43 7.19 14.88 70.83 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 4 1rne_c05 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 6 4 # 6 32 ASP F 46 ASP.? 6.64 O2 EDO F 103 35 SER F 51 SER.? -5.94 O2 EDO F 103s 75 TYR F 54 TYR.? 5.10 C2 EDO F 103 215 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 11.85 17.24 72.81 11.09 15.37 72.36 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 12.20 12.71 75.45 13.69 13.84 74.03 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 15.08 11.29 68.68 16.45 12.70 70.65 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 5.22 15.03 71.43 7.19 14.88 70.83 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 1rne_c05 source 1rne RENIN (ACTIVATED, GLYCOSYLATED, INHIBITED) (E.: 6 hits 1rne_c05 naa= 4 ULMN 4 1ro7_c00 ALPHA-2,3/8-SIALYLTRANSFERASE user 1 4 # 1 A 129 ARG A 40 ARG^? 16.77 O2 EDO A 103 A 156 TYR A 56 TYR^? 12.86 C2 EDO A 103 A 162 TYR A 54 TYR.? 12.54 C1 EDO A 103 A 188 HIS A 41 HIS^? 12.51 O2 EDO A 103 coo 13.26 -3.59 9.83 13.09 -6.11 8.08 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 24.49 1.42 8.60 23.51 -0.13 10.72 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo 29.93 -1.69 13.68 27.68 -2.80 12.45 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 18.14 -0.38 8.50 17.55 -1.78 9.95 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 ULMN 4 1ro7_c00 ALPHA-2,3/8-SIALYLTRANSFERASE user 2 4 # 2 A 129 ARG B 40 ARG^? 17.25 O1 CIT B 103 A 156 TYR B 56 TYR^? 12.51 O1 CIT B 103 A 162 TYR B 54 TYR.? 11.82 O7 CIT B 103 A 188 HIS B 41 HIS^? 11.37 O1 CIT B 103 coo 13.26 -3.59 9.83 13.09 -6.11 8.08 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 24.49 1.42 8.60 23.51 -0.13 10.72 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo 29.93 -1.69 13.68 27.68 -2.80 12.45 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 18.14 -0.38 8.50 17.55 -1.78 9.95 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 ULMN 4 1ro7_c00 ALPHA-2,3/8-SIALYLTRANSFERASE user 3 4 # 3 A 129 ARG C 40 ARG^? 17.96 O1 CIT C 104 A 156 TYR C 56 TYR^? 12.84 O1 CIT C 104 A 162 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 188 HIS C 41 HIS^? 12.16 O1 CIT C 104 coo 13.26 -3.59 9.83 13.09 -6.11 8.08 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 24.49 1.42 8.60 23.51 -0.13 10.72 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo 29.93 -1.69 13.68 27.68 -2.80 12.45 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 18.14 -0.38 8.50 17.55 -1.78 9.95 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 ULMN 4 1ro7_c00 ALPHA-2,3/8-SIALYLTRANSFERASE user 4 4 # 4 A 129 ARG D 40 ARG^? 16.76 O2 CIT D 103 A 156 TYR D 56 TYR^? 12.73 C2 CIT D 103 A 162 TYR D 54 TYR.? 11.66 C4 CIT D 103 A 188 HIS D 41 HIS^? 12.20 O1 CIT D 103 coo 13.26 -3.59 9.83 13.09 -6.11 8.08 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 24.49 1.42 8.60 23.51 -0.13 10.72 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 coo 29.93 -1.69 13.68 27.68 -2.80 12.45 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 18.14 -0.38 8.50 17.55 -1.78 9.95 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 ULMN 4 1ro7_c00 ALPHA-2,3/8-SIALYLTRANSFERASE user 5 4 # 5 A 129 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 156 TYR E 56 TYR^? 8.81 O2 EDO E 103 A 162 TYR E 54 TYR.? 6.56 O1 EDO F 103 A 188 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 13.26 -3.59 9.83 13.09 -6.11 8.08 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 24.49 1.42 8.60 23.51 -0.13 10.72 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo 29.93 -1.69 13.68 27.68 -2.80 12.45 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 18.14 -0.38 8.50 17.55 -1.78 9.95 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 4 1ro7_c00 ALPHA-2,3/8-SIALYLTRANSFERASE user 6 4 # 6 A 129 ARG F 40 ARG^? 16.45 O2 CIT F 104 A 156 TYR F 56 TYR^? 13.04 O1 CIT F 104 A 162 TYR F 54 TYR.? 5.10 C2 EDO F 103 A 188 HIS F 41 HIS^? 12.43 O1 CIT F 104 coo 13.26 -3.59 9.83 13.09 -6.11 8.08 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 24.49 1.42 8.60 23.51 -0.13 10.72 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 coo 29.93 -1.69 13.68 27.68 -2.80 12.45 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 18.14 -0.38 8.50 17.55 -1.78 9.95 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 1ro7_c00 source 1ro7 ALPHA-2,3/8-SIALYLTRANSFERASE : 6 hits 1ro7_c00 naa= 4 ULMN 4 1ro7_c02 ALPHA-2,3/8-SIALYLTRANSFERASE user 1 4 # 1 C 129 ARG A 40 ARG^? 16.77 O2 EDO A 103 C 156 TYR A 56 TYR^? 12.86 C2 EDO A 103 C 162 TYR A 54 TYR.? 12.54 C1 EDO A 103 C 188 HIS A 41 HIS^? 12.51 O2 EDO A 103 coo -21.93 -12.96 3.85 -20.61 -15.55 2.86 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -26.79 -5.72 -5.03 -24.66 -5.47 -3.25 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo -21.39 -0.36 -7.59 -20.89 -2.89 -6.49 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo -25.74 -10.27 -0.74 -23.71 -9.75 -0.67 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 ULMN 4 1ro7_c02 ALPHA-2,3/8-SIALYLTRANSFERASE user 2 4 # 2 C 129 ARG B 40 ARG^? 17.25 O1 CIT B 103 C 156 TYR B 56 TYR^? 12.51 O1 CIT B 103 C 162 TYR B 54 TYR.? 11.82 O7 CIT B 103 C 188 HIS B 41 HIS^? 11.37 O1 CIT B 103 coo -21.93 -12.96 3.85 -20.61 -15.55 2.86 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo -26.79 -5.72 -5.03 -24.66 -5.47 -3.25 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo -21.39 -0.36 -7.59 -20.89 -2.89 -6.49 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo -25.74 -10.27 -0.74 -23.71 -9.75 -0.67 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 ULMN 4 1ro7_c02 ALPHA-2,3/8-SIALYLTRANSFERASE user 3 4 # 3 C 129 ARG C 40 ARG^? 17.96 O1 CIT C 104 C 156 TYR C 56 TYR^? 12.84 O1 CIT C 104 C 162 TYR C 54 TYR.? 11.88 O3 CIT C 104 C 188 HIS C 41 HIS^? 12.16 O1 CIT C 104 coo -21.93 -12.96 3.85 -20.61 -15.55 2.86 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -26.79 -5.72 -5.03 -24.66 -5.47 -3.25 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo -21.39 -0.36 -7.59 -20.89 -2.89 -6.49 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo -25.74 -10.27 -0.74 -23.71 -9.75 -0.67 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 ULMN 4 1ro7_c02 ALPHA-2,3/8-SIALYLTRANSFERASE user 4 4 # 4 C 129 ARG E 40 ARG^? -5.36 O2 EDO E 103s C 156 TYR E 56 TYR^? 8.81 O2 EDO E 103 C 162 TYR E 54 TYR.? 6.56 O1 EDO F 103 C 188 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo -21.93 -12.96 3.85 -20.61 -15.55 2.86 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -26.79 -5.72 -5.03 -24.66 -5.47 -3.25 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo -21.39 -0.36 -7.59 -20.89 -2.89 -6.49 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo -25.74 -10.27 -0.74 -23.71 -9.75 -0.67 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 1ro7_c02 source 1ro7 ALPHA-2,3/8-SIALYLTRANSFERASE : 4 hits 1ro7_c02 naa= 4 ULMN 4 1sme_c06 PLASMEPSIN II user 1 4 # 1 A 34 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 37 SER A 51 SER.? 9.93 O6 CIT B 103 A 77 TYR A 54 TYR.? 12.54 C1 EDO A 103 A 214 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 51.75 60.57 19.10 52.05 60.90 21.19 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 51.10 65.11 20.73 52.62 63.74 19.42 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 58.03 63.52 22.21 57.19 63.97 19.60 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 48.59 58.89 25.78 50.13 59.74 24.61 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 4 1sme_c06 PLASMEPSIN II user 2 4 # 2 A 34 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 37 SER C 51 SER.? 10.55 O6 CIT D 103 A 77 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 214 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 51.75 60.57 19.10 52.05 60.90 21.19 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 51.10 65.11 20.73 52.62 63.74 19.42 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 58.03 63.52 22.21 57.19 63.97 19.60 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 48.59 58.89 25.78 50.13 59.74 24.61 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 4 1sme_c06 PLASMEPSIN II user 3 4 # 3 A 34 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 37 SER E 51 SER.? 10.11 C4 CIT F 104 A 77 TYR E 54 TYR.? 6.56 O1 EDO F 103 A 214 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 51.75 60.57 19.10 52.05 60.90 21.19 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 51.10 65.11 20.73 52.62 63.74 19.42 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 58.03 63.52 22.21 57.19 63.97 19.60 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 48.59 58.89 25.78 50.13 59.74 24.61 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1sme_c06 source 1sme PLASMEPSIN II : 3 hits 1sme_c06 naa= 4 ULMN 4 1uok_c02 OLIGO-1,6-GLUCOSIDASE user 1 4 # 1 103 HIS A 4 HIS.? -4.40 O2 EDO A 103s 199 ASP A 99 ASP^? 8.10 O2 EDO A 103 255 GLU A 101 GLU^? 18.10 O2 EDO A 103 329 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 49.45 28.31 18.34 50.63 29.96 17.82 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 49.16 35.16 15.19 51.08 34.43 15.65 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 52.57 37.12 10.17 53.37 35.95 11.75 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 59.16 37.82 13.95 57.63 37.03 15.12 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 4 1uok_c02 OLIGO-1,6-GLUCOSIDASE user 2 4 # 2 103 HIS B 4 HIS.? -4.11 O2 CIT B 103s 199 ASP B 99 ASP^? 7.47 O6 CIT B 103 255 GLU B 101 GLU^? 17.79 O2 CIT B 103 329 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 49.45 28.31 18.34 50.63 29.96 17.82 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 49.16 35.16 15.19 51.08 34.43 15.65 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 52.57 37.12 10.17 53.37 35.95 11.75 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 59.16 37.82 13.95 57.63 37.03 15.12 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 4 1uok_c02 OLIGO-1,6-GLUCOSIDASE user 3 4 # 3 103 HIS C 4 HIS.? -4.06 O2 CIT C 104s 199 ASP C 99 ASP^? 7.14 O2 CIT C 104 255 GLU C 101 GLU^? 17.42 O2 CIT C 104 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 49.45 28.31 18.34 50.63 29.96 17.82 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 49.16 35.16 15.19 51.08 34.43 15.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 52.57 37.12 10.17 53.37 35.95 11.75 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 59.16 37.82 13.95 57.63 37.03 15.12 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 4 1uok_c02 OLIGO-1,6-GLUCOSIDASE user 4 4 # 4 103 HIS D 4 HIS.? -4.16 O2 CIT D 103s 199 ASP D 99 ASP^? 6.89 O6 CIT D 103 255 GLU D 101 GLU^? 17.58 O6 CIT D 103 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 49.45 28.31 18.34 50.63 29.96 17.82 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 49.16 35.16 15.19 51.08 34.43 15.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 52.57 37.12 10.17 53.37 35.95 11.75 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 59.16 37.82 13.95 57.63 37.03 15.12 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 4 1uok_c02 OLIGO-1,6-GLUCOSIDASE user 5 4 # 5 103 HIS E 4 HIS.? -4.01 O2 CIT E 104s 199 ASP E 99 ASP^? 7.65 C2 CIT E 104 255 GLU E 101 GLU^? 17.69 O2 CIT E 104 329 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 49.45 28.31 18.34 50.63 29.96 17.82 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 52.57 37.12 10.17 53.37 35.95 11.75 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 59.16 37.82 13.95 57.63 37.03 15.12 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 4 1uok_c02 OLIGO-1,6-GLUCOSIDASE user 6 4 # 6 103 HIS F 4 HIS.? -4.07 O2 CIT F 104s 199 ASP F 99 ASP^? 6.97 O7 CIT F 104 255 GLU F 101 GLU^? 10.35 O2 EDO E 103 329 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 49.45 28.31 18.34 50.63 29.96 17.82 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 49.16 35.16 15.19 51.08 34.43 15.65 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 52.57 37.12 10.17 53.37 35.95 11.75 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 59.16 37.82 13.95 57.63 37.03 15.12 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1uok_c02 source 1uok OLIGO-1,6-GLUCOSIDASE : 6 hits 1uok_c02 naa= 4 ULMN 4 1xtc_c00 CHOLERA TOXIN user 1 4 # 1 A 7 ARG C 18 ARG~? -3.10 O1 EDO C 103s A 61 SER C 87 SER~? 9.82 O2 EDO C 103 A 110 GLU C 9 GLU.? 12.64 O3 CIT C 104 A 112 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo 40.84 -12.81 5.27 43.40 -12.96 7.11 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo 43.36 -8.81 2.69 45.06 -10.01 1.28 -34.89 -64.48 -33.73 -36.72 -64.13 -35.26 coo 50.78 -11.66 -4.90 52.36 -12.10 -6.21 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 46.91 -7.83 -2.12 47.28 -9.79 -1.54 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 4 1xtc_c00 CHOLERA TOXIN user 2 4 # 2 A 7 ARG D 18 ARG~? 14.38 O7 CIT D 103 A 61 SER D 87 SER~? 10.80 O7 CIT D 103 A 110 GLU D 9 GLU.? 12.31 O4 CIT D 103 A 112 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 40.84 -12.81 5.27 43.40 -12.96 7.11 -45.95 -58.51 3.75 -43.82 -60.51 4.85 coo 43.36 -8.81 2.69 45.06 -10.01 1.28 -42.31 -59.94 0.40 -44.63 -59.72 0.96 coo 50.78 -11.66 -4.90 52.36 -12.10 -6.21 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 46.91 -7.83 -2.12 47.28 -9.79 -1.54 -36.27 -63.51 0.47 -34.79 -65.02 0.31 1xtc_c00 source 1xtc CHOLERA TOXIN : 2 hits 1xtc_c00 naa= 4 ULMN 4 2apr_c05 ACID PROTEINASE (RHIZOPUSPEPSIN) (E.user 1 4 # 1 35 ASP A 46 ASP.? 9.57 O6 CIT B 103 38 SER A 51 SER.? 9.93 O6 CIT B 103 77 TYR A 54 TYR.? 12.54 C1 EDO A 103 218 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 41.14 58.72 105.19 42.39 59.85 103.92 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 46.04 57.35 103.96 44.97 58.52 105.78 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 47.21 64.36 106.26 46.67 62.33 108.12 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 41.33 60.20 97.63 42.00 60.96 99.49 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 4 2apr_c05 ACID PROTEINASE (RHIZOPUSPEPSIN) (E.user 2 4 # 2 35 ASP C 46 ASP.? 10.22 O6 CIT D 103 38 SER C 51 SER.? 10.55 O6 CIT D 103 77 TYR C 54 TYR.? 11.88 O3 CIT C 104 218 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 41.14 58.72 105.19 42.39 59.85 103.92 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 46.04 57.35 103.96 44.97 58.52 105.78 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 47.21 64.36 106.26 46.67 62.33 108.12 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 41.33 60.20 97.63 42.00 60.96 99.49 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 2apr_c05 source 2apr ACID PROTEINASE (RHIZOPUSPEPSIN) (E.C.3.4.23.6: 2 hits 2apr_c05 naa= 4 ULMN 4 2jxr_c05 LIGAND CP-081282 user 1 4 # 1 A 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 35 SER A 51 SER.? 9.93 O6 CIT B 103 A 75 TYR A 54 TYR.? 12.54 C1 EDO A 103 A 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo -20.05 66.65 43.47 -19.36 65.65 45.97 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 4 2jxr_c05 LIGAND CP-081282 user 2 4 # 2 A 32 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 35 SER B 51 SER.? 11.29 O1 EDO A 103 A 75 TYR B 54 TYR.? 11.82 O7 CIT B 103 A 215 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo -20.05 66.65 43.47 -19.36 65.65 45.97 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 4 2jxr_c05 LIGAND CP-081282 user 3 4 # 3 A 32 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 35 SER C 51 SER.? 10.55 O6 CIT D 103 A 75 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 215 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo -20.05 66.65 43.47 -19.36 65.65 45.97 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 4 2jxr_c05 LIGAND CP-081282 user 4 4 # 4 A 32 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 35 SER D 51 SER.? 10.41 O7 CIT C 104 A 75 TYR D 54 TYR.? 11.66 C4 CIT D 103 A 215 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo -20.05 66.65 43.47 -19.36 65.65 45.97 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 4 2jxr_c05 LIGAND CP-081282 user 5 4 # 5 A 32 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 35 SER E 51 SER.? 10.11 C4 CIT F 104 A 75 TYR E 54 TYR.? 6.56 O1 EDO F 103 A 215 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo -20.05 66.65 43.47 -19.36 65.65 45.97 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 4 2jxr_c05 LIGAND CP-081282 user 6 4 # 6 A 32 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 35 SER F 51 SER.? -5.94 O2 EDO F 103s A 75 TYR F 54 TYR.? 5.10 C2 EDO F 103 A 215 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo -20.05 66.65 43.47 -19.36 65.65 45.97 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 2jxr_c05 source 2jxr LIGAND CP-081282 : 6 hits 2jxr_c05 naa= 4 ULMN 3 12as_c00 ASPARAGINE SYNTHETASE user 1 3 # 1 A 46 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 100 ARG A 79 ARG~? -3.92 C2 EDO E 103s A 116 GLN A 78 GLN~? 10.77 O1 EDO A 103 coo 32.24 20.09 5.34 30.38 19.04 5.27 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 26.40 25.34 6.28 26.15 22.33 7.25 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 26.74 21.94 13.78 27.57 20.97 12.08 -24.81 -92.50 -33.55 -26.20 -94.06 -34.04 12as_c00 source 12as ASPARAGINE SYNTHETASE : 1 hits 12as_c00 naa= 3 ULMN 3 12as_c01 ASPARAGINE SYNTHETASE user 1 3 # 1 B 46 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 100 ARG A 79 ARG~? -3.92 C2 EDO E 103s B 116 GLN A 78 GLN~? 10.77 O1 EDO A 103 coo 32.18 48.37 12.48 33.96 49.46 12.97 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 39.04 43.25 11.37 38.30 45.35 13.56 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 37.43 42.63 19.41 36.76 44.08 17.97 -24.81 -92.50 -33.55 -26.20 -94.06 -34.04 12as_c01 source 12as ASPARAGINE SYNTHETASE : 1 hits 12as_c01 naa= 3 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 1 3 # 1 A 140 TYR A 54 TYR.? 12.54 C1 EDO A 103 B 190 LYS A 50 LYS.? -4.54 O3 CIT B 103s B 222 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 7.17 16.59 41.26 8.01 19.20 40.73 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 13.38 20.00 35.06 11.43 22.49 39.53 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo 9.76 26.58 38.10 11.63 25.78 38.76 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 2 3 # 2 A 140 TYR A 71 TYR~? -4.90 O2 EDO A 103s B 190 LYS A 65 LYS~? 12.23 O2 EDO A 103 B 222 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 7.17 16.59 41.26 8.01 19.20 40.73 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 13.38 20.00 35.06 11.43 22.49 39.53 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 9.76 26.58 38.10 11.63 25.78 38.76 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 3 3 # 3 A 140 TYR B 54 TYR.? 11.82 O7 CIT B 103 B 190 LYS B 50 LYS.? 6.61 O1 EDO A 103 B 222 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 7.17 16.59 41.26 8.01 19.20 40.73 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 13.38 20.00 35.06 11.43 22.49 39.53 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo 9.76 26.58 38.10 11.63 25.78 38.76 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 4 3 # 4 A 140 TYR B 71 TYR~? -4.80 O1 CIT B 103s B 190 LYS B 65 LYS~? 11.82 O5 CIT B 103 B 222 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 7.17 16.59 41.26 8.01 19.20 40.73 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 13.38 20.00 35.06 11.43 22.49 39.53 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 9.76 26.58 38.10 11.63 25.78 38.76 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 5 3 # 5 A 140 TYR C 54 TYR.? 11.88 O3 CIT C 104 B 190 LYS C 50 LYS.? -4.07 O4 CIT D 103s B 222 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 7.17 16.59 41.26 8.01 19.20 40.73 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 13.38 20.00 35.06 11.43 22.49 39.53 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo 9.76 26.58 38.10 11.63 25.78 38.76 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 6 3 # 6 A 140 TYR C 71 TYR~? -4.77 O1 CIT C 104s B 190 LYS C 65 LYS~? 12.16 O6 CIT C 104 B 222 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 7.17 16.59 41.26 8.01 19.20 40.73 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 13.38 20.00 35.06 11.43 22.49 39.53 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 9.76 26.58 38.10 11.63 25.78 38.76 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 7 3 # 7 A 140 TYR D 54 TYR.? 11.66 C4 CIT D 103 B 190 LYS C 50 LYS.? -4.07 O4 CIT D 103s B 222 ASP D 93 ASP~? 9.04 O4 CIT D 103 coo 7.17 16.59 41.26 8.01 19.20 40.73 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 13.38 20.00 35.06 11.43 22.49 39.53 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo 9.76 26.58 38.10 11.63 25.78 38.76 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 8 3 # 8 A 140 TYR D 54 TYR.? 11.66 C4 CIT D 103 B 190 LYS D 50 LYS.? -4.40 O3 CIT C 104s B 222 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 7.17 16.59 41.26 8.01 19.20 40.73 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 13.38 20.00 35.06 11.43 22.49 39.53 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 9.76 26.58 38.10 11.63 25.78 38.76 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 9 3 # 9 A 140 TYR D 71 TYR~? -4.87 O2 CIT D 103s B 190 LYS D 65 LYS~? 11.29 O6 CIT D 103 B 222 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 7.17 16.59 41.26 8.01 19.20 40.73 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 13.38 20.00 35.06 11.43 22.49 39.53 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 9.76 26.58 38.10 11.63 25.78 38.76 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 10 3 # 10 A 140 TYR E 54 TYR.? 6.56 O1 EDO F 103 B 190 LYS E 50 LYS.? -4.05 O4 CIT F 104s B 222 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 7.17 16.59 41.26 8.01 19.20 40.73 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 13.38 20.00 35.06 11.43 22.49 39.53 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo 9.76 26.58 38.10 11.63 25.78 38.76 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 11 3 # 11 A 140 TYR E 71 TYR~? -4.78 O2 CIT E 104s B 190 LYS E 65 LYS~? 11.89 O6 CIT E 104 B 222 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 7.17 16.59 41.26 8.01 19.20 40.73 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 13.38 20.00 35.06 11.43 22.49 39.53 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 9.76 26.58 38.10 11.63 25.78 38.76 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 12 3 # 12 A 140 TYR F 54 TYR.? 5.10 C2 EDO F 103 B 190 LYS F 50 LYS.? -3.77 O3 CIT E 104s B 222 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 7.17 16.59 41.26 8.01 19.20 40.73 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 13.38 20.00 35.06 11.43 22.49 39.53 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 9.76 26.58 38.10 11.63 25.78 38.76 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 13 3 # 13 A 140 TYR F 71 TYR~? -4.99 O2 CIT F 104s B 190 LYS F 65 LYS~? 10.97 O7 CIT F 104 B 222 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 7.17 16.59 41.26 8.01 19.20 40.73 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 13.38 20.00 35.06 11.43 22.49 39.53 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 9.76 26.58 38.10 11.63 25.78 38.76 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1a05_c00 source 1a05 3-ISOPROPYLMALATE DEHYDROGENASE : 13 hits 1a05_c00 naa= 3 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 1 3 # 1 A 190 LYS A 50 LYS.? -4.54 O3 CIT B 103s A 222 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 140 TYR A 54 TYR.? 12.54 C1 EDO A 103 coo -4.61 20.12 30.34 -2.74 22.65 25.95 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 1.51 16.60 24.17 0.82 19.23 24.79 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 2 3 # 2 A 190 LYS A 65 LYS~? 12.23 O2 EDO A 103 A 222 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 140 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo -4.61 20.12 30.34 -2.74 22.65 25.95 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 1.51 16.60 24.17 0.82 19.23 24.79 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 3 3 # 3 A 190 LYS B 50 LYS.? 6.61 O1 EDO A 103 A 222 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 140 TYR B 54 TYR.? 11.82 O7 CIT B 103 coo -4.61 20.12 30.34 -2.74 22.65 25.95 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 1.51 16.60 24.17 0.82 19.23 24.79 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 4 3 # 4 A 190 LYS B 65 LYS~? 11.82 O5 CIT B 103 A 222 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 140 TYR B 71 TYR~? -4.80 O1 CIT B 103s coo -4.61 20.12 30.34 -2.74 22.65 25.95 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 1.51 16.60 24.17 0.82 19.23 24.79 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 5 3 # 5 A 190 LYS C 50 LYS.? -4.07 O4 CIT D 103s A 222 ASP D 93 ASP~? 9.04 O4 CIT D 103 B 140 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo -4.61 20.12 30.34 -2.74 22.65 25.95 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 1.51 16.60 24.17 0.82 19.23 24.79 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 6 3 # 6 A 190 LYS C 50 LYS.? -4.07 O4 CIT D 103s A 222 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 140 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo -4.61 20.12 30.34 -2.74 22.65 25.95 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 1.51 16.60 24.17 0.82 19.23 24.79 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 7 3 # 7 A 190 LYS C 65 LYS~? 12.16 O6 CIT C 104 A 222 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 140 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo -4.61 20.12 30.34 -2.74 22.65 25.95 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 1.51 16.60 24.17 0.82 19.23 24.79 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 8 3 # 8 A 190 LYS D 50 LYS.? -4.40 O3 CIT C 104s A 222 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 140 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo -4.61 20.12 30.34 -2.74 22.65 25.95 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 1.51 16.60 24.17 0.82 19.23 24.79 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 9 3 # 9 A 190 LYS D 65 LYS~? 11.29 O6 CIT D 103 A 222 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 140 TYR D 71 TYR~? -4.87 O2 CIT D 103s coo -4.61 20.12 30.34 -2.74 22.65 25.95 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 1.51 16.60 24.17 0.82 19.23 24.79 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 10 3 # 10 A 190 LYS E 50 LYS.? -4.05 O4 CIT F 104s A 222 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 140 TYR E 54 TYR.? 6.56 O1 EDO F 103 coo -4.61 20.12 30.34 -2.74 22.65 25.95 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 1.51 16.60 24.17 0.82 19.23 24.79 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 11 3 # 11 A 190 LYS E 65 LYS~? 11.89 O6 CIT E 104 A 222 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 140 TYR E 71 TYR~? -4.78 O2 CIT E 104s coo -4.61 20.12 30.34 -2.74 22.65 25.95 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 1.51 16.60 24.17 0.82 19.23 24.79 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 12 3 # 12 A 190 LYS F 50 LYS.? -3.77 O3 CIT E 104s A 222 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 140 TYR F 54 TYR.? 5.10 C2 EDO F 103 coo -4.61 20.12 30.34 -2.74 22.65 25.95 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 1.51 16.60 24.17 0.82 19.23 24.79 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 13 3 # 13 A 190 LYS F 65 LYS~? 10.97 O7 CIT F 104 A 222 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 140 TYR F 71 TYR~? -4.99 O2 CIT F 104s coo -4.61 20.12 30.34 -2.74 22.65 25.95 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 1.51 16.60 24.17 0.82 19.23 24.79 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 1a05_c01 source 1a05 3-ISOPROPYLMALATE DEHYDROGENASE : 13 hits 1a05_c01 naa= 3 ULMN 3 1a0j_c12 TRYPSIN user 1 3 # 1 A 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 193 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo 25.57 41.22 61.68 24.18 39.98 62.50 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 22.33 45.48 59.73 23.35 43.67 60.06 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 22.57 32.23 64.13 21.98 32.82 64.22 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 1a0j_c12 TRYPSIN user 2 3 # 2 A 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 25.57 41.22 61.68 24.18 39.98 62.50 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 22.33 45.48 59.73 23.35 43.67 60.06 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 22.57 32.23 64.13 21.98 32.82 64.22 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1a0j_c12 TRYPSIN user 3 3 # 3 A 57 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 102 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 25.57 41.22 61.68 24.18 39.98 62.50 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 22.33 45.48 59.73 23.35 43.67 60.06 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 22.57 32.23 64.13 21.98 32.82 64.22 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1a0j_c12 TRYPSIN user 4 3 # 4 A 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 193 GLY B 57 GLY^? 9.92 O7 CIT B 103 coo 25.57 41.22 61.68 24.18 39.98 62.50 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 22.33 45.48 59.73 23.35 43.67 60.06 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 22.57 32.23 64.13 21.98 32.82 64.22 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 ULMN 3 1a0j_c12 TRYPSIN user 5 3 # 5 A 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 193 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 25.57 41.22 61.68 24.18 39.98 62.50 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 22.33 45.48 59.73 23.35 43.67 60.06 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 22.57 32.23 64.13 21.98 32.82 64.22 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1a0j_c12 TRYPSIN user 6 3 # 6 A 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 193 GLY C 57 GLY^? 10.09 O1 CIT C 104 coo 25.57 41.22 61.68 24.18 39.98 62.50 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 22.33 45.48 59.73 23.35 43.67 60.06 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 22.57 32.23 64.13 21.98 32.82 64.22 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 ULMN 3 1a0j_c12 TRYPSIN user 7 3 # 7 A 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 193 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 25.57 41.22 61.68 24.18 39.98 62.50 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 22.33 45.48 59.73 23.35 43.67 60.06 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 22.57 32.23 64.13 21.98 32.82 64.22 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1a0j_c12 TRYPSIN user 8 3 # 8 A 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 193 GLY D 57 GLY^? 9.79 C2 CIT D 103 coo 25.57 41.22 61.68 24.18 39.98 62.50 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 22.33 45.48 59.73 23.35 43.67 60.06 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 22.57 32.23 64.13 21.98 32.82 64.22 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 ULMN 3 1a0j_c12 TRYPSIN user 9 3 # 9 A 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 193 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 25.57 41.22 61.68 24.18 39.98 62.50 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 22.33 45.48 59.73 23.35 43.67 60.06 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 22.57 32.23 64.13 21.98 32.82 64.22 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1a0j_c12 TRYPSIN user 10 3 # 10 A 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 193 GLY E 57 GLY^? 9.68 O2 EDO E 103 coo 25.57 41.22 61.68 24.18 39.98 62.50 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 22.33 45.48 59.73 23.35 43.67 60.06 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 22.57 32.23 64.13 21.98 32.82 64.22 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 ULMN 3 1a0j_c12 TRYPSIN user 11 3 # 11 A 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 193 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 25.57 41.22 61.68 24.18 39.98 62.50 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 22.33 45.48 59.73 23.35 43.67 60.06 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 22.57 32.23 64.13 21.98 32.82 64.22 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1a0j_c12 TRYPSIN user 12 3 # 12 A 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 193 GLY F 57 GLY^? 10.08 O2 CIT F 104 coo 25.57 41.22 61.68 24.18 39.98 62.50 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 22.33 45.48 59.73 23.35 43.67 60.06 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 22.57 32.23 64.13 21.98 32.82 64.22 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 ULMN 3 1a0j_c12 TRYPSIN user 13 3 # 13 A 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 193 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 25.57 41.22 61.68 24.18 39.98 62.50 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 22.33 45.48 59.73 23.35 43.67 60.06 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 22.57 32.23 64.13 21.98 32.82 64.22 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1a0j_c12 source 1a0j TRYPSIN : 13 hits 1a0j_c12 naa= 3 ULMN 3 1a0j_c13 TRYPSIN user 1 3 # 1 B 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 193 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo 44.08 45.58 52.81 45.86 46.55 52.85 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 43.04 44.75 47.18 43.31 45.51 49.13 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 50.46 51.91 56.90 50.65 51.62 56.14 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 1a0j_c13 TRYPSIN user 2 3 # 2 B 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 44.08 45.58 52.81 45.86 46.55 52.85 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 43.04 44.75 47.18 43.31 45.51 49.13 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 50.46 51.91 56.90 50.65 51.62 56.14 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1a0j_c13 TRYPSIN user 3 3 # 3 B 57 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 102 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 44.08 45.58 52.81 45.86 46.55 52.85 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 43.04 44.75 47.18 43.31 45.51 49.13 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 50.46 51.91 56.90 50.65 51.62 56.14 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1a0j_c13 TRYPSIN user 4 3 # 4 B 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 193 GLY B 57 GLY^? 9.92 O7 CIT B 103 coo 44.08 45.58 52.81 45.86 46.55 52.85 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 43.04 44.75 47.18 43.31 45.51 49.13 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 50.46 51.91 56.90 50.65 51.62 56.14 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 ULMN 3 1a0j_c13 TRYPSIN user 5 3 # 5 B 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 193 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 44.08 45.58 52.81 45.86 46.55 52.85 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 43.04 44.75 47.18 43.31 45.51 49.13 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 50.46 51.91 56.90 50.65 51.62 56.14 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1a0j_c13 TRYPSIN user 6 3 # 6 B 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 193 GLY C 57 GLY^? 10.09 O1 CIT C 104 coo 44.08 45.58 52.81 45.86 46.55 52.85 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 43.04 44.75 47.18 43.31 45.51 49.13 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 50.46 51.91 56.90 50.65 51.62 56.14 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 ULMN 3 1a0j_c13 TRYPSIN user 7 3 # 7 B 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 193 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 44.08 45.58 52.81 45.86 46.55 52.85 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 43.04 44.75 47.18 43.31 45.51 49.13 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 50.46 51.91 56.90 50.65 51.62 56.14 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1a0j_c13 TRYPSIN user 8 3 # 8 B 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 193 GLY D 57 GLY^? 9.79 C2 CIT D 103 coo 44.08 45.58 52.81 45.86 46.55 52.85 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 43.04 44.75 47.18 43.31 45.51 49.13 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 50.46 51.91 56.90 50.65 51.62 56.14 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 ULMN 3 1a0j_c13 TRYPSIN user 9 3 # 9 B 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 193 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 44.08 45.58 52.81 45.86 46.55 52.85 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 43.04 44.75 47.18 43.31 45.51 49.13 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 50.46 51.91 56.90 50.65 51.62 56.14 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1a0j_c13 TRYPSIN user 10 3 # 10 B 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 193 GLY E 57 GLY^? 9.68 O2 EDO E 103 coo 44.08 45.58 52.81 45.86 46.55 52.85 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 43.04 44.75 47.18 43.31 45.51 49.13 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 50.46 51.91 56.90 50.65 51.62 56.14 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 ULMN 3 1a0j_c13 TRYPSIN user 11 3 # 11 B 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 193 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 44.08 45.58 52.81 45.86 46.55 52.85 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 43.04 44.75 47.18 43.31 45.51 49.13 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 50.46 51.91 56.90 50.65 51.62 56.14 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1a0j_c13 TRYPSIN user 12 3 # 12 B 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 193 GLY F 57 GLY^? 10.08 O2 CIT F 104 coo 44.08 45.58 52.81 45.86 46.55 52.85 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 43.04 44.75 47.18 43.31 45.51 49.13 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 50.46 51.91 56.90 50.65 51.62 56.14 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 ULMN 3 1a0j_c13 TRYPSIN user 13 3 # 13 B 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 193 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 44.08 45.58 52.81 45.86 46.55 52.85 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 43.04 44.75 47.18 43.31 45.51 49.13 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 50.46 51.91 56.90 50.65 51.62 56.14 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1a0j_c13 source 1a0j TRYPSIN : 13 hits 1a0j_c13 naa= 3 ULMN 3 1a0j_c14 TRYPSIN user 1 3 # 1 C 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 C 193 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo 34.37 41.18 73.21 34.04 43.09 73.87 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 34.89 38.34 78.12 35.11 39.59 76.42 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 35.43 51.03 72.12 35.20 50.72 72.87 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 1a0j_c14 TRYPSIN user 2 3 # 2 C 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 C 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 34.37 41.18 73.21 34.04 43.09 73.87 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 34.89 38.34 78.12 35.11 39.59 76.42 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 35.43 51.03 72.12 35.20 50.72 72.87 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1a0j_c14 TRYPSIN user 3 3 # 3 C 57 HIS A 74 HIS~? 11.00 C1 EDO E 103 C 102 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 34.37 41.18 73.21 34.04 43.09 73.87 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 34.89 38.34 78.12 35.11 39.59 76.42 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 35.43 51.03 72.12 35.20 50.72 72.87 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1a0j_c14 TRYPSIN user 4 3 # 4 C 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s C 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 C 193 GLY B 57 GLY^? 9.92 O7 CIT B 103 coo 34.37 41.18 73.21 34.04 43.09 73.87 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 34.89 38.34 78.12 35.11 39.59 76.42 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 35.43 51.03 72.12 35.20 50.72 72.87 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 ULMN 3 1a0j_c14 TRYPSIN user 5 3 # 5 C 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s C 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 C 193 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 34.37 41.18 73.21 34.04 43.09 73.87 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 34.89 38.34 78.12 35.11 39.59 76.42 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 35.43 51.03 72.12 35.20 50.72 72.87 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1a0j_c14 TRYPSIN user 6 3 # 6 C 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s C 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 C 193 GLY C 57 GLY^? 10.09 O1 CIT C 104 coo 34.37 41.18 73.21 34.04 43.09 73.87 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 34.89 38.34 78.12 35.11 39.59 76.42 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 35.43 51.03 72.12 35.20 50.72 72.87 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 ULMN 3 1a0j_c14 TRYPSIN user 7 3 # 7 C 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s C 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 C 193 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 34.37 41.18 73.21 34.04 43.09 73.87 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 34.89 38.34 78.12 35.11 39.59 76.42 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 35.43 51.03 72.12 35.20 50.72 72.87 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1a0j_c14 TRYPSIN user 8 3 # 8 C 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 C 193 GLY D 57 GLY^? 9.79 C2 CIT D 103 coo 34.37 41.18 73.21 34.04 43.09 73.87 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 34.89 38.34 78.12 35.11 39.59 76.42 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 35.43 51.03 72.12 35.20 50.72 72.87 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 ULMN 3 1a0j_c14 TRYPSIN user 9 3 # 9 C 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 C 193 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 34.37 41.18 73.21 34.04 43.09 73.87 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 34.89 38.34 78.12 35.11 39.59 76.42 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 35.43 51.03 72.12 35.20 50.72 72.87 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1a0j_c14 TRYPSIN user 10 3 # 10 C 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 C 193 GLY E 35 GLY.? 14.13 O2 CIT E 104 coo 34.37 41.18 73.21 34.04 43.09 73.87 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 34.89 38.34 78.12 35.11 39.59 76.42 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 35.43 51.03 72.12 35.20 50.72 72.87 -40.51 -91.26 -48.44 -40.06 -91.01 -47.82 ULMN 3 1a0j_c14 TRYPSIN user 11 3 # 11 C 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 C 193 GLY E 57 GLY^? 9.68 O2 EDO E 103 coo 34.37 41.18 73.21 34.04 43.09 73.87 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 34.89 38.34 78.12 35.11 39.59 76.42 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 35.43 51.03 72.12 35.20 50.72 72.87 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 ULMN 3 1a0j_c14 TRYPSIN user 12 3 # 12 C 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 C 193 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 34.37 41.18 73.21 34.04 43.09 73.87 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 34.89 38.34 78.12 35.11 39.59 76.42 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 35.43 51.03 72.12 35.20 50.72 72.87 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1a0j_c14 TRYPSIN user 13 3 # 13 C 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s C 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 C 193 GLY F 35 GLY.? 14.32 O2 CIT F 104 coo 34.37 41.18 73.21 34.04 43.09 73.87 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 34.89 38.34 78.12 35.11 39.59 76.42 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 35.43 51.03 72.12 35.20 50.72 72.87 -14.95 -90.79 -57.80 -15.39 -90.89 -58.42 ULMN 3 1a0j_c14 TRYPSIN user 14 3 # 14 C 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s C 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 C 193 GLY F 57 GLY^? 10.08 O2 CIT F 104 coo 34.37 41.18 73.21 34.04 43.09 73.87 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 34.89 38.34 78.12 35.11 39.59 76.42 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 35.43 51.03 72.12 35.20 50.72 72.87 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 ULMN 3 1a0j_c14 TRYPSIN user 15 3 # 15 C 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s C 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 C 193 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 34.37 41.18 73.21 34.04 43.09 73.87 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 34.89 38.34 78.12 35.11 39.59 76.42 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 35.43 51.03 72.12 35.20 50.72 72.87 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1a0j_c14 source 1a0j TRYPSIN : 15 hits 1a0j_c14 naa= 3 ULMN 3 1a0j_c15 TRYPSIN user 1 3 # 1 D 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 D 193 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo 8.19 15.01 95.72 7.78 16.53 97.01 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 13.53 16.28 93.98 11.45 16.21 94.40 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 1.80 21.25 100.04 2.61 21.42 100.18 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 1a0j_c15 TRYPSIN user 2 3 # 2 D 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 D 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 8.19 15.01 95.72 7.78 16.53 97.01 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 13.53 16.28 93.98 11.45 16.21 94.40 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 1.80 21.25 100.04 2.61 21.42 100.18 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1a0j_c15 TRYPSIN user 3 3 # 3 D 57 HIS A 74 HIS~? 11.00 C1 EDO E 103 D 102 ASP E 27 ASP~? 4.58 C1 EDO E 103 D 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 8.19 15.01 95.72 7.78 16.53 97.01 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 13.53 16.28 93.98 11.45 16.21 94.40 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 1.80 21.25 100.04 2.61 21.42 100.18 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1a0j_c15 TRYPSIN user 4 3 # 4 D 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s D 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 D 193 GLY B 57 GLY^? 9.92 O7 CIT B 103 coo 8.19 15.01 95.72 7.78 16.53 97.01 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 13.53 16.28 93.98 11.45 16.21 94.40 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 1.80 21.25 100.04 2.61 21.42 100.18 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 ULMN 3 1a0j_c15 TRYPSIN user 5 3 # 5 D 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s D 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 D 193 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 8.19 15.01 95.72 7.78 16.53 97.01 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 13.53 16.28 93.98 11.45 16.21 94.40 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 1.80 21.25 100.04 2.61 21.42 100.18 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1a0j_c15 TRYPSIN user 6 3 # 6 D 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s D 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 D 193 GLY C 57 GLY^? 10.09 O1 CIT C 104 coo 8.19 15.01 95.72 7.78 16.53 97.01 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 13.53 16.28 93.98 11.45 16.21 94.40 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 1.80 21.25 100.04 2.61 21.42 100.18 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 ULMN 3 1a0j_c15 TRYPSIN user 7 3 # 7 D 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s D 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 D 193 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 8.19 15.01 95.72 7.78 16.53 97.01 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 13.53 16.28 93.98 11.45 16.21 94.40 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 1.80 21.25 100.04 2.61 21.42 100.18 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1a0j_c15 TRYPSIN user 8 3 # 8 D 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s D 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 D 193 GLY D 57 GLY^? 9.79 C2 CIT D 103 coo 8.19 15.01 95.72 7.78 16.53 97.01 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 13.53 16.28 93.98 11.45 16.21 94.40 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 1.80 21.25 100.04 2.61 21.42 100.18 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 ULMN 3 1a0j_c15 TRYPSIN user 9 3 # 9 D 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s D 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 D 193 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 8.19 15.01 95.72 7.78 16.53 97.01 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 13.53 16.28 93.98 11.45 16.21 94.40 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 1.80 21.25 100.04 2.61 21.42 100.18 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1a0j_c15 TRYPSIN user 10 3 # 10 D 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 D 193 GLY E 57 GLY^? 9.68 O2 EDO E 103 coo 8.19 15.01 95.72 7.78 16.53 97.01 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 13.53 16.28 93.98 11.45 16.21 94.40 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 1.80 21.25 100.04 2.61 21.42 100.18 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 ULMN 3 1a0j_c15 TRYPSIN user 11 3 # 11 D 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 D 193 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 8.19 15.01 95.72 7.78 16.53 97.01 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 13.53 16.28 93.98 11.45 16.21 94.40 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 1.80 21.25 100.04 2.61 21.42 100.18 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1a0j_c15 TRYPSIN user 12 3 # 12 D 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s D 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 D 193 GLY F 57 GLY^? 10.08 O2 CIT F 104 coo 8.19 15.01 95.72 7.78 16.53 97.01 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 13.53 16.28 93.98 11.45 16.21 94.40 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 1.80 21.25 100.04 2.61 21.42 100.18 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 ULMN 3 1a0j_c15 TRYPSIN user 13 3 # 13 D 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s D 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 D 193 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 8.19 15.01 95.72 7.78 16.53 97.01 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 13.53 16.28 93.98 11.45 16.21 94.40 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 1.80 21.25 100.04 2.61 21.42 100.18 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1a0j_c15 source 1a0j TRYPSIN : 13 hits 1a0j_c15 naa= 3 ULMN 3 1a41_c01 TOPOISOMERASE I user 1 3 # 1 223 ARG A 79 ARG~? -3.92 C2 EDO E 103s 265 HIS A 74 HIS~? 11.00 C1 EDO E 103 274 TYR E 71 TYR~? -4.78 O2 CIT E 104s coo -15.18 55.46 8.55 -14.82 52.98 10.38 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo -14.48 45.59 11.18 -14.02 47.49 10.42 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 0.94 52.26 9.16 1.95 54.78 9.91 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 ULMN 3 1a41_c01 TOPOISOMERASE I user 2 3 # 2 223 ARG E 79 ARG~? -3.12 O5 CIT C 104s 265 HIS E 77 HIS~? -4.13 O1 CIT E 104s 274 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo -15.18 55.46 8.55 -14.82 52.98 10.38 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo -14.48 45.59 11.18 -14.02 47.49 10.42 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 0.94 52.26 9.16 1.95 54.78 9.91 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 1a41_c01 source 1a41 TOPOISOMERASE I : 2 hits 1a41_c01 naa= 3 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 1 3 # 1 B 13 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 40 LYS A 65 LYS~? 12.23 O2 EDO A 103 B 114 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 2 3 # 2 B 13 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 40 LYS B 50 LYS.? 6.61 O1 EDO A 103 B 114 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 3 3 # 3 B 13 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 40 LYS A 50 LYS.? -4.54 O3 CIT B 103s B 114 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 4 3 # 4 B 13 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 40 LYS B 65 LYS~? 11.82 O5 CIT B 103 B 114 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 5 3 # 5 B 13 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 40 LYS C 65 LYS~? 12.16 O6 CIT C 104 B 114 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 6 3 # 6 B 13 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 40 LYS D 50 LYS.? -4.40 O3 CIT C 104s B 114 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 7 3 # 7 B 13 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 40 LYS C 50 LYS.? -4.07 O4 CIT D 103s B 114 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 8 3 # 8 B 13 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 40 LYS D 65 LYS~? 11.29 O6 CIT D 103 B 114 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 9 3 # 9 B 13 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 40 LYS E 65 LYS~? 11.89 O6 CIT E 104 B 114 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 10 3 # 10 B 13 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 40 LYS F 50 LYS.? -3.77 O3 CIT E 104s B 114 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 11 3 # 11 B 13 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 40 LYS E 50 LYS.? -4.05 O4 CIT F 104s B 114 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 1a4y_c00 RIBONUCLEASE INHIBITOR user 12 3 # 12 B 13 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 40 LYS F 65 LYS~? 10.97 O7 CIT F 104 B 114 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 1.80 -13.66 41.28 2.01 -11.61 41.71 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 8.72 -5.06 38.24 5.16 -8.30 41.14 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo -3.17 -9.07 46.16 -1.65 -8.08 47.22 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 1a4y_c00 source 1a4y RIBONUCLEASE INHIBITOR : 12 hits 1a4y_c00 naa= 3 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 1 3 # 1 E 13 HIS A 4 HIS.? -4.40 O2 EDO A 103s E 40 LYS A 65 LYS~? 12.23 O2 EDO A 103 E 114 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 2 3 # 2 E 13 HIS A 4 HIS.? -4.40 O2 EDO A 103s E 40 LYS B 50 LYS.? 6.61 O1 EDO A 103 E 114 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 3 3 # 3 E 13 HIS B 4 HIS.? -4.11 O2 CIT B 103s E 40 LYS A 50 LYS.? -4.54 O3 CIT B 103s E 114 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 4 3 # 4 E 13 HIS B 4 HIS.? -4.11 O2 CIT B 103s E 40 LYS B 65 LYS~? 11.82 O5 CIT B 103 E 114 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 5 3 # 5 E 13 HIS C 4 HIS.? -4.06 O2 CIT C 104s E 40 LYS C 65 LYS~? 12.16 O6 CIT C 104 E 114 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 6 3 # 6 E 13 HIS C 4 HIS.? -4.06 O2 CIT C 104s E 40 LYS D 50 LYS.? -4.40 O3 CIT C 104s E 114 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 7 3 # 7 E 13 HIS D 4 HIS.? -4.16 O2 CIT D 103s E 40 LYS C 50 LYS.? -4.07 O4 CIT D 103s E 114 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 8 3 # 8 E 13 HIS D 4 HIS.? -4.16 O2 CIT D 103s E 40 LYS D 65 LYS~? 11.29 O6 CIT D 103 E 114 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 9 3 # 9 E 13 HIS E 4 HIS.? -4.01 O2 CIT E 104s E 40 LYS E 65 LYS~? 11.89 O6 CIT E 104 E 114 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 10 3 # 10 E 13 HIS E 4 HIS.? -4.01 O2 CIT E 104s E 40 LYS F 50 LYS.? -3.77 O3 CIT E 104s E 114 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 11 3 # 11 E 13 HIS F 4 HIS.? -4.07 O2 CIT F 104s E 40 LYS E 50 LYS.? -4.05 O4 CIT F 104s E 114 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 1a4y_c01 RIBONUCLEASE INHIBITOR user 12 3 # 12 E 13 HIS F 4 HIS.? -4.07 O2 CIT F 104s E 40 LYS F 65 LYS~? 10.97 O7 CIT F 104 E 114 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 22.66 18.80 -11.81 23.81 19.26 -10.13 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 21.57 20.13 -0.45 23.62 20.29 -5.74 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 30.88 19.38 -11.95 31.04 21.06 -10.71 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 1a4y_c01 source 1a4y RIBONUCLEASE INHIBITOR : 12 hits 1a4y_c01 naa= 3 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 1 3 # 1 A 49 GLU A 38 GLU^? 15.90 O2 EDO A 103 A 60 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 175 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 56.42 28.06 12.93 55.01 27.92 14.50 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 45.02 22.04 15.38 46.16 24.00 13.76 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 2 3 # 2 A 49 GLU A 52 GLU.? 13.60 O6 CIT B 103 A 60 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 175 TYR A 54 TYR.? 12.54 C1 EDO A 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 2.10 -81.17 -22.98 1.38 -79.30 -23.85 coo 56.42 28.06 12.93 55.01 27.92 14.50 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 45.02 22.04 15.38 46.16 24.00 13.76 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 3 3 # 3 A 49 GLU A 101 GLU^? 18.10 O2 EDO A 103 A 60 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 175 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 56.42 28.06 12.93 55.01 27.92 14.50 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 45.02 22.04 15.38 46.16 24.00 13.76 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 4 3 # 4 A 49 GLU B 52 GLU.? 15.03 O1 EDO A 103 A 60 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 175 TYR B 54 TYR.? 11.82 O7 CIT B 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -10.99 -99.25 -18.20 -12.86 -99.70 -17.22 coo 56.42 28.06 12.93 55.01 27.92 14.50 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 45.02 22.04 15.38 46.16 24.00 13.76 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 5 3 # 5 A 49 GLU B 101 GLU^? 17.79 O2 CIT B 103 A 60 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 175 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 56.42 28.06 12.93 55.01 27.92 14.50 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 45.02 22.04 15.38 46.16 24.00 13.76 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 6 3 # 6 A 49 GLU C 52 GLU.? 13.74 O6 CIT D 103 A 60 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 175 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 46.10 28.27 19.27 45.48 26.99 20.84 -34.68 -51.65 -19.33 -36.18 -50.53 -20.46 coo 56.42 28.06 12.93 55.01 27.92 14.50 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 45.02 22.04 15.38 46.16 24.00 13.76 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 7 3 # 7 A 49 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 60 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 175 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo 46.10 28.27 19.27 45.48 26.99 20.84 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 56.42 28.06 12.93 55.01 27.92 14.50 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 45.02 22.04 15.38 46.16 24.00 13.76 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 8 3 # 8 A 49 GLU D 52 GLU.? 13.73 O3 CIT C 104 A 60 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 175 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -38.82 -73.24 -13.34 -40.85 -73.92 -12.86 coo 56.42 28.06 12.93 55.01 27.92 14.50 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 45.02 22.04 15.38 46.16 24.00 13.76 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 9 3 # 9 A 49 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 60 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 175 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 56.42 28.06 12.93 55.01 27.92 14.50 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 45.02 22.04 15.38 46.16 24.00 13.76 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 10 3 # 10 A 49 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 60 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 175 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 56.42 28.06 12.93 55.01 27.92 14.50 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 45.02 22.04 15.38 46.16 24.00 13.76 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 11 3 # 11 A 49 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 60 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 175 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 56.42 28.06 12.93 55.01 27.92 14.50 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 45.02 22.04 15.38 46.16 24.00 13.76 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 12 3 # 12 A 49 GLU F 38 GLU^? 13.95 O2 EDO E 103 A 60 ASP F 27 ASP~? 14.00 O1 CIT F 104 A 175 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 56.42 28.06 12.93 55.01 27.92 14.50 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 45.02 22.04 15.38 46.16 24.00 13.76 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 13 3 # 13 A 49 GLU F 52 GLU.? -7.60 O2 EDO F 103s A 60 ASP E 93 ASP~? 8.62 O3 CIT E 104 A 175 TYR F 54 TYR.? 5.10 C2 EDO F 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -40.44 -68.98 -60.10 -41.76 -70.64 -60.63 coo 56.42 28.06 12.93 55.01 27.92 14.50 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 45.02 22.04 15.38 46.16 24.00 13.76 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 14 3 # 14 A 49 GLU F 52 GLU.? -7.60 O2 EDO F 103s A 60 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 175 TYR F 54 TYR.? 5.10 C2 EDO F 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -40.44 -68.98 -60.10 -41.76 -70.64 -60.63 coo 56.42 28.06 12.93 55.01 27.92 14.50 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 45.02 22.04 15.38 46.16 24.00 13.76 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 15 3 # 15 A 49 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 60 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 175 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 46.10 28.27 19.27 45.48 26.99 20.84 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 56.42 28.06 12.93 55.01 27.92 14.50 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 45.02 22.04 15.38 46.16 24.00 13.76 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 1a50_c03 source 1a50 TRYPTOPHAN SYNTHASE : 15 hits 1a50_c03 naa= 3 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 1 3 # 1 A 115 TYR A 3 TYR.? 14.44 O2 EDO A 103 A 125 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 156 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 2 3 # 2 A 115 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 125 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 156 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 3 3 # 3 A 115 TYR B 3 TYR.? 14.53 O2 CIT B 103 A 125 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 156 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 4 3 # 4 A 115 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 125 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 156 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 5 3 # 5 A 115 TYR C 3 TYR.? 14.43 O1 CIT C 104 A 125 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 156 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 6 3 # 6 A 115 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 125 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 156 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 7 3 # 7 A 115 TYR D 3 TYR.? 14.21 O2 CIT D 103 A 125 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 156 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 8 3 # 8 A 115 TYR D 71 TYR~? -4.87 O2 CIT D 103s A 125 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 156 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 9 3 # 9 A 115 TYR E 3 TYR.? 13.85 O2 EDO E 103 A 125 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 156 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 10 3 # 10 A 115 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 125 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 156 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 11 3 # 11 A 115 TYR F 3 TYR.? 7.56 O2 EDO E 103 A 125 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 156 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 ULMN 3 1a79_c00 TRNA ENDONUCLEASE user 12 3 # 12 A 115 TYR F 71 TYR~? -4.99 O2 CIT F 104s A 125 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 156 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 37.11 -19.03 58.81 39.12 -18.07 60.48 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 44.53 -22.25 60.75 45.90 -22.66 62.28 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 46.42 -20.06 51.80 44.79 -19.05 56.86 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1a79_c00 source 1a79 TRNA ENDONUCLEASE : 12 hits 1a79_c00 naa= 3 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 1 3 # 1 B 115 TYR A 3 TYR.? 14.44 O2 EDO A 103 B 125 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 156 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 2 3 # 2 B 115 TYR A 71 TYR~? -4.90 O2 EDO A 103s B 125 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 156 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 3 3 # 3 B 115 TYR B 3 TYR.? 14.53 O2 CIT B 103 B 125 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 156 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 4 3 # 4 B 115 TYR B 71 TYR~? -4.80 O1 CIT B 103s B 125 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 156 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 5 3 # 5 B 115 TYR C 3 TYR.? 14.43 O1 CIT C 104 B 125 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 156 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 6 3 # 6 B 115 TYR C 71 TYR~? -4.77 O1 CIT C 104s B 125 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 156 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 7 3 # 7 B 115 TYR D 3 TYR.? 14.21 O2 CIT D 103 B 125 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 156 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 8 3 # 8 B 115 TYR D 71 TYR~? -4.87 O2 CIT D 103s B 125 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 156 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 9 3 # 9 B 115 TYR E 3 TYR.? 13.85 O2 EDO E 103 B 125 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 156 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 10 3 # 10 B 115 TYR E 71 TYR~? -4.78 O2 CIT E 104s B 125 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 156 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 11 3 # 11 B 115 TYR F 3 TYR.? 7.56 O2 EDO E 103 B 125 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 156 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 ULMN 3 1a79_c01 TRNA ENDONUCLEASE user 12 3 # 12 B 115 TYR F 71 TYR~? -4.99 O2 CIT F 104s B 125 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 156 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 52.78 -23.08 19.46 51.79 -21.72 17.22 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 45.10 -24.12 17.42 43.96 -24.36 15.67 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 43.97 -19.59 26.02 45.10 -20.27 21.16 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1a79_c01 source 1a79 TRNA ENDONUCLEASE : 12 hits 1a79_c01 naa= 3 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 1 3 # 1 C 115 TYR A 3 TYR.? 14.44 O2 EDO A 103 C 125 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 156 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 2 3 # 2 C 115 TYR A 71 TYR~? -4.90 O2 EDO A 103s C 125 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 156 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 3 3 # 3 C 115 TYR B 3 TYR.? 14.53 O2 CIT B 103 C 125 HIS B 4 HIS.? -4.11 O2 CIT B 103s C 156 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 4 3 # 4 C 115 TYR B 71 TYR~? -4.80 O1 CIT B 103s C 125 HIS B 4 HIS.? -4.11 O2 CIT B 103s C 156 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 5 3 # 5 C 115 TYR C 3 TYR.? 14.43 O1 CIT C 104 C 125 HIS C 4 HIS.? -4.06 O2 CIT C 104s C 156 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 6 3 # 6 C 115 TYR C 71 TYR~? -4.77 O1 CIT C 104s C 125 HIS C 4 HIS.? -4.06 O2 CIT C 104s C 156 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 7 3 # 7 C 115 TYR D 3 TYR.? 14.21 O2 CIT D 103 C 125 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 156 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 8 3 # 8 C 115 TYR D 71 TYR~? -4.87 O2 CIT D 103s C 125 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 156 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 9 3 # 9 C 115 TYR E 3 TYR.? 13.85 O2 EDO E 103 C 125 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 156 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 10 3 # 10 C 115 TYR E 71 TYR~? -4.78 O2 CIT E 104s C 125 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 156 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 11 3 # 11 C 115 TYR F 3 TYR.? 7.56 O2 EDO E 103 C 125 HIS F 4 HIS.? -4.07 O2 CIT F 104s C 156 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 ULMN 3 1a79_c02 TRNA ENDONUCLEASE user 12 3 # 12 C 115 TYR F 71 TYR~? -4.99 O2 CIT F 104s C 125 HIS F 4 HIS.? -4.07 O2 CIT F 104s C 156 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 72.53 -8.86 48.33 70.89 -10.65 46.92 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 69.12 -16.18 50.82 68.25 -17.99 50.22 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 64.47 -11.13 56.60 66.23 -12.62 51.81 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1a79_c02 source 1a79 TRNA ENDONUCLEASE : 12 hits 1a79_c02 naa= 3 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 1 3 # 1 D 115 TYR A 3 TYR.? 14.44 O2 EDO A 103 D 125 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 156 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 54.10 1.42 85.16 54.14 4.17 85.62 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 61.27 5.43 85.32 62.73 6.38 86.49 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 60.28 4.62 76.00 58.35 6.41 80.65 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 2 3 # 2 D 115 TYR A 71 TYR~? -4.90 O2 EDO A 103s D 125 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 156 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 54.10 1.42 85.16 54.14 4.17 85.62 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 61.27 5.43 85.32 62.73 6.38 86.49 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 60.28 4.62 76.00 58.35 6.41 80.65 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 3 3 # 3 D 115 TYR B 3 TYR.? 14.53 O2 CIT B 103 D 125 HIS B 4 HIS.? -4.11 O2 CIT B 103s D 156 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 54.10 1.42 85.16 54.14 4.17 85.62 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 61.27 5.43 85.32 62.73 6.38 86.49 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 60.28 4.62 76.00 58.35 6.41 80.65 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 4 3 # 4 D 115 TYR B 71 TYR~? -4.80 O1 CIT B 103s D 125 HIS B 4 HIS.? -4.11 O2 CIT B 103s D 156 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 54.10 1.42 85.16 54.14 4.17 85.62 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 61.27 5.43 85.32 62.73 6.38 86.49 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 60.28 4.62 76.00 58.35 6.41 80.65 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 5 3 # 5 D 115 TYR C 3 TYR.? 14.43 O1 CIT C 104 D 125 HIS C 4 HIS.? -4.06 O2 CIT C 104s D 156 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 54.10 1.42 85.16 54.14 4.17 85.62 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 coo 61.27 5.43 85.32 62.73 6.38 86.49 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 60.28 4.62 76.00 58.35 6.41 80.65 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 6 3 # 6 D 115 TYR C 71 TYR~? -4.77 O1 CIT C 104s D 125 HIS C 4 HIS.? -4.06 O2 CIT C 104s D 156 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 54.10 1.42 85.16 54.14 4.17 85.62 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 61.27 5.43 85.32 62.73 6.38 86.49 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 60.28 4.62 76.00 58.35 6.41 80.65 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 7 3 # 7 D 115 TYR D 3 TYR.? 14.21 O2 CIT D 103 D 125 HIS D 4 HIS.? -4.16 O2 CIT D 103s D 156 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 54.10 1.42 85.16 54.14 4.17 85.62 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 61.27 5.43 85.32 62.73 6.38 86.49 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 60.28 4.62 76.00 58.35 6.41 80.65 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 8 3 # 8 D 115 TYR D 71 TYR~? -4.87 O2 CIT D 103s D 125 HIS D 4 HIS.? -4.16 O2 CIT D 103s D 156 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 54.10 1.42 85.16 54.14 4.17 85.62 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 61.27 5.43 85.32 62.73 6.38 86.49 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 60.28 4.62 76.00 58.35 6.41 80.65 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 9 3 # 9 D 115 TYR E 3 TYR.? 13.85 O2 EDO E 103 D 125 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 156 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 54.10 1.42 85.16 54.14 4.17 85.62 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 61.27 5.43 85.32 62.73 6.38 86.49 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 60.28 4.62 76.00 58.35 6.41 80.65 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 10 3 # 10 D 115 TYR E 71 TYR~? -4.78 O2 CIT E 104s D 125 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 156 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 54.10 1.42 85.16 54.14 4.17 85.62 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 61.27 5.43 85.32 62.73 6.38 86.49 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 60.28 4.62 76.00 58.35 6.41 80.65 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 11 3 # 11 D 115 TYR F 3 TYR.? 7.56 O2 EDO E 103 D 125 HIS F 4 HIS.? -4.07 O2 CIT F 104s D 156 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 54.10 1.42 85.16 54.14 4.17 85.62 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 coo 61.27 5.43 85.32 62.73 6.38 86.49 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 60.28 4.62 76.00 58.35 6.41 80.65 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 ULMN 3 1a79_c03 TRNA ENDONUCLEASE user 12 3 # 12 D 115 TYR F 71 TYR~? -4.99 O2 CIT F 104s D 125 HIS F 4 HIS.? -4.07 O2 CIT F 104s D 156 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 54.10 1.42 85.16 54.14 4.17 85.62 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 61.27 5.43 85.32 62.73 6.38 86.49 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 60.28 4.62 76.00 58.35 6.41 80.65 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1a79_c03 source 1a79 TRNA ENDONUCLEASE : 12 hits 1a79_c03 naa= 3 ULMN 3 1a8h_c02 METHIONYL-TRNA SYNTHETASE user 1 3 # 1 16 ALA B 70 ALA~? 12.64 O1 CIT B 103 19 HIS B 74 HIS~? 11.72 O1 CIT B 103 22 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 53.27 36.51 45.29 51.98 36.45 44.47 -5.62 -67.50 -7.22 -6.87 -66.61 -7.10 coo 46.88 33.59 48.26 46.24 34.32 46.40 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 48.05 31.12 44.60 48.20 33.05 43.77 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1a8h_c02 METHIONYL-TRNA SYNTHETASE user 2 3 # 2 16 ALA B 70 ALA~? 12.64 O1 CIT B 103 19 HIS B 77 HIS~? -4.07 O1 CIT B 103s 22 HIS B 74 HIS~? 11.72 O1 CIT B 103 coo 53.27 36.51 45.29 51.98 36.45 44.47 -5.62 -67.50 -7.22 -6.87 -66.61 -7.10 coo 46.88 33.59 48.26 46.24 34.32 46.40 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 48.05 31.12 44.60 48.20 33.05 43.77 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 ULMN 3 1a8h_c02 METHIONYL-TRNA SYNTHETASE user 3 3 # 3 16 ALA C 70 ALA~? 12.51 O1 CIT C 104 19 HIS C 74 HIS~? 12.10 O1 CIT C 104 22 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 53.27 36.51 45.29 51.98 36.45 44.47 -53.57 -78.01 -28.80 -55.09 -77.85 -28.87 coo 46.88 33.59 48.26 46.24 34.32 46.40 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 48.05 31.12 44.60 48.20 33.05 43.77 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1a8h_c02 METHIONYL-TRNA SYNTHETASE user 4 3 # 4 16 ALA C 70 ALA~? 12.51 O1 CIT C 104 19 HIS C 77 HIS~? -4.31 O1 CIT C 104s 22 HIS C 74 HIS~? 12.10 O1 CIT C 104 coo 53.27 36.51 45.29 51.98 36.45 44.47 -53.57 -78.01 -28.80 -55.09 -77.85 -28.87 coo 46.88 33.59 48.26 46.24 34.32 46.40 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 48.05 31.12 44.60 48.20 33.05 43.77 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 ULMN 3 1a8h_c02 METHIONYL-TRNA SYNTHETASE user 5 3 # 5 16 ALA E 70 ALA~? 12.37 O2 CIT E 104 19 HIS E 74 HIS~? 12.16 O1 CIT E 104 22 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 53.27 36.51 45.29 51.98 36.45 44.47 -45.75 -85.11 -45.81 -45.60 -86.59 -45.87 coo 46.88 33.59 48.26 46.24 34.32 46.40 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 48.05 31.12 44.60 48.20 33.05 43.77 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1a8h_c02 METHIONYL-TRNA SYNTHETASE user 6 3 # 6 16 ALA E 70 ALA~? 12.37 O2 CIT E 104 19 HIS E 77 HIS~? -4.13 O1 CIT E 104s 22 HIS E 74 HIS~? 12.16 O1 CIT E 104 coo 53.27 36.51 45.29 51.98 36.45 44.47 -45.75 -85.11 -45.81 -45.60 -86.59 -45.87 coo 46.88 33.59 48.26 46.24 34.32 46.40 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 48.05 31.12 44.60 48.20 33.05 43.77 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 ULMN 3 1a8h_c02 METHIONYL-TRNA SYNTHETASE user 7 3 # 7 16 ALA F 70 ALA~? 12.64 O2 CIT F 104 19 HIS F 74 HIS~? 11.52 O1 CIT F 104 22 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 53.27 36.51 45.29 51.98 36.45 44.47 -10.34 -85.12 -62.01 -10.33 -86.57 -61.57 coo 46.88 33.59 48.26 46.24 34.32 46.40 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 48.05 31.12 44.60 48.20 33.05 43.77 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 1a8h_c02 METHIONYL-TRNA SYNTHETASE user 8 3 # 8 16 ALA F 70 ALA~? 12.64 O2 CIT F 104 19 HIS F 77 HIS~? -3.59 O1 CIT F 104s 22 HIS F 74 HIS~? 11.52 O1 CIT F 104 coo 53.27 36.51 45.29 51.98 36.45 44.47 -10.34 -85.12 -62.01 -10.33 -86.57 -61.57 coo 46.88 33.59 48.26 46.24 34.32 46.40 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 48.05 31.12 44.60 48.20 33.05 43.77 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 1a8h_c02 source 1a8h METHIONYL-TRNA SYNTHETASE : 8 hits 1a8h_c02 naa= 3 ULMN 3 1ab4_c00 GYRASE A user 1 3 # 1 32 ARG A 79 ARG~? -3.92 C2 EDO E 103s 78 HIS E 41 HIS^? -3.94 C2 EDO E 103s 122 TYR F 54 TYR.? 5.10 C2 EDO F 103 coo 48.32 72.26 30.89 48.69 69.28 31.53 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 53.63 68.24 34.99 53.08 69.10 33.16 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 75.01 61.87 32.93 75.34 59.26 31.96 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 ULMN 3 1ab4_c00 GYRASE A user 2 3 # 2 32 ARG C 79 ARG~? -3.25 O5 CIT E 104s 78 HIS E 77 HIS~? -4.13 O1 CIT E 104s 122 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo 48.32 72.26 30.89 48.69 69.28 31.53 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo 53.63 68.24 34.99 53.08 69.10 33.16 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 75.01 61.87 32.93 75.34 59.26 31.96 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 1ab4_c00 source 1ab4 GYRASE A : 2 hits 1ab4_c00 naa= 3 ULMN 3 1aj8_c00 CITRATE SYNTHASE user 1 3 # 1 A 223 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 262 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 312 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 29.33 36.13 69.70 30.07 34.20 70.11 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 38.54 36.60 66.38 37.88 34.77 67.15 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 30.62 37.23 61.07 30.08 35.73 62.49 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1aj8_c00 CITRATE SYNTHASE user 2 3 # 2 A 223 HIS B 77 HIS~? -4.07 O1 CIT B 103s A 262 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 312 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 29.33 36.13 69.70 30.07 34.20 70.11 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 38.54 36.60 66.38 37.88 34.77 67.15 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 30.62 37.23 61.07 30.08 35.73 62.49 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1aj8_c00 CITRATE SYNTHASE user 3 3 # 3 A 223 HIS C 77 HIS~? -4.31 O1 CIT C 104s A 262 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 312 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 29.33 36.13 69.70 30.07 34.20 70.11 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 38.54 36.60 66.38 37.88 34.77 67.15 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 30.62 37.23 61.07 30.08 35.73 62.49 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1aj8_c00 CITRATE SYNTHASE user 4 3 # 4 A 223 HIS D 77 HIS~? -3.79 O1 CIT D 103s A 262 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 312 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 29.33 36.13 69.70 30.07 34.20 70.11 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 38.54 36.60 66.38 37.88 34.77 67.15 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 30.62 37.23 61.07 30.08 35.73 62.49 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1aj8_c00 CITRATE SYNTHASE user 5 3 # 5 A 223 HIS E 77 HIS~? -4.13 O1 CIT E 104s A 262 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 312 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 29.33 36.13 69.70 30.07 34.20 70.11 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 38.54 36.60 66.38 37.88 34.77 67.15 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 30.62 37.23 61.07 30.08 35.73 62.49 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1aj8_c00 CITRATE SYNTHASE user 6 3 # 6 A 223 HIS F 77 HIS~? -3.59 O1 CIT F 104s A 262 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 312 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 29.33 36.13 69.70 30.07 34.20 70.11 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 38.54 36.60 66.38 37.88 34.77 67.15 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 30.62 37.23 61.07 30.08 35.73 62.49 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 1aj8_c00 source 1aj8 CITRATE SYNTHASE : 6 hits 1aj8_c00 naa= 3 ULMN 3 1aj8_c01 CITRATE SYNTHASE user 1 3 # 1 B 223 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 262 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 312 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 23.86 29.50 91.20 24.12 31.58 91.00 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 29.35 31.42 99.15 28.72 33.09 98.04 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 20.42 28.25 99.26 20.25 29.62 97.63 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1aj8_c01 CITRATE SYNTHASE user 2 3 # 2 B 223 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 262 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 312 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 23.86 29.50 91.20 24.12 31.58 91.00 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 29.35 31.42 99.15 28.72 33.09 98.04 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 20.42 28.25 99.26 20.25 29.62 97.63 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1aj8_c01 CITRATE SYNTHASE user 3 3 # 3 B 223 HIS B 77 HIS~? -4.07 O1 CIT B 103s B 262 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 312 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 23.86 29.50 91.20 24.12 31.58 91.00 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 29.35 31.42 99.15 28.72 33.09 98.04 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 20.42 28.25 99.26 20.25 29.62 97.63 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1aj8_c01 CITRATE SYNTHASE user 4 3 # 4 B 223 HIS C 77 HIS~? -4.31 O1 CIT C 104s B 262 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 312 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 23.86 29.50 91.20 24.12 31.58 91.00 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 29.35 31.42 99.15 28.72 33.09 98.04 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 20.42 28.25 99.26 20.25 29.62 97.63 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1aj8_c01 CITRATE SYNTHASE user 5 3 # 5 B 223 HIS D 77 HIS~? -3.79 O1 CIT D 103s B 262 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 312 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 23.86 29.50 91.20 24.12 31.58 91.00 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 29.35 31.42 99.15 28.72 33.09 98.04 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 20.42 28.25 99.26 20.25 29.62 97.63 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1aj8_c01 CITRATE SYNTHASE user 6 3 # 6 B 223 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 262 HIS E 77 HIS~? -4.13 O1 CIT E 104s B 312 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 23.86 29.50 91.20 24.12 31.58 91.00 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 29.35 31.42 99.15 28.72 33.09 98.04 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 20.42 28.25 99.26 20.25 29.62 97.63 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1aj8_c01 CITRATE SYNTHASE user 7 3 # 7 B 223 HIS E 77 HIS~? -4.13 O1 CIT E 104s B 262 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 312 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 23.86 29.50 91.20 24.12 31.58 91.00 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 29.35 31.42 99.15 28.72 33.09 98.04 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 20.42 28.25 99.26 20.25 29.62 97.63 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1aj8_c01 CITRATE SYNTHASE user 8 3 # 8 B 223 HIS F 77 HIS~? -3.59 O1 CIT F 104s B 262 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 312 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 23.86 29.50 91.20 24.12 31.58 91.00 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 29.35 31.42 99.15 28.72 33.09 98.04 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 20.42 28.25 99.26 20.25 29.62 97.63 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 1aj8_c01 source 1aj8 CITRATE SYNTHASE : 8 hits 1aj8_c01 naa= 3 ULMN 3 1al6_c00 CITRATE SYNTHASE user 1 3 # 1 274 HIS A 4 HIS.? -4.40 O2 EDO A 103s 320 HIS A 77 HIS~? -4.41 C2 EDO A 103s 375 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1al6_c00 CITRATE SYNTHASE user 2 3 # 2 274 HIS A 77 HIS~? -4.41 C2 EDO A 103s 320 HIS A 4 HIS.? -4.40 O2 EDO A 103s 375 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1al6_c00 CITRATE SYNTHASE user 3 3 # 3 274 HIS B 4 HIS.? -4.11 O2 CIT B 103s 320 HIS B 77 HIS~? -4.07 O1 CIT B 103s 375 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1al6_c00 CITRATE SYNTHASE user 4 3 # 4 274 HIS B 77 HIS~? -4.07 O1 CIT B 103s 320 HIS B 4 HIS.? -4.11 O2 CIT B 103s 375 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1al6_c00 CITRATE SYNTHASE user 5 3 # 5 274 HIS C 4 HIS.? -4.06 O2 CIT C 104s 320 HIS C 77 HIS~? -4.31 O1 CIT C 104s 375 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1al6_c00 CITRATE SYNTHASE user 6 3 # 6 274 HIS C 77 HIS~? -4.31 O1 CIT C 104s 320 HIS C 4 HIS.? -4.06 O2 CIT C 104s 375 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1al6_c00 CITRATE SYNTHASE user 7 3 # 7 274 HIS D 4 HIS.? -4.16 O2 CIT D 103s 320 HIS D 77 HIS~? -3.79 O1 CIT D 103s 375 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1al6_c00 CITRATE SYNTHASE user 8 3 # 8 274 HIS D 77 HIS~? -3.79 O1 CIT D 103s 320 HIS D 4 HIS.? -4.16 O2 CIT D 103s 375 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1al6_c00 CITRATE SYNTHASE user 9 3 # 9 274 HIS E 4 HIS.? -4.01 O2 CIT E 104s 320 HIS E 77 HIS~? -4.13 O1 CIT E 104s 375 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1al6_c00 CITRATE SYNTHASE user 10 3 # 10 274 HIS E 77 HIS~? -4.13 O1 CIT E 104s 320 HIS E 4 HIS.? -4.01 O2 CIT E 104s 375 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1al6_c00 CITRATE SYNTHASE user 11 3 # 11 274 HIS F 4 HIS.? -4.07 O2 CIT F 104s 320 HIS F 77 HIS~? -3.59 O1 CIT F 104s 375 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 ULMN 3 1al6_c00 CITRATE SYNTHASE user 12 3 # 12 274 HIS F 77 HIS~? -3.59 O1 CIT F 104s 320 HIS F 4 HIS.? -4.07 O2 CIT F 104s 375 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 11.08 -2.90 2.00 11.09 -3.48 -0.01 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 17.22 -10.90 1.81 16.10 -10.23 0.18 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 20.14 -1.52 3.09 18.48 -1.53 1.77 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 1al6_c00 source 1al6 CITRATE SYNTHASE : 12 hits 1al6_c00 naa= 3 ULMN 3 1am5_c04 PEPSIN user 1 3 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -7.18 8.92 145.10 -8.77 8.81 143.59 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -12.30 10.35 145.24 -10.75 8.55 145.88 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo -8.20 12.64 138.30 -8.86 10.97 139.38 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 1am5_c04 source 1am5 PEPSIN : 1 hits 1am5_c04 naa= 3 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 1 3 # 1 179 ASP A 64 ASP~? 16.37 O2 EDO A 103 214 ASP B 93 ASP~? 9.77 O3 CIT B 103 289 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 26.86 59.76 46.36 25.42 58.23 45.92 3.85 -90.04 -12.91 5.79 -89.33 -13.36 coo 9.42 68.07 30.27 7.35 68.27 30.10 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 2 3 # 2 179 ASP A 69 ASP~? 12.13 O2 EDO A 103 214 ASP B 17 ASP~? 19.42 C4 CIT B 103 289 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 26.86 59.76 46.36 25.42 58.23 45.92 -8.70 -93.12 3.11 -9.77 -94.94 3.45 coo 9.42 68.07 30.27 7.35 68.27 30.10 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 3 3 # 3 179 ASP A 69 ASP~? 12.13 O2 EDO A 103 214 ASP B 93 ASP~? 9.77 O3 CIT B 103 289 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 26.86 59.76 46.36 25.42 58.23 45.92 3.85 -90.04 -12.91 5.79 -89.33 -13.36 coo 9.42 68.07 30.27 7.35 68.27 30.10 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 4 3 # 4 179 ASP B 64 ASP~? 16.93 O2 CIT B 103 214 ASP A 93 ASP~? 12.48 O1 EDO A 103 289 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 26.86 59.76 46.36 25.42 58.23 45.92 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo 9.42 68.07 30.27 7.35 68.27 30.10 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 5 3 # 5 179 ASP B 69 ASP~? 11.84 O5 CIT B 103 214 ASP A 93 ASP~? 12.48 O1 EDO A 103 289 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 26.86 59.76 46.36 25.42 58.23 45.92 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo 9.42 68.07 30.27 7.35 68.27 30.10 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 6 3 # 6 179 ASP B 69 ASP~? 11.84 O5 CIT B 103 214 ASP D 93 ASP~? 9.04 O4 CIT D 103 289 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 26.86 59.76 46.36 25.42 58.23 45.92 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 9.42 68.07 30.27 7.35 68.27 30.10 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 7 3 # 7 179 ASP B 69 ASP~? 11.84 O5 CIT B 103 214 ASP E 17 ASP~? 16.97 O4 CIT C 104 289 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 26.86 59.76 46.36 25.42 58.23 45.92 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 9.42 68.07 30.27 7.35 68.27 30.10 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 8 3 # 8 179 ASP B 69 ASP~? 11.84 O5 CIT B 103 214 ASP E 17 ASP~? 16.97 O4 CIT C 104 289 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 26.86 59.76 46.36 25.42 58.23 45.92 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 9.42 68.07 30.27 7.35 68.27 30.10 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 9 3 # 9 179 ASP C 17 ASP~? -3.95 O1 EDO C 103s 214 ASP F 99 ASP^? 6.97 O7 CIT F 104 289 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 26.86 59.76 46.36 25.42 58.23 45.92 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 9.42 68.07 30.27 7.35 68.27 30.10 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 10 3 # 10 179 ASP C 64 ASP~? 16.62 O2 CIT C 104 214 ASP A 64 ASP~? 16.37 O2 EDO A 103 289 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 26.86 59.76 46.36 25.42 58.23 45.92 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 9.42 68.07 30.27 7.35 68.27 30.10 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 11 3 # 11 179 ASP C 64 ASP~? 16.62 O2 CIT C 104 214 ASP A 64 ASP~? 16.37 O2 EDO A 103 289 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 26.86 59.76 46.36 25.42 58.23 45.92 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 9.42 68.07 30.27 7.35 68.27 30.10 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 12 3 # 12 179 ASP C 64 ASP~? 16.62 O2 CIT C 104 214 ASP D 93 ASP~? 9.04 O4 CIT D 103 289 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 26.86 59.76 46.36 25.42 58.23 45.92 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 9.42 68.07 30.27 7.35 68.27 30.10 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 13 3 # 13 179 ASP C 64 ASP~? 16.62 O2 CIT C 104 214 ASP E 69 ASP~? 11.60 O6 CIT E 104 289 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 26.86 59.76 46.36 25.42 58.23 45.92 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 9.42 68.07 30.27 7.35 68.27 30.10 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 14 3 # 14 179 ASP C 69 ASP~? 11.49 O6 CIT C 104 214 ASP D 93 ASP~? 9.04 O4 CIT D 103 289 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 26.86 59.76 46.36 25.42 58.23 45.92 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 9.42 68.07 30.27 7.35 68.27 30.10 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 15 3 # 15 179 ASP C 99 ASP^? 7.14 O2 CIT C 104 214 ASP E 69 ASP~? 11.60 O6 CIT E 104 289 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 26.86 59.76 46.36 25.42 58.23 45.92 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 9.42 68.07 30.27 7.35 68.27 30.10 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 16 3 # 16 179 ASP D 64 ASP~? 16.39 O2 CIT D 103 214 ASP C 93 ASP~? 9.74 O3 CIT C 104 289 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 26.86 59.76 46.36 25.42 58.23 45.92 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 9.42 68.07 30.27 7.35 68.27 30.10 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 17 3 # 17 179 ASP D 69 ASP~? 11.20 O6 CIT D 103 214 ASP C 93 ASP~? 9.74 O3 CIT C 104 289 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 26.86 59.76 46.36 25.42 58.23 45.92 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 9.42 68.07 30.27 7.35 68.27 30.10 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 18 3 # 18 179 ASP E 17 ASP~? 16.97 O4 CIT C 104 214 ASP D 99 ASP^? 6.89 O6 CIT D 103 289 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 26.86 59.76 46.36 25.42 58.23 45.92 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 9.42 68.07 30.27 7.35 68.27 30.10 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 19 3 # 19 179 ASP E 64 ASP~? 16.37 O2 CIT E 104 214 ASP C 27 ASP~? 13.15 O1 CIT C 104 289 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 26.86 59.76 46.36 25.42 58.23 45.92 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 9.42 68.07 30.27 7.35 68.27 30.10 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 20 3 # 20 179 ASP E 64 ASP~? 16.37 O2 CIT E 104 214 ASP C 69 ASP~? 11.49 O6 CIT C 104 289 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 26.86 59.76 46.36 25.42 58.23 45.92 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 9.42 68.07 30.27 7.35 68.27 30.10 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 21 3 # 21 179 ASP E 64 ASP~? 16.37 O2 CIT E 104 214 ASP F 93 ASP~? 9.52 O4 CIT F 104 289 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 26.86 59.76 46.36 25.42 58.23 45.92 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 coo 9.42 68.07 30.27 7.35 68.27 30.10 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 22 3 # 22 179 ASP E 69 ASP~? 11.60 O6 CIT E 104 214 ASP F 17 ASP~? 19.11 O1 CIT F 104 289 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 26.86 59.76 46.36 25.42 58.23 45.92 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 coo 9.42 68.07 30.27 7.35 68.27 30.10 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 23 3 # 23 179 ASP E 69 ASP~? 11.60 O6 CIT E 104 214 ASP F 93 ASP~? 9.52 O4 CIT F 104 289 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 26.86 59.76 46.36 25.42 58.23 45.92 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 coo 9.42 68.07 30.27 7.35 68.27 30.10 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 24 3 # 24 179 ASP E 99 ASP^? 7.65 C2 CIT E 104 214 ASP C 69 ASP~? 11.49 O6 CIT C 104 289 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 26.86 59.76 46.36 25.42 58.23 45.92 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 9.42 68.07 30.27 7.35 68.27 30.10 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 25 3 # 25 179 ASP F 64 ASP~? 16.52 O2 EDO E 103 214 ASP E 93 ASP~? 8.62 O3 CIT E 104 289 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 26.86 59.76 46.36 25.42 58.23 45.92 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 9.42 68.07 30.27 7.35 68.27 30.10 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 26 3 # 26 179 ASP F 69 ASP~? 11.68 O6 CIT F 104 214 ASP A 27 ASP~? 13.11 O2 EDO A 103 289 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 26.86 59.76 46.36 25.42 58.23 45.92 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 9.42 68.07 30.27 7.35 68.27 30.10 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 27 3 # 27 179 ASP F 69 ASP~? 11.68 O6 CIT F 104 214 ASP A 27 ASP~? 13.11 O2 EDO A 103 289 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 26.86 59.76 46.36 25.42 58.23 45.92 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 9.42 68.07 30.27 7.35 68.27 30.10 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 28 3 # 28 179 ASP F 69 ASP~? 11.68 O6 CIT F 104 214 ASP A 93 ASP~? 12.48 O1 EDO A 103 289 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 26.86 59.76 46.36 25.42 58.23 45.92 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo 9.42 68.07 30.27 7.35 68.27 30.10 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 29 3 # 29 179 ASP F 99 ASP^? 6.97 O7 CIT F 104 214 ASP A 93 ASP~? 12.48 O1 EDO A 103 289 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 26.86 59.76 46.36 25.42 58.23 45.92 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo 9.42 68.07 30.27 7.35 68.27 30.10 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1amy_c01 source 1amy ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE (ALPHA-AMY: 29 hits 1amy_c01 naa= 3 ULMN 3 1amy_c05 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 1 3 # 1 179 ASP A 99 ASP^? 8.10 O2 EDO A 103 204 GLU A 101 GLU^? 18.10 O2 EDO A 103 289 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 4.34 62.44 32.05 4.22 64.48 32.53 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 9.42 68.07 30.27 7.35 68.27 30.10 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1amy_c05 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 2 3 # 2 179 ASP B 99 ASP^? 7.47 O6 CIT B 103 204 GLU B 101 GLU^? 17.79 O2 CIT B 103 289 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 4.34 62.44 32.05 4.22 64.48 32.53 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 9.42 68.07 30.27 7.35 68.27 30.10 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1amy_c05 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 3 3 # 3 179 ASP C 99 ASP^? 7.14 O2 CIT C 104 204 GLU C 101 GLU^? 17.42 O2 CIT C 104 289 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 4.34 62.44 32.05 4.22 64.48 32.53 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 9.42 68.07 30.27 7.35 68.27 30.10 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1amy_c05 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 4 3 # 4 179 ASP D 99 ASP^? 6.89 O6 CIT D 103 204 GLU D 101 GLU^? 17.58 O6 CIT D 103 289 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 4.34 62.44 32.05 4.22 64.48 32.53 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 9.42 68.07 30.27 7.35 68.27 30.10 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1amy_c05 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 5 3 # 5 179 ASP E 99 ASP^? 7.65 C2 CIT E 104 204 GLU E 101 GLU^? 17.69 O2 CIT E 104 289 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 4.34 62.44 32.05 4.22 64.48 32.53 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 9.42 68.07 30.27 7.35 68.27 30.10 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1amy_c05 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 6 3 # 6 179 ASP F 99 ASP^? 6.97 O7 CIT F 104 204 GLU F 101 GLU^? 10.35 O2 EDO E 103 289 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 4.34 62.44 32.05 4.22 64.48 32.53 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 9.42 68.07 30.27 7.35 68.27 30.10 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1amy_c05 source 1amy ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE (ALPHA-AMY: 6 hits 1amy_c05 naa= 3 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 1 3 # 1 179 ASP A 64 ASP~? 16.37 O2 EDO A 103 227 GLU A 38 GLU^? 15.90 O2 EDO A 103 289 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 3.96 55.76 41.24 4.83 57.69 41.17 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 9.42 68.07 30.27 7.35 68.27 30.10 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 2 3 # 2 179 ASP A 64 ASP~? 16.37 O2 EDO A 103 227 GLU A 38 GLU^? 15.90 O2 EDO A 103 289 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 3.96 55.76 41.24 4.83 57.69 41.17 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 9.42 68.07 30.27 7.35 68.27 30.10 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 3 3 # 3 179 ASP A 64 ASP~? 16.37 O2 EDO A 103 227 GLU B 38 GLU^? 16.05 O1 CIT B 103 289 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 3.96 55.76 41.24 4.83 57.69 41.17 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 9.42 68.07 30.27 7.35 68.27 30.10 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 4 3 # 4 179 ASP A 69 ASP~? 12.13 O2 EDO A 103 227 GLU A 32 GLU~? 8.29 O4 CIT C 104 289 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 3.96 55.76 41.24 4.83 57.69 41.17 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 9.42 68.07 30.27 7.35 68.27 30.10 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 5 3 # 5 179 ASP A 99 ASP^? 8.10 O2 EDO A 103 227 GLU A 38 GLU^? 15.90 O2 EDO A 103 289 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 3.96 55.76 41.24 4.83 57.69 41.17 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 9.42 68.07 30.27 7.35 68.27 30.10 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 6 3 # 6 179 ASP A 99 ASP^? 8.10 O2 EDO A 103 227 GLU A 38 GLU^? 15.90 O2 EDO A 103 289 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 3.96 55.76 41.24 4.83 57.69 41.17 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 9.42 68.07 30.27 7.35 68.27 30.10 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 7 3 # 7 179 ASP A 99 ASP^? 8.10 O2 EDO A 103 227 GLU B 38 GLU^? 16.05 O1 CIT B 103 289 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 3.96 55.76 41.24 4.83 57.69 41.17 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 9.42 68.07 30.27 7.35 68.27 30.10 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 8 3 # 8 179 ASP B 64 ASP~? 16.93 O2 CIT B 103 227 GLU A 38 GLU^? 15.90 O2 EDO A 103 289 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 3.96 55.76 41.24 4.83 57.69 41.17 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 9.42 68.07 30.27 7.35 68.27 30.10 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 9 3 # 9 179 ASP B 64 ASP~? 16.93 O2 CIT B 103 227 GLU B 38 GLU^? 16.05 O1 CIT B 103 289 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 3.96 55.76 41.24 4.83 57.69 41.17 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 9.42 68.07 30.27 7.35 68.27 30.10 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 10 3 # 10 179 ASP B 64 ASP~? 16.93 O2 CIT B 103 227 GLU B 38 GLU^? 16.05 O1 CIT B 103 289 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 3.96 55.76 41.24 4.83 57.69 41.17 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 9.42 68.07 30.27 7.35 68.27 30.10 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 11 3 # 11 179 ASP B 69 ASP~? 11.84 O5 CIT B 103 227 GLU B 32 GLU~? 16.71 O1 CIT B 103 289 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 3.96 55.76 41.24 4.83 57.69 41.17 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 9.42 68.07 30.27 7.35 68.27 30.10 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 12 3 # 12 179 ASP B 99 ASP^? 7.47 O6 CIT B 103 227 GLU A 38 GLU^? 15.90 O2 EDO A 103 289 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 3.96 55.76 41.24 4.83 57.69 41.17 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 9.42 68.07 30.27 7.35 68.27 30.10 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 13 3 # 13 179 ASP B 99 ASP^? 7.47 O6 CIT B 103 227 GLU B 38 GLU^? 16.05 O1 CIT B 103 289 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 3.96 55.76 41.24 4.83 57.69 41.17 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 9.42 68.07 30.27 7.35 68.27 30.10 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 14 3 # 14 179 ASP B 99 ASP^? 7.47 O6 CIT B 103 227 GLU B 38 GLU^? 16.05 O1 CIT B 103 289 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 3.96 55.76 41.24 4.83 57.69 41.17 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 9.42 68.07 30.27 7.35 68.27 30.10 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 15 3 # 15 179 ASP C 64 ASP~? 16.62 O2 CIT C 104 227 GLU C 38 GLU^? 15.02 O1 CIT C 104 289 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 3.96 55.76 41.24 4.83 57.69 41.17 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 9.42 68.07 30.27 7.35 68.27 30.10 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 16 3 # 16 179 ASP C 64 ASP~? 16.62 O2 CIT C 104 227 GLU C 38 GLU^? 15.02 O1 CIT C 104 289 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 3.96 55.76 41.24 4.83 57.69 41.17 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 9.42 68.07 30.27 7.35 68.27 30.10 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 17 3 # 17 179 ASP C 64 ASP~? 16.62 O2 CIT C 104 227 GLU D 38 GLU^? 15.43 O2 CIT D 103 289 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 3.96 55.76 41.24 4.83 57.69 41.17 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 9.42 68.07 30.27 7.35 68.27 30.10 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 18 3 # 18 179 ASP C 69 ASP~? 11.49 O6 CIT C 104 227 GLU C 32 GLU~? 15.71 O1 CIT C 104 289 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 3.96 55.76 41.24 4.83 57.69 41.17 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 9.42 68.07 30.27 7.35 68.27 30.10 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 19 3 # 19 179 ASP C 99 ASP^? 7.14 O2 CIT C 104 227 GLU C 38 GLU^? 15.02 O1 CIT C 104 289 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 3.96 55.76 41.24 4.83 57.69 41.17 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 9.42 68.07 30.27 7.35 68.27 30.10 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 20 3 # 20 179 ASP C 99 ASP^? 7.14 O2 CIT C 104 227 GLU C 38 GLU^? 15.02 O1 CIT C 104 289 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 3.96 55.76 41.24 4.83 57.69 41.17 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 9.42 68.07 30.27 7.35 68.27 30.10 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 21 3 # 21 179 ASP C 99 ASP^? 7.14 O2 CIT C 104 227 GLU D 38 GLU^? 15.43 O2 CIT D 103 289 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 3.96 55.76 41.24 4.83 57.69 41.17 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 9.42 68.07 30.27 7.35 68.27 30.10 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 22 3 # 22 179 ASP D 64 ASP~? 16.39 O2 CIT D 103 227 GLU C 38 GLU^? 15.02 O1 CIT C 104 289 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 3.96 55.76 41.24 4.83 57.69 41.17 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 9.42 68.07 30.27 7.35 68.27 30.10 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 23 3 # 23 179 ASP D 64 ASP~? 16.39 O2 CIT D 103 227 GLU D 38 GLU^? 15.43 O2 CIT D 103 289 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 3.96 55.76 41.24 4.83 57.69 41.17 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 9.42 68.07 30.27 7.35 68.27 30.10 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 24 3 # 24 179 ASP D 64 ASP~? 16.39 O2 CIT D 103 227 GLU D 38 GLU^? 15.43 O2 CIT D 103 289 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 3.96 55.76 41.24 4.83 57.69 41.17 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 9.42 68.07 30.27 7.35 68.27 30.10 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 25 3 # 25 179 ASP D 69 ASP~? 11.20 O6 CIT D 103 227 GLU D 32 GLU~? 17.83 O1 CIT D 103 289 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 3.96 55.76 41.24 4.83 57.69 41.17 -63.28 -49.45 -6.05 -65.42 -49.45 -6.30 coo 9.42 68.07 30.27 7.35 68.27 30.10 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 26 3 # 26 179 ASP D 99 ASP^? 6.89 O6 CIT D 103 227 GLU C 38 GLU^? 15.02 O1 CIT C 104 289 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 3.96 55.76 41.24 4.83 57.69 41.17 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 9.42 68.07 30.27 7.35 68.27 30.10 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 27 3 # 27 179 ASP D 99 ASP^? 6.89 O6 CIT D 103 227 GLU D 38 GLU^? 15.43 O2 CIT D 103 289 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 3.96 55.76 41.24 4.83 57.69 41.17 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 9.42 68.07 30.27 7.35 68.27 30.10 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 28 3 # 28 179 ASP D 99 ASP^? 6.89 O6 CIT D 103 227 GLU D 38 GLU^? 15.43 O2 CIT D 103 289 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 3.96 55.76 41.24 4.83 57.69 41.17 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 9.42 68.07 30.27 7.35 68.27 30.10 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 29 3 # 29 179 ASP E 64 ASP~? 16.37 O2 CIT E 104 227 GLU E 38 GLU^? 8.47 O1 EDO E 103 289 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 3.96 55.76 41.24 4.83 57.69 41.17 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 9.42 68.07 30.27 7.35 68.27 30.10 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 30 3 # 30 179 ASP E 64 ASP~? 16.37 O2 CIT E 104 227 GLU E 38 GLU^? 8.47 O1 EDO E 103 289 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 3.96 55.76 41.24 4.83 57.69 41.17 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 9.42 68.07 30.27 7.35 68.27 30.10 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 31 3 # 31 179 ASP E 64 ASP~? 16.37 O2 CIT E 104 227 GLU F 38 GLU^? 13.95 O2 EDO E 103 289 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 3.96 55.76 41.24 4.83 57.69 41.17 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 9.42 68.07 30.27 7.35 68.27 30.10 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 32 3 # 32 179 ASP E 69 ASP~? 11.60 O6 CIT E 104 227 GLU E 32 GLU~? 15.49 O1 EDO E 103 289 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 3.96 55.76 41.24 4.83 57.69 41.17 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 9.42 68.07 30.27 7.35 68.27 30.10 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 33 3 # 33 179 ASP E 99 ASP^? 7.65 C2 CIT E 104 227 GLU E 38 GLU^? 8.47 O1 EDO E 103 289 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 3.96 55.76 41.24 4.83 57.69 41.17 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 9.42 68.07 30.27 7.35 68.27 30.10 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 34 3 # 34 179 ASP E 99 ASP^? 7.65 C2 CIT E 104 227 GLU E 38 GLU^? 8.47 O1 EDO E 103 289 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 3.96 55.76 41.24 4.83 57.69 41.17 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 9.42 68.07 30.27 7.35 68.27 30.10 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 35 3 # 35 179 ASP E 99 ASP^? 7.65 C2 CIT E 104 227 GLU F 38 GLU^? 13.95 O2 EDO E 103 289 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 3.96 55.76 41.24 4.83 57.69 41.17 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 9.42 68.07 30.27 7.35 68.27 30.10 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 36 3 # 36 179 ASP F 64 ASP~? 16.52 O2 EDO E 103 227 GLU E 38 GLU^? 8.47 O1 EDO E 103 289 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 3.96 55.76 41.24 4.83 57.69 41.17 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 9.42 68.07 30.27 7.35 68.27 30.10 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 37 3 # 37 179 ASP F 64 ASP~? 16.52 O2 EDO E 103 227 GLU F 38 GLU^? 13.95 O2 EDO E 103 289 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 3.96 55.76 41.24 4.83 57.69 41.17 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 9.42 68.07 30.27 7.35 68.27 30.10 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 38 3 # 38 179 ASP F 64 ASP~? 16.52 O2 EDO E 103 227 GLU F 38 GLU^? 13.95 O2 EDO E 103 289 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 3.96 55.76 41.24 4.83 57.69 41.17 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 9.42 68.07 30.27 7.35 68.27 30.10 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 39 3 # 39 179 ASP F 69 ASP~? 11.68 O6 CIT F 104 227 GLU F 32 GLU~? 16.06 O1 CIT F 104 289 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 3.96 55.76 41.24 4.83 57.69 41.17 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 9.42 68.07 30.27 7.35 68.27 30.10 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 40 3 # 40 179 ASP F 99 ASP^? 6.97 O7 CIT F 104 227 GLU E 38 GLU^? 8.47 O1 EDO E 103 289 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 3.96 55.76 41.24 4.83 57.69 41.17 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 9.42 68.07 30.27 7.35 68.27 30.10 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 41 3 # 41 179 ASP F 99 ASP^? 6.97 O7 CIT F 104 227 GLU F 38 GLU^? 13.95 O2 EDO E 103 289 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -0.62 65.95 29.97 0.31 67.47 31.05 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 3.96 55.76 41.24 4.83 57.69 41.17 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 9.42 68.07 30.27 7.35 68.27 30.10 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1amy_c06 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 42 3 # 42 179 ASP F 99 ASP^? 6.97 O7 CIT F 104 227 GLU F 38 GLU^? 13.95 O2 EDO E 103 289 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo -0.62 65.95 29.97 0.31 67.47 31.05 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 3.96 55.76 41.24 4.83 57.69 41.17 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 9.42 68.07 30.27 7.35 68.27 30.10 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 1amy_c06 source 1amy ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE (ALPHA-AMY: 42 hits 1amy_c06 naa= 3 ULMN 3 1apt_c04 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 1 3 # 1 E 33 ASP A 46 ASP.? 9.57 O6 CIT B 103 E 36 SER A 51 SER.? 9.93 O6 CIT B 103 E 213 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 26.30 12.96 16.78 25.46 12.99 18.72 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 28.33 15.15 21.27 28.70 13.12 19.97 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 20.15 16.04 19.79 21.65 14.49 19.86 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1apt_c04 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 2 3 # 2 E 33 ASP B 46 ASP.? 11.17 O1 EDO A 103 E 36 SER B 51 SER.? 11.29 O1 EDO A 103 E 213 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 26.30 12.96 16.78 25.46 12.99 18.72 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 28.33 15.15 21.27 28.70 13.12 19.97 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 20.15 16.04 19.79 21.65 14.49 19.86 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1apt_c04 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 3 3 # 3 E 33 ASP C 46 ASP.? 10.22 O6 CIT D 103 E 36 SER C 51 SER.? 10.55 O6 CIT D 103 E 213 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 26.30 12.96 16.78 25.46 12.99 18.72 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 28.33 15.15 21.27 28.70 13.12 19.97 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 20.15 16.04 19.79 21.65 14.49 19.86 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1apt_c04 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 4 3 # 4 E 33 ASP D 46 ASP.? 10.10 O7 CIT C 104 E 36 SER D 51 SER.? 10.41 O7 CIT C 104 E 213 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 26.30 12.96 16.78 25.46 12.99 18.72 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 28.33 15.15 21.27 28.70 13.12 19.97 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 20.15 16.04 19.79 21.65 14.49 19.86 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1apt_c04 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 5 3 # 5 E 33 ASP E 46 ASP.? 9.98 C4 CIT F 104 E 36 SER E 51 SER.? 10.11 C4 CIT F 104 E 213 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 26.30 12.96 16.78 25.46 12.99 18.72 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 28.33 15.15 21.27 28.70 13.12 19.97 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 20.15 16.04 19.79 21.65 14.49 19.86 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1apt_c04 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 6 3 # 6 E 33 ASP F 46 ASP.? 6.64 O2 EDO F 103 E 36 SER F 51 SER.? -5.94 O2 EDO F 103s E 213 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 26.30 12.96 16.78 25.46 12.99 18.72 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 28.33 15.15 21.27 28.70 13.12 19.97 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 20.15 16.04 19.79 21.65 14.49 19.86 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 1apt_c04 source 1apt ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET (LYSTA IS : 6 hits 1apt_c04 naa= 3 ULMN 3 1aq2_c00 PHOSPHOENOLPYRUVATE CARBOXYKINASE user 1 3 # 1 232 HIS A 4 HIS.? -4.40 O2 EDO A 103s 254 LYS A 65 LYS~? 12.23 O2 EDO A 103 333 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 28.11 -1.15 8.51 29.21 0.63 8.34 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 26.09 4.87 14.60 27.89 3.33 10.26 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 37.35 7.47 11.84 34.90 6.11 10.60 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1aq2_c00 PHOSPHOENOLPYRUVATE CARBOXYKINASE user 2 3 # 2 232 HIS B 4 HIS.? -4.11 O2 CIT B 103s 254 LYS B 65 LYS~? 11.82 O5 CIT B 103 333 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 28.11 -1.15 8.51 29.21 0.63 8.34 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 26.09 4.87 14.60 27.89 3.33 10.26 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 37.35 7.47 11.84 34.90 6.11 10.60 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1aq2_c00 PHOSPHOENOLPYRUVATE CARBOXYKINASE user 3 3 # 3 232 HIS D 4 HIS.? -4.16 O2 CIT D 103s 254 LYS D 65 LYS~? 11.29 O6 CIT D 103 333 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 28.11 -1.15 8.51 29.21 0.63 8.34 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 26.09 4.87 14.60 27.89 3.33 10.26 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 37.35 7.47 11.84 34.90 6.11 10.60 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 1aq2_c00 source 1aq2 PHOSPHOENOLPYRUVATE CARBOXYKINASE : 3 hits 1aq2_c00 naa= 3 ULMN 3 1aql_c02 BILE-SALT ACTIVATED LIPASE user 1 3 # 1 A 194 SER C 87 SER~? 9.82 O2 EDO C 103 A 292 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 322 HIS C 41 HIS^? 12.16 O1 CIT C 104 coo 36.34 32.23 39.60 36.43 34.62 39.93 -34.89 -64.48 -33.73 -36.72 -64.13 -35.26 coo 19.73 19.18 41.39 21.50 18.65 40.34 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 41.69 45.14 46.60 41.78 47.19 46.18 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 ULMN 3 1aql_c02 BILE-SALT ACTIVATED LIPASE user 2 3 # 2 A 194 SER E 87 SER~? 10.44 O7 CIT E 104 A 292 ASP C 27 ASP~? 13.15 O1 CIT C 104 A 322 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 36.34 32.23 39.60 36.43 34.62 39.93 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 coo 19.73 19.18 41.39 21.50 18.65 40.34 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 41.69 45.14 46.60 41.78 47.19 46.18 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 1aql_c02 source 1aql BILE-SALT ACTIVATED LIPASE : 2 hits 1aql_c02 naa= 3 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 1 3 # 1 B 325 ARG A 18 ARG~? 14.68 C2 EDO E 103 B 342 ASP F 64 ASP~? 16.52 O2 EDO E 103 B 531 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -13.40 -85.38 -40.50 -10.48 -85.51 -41.44 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 2 3 # 2 B 325 ARG A 53 ARG.? 15.50 C1 EDO A 103 B 342 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 531 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 3 3 # 3 B 325 ARG B 53 ARG.? 13.69 O3 CIT B 103 B 342 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 531 ARG A 53 ARG.? 15.50 C1 EDO A 103 coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 4 3 # 4 B 325 ARG B 53 ARG.? 13.69 O3 CIT B 103 B 342 ASP B 93 ASP~? 9.77 O3 CIT B 103 B 531 ARG A 53 ARG.? 15.50 C1 EDO A 103 coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 3.85 -90.04 -12.91 5.79 -89.33 -13.36 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 5 3 # 5 B 325 ARG C 53 ARG.? 12.90 O3 CIT C 104 B 342 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 531 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 6 3 # 6 B 325 ARG C 79 ARG~? -3.25 O5 CIT E 104s B 342 ASP C 27 ASP~? 13.15 O1 CIT C 104 B 531 ARG C 18 ARG~? -3.10 O1 EDO C 103s coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 7 3 # 7 B 325 ARG D 53 ARG.? 12.25 O4 CIT D 103 B 342 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 531 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 8 3 # 8 B 325 ARG E 18 ARG~? 11.85 O4 CIT C 104 B 342 ASP A 27 ASP~? 13.11 O2 EDO A 103 B 531 ARG C 89 ARG.? 16.36 O3 CIT C 104 coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 9 3 # 9 B 325 ARG E 53 ARG.? 4.89 O1 EDO F 103 B 342 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 531 ARG F 53 ARG.? -5.38 O1 EDO F 103s coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 10 3 # 10 B 325 ARG E 53 ARG.? 4.89 O1 EDO F 103 B 342 ASP E 93 ASP~? 8.62 O3 CIT E 104 B 531 ARG F 53 ARG.? -5.38 O1 EDO F 103s coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 11 3 # 11 B 325 ARG E 79 ARG~? -3.12 O5 CIT C 104s B 342 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 531 ARG E 18 ARG~? 11.85 O4 CIT C 104 coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 12 3 # 12 B 325 ARG F 53 ARG.? -5.38 O1 EDO F 103s B 342 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 531 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1asy_c00 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 13 3 # 13 B 325 ARG F 79 ARG~? 14.02 O1 CIT F 104 B 342 ASP F 27 ASP~? 14.00 O1 CIT F 104 B 531 ARG F 18 ARG~? 15.26 O3 CIT F 104 coo 68.60 41.07 -12.62 69.17 40.45 -9.67 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 coo 73.51 47.41 -3.97 72.62 46.48 -5.62 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 59.93 41.82 -5.59 61.38 39.13 -5.79 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 1asy_c00 source 1asy TRANSFER RIBONUCLEIC ACID (TRNAASP) : 13 hits 1asy_c00 naa= 3 ULMN 3 1asy_c01 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 1 3 # 1 A 325 ARG A 18 ARG~? 14.68 C2 EDO E 103 A 342 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 531 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 73.40 61.96 -24.99 72.46 63.92 -22.84 -13.40 -85.38 -40.50 -10.48 -85.51 -41.44 coo 66.77 64.93 -14.03 68.02 64.49 -15.66 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 80.46 68.51 -18.35 79.98 68.55 -21.36 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1asy_c01 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 2 3 # 2 A 325 ARG A 79 ARG~? -3.92 C2 EDO E 103s A 342 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 531 ARG A 18 ARG~? 14.68 C2 EDO E 103 coo 73.40 61.96 -24.99 72.46 63.92 -22.84 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 66.77 64.93 -14.03 68.02 64.49 -15.66 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 80.46 68.51 -18.35 79.98 68.55 -21.36 -13.40 -85.38 -40.50 -10.48 -85.51 -41.44 ULMN 3 1asy_c01 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 3 3 # 3 A 325 ARG B 79 ARG~? -14.20 C2 CIT B 103s A 342 ASP B 27 ASP~? 12.32 O1 CIT B 103 A 531 ARG B 18 ARG~? 17.41 C4 CIT B 103 coo 73.40 61.96 -24.99 72.46 63.92 -22.84 -3.07 -78.73 4.51 -0.79 -79.91 6.20 coo 66.77 64.93 -14.03 68.02 64.49 -15.66 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 80.46 68.51 -18.35 79.98 68.55 -21.36 -4.30 -89.74 3.62 -5.35 -92.05 5.29 ULMN 3 1asy_c01 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 4 3 # 4 A 325 ARG C 53 ARG.? 12.90 O3 CIT C 104 A 342 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 531 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 73.40 61.96 -24.99 72.46 63.92 -22.84 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 coo 66.77 64.93 -14.03 68.02 64.49 -15.66 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 80.46 68.51 -18.35 79.98 68.55 -21.36 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1asy_c01 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 5 3 # 5 A 325 ARG C 79 ARG~? -3.25 O5 CIT E 104s A 342 ASP C 27 ASP~? 13.15 O1 CIT C 104 A 531 ARG C 18 ARG~? -3.10 O1 EDO C 103s coo 73.40 61.96 -24.99 72.46 63.92 -22.84 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo 66.77 64.93 -14.03 68.02 64.49 -15.66 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 80.46 68.51 -18.35 79.98 68.55 -21.36 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 ULMN 3 1asy_c01 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 6 3 # 6 A 325 ARG D 53 ARG.? 12.25 O4 CIT D 103 A 342 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 531 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 73.40 61.96 -24.99 72.46 63.92 -22.84 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo 66.77 64.93 -14.03 68.02 64.49 -15.66 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 80.46 68.51 -18.35 79.98 68.55 -21.36 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1asy_c01 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 7 3 # 7 A 325 ARG D 79 ARG~? 11.98 O1 CIT D 103 A 342 ASP D 27 ASP~? 12.70 O1 CIT D 103 A 531 ARG D 18 ARG~? 14.38 O7 CIT D 103 coo 73.40 61.96 -24.99 72.46 63.92 -22.84 -51.92 -50.29 3.38 -54.60 -50.62 1.89 coo 66.77 64.93 -14.03 68.02 64.49 -15.66 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 80.46 68.51 -18.35 79.98 68.55 -21.36 -45.95 -58.51 3.75 -43.82 -60.51 4.85 ULMN 3 1asy_c01 TRANSFER RIBONUCLEIC ACID (TRNAASP) user 8 3 # 8 A 325 ARG E 79 ARG~? -3.12 O5 CIT C 104s A 342 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 531 ARG E 18 ARG~? 11.85 O4 CIT C 104 coo 73.40 61.96 -24.99 72.46 63.92 -22.84 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo 66.77 64.93 -14.03 68.02 64.49 -15.66 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 80.46 68.51 -18.35 79.98 68.55 -21.36 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 1asy_c01 source 1asy TRANSFER RIBONUCLEIC ACID (TRNAASP) : 8 hits 1asy_c01 naa= 3 ULMN 3 1azy_c00 THYMIDINE PHOSPHORYLASE user 1 3 # 1 A 85 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 171 ARG B 40 ARG^? 17.25 O1 CIT B 103 A 190 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 22.59 2.26 43.22 21.17 3.47 42.27 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 13.63 3.81 28.83 14.49 2.91 31.59 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 24.97 7.47 37.69 21.24 10.69 35.89 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1azy_c00 THYMIDINE PHOSPHORYLASE user 2 3 # 2 A 85 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 171 ARG C 40 ARG^? 17.96 O1 CIT C 104 A 190 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 22.59 2.26 43.22 21.17 3.47 42.27 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 13.63 3.81 28.83 14.49 2.91 31.59 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 24.97 7.47 37.69 21.24 10.69 35.89 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1azy_c00 THYMIDINE PHOSPHORYLASE user 3 3 # 3 A 85 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 171 ARG F 40 ARG^? 16.45 O2 CIT F 104 A 190 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 22.59 2.26 43.22 21.17 3.47 42.27 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 13.63 3.81 28.83 14.49 2.91 31.59 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 24.97 7.47 37.69 21.24 10.69 35.89 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 1azy_c00 source 1azy THYMIDINE PHOSPHORYLASE : 3 hits 1azy_c00 naa= 3 ULMN 3 1azy_c01 THYMIDINE PHOSPHORYLASE user 1 3 # 1 B 85 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 171 ARG B 40 ARG^? 17.25 O1 CIT B 103 B 190 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo -6.44 4.86 -3.45 -5.03 5.97 -2.36 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 2.83 4.83 10.84 1.96 4.32 7.97 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo -8.96 9.04 2.88 -5.39 12.11 5.08 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1azy_c01 THYMIDINE PHOSPHORYLASE user 2 3 # 2 B 85 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 171 ARG C 40 ARG^? 17.96 O1 CIT C 104 B 190 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo -6.44 4.86 -3.45 -5.03 5.97 -2.36 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 2.83 4.83 10.84 1.96 4.32 7.97 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -8.96 9.04 2.88 -5.39 12.11 5.08 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1azy_c01 THYMIDINE PHOSPHORYLASE user 3 3 # 3 B 85 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 171 ARG F 40 ARG^? 16.45 O2 CIT F 104 B 190 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo -6.44 4.86 -3.45 -5.03 5.97 -2.36 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 2.83 4.83 10.84 1.96 4.32 7.97 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo -8.96 9.04 2.88 -5.39 12.11 5.08 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 1azy_c01 source 1azy THYMIDINE PHOSPHORYLASE : 3 hits 1azy_c01 naa= 3 ULMN 3 1b02_c02 THYMIDYLATE SYNTHASE user 1 3 # 1 A 71 GLU C 21 GLU~? 6.35 O1 EDO C 103 A 161 CYH E 88 CYH.? 7.64 O3 CIT E 104 A 192 ASN E 90 ASN~? -4.46 O2 EDO C 103s coo 1.71 48.67 0.56 0.18 47.85 1.75 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo -2.78 50.68 10.78 -4.68 50.49 8.71 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 coo -0.10 43.44 8.03 -1.33 45.05 7.36 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 ULMN 3 1b02_c02 THYMIDYLATE SYNTHASE user 2 3 # 2 A 71 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 161 CYH C 88 CYH~? 7.95 C4 CIT C 104 A 192 ASN C 90 ASN~? 14.00 O3 CIT C 104 coo 1.71 48.67 0.56 0.18 47.85 1.75 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo -2.78 50.68 10.78 -4.68 50.49 8.71 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo -0.10 43.44 8.03 -1.33 45.05 7.36 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 1b02_c02 source 1b02 THYMIDYLATE SYNTHASE : 2 hits 1b02_c02 naa= 3 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 1 3 # 1 A 109 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 182 GLU A 101 GLU^? 18.10 O2 EDO A 103 A 286 ASN B 44 ASN.? 13.13 O1 EDO A 103 coo 26.03 44.66 108.90 25.67 42.61 108.82 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 18.06 44.02 105.38 18.08 45.37 107.03 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 25.47 38.28 112.06 27.26 39.30 111.54 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 2 3 # 2 A 109 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 182 GLU B 48 GLU.? 3.87 O1 EDO A 103 A 286 ASN B 44 ASN.? 13.13 O1 EDO A 103 coo 26.03 44.66 108.90 25.67 42.61 108.82 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 18.06 44.02 105.38 18.08 45.37 107.03 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 25.47 38.28 112.06 27.26 39.30 111.54 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 3 3 # 3 A 109 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 182 GLU A 48 GLU.? -2.39 O6 CIT B 103s A 286 ASN A 44 ASN.? 11.73 O6 CIT B 103 coo 26.03 44.66 108.90 25.67 42.61 108.82 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 18.06 44.02 105.38 18.08 45.37 107.03 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 25.47 38.28 112.06 27.26 39.30 111.54 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 4 3 # 4 A 109 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 182 GLU B 101 GLU^? 17.79 O2 CIT B 103 A 286 ASN A 44 ASN.? 11.73 O6 CIT B 103 coo 26.03 44.66 108.90 25.67 42.61 108.82 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 18.06 44.02 105.38 18.08 45.37 107.03 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 25.47 38.28 112.06 27.26 39.30 111.54 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 5 3 # 5 A 109 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 182 GLU C 48 GLU.? -2.75 O6 CIT D 103s A 286 ASN D -5 ASN.? 16.01 O6 CIT D 103 coo 26.03 44.66 108.90 25.67 42.61 108.82 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 18.06 44.02 105.38 18.08 45.37 107.03 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 25.47 38.28 112.06 27.26 39.30 111.54 -38.30 -48.37 -26.01 -39.87 -49.66 -25.30 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 6 3 # 6 A 109 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 182 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 286 ASN D 44 ASN.? 12.24 O2 CIT C 104 coo 26.03 44.66 108.90 25.67 42.61 108.82 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 18.06 44.02 105.38 18.08 45.37 107.03 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 25.47 38.28 112.06 27.26 39.30 111.54 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 7 3 # 7 A 109 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 182 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 286 ASN D 44 ASN.? 12.24 O2 CIT C 104 coo 26.03 44.66 108.90 25.67 42.61 108.82 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 18.06 44.02 105.38 18.08 45.37 107.03 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 25.47 38.28 112.06 27.26 39.30 111.54 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 8 3 # 8 A 109 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 182 GLU C 48 GLU.? -2.75 O6 CIT D 103s A 286 ASN C 44 ASN.? 11.91 O6 CIT D 103 coo 26.03 44.66 108.90 25.67 42.61 108.82 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 18.06 44.02 105.38 18.08 45.37 107.03 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 25.47 38.28 112.06 27.26 39.30 111.54 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 9 3 # 9 A 109 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 182 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 286 ASN C 44 ASN.? 11.91 O6 CIT D 103 coo 26.03 44.66 108.90 25.67 42.61 108.82 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 18.06 44.02 105.38 18.08 45.37 107.03 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 25.47 38.28 112.06 27.26 39.30 111.54 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 10 3 # 10 A 109 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 182 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 286 ASN F 44 ASN.? 8.45 O2 EDO F 103 coo 26.03 44.66 108.90 25.67 42.61 108.82 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 18.06 44.02 105.38 18.08 45.37 107.03 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 25.47 38.28 112.06 27.26 39.30 111.54 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 11 3 # 11 A 109 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 182 GLU F 48 GLU.? -3.15 C4 CIT E 104s A 286 ASN F 44 ASN.? 8.45 O2 EDO F 103 coo 26.03 44.66 108.90 25.67 42.61 108.82 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 18.06 44.02 105.38 18.08 45.37 107.03 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 25.47 38.28 112.06 27.26 39.30 111.54 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 ULMN 3 1b57_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 12 3 # 12 A 109 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 182 GLU E 48 GLU.? -2.93 O7 CIT F 104s A 286 ASN E 44 ASN.? 11.90 O7 CIT F 104 coo 26.03 44.66 108.90 25.67 42.61 108.82 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 18.06 44.02 105.38 18.08 45.37 107.03 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 25.47 38.28 112.06 27.26 39.30 111.54 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 1b57_c00 source 1b57 FRUCTOSE-BISPHOSPHATE ALDOLASE II : 12 hits 1b57_c00 naa= 3 ULMN 3 1b57_c01 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 1 3 # 1 B 109 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 182 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 286 ASN B 44 ASN.? 13.13 O1 EDO A 103 coo 13.82 69.26 132.27 11.87 70.14 132.51 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 8.74 63.05 136.42 9.87 62.19 134.79 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 8.26 72.60 129.22 10.14 73.45 129.80 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 ULMN 3 1b57_c01 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 2 3 # 2 B 109 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 182 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 286 ASN A 44 ASN.? 11.73 O6 CIT B 103 coo 13.82 69.26 132.27 11.87 70.14 132.51 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 8.74 63.05 136.42 9.87 62.19 134.79 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 8.26 72.60 129.22 10.14 73.45 129.80 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 ULMN 3 1b57_c01 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 3 3 # 3 B 109 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 182 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 286 ASN D -5 ASN.? 16.01 O6 CIT D 103 coo 13.82 69.26 132.27 11.87 70.14 132.51 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 8.74 63.05 136.42 9.87 62.19 134.79 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 8.26 72.60 129.22 10.14 73.45 129.80 -38.30 -48.37 -26.01 -39.87 -49.66 -25.30 ULMN 3 1b57_c01 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 4 3 # 4 B 109 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 182 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 286 ASN D 44 ASN.? 12.24 O2 CIT C 104 coo 13.82 69.26 132.27 11.87 70.14 132.51 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 8.74 63.05 136.42 9.87 62.19 134.79 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 8.26 72.60 129.22 10.14 73.45 129.80 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 ULMN 3 1b57_c01 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 5 3 # 5 B 109 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 182 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 286 ASN C 44 ASN.? 11.91 O6 CIT D 103 coo 13.82 69.26 132.27 11.87 70.14 132.51 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 8.74 63.05 136.42 9.87 62.19 134.79 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 8.26 72.60 129.22 10.14 73.45 129.80 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 ULMN 3 1b57_c01 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 6 3 # 6 B 109 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 182 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 286 ASN F 44 ASN.? 8.45 O2 EDO F 103 coo 13.82 69.26 132.27 11.87 70.14 132.51 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 8.74 63.05 136.42 9.87 62.19 134.79 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 8.26 72.60 129.22 10.14 73.45 129.80 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 ULMN 3 1b57_c01 FRUCTOSE-BISPHOSPHATE ALDOLASE II user 7 3 # 7 B 109 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 182 GLU E 48 GLU.? -2.93 O7 CIT F 104s B 286 ASN E 44 ASN.? 11.90 O7 CIT F 104 coo 13.82 69.26 132.27 11.87 70.14 132.51 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 8.74 63.05 136.42 9.87 62.19 134.79 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 8.26 72.60 129.22 10.14 73.45 129.80 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 1b57_c01 source 1b57 FRUCTOSE-BISPHOSPHATE ALDOLASE II : 7 hits 1b57_c01 naa= 3 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 1 3 # 1 A 60 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 148 CYH C 88 CYH~? 7.95 C4 CIT C 104 A 179 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 20.47 15.77 27.32 19.04 14.27 26.94 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 21.87 3.71 21.27 20.32 3.55 23.64 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 17.09 11.24 20.19 17.85 10.05 21.76 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 2 3 # 2 A 60 GLU A 48 GLU.? -2.39 O6 CIT B 103s A 148 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 179 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 20.47 15.77 27.32 19.04 14.27 26.94 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 21.87 3.71 21.27 20.32 3.55 23.64 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 17.09 11.24 20.19 17.85 10.05 21.76 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 3 3 # 3 A 60 GLU A 101 GLU^? 18.10 O2 EDO A 103 A 148 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 179 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 20.47 15.77 27.32 19.04 14.27 26.94 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 21.87 3.71 21.27 20.32 3.55 23.64 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 17.09 11.24 20.19 17.85 10.05 21.76 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 4 3 # 4 A 60 GLU B 48 GLU.? 3.87 O1 EDO A 103 A 148 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 179 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 20.47 15.77 27.32 19.04 14.27 26.94 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 21.87 3.71 21.27 20.32 3.55 23.64 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 17.09 11.24 20.19 17.85 10.05 21.76 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 5 3 # 5 A 60 GLU B 101 GLU^? 17.79 O2 CIT B 103 A 148 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 179 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 20.47 15.77 27.32 19.04 14.27 26.94 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 21.87 3.71 21.27 20.32 3.55 23.64 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 17.09 11.24 20.19 17.85 10.05 21.76 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 6 3 # 6 A 60 GLU C 21 GLU~? 6.35 O1 EDO C 103 A 148 CYH E 88 CYH.? 7.64 O3 CIT E 104 A 179 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 20.47 15.77 27.32 19.04 14.27 26.94 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 21.87 3.71 21.27 20.32 3.55 23.64 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 coo 17.09 11.24 20.19 17.85 10.05 21.76 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 7 3 # 7 A 60 GLU C 48 GLU.? -2.75 O6 CIT D 103s A 148 CYH D 60 CYH^? 5.69 O2 CIT D 103 A 179 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 20.47 15.77 27.32 19.04 14.27 26.94 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 21.87 3.71 21.27 20.32 3.55 23.64 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 17.09 11.24 20.19 17.85 10.05 21.76 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 8 3 # 8 A 60 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 148 CYH C 60 CYH^? 5.84 O1 CIT C 104 A 179 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 20.47 15.77 27.32 19.04 14.27 26.94 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 21.87 3.71 21.27 20.32 3.55 23.64 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 17.09 11.24 20.19 17.85 10.05 21.76 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 9 3 # 9 A 60 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 148 CYH C 60 CYH^? 5.84 O1 CIT C 104 A 179 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 20.47 15.77 27.32 19.04 14.27 26.94 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 21.87 3.71 21.27 20.32 3.55 23.64 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 17.09 11.24 20.19 17.85 10.05 21.76 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 10 3 # 10 A 60 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 148 CYH D 60 CYH^? 5.69 O2 CIT D 103 A 179 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 20.47 15.77 27.32 19.04 14.27 26.94 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 21.87 3.71 21.27 20.32 3.55 23.64 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 17.09 11.24 20.19 17.85 10.05 21.76 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 11 3 # 11 A 60 GLU E 48 GLU.? -2.93 O7 CIT F 104s A 148 CYH F 60 CYH^? 5.70 O2 CIT F 104 A 179 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 20.47 15.77 27.32 19.04 14.27 26.94 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 21.87 3.71 21.27 20.32 3.55 23.64 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 17.09 11.24 20.19 17.85 10.05 21.76 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 12 3 # 12 A 60 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 148 CYH E 60 CYH^? 5.61 O2 CIT E 104 A 179 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 20.47 15.77 27.32 19.04 14.27 26.94 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 21.87 3.71 21.27 20.32 3.55 23.64 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 17.09 11.24 20.19 17.85 10.05 21.76 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 13 3 # 13 A 60 GLU F 32 GLU~? 16.06 O1 CIT F 104 A 148 CYH F 60 CYH^? 5.70 O2 CIT F 104 A 179 ASP F 27 ASP~? 14.00 O1 CIT F 104 coo 20.47 15.77 27.32 19.04 14.27 26.94 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 21.87 3.71 21.27 20.32 3.55 23.64 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 17.09 11.24 20.19 17.85 10.05 21.76 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 14 3 # 14 A 60 GLU F 48 GLU.? -3.15 C4 CIT E 104s A 148 CYH E 60 CYH^? 5.61 O2 CIT E 104 A 179 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 20.47 15.77 27.32 19.04 14.27 26.94 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 21.87 3.71 21.27 20.32 3.55 23.64 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 17.09 11.24 20.19 17.85 10.05 21.76 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1b5d_c04 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 15 3 # 15 A 60 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 148 CYH F 60 CYH^? 5.70 O2 CIT F 104 A 179 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 20.47 15.77 27.32 19.04 14.27 26.94 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 21.87 3.71 21.27 20.32 3.55 23.64 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 17.09 11.24 20.19 17.85 10.05 21.76 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1b5d_c04 source 1b5d DEOXYCYTIDYLATE HYDROXYMETHYLASE : 15 hits 1b5d_c04 naa= 3 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 1 3 # 1 B 60 GLU A 32 GLU~? 8.29 O4 CIT C 104 B 148 CYH C 88 CYH~? 7.95 C4 CIT C 104 B 179 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 30.30 0.93 3.58 31.01 1.18 0.88 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 2 3 # 2 B 60 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 148 CYH B 60 CYH^? 5.88 O1 CIT B 103 B 179 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 30.30 0.93 3.58 31.01 1.18 0.88 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 3 3 # 3 B 60 GLU A 101 GLU^? 18.10 O2 EDO A 103 B 148 CYH A 60 CYH^? 5.96 O2 EDO A 103 B 179 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 30.30 0.93 3.58 31.01 1.18 0.88 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 4 3 # 4 B 60 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 148 CYH A 60 CYH^? 5.96 O2 EDO A 103 B 179 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 30.30 0.93 3.58 31.01 1.18 0.88 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 5 3 # 5 B 60 GLU B 101 GLU^? 17.79 O2 CIT B 103 B 148 CYH B 60 CYH^? 5.88 O1 CIT B 103 B 179 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 30.30 0.93 3.58 31.01 1.18 0.88 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 6 3 # 6 B 60 GLU C 21 GLU~? 6.35 O1 EDO C 103 B 148 CYH E 88 CYH.? 7.64 O3 CIT E 104 B 179 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 30.30 0.93 3.58 31.01 1.18 0.88 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 7 3 # 7 B 60 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 148 CYH D 60 CYH^? 5.69 O2 CIT D 103 B 179 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 30.30 0.93 3.58 31.01 1.18 0.88 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 8 3 # 8 B 60 GLU C 101 GLU^? 17.42 O2 CIT C 104 B 148 CYH C 60 CYH^? 5.84 O1 CIT C 104 B 179 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 30.30 0.93 3.58 31.01 1.18 0.88 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 9 3 # 9 B 60 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 148 CYH C 60 CYH^? 5.84 O1 CIT C 104 B 179 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 30.30 0.93 3.58 31.01 1.18 0.88 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 10 3 # 10 B 60 GLU D 101 GLU^? 17.58 O6 CIT D 103 B 148 CYH D 60 CYH^? 5.69 O2 CIT D 103 B 179 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 30.30 0.93 3.58 31.01 1.18 0.88 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 11 3 # 11 B 60 GLU E 48 GLU.? -2.93 O7 CIT F 104s B 148 CYH F 60 CYH^? 5.70 O2 CIT F 104 B 179 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 30.30 0.93 3.58 31.01 1.18 0.88 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 12 3 # 12 B 60 GLU E 101 GLU^? 17.69 O2 CIT E 104 B 148 CYH E 60 CYH^? 5.61 O2 CIT E 104 B 179 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 30.30 0.93 3.58 31.01 1.18 0.88 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 13 3 # 13 B 60 GLU F 32 GLU~? 16.06 O1 CIT F 104 B 148 CYH F 60 CYH^? 5.70 O2 CIT F 104 B 179 ASP F 27 ASP~? 14.00 O1 CIT F 104 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 30.30 0.93 3.58 31.01 1.18 0.88 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 14 3 # 14 B 60 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 148 CYH E 60 CYH^? 5.61 O2 CIT E 104 B 179 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 30.30 0.93 3.58 31.01 1.18 0.88 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1b5d_c05 DEOXYCYTIDYLATE HYDROXYMETHYLASE user 15 3 # 15 B 60 GLU F 101 GLU^? 10.35 O2 EDO E 103 B 148 CYH F 60 CYH^? 5.70 O2 CIT F 104 B 179 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 34.11 -11.05 -1.22 32.89 -9.54 -2.05 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 30.30 0.93 3.58 31.01 1.18 0.88 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 26.42 -6.51 0.59 28.13 -5.32 0.24 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1b5d_c05 source 1b5d DEOXYCYTIDYLATE HYDROXYMETHYLASE : 15 hits 1b5d_c05 naa= 3 ULMN 3 1b66_c00 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 1 3 # 1 A 133 GLU A 11 GLU.? 17.04 C1 EDO A 103 B 88 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 89 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 44.53 38.98 5.35 43.53 40.60 6.22 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 coo 58.74 13.49 55.78 58.72 14.38 57.67 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 60.89 12.20 60.42 60.43 13.81 61.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 ULMN 3 1b66_c00 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 2 3 # 2 A 133 GLU B 21 GLU~? 16.03 C2 CIT B 103 B 88 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 89 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 44.53 38.98 5.35 43.53 40.60 6.22 -9.13 -87.49 4.49 -7.49 -88.18 5.63 coo 58.74 13.49 55.78 58.72 14.38 57.67 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 60.89 12.20 60.42 60.43 13.81 61.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 ULMN 3 1b66_c00 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 3 3 # 3 A 133 GLU B 32 GLU~? 16.71 O1 CIT B 103 B 88 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 89 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 44.53 38.98 5.35 43.53 40.60 6.22 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 58.74 13.49 55.78 58.72 14.38 57.67 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 60.89 12.20 60.42 60.43 13.81 61.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 ULMN 3 1b66_c00 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 4 3 # 4 A 133 GLU D 11 GLU.? 15.90 O4 CIT D 103 B 88 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 89 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 44.53 38.98 5.35 43.53 40.60 6.22 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo 58.74 13.49 55.78 58.72 14.38 57.67 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 60.89 12.20 60.42 60.43 13.81 61.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 ULMN 3 1b66_c00 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 5 3 # 5 A 133 GLU D 38 GLU^? 15.43 O2 CIT D 103 B 88 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 89 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 44.53 38.98 5.35 43.53 40.60 6.22 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 58.74 13.49 55.78 58.72 14.38 57.67 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 60.89 12.20 60.42 60.43 13.81 61.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 ULMN 3 1b66_c00 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 6 3 # 6 A 133 GLU F 38 GLU^? 13.95 O2 EDO E 103 B 88 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 89 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 44.53 38.98 5.35 43.53 40.60 6.22 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 58.74 13.49 55.78 58.72 14.38 57.67 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 60.89 12.20 60.42 60.43 13.81 61.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 1b66_c00 source 1b66 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE : 6 hits 1b66_c00 naa= 3 ULMN 3 1b66_c02 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 1 3 # 1 A 133 GLU A 11 GLU.? 17.04 C1 EDO A 103 B 88 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 89 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 44.53 38.98 5.35 43.53 40.60 6.22 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 coo 58.74 13.49 55.78 58.72 14.38 57.67 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 60.89 12.20 60.42 60.43 13.81 61.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 ULMN 3 1b66_c02 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 2 3 # 2 A 133 GLU B 21 GLU~? 16.03 C2 CIT B 103 B 88 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 89 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 44.53 38.98 5.35 43.53 40.60 6.22 -9.13 -87.49 4.49 -7.49 -88.18 5.63 coo 58.74 13.49 55.78 58.72 14.38 57.67 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 60.89 12.20 60.42 60.43 13.81 61.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 ULMN 3 1b66_c02 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 3 3 # 3 A 133 GLU B 32 GLU~? 16.71 O1 CIT B 103 B 88 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 89 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 44.53 38.98 5.35 43.53 40.60 6.22 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 58.74 13.49 55.78 58.72 14.38 57.67 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 60.89 12.20 60.42 60.43 13.81 61.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 ULMN 3 1b66_c02 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 4 3 # 4 A 133 GLU D 11 GLU.? 15.90 O4 CIT D 103 B 88 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 89 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 44.53 38.98 5.35 43.53 40.60 6.22 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo 58.74 13.49 55.78 58.72 14.38 57.67 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 60.89 12.20 60.42 60.43 13.81 61.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 ULMN 3 1b66_c02 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 5 3 # 5 A 133 GLU D 38 GLU^? 15.43 O2 CIT D 103 B 88 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 89 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 44.53 38.98 5.35 43.53 40.60 6.22 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 58.74 13.49 55.78 58.72 14.38 57.67 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 60.89 12.20 60.42 60.43 13.81 61.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 ULMN 3 1b66_c02 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASEuser 6 3 # 6 A 133 GLU F 38 GLU^? 13.95 O2 EDO E 103 B 88 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 89 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 44.53 38.98 5.35 43.53 40.60 6.22 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 58.74 13.49 55.78 58.72 14.38 57.67 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 60.89 12.20 60.42 60.43 13.81 61.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 1b66_c02 source 1b66 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE : 6 hits 1b66_c02 naa= 3 ULMN 3 1bbs_c06 RENIN user 1 3 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 61.19 45.85 78.73 62.86 45.48 77.48 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 66.00 46.17 80.29 64.31 47.92 79.91 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 63.61 40.10 74.06 64.05 42.07 74.70 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 1bbs_c06 source 1bbs RENIN : 1 hits 1bbs_c06 naa= 3 ULMN 3 1bbs_c07 RENIN user 1 3 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 61.19 45.85 78.73 62.86 45.48 77.48 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 66.00 46.17 80.29 64.31 47.92 79.91 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 63.61 40.10 74.06 64.05 42.07 74.70 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 1bbs_c07 source 1bbs RENIN : 1 hits 1bbs_c07 naa= 3 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 1 3 # 1 A 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 A 141 THR A 61 THR^? 12.85 O2 EDO A 103 A 235 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 6.21 93.81 36.58 4.58 96.33 37.17 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 6.80 92.87 28.33 4.91 92.74 27.40 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 12.98 90.36 47.57 11.26 89.62 46.62 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 2 3 # 2 A 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 A 141 THR A 61 THR^? 12.85 O2 EDO A 103 A 235 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 6.21 93.81 36.58 4.58 96.33 37.17 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 6.80 92.87 28.33 4.91 92.74 27.40 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 12.98 90.36 47.57 11.26 89.62 46.62 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 3 3 # 3 A 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 A 141 THR B 61 THR^? 13.51 O2 CIT B 103 A 235 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 6.21 93.81 36.58 4.58 96.33 37.17 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 6.80 92.87 28.33 4.91 92.74 27.40 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 12.98 90.36 47.57 11.26 89.62 46.62 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 4 3 # 4 A 137 ARG B 40 ARG^? 17.25 O1 CIT B 103 A 141 THR B 37 THR^? 15.70 O1 CIT B 103 A 235 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 6.21 93.81 36.58 4.58 96.33 37.17 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 6.80 92.87 28.33 4.91 92.74 27.40 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 coo 12.98 90.36 47.57 11.26 89.62 46.62 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 5 3 # 5 A 137 ARG B 40 ARG^? 17.25 O1 CIT B 103 A 141 THR B 61 THR^? 13.51 O2 CIT B 103 A 235 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 6.21 93.81 36.58 4.58 96.33 37.17 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 6.80 92.87 28.33 4.91 92.74 27.40 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 12.98 90.36 47.57 11.26 89.62 46.62 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 6 3 # 6 A 137 ARG C 40 ARG^? 17.96 O1 CIT C 104 A 141 THR C 61 THR^? 13.10 O1 CIT C 104 A 235 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 6.21 93.81 36.58 4.58 96.33 37.17 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 6.80 92.87 28.33 4.91 92.74 27.40 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo 12.98 90.36 47.57 11.26 89.62 46.62 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 7 3 # 7 A 137 ARG D 40 ARG^? 16.76 O2 CIT D 103 A 141 THR D 61 THR^? 13.17 O2 CIT D 103 A 235 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 6.21 93.81 36.58 4.58 96.33 37.17 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 6.80 92.87 28.33 4.91 92.74 27.40 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo 12.98 90.36 47.57 11.26 89.62 46.62 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 8 3 # 8 A 137 ARG D 79 ARG~? 11.98 O1 CIT D 103 A 141 THR D 76 THR~? 10.83 O1 CIT D 103 A 235 ASP D 17 ASP~? 19.08 O1 CIT D 103 coo 6.21 93.81 36.58 4.58 96.33 37.17 -51.92 -50.29 3.38 -54.60 -50.62 1.89 coo 6.80 92.87 28.33 4.91 92.74 27.40 -54.46 -48.52 -2.23 -56.51 -49.34 -2.20 coo 12.98 90.36 47.57 11.26 89.62 46.62 -49.27 -65.18 4.30 -49.35 -67.27 4.77 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 9 3 # 9 A 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 141 THR E 37 THR^? 12.88 O1 EDO E 103 A 235 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 6.21 93.81 36.58 4.58 96.33 37.17 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 6.80 92.87 28.33 4.91 92.74 27.40 -34.67 -91.61 -48.59 -35.29 -92.29 -50.56 coo 12.98 90.36 47.57 11.26 89.62 46.62 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 10 3 # 10 A 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 141 THR E 61 THR^? 11.76 O1 EDO E 103 A 235 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 6.21 93.81 36.58 4.58 96.33 37.17 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 6.80 92.87 28.33 4.91 92.74 27.40 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo 12.98 90.36 47.57 11.26 89.62 46.62 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 11 3 # 11 A 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 141 THR E 61 THR^? 11.76 O1 EDO E 103 A 235 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 6.21 93.81 36.58 4.58 96.33 37.17 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 6.80 92.87 28.33 4.91 92.74 27.40 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo 12.98 90.36 47.57 11.26 89.62 46.62 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 12 3 # 12 A 137 ARG F 40 ARG^? 16.45 O2 CIT F 104 A 141 THR F 61 THR^? 11.09 O2 EDO E 103 A 235 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 6.21 93.81 36.58 4.58 96.33 37.17 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 6.80 92.87 28.33 4.91 92.74 27.40 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo 12.98 90.36 47.57 11.26 89.62 46.62 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1bd3_c00 URACIL PHOSPHORIBOSYLTRANSFERASE user 13 3 # 13 A 137 ARG F 40 ARG^? 16.45 O2 CIT F 104 A 141 THR F 61 THR^? 11.09 O2 EDO E 103 A 235 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 6.21 93.81 36.58 4.58 96.33 37.17 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 6.80 92.87 28.33 4.91 92.74 27.40 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo 12.98 90.36 47.57 11.26 89.62 46.62 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 1bd3_c00 source 1bd3 URACIL PHOSPHORIBOSYLTRANSFERASE : 13 hits 1bd3_c00 naa= 3 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 1 3 # 1 D 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 D 141 THR A 37 THR^? 15.29 O2 EDO A 103 D 235 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -27.88 -79.13 -19.84 -28.01 -79.96 -17.89 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 2 3 # 2 D 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 D 141 THR A 37 THR^? 15.29 O2 EDO A 103 D 235 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -27.88 -79.13 -19.84 -28.01 -79.96 -17.89 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 3 3 # 3 D 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 D 141 THR A 61 THR^? 12.85 O2 EDO A 103 D 235 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 4 3 # 4 D 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 D 141 THR A 61 THR^? 12.85 O2 EDO A 103 D 235 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 5 3 # 5 D 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 D 141 THR B 61 THR^? 13.51 O2 CIT B 103 D 235 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 6 3 # 6 D 137 ARG B 40 ARG^? 17.25 O1 CIT B 103 D 141 THR B 37 THR^? 15.70 O1 CIT B 103 D 235 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 7 3 # 7 D 137 ARG B 40 ARG^? 17.25 O1 CIT B 103 D 141 THR B 61 THR^? 13.51 O2 CIT B 103 D 235 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 8 3 # 8 D 137 ARG C 40 ARG^? 17.96 O1 CIT C 104 D 141 THR C 37 THR^? 15.86 O1 CIT C 104 D 235 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -59.71 -66.76 -26.49 -61.02 -66.76 -24.80 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 9 3 # 9 D 137 ARG C 40 ARG^? 17.96 O1 CIT C 104 D 141 THR C 61 THR^? 13.10 O1 CIT C 104 D 235 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 10 3 # 10 D 137 ARG C 79 ARG~? -3.25 O5 CIT E 104s D 141 THR E 76 THR~? 11.76 O1 CIT E 104 D 235 ASP C 27 ASP~? 13.15 O1 CIT C 104 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -41.22 -80.95 -36.62 -40.13 -82.58 -35.59 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 11 3 # 11 D 137 ARG C 79 ARG~? -3.25 O5 CIT E 104s D 141 THR E 76 THR~? 11.76 O1 CIT E 104 D 235 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -41.22 -80.95 -36.62 -40.13 -82.58 -35.59 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 12 3 # 12 D 137 ARG D 40 ARG^? 16.76 O2 CIT D 103 D 141 THR D 37 THR^? 15.68 O2 CIT D 103 D 235 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -60.31 -53.03 -17.12 -60.51 -52.85 -19.30 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 13 3 # 13 D 137 ARG D 40 ARG^? 16.76 O2 CIT D 103 D 141 THR D 61 THR^? 13.17 O2 CIT D 103 D 235 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 14 3 # 14 D 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s D 141 THR E 37 THR^? 12.88 O1 EDO E 103 D 235 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -34.67 -91.61 -48.59 -35.29 -92.29 -50.56 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 15 3 # 15 D 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s D 141 THR E 61 THR^? 11.76 O1 EDO E 103 D 235 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 16 3 # 16 D 137 ARG E 79 ARG~? -3.12 O5 CIT C 104s D 141 THR C 76 THR~? 11.98 O1 CIT C 104 D 235 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -48.60 -73.65 -37.71 -50.17 -72.60 -38.82 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 17 3 # 17 D 137 ARG F 40 ARG^? 16.45 O2 CIT F 104 D 141 THR F 37 THR^? 14.28 O2 EDO E 103 D 235 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -20.68 -92.02 -57.87 -20.13 -91.87 -55.81 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1bd3_c01 URACIL PHOSPHORIBOSYLTRANSFERASE user 18 3 # 18 D 137 ARG F 40 ARG^? 16.45 O2 CIT F 104 D 141 THR F 61 THR^? 11.09 O2 EDO E 103 D 235 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo -8.33 92.80 100.06 -7.71 95.33 98.44 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo -9.24 93.49 108.77 -7.37 94.21 109.61 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo -14.64 87.74 89.51 -12.89 87.43 90.65 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 1bd3_c01 source 1bd3 URACIL PHOSPHORIBOSYLTRANSFERASE : 18 hits 1bd3_c01 naa= 3 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 1 3 # 1 C 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 C 141 THR A 37 THR^? 15.29 O2 EDO A 103 C 235 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -27.88 -79.13 -19.84 -28.01 -79.96 -17.89 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 2 3 # 2 C 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 C 141 THR A 61 THR^? 12.85 O2 EDO A 103 C 235 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 3 3 # 3 C 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 C 141 THR A 61 THR^? 12.85 O2 EDO A 103 C 235 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 4 3 # 4 C 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 C 141 THR B 61 THR^? 13.51 O2 CIT B 103 C 235 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 5 3 # 5 C 137 ARG B 40 ARG^? 17.25 O1 CIT B 103 C 141 THR B 37 THR^? 15.70 O1 CIT B 103 C 235 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 6 3 # 6 C 137 ARG B 40 ARG^? 17.25 O1 CIT B 103 C 141 THR B 61 THR^? 13.51 O2 CIT B 103 C 235 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 7 3 # 7 C 137 ARG C 40 ARG^? 17.96 O1 CIT C 104 C 141 THR C 37 THR^? 15.86 O1 CIT C 104 C 235 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -59.71 -66.76 -26.49 -61.02 -66.76 -24.80 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 8 3 # 8 C 137 ARG C 40 ARG^? 17.96 O1 CIT C 104 C 141 THR C 61 THR^? 13.10 O1 CIT C 104 C 235 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 9 3 # 9 C 137 ARG C 79 ARG~? -3.25 O5 CIT E 104s C 141 THR E 76 THR~? 11.76 O1 CIT E 104 C 235 ASP C 27 ASP~? 13.15 O1 CIT C 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -41.22 -80.95 -36.62 -40.13 -82.58 -35.59 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 10 3 # 10 C 137 ARG D 40 ARG^? 16.76 O2 CIT D 103 C 141 THR D 37 THR^? 15.68 O2 CIT D 103 C 235 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -60.31 -53.03 -17.12 -60.51 -52.85 -19.30 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 11 3 # 11 C 137 ARG D 40 ARG^? 16.76 O2 CIT D 103 C 141 THR D 61 THR^? 13.17 O2 CIT D 103 C 235 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 12 3 # 12 C 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s C 141 THR E 37 THR^? 12.88 O1 EDO E 103 C 235 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -34.67 -91.61 -48.59 -35.29 -92.29 -50.56 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 13 3 # 13 C 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s C 141 THR E 61 THR^? 11.76 O1 EDO E 103 C 235 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 14 3 # 14 C 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s C 141 THR E 61 THR^? 11.76 O1 EDO E 103 C 235 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 15 3 # 15 C 137 ARG F 40 ARG^? 16.45 O2 CIT F 104 C 141 THR F 37 THR^? 14.28 O2 EDO E 103 C 235 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -20.68 -92.02 -57.87 -20.13 -91.87 -55.81 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 16 3 # 16 C 137 ARG F 40 ARG^? 16.45 O2 CIT F 104 C 141 THR F 61 THR^? 11.09 O2 EDO E 103 C 235 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1bd3_c02 URACIL PHOSPHORIBOSYLTRANSFERASE user 17 3 # 17 C 137 ARG F 40 ARG^? 16.45 O2 CIT F 104 C 141 THR F 61 THR^? 11.09 O2 EDO E 103 C 235 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -5.79 67.26 36.83 -4.57 64.58 37.74 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo -6.81 68.31 28.28 -4.82 68.47 27.57 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo -13.01 70.96 47.58 -11.44 71.65 46.34 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 1bd3_c02 source 1bd3 URACIL PHOSPHORIBOSYLTRANSFERASE : 17 hits 1bd3_c02 naa= 3 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 1 3 # 1 B 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 B 141 THR A 37 THR^? 15.29 O2 EDO A 103 B 235 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 8.28 67.78 108.81 6.22 67.65 109.43 -27.88 -79.13 -19.84 -28.01 -79.96 -17.89 coo 14.55 73.52 89.47 12.81 73.95 90.56 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 2 3 # 2 B 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 B 141 THR A 37 THR^? 15.29 O2 EDO A 103 B 235 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 8.28 67.78 108.81 6.22 67.65 109.43 -27.88 -79.13 -19.84 -28.01 -79.96 -17.89 coo 14.55 73.52 89.47 12.81 73.95 90.56 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 3 3 # 3 B 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 B 141 THR A 61 THR^? 12.85 O2 EDO A 103 B 235 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 8.28 67.78 108.81 6.22 67.65 109.43 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 14.55 73.52 89.47 12.81 73.95 90.56 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 4 3 # 4 B 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 B 141 THR A 61 THR^? 12.85 O2 EDO A 103 B 235 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 8.13 67.41 100.27 7.18 68.35 97.45 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 8.28 67.78 108.81 6.22 67.65 109.43 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 14.55 73.52 89.47 12.81 73.95 90.56 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 5 3 # 5 B 137 ARG A 40 ARG^? 16.77 O2 EDO A 103 B 141 THR B 61 THR^? 13.51 O2 CIT B 103 B 235 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 8.13 67.41 100.27 7.18 68.35 97.45 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 8.28 67.78 108.81 6.22 67.65 109.43 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 14.55 73.52 89.47 12.81 73.95 90.56 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 6 3 # 6 B 137 ARG B 40 ARG^? 17.25 O1 CIT B 103 B 141 THR B 37 THR^? 15.70 O1 CIT B 103 B 235 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 8.28 67.78 108.81 6.22 67.65 109.43 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 coo 14.55 73.52 89.47 12.81 73.95 90.56 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 7 3 # 7 B 137 ARG B 40 ARG^? 17.25 O1 CIT B 103 B 141 THR B 37 THR^? 15.70 O1 CIT B 103 B 235 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 8.28 67.78 108.81 6.22 67.65 109.43 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 coo 14.55 73.52 89.47 12.81 73.95 90.56 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 8 3 # 8 B 137 ARG B 40 ARG^? 17.25 O1 CIT B 103 B 141 THR B 61 THR^? 13.51 O2 CIT B 103 B 235 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 8.28 67.78 108.81 6.22 67.65 109.43 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 14.55 73.52 89.47 12.81 73.95 90.56 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 9 3 # 9 B 137 ARG C 40 ARG^? 17.96 O1 CIT C 104 B 141 THR C 37 THR^? 15.86 O1 CIT C 104 B 235 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 8.28 67.78 108.81 6.22 67.65 109.43 -59.71 -66.76 -26.49 -61.02 -66.76 -24.80 coo 14.55 73.52 89.47 12.81 73.95 90.56 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 10 3 # 10 B 137 ARG C 40 ARG^? 17.96 O1 CIT C 104 B 141 THR C 37 THR^? 15.86 O1 CIT C 104 B 235 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 8.28 67.78 108.81 6.22 67.65 109.43 -59.71 -66.76 -26.49 -61.02 -66.76 -24.80 coo 14.55 73.52 89.47 12.81 73.95 90.56 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 11 3 # 11 B 137 ARG C 40 ARG^? 17.96 O1 CIT C 104 B 141 THR C 61 THR^? 13.10 O1 CIT C 104 B 235 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 8.28 67.78 108.81 6.22 67.65 109.43 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo 14.55 73.52 89.47 12.81 73.95 90.56 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 12 3 # 12 B 137 ARG D 40 ARG^? 16.76 O2 CIT D 103 B 141 THR D 37 THR^? 15.68 O2 CIT D 103 B 235 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 8.13 67.41 100.27 7.18 68.35 97.45 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 8.28 67.78 108.81 6.22 67.65 109.43 -60.31 -53.03 -17.12 -60.51 -52.85 -19.30 coo 14.55 73.52 89.47 12.81 73.95 90.56 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 13 3 # 13 B 137 ARG D 40 ARG^? 16.76 O2 CIT D 103 B 141 THR D 61 THR^? 13.17 O2 CIT D 103 B 235 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 8.13 67.41 100.27 7.18 68.35 97.45 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 8.28 67.78 108.81 6.22 67.65 109.43 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo 14.55 73.52 89.47 12.81 73.95 90.56 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 14 3 # 14 B 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s B 141 THR E 37 THR^? 12.88 O1 EDO E 103 B 235 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 8.28 67.78 108.81 6.22 67.65 109.43 -34.67 -91.61 -48.59 -35.29 -92.29 -50.56 coo 14.55 73.52 89.47 12.81 73.95 90.56 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 15 3 # 15 B 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s B 141 THR E 37 THR^? 12.88 O1 EDO E 103 B 235 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 8.13 67.41 100.27 7.18 68.35 97.45 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 8.28 67.78 108.81 6.22 67.65 109.43 -34.67 -91.61 -48.59 -35.29 -92.29 -50.56 coo 14.55 73.52 89.47 12.81 73.95 90.56 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 16 3 # 16 B 137 ARG E 40 ARG^? -5.36 O2 EDO E 103s B 141 THR E 61 THR^? 11.76 O1 EDO E 103 B 235 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 8.13 67.41 100.27 7.18 68.35 97.45 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 8.28 67.78 108.81 6.22 67.65 109.43 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo 14.55 73.52 89.47 12.81 73.95 90.56 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 17 3 # 17 B 137 ARG F 40 ARG^? 16.45 O2 CIT F 104 B 141 THR F 37 THR^? 14.28 O2 EDO E 103 B 235 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 8.13 67.41 100.27 7.18 68.35 97.45 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 8.28 67.78 108.81 6.22 67.65 109.43 -20.68 -92.02 -57.87 -20.13 -91.87 -55.81 coo 14.55 73.52 89.47 12.81 73.95 90.56 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1bd3_c03 URACIL PHOSPHORIBOSYLTRANSFERASE user 18 3 # 18 B 137 ARG F 40 ARG^? 16.45 O2 CIT F 104 B 141 THR F 61 THR^? 11.09 O2 EDO E 103 B 235 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 8.13 67.41 100.27 7.18 68.35 97.45 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 8.28 67.78 108.81 6.22 67.65 109.43 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo 14.55 73.52 89.47 12.81 73.95 90.56 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 1bd3_c03 source 1bd3 URACIL PHOSPHORIBOSYLTRANSFERASE : 18 hits 1bd3_c03 naa= 3 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 1 3 # 1 14 ASP A 27 ASP~? 13.11 O2 EDO A 103 16 HIS A 41 HIS^? 12.51 O2 EDO A 103 67 GLY A 12 GLY.? 18.49 C1 EDO A 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -3.42 -86.00 -39.98 -3.58 -85.40 -39.51 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 2 3 # 2 14 ASP A 27 ASP~? 13.11 O2 EDO A 103 16 HIS A 41 HIS^? 12.51 O2 EDO A 103 67 GLY A 91 GLY~? 10.61 O1 EDO A 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 3 3 # 3 14 ASP B 27 ASP~? 12.32 O1 CIT B 103 16 HIS B 41 HIS^? 11.37 O1 CIT B 103 67 GLY B 12 GLY.? 16.79 O3 CIT B 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -1.76 -97.65 -2.49 -2.53 -97.53 -2.73 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 4 3 # 4 14 ASP B 27 ASP~? 12.32 O1 CIT B 103 16 HIS B 41 HIS^? 11.37 O1 CIT B 103 67 GLY B 91 GLY~? 7.97 O3 CIT B 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 3.29 -89.28 -7.61 2.92 -89.60 -8.27 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 5 3 # 5 14 ASP C 27 ASP~? 13.15 O1 CIT C 104 16 HIS C 41 HIS^? 12.16 O1 CIT C 104 67 GLY C 12 GLY.? 8.94 O2 EDO C 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -29.72 -59.63 -35.07 -30.25 -59.10 -34.73 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 6 3 # 6 14 ASP C 27 ASP~? 13.15 O1 CIT C 104 16 HIS C 41 HIS^? 12.16 O1 CIT C 104 67 GLY C 91 GLY~? 8.26 O4 CIT C 104 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 7 3 # 7 14 ASP C 99 ASP^? 7.14 O2 CIT C 104 16 HIS C 4 HIS.? -4.06 O2 CIT C 104s 67 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 8 3 # 8 14 ASP D 27 ASP~? 12.70 O1 CIT D 103 16 HIS D 41 HIS^? 12.20 O1 CIT D 103 67 GLY D 12 GLY.? 16.65 O4 CIT D 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -38.99 -65.10 3.52 -39.52 -65.51 3.06 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 9 3 # 9 14 ASP D 27 ASP~? 12.70 O1 CIT D 103 16 HIS D 41 HIS^? 12.20 O1 CIT D 103 67 GLY D 91 GLY~? 7.26 O4 CIT D 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 10 3 # 10 14 ASP E 27 ASP~? 4.58 C1 EDO E 103 16 HIS A 74 HIS~? 11.00 C1 EDO E 103 67 GLY A 42 GLY^? 14.43 O2 EDO A 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -12.08 -75.65 -26.58 -11.94 -76.42 -26.42 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 11 3 # 11 14 ASP E 27 ASP~? 4.58 C1 EDO E 103 16 HIS A 74 HIS~? 11.00 C1 EDO E 103 67 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 12 3 # 12 14 ASP E 27 ASP~? 4.58 C1 EDO E 103 16 HIS A 74 HIS~? 11.00 C1 EDO E 103 67 GLY A 91 GLY~? 10.61 O1 EDO A 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 13 3 # 13 14 ASP E 27 ASP~? 4.58 C1 EDO E 103 16 HIS E 41 HIS^? -3.94 C2 EDO E 103s 67 GLY A 14 GLY~? 18.08 C2 EDO E 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 14 3 # 14 14 ASP E 27 ASP~? 4.58 C1 EDO E 103 16 HIS E 41 HIS^? -3.94 C2 EDO E 103s 67 GLY E 12 GLY.? 8.67 O2 EDO C 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -26.84 -62.13 -38.29 -26.35 -62.68 -38.61 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 15 3 # 15 14 ASP E 27 ASP~? 4.58 C1 EDO E 103 16 HIS E 41 HIS^? -3.94 C2 EDO E 103s 67 GLY E 91 GLY~? 5.97 O2 EDO C 103 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 16 3 # 16 14 ASP E 99 ASP^? 7.65 C2 CIT E 104 16 HIS E 4 HIS.? -4.01 O2 CIT E 104s 67 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 17 3 # 17 14 ASP F 27 ASP~? 14.00 O1 CIT F 104 16 HIS F 41 HIS^? 12.43 O1 CIT F 104 67 GLY F 12 GLY.? 16.46 O3 CIT F 104 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -31.48 -68.61 -76.86 -32.00 -69.15 -76.49 ULMN 3 1be1_c02 GLUTAMATE MUTASE user 18 3 # 18 14 ASP F 27 ASP~? 14.00 O1 CIT F 104 16 HIS F 41 HIS^? 12.43 O1 CIT F 104 67 GLY F 91 GLY~? 8.30 O3 CIT F 104 coo -11.04 -6.46 -7.27 -10.57 -4.40 -7.48 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo -6.73 -11.42 -7.86 -5.41 -11.61 -6.26 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 10.06 -0.59 -9.79 9.66 -0.34 -9.05 -22.80 -67.12 -70.37 -23.31 -66.96 -69.76 1be1_c02 source 1be1 GLUTAMATE MUTASE : 18 hits 1be1_c02 naa= 3 ULMN 3 1bf2_c00 ISOAMYLASE user 1 3 # 1 375 ASP A 99 ASP^? 8.10 O2 EDO A 103 435 GLU A 101 GLU^? 18.10 O2 EDO A 103 510 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 88.62 69.90 41.16 89.05 70.67 43.04 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 89.52 76.11 40.17 89.01 75.16 41.97 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 84.89 77.60 46.67 85.63 75.79 46.03 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1bf2_c00 ISOAMYLASE user 2 3 # 2 375 ASP B 99 ASP^? 7.47 O6 CIT B 103 435 GLU B 101 GLU^? 17.79 O2 CIT B 103 510 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 88.62 69.90 41.16 89.05 70.67 43.04 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 89.52 76.11 40.17 89.01 75.16 41.97 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 84.89 77.60 46.67 85.63 75.79 46.03 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1bf2_c00 ISOAMYLASE user 3 3 # 3 375 ASP C 99 ASP^? 7.14 O2 CIT C 104 435 GLU C 101 GLU^? 17.42 O2 CIT C 104 510 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 88.62 69.90 41.16 89.05 70.67 43.04 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 89.52 76.11 40.17 89.01 75.16 41.97 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 84.89 77.60 46.67 85.63 75.79 46.03 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1bf2_c00 ISOAMYLASE user 4 3 # 4 375 ASP D 99 ASP^? 6.89 O6 CIT D 103 435 GLU D 101 GLU^? 17.58 O6 CIT D 103 510 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 88.62 69.90 41.16 89.05 70.67 43.04 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 89.52 76.11 40.17 89.01 75.16 41.97 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 84.89 77.60 46.67 85.63 75.79 46.03 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1bf2_c00 ISOAMYLASE user 5 3 # 5 375 ASP E 99 ASP^? 7.65 C2 CIT E 104 435 GLU E 101 GLU^? 17.69 O2 CIT E 104 510 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 88.62 69.90 41.16 89.05 70.67 43.04 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 89.52 76.11 40.17 89.01 75.16 41.97 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 84.89 77.60 46.67 85.63 75.79 46.03 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1bf2_c00 ISOAMYLASE user 6 3 # 6 375 ASP F 99 ASP^? 6.97 O7 CIT F 104 435 GLU F 101 GLU^? 10.35 O2 EDO E 103 510 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 88.62 69.90 41.16 89.05 70.67 43.04 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 89.52 76.11 40.17 89.01 75.16 41.97 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 84.89 77.60 46.67 85.63 75.79 46.03 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1bf2_c00 source 1bf2 ISOAMYLASE : 6 hits 1bf2_c00 naa= 3 ULMN 3 1bgl_c08 BETA-GALACTOSIDASE user 1 3 # 1 A 461 GLU A 38 GLU^? 15.90 O2 EDO A 103 A 503 TYR A 3 TYR.? 14.44 O2 EDO A 103 A 537 GLU B 38 GLU^? 16.05 O1 CIT B 103 coo 24.06 146.21 11.09 22.89 146.18 9.36 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 15.91 140.69 8.32 15.71 143.39 9.13 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 16.65 144.44 13.24 18.34 145.22 12.33 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 1bgl_c08 source 1bgl BETA-GALACTOSIDASE : 1 hits 1bgl_c08 naa= 3 ULMN 3 1bhg_c05 BETA-GLUCURONIDASE user 1 3 # 1 B 382 ARG E 18 ARG~? 11.85 O4 CIT C 104 B 451 GLU A 32 GLU~? 8.29 O4 CIT C 104 B 540 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 82.21 41.07 119.14 83.95 40.66 116.59 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo 86.52 35.28 112.74 87.08 36.38 110.99 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 83.38 41.19 112.55 85.47 40.59 112.72 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1bhg_c05 BETA-GLUCURONIDASE user 2 3 # 2 B 382 ARG E 79 ARG~? -3.12 O5 CIT C 104s B 451 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 540 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 82.21 41.07 119.14 83.95 40.66 116.59 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo 86.52 35.28 112.74 87.08 36.38 110.99 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 83.38 41.19 112.55 85.47 40.59 112.72 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 1bhg_c05 source 1bhg BETA-GLUCURONIDASE : 2 hits 1bhg_c05 naa= 3 ULMN 3 1bib_c00 BIRA BIFUNCTIONAL PROTEIN (ACTS AS Buser 1 3 # 1 118 ARG C 45 ARG.? 18.33 O6 CIT D 103 183 LYS C 50 LYS.? -4.07 O4 CIT D 103s 317 ARG C 89 ARG.? 16.36 O3 CIT C 104 coo 76.57 109.19 73.41 73.86 110.26 72.16 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 coo 82.09 117.51 66.37 80.60 114.32 71.44 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo 65.21 120.62 58.76 63.62 123.14 59.66 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 ULMN 3 1bib_c00 BIRA BIFUNCTIONAL PROTEIN (ACTS AS Buser 2 3 # 2 118 ARG D 45 ARG.? 18.60 O2 CIT C 104 183 LYS D 50 LYS.? -4.40 O3 CIT C 104s 317 ARG D 89 ARG.? 14.10 O4 CIT D 103 coo 76.57 109.19 73.41 73.86 110.26 72.16 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 coo 82.09 117.51 66.37 80.60 114.32 71.44 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 65.21 120.62 58.76 63.62 123.14 59.66 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 ULMN 3 1bib_c00 BIRA BIFUNCTIONAL PROTEIN (ACTS AS Buser 3 3 # 3 118 ARG E 45 ARG.? 12.04 O2 EDO E 103 183 LYS E 50 LYS.? -4.05 O4 CIT F 104s 317 ARG E 89 ARG.? -3.87 C2 EDO C 103s coo 76.57 109.19 73.41 73.86 110.26 72.16 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 coo 82.09 117.51 66.37 80.60 114.32 71.44 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo 65.21 120.62 58.76 63.62 123.14 59.66 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 1bib_c00 source 1bib BIRA BIFUNCTIONAL PROTEIN (ACTS AS BIOTIN OPER: 3 hits 1bib_c00 naa= 3 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 1 3 # 1 30 GLY A 57 GLY^? 10.14 C1 EDO A 103 48 HIS A 4 HIS.? -4.40 O2 EDO A 103s 99 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 12.38 5.55 24.25 13.27 5.59 24.39 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 coo 18.80 12.68 24.53 17.69 13.54 26.08 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 17.07 18.51 26.62 16.67 17.07 28.09 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 2 3 # 2 30 GLY A 81 GLY~? 4.93 C2 EDO A 103 48 HIS A 4 HIS.? -4.40 O2 EDO A 103s 99 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 12.38 5.55 24.25 13.27 5.59 24.39 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 coo 18.80 12.68 24.53 17.69 13.54 26.08 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 17.07 18.51 26.62 16.67 17.07 28.09 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 3 3 # 3 30 GLY A 81 GLY~? 4.93 C2 EDO A 103 48 HIS A 74 HIS~? 11.00 C1 EDO E 103 99 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 12.38 5.55 24.25 13.27 5.59 24.39 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 coo 18.80 12.68 24.53 17.69 13.54 26.08 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 17.07 18.51 26.62 16.67 17.07 28.09 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 4 3 # 4 30 GLY B 57 GLY^? 9.92 O7 CIT B 103 48 HIS B 4 HIS.? -4.11 O2 CIT B 103s 99 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 12.38 5.55 24.25 13.27 5.59 24.39 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 coo 18.80 12.68 24.53 17.69 13.54 26.08 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 17.07 18.51 26.62 16.67 17.07 28.09 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 5 3 # 5 30 GLY B 81 GLY~? 3.85 C2 CIT B 103 48 HIS B 4 HIS.? -4.11 O2 CIT B 103s 99 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 12.38 5.55 24.25 13.27 5.59 24.39 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 coo 18.80 12.68 24.53 17.69 13.54 26.08 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 17.07 18.51 26.62 16.67 17.07 28.09 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 6 3 # 6 30 GLY C 57 GLY^? 10.09 O1 CIT C 104 48 HIS C 4 HIS.? -4.06 O2 CIT C 104s 99 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 12.38 5.55 24.25 13.27 5.59 24.39 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 coo 18.80 12.68 24.53 17.69 13.54 26.08 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 17.07 18.51 26.62 16.67 17.07 28.09 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 7 3 # 7 30 GLY C 81 GLY~? -3.48 O5 CIT C 104s 48 HIS C 4 HIS.? -4.06 O2 CIT C 104s 99 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 12.38 5.55 24.25 13.27 5.59 24.39 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 coo 18.80 12.68 24.53 17.69 13.54 26.08 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 17.07 18.51 26.62 16.67 17.07 28.09 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 8 3 # 8 30 GLY D 57 GLY^? 9.79 C2 CIT D 103 48 HIS D 4 HIS.? -4.16 O2 CIT D 103s 99 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 12.38 5.55 24.25 13.27 5.59 24.39 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 coo 18.80 12.68 24.53 17.69 13.54 26.08 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 17.07 18.51 26.62 16.67 17.07 28.09 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 9 3 # 9 30 GLY D 81 GLY~? 3.79 O7 CIT D 103 48 HIS D 4 HIS.? -4.16 O2 CIT D 103s 99 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 12.38 5.55 24.25 13.27 5.59 24.39 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 coo 18.80 12.68 24.53 17.69 13.54 26.08 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 17.07 18.51 26.62 16.67 17.07 28.09 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 10 3 # 10 30 GLY E 57 GLY^? 9.68 O2 EDO E 103 48 HIS E 4 HIS.? -4.01 O2 CIT E 104s 99 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 12.38 5.55 24.25 13.27 5.59 24.39 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 coo 18.80 12.68 24.53 17.69 13.54 26.08 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 17.07 18.51 26.62 16.67 17.07 28.09 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 11 3 # 11 30 GLY E 81 GLY~? -3.27 O5 CIT E 104s 48 HIS E 4 HIS.? -4.01 O2 CIT E 104s 99 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 12.38 5.55 24.25 13.27 5.59 24.39 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 coo 18.80 12.68 24.53 17.69 13.54 26.08 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 17.07 18.51 26.62 16.67 17.07 28.09 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 12 3 # 12 30 GLY F 57 GLY^? 10.08 O2 CIT F 104 48 HIS F 4 HIS.? -4.07 O2 CIT F 104s 99 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 12.38 5.55 24.25 13.27 5.59 24.39 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 coo 18.80 12.68 24.53 17.69 13.54 26.08 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 17.07 18.51 26.62 16.67 17.07 28.09 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1bp2_c00 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSuser 13 3 # 13 30 GLY F 81 GLY~? -3.66 O5 CIT F 104s 48 HIS F 4 HIS.? -4.07 O2 CIT F 104s 99 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 12.38 5.55 24.25 13.27 5.59 24.39 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 coo 18.80 12.68 24.53 17.69 13.54 26.08 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 17.07 18.51 26.62 16.67 17.07 28.09 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1bp2_c00 source 1bp2 PHOSPHOLIPASE A2 (E.C.3.1.1.4) (PHOSPHATIDE AC: 13 hits 1bp2_c00 naa= 3 ULMN 3 1bqc_c01 BETA-MANNANASE user 1 3 # 1 A 50 ARG E 18 ARG~? 11.85 O4 CIT C 104 A 128 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 225 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 38.56 19.11 14.83 37.12 21.00 16.76 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo 36.48 24.43 22.02 36.86 26.34 21.13 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 40.16 23.71 17.01 38.52 24.96 17.40 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 1bqc_c01 source 1bqc BETA-MANNANASE : 1 hits 1bqc_c01 naa= 3 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 1 3 # 1 A 325 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 354 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 421 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 31.05 49.37 64.51 31.97 51.11 63.85 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 29.07 50.42 58.36 29.02 52.18 59.49 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 30.82 59.76 58.47 31.12 59.02 60.40 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 2 3 # 2 A 325 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 354 GLU A 101 GLU^? 18.10 O2 EDO A 103 A 421 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 31.05 49.37 64.51 31.97 51.11 63.85 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 29.07 50.42 58.36 29.02 52.18 59.49 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 30.82 59.76 58.47 31.12 59.02 60.40 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 3 3 # 3 A 325 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 354 GLU B 48 GLU.? 3.87 O1 EDO A 103 A 421 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 31.05 49.37 64.51 31.97 51.11 63.85 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 29.07 50.42 58.36 29.02 52.18 59.49 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 30.82 59.76 58.47 31.12 59.02 60.40 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 4 3 # 4 A 325 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 354 GLU A 48 GLU.? -2.39 O6 CIT B 103s A 421 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 31.05 49.37 64.51 31.97 51.11 63.85 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 29.07 50.42 58.36 29.02 52.18 59.49 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 30.82 59.76 58.47 31.12 59.02 60.40 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 5 3 # 5 A 325 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 354 GLU B 101 GLU^? 17.79 O2 CIT B 103 A 421 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 31.05 49.37 64.51 31.97 51.11 63.85 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 29.07 50.42 58.36 29.02 52.18 59.49 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 30.82 59.76 58.47 31.12 59.02 60.40 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 6 3 # 6 A 325 ASP C 17 ASP~? -3.95 O1 EDO C 103s A 354 GLU C 21 GLU~? 6.35 O1 EDO C 103 A 421 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 31.05 49.37 64.51 31.97 51.11 63.85 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 29.07 50.42 58.36 29.02 52.18 59.49 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 30.82 59.76 58.47 31.12 59.02 60.40 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 7 3 # 7 A 325 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 354 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 421 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 31.05 49.37 64.51 31.97 51.11 63.85 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 29.07 50.42 58.36 29.02 52.18 59.49 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 30.82 59.76 58.47 31.12 59.02 60.40 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 8 3 # 8 A 325 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 354 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 421 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 31.05 49.37 64.51 31.97 51.11 63.85 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 29.07 50.42 58.36 29.02 52.18 59.49 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 30.82 59.76 58.47 31.12 59.02 60.40 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 9 3 # 9 A 325 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 354 GLU C 48 GLU.? -2.75 O6 CIT D 103s A 421 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 31.05 49.37 64.51 31.97 51.11 63.85 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 29.07 50.42 58.36 29.02 52.18 59.49 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 30.82 59.76 58.47 31.12 59.02 60.40 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 10 3 # 10 A 325 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 354 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 421 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 31.05 49.37 64.51 31.97 51.11 63.85 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 29.07 50.42 58.36 29.02 52.18 59.49 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 30.82 59.76 58.47 31.12 59.02 60.40 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 11 3 # 11 A 325 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 354 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 421 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 31.05 49.37 64.51 31.97 51.11 63.85 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 29.07 50.42 58.36 29.02 52.18 59.49 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 30.82 59.76 58.47 31.12 59.02 60.40 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 12 3 # 12 A 325 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 354 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 421 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 31.05 49.37 64.51 31.97 51.11 63.85 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 29.07 50.42 58.36 29.02 52.18 59.49 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 30.82 59.76 58.47 31.12 59.02 60.40 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 13 3 # 13 A 325 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 354 GLU F 48 GLU.? -3.15 C4 CIT E 104s A 421 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 31.05 49.37 64.51 31.97 51.11 63.85 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 29.07 50.42 58.36 29.02 52.18 59.49 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 30.82 59.76 58.47 31.12 59.02 60.40 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 14 3 # 14 A 325 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 354 GLU E 48 GLU.? -2.93 O7 CIT F 104s A 421 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 31.05 49.37 64.51 31.97 51.11 63.85 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 29.07 50.42 58.36 29.02 52.18 59.49 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 30.82 59.76 58.47 31.12 59.02 60.40 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 ULMN 3 1bvz_c08 ALPHA-AMYLASE II user 15 3 # 15 A 325 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 354 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 421 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 31.05 49.37 64.51 31.97 51.11 63.85 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 29.07 50.42 58.36 29.02 52.18 59.49 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 30.82 59.76 58.47 31.12 59.02 60.40 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1bvz_c08 source 1bvz ALPHA-AMYLASE II : 15 hits 1bvz_c08 naa= 3 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 1 3 # 1 B 325 ASP A 27 ASP~? 13.11 O2 EDO A 103 B 354 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 421 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 25.90 8.19 53.87 25.36 6.97 52.29 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 27.87 10.66 47.95 27.82 8.60 48.27 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 26.02 1.87 43.38 25.90 1.97 45.49 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 2 3 # 2 B 325 ASP A 27 ASP~? 13.11 O2 EDO A 103 B 354 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 421 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 27.87 10.66 47.95 27.82 8.60 48.27 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 26.02 1.87 43.38 25.90 1.97 45.49 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 3 3 # 3 B 325 ASP A 64 ASP~? 16.37 O2 EDO A 103 B 354 GLU A 101 GLU^? 18.10 O2 EDO A 103 B 421 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 27.87 10.66 47.95 27.82 8.60 48.27 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 26.02 1.87 43.38 25.90 1.97 45.49 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 4 3 # 4 B 325 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 354 GLU A 101 GLU^? 18.10 O2 EDO A 103 B 421 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 27.87 10.66 47.95 27.82 8.60 48.27 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 26.02 1.87 43.38 25.90 1.97 45.49 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 5 3 # 5 B 325 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 354 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 421 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 27.87 10.66 47.95 27.82 8.60 48.27 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 26.02 1.87 43.38 25.90 1.97 45.49 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 6 3 # 6 B 325 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 354 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 421 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 27.87 10.66 47.95 27.82 8.60 48.27 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 26.02 1.87 43.38 25.90 1.97 45.49 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 7 3 # 7 B 325 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 354 GLU B 101 GLU^? 17.79 O2 CIT B 103 B 421 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 27.87 10.66 47.95 27.82 8.60 48.27 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 26.02 1.87 43.38 25.90 1.97 45.49 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 8 3 # 8 B 325 ASP C 17 ASP~? -3.95 O1 EDO C 103s B 354 GLU C 21 GLU~? 6.35 O1 EDO C 103 B 421 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 25.90 8.19 53.87 25.36 6.97 52.29 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 27.87 10.66 47.95 27.82 8.60 48.27 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 26.02 1.87 43.38 25.90 1.97 45.49 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 9 3 # 9 B 325 ASP C 64 ASP~? 16.62 O2 CIT C 104 B 354 GLU C 101 GLU^? 17.42 O2 CIT C 104 B 421 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 25.90 8.19 53.87 25.36 6.97 52.29 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 27.87 10.66 47.95 27.82 8.60 48.27 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 26.02 1.87 43.38 25.90 1.97 45.49 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 10 3 # 10 B 325 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 354 GLU C 101 GLU^? 17.42 O2 CIT C 104 B 421 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 25.90 8.19 53.87 25.36 6.97 52.29 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 27.87 10.66 47.95 27.82 8.60 48.27 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 26.02 1.87 43.38 25.90 1.97 45.49 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 11 3 # 11 B 325 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 354 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 421 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 25.90 8.19 53.87 25.36 6.97 52.29 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 27.87 10.66 47.95 27.82 8.60 48.27 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 26.02 1.87 43.38 25.90 1.97 45.49 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 12 3 # 12 B 325 ASP D 64 ASP~? 16.39 O2 CIT D 103 B 354 GLU D 101 GLU^? 17.58 O6 CIT D 103 B 421 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 27.87 10.66 47.95 27.82 8.60 48.27 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 26.02 1.87 43.38 25.90 1.97 45.49 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 13 3 # 13 B 325 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 354 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 421 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 27.87 10.66 47.95 27.82 8.60 48.27 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 26.02 1.87 43.38 25.90 1.97 45.49 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 14 3 # 14 B 325 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 354 GLU D 101 GLU^? 17.58 O6 CIT D 103 B 421 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 27.87 10.66 47.95 27.82 8.60 48.27 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 26.02 1.87 43.38 25.90 1.97 45.49 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 15 3 # 15 B 325 ASP E 17 ASP~? 16.97 O4 CIT C 104 B 354 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 421 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 25.90 8.19 53.87 25.36 6.97 52.29 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 27.87 10.66 47.95 27.82 8.60 48.27 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 26.02 1.87 43.38 25.90 1.97 45.49 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 16 3 # 16 B 325 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 354 GLU E 101 GLU^? 17.69 O2 CIT E 104 B 421 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 25.90 8.19 53.87 25.36 6.97 52.29 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 27.87 10.66 47.95 27.82 8.60 48.27 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 26.02 1.87 43.38 25.90 1.97 45.49 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 17 3 # 17 B 325 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 354 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 421 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 25.90 8.19 53.87 25.36 6.97 52.29 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 27.87 10.66 47.95 27.82 8.60 48.27 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 26.02 1.87 43.38 25.90 1.97 45.49 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 18 3 # 18 B 325 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 354 GLU E 48 GLU.? -2.93 O7 CIT F 104s B 421 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 25.90 8.19 53.87 25.36 6.97 52.29 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 27.87 10.66 47.95 27.82 8.60 48.27 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 26.02 1.87 43.38 25.90 1.97 45.49 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 ULMN 3 1bvz_c09 ALPHA-AMYLASE II user 19 3 # 19 B 325 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 354 GLU F 101 GLU^? 10.35 O2 EDO E 103 B 421 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 25.90 8.19 53.87 25.36 6.97 52.29 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 27.87 10.66 47.95 27.82 8.60 48.27 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 26.02 1.87 43.38 25.90 1.97 45.49 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1bvz_c09 source 1bvz ALPHA-AMYLASE II : 19 hits 1bvz_c09 naa= 3 ULMN 3 1bwd_c02 INOSAMINE-PHOSPHATE AMIDINOTRANSFERAuser 1 3 # 1 A 179 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 227 HIS A 41 HIS^? 12.51 O2 EDO A 103 A 332 CYH A 60 CYH^? 5.96 O2 EDO A 103 coo 123.98 30.59 1.90 124.68 28.67 1.28 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 119.16 28.51 2.63 120.67 28.31 1.13 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 114.70 31.13 -3.42 115.96 29.28 -1.69 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 ULMN 3 1bwd_c02 INOSAMINE-PHOSPHATE AMIDINOTRANSFERAuser 2 3 # 2 A 179 ASP B 27 ASP~? 12.32 O1 CIT B 103 A 227 HIS B 41 HIS^? 11.37 O1 CIT B 103 A 332 CYH B 60 CYH^? 5.88 O1 CIT B 103 coo 123.98 30.59 1.90 124.68 28.67 1.28 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 119.16 28.51 2.63 120.67 28.31 1.13 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 114.70 31.13 -3.42 115.96 29.28 -1.69 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 ULMN 3 1bwd_c02 INOSAMINE-PHOSPHATE AMIDINOTRANSFERAuser 3 3 # 3 A 179 ASP D 27 ASP~? 12.70 O1 CIT D 103 A 227 HIS D 41 HIS^? 12.20 O1 CIT D 103 A 332 CYH D 60 CYH^? 5.69 O2 CIT D 103 coo 123.98 30.59 1.90 124.68 28.67 1.28 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 119.16 28.51 2.63 120.67 28.31 1.13 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 114.70 31.13 -3.42 115.96 29.28 -1.69 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 ULMN 3 1bwd_c02 INOSAMINE-PHOSPHATE AMIDINOTRANSFERAuser 4 3 # 4 A 179 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 227 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 332 CYH E 60 CYH^? 5.61 O2 CIT E 104 coo 123.98 30.59 1.90 124.68 28.67 1.28 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 119.16 28.51 2.63 120.67 28.31 1.13 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 114.70 31.13 -3.42 115.96 29.28 -1.69 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 1bwd_c02 source 1bwd INOSAMINE-PHOSPHATE AMIDINOTRANSFERASE : 4 hits 1bwd_c02 naa= 3 ULMN 3 1bwd_c03 INOSAMINE-PHOSPHATE AMIDINOTRANSFERAuser 1 3 # 1 B 179 ASP B 27 ASP~? 12.32 O1 CIT B 103 B 227 HIS B 41 HIS^? 11.37 O1 CIT B 103 B 332 CYH B 60 CYH^? 5.88 O1 CIT B 103 coo 94.18 76.57 24.23 93.74 77.97 22.66 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 89.34 74.44 23.40 90.11 76.41 23.55 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 85.03 76.39 29.77 85.85 76.14 27.06 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 ULMN 3 1bwd_c03 INOSAMINE-PHOSPHATE AMIDINOTRANSFERAuser 2 3 # 2 B 179 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 227 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 332 CYH E 60 CYH^? 5.61 O2 CIT E 104 coo 94.18 76.57 24.23 93.74 77.97 22.66 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 89.34 74.44 23.40 90.11 76.41 23.55 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 85.03 76.39 29.77 85.85 76.14 27.06 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 1bwd_c03 source 1bwd INOSAMINE-PHOSPHATE AMIDINOTRANSFERASE : 2 hits 1bwd_c03 naa= 3 ULMN 3 1c54_c00 RIBONUCLEASE SA user 1 3 # 1 A 54 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 65 ARG E 79 ARG~? -3.12 O5 CIT C 104s A 85 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo -3.75 5.08 -16.45 -4.49 7.03 -16.67 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo -11.31 0.89 -21.51 -13.74 2.37 -20.15 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo -11.98 -0.40 -12.41 -12.65 1.37 -13.15 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1c54_c00 RIBONUCLEASE SA user 2 3 # 2 A 54 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 65 ARG C 40 ARG^? 17.96 O1 CIT C 104 A 85 HIS C 41 HIS^? 12.16 O1 CIT C 104 coo -3.75 5.08 -16.45 -4.49 7.03 -16.67 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo -11.31 0.89 -21.51 -13.74 2.37 -20.15 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -11.98 -0.40 -12.41 -12.65 1.37 -13.15 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 ULMN 3 1c54_c00 RIBONUCLEASE SA user 3 3 # 3 A 54 GLU F 48 GLU.? -3.15 C4 CIT E 104s A 65 ARG C 79 ARG~? -3.25 O5 CIT E 104s A 85 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo -3.75 5.08 -16.45 -4.49 7.03 -16.67 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo -11.31 0.89 -21.51 -13.74 2.37 -20.15 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo -11.98 -0.40 -12.41 -12.65 1.37 -13.15 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 1c54_c00 source 1c54 RIBONUCLEASE SA : 3 hits 1c54_c00 naa= 3 ULMN 3 1c82_c02 HYALURONATE LYASE user 1 3 # 1 A 399 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 408 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 480 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1c82_c02 HYALURONATE LYASE user 2 3 # 2 A 399 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 408 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 480 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1c82_c02 HYALURONATE LYASE user 3 3 # 3 A 399 HIS B 41 HIS^? 11.37 O1 CIT B 103 A 408 TYR B 56 TYR^? 12.51 O1 CIT B 103 A 480 ARG B 89 ARG.? 13.25 O3 CIT B 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 0.32 -96.47 -11.54 1.69 -95.10 -13.99 ULMN 3 1c82_c02 HYALURONATE LYASE user 4 3 # 4 A 399 HIS B 74 HIS~? 11.72 O1 CIT B 103 A 408 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 480 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1c82_c02 HYALURONATE LYASE user 5 3 # 5 A 399 HIS C 41 HIS^? 12.16 O1 CIT C 104 A 408 TYR C 56 TYR^? 12.84 O1 CIT C 104 A 480 ARG C 89 ARG.? 16.36 O3 CIT C 104 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 ULMN 3 1c82_c02 HYALURONATE LYASE user 6 3 # 6 A 399 HIS C 41 HIS^? 12.16 O1 CIT C 104 A 408 TYR C 56 TYR^? 12.84 O1 CIT C 104 A 480 ARG E 18 ARG~? 11.85 O4 CIT C 104 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 ULMN 3 1c82_c02 HYALURONATE LYASE user 7 3 # 7 A 399 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 408 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 480 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1c82_c02 HYALURONATE LYASE user 8 3 # 8 A 399 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 408 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 480 ARG D 45 ARG.? 18.60 O2 CIT C 104 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 ULMN 3 1c82_c02 HYALURONATE LYASE user 9 3 # 9 A 399 HIS D 41 HIS^? 12.20 O1 CIT D 103 A 408 TYR D 56 TYR^? 12.73 C2 CIT D 103 A 480 ARG D 89 ARG.? 14.10 O4 CIT D 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 ULMN 3 1c82_c02 HYALURONATE LYASE user 10 3 # 10 A 399 HIS D 74 HIS~? 11.86 O1 CIT D 103 A 408 TYR D 71 TYR~? -4.87 O2 CIT D 103s A 480 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1c82_c02 HYALURONATE LYASE user 11 3 # 11 A 399 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 408 TYR E 56 TYR^? 8.81 O2 EDO E 103 A 480 ARG C 18 ARG~? -3.10 O1 EDO C 103s coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 ULMN 3 1c82_c02 HYALURONATE LYASE user 12 3 # 12 A 399 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 408 TYR E 56 TYR^? 8.81 O2 EDO E 103 A 480 ARG E 89 ARG.? -3.87 C2 EDO C 103s coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 ULMN 3 1c82_c02 HYALURONATE LYASE user 13 3 # 13 A 399 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 408 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 480 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1c82_c02 HYALURONATE LYASE user 14 3 # 14 A 399 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 408 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 480 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 ULMN 3 1c82_c02 HYALURONATE LYASE user 15 3 # 15 A 399 HIS E 77 HIS~? -4.13 O1 CIT E 104s A 408 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 480 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 ULMN 3 1c82_c02 HYALURONATE LYASE user 16 3 # 16 A 399 HIS F 41 HIS^? 12.43 O1 CIT F 104 A 408 TYR F 56 TYR^? 13.04 O1 CIT F 104 A 480 ARG F 89 ARG.? 10.30 C2 EDO F 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -31.12 -63.92 -68.77 -30.34 -61.79 -66.66 ULMN 3 1c82_c02 HYALURONATE LYASE user 17 3 # 17 A 399 HIS F 74 HIS~? 11.52 O1 CIT F 104 A 408 TYR F 71 TYR~? -4.99 O2 CIT F 104s A 480 ARG E 45 ARG.? 12.04 O2 EDO E 103 coo 13.02 -18.02 35.24 12.75 -16.25 34.15 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 7.81 -17.82 32.55 9.60 -15.69 32.78 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo -6.46 -13.31 26.85 -4.21 -11.25 27.13 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 1c82_c02 source 1c82 HYALURONATE LYASE : 17 hits 1c82_c02 naa= 3 ULMN 3 1cb7_c06 GLUTAMATE MUTASE user 1 3 # 1 A 14 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 16 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 67 GLY A 28 GLY~? 12.77 C2 EDO E 103 coo 11.02 -13.08 77.25 10.70 -11.13 76.52 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 7.44 -8.54 76.22 7.57 -7.67 78.12 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 18.64 -11.26 77.99 18.99 -11.13 78.72 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 ULMN 3 1cb7_c06 GLUTAMATE MUTASE user 2 3 # 2 A 14 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 16 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 67 GLY A 28 GLY~? 12.77 C2 EDO E 103 coo 11.02 -13.08 77.25 10.70 -11.13 76.52 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 7.44 -8.54 76.22 7.57 -7.67 78.12 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 18.64 -11.26 77.99 18.99 -11.13 78.72 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 1cb7_c06 source 1cb7 GLUTAMATE MUTASE : 2 hits 1cb7_c06 naa= 3 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 1 3 # 1 229 ASP A 69 ASP~? 12.13 O2 EDO A 103 264 GLU A 38 GLU^? 15.90 O2 EDO A 103 328 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 59.69 92.71 39.85 58.53 92.03 41.47 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 45.39 90.72 40.63 45.07 89.14 41.90 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 2 3 # 2 229 ASP A 69 ASP~? 12.13 O2 EDO A 103 264 GLU A 38 GLU^? 15.90 O2 EDO A 103 328 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 59.69 92.71 39.85 58.53 92.03 41.47 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 45.39 90.72 40.63 45.07 89.14 41.90 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 3 3 # 3 229 ASP B 64 ASP~? 16.93 O2 CIT B 103 264 GLU B 32 GLU~? 16.71 O1 CIT B 103 328 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 59.69 92.71 39.85 58.53 92.03 41.47 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 45.39 90.72 40.63 45.07 89.14 41.90 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 4 3 # 4 229 ASP B 69 ASP~? 11.84 O5 CIT B 103 264 GLU B 38 GLU^? 16.05 O1 CIT B 103 328 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 59.69 92.71 39.85 58.53 92.03 41.47 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 45.39 90.72 40.63 45.07 89.14 41.90 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 5 3 # 5 229 ASP B 69 ASP~? 11.84 O5 CIT B 103 264 GLU B 38 GLU^? 16.05 O1 CIT B 103 328 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 59.69 92.71 39.85 58.53 92.03 41.47 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 45.39 90.72 40.63 45.07 89.14 41.90 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 6 3 # 6 229 ASP C 64 ASP~? 16.62 O2 CIT C 104 264 GLU C 32 GLU~? 15.71 O1 CIT C 104 328 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 59.69 92.71 39.85 58.53 92.03 41.47 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 45.39 90.72 40.63 45.07 89.14 41.90 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 7 3 # 7 229 ASP C 69 ASP~? 11.49 O6 CIT C 104 264 GLU C 38 GLU^? 15.02 O1 CIT C 104 328 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 59.69 92.71 39.85 58.53 92.03 41.47 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 45.39 90.72 40.63 45.07 89.14 41.90 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 8 3 # 8 229 ASP C 69 ASP~? 11.49 O6 CIT C 104 264 GLU C 38 GLU^? 15.02 O1 CIT C 104 328 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 59.69 92.71 39.85 58.53 92.03 41.47 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 45.39 90.72 40.63 45.07 89.14 41.90 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 9 3 # 9 229 ASP C 93 ASP~? 9.74 O3 CIT C 104 264 GLU E 11 GLU.? -3.18 O2 EDO C 103s 328 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 59.69 92.71 39.85 58.53 92.03 41.47 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 45.39 90.72 40.63 45.07 89.14 41.90 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 10 3 # 10 229 ASP D 69 ASP~? 11.20 O6 CIT D 103 264 GLU D 38 GLU^? 15.43 O2 CIT D 103 328 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 59.69 92.71 39.85 58.53 92.03 41.47 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 45.39 90.72 40.63 45.07 89.14 41.90 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 11 3 # 11 229 ASP D 69 ASP~? 11.20 O6 CIT D 103 264 GLU D 38 GLU^? 15.43 O2 CIT D 103 328 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 59.69 92.71 39.85 58.53 92.03 41.47 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 45.39 90.72 40.63 45.07 89.14 41.90 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 12 3 # 12 229 ASP E 17 ASP~? 16.97 O4 CIT C 104 264 GLU D 48 GLU.? -3.37 O7 CIT C 104s 328 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 59.69 92.71 39.85 58.53 92.03 41.47 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 45.39 90.72 40.63 45.07 89.14 41.90 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 13 3 # 13 229 ASP E 69 ASP~? 11.60 O6 CIT E 104 264 GLU E 38 GLU^? 8.47 O1 EDO E 103 328 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 59.69 92.71 39.85 58.53 92.03 41.47 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 45.39 90.72 40.63 45.07 89.14 41.90 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 14 3 # 14 229 ASP E 69 ASP~? 11.60 O6 CIT E 104 264 GLU E 38 GLU^? 8.47 O1 EDO E 103 328 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 59.69 92.71 39.85 58.53 92.03 41.47 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 45.39 90.72 40.63 45.07 89.14 41.90 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 15 3 # 15 229 ASP E 93 ASP~? 8.62 O3 CIT E 104 264 GLU C 11 GLU.? 13.80 O2 EDO C 103 328 ASP C 17 ASP~? -3.95 O1 EDO C 103s coo 45.62 80.42 43.69 45.65 82.01 45.07 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 59.69 92.71 39.85 58.53 92.03 41.47 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 45.39 90.72 40.63 45.07 89.14 41.90 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 16 3 # 16 229 ASP F 64 ASP~? 16.52 O2 EDO E 103 264 GLU F 32 GLU~? 16.06 O1 CIT F 104 328 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 59.69 92.71 39.85 58.53 92.03 41.47 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 45.39 90.72 40.63 45.07 89.14 41.90 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 17 3 # 17 229 ASP F 69 ASP~? 11.68 O6 CIT F 104 264 GLU F 38 GLU^? 13.95 O2 EDO E 103 328 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 59.69 92.71 39.85 58.53 92.03 41.47 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 45.39 90.72 40.63 45.07 89.14 41.90 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1cdg_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 18 3 # 18 229 ASP F 69 ASP~? 11.68 O6 CIT F 104 264 GLU F 38 GLU^? 13.95 O2 EDO E 103 328 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 59.69 92.71 39.85 58.53 92.03 41.47 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 45.39 90.72 40.63 45.07 89.14 41.90 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1cdg_c00 source 1cdg CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.C.2.4.1.19: 18 hits 1cdg_c00 naa= 3 ULMN 3 1cdg_c04 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 1 3 # 1 229 ASP A 64 ASP~? 16.37 O2 EDO A 103 257 GLU A 101 GLU^? 18.10 O2 EDO A 103 328 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 48.97 85.16 40.39 47.18 86.25 40.47 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 45.39 90.72 40.63 45.07 89.14 41.90 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1cdg_c04 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 2 3 # 2 229 ASP A 99 ASP^? 8.10 O2 EDO A 103 257 GLU A 101 GLU^? 18.10 O2 EDO A 103 328 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 48.97 85.16 40.39 47.18 86.25 40.47 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 45.39 90.72 40.63 45.07 89.14 41.90 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1cdg_c04 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 3 3 # 3 229 ASP B 64 ASP~? 16.93 O2 CIT B 103 257 GLU B 101 GLU^? 17.79 O2 CIT B 103 328 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 48.97 85.16 40.39 47.18 86.25 40.47 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 45.39 90.72 40.63 45.07 89.14 41.90 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1cdg_c04 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 4 3 # 4 229 ASP C 64 ASP~? 16.62 O2 CIT C 104 257 GLU C 101 GLU^? 17.42 O2 CIT C 104 328 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 45.62 80.42 43.69 45.65 82.01 45.07 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 48.97 85.16 40.39 47.18 86.25 40.47 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 45.39 90.72 40.63 45.07 89.14 41.90 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1cdg_c04 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 5 3 # 5 229 ASP D 64 ASP~? 16.39 O2 CIT D 103 257 GLU D 101 GLU^? 17.58 O6 CIT D 103 328 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 48.97 85.16 40.39 47.18 86.25 40.47 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 45.39 90.72 40.63 45.07 89.14 41.90 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1cdg_c04 CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.user 6 3 # 6 229 ASP D 99 ASP^? 6.89 O6 CIT D 103 257 GLU D 101 GLU^? 17.58 O6 CIT D 103 328 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 45.62 80.42 43.69 45.65 82.01 45.07 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 48.97 85.16 40.39 47.18 86.25 40.47 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 45.39 90.72 40.63 45.07 89.14 41.90 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 1cdg_c04 source 1cdg CYCLODEXTRIN GLYCOSYLTRANSFERASE (E.C.2.4.1.19: 6 hits 1cdg_c04 naa= 3 ULMN 3 1chm_c00 CREATINE AMIDINOHYDROLASE (E.C.3.5.3user 1 3 # 1 A 232 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 262 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 358 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 26.19 60.87 43.98 27.48 59.27 43.30 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 27.13 54.07 50.45 26.96 54.19 48.35 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 27.06 50.43 44.36 27.99 52.27 44.74 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 1chm_c00 source 1chm CREATINE AMIDINOHYDROLASE (E.C.3.5.3.3) : 1 hits 1chm_c00 naa= 3 ULMN 3 1cns_c00 CHITINASE user 1 3 # 1 A 67 GLU B 9 GLU.? 11.84 O3 CIT B 103 A 89 GLU B 11 GLU.? 15.97 O3 CIT B 103 A 120 SER B 87 SER~? 10.61 C4 CIT B 103 coo -24.35 9.53 67.64 -25.07 11.29 68.60 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo -31.18 6.91 75.60 -32.39 8.51 74.91 0.63 -96.18 -5.96 0.64 -98.22 -6.51 coo -34.73 8.57 68.21 -33.63 9.08 70.28 -2.02 -90.62 -3.15 -3.50 -89.66 -1.50 ULMN 3 1cns_c00 CHITINASE user 2 3 # 2 A 67 GLU B 13 GLU.? 22.42 C4 CIT B 103 A 89 GLU B 11 GLU.? 15.97 O3 CIT B 103 A 120 SER B 87 SER~? 10.61 C4 CIT B 103 coo -24.35 9.53 67.64 -25.07 11.29 68.60 -4.23-100.38 2.35 -5.07-101.78 1.01 coo -31.18 6.91 75.60 -32.39 8.51 74.91 0.63 -96.18 -5.96 0.64 -98.22 -6.51 coo -34.73 8.57 68.21 -33.63 9.08 70.28 -2.02 -90.62 -3.15 -3.50 -89.66 -1.50 ULMN 3 1cns_c00 CHITINASE user 3 3 # 3 A 67 GLU C 11 GLU.? 13.80 O2 EDO C 103 A 89 GLU E 11 GLU.? -3.18 O2 EDO C 103s A 120 SER E 87 SER~? 10.44 O7 CIT E 104 coo -24.35 9.53 67.64 -25.07 11.29 68.60 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo -31.18 6.91 75.60 -32.39 8.51 74.91 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo -34.73 8.57 68.21 -33.63 9.08 70.28 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 ULMN 3 1cns_c00 CHITINASE user 4 3 # 4 A 67 GLU E 9 GLU.? 7.76 O1 EDO F 103 A 89 GLU E 11 GLU.? -3.18 O2 EDO C 103s A 120 SER E 87 SER~? 10.44 O7 CIT E 104 coo -24.35 9.53 67.64 -25.07 11.29 68.60 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo -31.18 6.91 75.60 -32.39 8.51 74.91 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo -34.73 8.57 68.21 -33.63 9.08 70.28 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 ULMN 3 1cns_c00 CHITINASE user 5 3 # 5 A 67 GLU E 11 GLU.? -3.18 O2 EDO C 103s A 89 GLU C 11 GLU.? 13.80 O2 EDO C 103 A 120 SER C 87 SER~? 9.82 O2 EDO C 103 coo -24.35 9.53 67.64 -25.07 11.29 68.60 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo -31.18 6.91 75.60 -32.39 8.51 74.91 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo -34.73 8.57 68.21 -33.63 9.08 70.28 -34.89 -64.48 -33.73 -36.72 -64.13 -35.26 1cns_c00 source 1cns CHITINASE : 5 hits 1cns_c00 naa= 3 ULMN 3 1cns_c01 CHITINASE user 1 3 # 1 B 67 GLU C 11 GLU.? 13.80 O2 EDO C 103 B 89 GLU E 11 GLU.? -3.18 O2 EDO C 103s B 120 SER E 87 SER~? 10.44 O7 CIT E 104 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 ULMN 3 1cns_c01 CHITINASE user 2 3 # 2 B 67 GLU C 21 GLU~? 6.35 O1 EDO C 103 B 89 GLU E 11 GLU.? -3.18 O2 EDO C 103s B 120 SER C 87 SER~? 9.82 O2 EDO C 103 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -34.89 -64.48 -33.73 -36.72 -64.13 -35.26 ULMN 3 1cns_c01 CHITINASE user 3 3 # 3 B 67 GLU C 21 GLU~? 6.35 O1 EDO C 103 B 89 GLU E 11 GLU.? -3.18 O2 EDO C 103s B 120 SER E 87 SER~? 10.44 O7 CIT E 104 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 ULMN 3 1cns_c01 CHITINASE user 4 3 # 4 B 67 GLU E 11 GLU.? -3.18 O2 EDO C 103s B 89 GLU C 11 GLU.? 13.80 O2 EDO C 103 B 120 SER C 87 SER~? 9.82 O2 EDO C 103 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -34.89 -64.48 -33.73 -36.72 -64.13 -35.26 ULMN 3 1cns_c01 CHITINASE user 5 3 # 5 B 67 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 89 GLU C 11 GLU.? 13.80 O2 EDO C 103 B 120 SER C 87 SER~? 9.82 O2 EDO C 103 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -34.89 -64.48 -33.73 -36.72 -64.13 -35.26 ULMN 3 1cns_c01 CHITINASE user 6 3 # 6 B 67 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 89 GLU C 11 GLU.? 13.80 O2 EDO C 103 B 120 SER E 87 SER~? 10.44 O7 CIT E 104 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 1cns_c01 source 1cns CHITINASE : 6 hits 1cns_c01 naa= 3 ULMN 3 1cs1_c00 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 A 101 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 173 ASP C 46 ASP.? 10.22 O6 CIT D 103 C 48 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 25.00 -3.03 25.68 27.14 -4.51 26.75 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 24.35 4.55 25.11 25.94 3.23 25.53 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 29.84 -5.31 33.83 28.87 -5.97 30.97 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1cs1_c00 CYSTATHIONINE GAMMA-SYNTHASE user 2 3 # 2 A 101 TYR F 54 TYR.? 5.10 C2 EDO F 103 A 173 ASP F 46 ASP.? 6.64 O2 EDO F 103 C 48 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 25.00 -3.03 25.68 27.14 -4.51 26.75 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 24.35 4.55 25.11 25.94 3.23 25.53 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 29.84 -5.31 33.83 28.87 -5.97 30.97 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 1cs1_c00 source 1cs1 CYSTATHIONINE GAMMA-SYNTHASE : 2 hits 1cs1_c00 naa= 3 ULMN 3 1cs1_c01 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 A 48 ARG D 53 ARG.? 12.25 O4 CIT D 103 C 101 TYR C 54 TYR.? 11.88 O3 CIT C 104 C 173 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 32.27 5.62 48.15 31.93 6.48 51.06 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo 29.64 3.64 57.39 31.22 5.14 55.65 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 28.89 -3.78 58.23 30.38 -2.57 57.33 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 1cs1_c01 source 1cs1 CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1cs1_c01 naa= 3 ULMN 3 1cs1_c03 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 B 101 TYR C 54 TYR.? 11.88 O3 CIT C 104 B 173 ASP C 46 ASP.? 10.22 O6 CIT D 103 D 48 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 74.59 -12.57 45.75 72.37 -12.96 44.12 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 76.00 -6.96 50.63 74.29 -7.61 49.57 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 69.39 -8.90 38.17 70.70 -11.19 39.77 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 1cs1_c03 source 1cs1 CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1cs1_c03 naa= 3 ULMN 3 1ctn_c00 CHITINASE A (E.C.3.2.1.14) (PH 5.5, user 1 3 # 1 313 ASP B 17 ASP~? 19.42 C4 CIT B 103 315 GLU B 21 GLU~? 16.03 C2 CIT B 103 390 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 32.46 99.13 19.34 30.94 100.38 20.07 -8.70 -93.12 3.11 -9.77 -94.94 3.45 coo 32.04 94.22 18.23 30.57 94.75 16.88 -9.13 -87.49 4.49 -7.49 -88.18 5.63 coo 21.10 94.74 18.36 23.09 96.71 18.59 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 1ctn_c00 CHITINASE A (E.C.3.2.1.14) (PH 5.5, user 2 3 # 2 313 ASP C 17 ASP~? -3.95 O1 EDO C 103s 315 GLU C 21 GLU~? 6.35 O1 EDO C 103 390 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 32.46 99.13 19.34 30.94 100.38 20.07 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 32.04 94.22 18.23 30.57 94.75 16.88 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 21.10 94.74 18.36 23.09 96.71 18.59 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 1ctn_c00 CHITINASE A (E.C.3.2.1.14) (PH 5.5, user 3 3 # 3 313 ASP E 17 ASP~? 16.97 O4 CIT C 104 315 GLU E 21 GLU~? 9.95 O4 CIT C 104 390 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 32.46 99.13 19.34 30.94 100.38 20.07 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 32.04 94.22 18.23 30.57 94.75 16.88 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 21.10 94.74 18.36 23.09 96.71 18.59 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 ULMN 3 1ctn_c00 CHITINASE A (E.C.3.2.1.14) (PH 5.5, user 4 3 # 4 313 ASP F 17 ASP~? 19.11 O1 CIT F 104 315 GLU F 21 GLU~? 14.58 O1 CIT F 104 390 TYR F 56 TYR^? 13.04 O1 CIT F 104 coo 32.46 99.13 19.34 30.94 100.38 20.07 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 coo 32.04 94.22 18.23 30.57 94.75 16.88 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 21.10 94.74 18.36 23.09 96.71 18.59 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 1ctn_c00 source 1ctn CHITINASE A (E.C.3.2.1.14) (PH 5.5, 4 DEGREES : 4 hits 1ctn_c00 naa= 3 ULMN 3 1cwy_c00 AMYLOMALTASE user 1 3 # 1 A 293 ASP C 17 ASP~? -3.95 O1 EDO C 103s A 340 GLU C 21 GLU~? 6.35 O1 EDO C 103 A 395 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo -48.00 -26.48 6.86 -46.51 -25.94 5.49 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo -43.58 -29.03 7.13 -42.45 -27.34 7.75 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo -42.28 -26.47 -1.32 -44.06 -25.60 -0.58 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1cwy_c00 AMYLOMALTASE user 2 3 # 2 A 293 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 340 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 395 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo -48.00 -26.48 6.86 -46.51 -25.94 5.49 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo -43.58 -29.03 7.13 -42.45 -27.34 7.75 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo -42.28 -26.47 -1.32 -44.06 -25.60 -0.58 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 1cwy_c00 source 1cwy AMYLOMALTASE : 2 hits 1cwy_c00 naa= 3 ULMN 3 1d5r_c00 PHOSPHOINOSITIDE PHOSPHOTASE PTEN user 1 3 # 1 A 92 ASP C 17 ASP~? -3.95 O1 EDO C 103s A 124 CYH E 88 CYH.? 7.64 O3 CIT E 104 A 130 ARG C 18 ARG~? -3.10 O1 EDO C 103s coo 38.50 84.15 22.11 36.72 85.12 21.46 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 39.50 92.46 25.29 36.94 91.57 26.24 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 coo 39.28 86.97 26.61 39.95 87.60 23.68 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 ULMN 3 1d5r_c00 PHOSPHOINOSITIDE PHOSPHOTASE PTEN user 2 3 # 2 A 92 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 124 CYH C 88 CYH~? 7.95 C4 CIT C 104 A 130 ARG E 18 ARG~? 11.85 O4 CIT C 104 coo 38.50 84.15 22.11 36.72 85.12 21.46 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 39.50 92.46 25.29 36.94 91.57 26.24 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 39.28 86.97 26.61 39.95 87.60 23.68 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 1d5r_c00 source 1d5r PHOSPHOINOSITIDE PHOSPHOTASE PTEN : 2 hits 1d5r_c00 naa= 3 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 1 3 # 1 A 173 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 243 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 272 LYS A 50 LYS.? -4.54 O3 CIT B 103s coo 2.03 68.31 21.46 0.66 68.36 23.90 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 16.93 55.67 9.65 17.16 54.23 11.19 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 14.13 45.79 13.40 14.25 49.41 18.30 0.28 -82.73 -17.71 1.66 -84.44 -13.54 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 2 3 # 2 A 173 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 243 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 272 LYS B 50 LYS.? 6.61 O1 EDO A 103 coo 2.03 68.31 21.46 0.66 68.36 23.90 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 16.93 55.67 9.65 17.16 54.23 11.19 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 14.13 45.79 13.40 14.25 49.41 18.30 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 3 3 # 3 A 173 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 243 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 272 LYS C 50 LYS.? -4.07 O4 CIT D 103s coo 2.03 68.31 21.46 0.66 68.36 23.90 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 16.93 55.67 9.65 17.16 54.23 11.19 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 14.13 45.79 13.40 14.25 49.41 18.30 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 4 3 # 4 A 173 TYR D 71 TYR~? -4.87 O2 CIT D 103s A 243 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 272 LYS D 50 LYS.? -4.40 O3 CIT C 104s coo 2.03 68.31 21.46 0.66 68.36 23.90 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 16.93 55.67 9.65 17.16 54.23 11.19 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 14.13 45.79 13.40 14.25 49.41 18.30 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 5 3 # 5 A 173 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 243 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 272 LYS E 50 LYS.? -4.05 O4 CIT F 104s coo 2.03 68.31 21.46 0.66 68.36 23.90 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 16.93 55.67 9.65 17.16 54.23 11.19 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 14.13 45.79 13.40 14.25 49.41 18.30 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 6 3 # 6 A 173 TYR F 71 TYR~? -4.99 O2 CIT F 104s A 243 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 272 LYS F 50 LYS.? -3.77 O3 CIT E 104s coo 2.03 68.31 21.46 0.66 68.36 23.90 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 16.93 55.67 9.65 17.16 54.23 11.19 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 14.13 45.79 13.40 14.25 49.41 18.30 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 1d7r_c02 source 1d7r 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYRUVATE) : 6 hits 1d7r_c02 naa= 3 ULMN 3 1daa_c00 D-AMINO ACID AMINOTRANSFERASE user 1 3 # 1 A 145 LYS A 50 LYS.? -4.54 O3 CIT B 103s A 177 GLU B 9 GLU.? 11.84 O3 CIT B 103 A 201 LEU B 96 LEU^? 9.68 O7 CIT B 103 coo 46.63 -7.12 50.78 48.41 -11.39 47.79 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo 47.18 -4.46 40.10 47.54 -4.70 42.20 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 49.45 -5.57 45.73 49.73 -6.78 47.47 -4.76 -86.79 -16.51 -5.13 -86.53 -18.64 ULMN 3 1daa_c00 D-AMINO ACID AMINOTRANSFERASE user 2 3 # 2 A 145 LYS E 50 LYS.? -4.05 O4 CIT F 104s A 177 GLU F 9 GLU.? 7.31 C2 EDO F 103 A 201 LEU F 96 LEU^? 6.94 O1 EDO F 103 coo 46.63 -7.12 50.78 48.41 -11.39 47.79 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo 47.18 -4.46 40.10 47.54 -4.70 42.20 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 49.45 -5.57 45.73 49.73 -6.78 47.47 -26.37 -71.21 -59.60 -26.77 -70.69 -57.54 ULMN 3 1daa_c00 D-AMINO ACID AMINOTRANSFERASE user 3 3 # 3 A 145 LYS F 50 LYS.? -3.77 O3 CIT E 104s A 177 GLU E 9 GLU.? 7.76 O1 EDO F 103 A 201 LEU E 96 LEU^? 5.04 C1 EDO F 103 coo 46.63 -7.12 50.78 48.41 -11.39 47.79 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 47.18 -4.46 40.10 47.54 -4.70 42.20 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo 49.45 -5.57 45.73 49.73 -6.78 47.47 -32.10 -70.65 -53.43 -31.78 -70.83 -55.55 1daa_c00 source 1daa D-AMINO ACID AMINOTRANSFERASE : 3 hits 1daa_c00 naa= 3 ULMN 3 1daa_c01 D-AMINO ACID AMINOTRANSFERASE user 1 3 # 1 B 145 LYS A 50 LYS.? -4.54 O3 CIT B 103s B 177 GLU B 9 GLU.? 11.84 O3 CIT B 103 B 201 LEU B 96 LEU^? 9.68 O7 CIT B 103 coo 25.29 -4.12 49.41 22.68 -2.48 54.25 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo 27.00 6.35 51.01 26.30 4.53 50.18 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 23.74 1.68 49.50 22.87 -0.24 49.97 -4.76 -86.79 -16.51 -5.13 -86.53 -18.64 ULMN 3 1daa_c01 D-AMINO ACID AMINOTRANSFERASE user 2 3 # 2 B 145 LYS E 50 LYS.? -4.05 O4 CIT F 104s B 177 GLU F 9 GLU.? 7.31 C2 EDO F 103 B 201 LEU F 96 LEU^? 6.94 O1 EDO F 103 coo 25.29 -4.12 49.41 22.68 -2.48 54.25 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo 27.00 6.35 51.01 26.30 4.53 50.18 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 23.74 1.68 49.50 22.87 -0.24 49.97 -26.37 -71.21 -59.60 -26.77 -70.69 -57.54 ULMN 3 1daa_c01 D-AMINO ACID AMINOTRANSFERASE user 3 3 # 3 B 145 LYS E 65 LYS~? 11.89 O6 CIT E 104 B 177 GLU E 101 GLU^? 17.69 O2 CIT E 104 B 201 LEU E 2 LEU.? 11.93 O2 CIT E 104 coo 25.29 -4.12 49.41 22.68 -2.48 54.25 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 27.00 6.35 51.01 26.30 4.53 50.18 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 23.74 1.68 49.50 22.87 -0.24 49.97 -38.80 -84.65 -55.80 -40.65 -84.17 -56.89 ULMN 3 1daa_c01 D-AMINO ACID AMINOTRANSFERASE user 4 3 # 4 B 145 LYS F 50 LYS.? -3.77 O3 CIT E 104s B 177 GLU E 9 GLU.? 7.76 O1 EDO F 103 B 201 LEU E 96 LEU^? 5.04 C1 EDO F 103 coo 25.29 -4.12 49.41 22.68 -2.48 54.25 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 27.00 6.35 51.01 26.30 4.53 50.18 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo 23.74 1.68 49.50 22.87 -0.24 49.97 -32.10 -70.65 -53.43 -31.78 -70.83 -55.55 1daa_c01 source 1daa D-AMINO ACID AMINOTRANSFERASE : 4 hits 1daa_c01 naa= 3 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 1 3 # 1 A 132 THR D 63 THR.? 16.75 O2 CIT D 103 A 156 TYR D -3 TYR.? 15.53 O6 CIT D 103 A 160 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 10.50 56.87 17.73 11.24 57.93 19.43 -57.12 -48.47 -21.28 -59.10 -47.58 -21.26 coo 11.64 63.07 23.95 11.76 62.47 21.20 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 coo 5.78 61.30 21.65 8.04 62.89 17.54 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 1db3_c01 source 1db3 GDP-MANNOSE 4,6-DEHYDRATASE : 1 hits 1db3_c01 naa= 3 ULMN 3 1dco_c00 DCOH user 1 3 # 1 A 62 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 63 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 89 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 49.66 36.74 42.37 48.88 35.30 43.64 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 49.93 35.76 35.94 51.58 36.96 35.47 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 46.15 35.33 47.12 47.46 33.99 46.29 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 1dco_c00 source 1dco DCOH : 1 hits 1dco_c00 naa= 3 ULMN 3 1ddj_c12 PLASMINOGEN user 1 3 # 1 A 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 646 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 739 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 11.37 50.89 2.29 11.05 51.63 2.25 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1ddj_c12 PLASMINOGEN user 2 3 # 2 A 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 646 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 11.37 50.89 2.29 11.05 51.63 2.25 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c12 PLASMINOGEN user 3 3 # 3 A 603 HIS A 41 HIS^? 12.51 O2 EDO A 103 A 646 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 11.37 50.89 2.29 11.05 51.63 2.25 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c12 PLASMINOGEN user 4 3 # 4 A 603 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 11.37 50.89 2.29 11.05 51.63 2.25 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c12 PLASMINOGEN user 5 3 # 5 A 603 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 11.37 50.89 2.29 11.05 51.63 2.25 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1ddj_c12 PLASMINOGEN user 6 3 # 6 A 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 646 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 739 GLY B 35 GLY.? 14.63 O1 CIT B 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 11.37 50.89 2.29 11.05 51.63 2.25 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 ULMN 3 1ddj_c12 PLASMINOGEN user 7 3 # 7 A 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 646 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 11.37 50.89 2.29 11.05 51.63 2.25 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1ddj_c12 PLASMINOGEN user 8 3 # 8 A 603 HIS B 41 HIS^? 11.37 O1 CIT B 103 A 646 ASP B 27 ASP~? 12.32 O1 CIT B 103 A 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 11.37 50.89 2.29 11.05 51.63 2.25 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1ddj_c12 PLASMINOGEN user 9 3 # 9 A 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 646 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 739 GLY C 35 GLY.? 14.42 O1 CIT C 104 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 11.37 50.89 2.29 11.05 51.63 2.25 -59.78 -72.68 -26.82 -59.58 -72.16 -27.37 ULMN 3 1ddj_c12 PLASMINOGEN user 10 3 # 10 A 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 646 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 11.37 50.89 2.29 11.05 51.63 2.25 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1ddj_c12 PLASMINOGEN user 11 3 # 11 A 603 HIS C 41 HIS^? 12.16 O1 CIT C 104 A 646 ASP C 27 ASP~? 13.15 O1 CIT C 104 A 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 11.37 50.89 2.29 11.05 51.63 2.25 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1ddj_c12 PLASMINOGEN user 12 3 # 12 A 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 646 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 739 GLY D 35 GLY.? 14.30 O2 CIT D 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 11.37 50.89 2.29 11.05 51.63 2.25 -59.28 -47.39 -16.68 -59.38 -47.87 -16.04 ULMN 3 1ddj_c12 PLASMINOGEN user 13 3 # 13 A 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 646 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 11.37 50.89 2.29 11.05 51.63 2.25 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1ddj_c12 PLASMINOGEN user 14 3 # 14 A 603 HIS D 41 HIS^? 12.20 O1 CIT D 103 A 646 ASP D 27 ASP~? 12.70 O1 CIT D 103 A 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 11.37 50.89 2.29 11.05 51.63 2.25 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1ddj_c12 PLASMINOGEN user 15 3 # 15 A 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 646 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 739 GLY E 35 GLY.? 14.13 O2 CIT E 104 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 11.37 50.89 2.29 11.05 51.63 2.25 -40.51 -91.26 -48.44 -40.06 -91.01 -47.82 ULMN 3 1ddj_c12 PLASMINOGEN user 16 3 # 16 A 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 646 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 739 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 11.37 50.89 2.29 11.05 51.63 2.25 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1ddj_c12 PLASMINOGEN user 17 3 # 17 A 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 11.37 50.89 2.29 11.05 51.63 2.25 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1ddj_c12 PLASMINOGEN user 18 3 # 18 A 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 739 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 11.37 50.89 2.29 11.05 51.63 2.25 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1ddj_c12 PLASMINOGEN user 19 3 # 19 A 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 646 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 739 GLY F 35 GLY.? 14.32 O2 CIT F 104 coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 11.37 50.89 2.29 11.05 51.63 2.25 -14.95 -90.79 -57.80 -15.39 -90.89 -58.42 ULMN 3 1ddj_c12 PLASMINOGEN user 20 3 # 20 A 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 646 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 11.37 50.89 2.29 11.05 51.63 2.25 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 ULMN 3 1ddj_c12 PLASMINOGEN user 21 3 # 21 A 603 HIS F 41 HIS^? 12.43 O1 CIT F 104 A 646 ASP F 27 ASP~? 14.00 O1 CIT F 104 A 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 17.92 60.45 -3.51 16.63 61.88 -2.68 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 18.60 56.26 -8.31 18.53 57.26 -6.47 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 11.37 50.89 2.29 11.05 51.63 2.25 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1ddj_c12 source 1ddj PLASMINOGEN : 21 hits 1ddj_c12 naa= 3 ULMN 3 1ddj_c13 PLASMINOGEN user 1 3 # 1 B 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 646 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 739 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1ddj_c13 PLASMINOGEN user 2 3 # 2 B 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 646 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c13 PLASMINOGEN user 3 3 # 3 B 603 HIS A 41 HIS^? 12.51 O2 EDO A 103 B 646 ASP A 27 ASP~? 13.11 O2 EDO A 103 B 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c13 PLASMINOGEN user 4 3 # 4 B 603 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c13 PLASMINOGEN user 5 3 # 5 B 603 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1ddj_c13 PLASMINOGEN user 6 3 # 6 B 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 646 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 739 GLY B 35 GLY.? 14.63 O1 CIT B 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 ULMN 3 1ddj_c13 PLASMINOGEN user 7 3 # 7 B 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 646 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1ddj_c13 PLASMINOGEN user 8 3 # 8 B 603 HIS B 41 HIS^? 11.37 O1 CIT B 103 B 646 ASP B 27 ASP~? 12.32 O1 CIT B 103 B 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1ddj_c13 PLASMINOGEN user 9 3 # 9 B 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 646 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 739 GLY C 35 GLY.? 14.42 O1 CIT C 104 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -59.78 -72.68 -26.82 -59.58 -72.16 -27.37 ULMN 3 1ddj_c13 PLASMINOGEN user 10 3 # 10 B 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 646 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1ddj_c13 PLASMINOGEN user 11 3 # 11 B 603 HIS C 41 HIS^? 12.16 O1 CIT C 104 B 646 ASP C 27 ASP~? 13.15 O1 CIT C 104 B 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1ddj_c13 PLASMINOGEN user 12 3 # 12 B 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 646 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 739 GLY D 35 GLY.? 14.30 O2 CIT D 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -59.28 -47.39 -16.68 -59.38 -47.87 -16.04 ULMN 3 1ddj_c13 PLASMINOGEN user 13 3 # 13 B 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 646 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1ddj_c13 PLASMINOGEN user 14 3 # 14 B 603 HIS D 41 HIS^? 12.20 O1 CIT D 103 B 646 ASP D 27 ASP~? 12.70 O1 CIT D 103 B 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1ddj_c13 PLASMINOGEN user 15 3 # 15 B 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 646 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 739 GLY E 35 GLY.? 14.13 O2 CIT E 104 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -40.51 -91.26 -48.44 -40.06 -91.01 -47.82 ULMN 3 1ddj_c13 PLASMINOGEN user 16 3 # 16 B 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 646 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 739 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1ddj_c13 PLASMINOGEN user 17 3 # 17 B 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c13 PLASMINOGEN user 18 3 # 18 B 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1ddj_c13 PLASMINOGEN user 19 3 # 19 B 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 739 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1ddj_c13 PLASMINOGEN user 20 3 # 20 B 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 646 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 739 GLY F 35 GLY.? 14.32 O2 CIT F 104 coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -14.95 -90.79 -57.80 -15.39 -90.89 -58.42 ULMN 3 1ddj_c13 PLASMINOGEN user 21 3 # 21 B 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 646 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 ULMN 3 1ddj_c13 PLASMINOGEN user 22 3 # 22 B 603 HIS F 41 HIS^? 12.43 O1 CIT F 104 B 646 ASP F 27 ASP~? 14.00 O1 CIT F 104 B 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo -28.76 37.11 -20.75 -29.48 38.32 -19.19 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo -23.42 34.83 -23.78 -25.09 36.03 -23.31 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo -24.60 49.24 -23.60 -24.80 48.99 -22.86 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1ddj_c13 source 1ddj PLASMINOGEN : 22 hits 1ddj_c13 naa= 3 ULMN 3 1ddj_c14 PLASMINOGEN user 1 3 # 1 C 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 646 ASP A 99 ASP^? 8.10 O2 EDO A 103 C 739 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 16.06 55.72 54.73 15.97 56.49 56.70 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 9.38 49.29 65.28 9.01 50.03 65.31 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1ddj_c14 PLASMINOGEN user 2 3 # 2 C 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 646 ASP A 99 ASP^? 8.10 O2 EDO A 103 C 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 16.06 55.72 54.73 15.97 56.49 56.70 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 9.38 49.29 65.28 9.01 50.03 65.31 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c14 PLASMINOGEN user 3 3 # 3 C 603 HIS A 41 HIS^? 12.51 O2 EDO A 103 C 646 ASP A 27 ASP~? 13.11 O2 EDO A 103 C 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 16.06 55.72 54.73 15.97 56.49 56.70 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 9.38 49.29 65.28 9.01 50.03 65.31 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c14 PLASMINOGEN user 4 3 # 4 C 603 HIS A 74 HIS~? 11.00 C1 EDO E 103 C 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 16.06 55.72 54.73 15.97 56.49 56.70 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 9.38 49.29 65.28 9.01 50.03 65.31 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c14 PLASMINOGEN user 5 3 # 5 C 603 HIS A 74 HIS~? 11.00 C1 EDO E 103 C 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 16.06 55.72 54.73 15.97 56.49 56.70 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 9.38 49.29 65.28 9.01 50.03 65.31 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1ddj_c14 PLASMINOGEN user 6 3 # 6 C 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s C 646 ASP B 99 ASP^? 7.47 O6 CIT B 103 C 739 GLY B 35 GLY.? 14.63 O1 CIT B 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 16.06 55.72 54.73 15.97 56.49 56.70 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 9.38 49.29 65.28 9.01 50.03 65.31 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 ULMN 3 1ddj_c14 PLASMINOGEN user 7 3 # 7 C 603 HIS B 41 HIS^? 11.37 O1 CIT B 103 C 646 ASP B 27 ASP~? 12.32 O1 CIT B 103 C 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 16.06 55.72 54.73 15.97 56.49 56.70 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 9.38 49.29 65.28 9.01 50.03 65.31 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1ddj_c14 PLASMINOGEN user 8 3 # 8 C 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s C 646 ASP C 99 ASP^? 7.14 O2 CIT C 104 C 739 GLY C 35 GLY.? 14.42 O1 CIT C 104 coo 15.33 59.81 59.60 13.98 60.99 60.69 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 16.06 55.72 54.73 15.97 56.49 56.70 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 9.38 49.29 65.28 9.01 50.03 65.31 -59.78 -72.68 -26.82 -59.58 -72.16 -27.37 ULMN 3 1ddj_c14 PLASMINOGEN user 9 3 # 9 C 603 HIS C 41 HIS^? 12.16 O1 CIT C 104 C 646 ASP C 27 ASP~? 13.15 O1 CIT C 104 C 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 15.33 59.81 59.60 13.98 60.99 60.69 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 16.06 55.72 54.73 15.97 56.49 56.70 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 9.38 49.29 65.28 9.01 50.03 65.31 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1ddj_c14 PLASMINOGEN user 10 3 # 10 C 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 646 ASP D 99 ASP^? 6.89 O6 CIT D 103 C 739 GLY D 35 GLY.? 14.30 O2 CIT D 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 16.06 55.72 54.73 15.97 56.49 56.70 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 9.38 49.29 65.28 9.01 50.03 65.31 -59.28 -47.39 -16.68 -59.38 -47.87 -16.04 ULMN 3 1ddj_c14 PLASMINOGEN user 11 3 # 11 C 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 646 ASP D 99 ASP^? 6.89 O6 CIT D 103 C 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 16.06 55.72 54.73 15.97 56.49 56.70 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 9.38 49.29 65.28 9.01 50.03 65.31 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1ddj_c14 PLASMINOGEN user 12 3 # 12 C 603 HIS D 41 HIS^? 12.20 O1 CIT D 103 C 646 ASP D 27 ASP~? 12.70 O1 CIT D 103 C 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 16.06 55.72 54.73 15.97 56.49 56.70 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 9.38 49.29 65.28 9.01 50.03 65.31 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1ddj_c14 PLASMINOGEN user 13 3 # 13 C 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 646 ASP E 99 ASP^? 7.65 C2 CIT E 104 C 739 GLY E 35 GLY.? 14.13 O2 CIT E 104 coo 15.33 59.81 59.60 13.98 60.99 60.69 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 16.06 55.72 54.73 15.97 56.49 56.70 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 9.38 49.29 65.28 9.01 50.03 65.31 -40.51 -91.26 -48.44 -40.06 -91.01 -47.82 ULMN 3 1ddj_c14 PLASMINOGEN user 14 3 # 14 C 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 16.06 55.72 54.73 15.97 56.49 56.70 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 9.38 49.29 65.28 9.01 50.03 65.31 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c14 PLASMINOGEN user 15 3 # 15 C 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo 15.33 59.81 59.60 13.98 60.99 60.69 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 16.06 55.72 54.73 15.97 56.49 56.70 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 9.38 49.29 65.28 9.01 50.03 65.31 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1ddj_c14 PLASMINOGEN user 16 3 # 16 C 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 739 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 15.33 59.81 59.60 13.98 60.99 60.69 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 16.06 55.72 54.73 15.97 56.49 56.70 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 9.38 49.29 65.28 9.01 50.03 65.31 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1ddj_c14 PLASMINOGEN user 17 3 # 17 C 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s C 646 ASP F 99 ASP^? 6.97 O7 CIT F 104 C 739 GLY F 35 GLY.? 14.32 O2 CIT F 104 coo 15.33 59.81 59.60 13.98 60.99 60.69 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 16.06 55.72 54.73 15.97 56.49 56.70 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 9.38 49.29 65.28 9.01 50.03 65.31 -14.95 -90.79 -57.80 -15.39 -90.89 -58.42 ULMN 3 1ddj_c14 PLASMINOGEN user 18 3 # 18 C 603 HIS F 41 HIS^? 12.43 O1 CIT F 104 C 646 ASP F 27 ASP~? 14.00 O1 CIT F 104 C 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 15.33 59.81 59.60 13.98 60.99 60.69 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 16.06 55.72 54.73 15.97 56.49 56.70 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 9.38 49.29 65.28 9.01 50.03 65.31 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1ddj_c14 source 1ddj PLASMINOGEN : 18 hits 1ddj_c14 naa= 3 ULMN 3 1ddj_c15 PLASMINOGEN user 1 3 # 1 D 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 646 ASP A 99 ASP^? 8.10 O2 EDO A 103 D 739 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1ddj_c15 PLASMINOGEN user 2 3 # 2 D 603 HIS A 41 HIS^? 12.51 O2 EDO A 103 D 646 ASP A 27 ASP~? 13.11 O2 EDO A 103 D 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c15 PLASMINOGEN user 3 3 # 3 D 603 HIS A 74 HIS~? 11.00 C1 EDO E 103 D 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 D 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1ddj_c15 PLASMINOGEN user 4 3 # 4 D 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s D 646 ASP B 99 ASP^? 7.47 O6 CIT B 103 D 739 GLY B 35 GLY.? 14.63 O1 CIT B 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 ULMN 3 1ddj_c15 PLASMINOGEN user 5 3 # 5 D 603 HIS B 41 HIS^? 11.37 O1 CIT B 103 D 646 ASP B 27 ASP~? 12.32 O1 CIT B 103 D 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1ddj_c15 PLASMINOGEN user 6 3 # 6 D 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s D 646 ASP C 99 ASP^? 7.14 O2 CIT C 104 D 739 GLY C 35 GLY.? 14.42 O1 CIT C 104 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -59.78 -72.68 -26.82 -59.58 -72.16 -27.37 ULMN 3 1ddj_c15 PLASMINOGEN user 7 3 # 7 D 603 HIS C 41 HIS^? 12.16 O1 CIT C 104 D 646 ASP C 27 ASP~? 13.15 O1 CIT C 104 D 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo -30.51 33.83 43.05 -30.50 33.12 45.03 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1ddj_c15 PLASMINOGEN user 8 3 # 8 D 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s D 646 ASP D 99 ASP^? 6.89 O6 CIT D 103 D 739 GLY D 35 GLY.? 14.30 O2 CIT D 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -59.28 -47.39 -16.68 -59.38 -47.87 -16.04 ULMN 3 1ddj_c15 PLASMINOGEN user 9 3 # 9 D 603 HIS D 41 HIS^? 12.20 O1 CIT D 103 D 646 ASP D 27 ASP~? 12.70 O1 CIT D 103 D 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1ddj_c15 PLASMINOGEN user 10 3 # 10 D 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s D 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 D 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ddj_c15 PLASMINOGEN user 11 3 # 11 D 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s D 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 D 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo -30.51 33.83 43.05 -30.50 33.12 45.03 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1ddj_c15 PLASMINOGEN user 12 3 # 12 D 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s D 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 D 739 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo -30.51 33.83 43.05 -30.50 33.12 45.03 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1ddj_c15 PLASMINOGEN user 13 3 # 13 D 603 HIS F 41 HIS^? 12.43 O1 CIT F 104 D 646 ASP F 27 ASP~? 14.00 O1 CIT F 104 D 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo -30.51 33.83 43.05 -30.50 33.12 45.03 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo -25.73 33.05 39.28 -27.50 34.05 39.88 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo -27.66 47.32 40.66 -27.81 47.01 41.41 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1ddj_c15 source 1ddj PLASMINOGEN : 13 hits 1ddj_c15 naa= 3 ULMN 3 1dfo_c04 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 A 57 GLU C 9 GLU.? 12.64 O3 CIT C 104 A 226 THR B 63 THR.? 17.42 O2 CIT B 103 A 229 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 9.66 102.78 70.07 9.79 101.18 71.42 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 7.24 97.46 49.60 8.11 95.69 48.80 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 coo 10.53 97.56 43.71 9.33 93.71 47.17 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1dfo_c04 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 A 57 GLU C 11 GLU.? 13.80 O2 EDO C 103 A 226 THR B 63 THR.? 17.42 O2 CIT B 103 A 229 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 9.66 102.78 70.07 9.79 101.18 71.42 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 7.24 97.46 49.60 8.11 95.69 48.80 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 coo 10.53 97.56 43.71 9.33 93.71 47.17 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 1dfo_c04 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 2 hits 1dfo_c04 naa= 3 ULMN 3 1dfo_c05 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 B 57 GLU C 9 GLU.? 12.64 O3 CIT C 104 B 226 THR B 63 THR.? 17.42 O2 CIT B 103 B 229 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 15.90 87.61 49.61 13.92 86.96 49.36 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 20.74 95.78 68.68 19.29 96.84 69.83 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 coo 22.32 101.61 71.64 17.89 98.63 71.55 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1dfo_c05 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 B 57 GLU C 11 GLU.? 13.80 O2 EDO C 103 B 226 THR B 63 THR.? 17.42 O2 CIT B 103 B 229 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 15.90 87.61 49.61 13.92 86.96 49.36 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 20.74 95.78 68.68 19.29 96.84 69.83 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 coo 22.32 101.61 71.64 17.89 98.63 71.55 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 1dfo_c05 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 2 hits 1dfo_c05 naa= 3 ULMN 3 1dfo_c06 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 C 57 GLU C 9 GLU.? 12.64 O3 CIT C 104 C 226 THR B 63 THR.? 17.42 O2 CIT B 103 C 229 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 5.43 40.40 61.63 4.27 41.99 60.90 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 22.16 45.88 73.63 23.23 47.70 73.25 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 coo 28.90 45.91 73.55 25.22 49.72 72.97 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1dfo_c06 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 C 57 GLU C 11 GLU.? 13.80 O2 EDO C 103 C 226 THR B 63 THR.? 17.42 O2 CIT B 103 C 229 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 5.43 40.40 61.63 4.27 41.99 60.90 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 22.16 45.88 73.63 23.23 47.70 73.25 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 coo 28.90 45.91 73.55 25.22 49.72 72.97 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 1dfo_c06 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 2 hits 1dfo_c06 naa= 3 ULMN 3 1dfo_c07 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 D 57 GLU C 9 GLU.? 12.64 O3 CIT C 104 D 226 THR B 63 THR.? 17.42 O2 CIT B 103 D 229 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 26.07 55.89 66.14 25.33 56.50 68.01 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 11.79 47.62 52.67 10.10 46.51 53.39 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 coo 10.05 41.79 49.80 7.94 44.71 53.76 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1dfo_c07 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 D 57 GLU C 11 GLU.? 13.80 O2 EDO C 103 D 226 THR B 63 THR.? 17.42 O2 CIT B 103 D 229 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 26.07 55.89 66.14 25.33 56.50 68.01 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 11.79 47.62 52.67 10.10 46.51 53.39 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 coo 10.05 41.79 49.80 7.94 44.71 53.76 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 1dfo_c07 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 2 hits 1dfo_c07 naa= 3 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 1 3 # 1 A 44 THR A 61 THR^? 12.85 O2 EDO A 103 A 45 THR A 37 THR^? 15.29 O2 EDO A 103 A 161 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 26.16 88.25 79.16 25.22 89.47 80.71 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 27.73 89.90 76.08 29.24 91.46 75.95 -27.88 -79.13 -19.84 -28.01 -79.96 -17.89 coo 33.83 91.15 88.62 31.07 91.06 83.02 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 2 3 # 2 A 44 THR B 61 THR^? 13.51 O2 CIT B 103 A 45 THR B 37 THR^? 15.70 O1 CIT B 103 A 161 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 26.16 88.25 79.16 25.22 89.47 80.71 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 27.73 89.90 76.08 29.24 91.46 75.95 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 coo 33.83 91.15 88.62 31.07 91.06 83.02 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 3 3 # 3 A 44 THR C 61 THR^? 13.10 O1 CIT C 104 A 45 THR C 37 THR^? 15.86 O1 CIT C 104 A 161 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 26.16 88.25 79.16 25.22 89.47 80.71 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo 27.73 89.90 76.08 29.24 91.46 75.95 -59.71 -66.76 -26.49 -61.02 -66.76 -24.80 coo 33.83 91.15 88.62 31.07 91.06 83.02 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 4 3 # 4 A 44 THR D 61 THR^? 13.17 O2 CIT D 103 A 45 THR D 37 THR^? 15.68 O2 CIT D 103 A 161 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 26.16 88.25 79.16 25.22 89.47 80.71 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo 27.73 89.90 76.08 29.24 91.46 75.95 -60.31 -53.03 -17.12 -60.51 -52.85 -19.30 coo 33.83 91.15 88.62 31.07 91.06 83.02 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 5 3 # 5 A 44 THR E 61 THR^? 11.76 O1 EDO E 103 A 45 THR E 37 THR^? 12.88 O1 EDO E 103 A 161 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 26.16 88.25 79.16 25.22 89.47 80.71 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo 27.73 89.90 76.08 29.24 91.46 75.95 -34.67 -91.61 -48.59 -35.29 -92.29 -50.56 coo 33.83 91.15 88.62 31.07 91.06 83.02 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 6 3 # 6 A 44 THR F 61 THR^? 11.09 O2 EDO E 103 A 45 THR F 37 THR^? 14.28 O2 EDO E 103 A 161 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 26.16 88.25 79.16 25.22 89.47 80.71 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo 27.73 89.90 76.08 29.24 91.46 75.95 -20.68 -92.02 -57.87 -20.13 -91.87 -55.81 coo 33.83 91.15 88.62 31.07 91.06 83.02 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1dhp_c02 source 1dhp DIHYDRODIPICOLINATE SYNTHASE : 6 hits 1dhp_c02 naa= 3 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 1 3 # 1 B 44 THR A 61 THR^? 12.85 O2 EDO A 103 B 45 THR A 37 THR^? 15.29 O2 EDO A 103 B 161 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 7.39 128.28 94.56 8.34 126.36 94.79 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 5.75 129.25 91.25 4.29 128.16 90.07 -27.88 -79.13 -19.84 -28.01 -79.96 -17.89 coo -0.17 119.75 99.65 2.51 123.83 95.70 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 2 3 # 2 B 44 THR B 61 THR^? 13.51 O2 CIT B 103 B 45 THR B 37 THR^? 15.70 O1 CIT B 103 B 161 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 7.39 128.28 94.56 8.34 126.36 94.79 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 5.75 129.25 91.25 4.29 128.16 90.07 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 coo -0.17 119.75 99.65 2.51 123.83 95.70 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 3 3 # 3 B 44 THR C 61 THR^? 13.10 O1 CIT C 104 B 45 THR C 37 THR^? 15.86 O1 CIT C 104 B 161 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 7.39 128.28 94.56 8.34 126.36 94.79 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo 5.75 129.25 91.25 4.29 128.16 90.07 -59.71 -66.76 -26.49 -61.02 -66.76 -24.80 coo -0.17 119.75 99.65 2.51 123.83 95.70 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 4 3 # 4 B 44 THR D 61 THR^? 13.17 O2 CIT D 103 B 45 THR D 37 THR^? 15.68 O2 CIT D 103 B 161 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 7.39 128.28 94.56 8.34 126.36 94.79 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo 5.75 129.25 91.25 4.29 128.16 90.07 -60.31 -53.03 -17.12 -60.51 -52.85 -19.30 coo -0.17 119.75 99.65 2.51 123.83 95.70 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 5 3 # 5 B 44 THR E 61 THR^? 11.76 O1 EDO E 103 B 45 THR E 37 THR^? 12.88 O1 EDO E 103 B 161 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 7.39 128.28 94.56 8.34 126.36 94.79 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo 5.75 129.25 91.25 4.29 128.16 90.07 -34.67 -91.61 -48.59 -35.29 -92.29 -50.56 coo -0.17 119.75 99.65 2.51 123.83 95.70 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 6 3 # 6 B 44 THR F 61 THR^? 11.09 O2 EDO E 103 B 45 THR F 37 THR^? 14.28 O2 EDO E 103 B 161 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 7.39 128.28 94.56 8.34 126.36 94.79 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo 5.75 129.25 91.25 4.29 128.16 90.07 -20.68 -92.02 -57.87 -20.13 -91.87 -55.81 coo -0.17 119.75 99.65 2.51 123.83 95.70 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1dhp_c03 source 1dhp DIHYDRODIPICOLINATE SYNTHASE : 6 hits 1dhp_c03 naa= 3 ULMN 3 1din_c00 DIENELACTONE HYDROLASE user 1 3 # 1 123 CYH A 60 CYH^? 5.96 O2 EDO A 103 171 ASP A 99 ASP^? 8.10 O2 EDO A 103 202 HIS A 4 HIS.? -4.40 O2 EDO A 103s coo 13.53 50.63 6.92 14.43 49.91 4.38 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 11.86 58.52 0.90 11.25 56.63 1.71 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 12.37 53.26 1.34 11.86 52.62 3.19 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 ULMN 3 1din_c00 DIENELACTONE HYDROLASE user 2 3 # 2 123 CYH B 60 CYH^? 5.88 O1 CIT B 103 171 ASP B 99 ASP^? 7.47 O6 CIT B 103 202 HIS B 4 HIS.? -4.11 O2 CIT B 103s coo 13.53 50.63 6.92 14.43 49.91 4.38 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 11.86 58.52 0.90 11.25 56.63 1.71 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 12.37 53.26 1.34 11.86 52.62 3.19 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 ULMN 3 1din_c00 DIENELACTONE HYDROLASE user 3 3 # 3 123 CYH C 60 CYH^? 5.84 O1 CIT C 104 171 ASP C 99 ASP^? 7.14 O2 CIT C 104 202 HIS C 4 HIS.? -4.06 O2 CIT C 104s coo 13.53 50.63 6.92 14.43 49.91 4.38 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 11.86 58.52 0.90 11.25 56.63 1.71 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 12.37 53.26 1.34 11.86 52.62 3.19 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 ULMN 3 1din_c00 DIENELACTONE HYDROLASE user 4 3 # 4 123 CYH D 60 CYH^? 5.69 O2 CIT D 103 171 ASP D 99 ASP^? 6.89 O6 CIT D 103 202 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 13.53 50.63 6.92 14.43 49.91 4.38 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 11.86 58.52 0.90 11.25 56.63 1.71 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 12.37 53.26 1.34 11.86 52.62 3.19 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 ULMN 3 1din_c00 DIENELACTONE HYDROLASE user 5 3 # 5 123 CYH E 60 CYH^? 5.61 O2 CIT E 104 171 ASP E 99 ASP^? 7.65 C2 CIT E 104 202 HIS E 4 HIS.? -4.01 O2 CIT E 104s coo 13.53 50.63 6.92 14.43 49.91 4.38 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 11.86 58.52 0.90 11.25 56.63 1.71 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 12.37 53.26 1.34 11.86 52.62 3.19 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 ULMN 3 1din_c00 DIENELACTONE HYDROLASE user 6 3 # 6 123 CYH F 60 CYH^? 5.70 O2 CIT F 104 171 ASP F 99 ASP^? 6.97 O7 CIT F 104 202 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 13.53 50.63 6.92 14.43 49.91 4.38 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 11.86 58.52 0.90 11.25 56.63 1.71 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 12.37 53.26 1.34 11.86 52.62 3.19 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 1din_c00 source 1din DIENELACTONE HYDROLASE : 6 hits 1din_c00 naa= 3 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 1 3 # 1 E 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s E 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 E 193 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 10.90 32.83 25.96 10.83 30.68 25.98 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 4.57 20.60 30.29 4.74 21.36 30.66 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 2 3 # 2 E 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s E 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 E 193 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 10.90 32.83 25.96 10.83 30.68 25.98 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 4.57 20.60 30.29 4.74 21.36 30.66 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 3 3 # 3 E 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s E 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 E 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 10.90 32.83 25.96 10.83 30.68 25.98 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 4.57 20.60 30.29 4.74 21.36 30.66 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 4 3 # 4 E 57 HIS A 74 HIS~? 11.00 C1 EDO E 103 E 102 ASP E 27 ASP~? 4.58 C1 EDO E 103 E 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 10.90 32.83 25.96 10.83 30.68 25.98 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 4.57 20.60 30.29 4.74 21.36 30.66 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 5 3 # 5 E 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s E 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 E 193 GLY B 35 GLY.? 14.63 O1 CIT B 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 10.90 32.83 25.96 10.83 30.68 25.98 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 4.57 20.60 30.29 4.74 21.36 30.66 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 6 3 # 6 E 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s E 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 E 193 GLY B 57 GLY^? 9.92 O7 CIT B 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 10.90 32.83 25.96 10.83 30.68 25.98 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 4.57 20.60 30.29 4.74 21.36 30.66 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 7 3 # 7 E 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s E 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 E 193 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 10.90 32.83 25.96 10.83 30.68 25.98 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 4.57 20.60 30.29 4.74 21.36 30.66 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 8 3 # 8 E 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s E 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 E 193 GLY C 57 GLY^? 10.09 O1 CIT C 104 coo 11.39 26.86 25.95 9.85 26.64 27.36 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 10.90 32.83 25.96 10.83 30.68 25.98 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 4.57 20.60 30.29 4.74 21.36 30.66 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 9 3 # 9 E 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s E 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 E 193 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 11.39 26.86 25.95 9.85 26.64 27.36 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 10.90 32.83 25.96 10.83 30.68 25.98 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 4.57 20.60 30.29 4.74 21.36 30.66 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 10 3 # 10 E 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s E 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 E 193 GLY D 35 GLY.? 14.30 O2 CIT D 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 10.90 32.83 25.96 10.83 30.68 25.98 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 4.57 20.60 30.29 4.74 21.36 30.66 -59.28 -47.39 -16.68 -59.38 -47.87 -16.04 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 11 3 # 11 E 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s E 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 E 193 GLY D 57 GLY^? 9.79 C2 CIT D 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 10.90 32.83 25.96 10.83 30.68 25.98 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 4.57 20.60 30.29 4.74 21.36 30.66 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 12 3 # 12 E 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s E 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 E 193 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 10.90 32.83 25.96 10.83 30.68 25.98 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 4.57 20.60 30.29 4.74 21.36 30.66 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 13 3 # 13 E 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s E 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 E 193 GLY E 35 GLY.? 14.13 O2 CIT E 104 coo 11.39 26.86 25.95 9.85 26.64 27.36 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 10.90 32.83 25.96 10.83 30.68 25.98 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 4.57 20.60 30.29 4.74 21.36 30.66 -40.51 -91.26 -48.44 -40.06 -91.01 -47.82 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 14 3 # 14 E 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s E 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 E 193 GLY E 57 GLY^? 9.68 O2 EDO E 103 coo 11.39 26.86 25.95 9.85 26.64 27.36 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 10.90 32.83 25.96 10.83 30.68 25.98 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 4.57 20.60 30.29 4.74 21.36 30.66 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 15 3 # 15 E 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s E 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 E 193 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 11.39 26.86 25.95 9.85 26.64 27.36 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 10.90 32.83 25.96 10.83 30.68 25.98 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 4.57 20.60 30.29 4.74 21.36 30.66 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 16 3 # 16 E 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s E 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 E 193 GLY F 35 GLY.? 14.32 O2 CIT F 104 coo 11.39 26.86 25.95 9.85 26.64 27.36 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 10.90 32.83 25.96 10.83 30.68 25.98 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 4.57 20.60 30.29 4.74 21.36 30.66 -14.95 -90.79 -57.80 -15.39 -90.89 -58.42 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 17 3 # 17 E 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s E 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 E 193 GLY F 57 GLY^? 10.08 O2 CIT F 104 coo 11.39 26.86 25.95 9.85 26.64 27.36 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 10.90 32.83 25.96 10.83 30.68 25.98 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 4.57 20.60 30.29 4.74 21.36 30.66 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 ULMN 3 1ds2_c02 PROTEINASE B (SGPB user 18 3 # 18 E 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s E 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 E 193 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 11.39 26.86 25.95 9.85 26.64 27.36 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 10.90 32.83 25.96 10.83 30.68 25.98 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 4.57 20.60 30.29 4.74 21.36 30.66 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1ds2_c02 source 1ds2 PROTEINASE B (SGPB : 18 hits 1ds2_c02 naa= 3 ULMN 3 1dub_c13 2-ENOYL-COA HYDRATASE user 1 3 # 1 B 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 B 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 88.87 114.43 152.30 88.45 115.15 152.32 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 85.20 111.99 152.05 86.60 110.89 150.91 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 88.14 113.46 145.73 86.79 113.92 147.30 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 1dub_c13 2-ENOYL-COA HYDRATASE user 2 3 # 2 B 141 GLY B 94 GLY.? 8.02 O3 CIT B 103 B 144 GLU B 9 GLU.? 11.84 O3 CIT B 103 B 164 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 88.87 114.43 152.30 88.45 115.15 152.32 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 85.20 111.99 152.05 86.60 110.89 150.91 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 88.14 113.46 145.73 86.79 113.92 147.30 0.63 -96.18 -5.96 0.64 -98.22 -6.51 ULMN 3 1dub_c13 2-ENOYL-COA HYDRATASE user 3 3 # 3 B 141 GLY D 94 GLY.? 7.85 O4 CIT D 103 B 144 GLU D 9 GLU.? 12.31 O4 CIT D 103 B 164 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 88.87 114.43 152.30 88.45 115.15 152.32 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 85.20 111.99 152.05 86.60 110.89 150.91 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 88.14 113.46 145.73 86.79 113.92 147.30 -36.27 -63.51 0.47 -34.79 -65.02 0.31 1dub_c13 source 1dub 2-ENOYL-COA HYDRATASE : 3 hits 1dub_c13 naa= 3 ULMN 3 1dub_c14 2-ENOYL-COA HYDRATASE user 1 3 # 1 C 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 C 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 C 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 56.28 104.55 135.84 56.09 105.34 136.05 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 58.46 103.90 139.48 57.57 102.00 139.16 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 51.71 102.03 140.09 53.02 103.62 140.54 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 1dub_c14 2-ENOYL-COA HYDRATASE user 2 3 # 2 C 141 GLY B 94 GLY.? 8.02 O3 CIT B 103 C 144 GLU B 9 GLU.? 11.84 O3 CIT B 103 C 164 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 56.28 104.55 135.84 56.09 105.34 136.05 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 58.46 103.90 139.48 57.57 102.00 139.16 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 51.71 102.03 140.09 53.02 103.62 140.54 0.63 -96.18 -5.96 0.64 -98.22 -6.51 ULMN 3 1dub_c14 2-ENOYL-COA HYDRATASE user 3 3 # 3 C 141 GLY D 94 GLY.? 7.85 O4 CIT D 103 C 144 GLU D 9 GLU.? 12.31 O4 CIT D 103 C 164 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 56.28 104.55 135.84 56.09 105.34 136.05 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 58.46 103.90 139.48 57.57 102.00 139.16 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 51.71 102.03 140.09 53.02 103.62 140.54 -36.27 -63.51 0.47 -34.79 -65.02 0.31 1dub_c14 source 1dub 2-ENOYL-COA HYDRATASE : 3 hits 1dub_c14 naa= 3 ULMN 3 1dub_c15 2-ENOYL-COA HYDRATASE user 1 3 # 1 D 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 D 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 D 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 86.19 80.64 132.77 86.38 79.85 132.93 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 84.75 81.24 136.88 85.62 83.14 136.43 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 91.47 83.05 136.24 90.35 81.38 136.84 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 1dub_c15 2-ENOYL-COA HYDRATASE user 2 3 # 2 D 141 GLY A 94 GLY.? 10.50 C1 EDO A 103 D 144 GLU A 9 GLU.? 14.22 C1 EDO A 103 D 164 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 86.19 80.64 132.77 86.38 79.85 132.93 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo 84.75 81.24 136.88 85.62 83.14 136.43 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 coo 91.47 83.05 136.24 90.35 81.38 136.84 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 ULMN 3 1dub_c15 2-ENOYL-COA HYDRATASE user 3 3 # 3 D 141 GLY B 94 GLY.? 8.02 O3 CIT B 103 D 144 GLU B 9 GLU.? 11.84 O3 CIT B 103 D 164 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 86.19 80.64 132.77 86.38 79.85 132.93 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 84.75 81.24 136.88 85.62 83.14 136.43 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 91.47 83.05 136.24 90.35 81.38 136.84 0.63 -96.18 -5.96 0.64 -98.22 -6.51 ULMN 3 1dub_c15 2-ENOYL-COA HYDRATASE user 4 3 # 4 D 141 GLY D 94 GLY.? 7.85 O4 CIT D 103 D 144 GLU D 9 GLU.? 12.31 O4 CIT D 103 D 164 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 86.19 80.64 132.77 86.38 79.85 132.93 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 84.75 81.24 136.88 85.62 83.14 136.43 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 91.47 83.05 136.24 90.35 81.38 136.84 -36.27 -63.51 0.47 -34.79 -65.02 0.31 1dub_c15 source 1dub 2-ENOYL-COA HYDRATASE : 4 hits 1dub_c15 naa= 3 ULMN 3 1dub_c16 2-ENOYL-COA HYDRATASE user 1 3 # 1 E 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 E 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 E 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 90.07 81.07 170.50 90.23 80.26 170.38 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 87.05 81.30 167.53 86.38 82.74 168.94 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 84.40 80.02 173.80 85.08 79.06 172.03 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 1dub_c16 2-ENOYL-COA HYDRATASE user 2 3 # 2 E 141 GLY B 94 GLY.? 8.02 O3 CIT B 103 E 144 GLU B 9 GLU.? 11.84 O3 CIT B 103 E 164 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 90.07 81.07 170.50 90.23 80.26 170.38 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 87.05 81.30 167.53 86.38 82.74 168.94 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 84.40 80.02 173.80 85.08 79.06 172.03 0.63 -96.18 -5.96 0.64 -98.22 -6.51 1dub_c16 source 1dub 2-ENOYL-COA HYDRATASE : 2 hits 1dub_c16 naa= 3 ULMN 3 1dub_c17 2-ENOYL-COA HYDRATASE user 1 3 # 1 F 141 GLY A 28 GLY~? 12.77 C2 EDO E 103 F 144 GLU E 21 GLU~? 9.95 O4 CIT C 104 F 164 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 57.12 70.68 155.10 57.52 69.95 155.02 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 60.62 73.13 154.21 59.05 74.26 153.35 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 56.75 71.71 148.46 58.44 71.01 149.54 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 1dub_c17 2-ENOYL-COA HYDRATASE user 2 3 # 2 F 141 GLY B 94 GLY.? 8.02 O3 CIT B 103 F 144 GLU B 9 GLU.? 11.84 O3 CIT B 103 F 164 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 57.12 70.68 155.10 57.52 69.95 155.02 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 60.62 73.13 154.21 59.05 74.26 153.35 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 56.75 71.71 148.46 58.44 71.01 149.54 0.63 -96.18 -5.96 0.64 -98.22 -6.51 ULMN 3 1dub_c17 2-ENOYL-COA HYDRATASE user 3 3 # 3 F 141 GLY D 94 GLY.? 7.85 O4 CIT D 103 F 144 GLU D 9 GLU.? 12.31 O4 CIT D 103 F 164 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 57.12 70.68 155.10 57.52 69.95 155.02 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 60.62 73.13 154.21 59.05 74.26 153.35 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 56.75 71.71 148.46 58.44 71.01 149.54 -36.27 -63.51 0.47 -34.79 -65.02 0.31 1dub_c17 source 1dub 2-ENOYL-COA HYDRATASE : 3 hits 1dub_c17 naa= 3 ULMN 3 1e2t_c00 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 1 3 # 1 A 69 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 107 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 122 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 107.06 101.85 70.21 107.82 99.27 70.56 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 112.02 99.34 69.11 112.26 101.12 70.20 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 114.37 105.59 70.16 113.40 104.00 71.21 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1e2t_c00 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 2 3 # 2 A 69 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 107 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 122 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 107.06 101.85 70.21 107.82 99.27 70.56 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 112.02 99.34 69.11 112.26 101.12 70.20 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 114.37 105.59 70.16 113.40 104.00 71.21 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1e2t_c00 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 3 3 # 3 A 69 CYH C 60 CYH^? 5.84 O1 CIT C 104 A 107 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 122 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 107.06 101.85 70.21 107.82 99.27 70.56 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 112.02 99.34 69.11 112.26 101.12 70.20 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 114.37 105.59 70.16 113.40 104.00 71.21 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1e2t_c00 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 4 3 # 4 A 69 CYH D 60 CYH^? 5.69 O2 CIT D 103 A 107 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 122 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 107.06 101.85 70.21 107.82 99.27 70.56 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 112.02 99.34 69.11 112.26 101.12 70.20 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 114.37 105.59 70.16 113.40 104.00 71.21 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1e2t_c00 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 5 3 # 5 A 69 CYH E 60 CYH^? 5.61 O2 CIT E 104 A 107 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 122 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 107.06 101.85 70.21 107.82 99.27 70.56 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 112.02 99.34 69.11 112.26 101.12 70.20 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 114.37 105.59 70.16 113.40 104.00 71.21 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1e2t_c00 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 6 3 # 6 A 69 CYH F 60 CYH^? 5.70 O2 CIT F 104 A 107 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 122 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 107.06 101.85 70.21 107.82 99.27 70.56 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 112.02 99.34 69.11 112.26 101.12 70.20 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 114.37 105.59 70.16 113.40 104.00 71.21 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1e2t_c00 source 1e2t N-HYDROXYARYLAMINE O-ACETYLTRANSFERASE : 6 hits 1e2t_c00 naa= 3 ULMN 3 1e2t_c01 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 1 3 # 1 B 69 CYH A 60 CYH^? 5.96 O2 EDO A 103 B 107 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 122 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 71.18 90.15 69.62 72.19 87.91 68.26 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 68.66 85.12 69.19 67.36 86.67 68.68 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 63.06 88.82 69.94 64.68 88.56 68.63 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1e2t_c01 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 2 3 # 2 B 69 CYH B 60 CYH^? 5.88 O1 CIT B 103 B 107 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 122 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 71.18 90.15 69.62 72.19 87.91 68.26 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 68.66 85.12 69.19 67.36 86.67 68.68 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 63.06 88.82 69.94 64.68 88.56 68.63 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1e2t_c01 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 3 3 # 3 B 69 CYH C 60 CYH^? 5.84 O1 CIT C 104 B 107 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 122 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 71.18 90.15 69.62 72.19 87.91 68.26 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 68.66 85.12 69.19 67.36 86.67 68.68 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 63.06 88.82 69.94 64.68 88.56 68.63 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1e2t_c01 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 4 3 # 4 B 69 CYH D 60 CYH^? 5.69 O2 CIT D 103 B 107 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 122 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 71.18 90.15 69.62 72.19 87.91 68.26 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 68.66 85.12 69.19 67.36 86.67 68.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 63.06 88.82 69.94 64.68 88.56 68.63 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1e2t_c01 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 5 3 # 5 B 69 CYH E 60 CYH^? 5.61 O2 CIT E 104 B 107 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 122 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 71.18 90.15 69.62 72.19 87.91 68.26 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 68.66 85.12 69.19 67.36 86.67 68.68 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 63.06 88.82 69.94 64.68 88.56 68.63 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1e2t_c01 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 6 3 # 6 B 69 CYH F 60 CYH^? 5.70 O2 CIT F 104 B 107 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 122 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 71.18 90.15 69.62 72.19 87.91 68.26 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 68.66 85.12 69.19 67.36 86.67 68.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 63.06 88.82 69.94 64.68 88.56 68.63 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1e2t_c01 source 1e2t N-HYDROXYARYLAMINE O-ACETYLTRANSFERASE : 6 hits 1e2t_c01 naa= 3 ULMN 3 1e2t_c02 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 1 3 # 1 C 69 CYH A 60 CYH^? 5.96 O2 EDO A 103 C 107 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 122 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 87.22 70.88 82.51 87.10 73.53 83.33 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 83.94 73.51 86.28 84.82 71.77 87.03 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 83.85 67.31 89.02 85.24 68.84 88.61 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1e2t_c02 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 2 3 # 2 C 69 CYH B 60 CYH^? 5.88 O1 CIT B 103 C 107 HIS B 4 HIS.? -4.11 O2 CIT B 103s C 122 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 87.22 70.88 82.51 87.10 73.53 83.33 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 83.94 73.51 86.28 84.82 71.77 87.03 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 83.85 67.31 89.02 85.24 68.84 88.61 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1e2t_c02 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 3 3 # 3 C 69 CYH C 60 CYH^? 5.84 O1 CIT C 104 C 107 HIS C 4 HIS.? -4.06 O2 CIT C 104s C 122 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 87.22 70.88 82.51 87.10 73.53 83.33 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 83.94 73.51 86.28 84.82 71.77 87.03 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 83.85 67.31 89.02 85.24 68.84 88.61 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1e2t_c02 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 4 3 # 4 C 69 CYH D 60 CYH^? 5.69 O2 CIT D 103 C 107 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 122 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 87.22 70.88 82.51 87.10 73.53 83.33 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 83.94 73.51 86.28 84.82 71.77 87.03 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 83.85 67.31 89.02 85.24 68.84 88.61 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1e2t_c02 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 5 3 # 5 C 69 CYH E 60 CYH^? 5.61 O2 CIT E 104 C 107 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 122 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 87.22 70.88 82.51 87.10 73.53 83.33 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 83.94 73.51 86.28 84.82 71.77 87.03 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 83.85 67.31 89.02 85.24 68.84 88.61 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1e2t_c02 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 6 3 # 6 C 69 CYH F 60 CYH^? 5.70 O2 CIT F 104 C 107 HIS F 4 HIS.? -4.07 O2 CIT F 104s C 122 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 87.22 70.88 82.51 87.10 73.53 83.33 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 83.94 73.51 86.28 84.82 71.77 87.03 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 83.85 67.31 89.02 85.24 68.84 88.61 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1e2t_c02 source 1e2t N-HYDROXYARYLAMINE O-ACETYLTRANSFERASE : 6 hits 1e2t_c02 naa= 3 ULMN 3 1e2t_c03 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 1 3 # 1 D 69 CYH A 60 CYH^? 5.96 O2 EDO A 103 D 107 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 122 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 103.83 82.01 50.25 102.30 84.27 50.28 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 104.67 87.04 47.86 104.93 85.42 46.57 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 108.03 83.30 43.35 106.06 83.62 44.11 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1e2t_c03 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 2 3 # 2 D 69 CYH B 60 CYH^? 5.88 O1 CIT B 103 D 107 HIS B 4 HIS.? -4.11 O2 CIT B 103s D 122 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 103.83 82.01 50.25 102.30 84.27 50.28 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 104.67 87.04 47.86 104.93 85.42 46.57 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 108.03 83.30 43.35 106.06 83.62 44.11 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1e2t_c03 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 3 3 # 3 D 69 CYH C 60 CYH^? 5.84 O1 CIT C 104 D 107 HIS C 4 HIS.? -4.06 O2 CIT C 104s D 122 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 103.83 82.01 50.25 102.30 84.27 50.28 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 104.67 87.04 47.86 104.93 85.42 46.57 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 108.03 83.30 43.35 106.06 83.62 44.11 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1e2t_c03 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 4 3 # 4 D 69 CYH D 60 CYH^? 5.69 O2 CIT D 103 D 107 HIS D 4 HIS.? -4.16 O2 CIT D 103s D 122 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 103.83 82.01 50.25 102.30 84.27 50.28 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 104.67 87.04 47.86 104.93 85.42 46.57 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 108.03 83.30 43.35 106.06 83.62 44.11 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1e2t_c03 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 5 3 # 5 D 69 CYH E 60 CYH^? 5.61 O2 CIT E 104 D 107 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 122 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 103.83 82.01 50.25 102.30 84.27 50.28 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 104.67 87.04 47.86 104.93 85.42 46.57 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 108.03 83.30 43.35 106.06 83.62 44.11 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1e2t_c03 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 6 3 # 6 D 69 CYH F 60 CYH^? 5.70 O2 CIT F 104 D 107 HIS F 4 HIS.? -4.07 O2 CIT F 104s D 122 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 103.83 82.01 50.25 102.30 84.27 50.28 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 104.67 87.04 47.86 104.93 85.42 46.57 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 108.03 83.30 43.35 106.06 83.62 44.11 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1e2t_c03 source 1e2t N-HYDROXYARYLAMINE O-ACETYLTRANSFERASE : 6 hits 1e2t_c03 naa= 3 ULMN 3 1e2t_c04 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 1 3 # 1 E 69 CYH A 60 CYH^? 5.96 O2 EDO A 103 E 107 HIS A 4 HIS.? -4.40 O2 EDO A 103s E 122 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 26.92 104.93 15.26 26.00 102.32 15.14 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 21.83 102.75 16.48 21.72 104.53 15.38 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 19.90 109.15 15.39 20.77 107.51 14.36 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1e2t_c04 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 2 3 # 2 E 69 CYH B 60 CYH^? 5.88 O1 CIT B 103 E 107 HIS B 4 HIS.? -4.11 O2 CIT B 103s E 122 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 26.92 104.93 15.26 26.00 102.32 15.14 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 21.83 102.75 16.48 21.72 104.53 15.38 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 19.90 109.15 15.39 20.77 107.51 14.36 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1e2t_c04 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 3 3 # 3 E 69 CYH C 60 CYH^? 5.84 O1 CIT C 104 E 107 HIS C 4 HIS.? -4.06 O2 CIT C 104s E 122 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 26.92 104.93 15.26 26.00 102.32 15.14 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 21.83 102.75 16.48 21.72 104.53 15.38 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 19.90 109.15 15.39 20.77 107.51 14.36 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1e2t_c04 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 4 3 # 4 E 69 CYH D 60 CYH^? 5.69 O2 CIT D 103 E 107 HIS D 4 HIS.? -4.16 O2 CIT D 103s E 122 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 26.92 104.93 15.26 26.00 102.32 15.14 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 21.83 102.75 16.48 21.72 104.53 15.38 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 19.90 109.15 15.39 20.77 107.51 14.36 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1e2t_c04 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 5 3 # 5 E 69 CYH E 60 CYH^? 5.61 O2 CIT E 104 E 107 HIS E 4 HIS.? -4.01 O2 CIT E 104s E 122 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 26.92 104.93 15.26 26.00 102.32 15.14 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 21.83 102.75 16.48 21.72 104.53 15.38 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 19.90 109.15 15.39 20.77 107.51 14.36 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1e2t_c04 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 6 3 # 6 E 69 CYH F 60 CYH^? 5.70 O2 CIT F 104 E 107 HIS F 4 HIS.? -4.07 O2 CIT F 104s E 122 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 26.92 104.93 15.26 26.00 102.32 15.14 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 21.83 102.75 16.48 21.72 104.53 15.38 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 19.90 109.15 15.39 20.77 107.51 14.36 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1e2t_c04 source 1e2t N-HYDROXYARYLAMINE O-ACETYLTRANSFERASE : 6 hits 1e2t_c04 naa= 3 ULMN 3 1e2t_c05 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 1 3 # 1 F 69 CYH A 60 CYH^? 5.96 O2 EDO A 103 F 107 HIS A 4 HIS.? -4.40 O2 EDO A 103s F 122 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 61.95 90.52 15.40 60.72 88.41 16.77 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 64.03 85.31 15.74 65.44 86.77 16.21 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 69.94 88.54 14.99 68.36 88.38 16.36 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1e2t_c05 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 2 3 # 2 F 69 CYH B 60 CYH^? 5.88 O1 CIT B 103 F 107 HIS B 4 HIS.? -4.11 O2 CIT B 103s F 122 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 61.95 90.52 15.40 60.72 88.41 16.77 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 64.03 85.31 15.74 65.44 86.77 16.21 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 69.94 88.54 14.99 68.36 88.38 16.36 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1e2t_c05 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 3 3 # 3 F 69 CYH C 60 CYH^? 5.84 O1 CIT C 104 F 107 HIS C 4 HIS.? -4.06 O2 CIT C 104s F 122 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 61.95 90.52 15.40 60.72 88.41 16.77 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 64.03 85.31 15.74 65.44 86.77 16.21 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 69.94 88.54 14.99 68.36 88.38 16.36 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1e2t_c05 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 4 3 # 4 F 69 CYH D 60 CYH^? 5.69 O2 CIT D 103 F 107 HIS D 4 HIS.? -4.16 O2 CIT D 103s F 122 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 61.95 90.52 15.40 60.72 88.41 16.77 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 64.03 85.31 15.74 65.44 86.77 16.21 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 69.94 88.54 14.99 68.36 88.38 16.36 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1e2t_c05 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 5 3 # 5 F 69 CYH E 60 CYH^? 5.61 O2 CIT E 104 F 107 HIS E 4 HIS.? -4.01 O2 CIT E 104s F 122 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 61.95 90.52 15.40 60.72 88.41 16.77 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 64.03 85.31 15.74 65.44 86.77 16.21 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 69.94 88.54 14.99 68.36 88.38 16.36 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1e2t_c05 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 6 3 # 6 F 69 CYH F 60 CYH^? 5.70 O2 CIT F 104 F 107 HIS F 4 HIS.? -4.07 O2 CIT F 104s F 122 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 61.95 90.52 15.40 60.72 88.41 16.77 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 64.03 85.31 15.74 65.44 86.77 16.21 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 69.94 88.54 14.99 68.36 88.38 16.36 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1e2t_c05 source 1e2t N-HYDROXYARYLAMINE O-ACETYLTRANSFERASE : 6 hits 1e2t_c05 naa= 3 ULMN 3 1e2t_c06 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 1 3 # 1 G 69 CYH A 60 CYH^? 5.96 O2 EDO A 103 G 107 HIS A 4 HIS.? -4.40 O2 EDO A 103s G 122 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 29.36 85.15 35.54 31.07 87.28 35.30 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 28.98 90.29 37.87 28.74 88.77 39.28 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 25.53 86.86 42.58 27.46 86.99 41.71 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1e2t_c06 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 2 3 # 2 G 69 CYH B 60 CYH^? 5.88 O1 CIT B 103 G 107 HIS B 4 HIS.? -4.11 O2 CIT B 103s G 122 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 29.36 85.15 35.54 31.07 87.28 35.30 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 28.98 90.29 37.87 28.74 88.77 39.28 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 25.53 86.86 42.58 27.46 86.99 41.71 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1e2t_c06 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 3 3 # 3 G 69 CYH C 60 CYH^? 5.84 O1 CIT C 104 G 107 HIS C 4 HIS.? -4.06 O2 CIT C 104s G 122 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 29.36 85.15 35.54 31.07 87.28 35.30 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 28.98 90.29 37.87 28.74 88.77 39.28 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 25.53 86.86 42.58 27.46 86.99 41.71 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1e2t_c06 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 4 3 # 4 G 69 CYH D 60 CYH^? 5.69 O2 CIT D 103 G 107 HIS D 4 HIS.? -4.16 O2 CIT D 103s G 122 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 29.36 85.15 35.54 31.07 87.28 35.30 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 28.98 90.29 37.87 28.74 88.77 39.28 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 25.53 86.86 42.58 27.46 86.99 41.71 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1e2t_c06 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 5 3 # 5 G 69 CYH E 60 CYH^? 5.61 O2 CIT E 104 G 107 HIS E 4 HIS.? -4.01 O2 CIT E 104s G 122 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 29.36 85.15 35.54 31.07 87.28 35.30 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 28.98 90.29 37.87 28.74 88.77 39.28 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 25.53 86.86 42.58 27.46 86.99 41.71 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1e2t_c06 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 6 3 # 6 G 69 CYH F 60 CYH^? 5.70 O2 CIT F 104 G 107 HIS F 4 HIS.? -4.07 O2 CIT F 104s G 122 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 29.36 85.15 35.54 31.07 87.28 35.30 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 28.98 90.29 37.87 28.74 88.77 39.28 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 25.53 86.86 42.58 27.46 86.99 41.71 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1e2t_c06 source 1e2t N-HYDROXYARYLAMINE O-ACETYLTRANSFERASE : 6 hits 1e2t_c06 naa= 3 ULMN 3 1e2t_c07 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 1 3 # 1 H 69 CYH A 60 CYH^? 5.96 O2 EDO A 103 H 107 HIS A 4 HIS.? -4.40 O2 EDO A 103s H 122 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 44.08 72.69 2.52 44.26 75.30 1.64 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 47.49 75.16 -1.32 46.47 73.52 -2.11 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 47.09 69.01 -4.12 45.87 70.66 -3.64 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1e2t_c07 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 2 3 # 2 H 69 CYH B 60 CYH^? 5.88 O1 CIT B 103 H 107 HIS B 4 HIS.? -4.11 O2 CIT B 103s H 122 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 44.08 72.69 2.52 44.26 75.30 1.64 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 47.49 75.16 -1.32 46.47 73.52 -2.11 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 47.09 69.01 -4.12 45.87 70.66 -3.64 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1e2t_c07 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 3 3 # 3 H 69 CYH C 60 CYH^? 5.84 O1 CIT C 104 H 107 HIS C 4 HIS.? -4.06 O2 CIT C 104s H 122 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 44.08 72.69 2.52 44.26 75.30 1.64 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 47.49 75.16 -1.32 46.47 73.52 -2.11 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 47.09 69.01 -4.12 45.87 70.66 -3.64 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1e2t_c07 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 4 3 # 4 H 69 CYH D 60 CYH^? 5.69 O2 CIT D 103 H 107 HIS D 4 HIS.? -4.16 O2 CIT D 103s H 122 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 44.08 72.69 2.52 44.26 75.30 1.64 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 47.49 75.16 -1.32 46.47 73.52 -2.11 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 47.09 69.01 -4.12 45.87 70.66 -3.64 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1e2t_c07 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 5 3 # 5 H 69 CYH E 60 CYH^? 5.61 O2 CIT E 104 H 107 HIS E 4 HIS.? -4.01 O2 CIT E 104s H 122 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 44.08 72.69 2.52 44.26 75.30 1.64 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 47.49 75.16 -1.32 46.47 73.52 -2.11 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 47.09 69.01 -4.12 45.87 70.66 -3.64 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1e2t_c07 N-HYDROXYARYLAMINE O-ACETYLTRANSFERAuser 6 3 # 6 H 69 CYH F 60 CYH^? 5.70 O2 CIT F 104 H 107 HIS F 4 HIS.? -4.07 O2 CIT F 104s H 122 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 44.08 72.69 2.52 44.26 75.30 1.64 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 47.49 75.16 -1.32 46.47 73.52 -2.11 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 47.09 69.01 -4.12 45.87 70.66 -3.64 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1e2t_c07 source 1e2t N-HYDROXYARYLAMINE O-ACETYLTRANSFERASE : 6 hits 1e2t_c07 naa= 3 ULMN 3 1e3v_c02 STEROID DELTA-ISOMERASE user 1 3 # 1 A 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 40 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 103 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 3.86 -20.80 85.74 4.58 -18.11 85.73 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 8.98 -11.19 82.60 6.87 -11.00 82.49 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 5.15 -17.92 79.35 5.03 -16.26 80.65 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1e3v_c02 STEROID DELTA-ISOMERASE user 2 3 # 2 A 16 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 40 ASP B 64 ASP~? 16.93 O2 CIT B 103 A 103 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 3.86 -20.80 85.74 4.58 -18.11 85.73 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 8.98 -11.19 82.60 6.87 -11.00 82.49 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 5.15 -17.92 79.35 5.03 -16.26 80.65 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1e3v_c02 STEROID DELTA-ISOMERASE user 3 3 # 3 A 16 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 40 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 103 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 3.86 -20.80 85.74 4.58 -18.11 85.73 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 8.98 -11.19 82.60 6.87 -11.00 82.49 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 5.15 -17.92 79.35 5.03 -16.26 80.65 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1e3v_c02 STEROID DELTA-ISOMERASE user 4 3 # 4 A 16 TYR D -3 TYR.? 15.53 O6 CIT D 103 A 40 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 103 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 3.86 -20.80 85.74 4.58 -18.11 85.73 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 coo 8.98 -11.19 82.60 6.87 -11.00 82.49 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 5.15 -17.92 79.35 5.03 -16.26 80.65 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1e3v_c02 STEROID DELTA-ISOMERASE user 5 3 # 5 A 16 TYR D 71 TYR~? -4.87 O2 CIT D 103s A 40 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 103 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 3.86 -20.80 85.74 4.58 -18.11 85.73 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 8.98 -11.19 82.60 6.87 -11.00 82.49 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 5.15 -17.92 79.35 5.03 -16.26 80.65 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1e3v_c02 STEROID DELTA-ISOMERASE user 6 3 # 6 A 16 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 40 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 103 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 3.86 -20.80 85.74 4.58 -18.11 85.73 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 8.98 -11.19 82.60 6.87 -11.00 82.49 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 5.15 -17.92 79.35 5.03 -16.26 80.65 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1e3v_c02 STEROID DELTA-ISOMERASE user 7 3 # 7 A 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s A 40 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 103 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 3.86 -20.80 85.74 4.58 -18.11 85.73 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 8.98 -11.19 82.60 6.87 -11.00 82.49 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 5.15 -17.92 79.35 5.03 -16.26 80.65 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 1e3v_c02 source 1e3v STEROID DELTA-ISOMERASE : 7 hits 1e3v_c02 naa= 3 ULMN 3 1e3v_c03 STEROID DELTA-ISOMERASE user 1 3 # 1 B 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s B 40 ASP A 64 ASP~? 16.37 O2 EDO A 103 B 103 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 4.95 -16.38 58.56 5.78 -19.05 58.68 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 9.81 -26.10 62.11 7.73 -26.45 62.06 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 5.71 -19.27 64.99 5.64 -20.90 63.63 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1e3v_c03 STEROID DELTA-ISOMERASE user 2 3 # 2 B 16 TYR B 71 TYR~? -4.80 O1 CIT B 103s B 40 ASP B 64 ASP~? 16.93 O2 CIT B 103 B 103 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 4.95 -16.38 58.56 5.78 -19.05 58.68 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 9.81 -26.10 62.11 7.73 -26.45 62.06 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 5.71 -19.27 64.99 5.64 -20.90 63.63 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1e3v_c03 STEROID DELTA-ISOMERASE user 3 3 # 3 B 16 TYR C 71 TYR~? -4.77 O1 CIT C 104s B 40 ASP C 64 ASP~? 16.62 O2 CIT C 104 B 103 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 4.95 -16.38 58.56 5.78 -19.05 58.68 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 9.81 -26.10 62.11 7.73 -26.45 62.06 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 5.71 -19.27 64.99 5.64 -20.90 63.63 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1e3v_c03 STEROID DELTA-ISOMERASE user 4 3 # 4 B 16 TYR D -3 TYR.? 15.53 O6 CIT D 103 B 40 ASP D 69 ASP~? 11.20 O6 CIT D 103 B 103 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 4.95 -16.38 58.56 5.78 -19.05 58.68 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 coo 9.81 -26.10 62.11 7.73 -26.45 62.06 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 5.71 -19.27 64.99 5.64 -20.90 63.63 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1e3v_c03 STEROID DELTA-ISOMERASE user 5 3 # 5 B 16 TYR D 71 TYR~? -4.87 O2 CIT D 103s B 40 ASP D 64 ASP~? 16.39 O2 CIT D 103 B 103 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 4.95 -16.38 58.56 5.78 -19.05 58.68 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 9.81 -26.10 62.11 7.73 -26.45 62.06 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 5.71 -19.27 64.99 5.64 -20.90 63.63 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1e3v_c03 STEROID DELTA-ISOMERASE user 6 3 # 6 B 16 TYR E 71 TYR~? -4.78 O2 CIT E 104s B 40 ASP E 64 ASP~? 16.37 O2 CIT E 104 B 103 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 4.95 -16.38 58.56 5.78 -19.05 58.68 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 9.81 -26.10 62.11 7.73 -26.45 62.06 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 5.71 -19.27 64.99 5.64 -20.90 63.63 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1e3v_c03 STEROID DELTA-ISOMERASE user 7 3 # 7 B 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s B 40 ASP F 64 ASP~? 16.52 O2 EDO E 103 B 103 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 4.95 -16.38 58.56 5.78 -19.05 58.68 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 9.81 -26.10 62.11 7.73 -26.45 62.06 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 5.71 -19.27 64.99 5.64 -20.90 63.63 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 1e3v_c03 source 1e3v STEROID DELTA-ISOMERASE : 7 hits 1e3v_c03 naa= 3 ULMN 3 1e7l_c01 RECOMBINATION ENDONUCLEASE VII user 1 3 # 1 B 41 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 43 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 65 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 20.15 22.08 34.36 20.84 20.10 34.21 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 19.55 18.91 30.27 18.21 18.65 31.84 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 10.90 21.31 28.81 12.14 22.15 30.31 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 1e7l_c01 RECOMBINATION ENDONUCLEASE VII user 2 3 # 2 B 41 HIS B 77 HIS~? -4.07 O1 CIT B 103s B 43 HIS B 74 HIS~? 11.72 O1 CIT B 103 B 65 GLU B 32 GLU~? 16.71 O1 CIT B 103 coo 20.15 22.08 34.36 20.84 20.10 34.21 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 19.55 18.91 30.27 18.21 18.65 31.84 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 10.90 21.31 28.81 12.14 22.15 30.31 -13.30 -70.03 1.72 -15.18 -69.84 2.73 ULMN 3 1e7l_c01 RECOMBINATION ENDONUCLEASE VII user 3 3 # 3 B 41 HIS C 77 HIS~? -4.31 O1 CIT C 104s B 43 HIS C 74 HIS~? 12.10 O1 CIT C 104 B 65 GLU C 32 GLU~? 15.71 O1 CIT C 104 coo 20.15 22.08 34.36 20.84 20.10 34.21 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 19.55 18.91 30.27 18.21 18.65 31.84 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 10.90 21.31 28.81 12.14 22.15 30.31 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 ULMN 3 1e7l_c01 RECOMBINATION ENDONUCLEASE VII user 4 3 # 4 B 41 HIS D 77 HIS~? -3.79 O1 CIT D 103s B 43 HIS D 74 HIS~? 11.86 O1 CIT D 103 B 65 GLU D 32 GLU~? 17.83 O1 CIT D 103 coo 20.15 22.08 34.36 20.84 20.10 34.21 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 19.55 18.91 30.27 18.21 18.65 31.84 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo 10.90 21.31 28.81 12.14 22.15 30.31 -63.28 -49.45 -6.05 -65.42 -49.45 -6.30 ULMN 3 1e7l_c01 RECOMBINATION ENDONUCLEASE VII user 5 3 # 5 B 41 HIS E 77 HIS~? -4.13 O1 CIT E 104s B 43 HIS E 74 HIS~? 12.16 O1 CIT E 104 B 65 GLU E 32 GLU~? 15.49 O1 EDO E 103 coo 20.15 22.08 34.36 20.84 20.10 34.21 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 19.55 18.91 30.27 18.21 18.65 31.84 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 10.90 21.31 28.81 12.14 22.15 30.31 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 ULMN 3 1e7l_c01 RECOMBINATION ENDONUCLEASE VII user 6 3 # 6 B 41 HIS F 77 HIS~? -3.59 O1 CIT F 104s B 43 HIS F 74 HIS~? 11.52 O1 CIT F 104 B 65 GLU F 32 GLU~? 16.06 O1 CIT F 104 coo 20.15 22.08 34.36 20.84 20.10 34.21 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 19.55 18.91 30.27 18.21 18.65 31.84 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 10.90 21.31 28.81 12.14 22.15 30.31 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 1e7l_c01 source 1e7l RECOMBINATION ENDONUCLEASE VII : 6 hits 1e7l_c01 naa= 3 ULMN 3 1eag_c04 PEPTIDE INHIBITOR user 1 3 # 1 A 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 35 SER A 51 SER.? 9.93 O6 CIT B 103 A 218 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 47.22 22.34 8.57 45.16 22.02 9.13 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 43.58 20.85 5.15 44.62 23.01 5.76 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 44.05 16.99 12.67 44.05 18.89 11.74 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1eag_c04 PEPTIDE INHIBITOR user 2 3 # 2 A 32 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 35 SER B 51 SER.? 11.29 O1 EDO A 103 A 218 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 47.22 22.34 8.57 45.16 22.02 9.13 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 43.58 20.85 5.15 44.62 23.01 5.76 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 44.05 16.99 12.67 44.05 18.89 11.74 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1eag_c04 PEPTIDE INHIBITOR user 3 3 # 3 A 32 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 35 SER C 51 SER.? 10.55 O6 CIT D 103 A 218 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 47.22 22.34 8.57 45.16 22.02 9.13 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 43.58 20.85 5.15 44.62 23.01 5.76 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 44.05 16.99 12.67 44.05 18.89 11.74 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1eag_c04 PEPTIDE INHIBITOR user 4 3 # 4 A 32 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 35 SER D 51 SER.? 10.41 O7 CIT C 104 A 218 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 47.22 22.34 8.57 45.16 22.02 9.13 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 43.58 20.85 5.15 44.62 23.01 5.76 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 44.05 16.99 12.67 44.05 18.89 11.74 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1eag_c04 PEPTIDE INHIBITOR user 5 3 # 5 A 32 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 35 SER E 51 SER.? 10.11 C4 CIT F 104 A 218 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 47.22 22.34 8.57 45.16 22.02 9.13 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 43.58 20.85 5.15 44.62 23.01 5.76 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 44.05 16.99 12.67 44.05 18.89 11.74 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1eag_c04 PEPTIDE INHIBITOR user 6 3 # 6 A 32 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 35 SER F 51 SER.? -5.94 O2 EDO F 103s A 218 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 47.22 22.34 8.57 45.16 22.02 9.13 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 43.58 20.85 5.15 44.62 23.01 5.76 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 44.05 16.99 12.67 44.05 18.89 11.74 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 1eag_c04 source 1eag PEPTIDE INHIBITOR : 6 hits 1eag_c04 naa= 3 ULMN 3 1eed_c04 ENDOTHIAPEPSIN (E.C.3.4.23.22) COMPLuser 1 3 # 1 P 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 P 35 SER A 51 SER.? 9.93 O6 CIT B 103 P 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 10.15 33.41 11.98 7.98 33.66 12.07 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 7.57 37.60 10.00 8.86 37.02 12.03 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 4.04 29.97 8.82 4.78 31.15 10.46 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1eed_c04 ENDOTHIAPEPSIN (E.C.3.4.23.22) COMPLuser 2 3 # 2 P 32 ASP C 46 ASP.? 10.22 O6 CIT D 103 P 35 SER C 51 SER.? 10.55 O6 CIT D 103 P 215 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 10.15 33.41 11.98 7.98 33.66 12.07 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 7.57 37.60 10.00 8.86 37.02 12.03 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 4.04 29.97 8.82 4.78 31.15 10.46 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 1eed_c04 source 1eed ENDOTHIAPEPSIN (E.C.3.4.23.22) COMPLEX WITH TH: 2 hits 1eed_c04 naa= 3 ULMN 3 1ef8_c01 METHYLMALONYL COA DECARBOXYLASE user 1 3 # 1 B 66 HIS A 41 HIS^? 12.51 O2 EDO A 103 B 110 GLY A 42 GLY^? 14.43 O2 EDO A 103 B 140 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 15.25 42.02 9.50 15.08 40.17 8.54 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 16.54 37.86 10.86 17.07 37.78 11.48 -12.08 -75.65 -26.58 -11.94 -76.42 -26.42 coo 8.70 35.97 10.91 11.44 36.02 10.35 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ef8_c01 METHYLMALONYL COA DECARBOXYLASE user 2 3 # 2 B 66 HIS B 41 HIS^? 11.37 O1 CIT B 103 B 110 GLY B 42 GLY^? 14.02 O1 CIT B 103 B 140 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 15.25 42.02 9.50 15.08 40.17 8.54 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 16.54 37.86 10.86 17.07 37.78 11.48 -16.95 -88.05 -8.22 -16.29 -87.98 -8.72 coo 8.70 35.97 10.91 11.44 36.02 10.35 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ef8_c01 METHYLMALONYL COA DECARBOXYLASE user 3 3 # 3 B 66 HIS C 41 HIS^? 12.16 O1 CIT C 104 B 110 GLY C 42 GLY^? 14.18 O1 CIT C 104 B 140 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 15.25 42.02 9.50 15.08 40.17 8.54 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 16.54 37.86 10.86 17.07 37.78 11.48 -46.70 -55.40 -28.61 -46.31 -55.96 -28.16 coo 8.70 35.97 10.91 11.44 36.02 10.35 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ef8_c01 METHYLMALONYL COA DECARBOXYLASE user 4 3 # 4 B 66 HIS D 41 HIS^? 12.20 O1 CIT D 103 B 110 GLY D 42 GLY^? 14.38 C1 CIT D 103 B 140 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo 15.25 42.02 9.50 15.08 40.17 8.54 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 16.54 37.86 10.86 17.07 37.78 11.48 -52.42 -66.59 -9.79 -51.76 -66.17 -10.02 coo 8.70 35.97 10.91 11.44 36.02 10.35 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1ef8_c01 METHYLMALONYL COA DECARBOXYLASE user 5 3 # 5 B 66 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 110 GLY E 42 GLY^? 5.78 O2 EDO E 103 B 140 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 15.25 42.02 9.50 15.08 40.17 8.54 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 16.54 37.86 10.86 17.07 37.78 11.48 -23.13 -79.15 -45.19 -23.65 -78.62 -45.54 coo 8.70 35.97 10.91 11.44 36.02 10.35 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1ef8_c01 METHYLMALONYL COA DECARBOXYLASE user 6 3 # 6 B 66 HIS F 41 HIS^? 12.43 O1 CIT F 104 B 110 GLY F 42 GLY^? 14.33 O2 CIT F 104 B 140 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo 15.25 42.02 9.50 15.08 40.17 8.54 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 16.54 37.86 10.86 17.07 37.78 11.48 -33.76 -82.86 -64.67 -33.34 -82.22 -64.40 coo 8.70 35.97 10.91 11.44 36.02 10.35 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 1ef8_c01 source 1ef8 METHYLMALONYL COA DECARBOXYLASE : 6 hits 1ef8_c01 naa= 3 ULMN 3 1ef8_c02 METHYLMALONYL COA DECARBOXYLASE user 1 3 # 1 C 66 HIS A 41 HIS^? 12.51 O2 EDO A 103 C 110 GLY A 42 GLY^? 14.43 O2 EDO A 103 C 140 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo -9.82 10.01 28.41 -9.17 11.02 26.71 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo -5.73 12.49 27.77 -5.15 12.61 28.37 -12.08 -75.65 -26.58 -11.94 -76.42 -26.42 coo -4.68 8.05 21.05 -4.91 10.19 22.84 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ef8_c02 METHYLMALONYL COA DECARBOXYLASE user 2 3 # 2 C 66 HIS B 41 HIS^? 11.37 O1 CIT B 103 C 110 GLY B 42 GLY^? 14.02 O1 CIT B 103 C 140 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -9.82 10.01 28.41 -9.17 11.02 26.71 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -5.73 12.49 27.77 -5.15 12.61 28.37 -16.95 -88.05 -8.22 -16.29 -87.98 -8.72 coo -4.68 8.05 21.05 -4.91 10.19 22.84 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ef8_c02 METHYLMALONYL COA DECARBOXYLASE user 3 3 # 3 C 66 HIS C 41 HIS^? 12.16 O1 CIT C 104 C 110 GLY C 42 GLY^? 14.18 O1 CIT C 104 C 140 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -9.82 10.01 28.41 -9.17 11.02 26.71 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo -5.73 12.49 27.77 -5.15 12.61 28.37 -46.70 -55.40 -28.61 -46.31 -55.96 -28.16 coo -4.68 8.05 21.05 -4.91 10.19 22.84 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ef8_c02 METHYLMALONYL COA DECARBOXYLASE user 4 3 # 4 C 66 HIS D 41 HIS^? 12.20 O1 CIT D 103 C 110 GLY D 42 GLY^? 14.38 C1 CIT D 103 C 140 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo -9.82 10.01 28.41 -9.17 11.02 26.71 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo -5.73 12.49 27.77 -5.15 12.61 28.37 -52.42 -66.59 -9.79 -51.76 -66.17 -10.02 coo -4.68 8.05 21.05 -4.91 10.19 22.84 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1ef8_c02 METHYLMALONYL COA DECARBOXYLASE user 5 3 # 5 C 66 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 110 GLY E 42 GLY^? 5.78 O2 EDO E 103 C 140 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo -9.82 10.01 28.41 -9.17 11.02 26.71 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -5.73 12.49 27.77 -5.15 12.61 28.37 -23.13 -79.15 -45.19 -23.65 -78.62 -45.54 coo -4.68 8.05 21.05 -4.91 10.19 22.84 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1ef8_c02 METHYLMALONYL COA DECARBOXYLASE user 6 3 # 6 C 66 HIS F 41 HIS^? 12.43 O1 CIT F 104 C 110 GLY F 42 GLY^? 14.33 O2 CIT F 104 C 140 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo -9.82 10.01 28.41 -9.17 11.02 26.71 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo -5.73 12.49 27.77 -5.15 12.61 28.37 -33.76 -82.86 -64.67 -33.34 -82.22 -64.40 coo -4.68 8.05 21.05 -4.91 10.19 22.84 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 1ef8_c02 source 1ef8 METHYLMALONYL COA DECARBOXYLASE : 6 hits 1ef8_c02 naa= 3 ULMN 3 1ehy_c01 SOLUBLE EPOXIDE HYDROLASE user 1 3 # 1 B 107 ASP D 27 ASP~? 12.70 O1 CIT D 103 B 246 ASP D 17 ASP~? 19.08 O1 CIT D 103 B 275 HIS D 41 HIS^? 12.20 O1 CIT D 103 coo 34.84 56.77 81.62 34.95 54.74 82.03 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 43.18 49.30 68.39 44.75 49.87 69.78 -49.27 -65.18 4.30 -49.35 -67.27 4.77 coo 38.73 55.10 77.62 36.80 55.01 78.46 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 ULMN 3 1ehy_c01 SOLUBLE EPOXIDE HYDROLASE user 2 3 # 2 B 107 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 246 ASP A 69 ASP~? 12.13 O2 EDO A 103 B 275 HIS A 74 HIS~? 11.00 C1 EDO E 103 coo 34.84 56.77 81.62 34.95 54.74 82.03 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 43.18 49.30 68.39 44.75 49.87 69.78 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 38.73 55.10 77.62 36.80 55.01 78.46 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 ULMN 3 1ehy_c01 SOLUBLE EPOXIDE HYDROLASE user 3 3 # 3 B 107 ASP F 27 ASP~? 14.00 O1 CIT F 104 B 246 ASP F 17 ASP~? 19.11 O1 CIT F 104 B 275 HIS F 41 HIS^? 12.43 O1 CIT F 104 coo 34.84 56.77 81.62 34.95 54.74 82.03 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 43.18 49.30 68.39 44.75 49.87 69.78 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 coo 38.73 55.10 77.62 36.80 55.01 78.46 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 1ehy_c01 source 1ehy SOLUBLE EPOXIDE HYDROLASE : 3 hits 1ehy_c01 naa= 3 ULMN 3 1ehy_c02 SOLUBLE EPOXIDE HYDROLASE user 1 3 # 1 C 107 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 246 ASP A 69 ASP~? 12.13 O2 EDO A 103 C 275 HIS A 74 HIS~? 11.00 C1 EDO E 103 coo 1.90 35.26 72.76 3.20 35.74 71.18 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 12.03 20.33 71.56 10.48 19.25 70.56 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 3.92 29.96 71.75 4.22 31.96 72.31 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 ULMN 3 1ehy_c02 SOLUBLE EPOXIDE HYDROLASE user 2 3 # 2 C 107 ASP F 99 ASP^? 6.97 O7 CIT F 104 C 246 ASP F 27 ASP~? 14.00 O1 CIT F 104 C 275 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 1.90 35.26 72.76 3.20 35.74 71.18 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 12.03 20.33 71.56 10.48 19.25 70.56 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 3.92 29.96 71.75 4.22 31.96 72.31 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 1ehy_c02 source 1ehy SOLUBLE EPOXIDE HYDROLASE : 2 hits 1ehy_c02 naa= 3 ULMN 3 1ehy_c03 SOLUBLE EPOXIDE HYDROLASE user 1 3 # 1 D 107 ASP E 27 ASP~? 4.58 C1 EDO E 103 D 246 ASP A 69 ASP~? 12.13 O2 EDO A 103 D 275 HIS A 74 HIS~? 11.00 C1 EDO E 103 coo 37.41 19.89 81.58 37.64 21.98 81.53 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 23.50 26.43 88.52 24.76 26.47 90.29 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 33.16 21.44 85.29 34.07 21.53 83.40 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 1ehy_c03 source 1ehy SOLUBLE EPOXIDE HYDROLASE : 1 hits 1ehy_c03 naa= 3 ULMN 3 1emd_c01 MALATE DEHYDROGENASE (E.C.1.1.1.37) user 1 3 # 1 150 ASP E 27 ASP~? 4.58 C1 EDO E 103 153 ARG A 79 ARG~? -3.92 C2 EDO E 103s 177 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 6.83 2.75 19.17 7.40 0.75 19.11 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 1.78 0.50 17.43 2.55 -2.31 16.44 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 9.81 -2.34 18.22 7.84 -2.69 17.56 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 1emd_c01 source 1emd MALATE DEHYDROGENASE (E.C.1.1.1.37) : 1 hits 1emd_c01 naa= 3 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 1 3 # 1 A 229 ALA A 24 ALA~? 12.06 C2 EDO E 103 A 257 ALA A 22 ALA~? 8.81 C2 EDO A 103 A 328 ASP A 17 ASP~? 17.77 C2 EDO E 103 coo 39.84 24.12 8.44 38.50 24.23 9.11 -20.53 -76.91 -34.66 -20.26 -76.22 -36.01 coo 43.22 26.73 5.37 41.81 27.09 5.79 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 coo 38.17 34.10 6.67 37.72 32.06 6.84 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 2 3 # 2 A 229 ALA A 80 ALA~? 7.00 C2 EDO A 103 A 257 ALA A 22 ALA~? 8.81 C2 EDO A 103 A 328 ASP A 27 ASP~? 13.11 O2 EDO A 103 coo 39.84 24.12 8.44 38.50 24.23 9.11 -20.19 -86.09 -35.24 -20.75 -85.14 -34.17 coo 43.22 26.73 5.37 41.81 27.09 5.79 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 coo 38.17 34.10 6.67 37.72 32.06 6.84 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 3 3 # 3 A 229 ALA B 24 ALA~? 13.47 O1 CIT B 103 A 257 ALA B 22 ALA~? 8.36 O1 CIT B 103 A 328 ASP B 17 ASP~? 19.42 C4 CIT B 103 coo 39.84 24.12 8.44 38.50 24.23 9.11 -13.42 -82.15 1.65 -13.47 -82.92 2.96 coo 43.22 26.73 5.37 41.81 27.09 5.79 -8.49 -83.66 -0.03 -7.52 -84.08 -1.05 coo 38.17 34.10 6.67 37.72 32.06 6.84 -8.70 -93.12 3.11 -9.77 -94.94 3.45 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 4 3 # 4 A 229 ALA B 80 ALA~? 6.55 O1 CIT B 103 A 257 ALA B 22 ALA~? 8.36 O1 CIT B 103 A 328 ASP B 27 ASP~? 12.32 O1 CIT B 103 coo 39.84 24.12 8.44 38.50 24.23 9.11 -4.95 -80.68 -0.86 -6.33 -80.07 -1.20 coo 43.22 26.73 5.37 41.81 27.09 5.79 -8.49 -83.66 -0.03 -7.52 -84.08 -1.05 coo 38.17 34.10 6.67 37.72 32.06 6.84 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 5 3 # 5 A 229 ALA C 24 ALA~? 13.64 O1 EDO C 103 A 257 ALA C 22 ALA~? 8.59 C2 CIT C 104 A 328 ASP C 17 ASP~? -3.95 O1 EDO C 103s coo 39.84 24.12 8.44 38.50 24.23 9.11 -48.96 -62.61 -38.35 -48.38 -62.01 -39.66 coo 43.22 26.73 5.37 41.81 27.09 5.79 -44.35 -64.88 -36.60 -43.33 -65.13 -35.53 coo 38.17 34.10 6.67 37.72 32.06 6.84 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 6 3 # 6 A 229 ALA C 80 ALA~? 6.86 O1 CIT C 104 A 257 ALA C 22 ALA~? 8.59 C2 CIT C 104 A 328 ASP C 27 ASP~? 13.15 O1 CIT C 104 coo 39.84 24.12 8.44 38.50 24.23 9.11 -44.02 -69.49 -35.47 -45.39 -69.01 -34.93 coo 43.22 26.73 5.37 41.81 27.09 5.79 -44.35 -64.88 -36.60 -43.33 -65.13 -35.53 coo 38.17 34.10 6.67 37.72 32.06 6.84 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 7 3 # 7 A 229 ALA D 24 ALA~? 13.47 O1 CIT D 103 A 257 ALA D 22 ALA~? 7.88 O1 CIT D 103 A 328 ASP D 17 ASP~? 19.08 O1 CIT D 103 coo 39.84 24.12 8.44 38.50 24.23 9.11 -57.08 -59.15 -2.14 -57.28 -59.76 -0.76 coo 43.22 26.73 5.37 41.81 27.09 5.79 -51.90 -57.58 -1.45 -50.39 -57.48 -1.80 coo 38.17 34.10 6.67 37.72 32.06 6.84 -49.27 -65.18 4.30 -49.35 -67.27 4.77 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 8 3 # 8 A 229 ALA D 80 ALA~? 6.01 O1 CIT D 103 A 257 ALA D 22 ALA~? 7.88 O1 CIT D 103 A 328 ASP D 27 ASP~? 12.70 O1 CIT D 103 coo 39.84 24.12 8.44 38.50 24.23 9.11 -50.09 -53.10 -1.75 -51.22 -53.48 -2.77 coo 43.22 26.73 5.37 41.81 27.09 5.79 -51.90 -57.58 -1.45 -50.39 -57.48 -1.80 coo 38.17 34.10 6.67 37.72 32.06 6.84 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 9 3 # 9 A 229 ALA E 22 ALA~? 8.49 O1 CIT E 104 A 257 ALA E 24 ALA~? 10.19 C1 EDO E 103 A 328 ASP A 27 ASP~? 13.11 O2 EDO A 103 coo 39.84 24.12 8.44 38.50 24.23 9.11 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 coo 43.22 26.73 5.37 41.81 27.09 5.79 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 coo 38.17 34.10 6.67 37.72 32.06 6.84 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 10 3 # 10 A 229 ALA E 24 ALA~? 10.19 C1 EDO E 103 A 257 ALA E 22 ALA~? 8.49 O1 CIT E 104 A 328 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 39.84 24.12 8.44 38.50 24.23 9.11 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 coo 43.22 26.73 5.37 41.81 27.09 5.79 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 coo 38.17 34.10 6.67 37.72 32.06 6.84 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 11 3 # 11 A 229 ALA E 80 ALA~? 6.56 O1 CIT E 104 A 257 ALA E 22 ALA~? 8.49 O1 CIT E 104 A 328 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 39.84 24.12 8.44 38.50 24.23 9.11 -37.12 -76.28 -38.33 -36.63 -77.60 -38.82 coo 43.22 26.73 5.37 41.81 27.09 5.79 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 coo 38.17 34.10 6.67 37.72 32.06 6.84 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 12 3 # 12 A 229 ALA F 24 ALA~? 13.16 O1 CIT F 104 A 257 ALA F 22 ALA~? 7.57 O1 CIT F 104 A 328 ASP F 17 ASP~? 19.11 O1 CIT F 104 coo 39.84 24.12 8.44 38.50 24.23 9.11 -25.76 -87.10 -72.06 -26.27 -87.27 -73.51 coo 43.22 26.73 5.37 41.81 27.09 5.79 -24.19 -81.70 -72.40 -24.12 -80.23 -71.87 coo 38.17 34.10 6.67 37.72 32.06 6.84 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 13 3 # 13 A 229 ALA F 80 ALA~? 5.70 O1 CIT F 104 A 257 ALA F 22 ALA~? 7.57 O1 CIT F 104 A 328 ASP F 27 ASP~? 14.00 O1 CIT F 104 coo 39.84 24.12 8.44 38.50 24.23 9.11 -19.77 -80.17 -71.91 -20.13 -81.28 -70.95 coo 43.22 26.73 5.37 41.81 27.09 5.79 -24.19 -81.70 -72.40 -24.12 -80.23 -71.87 coo 38.17 34.10 6.67 37.72 32.06 6.84 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 1eo7_c00 source 1eo7 CYCLODEXTRIN GLYCOSYLTRANSFERASE : 13 hits 1eo7_c00 naa= 3 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 1 3 # 1 A 38 THR A 61 THR^? 12.85 O2 EDO A 103 A 159 LYS A 65 LYS~? 12.23 O2 EDO A 103 A 193 GLU B 48 GLU.? 3.87 O1 EDO A 103 coo -2.58 16.31 54.79 -4.02 14.93 55.64 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 2 3 # 2 A 38 THR B 61 THR^? 13.51 O2 CIT B 103 A 159 LYS B 65 LYS~? 11.82 O5 CIT B 103 A 193 GLU A 48 GLU.? -2.39 O6 CIT B 103s coo -2.58 16.31 54.79 -4.02 14.93 55.64 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 3 3 # 3 A 38 THR C 61 THR^? 13.10 O1 CIT C 104 A 159 LYS C 65 LYS~? 12.16 O6 CIT C 104 A 193 GLU D 48 GLU.? -3.37 O7 CIT C 104s coo -2.58 16.31 54.79 -4.02 14.93 55.64 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 4 3 # 4 A 38 THR D 61 THR^? 13.17 O2 CIT D 103 A 159 LYS D 65 LYS~? 11.29 O6 CIT D 103 A 193 GLU C 48 GLU.? -2.75 O6 CIT D 103s coo -2.58 16.31 54.79 -4.02 14.93 55.64 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 5 3 # 5 A 38 THR E 61 THR^? 11.76 O1 EDO E 103 A 159 LYS E 65 LYS~? 11.89 O6 CIT E 104 A 193 GLU F 48 GLU.? -3.15 C4 CIT E 104s coo -2.58 16.31 54.79 -4.02 14.93 55.64 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 6 3 # 6 A 38 THR F 61 THR^? 11.09 O2 EDO E 103 A 159 LYS F 65 LYS~? 10.97 O7 CIT F 104 A 193 GLU E 48 GLU.? -2.93 O7 CIT F 104s coo -2.58 16.31 54.79 -4.02 14.93 55.64 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 1et0_c02 source 1et0 4-AMINO-4-DEOXYCHORISMATE LYASE : 6 hits 1et0_c02 naa= 3 ULMN 3 1euu_c00 SIALIDASE user 1 3 # 1 92 ASP A 99 ASP^? 8.10 O2 EDO A 103 260 GLU B 52 GLU.? 15.03 O1 EDO A 103 370 TYR B 54 TYR.? 11.82 O7 CIT B 103 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 -10.99 -99.25 -18.20 -12.86 -99.70 -17.22 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 ULMN 3 1euu_c00 SIALIDASE user 2 3 # 2 92 ASP B 99 ASP^? 7.47 O6 CIT B 103 260 GLU A 52 GLU.? 13.60 O6 CIT B 103 370 TYR A 54 TYR.? 12.54 C1 EDO A 103 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 2.10 -81.17 -22.98 1.38 -79.30 -23.85 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 ULMN 3 1euu_c00 SIALIDASE user 3 3 # 3 92 ASP C 46 ASP.? 10.22 O6 CIT D 103 260 GLU D 101 GLU^? 17.58 O6 CIT D 103 370 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 1euu_c00 SIALIDASE user 4 3 # 4 92 ASP C 99 ASP^? 7.14 O2 CIT C 104 260 GLU D 52 GLU.? 13.73 O3 CIT C 104 370 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 -38.82 -73.24 -13.34 -40.85 -73.92 -12.86 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 ULMN 3 1euu_c00 SIALIDASE user 5 3 # 5 92 ASP D 99 ASP^? 6.89 O6 CIT D 103 260 GLU C 52 GLU.? 13.74 O6 CIT D 103 370 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 -34.68 -51.65 -19.33 -36.18 -50.53 -20.46 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 1euu_c00 SIALIDASE user 6 3 # 6 92 ASP E 64 ASP~? 16.37 O2 CIT E 104 260 GLU E 101 GLU^? 17.69 O2 CIT E 104 370 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1euu_c00 SIALIDASE user 7 3 # 7 92 ASP E 99 ASP^? 7.65 C2 CIT E 104 260 GLU F 52 GLU.? -7.60 O2 EDO F 103s 370 TYR F 54 TYR.? 5.10 C2 EDO F 103 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 -40.44 -68.98 -60.10 -41.76 -70.64 -60.63 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 1euu_c00 source 1euu SIALIDASE : 7 hits 1euu_c00 naa= 3 ULMN 3 1eyi_c00 FRUCTOSE-1,6-BISPHOSPHATASE user 1 3 # 1 A 68 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 74 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 98 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 17.19 9.05 25.28 15.77 9.98 26.53 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 15.99 8.54 17.36 14.96 7.80 19.05 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 16.31 12.85 18.11 16.71 11.79 19.90 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 1eyi_c00 source 1eyi FRUCTOSE-1,6-BISPHOSPHATASE : 1 hits 1eyi_c00 naa= 3 ULMN 3 1f6d_c02 UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE user 1 3 # 1 C 95 ASP A 46 ASP.? 9.57 O6 CIT B 103 C 117 GLU A 48 GLU.? -2.39 O6 CIT B 103s C 131 GLU A 52 GLU.? 13.60 O6 CIT B 103 coo 68.01 56.37 72.57 68.42 56.10 70.51 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 66.59 62.50 67.44 67.57 60.64 67.12 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 69.24 52.27 71.96 69.91 50.26 71.89 2.10 -81.17 -22.98 1.38 -79.30 -23.85 ULMN 3 1f6d_c02 UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE user 2 3 # 2 C 95 ASP B 46 ASP.? 11.17 O1 EDO A 103 C 117 GLU B 48 GLU.? 3.87 O1 EDO A 103 C 131 GLU B 52 GLU.? 15.03 O1 EDO A 103 coo 68.01 56.37 72.57 68.42 56.10 70.51 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 66.59 62.50 67.44 67.57 60.64 67.12 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 69.24 52.27 71.96 69.91 50.26 71.89 -10.99 -99.25 -18.20 -12.86 -99.70 -17.22 ULMN 3 1f6d_c02 UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE user 3 3 # 3 C 95 ASP C 46 ASP.? 10.22 O6 CIT D 103 C 117 GLU C 48 GLU.? -2.75 O6 CIT D 103s C 131 GLU C 52 GLU.? 13.74 O6 CIT D 103 coo 68.01 56.37 72.57 68.42 56.10 70.51 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 66.59 62.50 67.44 67.57 60.64 67.12 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 69.24 52.27 71.96 69.91 50.26 71.89 -34.68 -51.65 -19.33 -36.18 -50.53 -20.46 ULMN 3 1f6d_c02 UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE user 4 3 # 4 C 95 ASP D 46 ASP.? 10.10 O7 CIT C 104 C 117 GLU D 48 GLU.? -3.37 O7 CIT C 104s C 131 GLU D 52 GLU.? 13.73 O3 CIT C 104 coo 68.01 56.37 72.57 68.42 56.10 70.51 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 66.59 62.50 67.44 67.57 60.64 67.12 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 69.24 52.27 71.96 69.91 50.26 71.89 -38.82 -73.24 -13.34 -40.85 -73.92 -12.86 ULMN 3 1f6d_c02 UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE user 5 3 # 5 C 95 ASP E 17 ASP~? 16.97 O4 CIT C 104 C 117 GLU C 11 GLU.? 13.80 O2 EDO C 103 C 131 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 68.01 56.37 72.57 68.42 56.10 70.51 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 66.59 62.50 67.44 67.57 60.64 67.12 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 69.24 52.27 71.96 69.91 50.26 71.89 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1f6d_c02 UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE user 6 3 # 6 C 95 ASP F 46 ASP.? 6.64 O2 EDO F 103 C 117 GLU F 48 GLU.? -3.15 C4 CIT E 104s C 131 GLU F 52 GLU.? -7.60 O2 EDO F 103s coo 68.01 56.37 72.57 68.42 56.10 70.51 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 66.59 62.50 67.44 67.57 60.64 67.12 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 69.24 52.27 71.96 69.91 50.26 71.89 -40.44 -68.98 -60.10 -41.76 -70.64 -60.63 1f6d_c02 source 1f6d UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE : 6 hits 1f6d_c02 naa= 3 ULMN 3 1f8m_c00 ISOCITRATE LYASE user 1 3 # 1 A 180 HIS A 41 HIS^? 12.51 O2 EDO A 103 A 191 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 228 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo 26.35 46.39 51.64 24.52 45.66 52.39 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 16.62 40.80 48.93 16.46 38.74 50.82 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 24.60 42.24 47.99 21.60 41.75 48.44 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1f8m_c00 ISOCITRATE LYASE user 2 3 # 2 A 180 HIS B 41 HIS^? 11.37 O1 CIT B 103 A 191 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 228 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo 26.35 46.39 51.64 24.52 45.66 52.39 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 16.62 40.80 48.93 16.46 38.74 50.82 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 24.60 42.24 47.99 21.60 41.75 48.44 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1f8m_c00 ISOCITRATE LYASE user 3 3 # 3 A 180 HIS C 41 HIS^? 12.16 O1 CIT C 104 A 191 CYH C 60 CYH^? 5.84 O1 CIT C 104 A 228 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo 26.35 46.39 51.64 24.52 45.66 52.39 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 16.62 40.80 48.93 16.46 38.74 50.82 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 24.60 42.24 47.99 21.60 41.75 48.44 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1f8m_c00 ISOCITRATE LYASE user 4 3 # 4 A 180 HIS D 41 HIS^? 12.20 O1 CIT D 103 A 191 CYH D 60 CYH^? 5.69 O2 CIT D 103 A 228 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo 26.35 46.39 51.64 24.52 45.66 52.39 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 16.62 40.80 48.93 16.46 38.74 50.82 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 24.60 42.24 47.99 21.60 41.75 48.44 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1f8m_c00 ISOCITRATE LYASE user 5 3 # 5 A 180 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 191 CYH E 60 CYH^? 5.61 O2 CIT E 104 A 228 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo 26.35 46.39 51.64 24.52 45.66 52.39 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 16.62 40.80 48.93 16.46 38.74 50.82 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 24.60 42.24 47.99 21.60 41.75 48.44 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 ULMN 3 1f8m_c00 ISOCITRATE LYASE user 6 3 # 6 A 180 HIS F 41 HIS^? 12.43 O1 CIT F 104 A 191 CYH F 60 CYH^? 5.70 O2 CIT F 104 A 228 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo 26.35 46.39 51.64 24.52 45.66 52.39 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 16.62 40.80 48.93 16.46 38.74 50.82 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 24.60 42.24 47.99 21.60 41.75 48.44 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 1f8m_c00 source 1f8m ISOCITRATE LYASE : 6 hits 1f8m_c00 naa= 3 ULMN 3 1f8m_c01 ISOCITRATE LYASE user 1 3 # 1 B 180 HIS A 41 HIS^? 12.51 O2 EDO A 103 B 191 CYH A 60 CYH^? 5.96 O2 EDO A 103 B 228 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo -1.29 58.02 79.43 0.64 57.19 79.31 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 8.78 59.01 84.54 9.56 56.29 85.16 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 0.68 59.10 84.66 3.77 58.91 84.59 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1f8m_c01 ISOCITRATE LYASE user 2 3 # 2 B 180 HIS B 41 HIS^? 11.37 O1 CIT B 103 B 191 CYH B 60 CYH^? 5.88 O1 CIT B 103 B 228 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo -1.29 58.02 79.43 0.64 57.19 79.31 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 8.78 59.01 84.54 9.56 56.29 85.16 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 0.68 59.10 84.66 3.77 58.91 84.59 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1f8m_c01 ISOCITRATE LYASE user 3 3 # 3 B 180 HIS C 41 HIS^? 12.16 O1 CIT C 104 B 191 CYH C 60 CYH^? 5.84 O1 CIT C 104 B 228 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo -1.29 58.02 79.43 0.64 57.19 79.31 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 8.78 59.01 84.54 9.56 56.29 85.16 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 0.68 59.10 84.66 3.77 58.91 84.59 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1f8m_c01 ISOCITRATE LYASE user 4 3 # 4 B 180 HIS D 41 HIS^? 12.20 O1 CIT D 103 B 191 CYH D 60 CYH^? 5.69 O2 CIT D 103 B 228 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo -1.29 58.02 79.43 0.64 57.19 79.31 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 8.78 59.01 84.54 9.56 56.29 85.16 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 0.68 59.10 84.66 3.77 58.91 84.59 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1f8m_c01 ISOCITRATE LYASE user 5 3 # 5 B 180 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 191 CYH E 60 CYH^? 5.61 O2 CIT E 104 B 228 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo -1.29 58.02 79.43 0.64 57.19 79.31 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 8.78 59.01 84.54 9.56 56.29 85.16 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 0.68 59.10 84.66 3.77 58.91 84.59 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 ULMN 3 1f8m_c01 ISOCITRATE LYASE user 6 3 # 6 B 180 HIS F 41 HIS^? 12.43 O1 CIT F 104 B 191 CYH F 60 CYH^? 5.70 O2 CIT F 104 B 228 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo -1.29 58.02 79.43 0.64 57.19 79.31 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 8.78 59.01 84.54 9.56 56.29 85.16 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 0.68 59.10 84.66 3.77 58.91 84.59 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 1f8m_c01 source 1f8m ISOCITRATE LYASE : 6 hits 1f8m_c01 naa= 3 ULMN 3 1f8m_c02 ISOCITRATE LYASE user 1 3 # 1 C 180 HIS A 41 HIS^? 12.51 O2 EDO A 103 C 191 CYH A 60 CYH^? 5.96 O2 EDO A 103 C 228 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo 2.43 65.34 36.80 3.92 66.76 37.21 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 13.01 68.26 34.18 13.01 71.04 33.71 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 5.82 65.41 32.29 8.60 66.57 33.01 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1f8m_c02 ISOCITRATE LYASE user 2 3 # 2 C 180 HIS B 41 HIS^? 11.37 O1 CIT B 103 C 191 CYH B 60 CYH^? 5.88 O1 CIT B 103 C 228 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo 2.43 65.34 36.80 3.92 66.76 37.21 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 13.01 68.26 34.18 13.01 71.04 33.71 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 5.82 65.41 32.29 8.60 66.57 33.01 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1f8m_c02 ISOCITRATE LYASE user 3 3 # 3 C 180 HIS C 41 HIS^? 12.16 O1 CIT C 104 C 191 CYH C 60 CYH^? 5.84 O1 CIT C 104 C 228 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo 2.43 65.34 36.80 3.92 66.76 37.21 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 13.01 68.26 34.18 13.01 71.04 33.71 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 5.82 65.41 32.29 8.60 66.57 33.01 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1f8m_c02 ISOCITRATE LYASE user 4 3 # 4 C 180 HIS D 41 HIS^? 12.20 O1 CIT D 103 C 191 CYH D 60 CYH^? 5.69 O2 CIT D 103 C 228 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo 2.43 65.34 36.80 3.92 66.76 37.21 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 13.01 68.26 34.18 13.01 71.04 33.71 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 5.82 65.41 32.29 8.60 66.57 33.01 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1f8m_c02 ISOCITRATE LYASE user 5 3 # 5 C 180 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 191 CYH E 60 CYH^? 5.61 O2 CIT E 104 C 228 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo 2.43 65.34 36.80 3.92 66.76 37.21 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 13.01 68.26 34.18 13.01 71.04 33.71 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 5.82 65.41 32.29 8.60 66.57 33.01 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 ULMN 3 1f8m_c02 ISOCITRATE LYASE user 6 3 # 6 C 180 HIS F 41 HIS^? 12.43 O1 CIT F 104 C 191 CYH F 60 CYH^? 5.70 O2 CIT F 104 C 228 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo 2.43 65.34 36.80 3.92 66.76 37.21 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 13.01 68.26 34.18 13.01 71.04 33.71 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 5.82 65.41 32.29 8.60 66.57 33.01 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 1f8m_c02 source 1f8m ISOCITRATE LYASE : 6 hits 1f8m_c02 naa= 3 ULMN 3 1f8m_c03 ISOCITRATE LYASE user 1 3 # 1 D 180 HIS A 41 HIS^? 12.51 O2 EDO A 103 D 191 CYH A 60 CYH^? 5.96 O2 EDO A 103 D 228 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo 17.18 84.74 69.76 15.58 84.83 68.40 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 5.89 86.47 69.92 5.21 88.39 67.91 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 13.48 87.80 72.67 10.60 87.44 71.57 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1f8m_c03 ISOCITRATE LYASE user 2 3 # 2 D 180 HIS B 41 HIS^? 11.37 O1 CIT B 103 D 191 CYH B 60 CYH^? 5.88 O1 CIT B 103 D 228 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo 17.18 84.74 69.76 15.58 84.83 68.40 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 5.89 86.47 69.92 5.21 88.39 67.91 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 13.48 87.80 72.67 10.60 87.44 71.57 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1f8m_c03 ISOCITRATE LYASE user 3 3 # 3 D 180 HIS C 41 HIS^? 12.16 O1 CIT C 104 D 191 CYH C 60 CYH^? 5.84 O1 CIT C 104 D 228 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo 17.18 84.74 69.76 15.58 84.83 68.40 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 5.89 86.47 69.92 5.21 88.39 67.91 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 13.48 87.80 72.67 10.60 87.44 71.57 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1f8m_c03 ISOCITRATE LYASE user 4 3 # 4 D 180 HIS D 41 HIS^? 12.20 O1 CIT D 103 D 191 CYH D 60 CYH^? 5.69 O2 CIT D 103 D 228 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo 17.18 84.74 69.76 15.58 84.83 68.40 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 5.89 86.47 69.92 5.21 88.39 67.91 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 13.48 87.80 72.67 10.60 87.44 71.57 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1f8m_c03 ISOCITRATE LYASE user 5 3 # 5 D 180 HIS E 41 HIS^? -3.94 C2 EDO E 103s D 191 CYH E 60 CYH^? 5.61 O2 CIT E 104 D 228 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo 17.18 84.74 69.76 15.58 84.83 68.40 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 5.89 86.47 69.92 5.21 88.39 67.91 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 13.48 87.80 72.67 10.60 87.44 71.57 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 ULMN 3 1f8m_c03 ISOCITRATE LYASE user 6 3 # 6 D 180 HIS F 41 HIS^? 12.43 O1 CIT F 104 D 191 CYH F 60 CYH^? 5.70 O2 CIT F 104 D 228 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo 17.18 84.74 69.76 15.58 84.83 68.40 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 5.89 86.47 69.92 5.21 88.39 67.91 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 13.48 87.80 72.67 10.60 87.44 71.57 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 1f8m_c03 source 1f8m ISOCITRATE LYASE : 6 hits 1f8m_c03 naa= 3 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 1 3 # 1 C 137 TYR D -3 TYR.? 15.53 O6 CIT D 103 C 142 LEU D -4 LEU.? 18.19 O6 CIT D 103 C 165 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 -41.19 -43.16 -26.17 -40.23 -41.76 -24.83 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 1fdy_c02 source 1fdy N-ACETYLNEURAMINATE LYASE : 1 hits 1fdy_c02 naa= 3 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 1 3 # 1 A 94 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 198 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 206 CYH A 88 CYH.? 9.02 C1 EDO A 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 51.25 11.31 6.04 51.91 8.58 5.83 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 38.98 17.42 20.63 38.42 14.68 20.70 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 2 3 # 2 A 94 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 198 CYH C 88 CYH~? 7.95 C4 CIT C 104 A 206 CYH C 60 CYH^? 5.84 O1 CIT C 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 51.25 11.31 6.04 51.91 8.58 5.83 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 38.98 17.42 20.63 38.42 14.68 20.70 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 3 3 # 3 A 94 GLU A 52 GLU.? 13.60 O6 CIT B 103 A 198 CYH A 88 CYH.? 9.02 C1 EDO A 103 A 206 CYH A 60 CYH^? 5.96 O2 EDO A 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 2.10 -81.17 -22.98 1.38 -79.30 -23.85 coo 51.25 11.31 6.04 51.91 8.58 5.83 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 coo 38.98 17.42 20.63 38.42 14.68 20.70 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 4 3 # 4 A 94 GLU B 32 GLU~? 16.71 O1 CIT B 103 A 198 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 206 CYH B 88 CYH~? 7.91 O3 CIT B 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 51.25 11.31 6.04 51.91 8.58 5.83 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 38.98 17.42 20.63 38.42 14.68 20.70 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 5 3 # 5 A 94 GLU B 52 GLU.? 15.03 O1 EDO A 103 A 198 CYH B 88 CYH~? 7.91 O3 CIT B 103 A 206 CYH B 60 CYH^? 5.88 O1 CIT B 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -10.99 -99.25 -18.20 -12.86 -99.70 -17.22 coo 51.25 11.31 6.04 51.91 8.58 5.83 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 coo 38.98 17.42 20.63 38.42 14.68 20.70 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 6 3 # 6 A 94 GLU C 32 GLU~? 15.71 O1 CIT C 104 A 198 CYH C 60 CYH^? 5.84 O1 CIT C 104 A 206 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 51.25 11.31 6.04 51.91 8.58 5.83 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 38.98 17.42 20.63 38.42 14.68 20.70 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 7 3 # 7 A 94 GLU C 52 GLU.? 13.74 O6 CIT D 103 A 198 CYH C 88 CYH~? 7.95 C4 CIT C 104 A 206 CYH C 60 CYH^? 5.84 O1 CIT C 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -34.68 -51.65 -19.33 -36.18 -50.53 -20.46 coo 51.25 11.31 6.04 51.91 8.58 5.83 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 38.98 17.42 20.63 38.42 14.68 20.70 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 8 3 # 8 A 94 GLU D 32 GLU~? 17.83 O1 CIT D 103 A 198 CYH D 60 CYH^? 5.69 O2 CIT D 103 A 206 CYH D 88 CYH.? 7.80 O4 CIT D 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -63.28 -49.45 -6.05 -65.42 -49.45 -6.30 coo 51.25 11.31 6.04 51.91 8.58 5.83 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 38.98 17.42 20.63 38.42 14.68 20.70 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 9 3 # 9 A 94 GLU D 52 GLU.? 13.73 O3 CIT C 104 A 198 CYH D 88 CYH.? 7.80 O4 CIT D 103 A 206 CYH D 60 CYH^? 5.69 O2 CIT D 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -38.82 -73.24 -13.34 -40.85 -73.92 -12.86 coo 51.25 11.31 6.04 51.91 8.58 5.83 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 coo 38.98 17.42 20.63 38.42 14.68 20.70 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 10 3 # 10 A 94 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 198 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 206 CYH A 88 CYH.? 9.02 C1 EDO A 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 51.25 11.31 6.04 51.91 8.58 5.83 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 38.98 17.42 20.63 38.42 14.68 20.70 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 11 3 # 11 A 94 GLU E 32 GLU~? 15.49 O1 EDO E 103 A 198 CYH E 60 CYH^? 5.61 O2 CIT E 104 A 206 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 51.25 11.31 6.04 51.91 8.58 5.83 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 38.98 17.42 20.63 38.42 14.68 20.70 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 12 3 # 12 A 94 GLU F 52 GLU.? -7.60 O2 EDO F 103s A 198 CYH F 88 CYH.? 7.60 O3 CIT F 104 A 206 CYH F 60 CYH^? 5.70 O2 CIT F 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -40.44 -68.98 -60.10 -41.76 -70.64 -60.63 coo 51.25 11.31 6.04 51.91 8.58 5.83 -27.14 -69.89 -70.66 -26.83 -72.10 -69.05 coo 38.98 17.42 20.63 38.42 14.68 20.70 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 ULMN 3 1ff3_c00 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 13 3 # 13 A 94 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 198 CYH A 88 CYH.? 9.02 C1 EDO A 103 A 206 CYH A 60 CYH^? 5.96 O2 EDO A 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 51.25 11.31 6.04 51.91 8.58 5.83 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 coo 38.98 17.42 20.63 38.42 14.68 20.70 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 1ff3_c00 source 1ff3 PEPTIDE METHIONINE SULFOXIDE REDUCTASE : 13 hits 1ff3_c00 naa= 3 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 1 3 # 1 A 94 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 198 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 206 CYH A 88 CYH.? 9.02 C1 EDO A 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 51.25 11.31 6.04 51.91 8.58 5.83 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 38.98 17.42 20.63 38.42 14.68 20.70 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 2 3 # 2 A 94 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 198 CYH C 88 CYH~? 7.95 C4 CIT C 104 A 206 CYH C 60 CYH^? 5.84 O1 CIT C 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 51.25 11.31 6.04 51.91 8.58 5.83 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 38.98 17.42 20.63 38.42 14.68 20.70 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 3 3 # 3 A 94 GLU A 52 GLU.? 13.60 O6 CIT B 103 A 198 CYH A 88 CYH.? 9.02 C1 EDO A 103 A 206 CYH A 60 CYH^? 5.96 O2 EDO A 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 2.10 -81.17 -22.98 1.38 -79.30 -23.85 coo 51.25 11.31 6.04 51.91 8.58 5.83 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 coo 38.98 17.42 20.63 38.42 14.68 20.70 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 4 3 # 4 A 94 GLU B 32 GLU~? 16.71 O1 CIT B 103 A 198 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 206 CYH B 88 CYH~? 7.91 O3 CIT B 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 51.25 11.31 6.04 51.91 8.58 5.83 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 38.98 17.42 20.63 38.42 14.68 20.70 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 5 3 # 5 A 94 GLU B 52 GLU.? 15.03 O1 EDO A 103 A 198 CYH B 88 CYH~? 7.91 O3 CIT B 103 A 206 CYH B 60 CYH^? 5.88 O1 CIT B 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -10.99 -99.25 -18.20 -12.86 -99.70 -17.22 coo 51.25 11.31 6.04 51.91 8.58 5.83 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 coo 38.98 17.42 20.63 38.42 14.68 20.70 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 6 3 # 6 A 94 GLU C 32 GLU~? 15.71 O1 CIT C 104 A 198 CYH C 60 CYH^? 5.84 O1 CIT C 104 A 206 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 51.25 11.31 6.04 51.91 8.58 5.83 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 38.98 17.42 20.63 38.42 14.68 20.70 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 7 3 # 7 A 94 GLU C 52 GLU.? 13.74 O6 CIT D 103 A 198 CYH C 88 CYH~? 7.95 C4 CIT C 104 A 206 CYH C 60 CYH^? 5.84 O1 CIT C 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -34.68 -51.65 -19.33 -36.18 -50.53 -20.46 coo 51.25 11.31 6.04 51.91 8.58 5.83 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 38.98 17.42 20.63 38.42 14.68 20.70 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 8 3 # 8 A 94 GLU D 32 GLU~? 17.83 O1 CIT D 103 A 198 CYH D 60 CYH^? 5.69 O2 CIT D 103 A 206 CYH D 88 CYH.? 7.80 O4 CIT D 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -63.28 -49.45 -6.05 -65.42 -49.45 -6.30 coo 51.25 11.31 6.04 51.91 8.58 5.83 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 38.98 17.42 20.63 38.42 14.68 20.70 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 9 3 # 9 A 94 GLU D 52 GLU.? 13.73 O3 CIT C 104 A 198 CYH D 88 CYH.? 7.80 O4 CIT D 103 A 206 CYH D 60 CYH^? 5.69 O2 CIT D 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -38.82 -73.24 -13.34 -40.85 -73.92 -12.86 coo 51.25 11.31 6.04 51.91 8.58 5.83 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 coo 38.98 17.42 20.63 38.42 14.68 20.70 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 10 3 # 10 A 94 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 198 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 206 CYH A 88 CYH.? 9.02 C1 EDO A 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 51.25 11.31 6.04 51.91 8.58 5.83 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 38.98 17.42 20.63 38.42 14.68 20.70 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 11 3 # 11 A 94 GLU E 32 GLU~? 15.49 O1 EDO E 103 A 198 CYH E 60 CYH^? 5.61 O2 CIT E 104 A 206 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 51.25 11.31 6.04 51.91 8.58 5.83 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 38.98 17.42 20.63 38.42 14.68 20.70 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 12 3 # 12 A 94 GLU F 52 GLU.? -7.60 O2 EDO F 103s A 198 CYH F 88 CYH.? 7.60 O3 CIT F 104 A 206 CYH F 60 CYH^? 5.70 O2 CIT F 104 coo 49.92 26.66 0.19 51.26 25.02 0.19 -40.44 -68.98 -60.10 -41.76 -70.64 -60.63 coo 51.25 11.31 6.04 51.91 8.58 5.83 -27.14 -69.89 -70.66 -26.83 -72.10 -69.05 coo 38.98 17.42 20.63 38.42 14.68 20.70 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 ULMN 3 1ff3_c01 PEPTIDE METHIONINE SULFOXIDE REDUCTAuser 13 3 # 13 A 94 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 198 CYH A 88 CYH.? 9.02 C1 EDO A 103 A 206 CYH A 60 CYH^? 5.96 O2 EDO A 103 coo 49.92 26.66 0.19 51.26 25.02 0.19 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 51.25 11.31 6.04 51.91 8.58 5.83 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 coo 38.98 17.42 20.63 38.42 14.68 20.70 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 1ff3_c01 source 1ff3 PEPTIDE METHIONINE SULFOXIDE REDUCTASE : 13 hits 1ff3_c01 naa= 3 ULMN 3 1fhl_c00 BETA-1,4-GALACTANASE user 1 3 # 1 A 45 ARG C 53 ARG.? 12.90 O3 CIT C 104 A 136 GLU C 11 GLU.? 13.80 O2 EDO C 103 A 246 GLU C 9 GLU.? 12.64 O3 CIT C 104 coo 13.48 30.30 107.06 11.75 30.99 109.44 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 coo 9.46 32.37 115.82 8.50 34.20 115.47 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 11.99 34.33 109.92 10.08 34.19 110.77 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 ULMN 3 1fhl_c00 BETA-1,4-GALACTANASE user 2 3 # 2 A 45 ARG E 18 ARG~? 11.85 O4 CIT C 104 A 136 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 246 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 13.48 30.30 107.06 11.75 30.99 109.44 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo 9.46 32.37 115.82 8.50 34.20 115.47 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 11.99 34.33 109.92 10.08 34.19 110.77 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 1fhl_c00 source 1fhl BETA-1,4-GALACTANASE : 2 hits 1fhl_c00 naa= 3 ULMN 3 1fob_c00 BETA-1,4-GALACTANASE user 1 3 # 1 A 45 ARG E 18 ARG~? 11.85 O4 CIT C 104 A 136 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 246 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 13.94 29.84 106.80 11.67 30.40 108.79 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo 9.52 31.97 115.23 8.45 33.74 114.72 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 11.92 33.82 109.35 10.10 33.50 110.39 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 1fob_c00 source 1fob BETA-1,4-GALACTANASE : 1 hits 1fob_c00 naa= 3 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 1 3 # 1 A 317 GLU A 48 GLU.? -2.39 O6 CIT B 103s A 319 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 359 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 14.41 12.40 16.42 12.92 13.74 15.71 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 12.25 13.04 23.85 11.56 15.02 23.93 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 10.89 14.95 28.28 12.39 12.53 29.31 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 2 3 # 2 A 317 GLU B 13 GLU.? 22.42 C4 CIT B 103 A 319 ASP B 17 ASP~? 19.42 C4 CIT B 103 A 359 ARG B 18 ARG~? 17.41 C4 CIT B 103 coo 14.41 12.40 16.42 12.92 13.74 15.71 -4.23-100.38 2.35 -5.07-101.78 1.01 coo 12.25 13.04 23.85 11.56 15.02 23.93 -8.70 -93.12 3.11 -9.77 -94.94 3.45 coo 10.89 14.95 28.28 12.39 12.53 29.31 -4.30 -89.74 3.62 -5.35 -92.05 5.29 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 3 3 # 3 A 317 GLU B 48 GLU.? 3.87 O1 EDO A 103 A 319 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 359 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 14.41 12.40 16.42 12.92 13.74 15.71 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 12.25 13.04 23.85 11.56 15.02 23.93 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 10.89 14.95 28.28 12.39 12.53 29.31 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 4 3 # 4 A 317 GLU C 48 GLU.? -2.75 O6 CIT D 103s A 319 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 359 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 14.41 12.40 16.42 12.92 13.74 15.71 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 12.25 13.04 23.85 11.56 15.02 23.93 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 10.89 14.95 28.28 12.39 12.53 29.31 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 5 3 # 5 A 317 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 319 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 359 ARG D 45 ARG.? 18.60 O2 CIT C 104 coo 14.41 12.40 16.42 12.92 13.74 15.71 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 12.25 13.04 23.85 11.56 15.02 23.93 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 10.89 14.95 28.28 12.39 12.53 29.31 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 6 3 # 6 A 317 GLU E 48 GLU.? -2.93 O7 CIT F 104s A 319 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 359 ARG E 45 ARG.? 12.04 O2 EDO E 103 coo 14.41 12.40 16.42 12.92 13.74 15.71 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 12.25 13.04 23.85 11.56 15.02 23.93 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 10.89 14.95 28.28 12.39 12.53 29.31 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 7 3 # 7 A 317 GLU F 48 GLU.? -3.15 C4 CIT E 104s A 319 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 359 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 14.41 12.40 16.42 12.92 13.74 15.71 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 12.25 13.04 23.85 11.56 15.02 23.93 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 10.89 14.95 28.28 12.39 12.53 29.31 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 1fr8_c00 source 1fr8 BETA 1,4 GALACTOSYLTRANSFERASE : 7 hits 1fr8_c00 naa= 3 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 1 3 # 1 B 317 GLU A 32 GLU~? 8.29 O4 CIT C 104 B 319 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 359 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 10.77 13.13 40.94 11.03 14.73 39.51 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 3.77 12.64 38.21 3.35 14.53 37.39 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 2 3 # 2 B 317 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 319 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 359 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 3.77 12.64 38.21 3.35 14.53 37.39 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 3 3 # 3 B 317 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 319 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 359 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 3.77 12.64 38.21 3.35 14.53 37.39 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 4 3 # 4 B 317 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 319 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 359 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 3.77 12.64 38.21 3.35 14.53 37.39 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 5 3 # 5 B 317 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 319 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 359 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 3.77 12.64 38.21 3.35 14.53 37.39 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 6 3 # 6 B 317 GLU B 52 GLU.? 15.03 O1 EDO A 103 B 319 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 359 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -10.99 -99.25 -18.20 -12.86 -99.70 -17.22 coo 3.77 12.64 38.21 3.35 14.53 37.39 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 7 3 # 7 B 317 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 319 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 359 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 3.77 12.64 38.21 3.35 14.53 37.39 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 8 3 # 8 B 317 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 319 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 359 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 3.77 12.64 38.21 3.35 14.53 37.39 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 9 3 # 9 B 317 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 319 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 359 ARG D 45 ARG.? 18.60 O2 CIT C 104 coo 10.77 13.13 40.94 11.03 14.73 39.51 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 3.77 12.64 38.21 3.35 14.53 37.39 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 10 3 # 10 B 317 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 319 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 359 ARG D 45 ARG.? 18.60 O2 CIT C 104 coo 10.77 13.13 40.94 11.03 14.73 39.51 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 3.77 12.64 38.21 3.35 14.53 37.39 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 11 3 # 11 B 317 GLU E 48 GLU.? -2.93 O7 CIT F 104s B 319 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 359 ARG E 45 ARG.? 12.04 O2 EDO E 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 3.77 12.64 38.21 3.35 14.53 37.39 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 12 3 # 12 B 317 GLU E 48 GLU.? -2.93 O7 CIT F 104s B 319 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 359 ARG E 45 ARG.? 12.04 O2 EDO E 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 3.77 12.64 38.21 3.35 14.53 37.39 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 13 3 # 13 B 317 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 319 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 359 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 3.77 12.64 38.21 3.35 14.53 37.39 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 ULMN 3 1fr8_c01 BETA 1,4 GALACTOSYLTRANSFERASE user 14 3 # 14 B 317 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 319 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 359 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 10.77 13.13 40.94 11.03 14.73 39.51 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 3.77 12.64 38.21 3.35 14.53 37.39 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -1.16 15.32 35.60 -3.32 13.56 36.98 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 1fr8_c01 source 1fr8 BETA 1,4 GALACTOSYLTRANSFERASE : 14 hits 1fr8_c01 naa= 3 ULMN 3 1fuq_c00 FUMARASE C user 1 3 # 1 A 324 LYS A 65 LYS~? 12.23 O2 EDO A 103 A 331 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 188 HIS A 4 HIS.? -4.40 O2 EDO A 103s coo 130.22 155.23 83.49 125.21 153.71 84.04 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 120.90 152.23 75.28 120.94 153.09 77.19 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 122.04 152.80 81.06 120.71 154.37 81.46 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 ULMN 3 1fuq_c00 FUMARASE C user 2 3 # 2 A 324 LYS B 65 LYS~? 11.82 O5 CIT B 103 A 331 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 188 HIS B 4 HIS.? -4.11 O2 CIT B 103s coo 130.22 155.23 83.49 125.21 153.71 84.04 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 120.90 152.23 75.28 120.94 153.09 77.19 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 122.04 152.80 81.06 120.71 154.37 81.46 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 ULMN 3 1fuq_c00 FUMARASE C user 3 3 # 3 A 324 LYS C 65 LYS~? 12.16 O6 CIT C 104 A 331 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 188 HIS C 4 HIS.? -4.06 O2 CIT C 104s coo 130.22 155.23 83.49 125.21 153.71 84.04 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 120.90 152.23 75.28 120.94 153.09 77.19 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 122.04 152.80 81.06 120.71 154.37 81.46 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 ULMN 3 1fuq_c00 FUMARASE C user 4 3 # 4 A 324 LYS D 65 LYS~? 11.29 O6 CIT D 103 A 331 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 188 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 130.22 155.23 83.49 125.21 153.71 84.04 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 120.90 152.23 75.28 120.94 153.09 77.19 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 122.04 152.80 81.06 120.71 154.37 81.46 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 ULMN 3 1fuq_c00 FUMARASE C user 5 3 # 5 A 324 LYS E 65 LYS~? 11.89 O6 CIT E 104 A 331 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 188 HIS E 4 HIS.? -4.01 O2 CIT E 104s coo 130.22 155.23 83.49 125.21 153.71 84.04 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 120.90 152.23 75.28 120.94 153.09 77.19 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 122.04 152.80 81.06 120.71 154.37 81.46 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 ULMN 3 1fuq_c00 FUMARASE C user 6 3 # 6 A 324 LYS F 65 LYS~? 10.97 O7 CIT F 104 A 331 GLU E 48 GLU.? -2.93 O7 CIT F 104s B 188 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 130.22 155.23 83.49 125.21 153.71 84.04 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 120.90 152.23 75.28 120.94 153.09 77.19 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 122.04 152.80 81.06 120.71 154.37 81.46 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 1fuq_c00 source 1fuq FUMARASE C : 6 hits 1fuq_c00 naa= 3 ULMN 3 1gal_c00 GLUCOSE OXIDASE (E.C.1.1.3.4) user 1 3 # 1 412 GLU B 32 GLU~? 16.71 O1 CIT B 103 516 HIS B 77 HIS~? -4.07 O1 CIT B 103s 559 HIS B 74 HIS~? 11.72 O1 CIT B 103 coo 49.01 14.50 52.53 46.99 14.61 52.78 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 41.59 7.83 54.15 41.16 9.87 53.87 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 42.22 14.55 52.50 43.91 14.87 53.60 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 1gal_c00 source 1gal GLUCOSE OXIDASE (E.C.1.1.3.4) : 1 hits 1gal_c00 naa= 3 ULMN 3 1geq_c02 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 1 3 # 1 A 36 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 47 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 161 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 37.12 18.35 73.76 37.09 16.69 72.44 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 29.81 8.06 73.13 30.21 10.11 72.95 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 37.29 15.56 67.90 37.37 13.79 70.08 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 1geq_c02 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 2 3 # 2 A 36 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 47 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 161 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 37.12 18.35 73.76 37.09 16.69 72.44 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 29.81 8.06 73.13 30.21 10.11 72.95 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 37.29 15.56 67.90 37.37 13.79 70.08 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 1geq_c02 source 1geq TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT : 2 hits 1geq_c02 naa= 3 ULMN 3 1geq_c03 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 1 3 # 1 B 36 GLU D 101 GLU^? 17.58 O6 CIT D 103 B 47 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 161 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 53.87 35.49 53.22 55.44 35.72 54.61 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 63.47 43.65 53.95 61.45 43.07 54.06 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 56.38 35.81 59.19 58.25 35.77 57.10 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 1geq_c03 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 2 3 # 2 B 36 GLU D 101 GLU^? 17.58 O6 CIT D 103 B 47 ASP D 69 ASP~? 11.20 O6 CIT D 103 B 161 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 53.87 35.49 53.22 55.44 35.72 54.61 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 63.47 43.65 53.95 61.45 43.07 54.06 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 56.38 35.81 59.19 58.25 35.77 57.10 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 1geq_c03 source 1geq TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT : 2 hits 1geq_c03 naa= 3 ULMN 3 1gsa_c00 GLUTATHIONE SYNTHETASE user 1 3 # 1 160 LYS F 65 LYS~? 10.97 O7 CIT F 104 210 ARG A 79 ARG~? -3.92 C2 EDO E 103s 225 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo 17.51 28.50 73.42 17.24 23.02 75.86 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 24.74 11.56 73.05 25.29 14.32 71.80 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 27.81 15.44 77.10 25.66 16.50 75.19 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 1gsa_c00 source 1gsa GLUTATHIONE SYNTHETASE : 1 hits 1gsa_c00 naa= 3 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 1 3 # 1 A 50 ASP A 17 ASP~? 17.77 C2 EDO E 103 A 327 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 339 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 75.11 41.01 160.30 76.65 40.06 161.41 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 82.23 40.35 159.87 85.09 40.67 161.01 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 2 3 # 2 A 50 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 327 GLU F 21 GLU~? 14.58 O1 CIT F 104 A 339 ARG F 18 ARG~? 15.26 O3 CIT F 104 coo 85.81 57.99 116.01 86.03 55.86 115.89 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 75.11 41.01 160.30 76.65 40.06 161.41 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 82.23 40.35 159.87 85.09 40.67 161.01 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 3 3 # 3 A 50 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 327 GLU F 21 GLU~? 14.58 O1 CIT F 104 A 339 ARG F 79 ARG~? 14.02 O1 CIT F 104 coo 85.81 57.99 116.01 86.03 55.86 115.89 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 75.11 41.01 160.30 76.65 40.06 161.41 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 82.23 40.35 159.87 85.09 40.67 161.01 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 4 3 # 4 A 50 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 327 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 339 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 75.11 41.01 160.30 76.65 40.06 161.41 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 82.23 40.35 159.87 85.09 40.67 161.01 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 5 3 # 5 A 50 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 327 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 339 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 75.11 41.01 160.30 76.65 40.06 161.41 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 82.23 40.35 159.87 85.09 40.67 161.01 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 6 3 # 6 A 50 ASP B 17 ASP~? 19.42 C4 CIT B 103 A 327 GLU C 11 GLU.? 13.80 O2 EDO C 103 A 339 ARG E 18 ARG~? 11.85 O4 CIT C 104 coo 85.81 57.99 116.01 86.03 55.86 115.89 -8.70 -93.12 3.11 -9.77 -94.94 3.45 coo 75.11 41.01 160.30 76.65 40.06 161.41 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 82.23 40.35 159.87 85.09 40.67 161.01 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 7 3 # 7 A 50 ASP B 27 ASP~? 12.32 O1 CIT B 103 A 327 GLU E 11 GLU.? -3.18 O2 EDO C 103s A 339 ARG C 18 ARG~? -3.10 O1 EDO C 103s coo 85.81 57.99 116.01 86.03 55.86 115.89 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 75.11 41.01 160.30 76.65 40.06 161.41 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 82.23 40.35 159.87 85.09 40.67 161.01 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 8 3 # 8 A 50 ASP B 27 ASP~? 12.32 O1 CIT B 103 A 327 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 339 ARG E 45 ARG.? 12.04 O2 EDO E 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 75.11 41.01 160.30 76.65 40.06 161.41 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 82.23 40.35 159.87 85.09 40.67 161.01 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 9 3 # 9 A 50 ASP B 93 ASP~? 9.77 O3 CIT B 103 A 327 GLU D 11 GLU.? 15.90 O4 CIT D 103 A 339 ARG D 89 ARG.? 14.10 O4 CIT D 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 3.85 -90.04 -12.91 5.79 -89.33 -13.36 coo 75.11 41.01 160.30 76.65 40.06 161.41 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo 82.23 40.35 159.87 85.09 40.67 161.01 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 10 3 # 10 A 50 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 327 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 339 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 75.11 41.01 160.30 76.65 40.06 161.41 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 82.23 40.35 159.87 85.09 40.67 161.01 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 11 3 # 11 A 50 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 327 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 339 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 75.11 41.01 160.30 76.65 40.06 161.41 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 82.23 40.35 159.87 85.09 40.67 161.01 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 12 3 # 12 A 50 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 327 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 339 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 75.11 41.01 160.30 76.65 40.06 161.41 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 82.23 40.35 159.87 85.09 40.67 161.01 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 13 3 # 13 A 50 ASP D 93 ASP~? 9.04 O4 CIT D 103 A 327 GLU B 52 GLU.? 15.03 O1 EDO A 103 A 339 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 75.11 41.01 160.30 76.65 40.06 161.41 -10.99 -99.25 -18.20 -12.86 -99.70 -17.22 coo 82.23 40.35 159.87 85.09 40.67 161.01 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 14 3 # 14 A 50 ASP D 93 ASP~? 9.04 O4 CIT D 103 A 327 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 339 ARG A 18 ARG~? 14.68 C2 EDO E 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 75.11 41.01 160.30 76.65 40.06 161.41 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 82.23 40.35 159.87 85.09 40.67 161.01 -13.40 -85.38 -40.50 -10.48 -85.51 -41.44 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 15 3 # 15 A 50 ASP D 93 ASP~? 9.04 O4 CIT D 103 A 327 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 339 ARG E 45 ARG.? 12.04 O2 EDO E 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 75.11 41.01 160.30 76.65 40.06 161.41 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 82.23 40.35 159.87 85.09 40.67 161.01 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 16 3 # 16 A 50 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 327 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 339 ARG E 45 ARG.? 12.04 O2 EDO E 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 75.11 41.01 160.30 76.65 40.06 161.41 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 82.23 40.35 159.87 85.09 40.67 161.01 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 17 3 # 17 A 50 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 327 GLU B 21 GLU~? 16.03 C2 CIT B 103 A 339 ARG B 18 ARG~? 17.41 C4 CIT B 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 75.11 41.01 160.30 76.65 40.06 161.41 -9.13 -87.49 4.49 -7.49 -88.18 5.63 coo 82.23 40.35 159.87 85.09 40.67 161.01 -4.30 -89.74 3.62 -5.35 -92.05 5.29 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 18 3 # 18 A 50 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 327 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 339 ARG D 45 ARG.? 18.60 O2 CIT C 104 coo 85.81 57.99 116.01 86.03 55.86 115.89 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 75.11 41.01 160.30 76.65 40.06 161.41 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 82.23 40.35 159.87 85.09 40.67 161.01 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 19 3 # 19 A 50 ASP E 93 ASP~? 8.62 O3 CIT E 104 A 327 GLU D 11 GLU.? 15.90 O4 CIT D 103 A 339 ARG D 89 ARG.? 14.10 O4 CIT D 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 75.11 41.01 160.30 76.65 40.06 161.41 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo 82.23 40.35 159.87 85.09 40.67 161.01 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 20 3 # 20 A 50 ASP F 17 ASP~? 19.11 O1 CIT F 104 A 327 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 339 ARG E 79 ARG~? -3.12 O5 CIT C 104s coo 85.81 57.99 116.01 86.03 55.86 115.89 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 coo 75.11 41.01 160.30 76.65 40.06 161.41 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 82.23 40.35 159.87 85.09 40.67 161.01 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 21 3 # 21 A 50 ASP F 17 ASP~? 19.11 O1 CIT F 104 A 327 GLU C 11 GLU.? 13.80 O2 EDO C 103 A 339 ARG E 18 ARG~? 11.85 O4 CIT C 104 coo 85.81 57.99 116.01 86.03 55.86 115.89 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 coo 75.11 41.01 160.30 76.65 40.06 161.41 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 82.23 40.35 159.87 85.09 40.67 161.01 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 22 3 # 22 A 50 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 327 GLU B 101 GLU^? 17.79 O2 CIT B 103 A 339 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 75.11 41.01 160.30 76.65 40.06 161.41 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 82.23 40.35 159.87 85.09 40.67 161.01 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 23 3 # 23 A 50 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 327 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 339 ARG D 45 ARG.? 18.60 O2 CIT C 104 coo 85.81 57.99 116.01 86.03 55.86 115.89 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 75.11 41.01 160.30 76.65 40.06 161.41 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 82.23 40.35 159.87 85.09 40.67 161.01 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 24 3 # 24 A 50 ASP F 93 ASP~? 9.52 O4 CIT F 104 A 327 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 339 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 coo 75.11 41.01 160.30 76.65 40.06 161.41 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 82.23 40.35 159.87 85.09 40.67 161.01 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1hto_c00 GLUTAMINE SYNTHETASE user 25 3 # 25 A 50 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 327 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 339 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 85.81 57.99 116.01 86.03 55.86 115.89 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 75.11 41.01 160.30 76.65 40.06 161.41 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 82.23 40.35 159.87 85.09 40.67 161.01 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 1hto_c00 source 1hto GLUTAMINE SYNTHETASE : 25 hits 1hto_c00 naa= 3 ULMN 3 1i29_c03 CSDB user 1 3 # 1 A 128 VAL A 85 VAL~? 7.69 O1 EDO A 103 A 200 ASP A 17 ASP~? 17.77 C2 EDO E 103 A 226 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -12.84 -90.95 -34.87 -13.67 -92.95 -34.50 coo 24.51 43.28 11.18 25.17 44.50 9.58 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 34.47 51.09 7.19 28.58 51.18 7.53 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1i29_c03 source 1i29 CSDB : 1 hits 1i29_c03 naa= 3 ULMN 3 1ig8_c00 HEXOKINASE PII user 1 3 # 1 A 158 SER A 51 SER.? 9.93 O6 CIT B 103 A 173 ARG B 53 ARG.? 13.69 O3 CIT B 103 A 211 ASP A 46 ASP.? 9.57 O6 CIT B 103 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 18.77 77.82 11.69 20.55 80.22 10.73 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 ULMN 3 1ig8_c00 HEXOKINASE PII user 2 3 # 2 A 158 SER B 51 SER.? 11.29 O1 EDO A 103 A 173 ARG A 53 ARG.? 15.50 C1 EDO A 103 A 211 ASP B 46 ASP.? 11.17 O1 EDO A 103 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 18.77 77.82 11.69 20.55 80.22 10.73 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 ULMN 3 1ig8_c00 HEXOKINASE PII user 3 3 # 3 A 158 SER B 51 SER.? 11.29 O1 EDO A 103 A 173 ARG B 89 ARG.? 13.25 O3 CIT B 103 A 211 ASP B 46 ASP.? 11.17 O1 EDO A 103 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 18.77 77.82 11.69 20.55 80.22 10.73 0.32 -96.47 -11.54 1.69 -95.10 -13.99 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 ULMN 3 1ig8_c00 HEXOKINASE PII user 4 3 # 4 A 158 SER C 51 SER.? 10.55 O6 CIT D 103 A 173 ARG C 89 ARG.? 16.36 O3 CIT C 104 A 211 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 18.77 77.82 11.69 20.55 80.22 10.73 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1ig8_c00 HEXOKINASE PII user 5 3 # 5 A 158 SER C 51 SER.? 10.55 O6 CIT D 103 A 173 ARG D 53 ARG.? 12.25 O4 CIT D 103 A 211 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 18.77 77.82 11.69 20.55 80.22 10.73 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1ig8_c00 HEXOKINASE PII user 6 3 # 6 A 158 SER D 51 SER.? 10.41 O7 CIT C 104 A 173 ARG C 53 ARG.? 12.90 O3 CIT C 104 A 211 ASP D 46 ASP.? 10.10 O7 CIT C 104 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 18.77 77.82 11.69 20.55 80.22 10.73 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 ULMN 3 1ig8_c00 HEXOKINASE PII user 7 3 # 7 A 158 SER D 51 SER.? 10.41 O7 CIT C 104 A 173 ARG D 89 ARG.? 14.10 O4 CIT D 103 A 211 ASP D 46 ASP.? 10.10 O7 CIT C 104 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 18.77 77.82 11.69 20.55 80.22 10.73 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 ULMN 3 1ig8_c00 HEXOKINASE PII user 8 3 # 8 A 158 SER E 51 SER.? 10.11 C4 CIT F 104 A 173 ARG F 53 ARG.? -5.38 O1 EDO F 103s A 211 ASP E 46 ASP.? 9.98 C4 CIT F 104 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 18.77 77.82 11.69 20.55 80.22 10.73 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 ULMN 3 1ig8_c00 HEXOKINASE PII user 9 3 # 9 A 158 SER F 51 SER.? -5.94 O2 EDO F 103s A 173 ARG E 53 ARG.? 4.89 O1 EDO F 103 A 211 ASP F 46 ASP.? 6.64 O2 EDO F 103 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 18.77 77.82 11.69 20.55 80.22 10.73 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 ULMN 3 1ig8_c00 HEXOKINASE PII user 10 3 # 10 A 158 SER F 51 SER.? -5.94 O2 EDO F 103s A 173 ARG F 89 ARG.? 10.30 C2 EDO F 103 A 211 ASP F 46 ASP.? 6.64 O2 EDO F 103 coo 22.72 76.24 0.23 24.60 76.86 -1.25 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 18.77 77.82 11.69 20.55 80.22 10.73 -31.12 -63.92 -68.77 -30.34 -61.79 -66.66 coo 26.87 77.59 -3.91 27.39 79.28 -2.83 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 1ig8_c00 source 1ig8 HEXOKINASE PII : 10 hits 1ig8_c00 naa= 3 ULMN 3 1inp_c02 INOSITOL POLYPHOSPHATE 1-PHOSPHATASEuser 1 3 # 1 54 ASP B 64 ASP~? 16.93 O2 CIT B 103 158 THR B 61 THR^? 13.51 O2 CIT B 103 317 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -2.63 8.40 35.07 -3.66 9.81 36.17 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo -5.30 12.75 41.86 -4.34 13.05 39.99 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo -12.63 17.64 33.66 -10.65 17.90 34.40 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1inp_c02 INOSITOL POLYPHOSPHATE 1-PHOSPHATASEuser 2 3 # 2 54 ASP B 99 ASP^? 7.47 O6 CIT B 103 158 THR B 61 THR^? 13.51 O2 CIT B 103 317 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo -2.63 8.40 35.07 -3.66 9.81 36.17 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -5.30 12.75 41.86 -4.34 13.05 39.99 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo -12.63 17.64 33.66 -10.65 17.90 34.40 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1inp_c02 INOSITOL POLYPHOSPHATE 1-PHOSPHATASEuser 3 3 # 3 54 ASP C 64 ASP~? 16.62 O2 CIT C 104 158 THR C 61 THR^? 13.10 O1 CIT C 104 317 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -2.63 8.40 35.07 -3.66 9.81 36.17 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo -5.30 12.75 41.86 -4.34 13.05 39.99 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo -12.63 17.64 33.66 -10.65 17.90 34.40 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1inp_c02 INOSITOL POLYPHOSPHATE 1-PHOSPHATASEuser 4 3 # 4 54 ASP C 99 ASP^? 7.14 O2 CIT C 104 158 THR C 61 THR^? 13.10 O1 CIT C 104 317 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo -2.63 8.40 35.07 -3.66 9.81 36.17 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -5.30 12.75 41.86 -4.34 13.05 39.99 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 coo -12.63 17.64 33.66 -10.65 17.90 34.40 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1inp_c02 INOSITOL POLYPHOSPHATE 1-PHOSPHATASEuser 5 3 # 5 54 ASP E 64 ASP~? 16.37 O2 CIT E 104 158 THR E 61 THR^? 11.76 O1 EDO E 103 317 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -2.63 8.40 35.07 -3.66 9.81 36.17 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo -5.30 12.75 41.86 -4.34 13.05 39.99 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo -12.63 17.64 33.66 -10.65 17.90 34.40 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1inp_c02 INOSITOL POLYPHOSPHATE 1-PHOSPHATASEuser 6 3 # 6 54 ASP E 99 ASP^? 7.65 C2 CIT E 104 158 THR E 61 THR^? 11.76 O1 EDO E 103 317 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo -2.63 8.40 35.07 -3.66 9.81 36.17 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -5.30 12.75 41.86 -4.34 13.05 39.99 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo -12.63 17.64 33.66 -10.65 17.90 34.40 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1inp_c02 INOSITOL POLYPHOSPHATE 1-PHOSPHATASEuser 7 3 # 7 54 ASP F 64 ASP~? 16.52 O2 EDO E 103 158 THR F 61 THR^? 11.09 O2 EDO E 103 317 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -2.63 8.40 35.07 -3.66 9.81 36.17 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo -5.30 12.75 41.86 -4.34 13.05 39.99 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo -12.63 17.64 33.66 -10.65 17.90 34.40 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1inp_c02 INOSITOL POLYPHOSPHATE 1-PHOSPHATASEuser 8 3 # 8 54 ASP F 99 ASP^? 6.97 O7 CIT F 104 158 THR F 61 THR^? 11.09 O2 EDO E 103 317 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo -2.63 8.40 35.07 -3.66 9.81 36.17 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -5.30 12.75 41.86 -4.34 13.05 39.99 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 coo -12.63 17.64 33.66 -10.65 17.90 34.40 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1inp_c02 source 1inp INOSITOL POLYPHOSPHATE 1-PHOSPHATASE (1-PTASE): 8 hits 1inp_c02 naa= 3 ULMN 3 1ir3_c02 INSULIN RECEPTOR user 1 3 # 1 A1132 ASP A 93 ASP~? 12.48 O1 EDO A 103 A1134 ALA A 92 ALA~? 7.55 O1 EDO A 103 A1137 ASN A 90 ASN~? 16.38 O1 EDO A 103 coo -27.05 34.58 17.12 -25.81 32.84 17.16 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo -20.53 36.39 15.81 -20.80 35.01 16.40 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo -23.72 34.69 12.49 -24.32 32.83 13.34 -4.88 -95.45 -33.14 -2.88 -95.87 -33.61 ULMN 3 1ir3_c02 INSULIN RECEPTOR user 2 3 # 2 A1132 ASP D 93 ASP~? 9.04 O4 CIT D 103 A1134 ALA D 92 ALA~? 3.89 O4 CIT D 103 A1137 ASN D 90 ASN~? 12.97 O4 CIT D 103 coo -27.05 34.58 17.12 -25.81 32.84 17.16 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo -20.53 36.39 15.81 -20.80 35.01 16.40 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo -23.72 34.69 12.49 -24.32 32.83 13.34 -32.84 -58.19 -3.59 -31.15 -59.37 -2.96 1ir3_c02 source 1ir3 INSULIN RECEPTOR : 2 hits 1ir3_c02 naa= 3 ULMN 3 1itx_c00 GLYCOSYL HYDROLASE user 1 3 # 1 A 202 ASP B 17 ASP~? 19.42 C4 CIT B 103 A 204 GLU B 21 GLU~? 16.03 C2 CIT B 103 A 279 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 5.85 5.60 30.32 5.00 7.49 29.88 -8.70 -93.12 3.11 -9.77 -94.94 3.45 coo 7.79 1.83 27.81 9.08 3.25 26.92 -9.13 -87.49 4.49 -7.49 -88.18 5.63 coo 8.22 7.77 18.64 7.58 8.47 21.28 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 1itx_c00 GLYCOSYL HYDROLASE user 2 3 # 2 A 202 ASP C 17 ASP~? -3.95 O1 EDO C 103s A 204 GLU C 21 GLU~? 6.35 O1 EDO C 103 A 279 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 5.85 5.60 30.32 5.00 7.49 29.88 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 7.79 1.83 27.81 9.08 3.25 26.92 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 8.22 7.77 18.64 7.58 8.47 21.28 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 1itx_c00 GLYCOSYL HYDROLASE user 3 3 # 3 A 202 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 204 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 279 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 5.85 5.60 30.32 5.00 7.49 29.88 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 7.79 1.83 27.81 9.08 3.25 26.92 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 8.22 7.77 18.64 7.58 8.47 21.28 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 1itx_c00 source 1itx GLYCOSYL HYDROLASE : 3 hits 1itx_c00 naa= 3 ULMN 3 1j53_c00 DNA POLYMERASE III, EPSILON CHAIN user 1 3 # 1 A 14 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 61 GLU E 32 GLU~? 15.49 O1 EDO E 103 A 162 HIS A 74 HIS~? 11.00 C1 EDO E 103 coo -1.50 25.58 -6.20 -2.54 26.76 -4.79 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo -4.89 20.85 5.22 -3.95 21.69 6.91 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo -7.53 27.82 -3.33 -8.58 28.59 -1.68 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 1j53_c00 source 1j53 DNA POLYMERASE III, EPSILON CHAIN : 1 hits 1j53_c00 naa= 3 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 1 3 # 1 A 55 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 58 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 424 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 58.42 47.76 20.67 58.01 49.10 19.12 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 58.59 41.80 18.81 58.94 43.89 18.94 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 52.85 46.34 13.34 54.09 44.97 14.42 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 2 3 # 2 A 55 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 58 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 424 GLU A 48 GLU.? -2.39 O6 CIT B 103s coo 58.42 47.76 20.67 58.01 49.10 19.12 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 58.59 41.80 18.81 58.94 43.89 18.94 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 52.85 46.34 13.34 54.09 44.97 14.42 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 3 3 # 3 A 55 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 58 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 424 GLU B 48 GLU.? 3.87 O1 EDO A 103 coo 58.42 47.76 20.67 58.01 49.10 19.12 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 58.59 41.80 18.81 58.94 43.89 18.94 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 52.85 46.34 13.34 54.09 44.97 14.42 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 4 3 # 4 A 55 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 58 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 424 GLU B 48 GLU.? 3.87 O1 EDO A 103 coo 58.42 47.76 20.67 58.01 49.10 19.12 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 58.59 41.80 18.81 58.94 43.89 18.94 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 52.85 46.34 13.34 54.09 44.97 14.42 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 5 3 # 5 A 55 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 58 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 424 GLU A 48 GLU.? -2.39 O6 CIT B 103s coo 58.42 47.76 20.67 58.01 49.10 19.12 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 58.59 41.80 18.81 58.94 43.89 18.94 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 52.85 46.34 13.34 54.09 44.97 14.42 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 6 3 # 6 A 55 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 58 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 424 GLU C 48 GLU.? -2.75 O6 CIT D 103s coo 58.42 47.76 20.67 58.01 49.10 19.12 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 58.59 41.80 18.81 58.94 43.89 18.94 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 52.85 46.34 13.34 54.09 44.97 14.42 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 7 3 # 7 A 55 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 58 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 424 GLU D 48 GLU.? -3.37 O7 CIT C 104s coo 58.42 47.76 20.67 58.01 49.10 19.12 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 58.59 41.80 18.81 58.94 43.89 18.94 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 52.85 46.34 13.34 54.09 44.97 14.42 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 8 3 # 8 A 55 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 58 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 424 GLU D 48 GLU.? -3.37 O7 CIT C 104s coo 58.42 47.76 20.67 58.01 49.10 19.12 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 58.59 41.80 18.81 58.94 43.89 18.94 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 52.85 46.34 13.34 54.09 44.97 14.42 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 9 3 # 9 A 55 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 58 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 424 GLU C 48 GLU.? -2.75 O6 CIT D 103s coo 58.42 47.76 20.67 58.01 49.10 19.12 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 58.59 41.80 18.81 58.94 43.89 18.94 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 52.85 46.34 13.34 54.09 44.97 14.42 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 10 3 # 10 A 55 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 58 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 424 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 58.42 47.76 20.67 58.01 49.10 19.12 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 58.59 41.80 18.81 58.94 43.89 18.94 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 52.85 46.34 13.34 54.09 44.97 14.42 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 11 3 # 11 A 55 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 58 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 424 GLU E 48 GLU.? -2.93 O7 CIT F 104s coo 58.42 47.76 20.67 58.01 49.10 19.12 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 58.59 41.80 18.81 58.94 43.89 18.94 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 52.85 46.34 13.34 54.09 44.97 14.42 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 12 3 # 12 A 55 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 58 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 424 GLU F 101 GLU^? 10.35 O2 EDO E 103 coo 58.42 47.76 20.67 58.01 49.10 19.12 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 58.59 41.80 18.81 58.94 43.89 18.94 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 52.85 46.34 13.34 54.09 44.97 14.42 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 13 3 # 13 A 55 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 58 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 424 GLU F 48 GLU.? -3.15 C4 CIT E 104s coo 58.42 47.76 20.67 58.01 49.10 19.12 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 58.59 41.80 18.81 58.94 43.89 18.94 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 52.85 46.34 13.34 54.09 44.97 14.42 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 14 3 # 14 A 55 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 58 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 424 GLU F 48 GLU.? -3.15 C4 CIT E 104s coo 58.42 47.76 20.67 58.01 49.10 19.12 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 58.59 41.80 18.81 58.94 43.89 18.94 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 52.85 46.34 13.34 54.09 44.97 14.42 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 15 3 # 15 A 55 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 58 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 424 GLU E 48 GLU.? -2.93 O7 CIT F 104s coo 58.42 47.76 20.67 58.01 49.10 19.12 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 58.59 41.80 18.81 58.94 43.89 18.94 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 52.85 46.34 13.34 54.09 44.97 14.42 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 1js4_c00 source 1js4 ENDO-EXOCELLULASE E4 : 15 hits 1js4_c00 naa= 3 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 1 3 # 1 B 55 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 58 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 424 GLU A 48 GLU.? -2.39 O6 CIT B 103s coo 112.10 61.46 19.99 111.82 60.65 18.07 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 117.85 63.62 21.08 115.96 63.25 20.18 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 118.47 57.23 15.57 119.32 58.77 16.73 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 2 3 # 2 B 55 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 58 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 424 GLU B 48 GLU.? 3.87 O1 EDO A 103 coo 112.10 61.46 19.99 111.82 60.65 18.07 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 117.85 63.62 21.08 115.96 63.25 20.18 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 118.47 57.23 15.57 119.32 58.77 16.73 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 3 3 # 3 B 55 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 58 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 424 GLU B 48 GLU.? 3.87 O1 EDO A 103 coo 112.10 61.46 19.99 111.82 60.65 18.07 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 117.85 63.62 21.08 115.96 63.25 20.18 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 118.47 57.23 15.57 119.32 58.77 16.73 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 4 3 # 4 B 55 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 58 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 424 GLU A 48 GLU.? -2.39 O6 CIT B 103s coo 112.10 61.46 19.99 111.82 60.65 18.07 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 117.85 63.62 21.08 115.96 63.25 20.18 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 118.47 57.23 15.57 119.32 58.77 16.73 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 5 3 # 5 B 55 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 58 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 424 GLU C 48 GLU.? -2.75 O6 CIT D 103s coo 112.10 61.46 19.99 111.82 60.65 18.07 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 117.85 63.62 21.08 115.96 63.25 20.18 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 118.47 57.23 15.57 119.32 58.77 16.73 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 6 3 # 6 B 55 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 58 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 424 GLU D 48 GLU.? -3.37 O7 CIT C 104s coo 112.10 61.46 19.99 111.82 60.65 18.07 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 117.85 63.62 21.08 115.96 63.25 20.18 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 118.47 57.23 15.57 119.32 58.77 16.73 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 7 3 # 7 B 55 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 58 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 424 GLU D 48 GLU.? -3.37 O7 CIT C 104s coo 112.10 61.46 19.99 111.82 60.65 18.07 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 117.85 63.62 21.08 115.96 63.25 20.18 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 118.47 57.23 15.57 119.32 58.77 16.73 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 8 3 # 8 B 55 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 58 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 424 GLU C 48 GLU.? -2.75 O6 CIT D 103s coo 112.10 61.46 19.99 111.82 60.65 18.07 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 117.85 63.62 21.08 115.96 63.25 20.18 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 118.47 57.23 15.57 119.32 58.77 16.73 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 9 3 # 9 B 55 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 58 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 424 GLU E 48 GLU.? -2.93 O7 CIT F 104s coo 112.10 61.46 19.99 111.82 60.65 18.07 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 117.85 63.62 21.08 115.96 63.25 20.18 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 118.47 57.23 15.57 119.32 58.77 16.73 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 10 3 # 10 B 55 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 58 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 424 GLU F 48 GLU.? -3.15 C4 CIT E 104s coo 112.10 61.46 19.99 111.82 60.65 18.07 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 117.85 63.62 21.08 115.96 63.25 20.18 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 118.47 57.23 15.57 119.32 58.77 16.73 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 11 3 # 11 B 55 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 58 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 424 GLU F 48 GLU.? -3.15 C4 CIT E 104s coo 112.10 61.46 19.99 111.82 60.65 18.07 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 117.85 63.62 21.08 115.96 63.25 20.18 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 118.47 57.23 15.57 119.32 58.77 16.73 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 12 3 # 12 B 55 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 58 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 424 GLU E 48 GLU.? -2.93 O7 CIT F 104s coo 112.10 61.46 19.99 111.82 60.65 18.07 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 117.85 63.62 21.08 115.96 63.25 20.18 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 118.47 57.23 15.57 119.32 58.77 16.73 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 1js4_c01 source 1js4 ENDO-EXOCELLULASE E4 : 12 hits 1js4_c01 naa= 3 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 1 3 # 1 C 1 CYH A 88 CYH.? 9.02 C1 EDO A 103 C 98 ASN A 90 ASN~? 16.38 O1 EDO A 103 C 99 GLY A 91 GLY~? 10.61 O1 EDO A 103 coo 4.88 17.74 73.58 7.14 19.23 72.93 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 coo 8.21 16.91 78.64 7.09 18.75 78.67 -4.88 -95.45 -33.14 -2.88 -95.87 -33.61 coo 11.04 18.39 74.90 10.95 17.56 74.65 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 2 3 # 2 C 1 CYH A 88 CYH.? 9.02 C1 EDO A 103 C 98 ASN A 90 ASN~? 16.38 O1 EDO A 103 C 99 GLY A 94 GLY.? 10.50 C1 EDO A 103 coo 4.88 17.74 73.58 7.14 19.23 72.93 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 coo 8.21 16.91 78.64 7.09 18.75 78.67 -4.88 -95.45 -33.14 -2.88 -95.87 -33.61 coo 11.04 18.39 74.90 10.95 17.56 74.65 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 3 3 # 3 C 1 CYH B 88 CYH~? 7.91 O3 CIT B 103 C 98 ASN B 90 ASN~? 13.61 O3 CIT B 103 C 99 GLY B 91 GLY~? 7.97 O3 CIT B 103 coo 4.88 17.74 73.58 7.14 19.23 72.93 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 coo 8.21 16.91 78.64 7.09 18.75 78.67 4.74 -92.94 -10.60 5.13 -95.02 -10.92 coo 11.04 18.39 74.90 10.95 17.56 74.65 3.29 -89.28 -7.61 2.92 -89.60 -8.27 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 4 3 # 4 C 1 CYH B 88 CYH~? 7.91 O3 CIT B 103 C 98 ASN B 90 ASN~? 13.61 O3 CIT B 103 C 99 GLY B 94 GLY.? 8.02 O3 CIT B 103 coo 4.88 17.74 73.58 7.14 19.23 72.93 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 coo 8.21 16.91 78.64 7.09 18.75 78.67 4.74 -92.94 -10.60 5.13 -95.02 -10.92 coo 11.04 18.39 74.90 10.95 17.56 74.65 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 5 3 # 5 C 1 CYH C 88 CYH~? 7.95 C4 CIT C 104 C 98 ASN C 90 ASN~? 14.00 O3 CIT C 104 C 99 GLY C 91 GLY~? 8.26 O4 CIT C 104 coo 4.88 17.74 73.58 7.14 19.23 72.93 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 8.21 16.91 78.64 7.09 18.75 78.67 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo 11.04 18.39 74.90 10.95 17.56 74.65 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 6 3 # 6 C 1 CYH C 88 CYH~? 7.95 C4 CIT C 104 C 98 ASN C 90 ASN~? 14.00 O3 CIT C 104 C 99 GLY C 94 GLY.? 8.41 O3 CIT C 104 coo 4.88 17.74 73.58 7.14 19.23 72.93 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 8.21 16.91 78.64 7.09 18.75 78.67 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo 11.04 18.39 74.90 10.95 17.56 74.65 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 7 3 # 7 C 1 CYH D 88 CYH.? 7.80 O4 CIT D 103 C 98 ASN D 90 ASN~? 12.97 O4 CIT D 103 C 99 GLY D 91 GLY~? 7.26 O4 CIT D 103 coo 4.88 17.74 73.58 7.14 19.23 72.93 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 coo 8.21 16.91 78.64 7.09 18.75 78.67 -32.84 -58.19 -3.59 -31.15 -59.37 -2.96 coo 11.04 18.39 74.90 10.95 17.56 74.65 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 8 3 # 8 C 1 CYH D 88 CYH.? 7.80 O4 CIT D 103 C 98 ASN D 90 ASN~? 12.97 O4 CIT D 103 C 99 GLY D 94 GLY.? 7.85 O4 CIT D 103 coo 4.88 17.74 73.58 7.14 19.23 72.93 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 coo 8.21 16.91 78.64 7.09 18.75 78.67 -32.84 -58.19 -3.59 -31.15 -59.37 -2.96 coo 11.04 18.39 74.90 10.95 17.56 74.65 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 9 3 # 9 C 1 CYH E 88 CYH.? 7.64 O3 CIT E 104 C 98 ASN E 90 ASN~? -4.46 O2 EDO C 103s C 99 GLY E 91 GLY~? 5.97 O2 EDO C 103 coo 4.88 17.74 73.58 7.14 19.23 72.93 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 coo 8.21 16.91 78.64 7.09 18.75 78.67 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo 11.04 18.39 74.90 10.95 17.56 74.65 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 10 3 # 10 C 1 CYH E 88 CYH.? 7.64 O3 CIT E 104 C 98 ASN E 90 ASN~? -4.46 O2 EDO C 103s C 99 GLY E 94 GLY.? 7.76 O3 CIT E 104 coo 4.88 17.74 73.58 7.14 19.23 72.93 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 coo 8.21 16.91 78.64 7.09 18.75 78.67 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo 11.04 18.39 74.90 10.95 17.56 74.65 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 11 3 # 11 C 1 CYH F 88 CYH.? 7.60 O3 CIT F 104 C 98 ASN F 90 ASN~? 14.08 O1 EDO F 103 C 99 GLY F 91 GLY~? 8.30 O3 CIT F 104 coo 4.88 17.74 73.58 7.14 19.23 72.93 -27.14 -69.89 -70.66 -26.83 -72.10 -69.05 coo 8.21 16.91 78.64 7.09 18.75 78.67 -25.28 -63.01 -68.95 -26.65 -61.43 -69.45 coo 11.04 18.39 74.90 10.95 17.56 74.65 -22.80 -67.12 -70.37 -23.31 -66.96 -69.76 ULMN 3 1jxa_c04 GLUCOSAMINE 6-PHOSPHATE SYNTHASE user 12 3 # 12 C 1 CYH F 88 CYH.? 7.60 O3 CIT F 104 C 98 ASN F 90 ASN~? 14.08 O1 EDO F 103 C 99 GLY F 94 GLY.? 8.80 O3 CIT F 104 coo 4.88 17.74 73.58 7.14 19.23 72.93 -27.14 -69.89 -70.66 -26.83 -72.10 -69.05 coo 8.21 16.91 78.64 7.09 18.75 78.67 -25.28 -63.01 -68.95 -26.65 -61.43 -69.45 coo 11.04 18.39 74.90 10.95 17.56 74.65 -26.33 -67.76 -65.92 -25.64 -68.13 -65.72 1jxa_c04 source 1jxa GLUCOSAMINE 6-PHOSPHATE SYNTHASE : 12 hits 1jxa_c04 naa= 3 ULMN 3 1k4t_c00 5'-D(*AP*AP*AP*AP*AP*GP*AP*CP*TP*T)-user 1 3 # 1 A 488 ARG A 79 ARG~? -3.92 C2 EDO E 103s A 590 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 632 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 19.23 7.38 20.83 18.34 7.79 23.74 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 23.20 10.66 21.48 21.07 10.68 23.70 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 20.55 9.13 29.66 21.88 8.70 28.08 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1k4t_c00 5'-D(*AP*AP*AP*AP*AP*GP*AP*CP*TP*T)-user 2 3 # 2 A 488 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 590 ARG A 79 ARG~? -3.92 C2 EDO E 103s A 632 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 19.23 7.38 20.83 18.34 7.79 23.74 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 23.20 10.66 21.48 21.07 10.68 23.70 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 20.55 9.13 29.66 21.88 8.70 28.08 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 1k4t_c00 source 1k4t 5'-D(*AP*AP*AP*AP*AP*GP*AP*CP*TP*T)-3' : 2 hits 1k4t_c00 naa= 3 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 1 3 # 1 A 2 GLU A 101 GLU^? 18.10 O2 EDO A 103 A 56 LYS A 65 LYS~? 12.23 O2 EDO A 103 A 258 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo 42.33 1.56 26.99 42.38 2.91 28.66 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 2 3 # 2 A 2 GLU B 101 GLU^? 17.79 O2 CIT B 103 A 56 LYS B 65 LYS~? 11.82 O5 CIT B 103 A 258 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo 42.33 1.56 26.99 42.38 2.91 28.66 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 3 3 # 3 A 2 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 56 LYS C 65 LYS~? 12.16 O6 CIT C 104 A 258 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo 42.33 1.56 26.99 42.38 2.91 28.66 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 4 3 # 4 A 2 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 56 LYS D 50 LYS.? -4.40 O3 CIT C 104s A 258 ARG E 79 ARG~? -3.12 O5 CIT C 104s coo 42.33 1.56 26.99 42.38 2.91 28.66 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 5 3 # 5 A 2 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 56 LYS D 65 LYS~? 11.29 O6 CIT D 103 A 258 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo 42.33 1.56 26.99 42.38 2.91 28.66 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 6 3 # 6 A 2 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 56 LYS E 65 LYS~? 11.89 O6 CIT E 104 A 258 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo 42.33 1.56 26.99 42.38 2.91 28.66 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 7 3 # 7 A 2 GLU F 48 GLU.? -3.15 C4 CIT E 104s A 56 LYS F 50 LYS.? -3.77 O3 CIT E 104s A 258 ARG C 79 ARG~? -3.25 O5 CIT E 104s coo 42.33 1.56 26.99 42.38 2.91 28.66 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 8 3 # 8 A 2 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 56 LYS F 65 LYS~? 10.97 O7 CIT F 104 A 258 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 42.33 1.56 26.99 42.38 2.91 28.66 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 9 3 # 9 A 2 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 56 LYS F 65 LYS~? 10.97 O7 CIT F 104 A 258 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo 42.33 1.56 26.99 42.38 2.91 28.66 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 1k82_c00 source 1k82 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE : 9 hits 1k82_c00 naa= 3 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 1 3 # 1 B 2 GLU A 101 GLU^? 18.10 O2 EDO A 103 B 56 LYS A 65 LYS~? 12.23 O2 EDO A 103 B 258 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 2.64 1.83 34.81 1.56 1.13 32.02 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 2 3 # 2 B 2 GLU B 101 GLU^? 17.79 O2 CIT B 103 B 56 LYS B 65 LYS~? 11.82 O5 CIT B 103 B 258 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 2.64 1.83 34.81 1.56 1.13 32.02 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 3 3 # 3 B 2 GLU C 101 GLU^? 17.42 O2 CIT C 104 B 56 LYS C 65 LYS~? 12.16 O6 CIT C 104 B 258 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 2.64 1.83 34.81 1.56 1.13 32.02 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 4 3 # 4 B 2 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 56 LYS D 50 LYS.? -4.40 O3 CIT C 104s B 258 ARG E 79 ARG~? -3.12 O5 CIT C 104s coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 2.64 1.83 34.81 1.56 1.13 32.02 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 5 3 # 5 B 2 GLU D 101 GLU^? 17.58 O6 CIT D 103 B 56 LYS D 65 LYS~? 11.29 O6 CIT D 103 B 258 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 2.64 1.83 34.81 1.56 1.13 32.02 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 6 3 # 6 B 2 GLU E 101 GLU^? 17.69 O2 CIT E 104 B 56 LYS E 65 LYS~? 11.89 O6 CIT E 104 B 258 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 2.64 1.83 34.81 1.56 1.13 32.02 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 7 3 # 7 B 2 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 56 LYS F 50 LYS.? -3.77 O3 CIT E 104s B 258 ARG C 79 ARG~? -3.25 O5 CIT E 104s coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 2.64 1.83 34.81 1.56 1.13 32.02 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 8 3 # 8 B 2 GLU F 101 GLU^? 10.35 O2 EDO E 103 B 56 LYS F 65 LYS~? 10.97 O7 CIT F 104 B 258 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 2.64 1.83 34.81 1.56 1.13 32.02 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 9 3 # 9 B 2 GLU F 101 GLU^? 10.35 O2 EDO E 103 B 56 LYS F 65 LYS~? 10.97 O7 CIT F 104 B 258 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 2.64 1.83 34.81 1.56 1.13 32.02 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 1k82_c01 source 1k82 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE : 9 hits 1k82_c01 naa= 3 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 1 3 # 1 C 2 GLU A 101 GLU^? 18.10 O2 EDO A 103 C 56 LYS A 65 LYS~? 12.23 O2 EDO A 103 C 258 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 2 3 # 2 C 2 GLU B 101 GLU^? 17.79 O2 CIT B 103 C 56 LYS B 65 LYS~? 11.82 O5 CIT B 103 C 258 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 3 3 # 3 C 2 GLU C 101 GLU^? 17.42 O2 CIT C 104 C 56 LYS C 65 LYS~? 12.16 O6 CIT C 104 C 258 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 4 3 # 4 C 2 GLU D 48 GLU.? -3.37 O7 CIT C 104s C 56 LYS D 50 LYS.? -4.40 O3 CIT C 104s C 258 ARG E 79 ARG~? -3.12 O5 CIT C 104s coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 5 3 # 5 C 2 GLU D 101 GLU^? 17.58 O6 CIT D 103 C 56 LYS D 65 LYS~? 11.29 O6 CIT D 103 C 258 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 6 3 # 6 C 2 GLU E 101 GLU^? 17.69 O2 CIT E 104 C 56 LYS E 65 LYS~? 11.89 O6 CIT E 104 C 258 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 7 3 # 7 C 2 GLU F 48 GLU.? -3.15 C4 CIT E 104s C 56 LYS F 50 LYS.? -3.77 O3 CIT E 104s C 258 ARG C 79 ARG~? -3.25 O5 CIT E 104s coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 8 3 # 8 C 2 GLU F 101 GLU^? 10.35 O2 EDO E 103 C 56 LYS F 65 LYS~? 10.97 O7 CIT F 104 C 258 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 1k82_c02 source 1k82 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE : 8 hits 1k82_c02 naa= 3 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 1 3 # 1 D 2 GLU A 101 GLU^? 18.10 O2 EDO A 103 D 56 LYS A 65 LYS~? 12.23 O2 EDO A 103 D 258 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 2 3 # 2 D 2 GLU B 101 GLU^? 17.79 O2 CIT B 103 D 56 LYS B 65 LYS~? 11.82 O5 CIT B 103 D 258 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 3 3 # 3 D 2 GLU C 101 GLU^? 17.42 O2 CIT C 104 D 56 LYS C 65 LYS~? 12.16 O6 CIT C 104 D 258 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 4 3 # 4 D 2 GLU D 48 GLU.? -3.37 O7 CIT C 104s D 56 LYS D 50 LYS.? -4.40 O3 CIT C 104s D 258 ARG E 79 ARG~? -3.12 O5 CIT C 104s coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 5 3 # 5 D 2 GLU D 101 GLU^? 17.58 O6 CIT D 103 D 56 LYS D 65 LYS~? 11.29 O6 CIT D 103 D 258 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 6 3 # 6 D 2 GLU E 101 GLU^? 17.69 O2 CIT E 104 D 56 LYS E 65 LYS~? 11.89 O6 CIT E 104 D 258 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 7 3 # 7 D 2 GLU F 48 GLU.? -3.15 C4 CIT E 104s D 56 LYS F 50 LYS.? -3.77 O3 CIT E 104s D 258 ARG C 79 ARG~? -3.25 O5 CIT E 104s coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 8 3 # 8 D 2 GLU F 101 GLU^? 10.35 O2 EDO E 103 D 56 LYS F 65 LYS~? 10.97 O7 CIT F 104 D 258 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 1k82_c03 source 1k82 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE : 8 hits 1k82_c03 naa= 3 ULMN 3 1kim_c00 THYMIDINE KINASE user 1 3 # 1 A 83 GLU B 9 GLU.? 11.84 O3 CIT B 103 A 163 ARG B 53 ARG.? 13.69 O3 CIT B 103 A 222 ARG B 89 ARG.? 13.25 O3 CIT B 103 coo 51.27 81.34 48.31 51.67 80.79 50.28 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 48.06 78.22 50.94 48.51 78.27 53.98 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 coo 54.85 84.16 52.60 54.26 81.23 53.34 0.32 -96.47 -11.54 1.69 -95.10 -13.99 ULMN 3 1kim_c00 THYMIDINE KINASE user 2 3 # 2 A 83 GLU B 9 GLU.? 11.84 O3 CIT B 103 A 163 ARG B 89 ARG.? 13.25 O3 CIT B 103 A 222 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo 51.27 81.34 48.31 51.67 80.79 50.28 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 48.06 78.22 50.94 48.51 78.27 53.98 0.32 -96.47 -11.54 1.69 -95.10 -13.99 coo 54.85 84.16 52.60 54.26 81.23 53.34 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1kim_c00 THYMIDINE KINASE user 3 3 # 3 A 83 GLU C 9 GLU.? 12.64 O3 CIT C 104 A 163 ARG C 53 ARG.? 12.90 O3 CIT C 104 A 222 ARG C 89 ARG.? 16.36 O3 CIT C 104 coo 51.27 81.34 48.31 51.67 80.79 50.28 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 48.06 78.22 50.94 48.51 78.27 53.98 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 coo 54.85 84.16 52.60 54.26 81.23 53.34 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 ULMN 3 1kim_c00 THYMIDINE KINASE user 4 3 # 4 A 83 GLU C 9 GLU.? 12.64 O3 CIT C 104 A 163 ARG C 89 ARG.? 16.36 O3 CIT C 104 A 222 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 51.27 81.34 48.31 51.67 80.79 50.28 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 48.06 78.22 50.94 48.51 78.27 53.98 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo 54.85 84.16 52.60 54.26 81.23 53.34 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1kim_c00 THYMIDINE KINASE user 5 3 # 5 A 83 GLU D 9 GLU.? 12.31 O4 CIT D 103 A 163 ARG D 53 ARG.? 12.25 O4 CIT D 103 A 222 ARG D 89 ARG.? 14.10 O4 CIT D 103 coo 51.27 81.34 48.31 51.67 80.79 50.28 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 48.06 78.22 50.94 48.51 78.27 53.98 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo 54.85 84.16 52.60 54.26 81.23 53.34 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 ULMN 3 1kim_c00 THYMIDINE KINASE user 6 3 # 6 A 83 GLU D 9 GLU.? 12.31 O4 CIT D 103 A 163 ARG D 89 ARG.? 14.10 O4 CIT D 103 A 222 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 51.27 81.34 48.31 51.67 80.79 50.28 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 48.06 78.22 50.94 48.51 78.27 53.98 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 coo 54.85 84.16 52.60 54.26 81.23 53.34 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1kim_c00 THYMIDINE KINASE user 7 3 # 7 A 83 GLU E 9 GLU.? 7.76 O1 EDO F 103 A 163 ARG E 53 ARG.? 4.89 O1 EDO F 103 A 222 ARG E 89 ARG.? -3.87 C2 EDO C 103s coo 51.27 81.34 48.31 51.67 80.79 50.28 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo 48.06 78.22 50.94 48.51 78.27 53.98 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 54.85 84.16 52.60 54.26 81.23 53.34 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 ULMN 3 1kim_c00 THYMIDINE KINASE user 8 3 # 8 A 83 GLU E 9 GLU.? 7.76 O1 EDO F 103 A 163 ARG E 89 ARG.? -3.87 C2 EDO C 103s A 222 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 51.27 81.34 48.31 51.67 80.79 50.28 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo 48.06 78.22 50.94 48.51 78.27 53.98 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo 54.85 84.16 52.60 54.26 81.23 53.34 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1kim_c00 THYMIDINE KINASE user 9 3 # 9 A 83 GLU F 9 GLU.? 7.31 C2 EDO F 103 A 163 ARG F 53 ARG.? -5.38 O1 EDO F 103s A 222 ARG F 89 ARG.? 10.30 C2 EDO F 103 coo 51.27 81.34 48.31 51.67 80.79 50.28 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 48.06 78.22 50.94 48.51 78.27 53.98 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 coo 54.85 84.16 52.60 54.26 81.23 53.34 -31.12 -63.92 -68.77 -30.34 -61.79 -66.66 ULMN 3 1kim_c00 THYMIDINE KINASE user 10 3 # 10 A 83 GLU F 9 GLU.? 7.31 C2 EDO F 103 A 163 ARG F 89 ARG.? 10.30 C2 EDO F 103 A 222 ARG F 53 ARG.? -5.38 O1 EDO F 103s coo 51.27 81.34 48.31 51.67 80.79 50.28 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 48.06 78.22 50.94 48.51 78.27 53.98 -31.12 -63.92 -68.77 -30.34 -61.79 -66.66 coo 54.85 84.16 52.60 54.26 81.23 53.34 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 1kim_c00 source 1kim THYMIDINE KINASE : 10 hits 1kim_c00 naa= 3 ULMN 3 1knp_c00 L-ASPARTATE OXIDASE user 1 3 # 1 A 290 ARG A 40 ARG^? 16.77 O2 EDO A 103 A 351 HIS A 41 HIS^? 12.51 O2 EDO A 103 A 386 LEU A 59 LEU^? 10.77 O2 EDO A 103 coo 57.36 53.34 128.83 58.45 50.56 128.34 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 60.60 50.64 133.59 60.63 48.82 132.56 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 63.28 54.23 126.45 63.53 52.07 126.70 -17.38 -80.52 -20.70 -17.58 -81.04 -18.55 ULMN 3 1knp_c00 L-ASPARTATE OXIDASE user 2 3 # 2 A 290 ARG B 40 ARG^? 17.25 O1 CIT B 103 A 351 HIS B 41 HIS^? 11.37 O1 CIT B 103 A 386 LEU B 59 LEU^? 10.90 O2 CIT B 103 coo 57.36 53.34 128.83 58.45 50.56 128.34 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 60.60 50.64 133.59 60.63 48.82 132.56 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 63.28 54.23 126.45 63.53 52.07 126.70 -14.93 -80.44 -13.27 -15.13 -79.38 -15.15 ULMN 3 1knp_c00 L-ASPARTATE OXIDASE user 3 3 # 3 A 290 ARG C 40 ARG^? 17.96 O1 CIT C 104 A 351 HIS C 41 HIS^? 12.16 O1 CIT C 104 A 386 LEU C 59 LEU^? 10.89 O1 CIT C 104 coo 57.36 53.34 128.83 58.45 50.56 128.34 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 60.60 50.64 133.59 60.63 48.82 132.56 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 63.28 54.23 126.45 63.53 52.07 126.70 -50.97 -61.87 -23.60 -52.03 -62.27 -21.69 ULMN 3 1knp_c00 L-ASPARTATE OXIDASE user 4 3 # 4 A 290 ARG D 40 ARG^? 16.76 O2 CIT D 103 A 351 HIS D 41 HIS^? 12.20 O1 CIT D 103 A 386 LEU D 59 LEU^? 10.68 O2 CIT D 103 coo 57.36 53.34 128.83 58.45 50.56 128.34 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 60.60 50.64 133.59 60.63 48.82 132.56 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 63.28 54.23 126.45 63.53 52.07 126.70 -52.26 -59.76 -16.21 -51.85 -59.33 -18.29 ULMN 3 1knp_c00 L-ASPARTATE OXIDASE user 5 3 # 5 A 290 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 351 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 386 LEU E 59 LEU^? 9.06 O2 EDO E 103 coo 57.36 53.34 128.83 58.45 50.56 128.34 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 60.60 50.64 133.59 60.63 48.82 132.56 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 63.28 54.23 126.45 63.53 52.07 126.70 -29.71 -82.47 -50.91 -29.82 -82.98 -52.96 ULMN 3 1knp_c00 L-ASPARTATE OXIDASE user 6 3 # 6 A 290 ARG F 40 ARG^? 16.45 O2 CIT F 104 A 351 HIS F 41 HIS^? 12.43 O1 CIT F 104 A 386 LEU F 59 LEU^? 10.61 O2 CIT F 104 coo 57.36 53.34 128.83 58.45 50.56 128.34 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 60.60 50.64 133.59 60.63 48.82 132.56 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 63.28 54.23 126.45 63.53 52.07 126.70 -26.99 -83.61 -58.38 -26.66 -84.07 -56.20 1knp_c00 source 1knp L-ASPARTATE OXIDASE : 6 hits 1knp_c00 naa= 3 ULMN 3 1lam_c00 LEUCINE AMINOPEPTIDASE user 1 3 # 1 255 ASP A 99 ASP^? 8.10 O2 EDO A 103 262 LYS A 65 LYS~? 12.23 O2 EDO A 103 336 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo 61.88 50.78 12.96 63.84 50.60 13.71 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 63.59 44.40 18.32 63.20 49.74 17.95 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 72.60 57.42 15.86 71.61 56.68 18.70 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1lam_c00 LEUCINE AMINOPEPTIDASE user 2 3 # 2 255 ASP B 99 ASP^? 7.47 O6 CIT B 103 262 LYS B 65 LYS~? 11.82 O5 CIT B 103 336 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo 61.88 50.78 12.96 63.84 50.60 13.71 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 63.59 44.40 18.32 63.20 49.74 17.95 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 72.60 57.42 15.86 71.61 56.68 18.70 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1lam_c00 LEUCINE AMINOPEPTIDASE user 3 3 # 3 255 ASP C 93 ASP~? 9.74 O3 CIT C 104 262 LYS D 50 LYS.? -4.40 O3 CIT C 104s 336 ARG E 79 ARG~? -3.12 O5 CIT C 104s coo 61.88 50.78 12.96 63.84 50.60 13.71 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 63.59 44.40 18.32 63.20 49.74 17.95 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 72.60 57.42 15.86 71.61 56.68 18.70 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 ULMN 3 1lam_c00 LEUCINE AMINOPEPTIDASE user 4 3 # 4 255 ASP C 99 ASP^? 7.14 O2 CIT C 104 262 LYS C 65 LYS~? 12.16 O6 CIT C 104 336 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo 61.88 50.78 12.96 63.84 50.60 13.71 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 63.59 44.40 18.32 63.20 49.74 17.95 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 72.60 57.42 15.86 71.61 56.68 18.70 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1lam_c00 LEUCINE AMINOPEPTIDASE user 5 3 # 5 255 ASP D 99 ASP^? 6.89 O6 CIT D 103 262 LYS D 65 LYS~? 11.29 O6 CIT D 103 336 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo 61.88 50.78 12.96 63.84 50.60 13.71 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 63.59 44.40 18.32 63.20 49.74 17.95 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 72.60 57.42 15.86 71.61 56.68 18.70 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1lam_c00 LEUCINE AMINOPEPTIDASE user 6 3 # 6 255 ASP E 93 ASP~? 8.62 O3 CIT E 104 262 LYS F 50 LYS.? -3.77 O3 CIT E 104s 336 ARG C 79 ARG~? -3.25 O5 CIT E 104s coo 61.88 50.78 12.96 63.84 50.60 13.71 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 63.59 44.40 18.32 63.20 49.74 17.95 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 72.60 57.42 15.86 71.61 56.68 18.70 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 ULMN 3 1lam_c00 LEUCINE AMINOPEPTIDASE user 7 3 # 7 255 ASP E 99 ASP^? 7.65 C2 CIT E 104 262 LYS E 65 LYS~? 11.89 O6 CIT E 104 336 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo 61.88 50.78 12.96 63.84 50.60 13.71 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 63.59 44.40 18.32 63.20 49.74 17.95 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 72.60 57.42 15.86 71.61 56.68 18.70 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 ULMN 3 1lam_c00 LEUCINE AMINOPEPTIDASE user 8 3 # 8 255 ASP F 99 ASP^? 6.97 O7 CIT F 104 262 LYS F 65 LYS~? 10.97 O7 CIT F 104 336 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo 61.88 50.78 12.96 63.84 50.60 13.71 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 63.59 44.40 18.32 63.20 49.74 17.95 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 72.60 57.42 15.86 71.61 56.68 18.70 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 1lam_c00 source 1lam LEUCINE AMINOPEPTIDASE : 8 hits 1lam_c00 naa= 3 ULMN 3 1lcb_c02 THYMIDYLATE SYNTHASE user 1 3 # 1 60 GLU C 21 GLU~? 6.35 O1 EDO C 103 198 CYH E 88 CYH.? 7.64 O3 CIT E 104 229 ASN E 90 ASN~? -4.46 O2 EDO C 103s coo 11.57 50.45 -41.48 12.95 49.39 -42.73 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 9.92 49.50 -53.84 12.48 47.89 -53.69 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 coo 9.79 43.22 -47.74 11.15 44.81 -48.24 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 ULMN 3 1lcb_c02 THYMIDYLATE SYNTHASE user 2 3 # 2 60 GLU E 21 GLU~? 9.95 O4 CIT C 104 198 CYH C 88 CYH~? 7.95 C4 CIT C 104 229 ASN C 90 ASN~? 14.00 O3 CIT C 104 coo 11.57 50.45 -41.48 12.95 49.39 -42.73 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 9.92 49.50 -53.84 12.48 47.89 -53.69 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 coo 9.79 43.22 -47.74 11.15 44.81 -48.24 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 1lcb_c02 source 1lcb THYMIDYLATE SYNTHASE : 2 hits 1lcb_c02 naa= 3 ULMN 3 1lci_c00 LUCIFERASE user 1 3 # 1 218 ARG A 40 ARG^? 16.77 O2 EDO A 103 245 HIS A 4 HIS.? -4.40 O2 EDO A 103s 343 THR A 61 THR^? 12.85 O2 EDO A 103 coo 18.11 85.25 41.19 18.04 83.33 43.59 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 5.34 86.23 43.48 6.16 87.26 45.12 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 9.06 92.76 42.80 7.04 92.63 42.14 -23.25 -82.29 -18.58 -22.99 -80.29 -17.87 ULMN 3 1lci_c00 LUCIFERASE user 2 3 # 2 218 ARG A 40 ARG^? 16.77 O2 EDO A 103 245 HIS B 4 HIS.? -4.11 O2 CIT B 103s 343 THR B 61 THR^? 13.51 O2 CIT B 103 coo 18.11 85.25 41.19 18.04 83.33 43.59 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 5.34 86.23 43.48 6.16 87.26 45.12 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 9.06 92.76 42.80 7.04 92.63 42.14 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 ULMN 3 1lci_c00 LUCIFERASE user 3 3 # 3 218 ARG C 40 ARG^? 17.96 O1 CIT C 104 245 HIS C 4 HIS.? -4.06 O2 CIT C 104s 343 THR C 61 THR^? 13.10 O1 CIT C 104 coo 18.11 85.25 41.19 18.04 83.33 43.59 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 5.34 86.23 43.48 6.16 87.26 45.12 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 9.06 92.76 42.80 7.04 92.63 42.14 -55.37 -66.53 -23.20 -56.60 -65.01 -22.30 ULMN 3 1lci_c00 LUCIFERASE user 4 3 # 4 218 ARG D 40 ARG^? 16.76 O2 CIT D 103 245 HIS D 4 HIS.? -4.16 O2 CIT D 103s 343 THR D 61 THR^? 13.17 O2 CIT D 103 coo 18.11 85.25 41.19 18.04 83.33 43.59 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 5.34 86.23 43.48 6.16 87.26 45.12 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 9.06 92.76 42.80 7.04 92.63 42.14 -55.18 -54.33 -18.40 -56.25 -55.57 -19.83 ULMN 3 1lci_c00 LUCIFERASE user 5 3 # 5 218 ARG F 18 ARG~? 15.26 O3 CIT F 104 245 HIS F 77 HIS~? -3.59 O1 CIT F 104s 343 THR F 76 THR~? 10.78 O1 CIT F 104 coo 18.11 85.25 41.19 18.04 83.33 43.59 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 coo 5.34 86.23 43.48 6.16 87.26 45.12 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 9.06 92.76 42.80 7.04 92.63 42.14 -15.02 -84.48 -71.94 -15.75 -86.50 -72.18 ULMN 3 1lci_c00 LUCIFERASE user 6 3 # 6 218 ARG F 40 ARG^? 16.45 O2 CIT F 104 245 HIS F 4 HIS.? -4.07 O2 CIT F 104s 343 THR F 61 THR^? 11.09 O2 EDO E 103 coo 18.11 85.25 41.19 18.04 83.33 43.59 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 5.34 86.23 43.48 6.16 87.26 45.12 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 9.06 92.76 42.80 7.04 92.63 42.14 -21.85 -86.87 -56.25 -23.11 -87.95 -54.91 1lci_c00 source 1lci LUCIFERASE : 6 hits 1lci_c00 naa= 3 ULMN 3 1ldm_c01 M4 LACTATE DEHYDROGENASE user 1 3 # 1 166 ASP E 27 ASP~? 4.58 C1 EDO E 103 169 ARG A 79 ARG~? -3.92 C2 EDO E 103s 193 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 20.88 15.91 3.60 20.25 17.72 4.50 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 17.70 17.91 -0.80 15.74 19.74 0.84 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 18.81 19.85 7.63 17.55 19.89 5.97 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 1ldm_c01 source 1ldm M4 LACTATE DEHYDROGENASE : 1 hits 1ldm_c01 naa= 3 ULMN 3 1lij_c01 ADENOSINE KINASE user 1 3 # 1 A 316 ALA A 15 ALA~? 15.06 C1 EDO A 103 A 317 GLY A 14 GLY~? 18.08 C2 EDO E 103 A 318 ASP A 17 ASP~? 17.77 C2 EDO E 103 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -7.92 -83.12 -38.44 -6.92 -83.81 -37.59 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 ULMN 3 1lij_c01 ADENOSINE KINASE user 2 3 # 2 A 316 ALA A 92 ALA~? 7.55 O1 EDO A 103 A 317 GLY A 91 GLY~? 10.61 O1 EDO A 103 A 318 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1lij_c01 ADENOSINE KINASE user 3 3 # 3 A 316 ALA A 92 ALA~? 7.55 O1 EDO A 103 A 317 GLY A 94 GLY.? 10.50 C1 EDO A 103 A 318 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1lij_c01 ADENOSINE KINASE user 4 3 # 4 A 316 ALA B 15 ALA~? 14.11 C4 CIT B 103 A 317 GLY B 14 GLY~? 17.66 C4 CIT B 103 A 318 ASP B 17 ASP~? 19.42 C4 CIT B 103 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -5.10 -93.70 -1.33 -4.68 -94.25 -2.68 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -5.53 -95.57 1.94 -5.32 -95.64 1.14 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -8.70 -93.12 3.11 -9.77 -94.94 3.45 ULMN 3 1lij_c01 ADENOSINE KINASE user 5 3 # 5 A 316 ALA B 92 ALA~? 4.16 O3 CIT B 103 A 317 GLY B 91 GLY~? 7.97 O3 CIT B 103 A 318 ASP B 93 ASP~? 9.77 O3 CIT B 103 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 3.29 -89.28 -7.61 2.92 -89.60 -8.27 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 3.85 -90.04 -12.91 5.79 -89.33 -13.36 ULMN 3 1lij_c01 ADENOSINE KINASE user 6 3 # 6 A 316 ALA B 92 ALA~? 4.16 O3 CIT B 103 A 317 GLY B 94 GLY.? 8.02 O3 CIT B 103 A 318 ASP B 93 ASP~? 9.77 O3 CIT B 103 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 3.85 -90.04 -12.91 5.79 -89.33 -13.36 ULMN 3 1lij_c01 ADENOSINE KINASE user 7 3 # 7 A 316 ALA C 15 ALA~? 8.64 C1 EDO C 103 A 317 GLY C 14 GLY~? 3.87 C1 EDO C 103 A 318 ASP C 17 ASP~? -3.95 O1 EDO C 103s coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 ULMN 3 1lij_c01 ADENOSINE KINASE user 8 3 # 8 A 316 ALA C 92 ALA~? 4.69 O3 CIT C 104 A 317 GLY C 91 GLY~? 8.26 O4 CIT C 104 A 318 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1lij_c01 ADENOSINE KINASE user 9 3 # 9 A 316 ALA C 92 ALA~? 4.69 O3 CIT C 104 A 317 GLY C 94 GLY.? 8.41 O3 CIT C 104 A 318 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1lij_c01 ADENOSINE KINASE user 10 3 # 10 A 316 ALA D 15 ALA~? 14.37 O4 CIT D 103 A 317 GLY D 14 GLY~? 17.95 O7 CIT D 103 A 318 ASP D 17 ASP~? 19.08 O1 CIT D 103 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -43.98 -63.95 1.87 -42.83 -64.36 0.99 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -44.90 -65.50 5.30 -44.33 -65.47 4.79 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -49.27 -65.18 4.30 -49.35 -67.27 4.77 ULMN 3 1lij_c01 ADENOSINE KINASE user 11 3 # 11 A 316 ALA D 92 ALA~? 3.89 O4 CIT D 103 A 317 GLY D 91 GLY~? 7.26 O4 CIT D 103 A 318 ASP D 93 ASP~? 9.04 O4 CIT D 103 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 ULMN 3 1lij_c01 ADENOSINE KINASE user 12 3 # 12 A 316 ALA D 92 ALA~? 3.89 O4 CIT D 103 A 317 GLY D 94 GLY.? 7.85 O4 CIT D 103 A 318 ASP D 93 ASP~? 9.04 O4 CIT D 103 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 ULMN 3 1lij_c01 ADENOSINE KINASE user 13 3 # 13 A 316 ALA E 15 ALA~? 10.03 O2 EDO C 103 A 317 GLY E 14 GLY~? 13.52 O2 EDO C 103 A 318 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1lij_c01 ADENOSINE KINASE user 14 3 # 14 A 316 ALA E 92 ALA~? 4.01 O3 CIT E 104 A 317 GLY E 91 GLY~? 5.97 O2 EDO C 103 A 318 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1lij_c01 ADENOSINE KINASE user 15 3 # 15 A 316 ALA E 92 ALA~? 4.01 O3 CIT E 104 A 317 GLY E 94 GLY.? 7.76 O3 CIT E 104 A 318 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1lij_c01 ADENOSINE KINASE user 16 3 # 16 A 316 ALA F 15 ALA~? 13.96 O3 CIT F 104 A 317 GLY F 14 GLY~? 17.47 O3 CIT F 104 A 318 ASP F 17 ASP~? 19.11 O1 CIT F 104 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -30.55 -73.71 -75.60 -31.05 -72.60 -74.70 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -31.78 -74.33 -79.17 -31.74 -73.80 -78.55 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 ULMN 3 1lij_c01 ADENOSINE KINASE user 17 3 # 17 A 316 ALA F 30 ALA~? 11.84 O2 CIT F 104 A 317 GLY F 28 GLY~? 13.27 O1 CIT F 104 A 318 ASP F 27 ASP~? 14.00 O1 CIT F 104 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -19.58 -90.69 -64.73 -21.00 -90.58 -64.23 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -21.49 -91.20 -70.18 -21.31 -90.68 -69.63 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 ULMN 3 1lij_c01 ADENOSINE KINASE user 18 3 # 18 A 316 ALA F 92 ALA~? 4.20 O4 CIT F 104 A 317 GLY F 91 GLY~? 8.30 O3 CIT F 104 A 318 ASP F 93 ASP~? 9.52 O4 CIT F 104 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -22.80 -67.12 -70.37 -23.31 -66.96 -69.76 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 ULMN 3 1lij_c01 ADENOSINE KINASE user 19 3 # 19 A 316 ALA F 92 ALA~? 4.20 O4 CIT F 104 A 317 GLY F 94 GLY.? 8.80 O3 CIT F 104 A 318 ASP F 93 ASP~? 9.52 O4 CIT F 104 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -26.33 -67.76 -65.92 -25.64 -68.13 -65.72 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 1lij_c01 source 1lij ADENOSINE KINASE : 19 hits 1lij_c01 naa= 3 ULMN 3 1lio_c01 ADENOSINE KINASE user 1 3 # 1 A 316 ALA A 15 ALA~? 15.06 C1 EDO A 103 A 317 GLY A 14 GLY~? 18.08 C2 EDO E 103 A 318 ASP A 17 ASP~? 17.77 C2 EDO E 103 coo 27.04 23.54 41.85 25.72 24.19 42.18 -7.92 -83.12 -38.44 -6.92 -83.81 -37.59 coo 27.87 23.16 38.17 28.43 22.97 38.87 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 coo 32.11 22.71 40.58 33.42 24.22 39.78 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 ULMN 3 1lio_c01 ADENOSINE KINASE user 2 3 # 2 A 316 ALA A 92 ALA~? 7.55 O1 EDO A 103 A 317 GLY A 91 GLY~? 10.61 O1 EDO A 103 A 318 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 27.04 23.54 41.85 25.72 24.19 42.18 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 27.87 23.16 38.17 28.43 22.97 38.87 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo 32.11 22.71 40.58 33.42 24.22 39.78 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1lio_c01 ADENOSINE KINASE user 3 3 # 3 A 316 ALA A 92 ALA~? 7.55 O1 EDO A 103 A 317 GLY A 94 GLY.? 10.50 C1 EDO A 103 A 318 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 27.04 23.54 41.85 25.72 24.19 42.18 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 27.87 23.16 38.17 28.43 22.97 38.87 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo 32.11 22.71 40.58 33.42 24.22 39.78 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1lio_c01 ADENOSINE KINASE user 4 3 # 4 A 316 ALA B 15 ALA~? 14.11 C4 CIT B 103 A 317 GLY B 14 GLY~? 17.66 C4 CIT B 103 A 318 ASP B 17 ASP~? 19.42 C4 CIT B 103 coo 27.04 23.54 41.85 25.72 24.19 42.18 -5.10 -93.70 -1.33 -4.68 -94.25 -2.68 coo 27.87 23.16 38.17 28.43 22.97 38.87 -5.53 -95.57 1.94 -5.32 -95.64 1.14 coo 32.11 22.71 40.58 33.42 24.22 39.78 -8.70 -93.12 3.11 -9.77 -94.94 3.45 ULMN 3 1lio_c01 ADENOSINE KINASE user 5 3 # 5 A 316 ALA B 92 ALA~? 4.16 O3 CIT B 103 A 317 GLY B 91 GLY~? 7.97 O3 CIT B 103 A 318 ASP B 93 ASP~? 9.77 O3 CIT B 103 coo 27.04 23.54 41.85 25.72 24.19 42.18 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 27.87 23.16 38.17 28.43 22.97 38.87 3.29 -89.28 -7.61 2.92 -89.60 -8.27 coo 32.11 22.71 40.58 33.42 24.22 39.78 3.85 -90.04 -12.91 5.79 -89.33 -13.36 ULMN 3 1lio_c01 ADENOSINE KINASE user 6 3 # 6 A 316 ALA B 92 ALA~? 4.16 O3 CIT B 103 A 317 GLY B 94 GLY.? 8.02 O3 CIT B 103 A 318 ASP B 93 ASP~? 9.77 O3 CIT B 103 coo 27.04 23.54 41.85 25.72 24.19 42.18 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 27.87 23.16 38.17 28.43 22.97 38.87 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 32.11 22.71 40.58 33.42 24.22 39.78 3.85 -90.04 -12.91 5.79 -89.33 -13.36 ULMN 3 1lio_c01 ADENOSINE KINASE user 7 3 # 7 A 316 ALA C 15 ALA~? 8.64 C1 EDO C 103 A 317 GLY C 14 GLY~? 3.87 C1 EDO C 103 A 318 ASP C 17 ASP~? -3.95 O1 EDO C 103s coo 27.04 23.54 41.85 25.72 24.19 42.18 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo 27.87 23.16 38.17 28.43 22.97 38.87 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo 32.11 22.71 40.58 33.42 24.22 39.78 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 ULMN 3 1lio_c01 ADENOSINE KINASE user 8 3 # 8 A 316 ALA C 92 ALA~? 4.69 O3 CIT C 104 A 317 GLY C 91 GLY~? 8.26 O4 CIT C 104 A 318 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 27.04 23.54 41.85 25.72 24.19 42.18 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 coo 27.87 23.16 38.17 28.43 22.97 38.87 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo 32.11 22.71 40.58 33.42 24.22 39.78 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1lio_c01 ADENOSINE KINASE user 9 3 # 9 A 316 ALA C 92 ALA~? 4.69 O3 CIT C 104 A 317 GLY C 94 GLY.? 8.41 O3 CIT C 104 A 318 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 27.04 23.54 41.85 25.72 24.19 42.18 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 coo 27.87 23.16 38.17 28.43 22.97 38.87 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 coo 32.11 22.71 40.58 33.42 24.22 39.78 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1lio_c01 ADENOSINE KINASE user 10 3 # 10 A 316 ALA D 15 ALA~? 14.37 O4 CIT D 103 A 317 GLY D 14 GLY~? 17.95 O7 CIT D 103 A 318 ASP D 17 ASP~? 19.08 O1 CIT D 103 coo 27.04 23.54 41.85 25.72 24.19 42.18 -43.98 -63.95 1.87 -42.83 -64.36 0.99 coo 27.87 23.16 38.17 28.43 22.97 38.87 -44.90 -65.50 5.30 -44.33 -65.47 4.79 coo 32.11 22.71 40.58 33.42 24.22 39.78 -49.27 -65.18 4.30 -49.35 -67.27 4.77 ULMN 3 1lio_c01 ADENOSINE KINASE user 11 3 # 11 A 316 ALA D 92 ALA~? 3.89 O4 CIT D 103 A 317 GLY D 91 GLY~? 7.26 O4 CIT D 103 A 318 ASP D 93 ASP~? 9.04 O4 CIT D 103 coo 27.04 23.54 41.85 25.72 24.19 42.18 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo 27.87 23.16 38.17 28.43 22.97 38.87 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 coo 32.11 22.71 40.58 33.42 24.22 39.78 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 ULMN 3 1lio_c01 ADENOSINE KINASE user 12 3 # 12 A 316 ALA D 92 ALA~? 3.89 O4 CIT D 103 A 317 GLY D 94 GLY.? 7.85 O4 CIT D 103 A 318 ASP D 93 ASP~? 9.04 O4 CIT D 103 coo 27.04 23.54 41.85 25.72 24.19 42.18 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo 27.87 23.16 38.17 28.43 22.97 38.87 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 32.11 22.71 40.58 33.42 24.22 39.78 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 ULMN 3 1lio_c01 ADENOSINE KINASE user 13 3 # 13 A 316 ALA E 15 ALA~? 10.03 O2 EDO C 103 A 317 GLY E 14 GLY~? 13.52 O2 EDO C 103 A 318 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 27.04 23.54 41.85 25.72 24.19 42.18 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo 27.87 23.16 38.17 28.43 22.97 38.87 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 coo 32.11 22.71 40.58 33.42 24.22 39.78 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1lio_c01 ADENOSINE KINASE user 14 3 # 14 A 316 ALA E 92 ALA~? 4.01 O3 CIT E 104 A 317 GLY E 91 GLY~? 5.97 O2 EDO C 103 A 318 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 27.04 23.54 41.85 25.72 24.19 42.18 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 27.87 23.16 38.17 28.43 22.97 38.87 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 32.11 22.71 40.58 33.42 24.22 39.78 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1lio_c01 ADENOSINE KINASE user 15 3 # 15 A 316 ALA E 92 ALA~? 4.01 O3 CIT E 104 A 317 GLY E 94 GLY.? 7.76 O3 CIT E 104 A 318 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 27.04 23.54 41.85 25.72 24.19 42.18 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 27.87 23.16 38.17 28.43 22.97 38.87 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo 32.11 22.71 40.58 33.42 24.22 39.78 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1lio_c01 ADENOSINE KINASE user 16 3 # 16 A 316 ALA F 15 ALA~? 13.96 O3 CIT F 104 A 317 GLY F 14 GLY~? 17.47 O3 CIT F 104 A 318 ASP F 17 ASP~? 19.11 O1 CIT F 104 coo 27.04 23.54 41.85 25.72 24.19 42.18 -30.55 -73.71 -75.60 -31.05 -72.60 -74.70 coo 27.87 23.16 38.17 28.43 22.97 38.87 -31.78 -74.33 -79.17 -31.74 -73.80 -78.55 coo 32.11 22.71 40.58 33.42 24.22 39.78 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 ULMN 3 1lio_c01 ADENOSINE KINASE user 17 3 # 17 A 316 ALA F 30 ALA~? 11.84 O2 CIT F 104 A 317 GLY F 28 GLY~? 13.27 O1 CIT F 104 A 318 ASP F 27 ASP~? 14.00 O1 CIT F 104 coo 27.04 23.54 41.85 25.72 24.19 42.18 -19.58 -90.69 -64.73 -21.00 -90.58 -64.23 coo 27.87 23.16 38.17 28.43 22.97 38.87 -21.49 -91.20 -70.18 -21.31 -90.68 -69.63 coo 32.11 22.71 40.58 33.42 24.22 39.78 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 ULMN 3 1lio_c01 ADENOSINE KINASE user 18 3 # 18 A 316 ALA F 92 ALA~? 4.20 O4 CIT F 104 A 317 GLY F 91 GLY~? 8.30 O3 CIT F 104 A 318 ASP F 93 ASP~? 9.52 O4 CIT F 104 coo 27.04 23.54 41.85 25.72 24.19 42.18 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 27.87 23.16 38.17 28.43 22.97 38.87 -22.80 -67.12 -70.37 -23.31 -66.96 -69.76 coo 32.11 22.71 40.58 33.42 24.22 39.78 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 ULMN 3 1lio_c01 ADENOSINE KINASE user 19 3 # 19 A 316 ALA F 92 ALA~? 4.20 O4 CIT F 104 A 317 GLY F 94 GLY.? 8.80 O3 CIT F 104 A 318 ASP F 93 ASP~? 9.52 O4 CIT F 104 coo 27.04 23.54 41.85 25.72 24.19 42.18 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 27.87 23.16 38.17 28.43 22.97 38.87 -26.33 -67.76 -65.92 -25.64 -68.13 -65.72 coo 32.11 22.71 40.58 33.42 24.22 39.78 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 1lio_c01 source 1lio ADENOSINE KINASE : 19 hits 1lio_c01 naa= 3 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 1 3 # 1 A 44 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 45 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 261 PHE A 39 PHE^? 8.73 O2 EDO A 103 coo 49.89 1.93 30.83 50.54 1.43 32.81 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -21.74 -79.22 -26.25 -19.82 -80.03 -28.09 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 2 3 # 2 A 44 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 45 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 261 PHE A 62 PHE^? 8.30 O2 EDO A 103 coo 49.89 1.93 30.83 50.54 1.43 32.81 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -25.47 -86.10 -20.36 -24.36 -86.13 -22.89 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 3 3 # 3 A 44 HIS B 74 HIS~? 11.72 O1 CIT B 103 A 45 HIS B 77 HIS~? -4.07 O1 CIT B 103s A 261 PHE B 39 PHE^? 8.22 O1 CIT B 103 coo 49.89 1.93 30.83 50.54 1.43 32.81 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -14.83 -78.18 -6.28 -13.34 -80.32 -5.30 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 4 3 # 4 A 44 HIS B 74 HIS~? 11.72 O1 CIT B 103 A 45 HIS B 77 HIS~? -4.07 O1 CIT B 103s A 261 PHE B 58 PHE^? -4.80 O1 CIT B 103s coo 49.89 1.93 30.83 50.54 1.43 32.81 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -11.14 -82.54 -8.78 -8.55 -81.62 -8.22 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 5 3 # 5 A 44 HIS B 74 HIS~? 11.72 O1 CIT B 103 A 45 HIS B 77 HIS~? -4.07 O1 CIT B 103s A 261 PHE B 62 PHE^? 8.69 O2 CIT B 103 coo 49.89 1.93 30.83 50.54 1.43 32.81 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -10.74 -71.50 -12.21 -9.68 -73.15 -10.21 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 6 3 # 6 A 44 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 45 HIS C 77 HIS~? -4.31 O1 CIT C 104s A 261 PHE C 39 PHE^? 8.82 O1 CIT C 104 coo 49.89 1.93 30.83 50.54 1.43 32.81 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -52.46 -63.56 -30.58 -49.96 -63.04 -31.67 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 7 3 # 7 A 44 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 45 HIS C 77 HIS~? -4.31 O1 CIT C 104s A 261 PHE C 62 PHE^? 8.35 O1 CIT C 104 coo 49.89 1.93 30.83 50.54 1.43 32.81 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -54.36 -71.13 -24.12 -52.54 -70.86 -26.21 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 8 3 # 8 A 44 HIS D 74 HIS~? 11.86 O1 CIT D 103 A 45 HIS D 77 HIS~? -3.79 O1 CIT D 103s A 261 PHE D 39 PHE^? 8.71 O2 CIT D 103 coo 49.89 1.93 30.83 50.54 1.43 32.81 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -56.27 -57.17 -10.67 -54.36 -57.75 -8.75 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 9 3 # 9 A 44 HIS D 74 HIS~? 11.86 O1 CIT D 103 A 45 HIS D 77 HIS~? -3.79 O1 CIT D 103s A 261 PHE D 62 PHE^? 8.07 O2 CIT D 103 coo 49.89 1.93 30.83 50.54 1.43 32.81 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -53.64 -50.09 -16.77 -52.89 -50.72 -14.19 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 10 3 # 10 A 44 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 45 HIS E 77 HIS~? -4.13 O1 CIT E 104s A 261 PHE E 39 PHE^? -5.50 C1 EDO E 103s coo 49.89 1.93 30.83 50.54 1.43 32.81 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -31.49 -84.64 -44.22 -31.26 -82.07 -43.16 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 11 3 # 11 A 44 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 45 HIS E 77 HIS~? -4.13 O1 CIT E 104s A 261 PHE E 58 PHE^? 5.04 O2 CIT E 104 coo 49.89 1.93 30.83 50.54 1.43 32.81 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -30.99 -78.83 -46.17 -33.45 -77.60 -45.67 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 12 3 # 12 A 44 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 45 HIS E 77 HIS~? -4.13 O1 CIT E 104s A 261 PHE E 62 PHE^? 7.96 O2 CIT E 104 coo 49.89 1.93 30.83 50.54 1.43 32.81 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -38.83 -85.80 -50.65 -38.38 -84.14 -48.46 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 13 3 # 13 A 44 HIS F 74 HIS~? 11.52 O1 CIT F 104 A 45 HIS F 77 HIS~? -3.59 O1 CIT F 104s A 261 PHE F 39 PHE^? 8.84 O2 CIT F 104 coo 49.89 1.93 30.83 50.54 1.43 32.81 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -24.68 -87.05 -64.11 -25.42 -84.90 -65.71 ULMN 3 1luc_c00 BACTERIAL LUCIFERASE user 14 3 # 14 A 44 HIS F 74 HIS~? 11.52 O1 CIT F 104 A 45 HIS F 77 HIS~? -3.59 O1 CIT F 104s A 261 PHE F 62 PHE^? 8.18 O2 CIT F 104 coo 49.89 1.93 30.83 50.54 1.43 32.81 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 45.01 -1.52 29.84 44.56 -2.07 27.88 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 46.05 -5.25 41.21 44.22 -4.43 39.26 -17.45 -85.24 -57.40 -17.81 -84.27 -59.96 1luc_c00 source 1luc BACTERIAL LUCIFERASE : 14 hits 1luc_c00 naa= 3 ULMN 3 1m53_c03 ISOMALTULOSE SYNTHASE user 1 3 # 1 A 241 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 295 GLU A 101 GLU^? 18.10 O2 EDO A 103 A 369 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 16.11 33.72 80.99 14.10 33.54 81.63 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 12.19 31.08 87.29 11.13 32.66 86.38 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1m53_c03 ISOMALTULOSE SYNTHASE user 2 3 # 2 A 241 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 295 GLU B 101 GLU^? 17.79 O2 CIT B 103 A 369 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 16.11 33.72 80.99 14.10 33.54 81.63 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 12.19 31.08 87.29 11.13 32.66 86.38 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1m53_c03 ISOMALTULOSE SYNTHASE user 3 3 # 3 A 241 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 295 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 369 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 16.11 33.72 80.99 14.10 33.54 81.63 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 12.19 31.08 87.29 11.13 32.66 86.38 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1m53_c03 ISOMALTULOSE SYNTHASE user 4 3 # 4 A 241 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 295 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 369 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 16.11 33.72 80.99 14.10 33.54 81.63 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 12.19 31.08 87.29 11.13 32.66 86.38 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1m53_c03 ISOMALTULOSE SYNTHASE user 5 3 # 5 A 241 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 295 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 369 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 16.11 33.72 80.99 14.10 33.54 81.63 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 12.19 31.08 87.29 11.13 32.66 86.38 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1m53_c03 ISOMALTULOSE SYNTHASE user 6 3 # 6 A 241 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 295 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 369 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 16.11 33.72 80.99 14.10 33.54 81.63 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 12.19 31.08 87.29 11.13 32.66 86.38 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1m53_c03 source 1m53 ISOMALTULOSE SYNTHASE : 6 hits 1m53_c03 naa= 3 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 1 3 # 1 A 241 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 265 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 369 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 17.36 23.57 72.04 18.68 21.92 71.98 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 12.19 31.08 87.29 11.13 32.66 86.38 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 2 3 # 2 A 241 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 265 GLU A 38 GLU^? 15.90 O2 EDO A 103 A 369 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 17.36 23.57 72.04 18.68 21.92 71.98 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 12.19 31.08 87.29 11.13 32.66 86.38 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 3 3 # 3 A 241 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 265 GLU A 38 GLU^? 15.90 O2 EDO A 103 A 369 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 17.36 23.57 72.04 18.68 21.92 71.98 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 12.19 31.08 87.29 11.13 32.66 86.38 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 4 3 # 4 A 241 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 265 GLU B 38 GLU^? 16.05 O1 CIT B 103 A 369 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 17.36 23.57 72.04 18.68 21.92 71.98 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 12.19 31.08 87.29 11.13 32.66 86.38 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 5 3 # 5 A 241 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 265 GLU A 32 GLU~? 8.29 O4 CIT C 104 A 369 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 17.36 23.57 72.04 18.68 21.92 71.98 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 12.19 31.08 87.29 11.13 32.66 86.38 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 6 3 # 6 A 241 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 265 GLU A 38 GLU^? 15.90 O2 EDO A 103 A 369 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 17.36 23.57 72.04 18.68 21.92 71.98 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 12.19 31.08 87.29 11.13 32.66 86.38 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 7 3 # 7 A 241 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 265 GLU A 38 GLU^? 15.90 O2 EDO A 103 A 369 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 17.36 23.57 72.04 18.68 21.92 71.98 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 12.19 31.08 87.29 11.13 32.66 86.38 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 8 3 # 8 A 241 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 265 GLU B 38 GLU^? 16.05 O1 CIT B 103 A 369 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 17.36 23.57 72.04 18.68 21.92 71.98 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 12.19 31.08 87.29 11.13 32.66 86.38 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 9 3 # 9 A 241 ASP B 64 ASP~? 16.93 O2 CIT B 103 A 265 GLU A 38 GLU^? 15.90 O2 EDO A 103 A 369 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 17.36 23.57 72.04 18.68 21.92 71.98 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 12.19 31.08 87.29 11.13 32.66 86.38 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 10 3 # 10 A 241 ASP B 64 ASP~? 16.93 O2 CIT B 103 A 265 GLU B 32 GLU~? 16.71 O1 CIT B 103 A 369 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 17.36 23.57 72.04 18.68 21.92 71.98 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 12.19 31.08 87.29 11.13 32.66 86.38 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 11 3 # 11 A 241 ASP B 69 ASP~? 11.84 O5 CIT B 103 A 265 GLU B 32 GLU~? 16.71 O1 CIT B 103 A 369 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 17.36 23.57 72.04 18.68 21.92 71.98 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 12.19 31.08 87.29 11.13 32.66 86.38 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 12 3 # 12 A 241 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 265 GLU A 38 GLU^? 15.90 O2 EDO A 103 A 369 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 17.36 23.57 72.04 18.68 21.92 71.98 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 12.19 31.08 87.29 11.13 32.66 86.38 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 13 3 # 13 A 241 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 265 GLU B 38 GLU^? 16.05 O1 CIT B 103 A 369 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 17.36 23.57 72.04 18.68 21.92 71.98 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 12.19 31.08 87.29 11.13 32.66 86.38 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 14 3 # 14 A 241 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 265 GLU C 32 GLU~? 15.71 O1 CIT C 104 A 369 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 17.36 23.57 72.04 18.68 21.92 71.98 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 12.19 31.08 87.29 11.13 32.66 86.38 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 15 3 # 15 A 241 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 265 GLU C 38 GLU^? 15.02 O1 CIT C 104 A 369 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 17.36 23.57 72.04 18.68 21.92 71.98 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 12.19 31.08 87.29 11.13 32.66 86.38 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 16 3 # 16 A 241 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 265 GLU C 38 GLU^? 15.02 O1 CIT C 104 A 369 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 17.36 23.57 72.04 18.68 21.92 71.98 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 12.19 31.08 87.29 11.13 32.66 86.38 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 17 3 # 17 A 241 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 265 GLU D 38 GLU^? 15.43 O2 CIT D 103 A 369 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 17.36 23.57 72.04 18.68 21.92 71.98 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 12.19 31.08 87.29 11.13 32.66 86.38 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 18 3 # 18 A 241 ASP C 69 ASP~? 11.49 O6 CIT C 104 A 265 GLU C 32 GLU~? 15.71 O1 CIT C 104 A 369 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 17.36 23.57 72.04 18.68 21.92 71.98 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 12.19 31.08 87.29 11.13 32.66 86.38 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 19 3 # 19 A 241 ASP C 69 ASP~? 11.49 O6 CIT C 104 A 265 GLU C 38 GLU^? 15.02 O1 CIT C 104 A 369 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 17.36 23.57 72.04 18.68 21.92 71.98 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 12.19 31.08 87.29 11.13 32.66 86.38 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 20 3 # 20 A 241 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 265 GLU C 38 GLU^? 15.02 O1 CIT C 104 A 369 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 17.36 23.57 72.04 18.68 21.92 71.98 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 12.19 31.08 87.29 11.13 32.66 86.38 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 21 3 # 21 A 241 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 265 GLU D 38 GLU^? 15.43 O2 CIT D 103 A 369 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 17.36 23.57 72.04 18.68 21.92 71.98 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 12.19 31.08 87.29 11.13 32.66 86.38 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 22 3 # 22 A 241 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 265 GLU C 38 GLU^? 15.02 O1 CIT C 104 A 369 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 17.36 23.57 72.04 18.68 21.92 71.98 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 12.19 31.08 87.29 11.13 32.66 86.38 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 23 3 # 23 A 241 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 265 GLU D 32 GLU~? 17.83 O1 CIT D 103 A 369 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 17.36 23.57 72.04 18.68 21.92 71.98 -63.28 -49.45 -6.05 -65.42 -49.45 -6.30 coo 12.19 31.08 87.29 11.13 32.66 86.38 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 24 3 # 24 A 241 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 265 GLU D 38 GLU^? 15.43 O2 CIT D 103 A 369 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 17.36 23.57 72.04 18.68 21.92 71.98 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 12.19 31.08 87.29 11.13 32.66 86.38 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 25 3 # 25 A 241 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 265 GLU D 38 GLU^? 15.43 O2 CIT D 103 A 369 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 17.36 23.57 72.04 18.68 21.92 71.98 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 12.19 31.08 87.29 11.13 32.66 86.38 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 26 3 # 26 A 241 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 265 GLU D 32 GLU~? 17.83 O1 CIT D 103 A 369 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 17.36 23.57 72.04 18.68 21.92 71.98 -63.28 -49.45 -6.05 -65.42 -49.45 -6.30 coo 12.19 31.08 87.29 11.13 32.66 86.38 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 27 3 # 27 A 241 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 265 GLU D 38 GLU^? 15.43 O2 CIT D 103 A 369 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 17.36 23.57 72.04 18.68 21.92 71.98 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 12.19 31.08 87.29 11.13 32.66 86.38 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 28 3 # 28 A 241 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 265 GLU C 38 GLU^? 15.02 O1 CIT C 104 A 369 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 17.36 23.57 72.04 18.68 21.92 71.98 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 12.19 31.08 87.29 11.13 32.66 86.38 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 29 3 # 29 A 241 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 265 GLU D 38 GLU^? 15.43 O2 CIT D 103 A 369 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 17.36 23.57 72.04 18.68 21.92 71.98 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 12.19 31.08 87.29 11.13 32.66 86.38 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 30 3 # 30 A 241 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 265 GLU E 32 GLU~? 15.49 O1 EDO E 103 A 369 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 17.36 23.57 72.04 18.68 21.92 71.98 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 12.19 31.08 87.29 11.13 32.66 86.38 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 31 3 # 31 A 241 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 265 GLU E 38 GLU^? 8.47 O1 EDO E 103 A 369 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 17.36 23.57 72.04 18.68 21.92 71.98 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 12.19 31.08 87.29 11.13 32.66 86.38 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 32 3 # 32 A 241 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 265 GLU E 38 GLU^? 8.47 O1 EDO E 103 A 369 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 17.36 23.57 72.04 18.68 21.92 71.98 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 12.19 31.08 87.29 11.13 32.66 86.38 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 33 3 # 33 A 241 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 265 GLU F 38 GLU^? 13.95 O2 EDO E 103 A 369 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 17.36 23.57 72.04 18.68 21.92 71.98 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 12.19 31.08 87.29 11.13 32.66 86.38 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 34 3 # 34 A 241 ASP E 69 ASP~? 11.60 O6 CIT E 104 A 265 GLU E 32 GLU~? 15.49 O1 EDO E 103 A 369 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 17.36 23.57 72.04 18.68 21.92 71.98 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 12.19 31.08 87.29 11.13 32.66 86.38 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 35 3 # 35 A 241 ASP E 69 ASP~? 11.60 O6 CIT E 104 A 265 GLU E 38 GLU^? 8.47 O1 EDO E 103 A 369 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 17.36 23.57 72.04 18.68 21.92 71.98 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 12.19 31.08 87.29 11.13 32.66 86.38 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 36 3 # 36 A 241 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 265 GLU E 38 GLU^? 8.47 O1 EDO E 103 A 369 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 17.36 23.57 72.04 18.68 21.92 71.98 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 12.19 31.08 87.29 11.13 32.66 86.38 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 37 3 # 37 A 241 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 265 GLU F 38 GLU^? 13.95 O2 EDO E 103 A 369 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 17.36 23.57 72.04 18.68 21.92 71.98 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 12.19 31.08 87.29 11.13 32.66 86.38 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 38 3 # 38 A 241 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 265 GLU E 38 GLU^? 8.47 O1 EDO E 103 A 369 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 17.36 23.57 72.04 18.68 21.92 71.98 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 12.19 31.08 87.29 11.13 32.66 86.38 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 39 3 # 39 A 241 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 265 GLU F 32 GLU~? 16.06 O1 CIT F 104 A 369 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 17.36 23.57 72.04 18.68 21.92 71.98 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 12.19 31.08 87.29 11.13 32.66 86.38 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 40 3 # 40 A 241 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 265 GLU F 38 GLU^? 13.95 O2 EDO E 103 A 369 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 17.36 23.57 72.04 18.68 21.92 71.98 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 12.19 31.08 87.29 11.13 32.66 86.38 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 41 3 # 41 A 241 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 265 GLU F 38 GLU^? 13.95 O2 EDO E 103 A 369 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 17.36 23.57 72.04 18.68 21.92 71.98 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 12.19 31.08 87.29 11.13 32.66 86.38 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 42 3 # 42 A 241 ASP F 69 ASP~? 11.68 O6 CIT F 104 A 265 GLU F 32 GLU~? 16.06 O1 CIT F 104 A 369 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 17.36 23.57 72.04 18.68 21.92 71.98 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 12.19 31.08 87.29 11.13 32.66 86.38 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 43 3 # 43 A 241 ASP F 69 ASP~? 11.68 O6 CIT F 104 A 265 GLU F 38 GLU^? 13.95 O2 EDO E 103 A 369 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 17.36 23.57 72.04 18.68 21.92 71.98 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 12.19 31.08 87.29 11.13 32.66 86.38 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 44 3 # 44 A 241 ASP F 69 ASP~? 11.68 O6 CIT F 104 A 265 GLU F 38 GLU^? 13.95 O2 EDO E 103 A 369 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 17.36 23.57 72.04 18.68 21.92 71.98 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 12.19 31.08 87.29 11.13 32.66 86.38 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 45 3 # 45 A 241 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 265 GLU E 38 GLU^? 8.47 O1 EDO E 103 A 369 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 17.36 23.57 72.04 18.68 21.92 71.98 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 12.19 31.08 87.29 11.13 32.66 86.38 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 46 3 # 46 A 241 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 265 GLU F 38 GLU^? 13.95 O2 EDO E 103 A 369 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 17.36 23.57 72.04 18.68 21.92 71.98 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 12.19 31.08 87.29 11.13 32.66 86.38 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1m53_c05 ISOMALTULOSE SYNTHASE user 47 3 # 47 A 241 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 265 GLU F 38 GLU^? 13.95 O2 EDO E 103 A 369 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 17.36 23.57 72.04 18.68 21.92 71.98 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 12.19 31.08 87.29 11.13 32.66 86.38 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 1m53_c05 source 1m53 ISOMALTULOSE SYNTHASE : 47 hits 1m53_c05 naa= 3 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 1 3 # 1 A 241 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 279 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 369 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 16.54 46.37 63.94 14.77 45.79 62.95 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 12.19 31.08 87.29 11.13 32.66 86.38 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 2 3 # 2 A 241 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 279 GLU D 52 GLU.? 13.73 O3 CIT C 104 A 369 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 16.54 46.37 63.94 14.77 45.79 62.95 -38.82 -73.24 -13.34 -40.85 -73.92 -12.86 coo 12.19 31.08 87.29 11.13 32.66 86.38 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 3 3 # 3 A 241 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 279 GLU E 32 GLU~? 15.49 O1 EDO E 103 A 369 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 16.54 46.37 63.94 14.77 45.79 62.95 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 12.19 31.08 87.29 11.13 32.66 86.38 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 4 3 # 4 A 241 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 279 GLU A 9 GLU.? 14.22 C1 EDO A 103 A 369 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 16.54 46.37 63.94 14.77 45.79 62.95 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 coo 12.19 31.08 87.29 11.13 32.66 86.38 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 5 3 # 5 A 241 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 279 GLU A 9 GLU.? 14.22 C1 EDO A 103 A 369 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 16.54 46.37 63.94 14.77 45.79 62.95 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 coo 12.19 31.08 87.29 11.13 32.66 86.38 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 6 3 # 6 A 241 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 279 GLU B 9 GLU.? 11.84 O3 CIT B 103 A 369 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 16.54 46.37 63.94 14.77 45.79 62.95 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 12.19 31.08 87.29 11.13 32.66 86.38 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 7 3 # 7 A 241 ASP C 17 ASP~? -3.95 O1 EDO C 103s A 279 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 369 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 16.54 46.37 63.94 14.77 45.79 62.95 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 12.19 31.08 87.29 11.13 32.66 86.38 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 8 3 # 8 A 241 ASP C 93 ASP~? 9.74 O3 CIT C 104 A 279 GLU D 9 GLU.? 12.31 O4 CIT D 103 A 369 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 16.54 46.37 63.94 14.77 45.79 62.95 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 12.19 31.08 87.29 11.13 32.66 86.38 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 9 3 # 9 A 241 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 279 GLU C 9 GLU.? 12.64 O3 CIT C 104 A 369 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 16.54 46.37 63.94 14.77 45.79 62.95 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 12.19 31.08 87.29 11.13 32.66 86.38 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 10 3 # 10 A 241 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 279 GLU D 9 GLU.? 12.31 O4 CIT D 103 A 369 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 16.54 46.37 63.94 14.77 45.79 62.95 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 12.19 31.08 87.29 11.13 32.66 86.38 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 11 3 # 11 A 241 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 279 GLU D 9 GLU.? 12.31 O4 CIT D 103 A 369 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 16.54 46.37 63.94 14.77 45.79 62.95 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 12.19 31.08 87.29 11.13 32.66 86.38 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 12 3 # 12 A 241 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 279 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 369 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 16.54 46.37 63.94 14.77 45.79 62.95 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 12.19 31.08 87.29 11.13 32.66 86.38 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 13 3 # 13 A 241 ASP E 69 ASP~? 11.60 O6 CIT E 104 A 279 GLU C 32 GLU~? 15.71 O1 CIT C 104 A 369 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 16.54 46.37 63.94 14.77 45.79 62.95 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 12.19 31.08 87.29 11.13 32.66 86.38 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 14 3 # 14 A 241 ASP E 69 ASP~? 11.60 O6 CIT E 104 A 279 GLU C 32 GLU~? 15.71 O1 CIT C 104 A 369 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 16.54 46.37 63.94 14.77 45.79 62.95 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 12.19 31.08 87.29 11.13 32.66 86.38 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 15 3 # 15 A 241 ASP E 93 ASP~? 8.62 O3 CIT E 104 A 279 GLU F 9 GLU.? 7.31 C2 EDO F 103 A 369 ASP C 17 ASP~? -3.95 O1 EDO C 103s coo 11.74 38.14 80.19 10.63 36.40 80.65 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 16.54 46.37 63.94 14.77 45.79 62.95 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 12.19 31.08 87.29 11.13 32.66 86.38 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 16 3 # 16 A 241 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 279 GLU E 9 GLU.? 7.76 O1 EDO F 103 A 369 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 11.74 38.14 80.19 10.63 36.40 80.65 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 16.54 46.37 63.94 14.77 45.79 62.95 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo 12.19 31.08 87.29 11.13 32.66 86.38 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1m53_c06 ISOMALTULOSE SYNTHASE user 17 3 # 17 A 241 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 279 GLU F 9 GLU.? 7.31 C2 EDO F 103 A 369 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 11.74 38.14 80.19 10.63 36.40 80.65 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 16.54 46.37 63.94 14.77 45.79 62.95 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 12.19 31.08 87.29 11.13 32.66 86.38 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1m53_c06 source 1m53 ISOMALTULOSE SYNTHASE : 17 hits 1m53_c06 naa= 3 ULMN 3 1mas_c01 INOSINE-URIDINE NUCLEOSIDE N-RIBOHYDuser 1 3 # 1 B 10 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 168 ASN E 44 ASN.? 11.90 O7 CIT F 104 B 241 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo -17.05 -4.58 51.44 -17.53 -6.08 49.99 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -13.80 -8.69 44.98 -15.38 -8.70 46.39 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo -21.48 -14.16 44.54 -22.74 -13.73 42.93 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 1mas_c01 source 1mas INOSINE-URIDINE NUCLEOSIDE N-RIBOHYDROLASE : 1 hits 1mas_c01 naa= 3 ULMN 3 1mbb_c00 URIDINE DIPHOSPHO-N-ACETYLENOLPYRUVYuser 1 3 # 1 159 ARG E 89 ARG.? -3.87 C2 EDO C 103s 229 SER E 87 SER~? 10.44 O7 CIT E 104 325 GLU E 11 GLU.? -3.18 O2 EDO C 103s coo 2.54 15.84 18.57 3.24 17.85 16.30 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo 10.17 13.48 15.92 9.61 15.76 15.27 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 coo 5.42 13.04 19.75 5.74 13.81 17.79 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 1mbb_c00 source 1mbb URIDINE DIPHOSPHO-N-ACETYLENOLPYRUVYLGLUCOSAMI: 1 hits 1mbb_c00 naa= 3 ULMN 3 1mpp_c04 PEPSIN (RENIN) (E.C.3.4.23.23) user 1 3 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 20.97 14.47 32.28 19.66 15.96 31.62 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 16.04 14.72 33.82 17.27 13.71 31.95 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 20.65 22.00 33.80 20.06 20.56 32.39 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1mpp_c04 PEPSIN (RENIN) (E.C.3.4.23.23) user 2 3 # 2 32 ASP C 46 ASP.? 10.22 O6 CIT D 103 35 SER C 51 SER.? 10.55 O6 CIT D 103 215 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 20.97 14.47 32.28 19.66 15.96 31.62 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 16.04 14.72 33.82 17.27 13.71 31.95 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 20.65 22.00 33.80 20.06 20.56 32.39 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 1mpp_c04 source 1mpp PEPSIN (RENIN) (E.C.3.4.23.23) : 2 hits 1mpp_c04 naa= 3 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 1 3 # 1 A 465 GLY A 0 GLY.? 18.58 O2 EDO A 103 A 501 ASP B 17 ASP~? 19.42 C4 CIT B 103 B 367 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -8.70 -93.12 3.11 -9.77 -94.94 3.45 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 2 3 # 2 A 465 GLY A 0 GLY.? 18.58 O2 EDO A 103 A 501 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 367 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 3 3 # 3 A 465 GLY A 12 GLY.? 18.49 C1 EDO A 103 A 501 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 367 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -3.42 -86.00 -39.98 -3.58 -85.40 -39.51 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 4 3 # 4 A 465 GLY A 28 GLY~? 12.77 C2 EDO E 103 A 501 ASP A 64 ASP~? 16.37 O2 EDO A 103 B 367 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 5 3 # 5 A 465 GLY A 28 GLY~? 12.77 C2 EDO E 103 A 501 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 367 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 6 3 # 6 A 465 GLY A 35 GLY.? 14.47 O2 EDO A 103 A 501 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 367 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 7 3 # 7 A 465 GLY A 91 GLY~? 10.61 O1 EDO A 103 A 501 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 367 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 8 3 # 8 A 465 GLY A 91 GLY~? 10.61 O1 EDO A 103 A 501 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 367 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 9 3 # 9 A 465 GLY B 0 GLY.? 18.42 O2 CIT B 103 A 501 ASP A 17 ASP~? 17.77 C2 EDO E 103 B 367 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -11.68 -66.89 -21.61 -12.41 -67.26 -21.40 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 10 3 # 10 A 465 GLY B 0 GLY.? 18.42 O2 CIT B 103 A 501 ASP A 17 ASP~? 17.77 C2 EDO E 103 B 367 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -11.68 -66.89 -21.61 -12.41 -67.26 -21.40 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 11 3 # 11 A 465 GLY B 35 GLY.? 14.63 O1 CIT B 103 A 501 ASP D 93 ASP~? 9.04 O4 CIT D 103 B 367 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 12 3 # 12 A 465 GLY C 0 GLY.? 18.38 O2 CIT C 104 A 501 ASP D 17 ASP~? 19.08 O1 CIT D 103 B 367 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -58.43 -72.91 -14.46 -58.32 -72.08 -14.62 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -49.27 -65.18 4.30 -49.35 -67.27 4.77 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 13 3 # 13 A 465 GLY C 12 GLY.? 8.94 O2 EDO C 103 A 501 ASP C 27 ASP~? 13.15 O1 CIT C 104 B 367 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -29.72 -59.63 -35.07 -30.25 -59.10 -34.73 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 14 3 # 14 A 465 GLY C 91 GLY~? 8.26 O4 CIT C 104 A 501 ASP A 64 ASP~? 16.37 O2 EDO A 103 B 367 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 15 3 # 15 A 465 GLY C 94 GLY.? 8.41 O3 CIT C 104 A 501 ASP C 69 ASP~? 11.49 O6 CIT C 104 B 367 TYR E 54 TYR.? 6.56 O1 EDO F 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 16 3 # 16 A 465 GLY D 0 GLY.? 18.60 O6 CIT D 103 A 501 ASP C 17 ASP~? -3.95 O1 EDO C 103s B 367 TYR D 56 TYR^? 12.73 C2 CIT D 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -52.56 -47.08 -27.07 -52.40 -46.76 -26.33 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 17 3 # 17 A 465 GLY E 0 GLY.? 18.62 O2 CIT E 104 A 501 ASP F 17 ASP~? 19.11 O1 CIT F 104 B 367 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 18 3 # 18 A 465 GLY E 12 GLY.? 8.67 O2 EDO C 103 A 501 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 367 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -26.84 -62.13 -38.29 -26.35 -62.68 -38.61 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 19 3 # 19 A 465 GLY E 28 GLY~? 10.11 C1 EDO E 103 A 501 ASP C 69 ASP~? 11.49 O6 CIT C 104 B 367 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -33.85 -86.59 -36.02 -34.04 -86.37 -36.75 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 20 3 # 20 A 465 GLY E 57 GLY^? 9.68 O2 EDO E 103 A 501 ASP C 17 ASP~? -3.95 O1 EDO C 103s B 367 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 21 3 # 21 A 465 GLY E 91 GLY~? 5.97 O2 EDO C 103 A 501 ASP A 27 ASP~? 13.11 O2 EDO A 103 B 367 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 22 3 # 22 A 465 GLY E 91 GLY~? 5.97 O2 EDO C 103 A 501 ASP A 27 ASP~? 13.11 O2 EDO A 103 B 367 TYR F 56 TYR^? 13.04 O1 CIT F 104 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 23 3 # 23 A 465 GLY E 91 GLY~? 5.97 O2 EDO C 103 A 501 ASP E 69 ASP~? 11.60 O6 CIT E 104 B 367 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 24 3 # 24 A 465 GLY E 94 GLY.? 7.76 O3 CIT E 104 A 501 ASP E 69 ASP~? 11.60 O6 CIT E 104 B 367 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 25 3 # 25 A 465 GLY F 0 GLY.? 9.67 O2 EDO E 103 A 501 ASP E 17 ASP~? 16.97 O4 CIT C 104 B 367 TYR F 56 TYR^? 13.04 O1 CIT F 104 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 1mro_c00 source 1mro METHYL-COENZYME M REDUCTASE : 25 hits 1mro_c00 naa= 3 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 1 3 # 1 D 465 GLY A 0 GLY.? 18.58 O2 EDO A 103 D 501 ASP B 17 ASP~? 19.42 C4 CIT B 103 E 367 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -8.70 -93.12 3.11 -9.77 -94.94 3.45 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 2 3 # 2 D 465 GLY A 0 GLY.? 18.58 O2 EDO A 103 D 501 ASP D 46 ASP.? 10.10 O7 CIT C 104 E 367 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 3 3 # 3 D 465 GLY A 12 GLY.? 18.49 C1 EDO A 103 D 501 ASP F 99 ASP^? 6.97 O7 CIT F 104 E 367 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -3.42 -86.00 -39.98 -3.58 -85.40 -39.51 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 4 3 # 4 D 465 GLY A 28 GLY~? 12.77 C2 EDO E 103 D 501 ASP A 64 ASP~? 16.37 O2 EDO A 103 E 367 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 5 3 # 5 D 465 GLY A 28 GLY~? 12.77 C2 EDO E 103 D 501 ASP A 99 ASP^? 8.10 O2 EDO A 103 E 367 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 6 3 # 6 D 465 GLY A 28 GLY~? 12.77 C2 EDO E 103 D 501 ASP E 46 ASP.? 9.98 C4 CIT F 104 E 367 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -26.53 -77.39 -32.75 -26.29 -77.89 -32.17 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 7 3 # 7 D 465 GLY A 35 GLY.? 14.47 O2 EDO A 103 D 501 ASP C 99 ASP^? 7.14 O2 CIT C 104 E 367 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 8 3 # 8 D 465 GLY A 91 GLY~? 10.61 O1 EDO A 103 D 501 ASP A 46 ASP.? 9.57 O6 CIT B 103 E 367 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 9 3 # 9 D 465 GLY A 91 GLY~? 10.61 O1 EDO A 103 D 501 ASP E 27 ASP~? 4.58 C1 EDO E 103 E 367 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 10 3 # 10 D 465 GLY B 0 GLY.? 18.42 O2 CIT B 103 D 501 ASP A 17 ASP~? 17.77 C2 EDO E 103 E 367 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -11.68 -66.89 -21.61 -12.41 -67.26 -21.40 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 11 3 # 11 D 465 GLY B 0 GLY.? 18.42 O2 CIT B 103 D 501 ASP A 17 ASP~? 17.77 C2 EDO E 103 E 367 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -11.68 -66.89 -21.61 -12.41 -67.26 -21.40 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 12 3 # 12 D 465 GLY B 35 GLY.? 14.63 O1 CIT B 103 D 501 ASP D 93 ASP~? 9.04 O4 CIT D 103 E 367 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 13 3 # 13 D 465 GLY C 0 GLY.? 18.38 O2 CIT C 104 D 501 ASP D 17 ASP~? 19.08 O1 CIT D 103 E 367 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -58.43 -72.91 -14.46 -58.32 -72.08 -14.62 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -49.27 -65.18 4.30 -49.35 -67.27 4.77 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 14 3 # 14 D 465 GLY C 12 GLY.? 8.94 O2 EDO C 103 D 501 ASP C 27 ASP~? 13.15 O1 CIT C 104 E 367 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -29.72 -59.63 -35.07 -30.25 -59.10 -34.73 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 15 3 # 15 D 465 GLY C 14 GLY~? 3.87 C1 EDO C 103 D 501 ASP A 27 ASP~? 13.11 O2 EDO A 103 E 367 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 16 3 # 16 D 465 GLY C 91 GLY~? 8.26 O4 CIT C 104 D 501 ASP A 64 ASP~? 16.37 O2 EDO A 103 E 367 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 17 3 # 17 D 465 GLY C 94 GLY.? 8.41 O3 CIT C 104 D 501 ASP C 69 ASP~? 11.49 O6 CIT C 104 E 367 TYR E 54 TYR.? 6.56 O1 EDO F 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 18 3 # 18 D 465 GLY D 0 GLY.? 18.60 O6 CIT D 103 D 501 ASP C 17 ASP~? -3.95 O1 EDO C 103s E 367 TYR D 56 TYR^? 12.73 C2 CIT D 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -52.56 -47.08 -27.07 -52.40 -46.76 -26.33 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 19 3 # 19 D 465 GLY E 0 GLY.? 18.62 O2 CIT E 104 D 501 ASP F 17 ASP~? 19.11 O1 CIT F 104 E 367 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 20 3 # 20 D 465 GLY E 12 GLY.? 8.67 O2 EDO C 103 D 501 ASP F 99 ASP^? 6.97 O7 CIT F 104 E 367 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -26.84 -62.13 -38.29 -26.35 -62.68 -38.61 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 21 3 # 21 D 465 GLY E 28 GLY~? 10.11 C1 EDO E 103 D 501 ASP C 69 ASP~? 11.49 O6 CIT C 104 E 367 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -33.85 -86.59 -36.02 -34.04 -86.37 -36.75 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 22 3 # 22 D 465 GLY E 57 GLY^? 9.68 O2 EDO E 103 D 501 ASP C 17 ASP~? -3.95 O1 EDO C 103s E 367 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 23 3 # 23 D 465 GLY E 91 GLY~? 5.97 O2 EDO C 103 D 501 ASP A 27 ASP~? 13.11 O2 EDO A 103 E 367 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 24 3 # 24 D 465 GLY E 91 GLY~? 5.97 O2 EDO C 103 D 501 ASP A 27 ASP~? 13.11 O2 EDO A 103 E 367 TYR F 56 TYR^? 13.04 O1 CIT F 104 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 25 3 # 25 D 465 GLY E 91 GLY~? 5.97 O2 EDO C 103 D 501 ASP E 69 ASP~? 11.60 O6 CIT E 104 E 367 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 26 3 # 26 D 465 GLY E 94 GLY.? 7.76 O3 CIT E 104 D 501 ASP E 69 ASP~? 11.60 O6 CIT E 104 E 367 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 27 3 # 27 D 465 GLY F 0 GLY.? 9.67 O2 EDO E 103 D 501 ASP E 17 ASP~? 16.97 O4 CIT C 104 E 367 TYR F 56 TYR^? 13.04 O1 CIT F 104 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 1mro_c01 source 1mro METHYL-COENZYME M REDUCTASE : 27 hits 1mro_c01 naa= 3 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 1 3 # 1 A 114 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 197 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 223 ALA A 66 ALA~? 15.93 O2 EDO A 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -31.02 -91.77 -19.75 -32.50 -91.62 -19.23 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 2 3 # 2 A 114 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 197 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 223 ALA A 70 ALA~? 12.31 O2 EDO A 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -30.35 -90.25 -25.71 -31.25 -89.23 -25.08 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 3 3 # 3 A 114 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 197 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 223 ALA A 22 ALA~? 8.81 C2 EDO A 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 4 3 # 4 A 114 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 197 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 223 ALA A 24 ALA~? 12.06 C2 EDO E 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -20.53 -76.91 -34.66 -20.26 -76.22 -36.01 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 5 3 # 5 A 114 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 197 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 223 ALA B 66 ALA~? 16.27 O2 CIT B 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -6.46 -64.83 -12.71 -6.93 -63.35 -12.67 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 6 3 # 6 A 114 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 197 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 223 ALA B 70 ALA~? 12.64 O1 CIT B 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -5.62 -67.50 -7.22 -6.87 -66.61 -7.10 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 7 3 # 7 A 114 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 197 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 223 ALA C 66 ALA~? 15.90 O2 CIT C 104 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -56.01 -78.91 -23.21 -57.42 -79.56 -23.18 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 8 3 # 8 A 114 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 197 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 223 ALA C 70 ALA~? 12.51 O1 CIT C 104 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -53.57 -78.01 -28.80 -55.09 -77.85 -28.87 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 9 3 # 9 A 114 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 197 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 223 ALA D 66 ALA~? 15.81 O6 CIT D 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -53.31 -42.21 -18.09 -54.48 -41.40 -18.74 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 10 3 # 10 A 114 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 197 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 223 ALA D 70 ALA~? 12.47 O2 CIT D 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -53.82 -43.25 -11.93 -55.23 -43.15 -12.59 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 11 3 # 11 A 114 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 197 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 223 ALA E 66 ALA~? 15.62 O2 CIT E 104 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -46.63 -87.00 -51.63 -47.44 -88.29 -51.81 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 12 3 # 12 A 114 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 197 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 223 ALA E 70 ALA~? 12.37 O2 CIT E 104 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -45.75 -85.11 -45.81 -45.60 -86.59 -45.87 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 13 3 # 13 A 114 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 197 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 223 ALA A 22 ALA~? 8.81 C2 EDO A 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 14 3 # 14 A 114 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 197 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 223 ALA A 24 ALA~? 12.06 C2 EDO E 103 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -20.53 -76.91 -34.66 -20.26 -76.22 -36.01 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 15 3 # 15 A 114 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 197 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 223 ALA F 66 ALA~? 15.98 O7 CIT F 104 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -9.56 -85.19 -55.88 -8.53 -86.23 -55.40 ULMN 3 1n2t_c02 L-CYSTEINE-CYSTINE LYASE C-DES user 16 3 # 16 A 114 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 197 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 223 ALA F 70 ALA~? 12.64 O2 CIT F 104 coo -61.68 -8.94 -28.01 -61.87 -7.73 -26.31 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -57.09 -14.53 -30.28 -57.60 -13.32 -28.61 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -56.49 -13.76 -16.93 -57.17 -13.93 -18.30 -10.34 -85.12 -62.01 -10.33 -86.57 -61.57 1n2t_c02 source 1n2t L-CYSTEINE-CYSTINE LYASE C-DES : 16 hits 1n2t_c02 naa= 3 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 1 3 # 1 B 114 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 197 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 223 ALA A 66 ALA~? 15.93 O2 EDO A 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -31.02 -91.77 -19.75 -32.50 -91.62 -19.23 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 2 3 # 2 B 114 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 197 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 223 ALA A 70 ALA~? 12.31 O2 EDO A 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -30.35 -90.25 -25.71 -31.25 -89.23 -25.08 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 3 3 # 3 B 114 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 197 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 223 ALA A 22 ALA~? 8.81 C2 EDO A 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 4 3 # 4 B 114 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 197 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 223 ALA A 24 ALA~? 12.06 C2 EDO E 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -20.53 -76.91 -34.66 -20.26 -76.22 -36.01 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 5 3 # 5 B 114 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 197 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 223 ALA B 66 ALA~? 16.27 O2 CIT B 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -6.46 -64.83 -12.71 -6.93 -63.35 -12.67 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 6 3 # 6 B 114 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 197 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 223 ALA B 70 ALA~? 12.64 O1 CIT B 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -5.62 -67.50 -7.22 -6.87 -66.61 -7.10 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 7 3 # 7 B 114 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 197 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 223 ALA C 66 ALA~? 15.90 O2 CIT C 104 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -56.01 -78.91 -23.21 -57.42 -79.56 -23.18 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 8 3 # 8 B 114 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 197 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 223 ALA C 70 ALA~? 12.51 O1 CIT C 104 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -53.57 -78.01 -28.80 -55.09 -77.85 -28.87 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 9 3 # 9 B 114 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 197 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 223 ALA D 66 ALA~? 15.81 O6 CIT D 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -53.31 -42.21 -18.09 -54.48 -41.40 -18.74 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 10 3 # 10 B 114 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 197 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 223 ALA D 70 ALA~? 12.47 O2 CIT D 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -53.82 -43.25 -11.93 -55.23 -43.15 -12.59 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 11 3 # 11 B 114 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 197 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 223 ALA E 66 ALA~? 15.62 O2 CIT E 104 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -46.63 -87.00 -51.63 -47.44 -88.29 -51.81 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 12 3 # 12 B 114 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 197 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 223 ALA E 70 ALA~? 12.37 O2 CIT E 104 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -45.75 -85.11 -45.81 -45.60 -86.59 -45.87 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 13 3 # 13 B 114 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 197 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 223 ALA A 22 ALA~? 8.81 C2 EDO A 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 14 3 # 14 B 114 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 197 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 223 ALA A 24 ALA~? 12.06 C2 EDO E 103 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -20.53 -76.91 -34.66 -20.26 -76.22 -36.01 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 15 3 # 15 B 114 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 197 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 223 ALA F 66 ALA~? 15.98 O7 CIT F 104 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -9.56 -85.19 -55.88 -8.53 -86.23 -55.40 ULMN 3 1n2t_c03 L-CYSTEINE-CYSTINE LYASE C-DES user 16 3 # 16 B 114 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 197 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 223 ALA F 70 ALA~? 12.64 O2 CIT F 104 coo -32.24 6.73 -26.90 -32.01 5.24 -25.44 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -36.83 12.62 -28.19 -36.31 11.10 -26.78 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -37.23 9.70 -15.15 -36.60 10.10 -16.48 -10.34 -85.12 -62.01 -10.33 -86.57 -61.57 1n2t_c03 source 1n2t L-CYSTEINE-CYSTINE LYASE C-DES : 16 hits 1n2t_c03 naa= 3 ULMN 3 1nhx_c00 PHOSPHOENOLPYRUVATE CARBOXYKINASE, Cuser 1 3 # 1 A 264 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 290 LYS B 50 LYS.? 6.61 O1 EDO A 103 A 405 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 41.33 25.99 28.05 41.95 26.95 29.80 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 37.11 33.75 31.82 38.72 27.95 29.90 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo 42.28 27.98 41.30 43.16 28.14 38.35 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1nhx_c00 PHOSPHOENOLPYRUVATE CARBOXYKINASE, Cuser 2 3 # 2 A 264 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 290 LYS A 50 LYS.? -4.54 O3 CIT B 103s A 405 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 41.33 25.99 28.05 41.95 26.95 29.80 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 37.11 33.75 31.82 38.72 27.95 29.90 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo 42.28 27.98 41.30 43.16 28.14 38.35 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1nhx_c00 PHOSPHOENOLPYRUVATE CARBOXYKINASE, Cuser 3 3 # 3 A 264 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 290 LYS D 50 LYS.? -4.40 O3 CIT C 104s A 405 ARG D 45 ARG.? 18.60 O2 CIT C 104 coo 41.33 25.99 28.05 41.95 26.95 29.80 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 37.11 33.75 31.82 38.72 27.95 29.90 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 42.28 27.98 41.30 43.16 28.14 38.35 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 ULMN 3 1nhx_c00 PHOSPHOENOLPYRUVATE CARBOXYKINASE, Cuser 4 3 # 4 A 264 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 290 LYS C 50 LYS.? -4.07 O4 CIT D 103s A 405 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 41.33 25.99 28.05 41.95 26.95 29.80 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 37.11 33.75 31.82 38.72 27.95 29.90 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo 42.28 27.98 41.30 43.16 28.14 38.35 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1nhx_c00 PHOSPHOENOLPYRUVATE CARBOXYKINASE, Cuser 5 3 # 5 A 264 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 290 LYS F 50 LYS.? -3.77 O3 CIT E 104s A 405 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 41.33 25.99 28.05 41.95 26.95 29.80 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 37.11 33.75 31.82 38.72 27.95 29.90 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 42.28 27.98 41.30 43.16 28.14 38.35 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 ULMN 3 1nhx_c00 PHOSPHOENOLPYRUVATE CARBOXYKINASE, Cuser 6 3 # 6 A 264 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 290 LYS E 50 LYS.? -4.05 O4 CIT F 104s A 405 ARG E 45 ARG.? 12.04 O2 EDO E 103 coo 41.33 25.99 28.05 41.95 26.95 29.80 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 37.11 33.75 31.82 38.72 27.95 29.90 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo 42.28 27.98 41.30 43.16 28.14 38.35 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 1nhx_c00 source 1nhx PHOSPHOENOLPYRUVATE CARBOXYKINASE, CYTOSOLIC : 6 hits 1nhx_c00 naa= 3 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 1 3 # 1 B 59 GLU A 32 GLU~? 8.29 O4 CIT C 104 B 128 HIS A 77 HIS~? -4.41 C2 EDO A 103s C 263 HIS A 41 HIS^? 12.51 O2 EDO A 103 coo 6.12 5.94 82.00 7.16 6.32 83.81 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 12.51 16.35 80.99 13.16 14.90 82.37 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 11.58 14.94 93.26 12.25 14.03 91.50 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 2 3 # 2 B 59 GLU A 32 GLU~? 8.29 O4 CIT C 104 B 128 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 263 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 6.12 5.94 82.00 7.16 6.32 83.81 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 12.51 16.35 80.99 13.16 14.90 82.37 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 11.58 14.94 93.26 12.25 14.03 91.50 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 3 3 # 3 B 59 GLU A 38 GLU^? 15.90 O2 EDO A 103 B 128 HIS A 41 HIS^? 12.51 O2 EDO A 103 C 263 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 6.12 5.94 82.00 7.16 6.32 83.81 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 12.51 16.35 80.99 13.16 14.90 82.37 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 11.58 14.94 93.26 12.25 14.03 91.50 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 4 3 # 4 B 59 GLU B 21 GLU~? 16.03 C2 CIT B 103 B 128 HIS B 41 HIS^? 11.37 O1 CIT B 103 C 263 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 6.12 5.94 82.00 7.16 6.32 83.81 -9.13 -87.49 4.49 -7.49 -88.18 5.63 coo 12.51 16.35 80.99 13.16 14.90 82.37 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 11.58 14.94 93.26 12.25 14.03 91.50 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 5 3 # 5 B 59 GLU B 32 GLU~? 16.71 O1 CIT B 103 B 128 HIS B 77 HIS~? -4.07 O1 CIT B 103s C 263 HIS B 41 HIS^? 11.37 O1 CIT B 103 coo 6.12 5.94 82.00 7.16 6.32 83.81 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 12.51 16.35 80.99 13.16 14.90 82.37 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 11.58 14.94 93.26 12.25 14.03 91.50 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 6 3 # 6 B 59 GLU B 38 GLU^? 16.05 O1 CIT B 103 B 128 HIS B 41 HIS^? 11.37 O1 CIT B 103 C 263 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 6.12 5.94 82.00 7.16 6.32 83.81 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 12.51 16.35 80.99 13.16 14.90 82.37 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 11.58 14.94 93.26 12.25 14.03 91.50 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 7 3 # 7 B 59 GLU C 21 GLU~? 6.35 O1 EDO C 103 B 128 HIS C 41 HIS^? 12.16 O1 CIT C 104 C 263 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 6.12 5.94 82.00 7.16 6.32 83.81 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 12.51 16.35 80.99 13.16 14.90 82.37 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 11.58 14.94 93.26 12.25 14.03 91.50 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 8 3 # 8 B 59 GLU C 32 GLU~? 15.71 O1 CIT C 104 B 128 HIS C 77 HIS~? -4.31 O1 CIT C 104s C 263 HIS C 41 HIS^? 12.16 O1 CIT C 104 coo 6.12 5.94 82.00 7.16 6.32 83.81 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 12.51 16.35 80.99 13.16 14.90 82.37 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 11.58 14.94 93.26 12.25 14.03 91.50 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 9 3 # 9 B 59 GLU C 38 GLU^? 15.02 O1 CIT C 104 B 128 HIS C 41 HIS^? 12.16 O1 CIT C 104 C 263 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 6.12 5.94 82.00 7.16 6.32 83.81 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 12.51 16.35 80.99 13.16 14.90 82.37 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 11.58 14.94 93.26 12.25 14.03 91.50 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 10 3 # 10 B 59 GLU D 32 GLU~? 17.83 O1 CIT D 103 B 128 HIS D 77 HIS~? -3.79 O1 CIT D 103s C 263 HIS D 41 HIS^? 12.20 O1 CIT D 103 coo 6.12 5.94 82.00 7.16 6.32 83.81 -63.28 -49.45 -6.05 -65.42 -49.45 -6.30 coo 12.51 16.35 80.99 13.16 14.90 82.37 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 11.58 14.94 93.26 12.25 14.03 91.50 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 11 3 # 11 B 59 GLU D 38 GLU^? 15.43 O2 CIT D 103 B 128 HIS D 41 HIS^? 12.20 O1 CIT D 103 C 263 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 6.12 5.94 82.00 7.16 6.32 83.81 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 12.51 16.35 80.99 13.16 14.90 82.37 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 11.58 14.94 93.26 12.25 14.03 91.50 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 12 3 # 12 B 59 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 128 HIS A 41 HIS^? 12.51 O2 EDO A 103 C 263 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 6.12 5.94 82.00 7.16 6.32 83.81 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 12.51 16.35 80.99 13.16 14.90 82.37 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 11.58 14.94 93.26 12.25 14.03 91.50 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 13 3 # 13 B 59 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 128 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 263 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 6.12 5.94 82.00 7.16 6.32 83.81 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 12.51 16.35 80.99 13.16 14.90 82.37 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 11.58 14.94 93.26 12.25 14.03 91.50 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 14 3 # 14 B 59 GLU E 32 GLU~? 15.49 O1 EDO E 103 B 128 HIS A 74 HIS~? 11.00 C1 EDO E 103 C 263 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 6.12 5.94 82.00 7.16 6.32 83.81 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 12.51 16.35 80.99 13.16 14.90 82.37 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 11.58 14.94 93.26 12.25 14.03 91.50 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 15 3 # 15 B 59 GLU E 32 GLU~? 15.49 O1 EDO E 103 B 128 HIS E 77 HIS~? -4.13 O1 CIT E 104s C 263 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 6.12 5.94 82.00 7.16 6.32 83.81 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 12.51 16.35 80.99 13.16 14.90 82.37 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 11.58 14.94 93.26 12.25 14.03 91.50 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 16 3 # 16 B 59 GLU E 38 GLU^? 8.47 O1 EDO E 103 B 128 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 263 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 6.12 5.94 82.00 7.16 6.32 83.81 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 12.51 16.35 80.99 13.16 14.90 82.37 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 11.58 14.94 93.26 12.25 14.03 91.50 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 17 3 # 17 B 59 GLU F 21 GLU~? 14.58 O1 CIT F 104 B 128 HIS F 41 HIS^? 12.43 O1 CIT F 104 C 263 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 6.12 5.94 82.00 7.16 6.32 83.81 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 12.51 16.35 80.99 13.16 14.90 82.37 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 11.58 14.94 93.26 12.25 14.03 91.50 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 18 3 # 18 B 59 GLU F 32 GLU~? 16.06 O1 CIT F 104 B 128 HIS F 77 HIS~? -3.59 O1 CIT F 104s C 263 HIS F 41 HIS^? 12.43 O1 CIT F 104 coo 6.12 5.94 82.00 7.16 6.32 83.81 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 12.51 16.35 80.99 13.16 14.90 82.37 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 11.58 14.94 93.26 12.25 14.03 91.50 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 ULMN 3 1ni4_c00 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 19 3 # 19 B 59 GLU F 38 GLU^? 13.95 O2 EDO E 103 B 128 HIS F 41 HIS^? 12.43 O1 CIT F 104 C 263 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 6.12 5.94 82.00 7.16 6.32 83.81 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 12.51 16.35 80.99 13.16 14.90 82.37 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 11.58 14.94 93.26 12.25 14.03 91.50 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 1ni4_c00 source 1ni4 PYRUVATE DEHYDROGENASE E1 COMPONENT: ALPHA SUB: 19 hits 1ni4_c00 naa= 3 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 1 3 # 1 A 263 HIS A 41 HIS^? 12.51 O2 EDO A 103 D 59 GLU A 32 GLU~? 8.29 O4 CIT C 104 D 128 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 2 3 # 2 A 263 HIS A 77 HIS~? -4.41 C2 EDO A 103s D 59 GLU A 38 GLU^? 15.90 O2 EDO A 103 D 128 HIS A 41 HIS^? 12.51 O2 EDO A 103 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 3 3 # 3 A 263 HIS A 77 HIS~? -4.41 C2 EDO A 103s D 59 GLU E 21 GLU~? 9.95 O4 CIT C 104 D 128 HIS A 41 HIS^? 12.51 O2 EDO A 103 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 4 3 # 4 A 263 HIS B 41 HIS^? 11.37 O1 CIT B 103 D 59 GLU B 32 GLU~? 16.71 O1 CIT B 103 D 128 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 5 3 # 5 A 263 HIS B 77 HIS~? -4.07 O1 CIT B 103s D 59 GLU B 21 GLU~? 16.03 C2 CIT B 103 D 128 HIS B 41 HIS^? 11.37 O1 CIT B 103 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -9.13 -87.49 4.49 -7.49 -88.18 5.63 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 6 3 # 6 A 263 HIS B 77 HIS~? -4.07 O1 CIT B 103s D 59 GLU B 38 GLU^? 16.05 O1 CIT B 103 D 128 HIS B 41 HIS^? 11.37 O1 CIT B 103 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 7 3 # 7 A 263 HIS C 41 HIS^? 12.16 O1 CIT C 104 D 59 GLU C 32 GLU~? 15.71 O1 CIT C 104 D 128 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 8 3 # 8 A 263 HIS C 77 HIS~? -4.31 O1 CIT C 104s D 59 GLU C 21 GLU~? 6.35 O1 EDO C 103 D 128 HIS C 41 HIS^? 12.16 O1 CIT C 104 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 9 3 # 9 A 263 HIS C 77 HIS~? -4.31 O1 CIT C 104s D 59 GLU C 38 GLU^? 15.02 O1 CIT C 104 D 128 HIS C 41 HIS^? 12.16 O1 CIT C 104 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 10 3 # 10 A 263 HIS D 41 HIS^? 12.20 O1 CIT D 103 D 59 GLU D 32 GLU~? 17.83 O1 CIT D 103 D 128 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -63.28 -49.45 -6.05 -65.42 -49.45 -6.30 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 11 3 # 11 A 263 HIS D 77 HIS~? -3.79 O1 CIT D 103s D 59 GLU D 38 GLU^? 15.43 O2 CIT D 103 D 128 HIS D 41 HIS^? 12.20 O1 CIT D 103 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 12 3 # 12 A 263 HIS E 41 HIS^? -3.94 C2 EDO E 103s D 59 GLU E 32 GLU~? 15.49 O1 EDO E 103 D 128 HIS A 74 HIS~? 11.00 C1 EDO E 103 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 13 3 # 13 A 263 HIS E 41 HIS^? -3.94 C2 EDO E 103s D 59 GLU E 32 GLU~? 15.49 O1 EDO E 103 D 128 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 14 3 # 14 A 263 HIS E 77 HIS~? -4.13 O1 CIT E 104s D 59 GLU A 32 GLU~? 8.29 O4 CIT C 104 D 128 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 15 3 # 15 A 263 HIS E 77 HIS~? -4.13 O1 CIT E 104s D 59 GLU E 21 GLU~? 9.95 O4 CIT C 104 D 128 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 16 3 # 16 A 263 HIS E 77 HIS~? -4.13 O1 CIT E 104s D 59 GLU E 38 GLU^? 8.47 O1 EDO E 103 D 128 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 17 3 # 17 A 263 HIS F 41 HIS^? 12.43 O1 CIT F 104 D 59 GLU F 32 GLU~? 16.06 O1 CIT F 104 D 128 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 18 3 # 18 A 263 HIS F 77 HIS~? -3.59 O1 CIT F 104s D 59 GLU F 21 GLU~? 14.58 O1 CIT F 104 D 128 HIS F 41 HIS^? 12.43 O1 CIT F 104 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 ULMN 3 1ni4_c01 PYRUVATE DEHYDROGENASE E1 COMPONENT:user 19 3 # 19 A 263 HIS F 77 HIS~? -3.59 O1 CIT F 104s D 59 GLU F 38 GLU^? 13.95 O2 EDO E 103 D 128 HIS F 41 HIS^? 12.43 O1 CIT F 104 coo 8.65 -19.64 67.59 7.76 -17.92 68.39 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 12.72 -5.58 71.72 12.08 -7.54 72.22 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 coo 4.03 -8.95 63.85 3.80 -9.89 65.71 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 1ni4_c01 source 1ni4 PYRUVATE DEHYDROGENASE E1 COMPONENT: ALPHA SUB: 19 hits 1ni4_c01 naa= 3 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 1 3 # 1 A 62 SER C 87 SER~? 9.82 O2 EDO C 103 A 154 ASP C 93 ASP~? 9.74 O3 CIT C 104 A 261 ARG E 18 ARG~? 11.85 O4 CIT C 104 coo 16.10 74.10 3.11 17.18 73.52 5.20 -34.89 -64.48 -33.73 -36.72 -64.13 -35.26 coo 16.07 84.71 8.14 15.20 82.81 8.14 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 10.59 77.85 4.81 13.09 76.36 5.76 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 2 3 # 2 A 62 SER E 87 SER~? 10.44 O7 CIT E 104 A 154 ASP E 93 ASP~? 8.62 O3 CIT E 104 A 261 ARG C 18 ARG~? -3.10 O1 EDO C 103s coo 16.10 74.10 3.11 17.18 73.52 5.20 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 coo 16.07 84.71 8.14 15.20 82.81 8.14 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 10.59 77.85 4.81 13.09 76.36 5.76 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 1o98_c00 source 1o98 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT PHOSPHOGLY: 2 hits 1o98_c00 naa= 3 ULMN 3 1ofd_c02 FERREDOXIN-DEPENDENT GLUTAMATE SYNTHuser 1 3 # 1 A 1 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 903 GLU C 9 GLU.? 12.64 O3 CIT C 104 A 972 LYS D 50 LYS.? -4.40 O3 CIT C 104s coo 88.42 112.53 24.94 87.72 110.88 27.11 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 61.58 117.15 13.99 62.31 115.51 15.12 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 60.18 107.64 21.53 58.13 110.55 17.14 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 ULMN 3 1ofd_c02 FERREDOXIN-DEPENDENT GLUTAMATE SYNTHuser 2 3 # 2 A 1 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 903 GLU D 9 GLU.? 12.31 O4 CIT D 103 A 972 LYS D 50 LYS.? -4.40 O3 CIT C 104s coo 88.42 112.53 24.94 87.72 110.88 27.11 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 61.58 117.15 13.99 62.31 115.51 15.12 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 60.18 107.64 21.53 58.13 110.55 17.14 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 1ofd_c02 source 1ofd FERREDOXIN-DEPENDENT GLUTAMATE SYNTHASE 2 : 2 hits 1ofd_c02 naa= 3 ULMN 3 1ofd_c03 FERREDOXIN-DEPENDENT GLUTAMATE SYNTHuser 1 3 # 1 B 1 CYH B 60 CYH^? 5.88 O1 CIT B 103 B 903 GLU C 9 GLU.? 12.64 O3 CIT C 104 B 972 LYS D 50 LYS.? -4.40 O3 CIT C 104s coo 31.47 38.87 24.90 30.94 36.98 26.93 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 4.13 40.53 14.21 5.06 38.89 15.19 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 4.08 30.40 21.12 1.62 33.28 16.83 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 ULMN 3 1ofd_c03 FERREDOXIN-DEPENDENT GLUTAMATE SYNTHuser 2 3 # 2 B 1 CYH B 60 CYH^? 5.88 O1 CIT B 103 B 903 GLU D 9 GLU.? 12.31 O4 CIT D 103 B 972 LYS D 50 LYS.? -4.40 O3 CIT C 104s coo 31.47 38.87 24.90 30.94 36.98 26.93 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 4.13 40.53 14.21 5.06 38.89 15.19 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 4.08 30.40 21.12 1.62 33.28 16.83 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 1ofd_c03 source 1ofd FERREDOXIN-DEPENDENT GLUTAMATE SYNTHASE 2 : 2 hits 1ofd_c03 naa= 3 ULMN 3 1opm_c00 1.14.17.0003 user 1 3 # 1 A 108 HIS B 77 HIS~? -4.07 O1 CIT B 103s A 170 GLN B 78 GLN~? 5.40 O5 CIT B 103 A 242 HIS B 4 HIS.? -4.11 O2 CIT B 103s coo 36.16 34.36 39.40 38.12 34.09 40.00 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 40.85 35.41 43.73 41.85 33.73 42.88 -0.37 -74.67 -3.06 0.37 -75.53 -4.88 coo 40.72 26.15 37.61 42.10 27.69 37.19 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 1opm_c00 source 1opm 1.14.17.0003 : 1 hits 1opm_c00 naa= 3 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 1 3 # 1 A 170 SER A 51 SER.? 9.93 O6 CIT B 103 A 239 VAL B 98 VAL^? 10.08 O6 CIT B 103 A 413 ASN A 44 ASN.? 11.73 O6 CIT B 103 coo 80.14 40.76 52.28 77.73 40.59 51.94 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 75.67 35.37 52.30 76.00 35.96 50.23 -6.59 -80.54 -18.55 -7.74 -81.60 -20.10 coo 81.75 35.21 52.13 80.92 37.12 51.69 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 2 3 # 2 A 170 SER B 51 SER.? 11.29 O1 EDO A 103 A 239 VAL A 98 VAL^? 10.78 O2 EDO A 103 A 413 ASN B 44 ASN.? 13.13 O1 EDO A 103 coo 80.14 40.76 52.28 77.73 40.59 51.94 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 75.67 35.37 52.30 76.00 35.96 50.23 -14.49 -89.93 -18.69 -13.13 -88.96 -17.28 coo 81.75 35.21 52.13 80.92 37.12 51.69 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 3 3 # 3 A 170 SER C 51 SER.? 10.55 O6 CIT D 103 A 239 VAL D 98 VAL^? 10.08 O6 CIT D 103 A 413 ASN C 44 ASN.? 11.91 O6 CIT D 103 coo 80.14 40.76 52.28 77.73 40.59 51.94 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 75.67 35.37 52.30 76.00 35.96 50.23 -43.56 -55.67 -18.17 -43.36 -57.44 -19.52 coo 81.75 35.21 52.13 80.92 37.12 51.69 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 4 3 # 4 A 170 SER D 51 SER.? 10.41 O7 CIT C 104 A 239 VAL C 98 VAL^? 10.01 O2 CIT C 104 A 413 ASN D 44 ASN.? 12.24 O2 CIT C 104 coo 80.14 40.76 52.28 77.73 40.59 51.94 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 75.67 35.37 52.30 76.00 35.96 50.23 -44.95 -67.54 -18.00 -44.95 -65.90 -16.52 coo 81.75 35.21 52.13 80.92 37.12 51.69 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 5 3 # 5 A 170 SER E 51 SER.? 10.11 C4 CIT F 104 A 239 VAL F 98 VAL^? 10.00 O7 CIT F 104 A 413 ASN E 44 ASN.? 11.90 O7 CIT F 104 coo 80.14 40.76 52.28 77.73 40.59 51.94 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 75.67 35.37 52.30 76.00 35.96 50.23 -22.84 -75.20 -55.36 -24.57 -75.00 -54.05 coo 81.75 35.21 52.13 80.92 37.12 51.69 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 6 3 # 6 A 170 SER F 51 SER.? -5.94 O2 EDO F 103s A 239 VAL E 98 VAL^? 9.07 O2 EDO F 103 A 413 ASN F 44 ASN.? 8.45 O2 EDO F 103 coo 80.14 40.76 52.28 77.73 40.59 51.94 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 75.67 35.37 52.30 76.00 35.96 50.23 -34.98 -76.13 -56.01 -33.27 -75.93 -57.38 coo 81.75 35.21 52.13 80.92 37.12 51.69 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 1oqz_c00 source 1oqz GLUTARYL ACYLASE : 6 hits 1oqz_c00 naa= 3 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 1 3 # 1 B 170 SER A 51 SER.? 9.93 O6 CIT B 103 B 239 VAL B 98 VAL^? 10.08 O6 CIT B 103 B 413 ASN A 44 ASN.? 11.73 O6 CIT B 103 coo 25.22 6.41 2.90 27.67 6.33 3.11 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 29.71 1.00 2.66 29.43 1.57 4.74 -6.59 -80.54 -18.55 -7.74 -81.60 -20.10 coo 23.72 0.88 2.95 24.56 2.79 3.34 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 2 3 # 2 B 170 SER B 51 SER.? 11.29 O1 EDO A 103 B 239 VAL A 98 VAL^? 10.78 O2 EDO A 103 B 413 ASN B 44 ASN.? 13.13 O1 EDO A 103 coo 25.22 6.41 2.90 27.67 6.33 3.11 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 29.71 1.00 2.66 29.43 1.57 4.74 -14.49 -89.93 -18.69 -13.13 -88.96 -17.28 coo 23.72 0.88 2.95 24.56 2.79 3.34 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 3 3 # 3 B 170 SER C 51 SER.? 10.55 O6 CIT D 103 B 239 VAL D 98 VAL^? 10.08 O6 CIT D 103 B 413 ASN C 44 ASN.? 11.91 O6 CIT D 103 coo 25.22 6.41 2.90 27.67 6.33 3.11 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 29.71 1.00 2.66 29.43 1.57 4.74 -43.56 -55.67 -18.17 -43.36 -57.44 -19.52 coo 23.72 0.88 2.95 24.56 2.79 3.34 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 4 3 # 4 B 170 SER D 51 SER.? 10.41 O7 CIT C 104 B 239 VAL C 98 VAL^? 10.01 O2 CIT C 104 B 413 ASN D 44 ASN.? 12.24 O2 CIT C 104 coo 25.22 6.41 2.90 27.67 6.33 3.11 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 29.71 1.00 2.66 29.43 1.57 4.74 -44.95 -67.54 -18.00 -44.95 -65.90 -16.52 coo 23.72 0.88 2.95 24.56 2.79 3.34 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 5 3 # 5 B 170 SER E 51 SER.? 10.11 C4 CIT F 104 B 239 VAL F 98 VAL^? 10.00 O7 CIT F 104 B 413 ASN E 44 ASN.? 11.90 O7 CIT F 104 coo 25.22 6.41 2.90 27.67 6.33 3.11 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 29.71 1.00 2.66 29.43 1.57 4.74 -22.84 -75.20 -55.36 -24.57 -75.00 -54.05 coo 23.72 0.88 2.95 24.56 2.79 3.34 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 6 3 # 6 B 170 SER F 51 SER.? -5.94 O2 EDO F 103s B 239 VAL E 98 VAL^? 9.07 O2 EDO F 103 B 413 ASN F 44 ASN.? 8.45 O2 EDO F 103 coo 25.22 6.41 2.90 27.67 6.33 3.11 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 29.71 1.00 2.66 29.43 1.57 4.74 -34.98 -76.13 -56.01 -33.27 -75.93 -57.38 coo 23.72 0.88 2.95 24.56 2.79 3.34 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 1oqz_c01 source 1oqz GLUTARYL ACYLASE : 6 hits 1oqz_c01 naa= 3 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 1 3 # 1 A 225 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 259 TYR A 3 TYR.? 14.44 O2 EDO A 103 A 552 ASP C 17 ASP~? -3.95 O1 EDO C 103s coo 11.34 95.90 25.54 12.13 96.42 23.67 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 14.91 97.39 18.63 13.39 95.60 20.20 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 46.37 82.54 38.83 45.97 84.66 38.77 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 2 3 # 2 A 225 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 259 TYR A 3 TYR.? 14.44 O2 EDO A 103 A 552 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 11.34 95.90 25.54 12.13 96.42 23.67 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 14.91 97.39 18.63 13.39 95.60 20.20 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 46.37 82.54 38.83 45.97 84.66 38.77 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 3 3 # 3 A 225 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 259 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 552 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 14.91 97.39 18.63 13.39 95.60 20.20 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 46.37 82.54 38.83 45.97 84.66 38.77 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 4 3 # 4 A 225 HIS A 41 HIS^? 12.51 O2 EDO A 103 A 259 TYR A 56 TYR^? 12.86 C2 EDO A 103 A 552 ASP F 46 ASP.? 6.64 O2 EDO F 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 14.91 97.39 18.63 13.39 95.60 20.20 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo 46.37 82.54 38.83 45.97 84.66 38.77 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 5 3 # 5 A 225 HIS A 41 HIS^? 12.51 O2 EDO A 103 A 259 TYR A 56 TYR^? 12.86 C2 EDO A 103 A 552 ASP F 93 ASP~? 9.52 O4 CIT F 104 coo 11.34 95.90 25.54 12.13 96.42 23.67 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 14.91 97.39 18.63 13.39 95.60 20.20 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo 46.37 82.54 38.83 45.97 84.66 38.77 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 6 3 # 6 A 225 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 259 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 552 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 14.91 97.39 18.63 13.39 95.60 20.20 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 46.37 82.54 38.83 45.97 84.66 38.77 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 7 3 # 7 A 225 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 259 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 552 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 14.91 97.39 18.63 13.39 95.60 20.20 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 46.37 82.54 38.83 45.97 84.66 38.77 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 8 3 # 8 A 225 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 259 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 552 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 14.91 97.39 18.63 13.39 95.60 20.20 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 46.37 82.54 38.83 45.97 84.66 38.77 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 9 3 # 9 A 225 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 259 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 552 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 11.34 95.90 25.54 12.13 96.42 23.67 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 14.91 97.39 18.63 13.39 95.60 20.20 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 46.37 82.54 38.83 45.97 84.66 38.77 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 10 3 # 10 A 225 HIS C 41 HIS^? 12.16 O1 CIT C 104 A 259 TYR C 56 TYR^? 12.84 O1 CIT C 104 A 552 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 14.91 97.39 18.63 13.39 95.60 20.20 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo 46.37 82.54 38.83 45.97 84.66 38.77 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 11 3 # 11 A 225 HIS C 41 HIS^? 12.16 O1 CIT C 104 A 259 TYR C 56 TYR^? 12.84 O1 CIT C 104 A 552 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 11.34 95.90 25.54 12.13 96.42 23.67 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 14.91 97.39 18.63 13.39 95.60 20.20 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo 46.37 82.54 38.83 45.97 84.66 38.77 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 12 3 # 12 A 225 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 259 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 552 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 14.91 97.39 18.63 13.39 95.60 20.20 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 46.37 82.54 38.83 45.97 84.66 38.77 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 13 3 # 13 A 225 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 259 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 552 ASP E 46 ASP.? 9.98 C4 CIT F 104 coo 11.34 95.90 25.54 12.13 96.42 23.67 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 14.91 97.39 18.63 13.39 95.60 20.20 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 46.37 82.54 38.83 45.97 84.66 38.77 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 14 3 # 14 A 225 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 259 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 552 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 11.34 95.90 25.54 12.13 96.42 23.67 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 14.91 97.39 18.63 13.39 95.60 20.20 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 46.37 82.54 38.83 45.97 84.66 38.77 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 15 3 # 15 A 225 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 259 TYR D 3 TYR.? 14.21 O2 CIT D 103 A 552 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 14.91 97.39 18.63 13.39 95.60 20.20 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 46.37 82.54 38.83 45.97 84.66 38.77 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 16 3 # 16 A 225 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 259 TYR E 3 TYR.? 13.85 O2 EDO E 103 A 552 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 14.91 97.39 18.63 13.39 95.60 20.20 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 46.37 82.54 38.83 45.97 84.66 38.77 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 17 3 # 17 A 225 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 259 TYR E 3 TYR.? 13.85 O2 EDO E 103 A 552 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 14.91 97.39 18.63 13.39 95.60 20.20 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 46.37 82.54 38.83 45.97 84.66 38.77 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 18 3 # 18 A 225 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 259 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 552 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 14.91 97.39 18.63 13.39 95.60 20.20 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 46.37 82.54 38.83 45.97 84.66 38.77 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 19 3 # 19 A 225 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 259 TYR E 56 TYR^? 8.81 O2 EDO E 103 A 552 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 11.34 95.90 25.54 12.13 96.42 23.67 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 14.91 97.39 18.63 13.39 95.60 20.20 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo 46.37 82.54 38.83 45.97 84.66 38.77 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 20 3 # 20 A 225 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 259 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 552 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 14.91 97.39 18.63 13.39 95.60 20.20 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 46.37 82.54 38.83 45.97 84.66 38.77 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 21 3 # 21 A 225 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 259 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 552 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 14.91 97.39 18.63 13.39 95.60 20.20 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 46.37 82.54 38.83 45.97 84.66 38.77 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1pj5_c00 N,N-DIMETHYLGLYCINE OXIDASE user 22 3 # 22 A 225 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 259 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 552 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 11.34 95.90 25.54 12.13 96.42 23.67 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 14.91 97.39 18.63 13.39 95.60 20.20 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 46.37 82.54 38.83 45.97 84.66 38.77 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 1pj5_c00 source 1pj5 N,N-DIMETHYLGLYCINE OXIDASE : 22 hits 1pj5_c00 naa= 3 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 1 3 # 1 A 248 ASP A 93 ASP~? 12.48 O1 EDO A 103 A 270 LYS B 50 LYS.? 6.61 O1 EDO A 103 A 382 MET A 83 MET?? 7.60 C2 EDO E 103 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -15.93 -87.48 -37.76 -18.71 -84.43 -38.90 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 2 3 # 2 A 248 ASP B 93 ASP~? 9.77 O3 CIT B 103 A 270 LYS A 50 LYS.? -4.54 O3 CIT B 103s A 382 MET B 83 MET?? 10.89 C2 CIT B 103 coo -27.63 121.99 45.48 -26.66 123.86 45.68 3.85 -90.04 -12.91 5.79 -89.33 -13.36 coo -32.20 115.91 49.56 -31.37 121.03 53.12 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -2.31 -85.02 -0.77 -4.92 -83.80 2.48 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 3 3 # 3 A 248 ASP C 93 ASP~? 9.74 O3 CIT C 104 A 270 LYS D 50 LYS.? -4.40 O3 CIT C 104s A 382 MET C 83 MET?? 8.31 O4 CIT E 104 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -39.14 -68.23 -36.02 -41.89 -67.07 -39.09 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 4 3 # 4 A 248 ASP D 93 ASP~? 9.04 O4 CIT D 103 A 270 LYS C 50 LYS.? -4.07 O4 CIT D 103s A 382 MET D 83 MET?? 10.29 O1 CIT D 103 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -46.36 -55.20 0.75 -50.38 -55.10 1.97 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 5 3 # 5 A 248 ASP E 93 ASP~? 8.62 O3 CIT E 104 A 270 LYS F 50 LYS.? -3.77 O3 CIT E 104s A 382 MET C 83 MET?? 8.31 O4 CIT E 104 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -39.14 -68.23 -36.02 -41.89 -67.07 -39.09 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 6 3 # 6 A 248 ASP E 93 ASP~? 8.62 O3 CIT E 104 A 270 LYS F 50 LYS.? -3.77 O3 CIT E 104s A 382 MET E 83 MET?? 8.24 O4 CIT C 104 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -35.89 -71.39 -37.70 -34.78 -74.19 -34.66 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 7 3 # 7 A 248 ASP F 93 ASP~? 9.52 O4 CIT F 104 A 270 LYS E 50 LYS.? -4.05 O4 CIT F 104s A 382 MET F 83 MET?? 10.32 O1 CIT F 104 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -21.81 -76.15 -74.24 -22.03 -80.13 -75.83 1pjq_c02 source 1pjq SIROHEME SYNTHASE : 7 hits 1pjq_c02 naa= 3 ULMN 3 1pow_c02 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 1 3 # 1 A 264 ARG A 40 ARG^? 16.77 O2 EDO A 103 A 479 PHE A 39 PHE^? 8.73 O2 EDO A 103 A 483 GLU A 38 GLU^? 15.90 O2 EDO A 103 coo 17.33 52.29 2.24 18.71 54.03 0.18 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 20.06 57.44 1.28 18.39 56.19 3.12 -21.74 -79.22 -26.25 -19.82 -80.03 -28.09 coo 17.33 54.96 -3.04 16.34 56.76 -2.51 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 ULMN 3 1pow_c02 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 2 3 # 2 A 264 ARG B 40 ARG^? 17.25 O1 CIT B 103 A 479 PHE B 39 PHE^? 8.22 O1 CIT B 103 A 483 GLU B 38 GLU^? 16.05 O1 CIT B 103 coo 17.33 52.29 2.24 18.71 54.03 0.18 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 20.06 57.44 1.28 18.39 56.19 3.12 -14.83 -78.18 -6.28 -13.34 -80.32 -5.30 coo 17.33 54.96 -3.04 16.34 56.76 -2.51 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 ULMN 3 1pow_c02 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 3 3 # 3 A 264 ARG C 40 ARG^? 17.96 O1 CIT C 104 A 479 PHE C 39 PHE^? 8.82 O1 CIT C 104 A 483 GLU C 38 GLU^? 15.02 O1 CIT C 104 coo 17.33 52.29 2.24 18.71 54.03 0.18 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 20.06 57.44 1.28 18.39 56.19 3.12 -52.46 -63.56 -30.58 -49.96 -63.04 -31.67 coo 17.33 54.96 -3.04 16.34 56.76 -2.51 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 ULMN 3 1pow_c02 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 4 3 # 4 A 264 ARG D 40 ARG^? 16.76 O2 CIT D 103 A 479 PHE D 39 PHE^? 8.71 O2 CIT D 103 A 483 GLU D 38 GLU^? 15.43 O2 CIT D 103 coo 17.33 52.29 2.24 18.71 54.03 0.18 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 20.06 57.44 1.28 18.39 56.19 3.12 -56.27 -57.17 -10.67 -54.36 -57.75 -8.75 coo 17.33 54.96 -3.04 16.34 56.76 -2.51 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 ULMN 3 1pow_c02 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 5 3 # 5 A 264 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 479 PHE E 39 PHE^? -5.50 C1 EDO E 103s A 483 GLU E 38 GLU^? 8.47 O1 EDO E 103 coo 17.33 52.29 2.24 18.71 54.03 0.18 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 20.06 57.44 1.28 18.39 56.19 3.12 -31.49 -84.64 -44.22 -31.26 -82.07 -43.16 coo 17.33 54.96 -3.04 16.34 56.76 -2.51 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 ULMN 3 1pow_c02 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 6 3 # 6 A 264 ARG F 40 ARG^? 16.45 O2 CIT F 104 A 479 PHE F 39 PHE^? 8.84 O2 CIT F 104 A 483 GLU F 38 GLU^? 13.95 O2 EDO E 103 coo 17.33 52.29 2.24 18.71 54.03 0.18 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 20.06 57.44 1.28 18.39 56.19 3.12 -24.68 -87.05 -64.11 -25.42 -84.90 -65.71 coo 17.33 54.96 -3.04 16.34 56.76 -2.51 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 1pow_c02 source 1pow PYRUVATE OXIDASE (E.C.1.2.3.3) (WILD TYPE) : 6 hits 1pow_c02 naa= 3 ULMN 3 1pow_c03 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 1 3 # 1 B 264 ARG A 40 ARG^? 16.77 O2 EDO A 103 B 479 PHE A 39 PHE^? 8.73 O2 EDO A 103 B 483 GLU A 38 GLU^? 15.90 O2 EDO A 103 coo -26.72 93.28 20.13 -28.02 93.55 17.39 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -29.34 90.48 15.69 -27.62 89.95 17.80 -21.74 -79.22 -26.25 -19.82 -80.03 -28.09 coo -26.63 95.49 14.65 -25.77 93.77 13.77 -22.95 -75.92 -20.07 -21.91 -75.34 -18.31 ULMN 3 1pow_c03 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 2 3 # 2 B 264 ARG B 40 ARG^? 17.25 O1 CIT B 103 B 479 PHE B 39 PHE^? 8.22 O1 CIT B 103 B 483 GLU B 38 GLU^? 16.05 O1 CIT B 103 coo -26.72 93.28 20.13 -28.02 93.55 17.39 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo -29.34 90.48 15.69 -27.62 89.95 17.80 -14.83 -78.18 -6.28 -13.34 -80.32 -5.30 coo -26.63 95.49 14.65 -25.77 93.77 13.77 -19.99 -76.00 -10.71 -21.18 -76.43 -12.41 ULMN 3 1pow_c03 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 3 3 # 3 B 264 ARG C 40 ARG^? 17.96 O1 CIT C 104 B 479 PHE C 39 PHE^? 8.82 O1 CIT C 104 B 483 GLU C 38 GLU^? 15.02 O1 CIT C 104 coo -26.72 93.28 20.13 -28.02 93.55 17.39 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -29.34 90.48 15.69 -27.62 89.95 17.80 -52.46 -63.56 -30.58 -49.96 -63.04 -31.67 coo -26.63 95.49 14.65 -25.77 93.77 13.77 -57.71 -61.40 -26.14 -56.90 -60.07 -24.69 ULMN 3 1pow_c03 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 4 3 # 4 B 264 ARG D 40 ARG^? 16.76 O2 CIT D 103 B 479 PHE D 39 PHE^? 8.71 O2 CIT D 103 B 483 GLU D 38 GLU^? 15.43 O2 CIT D 103 coo -26.72 93.28 20.13 -28.02 93.55 17.39 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo -29.34 90.48 15.69 -27.62 89.95 17.80 -56.27 -57.17 -10.67 -54.36 -57.75 -8.75 coo -26.63 95.49 14.65 -25.77 93.77 13.77 -59.74 -58.71 -16.88 -58.81 -60.16 -18.14 ULMN 3 1pow_c03 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 5 3 # 5 B 264 ARG E 40 ARG^? -5.36 O2 EDO E 103s B 479 PHE E 39 PHE^? -5.50 C1 EDO E 103s B 483 GLU E 38 GLU^? 8.47 O1 EDO E 103 coo -26.72 93.28 20.13 -28.02 93.55 17.39 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -29.34 90.48 15.69 -27.62 89.95 17.80 -31.49 -84.64 -44.22 -31.26 -82.07 -43.16 coo -26.63 95.49 14.65 -25.77 93.77 13.77 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 ULMN 3 1pow_c03 PYRUVATE OXIDASE (E.C.1.2.3.3) (WILDuser 6 3 # 6 B 264 ARG F 40 ARG^? 16.45 O2 CIT F 104 B 479 PHE F 39 PHE^? 8.84 O2 CIT F 104 B 483 GLU F 38 GLU^? 13.95 O2 EDO E 103 coo -26.72 93.28 20.13 -28.02 93.55 17.39 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo -29.34 90.48 15.69 -27.62 89.95 17.80 -24.68 -87.05 -64.11 -25.42 -84.90 -65.71 coo -26.63 95.49 14.65 -25.77 93.77 13.77 -26.47 -90.74 -58.30 -27.91 -90.73 -56.67 1pow_c03 source 1pow PYRUVATE OXIDASE (E.C.1.2.3.3) (WILD TYPE) : 6 hits 1pow_c03 naa= 3 ULMN 3 1pyl_c00 RIBONUCLEASE user 1 3 # 1 A 56 GLU A 101 GLU^? 18.10 O2 EDO A 103 A 67 ARG B 40 ARG^? 17.25 O1 CIT B 103 A 86 HIS B 41 HIS^? 11.37 O1 CIT B 103 coo 18.15 3.28 18.56 20.10 2.92 19.20 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 21.52 6.83 26.64 21.22 5.53 23.85 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 ULMN 3 1pyl_c00 RIBONUCLEASE user 2 3 # 2 A 56 GLU B 101 GLU^? 17.79 O2 CIT B 103 A 67 ARG A 40 ARG^? 16.77 O2 EDO A 103 A 86 HIS A 41 HIS^? 12.51 O2 EDO A 103 coo 18.15 3.28 18.56 20.10 2.92 19.20 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 21.52 6.83 26.64 21.22 5.53 23.85 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 ULMN 3 1pyl_c00 RIBONUCLEASE user 3 3 # 3 A 56 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 67 ARG D 40 ARG^? 16.76 O2 CIT D 103 A 86 HIS D 41 HIS^? 12.20 O1 CIT D 103 coo 18.15 3.28 18.56 20.10 2.92 19.20 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 21.52 6.83 26.64 21.22 5.53 23.85 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 ULMN 3 1pyl_c00 RIBONUCLEASE user 4 3 # 4 A 56 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 67 ARG E 79 ARG~? -3.12 O5 CIT C 104s A 86 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 18.15 3.28 18.56 20.10 2.92 19.20 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 21.52 6.83 26.64 21.22 5.53 23.85 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1pyl_c00 RIBONUCLEASE user 5 3 # 5 A 56 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 67 ARG C 40 ARG^? 17.96 O1 CIT C 104 A 86 HIS C 41 HIS^? 12.16 O1 CIT C 104 coo 18.15 3.28 18.56 20.10 2.92 19.20 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 21.52 6.83 26.64 21.22 5.53 23.85 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 ULMN 3 1pyl_c00 RIBONUCLEASE user 6 3 # 6 A 56 GLU E 38 GLU^? 8.47 O1 EDO E 103 A 67 ARG A 79 ARG~? -3.92 C2 EDO E 103s A 86 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 18.15 3.28 18.56 20.10 2.92 19.20 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 21.52 6.83 26.64 21.22 5.53 23.85 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1pyl_c00 RIBONUCLEASE user 7 3 # 7 A 56 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 67 ARG F 40 ARG^? 16.45 O2 CIT F 104 A 86 HIS F 41 HIS^? 12.43 O1 CIT F 104 coo 18.15 3.28 18.56 20.10 2.92 19.20 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 21.52 6.83 26.64 21.22 5.53 23.85 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 ULMN 3 1pyl_c00 RIBONUCLEASE user 8 3 # 8 A 56 GLU F 48 GLU.? -3.15 C4 CIT E 104s A 67 ARG C 79 ARG~? -3.25 O5 CIT E 104s A 86 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 18.15 3.28 18.56 20.10 2.92 19.20 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 21.52 6.83 26.64 21.22 5.53 23.85 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1pyl_c00 RIBONUCLEASE user 9 3 # 9 A 56 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 67 ARG A 79 ARG~? -3.92 C2 EDO E 103s A 86 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 18.15 3.28 18.56 20.10 2.92 19.20 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 21.52 6.83 26.64 21.22 5.53 23.85 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1pyl_c00 RIBONUCLEASE user 10 3 # 10 A 56 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 67 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 86 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo 18.15 3.28 18.56 20.10 2.92 19.20 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 21.52 6.83 26.64 21.22 5.53 23.85 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 22.36 -1.88 25.52 23.57 -0.73 24.25 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 1pyl_c00 source 1pyl RIBONUCLEASE : 10 hits 1pyl_c00 naa= 3 ULMN 3 1pyl_c01 RIBONUCLEASE user 1 3 # 1 B 56 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 67 ARG C 79 ARG~? -3.25 O5 CIT E 104s B 86 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 33.14 -5.53 11.32 32.45 -5.14 9.39 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 31.86 -4.62 2.25 31.08 -4.78 5.21 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo 25.42 -9.42 7.20 25.63 -7.36 7.52 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 1pyl_c01 source 1pyl RIBONUCLEASE : 1 hits 1pyl_c01 naa= 3 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 1 3 # 1 A 48 LEU A 100 LEU^? 13.85 O1 CIT B 103 A 58 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 120 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 34.02 69.29 75.26 34.82 67.82 76.74 -17.08 -87.25 -13.38 -14.97 -87.07 -12.96 coo 34.46 72.45 78.57 32.82 72.75 77.28 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 28.96 77.64 81.19 29.05 74.53 77.51 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 2 3 # 2 A 48 LEU A 100 LEU^? 13.85 O1 CIT B 103 A 58 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 120 LYS B 50 LYS.? 6.61 O1 EDO A 103 coo 34.02 69.29 75.26 34.82 67.82 76.74 -17.08 -87.25 -13.38 -14.97 -87.07 -12.96 coo 34.46 72.45 78.57 32.82 72.75 77.28 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 28.96 77.64 81.19 29.05 74.53 77.51 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 3 3 # 3 A 48 LEU B 100 LEU^? 13.83 O2 EDO A 103 A 58 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 120 LYS A 50 LYS.? -4.54 O3 CIT B 103s coo 34.02 69.29 75.26 34.82 67.82 76.74 -11.19 -77.10 -21.71 -11.33 -79.05 -22.56 coo 34.46 72.45 78.57 32.82 72.75 77.28 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 28.96 77.64 81.19 29.05 74.53 77.51 0.28 -82.73 -17.71 1.66 -84.44 -13.54 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 4 3 # 4 A 48 LEU B 100 LEU^? 13.83 O2 EDO A 103 A 58 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 120 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 34.02 69.29 75.26 34.82 67.82 76.74 -11.19 -77.10 -21.71 -11.33 -79.05 -22.56 coo 34.46 72.45 78.57 32.82 72.75 77.28 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 28.96 77.64 81.19 29.05 74.53 77.51 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 5 3 # 5 A 48 LEU C 100 LEU^? 13.72 O2 CIT D 103 A 58 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 120 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 34.02 69.29 75.26 34.82 67.82 76.74 -50.61 -66.45 -14.87 -49.30 -65.03 -13.86 coo 34.46 72.45 78.57 32.82 72.75 77.28 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 28.96 77.64 81.19 29.05 74.53 77.51 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 6 3 # 6 A 48 LEU C 100 LEU^? 13.72 O2 CIT D 103 A 58 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 120 LYS D 50 LYS.? -4.40 O3 CIT C 104s coo 34.02 69.29 75.26 34.82 67.82 76.74 -50.61 -66.45 -14.87 -49.30 -65.03 -13.86 coo 34.46 72.45 78.57 32.82 72.75 77.28 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 28.96 77.64 81.19 29.05 74.53 77.51 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 7 3 # 7 A 48 LEU D 100 LEU^? 13.70 O1 CIT C 104 A 58 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 120 LYS C 50 LYS.? -4.07 O4 CIT D 103s coo 34.02 69.29 75.26 34.82 67.82 76.74 -47.31 -55.74 -23.54 -46.04 -57.49 -23.79 coo 34.46 72.45 78.57 32.82 72.75 77.28 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 28.96 77.64 81.19 29.05 74.53 77.51 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 8 3 # 8 A 48 LEU D 100 LEU^? 13.70 O1 CIT C 104 A 58 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 120 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 34.02 69.29 75.26 34.82 67.82 76.74 -47.31 -55.74 -23.54 -46.04 -57.49 -23.79 coo 34.46 72.45 78.57 32.82 72.75 77.28 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 28.96 77.64 81.19 29.05 74.53 77.51 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 9 3 # 9 A 48 LEU E 100 LEU^? 13.74 O2 CIT F 104 A 58 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 120 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 34.02 69.29 75.26 34.82 67.82 76.74 -33.88 -81.47 -59.62 -32.42 -80.07 -60.48 coo 34.46 72.45 78.57 32.82 72.75 77.28 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 28.96 77.64 81.19 29.05 74.53 77.51 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 10 3 # 10 A 48 LEU E 100 LEU^? 13.74 O2 CIT F 104 A 58 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 120 LYS F 50 LYS.? -3.77 O3 CIT E 104s coo 34.02 69.29 75.26 34.82 67.82 76.74 -33.88 -81.47 -59.62 -32.42 -80.07 -60.48 coo 34.46 72.45 78.57 32.82 72.75 77.28 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 28.96 77.64 81.19 29.05 74.53 77.51 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 11 3 # 11 A 48 LEU F 100 LEU^? 8.24 O2 EDO E 103 A 58 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 120 LYS E 50 LYS.? -4.05 O4 CIT F 104s coo 34.02 69.29 75.26 34.82 67.82 76.74 -23.26 -79.30 -50.33 -25.04 -78.05 -50.01 coo 34.46 72.45 78.57 32.82 72.75 77.28 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 28.96 77.64 81.19 29.05 74.53 77.51 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 ULMN 3 1pym_c00 PHOSPHOENOLPYRUVATE MUTASE user 12 3 # 12 A 48 LEU F 100 LEU^? 8.24 O2 EDO E 103 A 58 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 120 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 34.02 69.29 75.26 34.82 67.82 76.74 -23.26 -79.30 -50.33 -25.04 -78.05 -50.01 coo 34.46 72.45 78.57 32.82 72.75 77.28 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 28.96 77.64 81.19 29.05 74.53 77.51 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1pym_c00 source 1pym PHOSPHOENOLPYRUVATE MUTASE : 12 hits 1pym_c00 naa= 3 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 1 3 # 1 B 48 LEU A 100 LEU^? 13.85 O1 CIT B 103 B 58 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 120 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 54.50 104.32 58.69 55.83 105.69 59.81 -17.08 -87.25 -13.38 -14.97 -87.07 -12.96 coo 57.63 101.19 59.83 56.60 100.89 57.99 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 61.58 95.88 55.22 58.18 99.30 54.71 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 2 3 # 2 B 48 LEU A 100 LEU^? 13.85 O1 CIT B 103 B 58 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 120 LYS B 50 LYS.? 6.61 O1 EDO A 103 coo 54.50 104.32 58.69 55.83 105.69 59.81 -17.08 -87.25 -13.38 -14.97 -87.07 -12.96 coo 57.63 101.19 59.83 56.60 100.89 57.99 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 61.58 95.88 55.22 58.18 99.30 54.71 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 3 3 # 3 B 48 LEU B 100 LEU^? 13.83 O2 EDO A 103 B 58 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 120 LYS A 50 LYS.? -4.54 O3 CIT B 103s coo 54.50 104.32 58.69 55.83 105.69 59.81 -11.19 -77.10 -21.71 -11.33 -79.05 -22.56 coo 57.63 101.19 59.83 56.60 100.89 57.99 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 61.58 95.88 55.22 58.18 99.30 54.71 0.28 -82.73 -17.71 1.66 -84.44 -13.54 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 4 3 # 4 B 48 LEU B 100 LEU^? 13.83 O2 EDO A 103 B 58 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 120 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 54.50 104.32 58.69 55.83 105.69 59.81 -11.19 -77.10 -21.71 -11.33 -79.05 -22.56 coo 57.63 101.19 59.83 56.60 100.89 57.99 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 61.58 95.88 55.22 58.18 99.30 54.71 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 5 3 # 5 B 48 LEU C 100 LEU^? 13.72 O2 CIT D 103 B 58 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 120 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 54.50 104.32 58.69 55.83 105.69 59.81 -50.61 -66.45 -14.87 -49.30 -65.03 -13.86 coo 57.63 101.19 59.83 56.60 100.89 57.99 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 61.58 95.88 55.22 58.18 99.30 54.71 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 6 3 # 6 B 48 LEU C 100 LEU^? 13.72 O2 CIT D 103 B 58 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 120 LYS D 50 LYS.? -4.40 O3 CIT C 104s coo 54.50 104.32 58.69 55.83 105.69 59.81 -50.61 -66.45 -14.87 -49.30 -65.03 -13.86 coo 57.63 101.19 59.83 56.60 100.89 57.99 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 61.58 95.88 55.22 58.18 99.30 54.71 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 7 3 # 7 B 48 LEU D 100 LEU^? 13.70 O1 CIT C 104 B 58 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 120 LYS C 50 LYS.? -4.07 O4 CIT D 103s coo 54.50 104.32 58.69 55.83 105.69 59.81 -47.31 -55.74 -23.54 -46.04 -57.49 -23.79 coo 57.63 101.19 59.83 56.60 100.89 57.99 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 61.58 95.88 55.22 58.18 99.30 54.71 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 8 3 # 8 B 48 LEU D 100 LEU^? 13.70 O1 CIT C 104 B 58 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 120 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 54.50 104.32 58.69 55.83 105.69 59.81 -47.31 -55.74 -23.54 -46.04 -57.49 -23.79 coo 57.63 101.19 59.83 56.60 100.89 57.99 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 61.58 95.88 55.22 58.18 99.30 54.71 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 9 3 # 9 B 48 LEU E 100 LEU^? 13.74 O2 CIT F 104 B 58 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 120 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 54.50 104.32 58.69 55.83 105.69 59.81 -33.88 -81.47 -59.62 -32.42 -80.07 -60.48 coo 57.63 101.19 59.83 56.60 100.89 57.99 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 61.58 95.88 55.22 58.18 99.30 54.71 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 10 3 # 10 B 48 LEU E 100 LEU^? 13.74 O2 CIT F 104 B 58 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 120 LYS F 50 LYS.? -3.77 O3 CIT E 104s coo 54.50 104.32 58.69 55.83 105.69 59.81 -33.88 -81.47 -59.62 -32.42 -80.07 -60.48 coo 57.63 101.19 59.83 56.60 100.89 57.99 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 61.58 95.88 55.22 58.18 99.30 54.71 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 11 3 # 11 B 48 LEU F 100 LEU^? 8.24 O2 EDO E 103 B 58 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 120 LYS E 50 LYS.? -4.05 O4 CIT F 104s coo 54.50 104.32 58.69 55.83 105.69 59.81 -23.26 -79.30 -50.33 -25.04 -78.05 -50.01 coo 57.63 101.19 59.83 56.60 100.89 57.99 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 61.58 95.88 55.22 58.18 99.30 54.71 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 ULMN 3 1pym_c01 PHOSPHOENOLPYRUVATE MUTASE user 12 3 # 12 B 48 LEU F 100 LEU^? 8.24 O2 EDO E 103 B 58 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 120 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 54.50 104.32 58.69 55.83 105.69 59.81 -23.26 -79.30 -50.33 -25.04 -78.05 -50.01 coo 57.63 101.19 59.83 56.60 100.89 57.99 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 61.58 95.88 55.22 58.18 99.30 54.71 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1pym_c01 source 1pym PHOSPHOENOLPYRUVATE MUTASE : 12 hits 1pym_c01 naa= 3 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 1 3 # 1 A 67 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 68 ALA A 66 ALA~? 15.93 O2 EDO A 103 A 72 LEU A 68 LEU~? 8.28 O2 EDO A 103 coo 46.76 7.59 18.65 45.27 6.01 18.52 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 48.88 4.35 16.59 48.73 5.09 15.20 -31.02 -91.77 -19.75 -32.50 -91.62 -19.23 coo 53.89 6.25 15.09 52.88 7.92 14.14 -25.35 -90.24 -20.94 -23.22 -90.71 -21.35 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 2 3 # 2 A 67 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 68 ALA A 67 ALA~? 12.65 O2 EDO A 103 A 72 LEU A 68 LEU~? 8.28 O2 EDO A 103 coo 46.76 7.59 18.65 45.27 6.01 18.52 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 48.88 4.35 16.59 48.73 5.09 15.20 -29.87 -88.33 -21.07 -29.62 -87.09 -20.21 coo 53.89 6.25 15.09 52.88 7.92 14.14 -25.35 -90.24 -20.94 -23.22 -90.71 -21.35 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 3 3 # 3 A 67 ASP B 64 ASP~? 16.93 O2 CIT B 103 A 68 ALA B 66 ALA~? 16.27 O2 CIT B 103 A 72 LEU B 68 LEU~? 8.47 O2 CIT B 103 coo 46.76 7.59 18.65 45.27 6.01 18.52 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 48.88 4.35 16.59 48.73 5.09 15.20 -6.46 -64.83 -12.71 -6.93 -63.35 -12.67 coo 53.89 6.25 15.09 52.88 7.92 14.14 -6.89 -70.80 -13.14 -5.91 -72.71 -13.57 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 4 3 # 4 A 67 ASP B 64 ASP~? 16.93 O2 CIT B 103 A 68 ALA B 67 ALA~? 13.32 O2 CIT B 103 A 72 LEU B 68 LEU~? 8.47 O2 CIT B 103 coo 46.76 7.59 18.65 45.27 6.01 18.52 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 48.88 4.35 16.59 48.73 5.09 15.20 -9.08 -66.99 -10.93 -10.52 -67.16 -11.45 coo 53.89 6.25 15.09 52.88 7.92 14.14 -6.89 -70.80 -13.14 -5.91 -72.71 -13.57 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 5 3 # 5 A 67 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 68 ALA C 66 ALA~? 15.90 O2 CIT C 104 A 72 LEU C 68 LEU~? 8.19 O2 CIT C 104 coo 46.76 7.59 18.65 45.27 6.01 18.52 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 48.88 4.35 16.59 48.73 5.09 15.20 -56.01 -78.91 -23.21 -57.42 -79.56 -23.18 coo 53.89 6.25 15.09 52.88 7.92 14.14 -52.21 -74.51 -23.05 -50.26 -73.52 -22.72 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 6 3 # 6 A 67 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 68 ALA C 67 ALA~? 13.02 O1 CIT C 104 A 72 LEU C 68 LEU~? 8.19 O2 CIT C 104 coo 46.76 7.59 18.65 45.27 6.01 18.52 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 48.88 4.35 16.59 48.73 5.09 15.20 -56.44 -75.71 -25.21 -57.34 -74.53 -24.80 coo 53.89 6.25 15.09 52.88 7.92 14.14 -52.21 -74.51 -23.05 -50.26 -73.52 -22.72 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 7 3 # 7 A 67 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 68 ALA D 66 ALA~? 15.81 O6 CIT D 103 A 72 LEU D 68 LEU~? 8.05 O6 CIT D 103 coo 46.76 7.59 18.65 45.27 6.01 18.52 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 48.88 4.35 16.59 48.73 5.09 15.20 -53.31 -42.21 -18.09 -54.48 -41.40 -18.74 coo 53.89 6.25 15.09 52.88 7.92 14.14 -50.69 -47.26 -16.46 -48.95 -48.50 -15.98 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 8 3 # 8 A 67 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 68 ALA D 67 ALA~? 12.76 O2 CIT D 103 A 72 LEU D 68 LEU~? 8.05 O6 CIT D 103 coo 46.76 7.59 18.65 45.27 6.01 18.52 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 48.88 4.35 16.59 48.73 5.09 15.20 -55.09 -45.19 -16.51 -55.94 -46.20 -17.30 coo 53.89 6.25 15.09 52.88 7.92 14.14 -50.69 -47.26 -16.46 -48.95 -48.50 -15.98 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 9 3 # 9 A 67 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 68 ALA E 24 ALA~? 10.19 C1 EDO E 103 A 72 LEU A 29 LEU~? 10.48 O2 EDO A 103 coo 46.76 7.59 18.65 45.27 6.01 18.52 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 48.88 4.35 16.59 48.73 5.09 15.20 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 coo 53.89 6.25 15.09 52.88 7.92 14.14 -26.95 -81.99 -31.30 -27.85 -83.90 -30.83 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 10 3 # 10 A 67 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 68 ALA E 66 ALA~? 15.62 O2 CIT E 104 A 72 LEU E 68 LEU~? 8.13 O2 CIT E 104 coo 46.76 7.59 18.65 45.27 6.01 18.52 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 48.88 4.35 16.59 48.73 5.09 15.20 -46.63 -87.00 -51.63 -47.44 -88.29 -51.81 coo 53.89 6.25 15.09 52.88 7.92 14.14 -42.16 -83.41 -51.47 -41.23 -81.44 -51.72 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 11 3 # 11 A 67 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 68 ALA E 67 ALA~? 12.61 O2 CIT E 104 A 72 LEU E 68 LEU~? 8.13 O2 CIT E 104 coo 46.76 7.59 18.65 45.27 6.01 18.52 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 48.88 4.35 16.59 48.73 5.09 15.20 -43.44 -87.76 -49.60 -42.32 -88.68 -50.03 coo 53.89 6.25 15.09 52.88 7.92 14.14 -42.16 -83.41 -51.47 -41.23 -81.44 -51.72 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 12 3 # 12 A 67 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 68 ALA F 66 ALA~? 15.98 O7 CIT F 104 A 72 LEU F 68 LEU~? 8.38 O7 CIT F 104 coo 46.76 7.59 18.65 45.27 6.01 18.52 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 48.88 4.35 16.59 48.73 5.09 15.20 -9.56 -85.19 -55.88 -8.53 -86.23 -55.40 coo 53.89 6.25 15.09 52.88 7.92 14.14 -14.42 -82.30 -57.16 -15.55 -80.53 -57.63 ULMN 3 1q6l_c05 3-KETO-L-GULONATE 6-PHOSPHATE DECARBuser 13 3 # 13 A 67 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 68 ALA F 67 ALA~? 12.75 O2 CIT F 104 A 72 LEU F 68 LEU~? 8.38 O7 CIT F 104 coo 46.76 7.59 18.65 45.27 6.01 18.52 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 48.88 4.35 16.59 48.73 5.09 15.20 -12.62 -86.76 -57.61 -13.72 -87.50 -56.90 coo 53.89 6.25 15.09 52.88 7.92 14.14 -14.42 -82.30 -57.16 -15.55 -80.53 -57.63 1q6l_c05 source 1q6l 3-KETO-L-GULONATE 6-PHOSPHATE DECARBOXYLASE : 13 hits 1q6l_c05 naa= 3 ULMN 3 1qgn_c16 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 A 110 ARG D 53 ARG.? 12.25 O4 CIT D 103 C 163 TYR C 54 TYR.? 11.88 O3 CIT C 104 C 236 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 39.01 29.77 22.02 37.48 31.30 19.84 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo 39.51 34.34 13.63 37.63 32.61 14.79 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 45.78 31.11 9.51 44.25 30.06 10.53 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1qgn_c16 CYSTATHIONINE GAMMA-SYNTHASE user 2 3 # 2 A 110 ARG E 53 ARG.? 4.89 O1 EDO F 103 C 163 TYR F 54 TYR.? 5.10 C2 EDO F 103 C 236 ASP F 46 ASP.? 6.64 O2 EDO F 103 coo 39.01 29.77 22.02 37.48 31.30 19.84 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 39.51 34.34 13.63 37.63 32.61 14.79 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 45.78 31.11 9.51 44.25 30.06 10.53 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 1qgn_c16 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 2 hits 1qgn_c16 naa= 3 ULMN 3 1qgn_c17 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 B 110 ARG D 53 ARG.? 12.25 O4 CIT D 103 D 163 TYR C 54 TYR.? 11.88 O3 CIT C 104 D 236 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 23.05 -7.35 32.81 21.30 -7.38 35.33 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo 21.28 -11.43 41.42 21.14 -8.83 40.39 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 28.41 -14.31 44.14 27.98 -12.36 43.41 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1qgn_c17 CYSTATHIONINE GAMMA-SYNTHASE user 2 3 # 2 B 110 ARG E 53 ARG.? 4.89 O1 EDO F 103 D 163 TYR F 54 TYR.? 5.10 C2 EDO F 103 D 236 ASP F 46 ASP.? 6.64 O2 EDO F 103 coo 23.05 -7.35 32.81 21.30 -7.38 35.33 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 21.28 -11.43 41.42 21.14 -8.83 40.39 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 28.41 -14.31 44.14 27.98 -12.36 43.41 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 1qgn_c17 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 2 hits 1qgn_c17 naa= 3 ULMN 3 1qgn_c18 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 A 163 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 236 ASP C 46 ASP.? 10.22 O6 CIT D 103 C 110 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 55.48 26.51 40.65 55.39 23.99 39.43 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 48.87 29.19 44.63 49.10 27.34 43.63 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 52.39 23.42 32.10 54.51 23.27 34.29 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 1qgn_c18 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c18 naa= 3 ULMN 3 1qgn_c19 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 B 163 TYR C 54 TYR.? 11.88 O3 CIT C 104 B 236 ASP C 46 ASP.? 10.22 O6 CIT D 103 D 110 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 32.99 -16.32 11.66 35.01 -14.70 12.72 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 26.18 -12.82 8.91 27.87 -11.87 9.77 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 34.79 -12.60 20.34 35.97 -13.92 17.84 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1qgn_c19 CYSTATHIONINE GAMMA-SYNTHASE user 2 3 # 2 B 163 TYR F 54 TYR.? 5.10 C2 EDO F 103 B 236 ASP F 46 ASP.? 6.64 O2 EDO F 103 D 110 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 32.99 -16.32 11.66 35.01 -14.70 12.72 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 26.18 -12.82 8.91 27.87 -11.87 9.77 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 34.79 -12.60 20.34 35.97 -13.92 17.84 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 1qgn_c19 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 2 hits 1qgn_c19 naa= 3 ULMN 3 1qgn_c20 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 E 110 ARG D 53 ARG.? 12.25 O4 CIT D 103 G 163 TYR C 54 TYR.? 11.88 O3 CIT C 104 G 236 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 60.40 -9.85 -55.76 62.00 -8.48 -58.01 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo 64.84 -10.79 -64.16 63.27 -8.78 -63.00 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 61.22 -16.97 -68.13 60.30 -15.38 -67.08 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1qgn_c20 CYSTATHIONINE GAMMA-SYNTHASE user 2 3 # 2 E 110 ARG E 53 ARG.? 4.89 O1 EDO F 103 G 163 TYR F 54 TYR.? 5.10 C2 EDO F 103 G 236 ASP F 46 ASP.? 6.64 O2 EDO F 103 coo 60.40 -9.85 -55.76 62.00 -8.48 -58.01 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 64.84 -10.79 -64.16 63.27 -8.78 -63.00 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 61.22 -16.97 -68.13 60.30 -15.38 -67.08 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 1qgn_c20 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 2 hits 1qgn_c20 naa= 3 ULMN 3 1qgn_c21 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 F 110 ARG D 53 ARG.? 12.25 O4 CIT D 103 H 163 TYR C 54 TYR.? 11.88 O3 CIT C 104 H 236 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 24.62 8.71 -44.89 24.77 10.53 -42.42 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 coo 20.90 10.83 -36.23 23.51 10.75 -37.23 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 17.57 3.99 -33.38 19.51 4.24 -34.16 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 1qgn_c21 CYSTATHIONINE GAMMA-SYNTHASE user 2 3 # 2 F 110 ARG E 53 ARG.? 4.89 O1 EDO F 103 H 163 TYR F 54 TYR.? 5.10 C2 EDO F 103 H 236 ASP F 46 ASP.? 6.64 O2 EDO F 103 coo 24.62 8.71 -44.89 24.77 10.53 -42.42 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 20.90 10.83 -36.23 23.51 10.75 -37.23 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 17.57 3.99 -33.38 19.51 4.24 -34.16 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 1qgn_c21 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 2 hits 1qgn_c21 naa= 3 ULMN 3 1qgn_c22 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 E 163 TYR C 54 TYR.? 11.88 O3 CIT C 104 E 236 ASP C 46 ASP.? 10.22 O6 CIT D 103 G 110 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 56.39 -25.68 -36.91 53.88 -25.46 -38.13 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 59.54 -19.27 -32.99 57.70 -19.44 -33.97 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 53.35 -22.70 -45.35 52.95 -24.81 -43.16 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 1qgn_c22 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c22 naa= 3 ULMN 3 1qgn_c23 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 F 163 TYR C 54 TYR.? 11.88 O3 CIT C 104 F 236 ASP C 46 ASP.? 10.22 O6 CIT D 103 H 110 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 14.88 -1.19 -65.80 16.37 -3.30 -64.72 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 18.75 5.49 -68.65 19.58 3.75 -67.80 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 18.56 -3.01 -57.11 17.14 -4.14 -59.58 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1qgn_c23 CYSTATHIONINE GAMMA-SYNTHASE user 2 3 # 2 F 163 TYR F 54 TYR.? 5.10 C2 EDO F 103 F 236 ASP F 46 ASP.? 6.64 O2 EDO F 103 H 110 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 14.88 -1.19 -65.80 16.37 -3.30 -64.72 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 18.75 5.49 -68.65 19.58 3.75 -67.80 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 18.56 -3.01 -57.11 17.14 -4.14 -59.58 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 1qgn_c23 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 2 hits 1qgn_c23 naa= 3 ULMN 3 1qho_c04 ALPHA-AMYLASE user 1 3 # 1 A 228 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 256 GLU A 101 GLU^? 18.10 O2 EDO A 103 A 329 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 30.54 71.65 32.58 31.73 72.26 30.92 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 37.87 70.12 31.80 36.61 69.74 30.15 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1qho_c04 ALPHA-AMYLASE user 2 3 # 2 A 228 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 256 GLU B 101 GLU^? 17.79 O2 CIT B 103 A 329 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 30.54 71.65 32.58 31.73 72.26 30.92 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 37.87 70.12 31.80 36.61 69.74 30.15 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1qho_c04 ALPHA-AMYLASE user 3 3 # 3 A 228 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 256 GLU C 101 GLU^? 17.42 O2 CIT C 104 A 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 28.46 69.88 26.74 30.40 70.70 26.53 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 30.54 71.65 32.58 31.73 72.26 30.92 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 37.87 70.12 31.80 36.61 69.74 30.15 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1qho_c04 ALPHA-AMYLASE user 4 3 # 4 A 228 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 256 GLU D 101 GLU^? 17.58 O6 CIT D 103 A 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 30.54 71.65 32.58 31.73 72.26 30.92 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 37.87 70.12 31.80 36.61 69.74 30.15 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1qho_c04 ALPHA-AMYLASE user 5 3 # 5 A 228 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 256 GLU E 101 GLU^? 17.69 O2 CIT E 104 A 329 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 28.46 69.88 26.74 30.40 70.70 26.53 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 30.54 71.65 32.58 31.73 72.26 30.92 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 37.87 70.12 31.80 36.61 69.74 30.15 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1qho_c04 ALPHA-AMYLASE user 6 3 # 6 A 228 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 256 GLU F 101 GLU^? 10.35 O2 EDO E 103 A 329 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 30.54 71.65 32.58 31.73 72.26 30.92 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 37.87 70.12 31.80 36.61 69.74 30.15 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1qho_c04 source 1qho ALPHA-AMYLASE : 6 hits 1qho_c04 naa= 3 ULMN 3 1qho_c05 ALPHA-AMYLASE user 1 3 # 1 A 228 ASP C 93 ASP~? 9.74 O3 CIT C 104 A 261 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 329 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 28.46 69.88 26.74 30.40 70.70 26.53 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 34.02 79.89 42.60 34.73 78.01 41.86 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 37.87 70.12 31.80 36.61 69.74 30.15 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1qho_c05 ALPHA-AMYLASE user 2 3 # 2 A 228 ASP E 93 ASP~? 8.62 O3 CIT E 104 A 261 ASP C 27 ASP~? 13.15 O1 CIT C 104 A 329 ASP C 17 ASP~? -3.95 O1 EDO C 103s coo 28.46 69.88 26.74 30.40 70.70 26.53 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 34.02 79.89 42.60 34.73 78.01 41.86 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 37.87 70.12 31.80 36.61 69.74 30.15 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 ULMN 3 1qho_c05 ALPHA-AMYLASE user 3 3 # 3 A 228 ASP F 69 ASP~? 11.68 O6 CIT F 104 A 261 ASP A 17 ASP~? 17.77 C2 EDO E 103 A 329 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 34.02 79.89 42.60 34.73 78.01 41.86 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 37.87 70.12 31.80 36.61 69.74 30.15 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1qho_c05 ALPHA-AMYLASE user 4 3 # 4 A 228 ASP F 69 ASP~? 11.68 O6 CIT F 104 A 261 ASP A 17 ASP~? 17.77 C2 EDO E 103 A 329 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 28.46 69.88 26.74 30.40 70.70 26.53 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 34.02 79.89 42.60 34.73 78.01 41.86 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 37.87 70.12 31.80 36.61 69.74 30.15 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1qho_c05 source 1qho ALPHA-AMYLASE : 4 hits 1qho_c05 naa= 3 ULMN 3 1qho_c07 ALPHA-AMYLASE user 1 3 # 1 A 228 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 260 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 329 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 30.73 81.29 37.61 31.23 82.07 35.69 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 37.87 70.12 31.80 36.61 69.74 30.15 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1qho_c07 ALPHA-AMYLASE user 2 3 # 2 A 228 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 260 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 329 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 30.73 81.29 37.61 31.23 82.07 35.69 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 37.87 70.12 31.80 36.61 69.74 30.15 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1qho_c07 ALPHA-AMYLASE user 3 3 # 3 A 228 ASP B 64 ASP~? 16.93 O2 CIT B 103 A 260 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 329 ASP B 69 ASP~? 11.84 O5 CIT B 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 30.73 81.29 37.61 31.23 82.07 35.69 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 37.87 70.12 31.80 36.61 69.74 30.15 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 ULMN 3 1qho_c07 ALPHA-AMYLASE user 4 3 # 4 A 228 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 260 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 329 ASP C 69 ASP~? 11.49 O6 CIT C 104 coo 28.46 69.88 26.74 30.40 70.70 26.53 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 30.73 81.29 37.61 31.23 82.07 35.69 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 37.87 70.12 31.80 36.61 69.74 30.15 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 ULMN 3 1qho_c07 ALPHA-AMYLASE user 5 3 # 5 A 228 ASP C 69 ASP~? 11.49 O6 CIT C 104 A 260 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 28.46 69.88 26.74 30.40 70.70 26.53 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 30.73 81.29 37.61 31.23 82.07 35.69 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 37.87 70.12 31.80 36.61 69.74 30.15 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1qho_c07 ALPHA-AMYLASE user 6 3 # 6 A 228 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 260 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 329 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 30.73 81.29 37.61 31.23 82.07 35.69 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 37.87 70.12 31.80 36.61 69.74 30.15 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1qho_c07 ALPHA-AMYLASE user 7 3 # 7 A 228 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 260 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 30.73 81.29 37.61 31.23 82.07 35.69 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 37.87 70.12 31.80 36.61 69.74 30.15 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1qho_c07 ALPHA-AMYLASE user 8 3 # 8 A 228 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 260 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 329 ASP E 69 ASP~? 11.60 O6 CIT E 104 coo 28.46 69.88 26.74 30.40 70.70 26.53 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 30.73 81.29 37.61 31.23 82.07 35.69 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 37.87 70.12 31.80 36.61 69.74 30.15 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 ULMN 3 1qho_c07 ALPHA-AMYLASE user 9 3 # 9 A 228 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 260 ASP A 17 ASP~? 17.77 C2 EDO E 103 A 329 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 28.46 69.88 26.74 30.40 70.70 26.53 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 30.73 81.29 37.61 31.23 82.07 35.69 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 37.87 70.12 31.80 36.61 69.74 30.15 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1qho_c07 ALPHA-AMYLASE user 10 3 # 10 A 228 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 260 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 329 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 28.46 69.88 26.74 30.40 70.70 26.53 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 30.73 81.29 37.61 31.23 82.07 35.69 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 37.87 70.12 31.80 36.61 69.74 30.15 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 ULMN 3 1qho_c07 ALPHA-AMYLASE user 11 3 # 11 A 228 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 260 ASP A 17 ASP~? 17.77 C2 EDO E 103 A 329 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 28.46 69.88 26.74 30.40 70.70 26.53 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 30.73 81.29 37.61 31.23 82.07 35.69 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo 37.87 70.12 31.80 36.61 69.74 30.15 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1qho_c07 source 1qho ALPHA-AMYLASE : 11 hits 1qho_c07 naa= 3 ULMN 3 1qrz_c20 PLASMINOGEN user 1 3 # 1 A 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1qrz_c20 PLASMINOGEN user 2 3 # 2 A 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1qrz_c20 PLASMINOGEN user 3 3 # 3 A 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 739 GLY A 0 GLY.? 18.58 O2 EDO A 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 ULMN 3 1qrz_c20 PLASMINOGEN user 4 3 # 4 A 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1qrz_c20 PLASMINOGEN user 5 3 # 5 A 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 739 GLY A 94 GLY.? 10.50 C1 EDO A 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 ULMN 3 1qrz_c20 PLASMINOGEN user 6 3 # 6 A 603 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1qrz_c20 PLASMINOGEN user 7 3 # 7 A 603 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1qrz_c20 PLASMINOGEN user 8 3 # 8 A 603 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 739 GLY E 28 GLY~? 10.11 C1 EDO E 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -33.85 -86.59 -36.02 -34.04 -86.37 -36.75 ULMN 3 1qrz_c20 PLASMINOGEN user 9 3 # 9 A 603 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 739 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1qrz_c20 PLASMINOGEN user 10 3 # 10 A 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 646 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 739 GLY B 0 GLY.? 18.42 O2 CIT B 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -11.68 -66.89 -21.61 -12.41 -67.26 -21.40 ULMN 3 1qrz_c20 PLASMINOGEN user 11 3 # 11 A 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 646 ASP B 69 ASP~? 11.84 O5 CIT B 103 A 739 GLY B 82 GLY~? 6.34 C4 CIT B 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 0.09 -82.40 -2.15 -0.72 -82.64 -2.19 ULMN 3 1qrz_c20 PLASMINOGEN user 12 3 # 12 A 603 HIS B 41 HIS^? 11.37 O1 CIT B 103 A 646 ASP B 27 ASP~? 12.32 O1 CIT B 103 A 739 GLY A 0 GLY.? 18.58 O2 EDO A 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 ULMN 3 1qrz_c20 PLASMINOGEN user 13 3 # 13 A 603 HIS B 74 HIS~? 11.72 O1 CIT B 103 A 646 ASP B 69 ASP~? 11.84 O5 CIT B 103 A 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1qrz_c20 PLASMINOGEN user 14 3 # 14 A 603 HIS B 74 HIS~? 11.72 O1 CIT B 103 A 646 ASP B 69 ASP~? 11.84 O5 CIT B 103 A 739 GLY B 82 GLY~? 6.34 C4 CIT B 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 0.09 -82.40 -2.15 -0.72 -82.64 -2.19 ULMN 3 1qrz_c20 PLASMINOGEN user 15 3 # 15 A 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 646 ASP C 69 ASP~? 11.49 O6 CIT C 104 A 739 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1qrz_c20 PLASMINOGEN user 16 3 # 16 A 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 646 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 739 GLY C 0 GLY.? 18.38 O2 CIT C 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -58.43 -72.91 -14.46 -58.32 -72.08 -14.62 ULMN 3 1qrz_c20 PLASMINOGEN user 17 3 # 17 A 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 646 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 739 GLY C 94 GLY.? 8.41 O3 CIT C 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 ULMN 3 1qrz_c20 PLASMINOGEN user 18 3 # 18 A 603 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 646 ASP C 69 ASP~? 11.49 O6 CIT C 104 A 739 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1qrz_c20 PLASMINOGEN user 19 3 # 19 A 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 739 GLY D 0 GLY.? 18.60 O6 CIT D 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -52.56 -47.08 -27.07 -52.40 -46.76 -26.33 ULMN 3 1qrz_c20 PLASMINOGEN user 20 3 # 20 A 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1qrz_c20 PLASMINOGEN user 21 3 # 21 A 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 739 GLY D 94 GLY.? 7.85 O4 CIT D 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 ULMN 3 1qrz_c20 PLASMINOGEN user 22 3 # 22 A 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 646 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1qrz_c20 PLASMINOGEN user 23 3 # 23 A 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 646 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 739 GLY D 82 GLY~? 6.55 O7 CIT D 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -45.10 -51.83 -0.42 -45.58 -52.48 -0.67 ULMN 3 1qrz_c20 PLASMINOGEN user 24 3 # 24 A 603 HIS D 74 HIS~? 11.86 O1 CIT D 103 A 646 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1qrz_c20 PLASMINOGEN user 25 3 # 25 A 603 HIS D 74 HIS~? 11.86 O1 CIT D 103 A 646 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 739 GLY D 82 GLY~? 6.55 O7 CIT D 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -45.10 -51.83 -0.42 -45.58 -52.48 -0.67 ULMN 3 1qrz_c20 PLASMINOGEN user 26 3 # 26 A 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 646 ASP E 69 ASP~? 11.60 O6 CIT E 104 A 739 GLY E 0 GLY.? 18.62 O2 CIT E 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 ULMN 3 1qrz_c20 PLASMINOGEN user 27 3 # 27 A 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 646 ASP E 69 ASP~? 11.60 O6 CIT E 104 A 739 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1qrz_c20 PLASMINOGEN user 28 3 # 28 A 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 646 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 739 GLY E 0 GLY.? 18.62 O2 CIT E 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 ULMN 3 1qrz_c20 PLASMINOGEN user 29 3 # 29 A 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 646 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 739 GLY E 94 GLY.? 7.76 O3 CIT E 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 ULMN 3 1qrz_c20 PLASMINOGEN user 30 3 # 30 A 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 739 GLY F 0 GLY.? 9.67 O2 EDO E 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 ULMN 3 1qrz_c20 PLASMINOGEN user 31 3 # 31 A 603 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 646 ASP E 69 ASP~? 11.60 O6 CIT E 104 A 739 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1qrz_c20 PLASMINOGEN user 32 3 # 32 A 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 646 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 739 GLY F 0 GLY.? 9.67 O2 EDO E 103 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 ULMN 3 1qrz_c20 PLASMINOGEN user 33 3 # 33 A 603 HIS F 74 HIS~? 11.52 O1 CIT F 104 A 646 ASP F 69 ASP~? 11.68 O6 CIT F 104 A 739 GLY F 82 GLY~? 6.43 O5 CIT F 104 coo -20.72 2.99 34.37 -21.94 1.82 35.61 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo -18.83 7.68 26.86 -20.89 7.78 26.56 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo -13.44 -7.35 30.08 -14.24 -7.41 30.34 -18.39 -75.04 -72.92 -19.02 -75.49 -72.70 1qrz_c20 source 1qrz PLASMINOGEN : 33 hits 1qrz_c20 naa= 3 ULMN 3 1qrz_c21 PLASMINOGEN user 1 3 # 1 B 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 739 GLY A 0 GLY.? 18.58 O2 EDO A 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 ULMN 3 1qrz_c21 PLASMINOGEN user 2 3 # 2 B 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 739 GLY A 94 GLY.? 10.50 C1 EDO A 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 ULMN 3 1qrz_c21 PLASMINOGEN user 3 3 # 3 B 603 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 B 739 GLY E 28 GLY~? 10.11 C1 EDO E 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -33.85 -86.59 -36.02 -34.04 -86.37 -36.75 ULMN 3 1qrz_c21 PLASMINOGEN user 4 3 # 4 B 603 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 739 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1qrz_c21 PLASMINOGEN user 5 3 # 5 B 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 646 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 739 GLY B 0 GLY.? 18.42 O2 CIT B 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -11.68 -66.89 -21.61 -12.41 -67.26 -21.40 ULMN 3 1qrz_c21 PLASMINOGEN user 6 3 # 6 B 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 646 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 739 GLY B 94 GLY.? 8.02 O3 CIT B 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 ULMN 3 1qrz_c21 PLASMINOGEN user 7 3 # 7 B 603 HIS B 41 HIS^? 11.37 O1 CIT B 103 B 646 ASP B 27 ASP~? 12.32 O1 CIT B 103 B 739 GLY A 0 GLY.? 18.58 O2 EDO A 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 ULMN 3 1qrz_c21 PLASMINOGEN user 8 3 # 8 B 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 646 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 739 GLY C 0 GLY.? 18.38 O2 CIT C 104 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -58.43 -72.91 -14.46 -58.32 -72.08 -14.62 ULMN 3 1qrz_c21 PLASMINOGEN user 9 3 # 9 B 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 646 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 739 GLY C 94 GLY.? 8.41 O3 CIT C 104 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 ULMN 3 1qrz_c21 PLASMINOGEN user 10 3 # 10 B 603 HIS C 41 HIS^? 12.16 O1 CIT C 104 B 646 ASP C 27 ASP~? 13.15 O1 CIT C 104 B 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1qrz_c21 PLASMINOGEN user 11 3 # 11 B 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 739 GLY D 0 GLY.? 18.60 O6 CIT D 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -52.56 -47.08 -27.07 -52.40 -46.76 -26.33 ULMN 3 1qrz_c21 PLASMINOGEN user 12 3 # 12 B 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 739 GLY D 94 GLY.? 7.85 O4 CIT D 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 ULMN 3 1qrz_c21 PLASMINOGEN user 13 3 # 13 B 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 646 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 739 GLY E 0 GLY.? 18.62 O2 CIT E 104 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 ULMN 3 1qrz_c21 PLASMINOGEN user 14 3 # 14 B 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 646 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 739 GLY E 94 GLY.? 7.76 O3 CIT E 104 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 ULMN 3 1qrz_c21 PLASMINOGEN user 15 3 # 15 B 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 739 GLY F 0 GLY.? 9.67 O2 EDO E 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 ULMN 3 1qrz_c21 PLASMINOGEN user 16 3 # 16 B 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 646 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 739 GLY F 0 GLY.? 9.67 O2 EDO E 103 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 ULMN 3 1qrz_c21 PLASMINOGEN user 17 3 # 17 B 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 646 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 739 GLY F 94 GLY.? 8.80 O3 CIT F 104 coo -48.36 3.10 -3.91 -49.78 2.04 -2.80 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -46.10 7.71 -10.96 -48.16 8.01 -11.35 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -41.48 -7.57 -8.71 -42.26 -7.67 -8.41 -26.33 -67.76 -65.92 -25.64 -68.13 -65.72 1qrz_c21 source 1qrz PLASMINOGEN : 17 hits 1qrz_c21 naa= 3 ULMN 3 1qrz_c22 PLASMINOGEN user 1 3 # 1 C 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 C 739 GLY A 0 GLY.? 18.58 O2 EDO A 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 7.82 1.25 3.03 7.30 1.31 3.65 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 ULMN 3 1qrz_c22 PLASMINOGEN user 2 3 # 2 C 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 C 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 7.82 1.25 3.03 7.30 1.31 3.65 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1qrz_c22 PLASMINOGEN user 3 3 # 3 C 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 C 739 GLY A 94 GLY.? 10.50 C1 EDO A 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 7.82 1.25 3.03 7.30 1.31 3.65 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 ULMN 3 1qrz_c22 PLASMINOGEN user 4 3 # 4 C 603 HIS A 77 HIS~? -4.41 C2 EDO A 103s C 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 C 739 GLY E 28 GLY~? 10.11 C1 EDO E 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 7.82 1.25 3.03 7.30 1.31 3.65 -33.85 -86.59 -36.02 -34.04 -86.37 -36.75 ULMN 3 1qrz_c22 PLASMINOGEN user 5 3 # 5 C 603 HIS A 77 HIS~? -4.41 C2 EDO A 103s C 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 739 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 7.82 1.25 3.03 7.30 1.31 3.65 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1qrz_c22 PLASMINOGEN user 6 3 # 6 C 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s C 646 ASP A 46 ASP.? 9.57 O6 CIT B 103 C 739 GLY B 0 GLY.? 18.42 O2 CIT B 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 7.82 1.25 3.03 7.30 1.31 3.65 -11.68 -66.89 -21.61 -12.41 -67.26 -21.40 ULMN 3 1qrz_c22 PLASMINOGEN user 7 3 # 7 C 603 HIS B 41 HIS^? 11.37 O1 CIT B 103 C 646 ASP B 27 ASP~? 12.32 O1 CIT B 103 C 739 GLY A 0 GLY.? 18.58 O2 EDO A 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 7.82 1.25 3.03 7.30 1.31 3.65 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 ULMN 3 1qrz_c22 PLASMINOGEN user 8 3 # 8 C 603 HIS B 74 HIS~? 11.72 O1 CIT B 103 C 646 ASP B 69 ASP~? 11.84 O5 CIT B 103 C 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 7.82 1.25 3.03 7.30 1.31 3.65 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1qrz_c22 PLASMINOGEN user 9 3 # 9 C 603 HIS B 74 HIS~? 11.72 O1 CIT B 103 C 646 ASP B 69 ASP~? 11.84 O5 CIT B 103 C 739 GLY B 82 GLY~? 6.34 C4 CIT B 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 7.82 1.25 3.03 7.30 1.31 3.65 0.09 -82.40 -2.15 -0.72 -82.64 -2.19 ULMN 3 1qrz_c22 PLASMINOGEN user 10 3 # 10 C 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s C 646 ASP D 46 ASP.? 10.10 O7 CIT C 104 C 739 GLY C 0 GLY.? 18.38 O2 CIT C 104 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 7.82 1.25 3.03 7.30 1.31 3.65 -58.43 -72.91 -14.46 -58.32 -72.08 -14.62 ULMN 3 1qrz_c22 PLASMINOGEN user 11 3 # 11 C 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s C 646 ASP D 46 ASP.? 10.10 O7 CIT C 104 C 739 GLY C 94 GLY.? 8.41 O3 CIT C 104 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 7.82 1.25 3.03 7.30 1.31 3.65 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 ULMN 3 1qrz_c22 PLASMINOGEN user 12 3 # 12 C 603 HIS C 41 HIS^? 12.16 O1 CIT C 104 C 646 ASP C 27 ASP~? 13.15 O1 CIT C 104 C 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 7.82 1.25 3.03 7.30 1.31 3.65 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1qrz_c22 PLASMINOGEN user 13 3 # 13 C 603 HIS C 74 HIS~? 12.10 O1 CIT C 104 C 646 ASP C 69 ASP~? 11.49 O6 CIT C 104 C 739 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 7.82 1.25 3.03 7.30 1.31 3.65 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1qrz_c22 PLASMINOGEN user 14 3 # 14 C 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 C 739 GLY D 0 GLY.? 18.60 O6 CIT D 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 7.82 1.25 3.03 7.30 1.31 3.65 -52.56 -47.08 -27.07 -52.40 -46.76 -26.33 ULMN 3 1qrz_c22 PLASMINOGEN user 15 3 # 15 C 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 C 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 7.82 1.25 3.03 7.30 1.31 3.65 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1qrz_c22 PLASMINOGEN user 16 3 # 16 C 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 C 739 GLY D 94 GLY.? 7.85 O4 CIT D 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 7.82 1.25 3.03 7.30 1.31 3.65 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 ULMN 3 1qrz_c22 PLASMINOGEN user 17 3 # 17 C 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 646 ASP F 46 ASP.? 6.64 O2 EDO F 103 C 739 GLY E 0 GLY.? 18.62 O2 CIT E 104 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 7.82 1.25 3.03 7.30 1.31 3.65 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 ULMN 3 1qrz_c22 PLASMINOGEN user 18 3 # 18 C 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 646 ASP F 46 ASP.? 6.64 O2 EDO F 103 C 739 GLY E 94 GLY.? 7.76 O3 CIT E 104 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 7.82 1.25 3.03 7.30 1.31 3.65 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 ULMN 3 1qrz_c22 PLASMINOGEN user 19 3 # 19 C 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 739 GLY F 0 GLY.? 9.67 O2 EDO E 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 7.82 1.25 3.03 7.30 1.31 3.65 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 ULMN 3 1qrz_c22 PLASMINOGEN user 20 3 # 20 C 603 HIS E 74 HIS~? 12.16 O1 CIT E 104 C 646 ASP E 69 ASP~? 11.60 O6 CIT E 104 C 739 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 7.82 1.25 3.03 7.30 1.31 3.65 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1qrz_c22 PLASMINOGEN user 21 3 # 21 C 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s C 646 ASP E 46 ASP.? 9.98 C4 CIT F 104 C 739 GLY F 0 GLY.? 9.67 O2 EDO E 103 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 7.82 1.25 3.03 7.30 1.31 3.65 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 ULMN 3 1qrz_c22 PLASMINOGEN user 22 3 # 22 C 603 HIS F 74 HIS~? 11.52 O1 CIT F 104 C 646 ASP F 69 ASP~? 11.68 O6 CIT F 104 C 739 GLY F 82 GLY~? 6.43 O5 CIT F 104 coo 1.49 -9.23 8.48 -0.19 -8.40 9.43 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 9.05 -13.82 8.74 8.78 -14.02 10.85 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 7.82 1.25 3.03 7.30 1.31 3.65 -18.39 -75.04 -72.92 -19.02 -75.49 -72.70 1qrz_c22 source 1qrz PLASMINOGEN : 22 hits 1qrz_c22 naa= 3 ULMN 3 1qrz_c23 PLASMINOGEN user 1 3 # 1 D 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 D 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1qrz_c23 PLASMINOGEN user 2 3 # 2 D 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 D 739 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1qrz_c23 PLASMINOGEN user 3 3 # 3 D 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 D 739 GLY A 0 GLY.? 18.58 O2 EDO A 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 ULMN 3 1qrz_c23 PLASMINOGEN user 4 3 # 4 D 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 D 739 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1qrz_c23 PLASMINOGEN user 5 3 # 5 D 603 HIS A 4 HIS.? -4.40 O2 EDO A 103s D 646 ASP B 46 ASP.? 11.17 O1 EDO A 103 D 739 GLY A 94 GLY.? 10.50 C1 EDO A 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 ULMN 3 1qrz_c23 PLASMINOGEN user 6 3 # 6 D 603 HIS A 77 HIS~? -4.41 C2 EDO A 103s D 646 ASP A 69 ASP~? 12.13 O2 EDO A 103 D 739 GLY E 28 GLY~? 10.11 C1 EDO E 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -33.85 -86.59 -36.02 -34.04 -86.37 -36.75 ULMN 3 1qrz_c23 PLASMINOGEN user 7 3 # 7 D 603 HIS A 77 HIS~? -4.41 C2 EDO A 103s D 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 D 739 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1qrz_c23 PLASMINOGEN user 8 3 # 8 D 603 HIS B 4 HIS.? -4.11 O2 CIT B 103s D 646 ASP A 46 ASP.? 9.57 O6 CIT B 103 D 739 GLY B 0 GLY.? 18.42 O2 CIT B 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -11.68 -66.89 -21.61 -12.41 -67.26 -21.40 ULMN 3 1qrz_c23 PLASMINOGEN user 9 3 # 9 D 603 HIS B 41 HIS^? 11.37 O1 CIT B 103 D 646 ASP B 27 ASP~? 12.32 O1 CIT B 103 D 739 GLY A 0 GLY.? 18.58 O2 EDO A 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -27.24 -88.88 -10.52 -27.68 -88.84 -11.22 ULMN 3 1qrz_c23 PLASMINOGEN user 10 3 # 10 D 603 HIS B 74 HIS~? 11.72 O1 CIT B 103 D 646 ASP B 69 ASP~? 11.84 O5 CIT B 103 D 739 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1qrz_c23 PLASMINOGEN user 11 3 # 11 D 603 HIS B 74 HIS~? 11.72 O1 CIT B 103 D 646 ASP B 69 ASP~? 11.84 O5 CIT B 103 D 739 GLY B 82 GLY~? 6.34 C4 CIT B 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo -45.82 1.31 41.67 -46.38 1.39 42.31 0.09 -82.40 -2.15 -0.72 -82.64 -2.19 ULMN 3 1qrz_c23 PLASMINOGEN user 12 3 # 12 D 603 HIS C 4 HIS.? -4.06 O2 CIT C 104s D 646 ASP D 46 ASP.? 10.10 O7 CIT C 104 D 739 GLY C 0 GLY.? 18.38 O2 CIT C 104 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -58.43 -72.91 -14.46 -58.32 -72.08 -14.62 ULMN 3 1qrz_c23 PLASMINOGEN user 13 3 # 13 D 603 HIS C 41 HIS^? 12.16 O1 CIT C 104 D 646 ASP C 27 ASP~? 13.15 O1 CIT C 104 D 739 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1qrz_c23 PLASMINOGEN user 14 3 # 14 D 603 HIS C 74 HIS~? 12.10 O1 CIT C 104 D 646 ASP C 69 ASP~? 11.49 O6 CIT C 104 D 739 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1qrz_c23 PLASMINOGEN user 15 3 # 15 D 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s D 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 D 739 GLY D 0 GLY.? 18.60 O6 CIT D 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -52.56 -47.08 -27.07 -52.40 -46.76 -26.33 ULMN 3 1qrz_c23 PLASMINOGEN user 16 3 # 16 D 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s D 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 D 739 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1qrz_c23 PLASMINOGEN user 17 3 # 17 D 603 HIS D 4 HIS.? -4.16 O2 CIT D 103s D 646 ASP C 46 ASP.? 10.22 O6 CIT D 103 D 739 GLY D 94 GLY.? 7.85 O4 CIT D 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 ULMN 3 1qrz_c23 PLASMINOGEN user 18 3 # 18 D 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 646 ASP E 69 ASP~? 11.60 O6 CIT E 104 D 739 GLY E 0 GLY.? 18.62 O2 CIT E 104 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 ULMN 3 1qrz_c23 PLASMINOGEN user 19 3 # 19 D 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 646 ASP E 69 ASP~? 11.60 O6 CIT E 104 D 739 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1qrz_c23 PLASMINOGEN user 20 3 # 20 D 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 646 ASP E 69 ASP~? 11.60 O6 CIT E 104 D 739 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1qrz_c23 PLASMINOGEN user 21 3 # 21 D 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 646 ASP F 46 ASP.? 6.64 O2 EDO F 103 D 739 GLY E 0 GLY.? 18.62 O2 CIT E 104 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 ULMN 3 1qrz_c23 PLASMINOGEN user 22 3 # 22 D 603 HIS E 4 HIS.? -4.01 O2 CIT E 104s D 646 ASP F 46 ASP.? 6.64 O2 EDO F 103 D 739 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1qrz_c23 PLASMINOGEN user 23 3 # 23 D 603 HIS E 41 HIS^? -3.94 C2 EDO E 103s D 646 ASP E 27 ASP~? 4.58 C1 EDO E 103 D 739 GLY F 0 GLY.? 9.67 O2 EDO E 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 ULMN 3 1qrz_c23 PLASMINOGEN user 24 3 # 24 D 603 HIS E 74 HIS~? 12.16 O1 CIT E 104 D 646 ASP E 69 ASP~? 11.60 O6 CIT E 104 D 739 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1qrz_c23 PLASMINOGEN user 25 3 # 25 D 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s D 646 ASP E 46 ASP.? 9.98 C4 CIT F 104 D 739 GLY F 0 GLY.? 9.67 O2 EDO E 103 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 ULMN 3 1qrz_c23 PLASMINOGEN user 26 3 # 26 D 603 HIS F 4 HIS.? -4.07 O2 CIT F 104s D 646 ASP E 46 ASP.? 9.98 C4 CIT F 104 D 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 ULMN 3 1qrz_c23 PLASMINOGEN user 27 3 # 27 D 603 HIS F 74 HIS~? 11.52 O1 CIT F 104 D 646 ASP F 69 ASP~? 11.68 O6 CIT F 104 D 739 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 ULMN 3 1qrz_c23 PLASMINOGEN user 28 3 # 28 D 603 HIS F 74 HIS~? 11.52 O1 CIT F 104 D 646 ASP F 69 ASP~? 11.68 O6 CIT F 104 D 739 GLY F 82 GLY~? 6.43 O5 CIT F 104 coo -52.57 -8.94 46.70 -54.06 -7.64 47.39 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo -45.30 -14.04 46.94 -45.65 -14.15 49.00 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo -45.82 1.31 41.67 -46.38 1.39 42.31 -18.39 -75.04 -72.92 -19.02 -75.49 -72.70 1qrz_c23 source 1qrz PLASMINOGEN : 28 hits 1qrz_c23 naa= 3 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 1 3 # 1 A 12 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 41 LYS A 65 LYS~? 12.23 O2 EDO A 103 A 119 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 2 3 # 2 A 12 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 41 LYS B 50 LYS.? 6.61 O1 EDO A 103 A 119 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 3 3 # 3 A 12 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 41 LYS A 50 LYS.? -4.54 O3 CIT B 103s A 119 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 4 3 # 4 A 12 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 41 LYS B 65 LYS~? 11.82 O5 CIT B 103 A 119 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 5 3 # 5 A 12 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 41 LYS C 65 LYS~? 12.16 O6 CIT C 104 A 119 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 6 3 # 6 A 12 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 41 LYS D 50 LYS.? -4.40 O3 CIT C 104s A 119 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 7 3 # 7 A 12 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 41 LYS C 50 LYS.? -4.07 O4 CIT D 103s A 119 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 8 3 # 8 A 12 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 41 LYS D 65 LYS~? 11.29 O6 CIT D 103 A 119 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 9 3 # 9 A 12 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 41 LYS E 65 LYS~? 11.89 O6 CIT E 104 A 119 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 10 3 # 10 A 12 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 41 LYS F 50 LYS.? -3.77 O3 CIT E 104s A 119 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 11 3 # 11 A 12 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 41 LYS E 50 LYS.? -4.05 O4 CIT F 104s A 119 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 1rbn_c01 RIBONUCLEASE A (E.C.3.1.27.5) DERIVAuser 12 3 # 12 A 12 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 41 LYS F 65 LYS~? 10.97 O7 CIT F 104 A 119 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 27.25 41.76 -6.97 28.67 40.32 -7.25 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 35.53 36.24 -0.58 31.10 37.46 -4.56 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 26.49 34.97 -12.73 26.25 33.07 -12.07 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 1rbn_c01 source 1rbn RIBONUCLEASE A (E.C.3.1.27.5) DERIVATIVE II CO: 12 hits 1rbn_c01 naa= 3 ULMN 3 1rgq_c01 NS4A PEPTIDE user 1 3 # 1 B 60 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 84 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 140 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1rgq_c01 NS4A PEPTIDE user 2 3 # 2 B 60 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 84 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 140 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 1rgq_c01 NS4A PEPTIDE user 3 3 # 3 B 60 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 84 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 140 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1rgq_c01 NS4A PEPTIDE user 4 3 # 4 B 60 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 84 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 140 GLY A 35 GLY.? 14.47 O2 EDO A 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -31.28 -83.78 -20.67 -30.97 -83.33 -21.23 ULMN 3 1rgq_c01 NS4A PEPTIDE user 5 3 # 5 B 60 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 84 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 140 GLY B 35 GLY.? 14.63 O1 CIT B 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -13.56 -66.77 -9.53 -13.72 -67.35 -8.97 ULMN 3 1rgq_c01 NS4A PEPTIDE user 6 3 # 6 B 60 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 84 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 140 GLY B 57 GLY^? 9.92 O7 CIT B 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 ULMN 3 1rgq_c01 NS4A PEPTIDE user 7 3 # 7 B 60 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 84 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 140 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1rgq_c01 NS4A PEPTIDE user 8 3 # 8 B 60 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 84 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 140 GLY C 35 GLY.? 14.42 O1 CIT C 104 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -59.78 -72.68 -26.82 -59.58 -72.16 -27.37 ULMN 3 1rgq_c01 NS4A PEPTIDE user 9 3 # 9 B 60 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 84 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 140 GLY C 57 GLY^? 10.09 O1 CIT C 104 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 ULMN 3 1rgq_c01 NS4A PEPTIDE user 10 3 # 10 B 60 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 84 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 140 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1rgq_c01 NS4A PEPTIDE user 11 3 # 11 B 60 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 84 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 140 GLY D 35 GLY.? 14.30 O2 CIT D 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -59.28 -47.39 -16.68 -59.38 -47.87 -16.04 ULMN 3 1rgq_c01 NS4A PEPTIDE user 12 3 # 12 B 60 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 84 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 140 GLY D 57 GLY^? 9.79 C2 CIT D 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 ULMN 3 1rgq_c01 NS4A PEPTIDE user 13 3 # 13 B 60 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 84 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 140 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1rgq_c01 NS4A PEPTIDE user 14 3 # 14 B 60 HIS D 41 HIS^? 12.20 O1 CIT D 103 B 84 ASP D 27 ASP~? 12.70 O1 CIT D 103 B 140 GLY C 0 GLY.? 18.38 O2 CIT C 104 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -58.43 -72.91 -14.46 -58.32 -72.08 -14.62 ULMN 3 1rgq_c01 NS4A PEPTIDE user 15 3 # 15 B 60 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 84 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 140 GLY E 35 GLY.? 14.13 O2 CIT E 104 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -40.51 -91.26 -48.44 -40.06 -91.01 -47.82 ULMN 3 1rgq_c01 NS4A PEPTIDE user 16 3 # 16 B 60 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 84 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 140 GLY E 57 GLY^? 9.68 O2 EDO E 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 ULMN 3 1rgq_c01 NS4A PEPTIDE user 17 3 # 17 B 60 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 84 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 140 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1rgq_c01 NS4A PEPTIDE user 18 3 # 18 B 60 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 84 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 140 GLY F 0 GLY.? 9.67 O2 EDO E 103 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 ULMN 3 1rgq_c01 NS4A PEPTIDE user 19 3 # 19 B 60 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 84 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 140 GLY F 35 GLY.? 14.32 O2 CIT F 104 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -14.95 -90.79 -57.80 -15.39 -90.89 -58.42 ULMN 3 1rgq_c01 NS4A PEPTIDE user 20 3 # 20 B 60 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 84 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 140 GLY F 57 GLY^? 10.08 O2 CIT F 104 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 ULMN 3 1rgq_c01 NS4A PEPTIDE user 21 3 # 21 B 60 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 84 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 140 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 ULMN 3 1rgq_c01 NS4A PEPTIDE user 22 3 # 22 B 60 HIS F 41 HIS^? 12.43 O1 CIT F 104 B 84 ASP F 27 ASP~? 14.00 O1 CIT F 104 B 140 GLY E 0 GLY.? 18.62 O2 CIT E 104 coo 20.71 17.85 -18.47 19.91 19.62 -17.68 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 23.40 21.01 -22.79 22.72 19.65 -21.32 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 11.52 20.17 -13.15 11.93 20.87 -13.16 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 1rgq_c01 source 1rgq NS4A PEPTIDE : 22 hits 1rgq_c01 naa= 3 ULMN 3 1rne_c04 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 1 3 # 1 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 35 SER A 51 SER.? 9.93 O6 CIT B 103 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 11.85 17.24 72.81 11.09 15.37 72.36 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 12.20 12.71 75.45 13.69 13.84 74.03 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 5.22 15.03 71.43 7.19 14.88 70.83 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1rne_c04 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 2 3 # 2 32 ASP B 46 ASP.? 11.17 O1 EDO A 103 35 SER B 51 SER.? 11.29 O1 EDO A 103 215 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 11.85 17.24 72.81 11.09 15.37 72.36 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 12.20 12.71 75.45 13.69 13.84 74.03 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo 5.22 15.03 71.43 7.19 14.88 70.83 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1rne_c04 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 3 3 # 3 32 ASP C 46 ASP.? 10.22 O6 CIT D 103 35 SER C 51 SER.? 10.55 O6 CIT D 103 215 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 11.85 17.24 72.81 11.09 15.37 72.36 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 12.20 12.71 75.45 13.69 13.84 74.03 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 5.22 15.03 71.43 7.19 14.88 70.83 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1rne_c04 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 4 3 # 4 32 ASP D 46 ASP.? 10.10 O7 CIT C 104 35 SER D 51 SER.? 10.41 O7 CIT C 104 215 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 11.85 17.24 72.81 11.09 15.37 72.36 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 12.20 12.71 75.45 13.69 13.84 74.03 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo 5.22 15.03 71.43 7.19 14.88 70.83 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1rne_c04 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 5 3 # 5 32 ASP E 46 ASP.? 9.98 C4 CIT F 104 35 SER E 51 SER.? 10.11 C4 CIT F 104 215 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 11.85 17.24 72.81 11.09 15.37 72.36 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 12.20 12.71 75.45 13.69 13.84 74.03 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 5.22 15.03 71.43 7.19 14.88 70.83 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1rne_c04 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 6 3 # 6 32 ASP F 46 ASP.? 6.64 O2 EDO F 103 35 SER F 51 SER.? -5.94 O2 EDO F 103s 215 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 11.85 17.24 72.81 11.09 15.37 72.36 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 12.20 12.71 75.45 13.69 13.84 74.03 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo 5.22 15.03 71.43 7.19 14.88 70.83 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 1rne_c04 source 1rne RENIN (ACTIVATED, GLYCOSYLATED, INHIBITED) (E.: 6 hits 1rne_c04 naa= 3 ULMN 3 1ro7_c03 ALPHA-2,3/8-SIALYLTRANSFERASE user 1 3 # 1 D 129 ARG A 40 ARG^? 16.77 O2 EDO A 103 D 156 TYR A 56 TYR^? 12.86 C2 EDO A 103 D 188 HIS A 41 HIS^? 12.51 O2 EDO A 103 coo -19.99 -38.81 30.91 -19.99 -39.90 28.04 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo -32.96 -44.88 30.49 -32.31 -42.65 28.92 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo -25.33 -42.26 31.79 -24.77 -40.56 30.70 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 ULMN 3 1ro7_c03 ALPHA-2,3/8-SIALYLTRANSFERASE user 2 3 # 2 D 129 ARG A 79 ARG~? -3.92 C2 EDO E 103s D 156 TYR E 56 TYR^? 8.81 O2 EDO E 103 D 188 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo -19.99 -38.81 30.91 -19.99 -39.90 28.04 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo -32.96 -44.88 30.49 -32.31 -42.65 28.92 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo -25.33 -42.26 31.79 -24.77 -40.56 30.70 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1ro7_c03 ALPHA-2,3/8-SIALYLTRANSFERASE user 3 3 # 3 D 129 ARG B 40 ARG^? 17.25 O1 CIT B 103 D 156 TYR B 56 TYR^? 12.51 O1 CIT B 103 D 188 HIS B 41 HIS^? 11.37 O1 CIT B 103 coo -19.99 -38.81 30.91 -19.99 -39.90 28.04 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo -32.96 -44.88 30.49 -32.31 -42.65 28.92 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo -25.33 -42.26 31.79 -24.77 -40.56 30.70 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 ULMN 3 1ro7_c03 ALPHA-2,3/8-SIALYLTRANSFERASE user 4 3 # 4 D 129 ARG C 40 ARG^? 17.96 O1 CIT C 104 D 156 TYR C 56 TYR^? 12.84 O1 CIT C 104 D 188 HIS C 41 HIS^? 12.16 O1 CIT C 104 coo -19.99 -38.81 30.91 -19.99 -39.90 28.04 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -32.96 -44.88 30.49 -32.31 -42.65 28.92 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo -25.33 -42.26 31.79 -24.77 -40.56 30.70 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 ULMN 3 1ro7_c03 ALPHA-2,3/8-SIALYLTRANSFERASE user 5 3 # 5 D 129 ARG D 40 ARG^? 16.76 O2 CIT D 103 D 156 TYR D 56 TYR^? 12.73 C2 CIT D 103 D 188 HIS D 41 HIS^? 12.20 O1 CIT D 103 coo -19.99 -38.81 30.91 -19.99 -39.90 28.04 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo -32.96 -44.88 30.49 -32.31 -42.65 28.92 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 coo -25.33 -42.26 31.79 -24.77 -40.56 30.70 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 ULMN 3 1ro7_c03 ALPHA-2,3/8-SIALYLTRANSFERASE user 6 3 # 6 D 129 ARG E 40 ARG^? -5.36 O2 EDO E 103s D 156 TYR E 56 TYR^? 8.81 O2 EDO E 103 D 188 HIS E 41 HIS^? -3.94 C2 EDO E 103s coo -19.99 -38.81 30.91 -19.99 -39.90 28.04 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -32.96 -44.88 30.49 -32.31 -42.65 28.92 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo -25.33 -42.26 31.79 -24.77 -40.56 30.70 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 ULMN 3 1ro7_c03 ALPHA-2,3/8-SIALYLTRANSFERASE user 7 3 # 7 D 129 ARG F 40 ARG^? 16.45 O2 CIT F 104 D 156 TYR F 56 TYR^? 13.04 O1 CIT F 104 D 188 HIS F 41 HIS^? 12.43 O1 CIT F 104 coo -19.99 -38.81 30.91 -19.99 -39.90 28.04 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo -32.96 -44.88 30.49 -32.31 -42.65 28.92 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 coo -25.33 -42.26 31.79 -24.77 -40.56 30.70 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 1ro7_c03 source 1ro7 ALPHA-2,3/8-SIALYLTRANSFERASE : 7 hits 1ro7_c03 naa= 3 ULMN 3 1roz_c00 DEOXYHYPUSINE SYNTHASE user 1 3 # 1 A 137 GLU B 21 GLU~? 16.03 C2 CIT B 103 A 288 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 329 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 29.27 18.78 14.99 27.16 18.62 14.76 -9.13 -87.49 4.49 -7.49 -88.18 5.63 coo 49.52 10.06 10.36 50.99 9.65 8.92 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 57.80 12.92 13.83 53.77 8.42 12.15 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1roz_c00 DEOXYHYPUSINE SYNTHASE user 2 3 # 2 A 137 GLU C 21 GLU~? 6.35 O1 EDO C 103 A 288 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 329 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 29.27 18.78 14.99 27.16 18.62 14.76 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 49.52 10.06 10.36 50.99 9.65 8.92 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 57.80 12.92 13.83 53.77 8.42 12.15 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1roz_c00 DEOXYHYPUSINE SYNTHASE user 3 3 # 3 A 137 GLU C 48 GLU.? -2.75 O6 CIT D 103s A 288 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 329 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 29.27 18.78 14.99 27.16 18.62 14.76 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 49.52 10.06 10.36 50.99 9.65 8.92 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 57.80 12.92 13.83 53.77 8.42 12.15 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1roz_c00 DEOXYHYPUSINE SYNTHASE user 4 3 # 4 A 137 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 288 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 329 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 29.27 18.78 14.99 27.16 18.62 14.76 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 49.52 10.06 10.36 50.99 9.65 8.92 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 57.80 12.92 13.83 53.77 8.42 12.15 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1roz_c00 DEOXYHYPUSINE SYNTHASE user 5 3 # 5 A 137 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 288 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 329 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 29.27 18.78 14.99 27.16 18.62 14.76 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 49.52 10.06 10.36 50.99 9.65 8.92 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 57.80 12.92 13.83 53.77 8.42 12.15 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1roz_c00 DEOXYHYPUSINE SYNTHASE user 6 3 # 6 A 137 GLU E 32 GLU~? 15.49 O1 EDO E 103 A 288 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 329 LYS B 50 LYS.? 6.61 O1 EDO A 103 coo 29.27 18.78 14.99 27.16 18.62 14.76 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 49.52 10.06 10.36 50.99 9.65 8.92 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 57.80 12.92 13.83 53.77 8.42 12.15 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 1roz_c00 source 1roz DEOXYHYPUSINE SYNTHASE : 6 hits 1roz_c00 naa= 3 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 1 3 # 1 B 137 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 288 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 329 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 2 3 # 2 B 137 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 288 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 329 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 3 3 # 3 B 137 GLU C 21 GLU~? 6.35 O1 EDO C 103 B 288 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 329 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 4 3 # 4 B 137 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 288 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 329 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 5 3 # 5 B 137 GLU D 11 GLU.? 15.90 O4 CIT D 103 B 288 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 329 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 6 3 # 6 B 137 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 288 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 329 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 7 3 # 7 B 137 GLU E 21 GLU~? 9.95 O4 CIT C 104 B 288 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 329 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 8 3 # 8 B 137 GLU E 32 GLU~? 15.49 O1 EDO E 103 B 288 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 329 LYS B 50 LYS.? 6.61 O1 EDO A 103 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 9 3 # 9 B 137 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 288 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 329 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 1roz_c01 source 1roz DEOXYHYPUSINE SYNTHASE : 9 hits 1roz_c01 naa= 3 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 1 3 # 1 B 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 193 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo -4.60 27.52 42.88 -4.63 27.41 40.76 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 2 3 # 2 B 57 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 102 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo -4.60 27.52 42.88 -4.63 27.41 40.76 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 3 3 # 3 B 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 193 GLY B 57 GLY^? 9.92 O7 CIT B 103 coo -4.60 27.52 42.88 -4.63 27.41 40.76 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 4 3 # 4 B 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 193 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo -4.60 27.52 42.88 -4.63 27.41 40.76 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 5 3 # 5 B 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 193 GLY C 57 GLY^? 10.09 O1 CIT C 104 coo -4.60 27.52 42.88 -4.63 27.41 40.76 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 6 3 # 6 B 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 193 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo -4.60 27.52 42.88 -4.63 27.41 40.76 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 7 3 # 7 B 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 193 GLY D 57 GLY^? 9.79 C2 CIT D 103 coo -4.60 27.52 42.88 -4.63 27.41 40.76 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 8 3 # 8 B 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 193 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo -4.60 27.52 42.88 -4.63 27.41 40.76 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 9 3 # 9 B 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 193 GLY E 57 GLY^? 9.68 O2 EDO E 103 coo -4.60 27.52 42.88 -4.63 27.41 40.76 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 10 3 # 10 B 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 193 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo -4.60 27.52 42.88 -4.63 27.41 40.76 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 11 3 # 11 B 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 193 GLY F 57 GLY^? 10.08 O2 CIT F 104 coo -4.60 27.52 42.88 -4.63 27.41 40.76 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 ULMN 3 1rtf_c06 TWO CHAIN TISSUE PLASMINOGEN ACTIVATuser 12 3 # 12 B 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 193 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo -4.60 27.52 42.88 -4.63 27.41 40.76 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -0.27 31.24 43.51 -1.49 29.62 42.98 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -6.81 22.81 34.74 -6.42 23.54 34.62 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1rtf_c06 source 1rtf TWO CHAIN TISSUE PLASMINOGEN ACTIVATOR : 12 hits 1rtf_c06 naa= 3 ULMN 3 1s3i_c00 10-FORMYLTETRAHYDROFOLATE DEHYDROGENuser 1 3 # 1 A 104 ILE A 25 ILE~? 7.68 C2 EDO E 103 A 106 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 142 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo -15.54 60.72 29.56 -16.71 61.53 30.10 -22.24 -81.29 -36.07 -22.27 -82.20 -37.12 coo -17.00 64.03 23.46 -18.21 65.65 22.90 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -17.05 67.91 26.85 -18.66 66.47 26.76 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 1s3i_c00 source 1s3i 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE : 1 hits 1s3i_c00 naa= 3 ULMN 3 1sll_c00 SIALIDASE L user 1 3 # 1 318 ASP A 46 ASP.? 9.57 O6 CIT B 103 595 GLU A 9 GLU.? 14.22 C1 EDO A 103 713 TYR A 54 TYR.? 12.54 C1 EDO A 103 coo 5.64 2.82 38.49 4.59 4.19 37.25 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 4.35 13.73 37.63 3.39 12.18 36.55 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 coo 3.76 10.25 31.38 3.16 9.87 34.10 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 ULMN 3 1sll_c00 SIALIDASE L user 2 3 # 2 318 ASP A 99 ASP^? 8.10 O2 EDO A 103 595 GLU B 52 GLU.? 15.03 O1 EDO A 103 713 TYR B 54 TYR.? 11.82 O7 CIT B 103 coo 5.64 2.82 38.49 4.59 4.19 37.25 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 4.35 13.73 37.63 3.39 12.18 36.55 -10.99 -99.25 -18.20 -12.86 -99.70 -17.22 coo 3.76 10.25 31.38 3.16 9.87 34.10 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 ULMN 3 1sll_c00 SIALIDASE L user 3 3 # 3 318 ASP B 99 ASP^? 7.47 O6 CIT B 103 595 GLU A 52 GLU.? 13.60 O6 CIT B 103 713 TYR A 54 TYR.? 12.54 C1 EDO A 103 coo 5.64 2.82 38.49 4.59 4.19 37.25 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 4.35 13.73 37.63 3.39 12.18 36.55 2.10 -81.17 -22.98 1.38 -79.30 -23.85 coo 3.76 10.25 31.38 3.16 9.87 34.10 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 ULMN 3 1sll_c00 SIALIDASE L user 4 3 # 4 318 ASP C 46 ASP.? 10.22 O6 CIT D 103 595 GLU C 9 GLU.? 12.64 O3 CIT C 104 713 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 5.64 2.82 38.49 4.59 4.19 37.25 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 4.35 13.73 37.63 3.39 12.18 36.55 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 3.76 10.25 31.38 3.16 9.87 34.10 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 1sll_c00 SIALIDASE L user 5 3 # 5 318 ASP C 46 ASP.? 10.22 O6 CIT D 103 595 GLU D 101 GLU^? 17.58 O6 CIT D 103 713 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 5.64 2.82 38.49 4.59 4.19 37.25 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 4.35 13.73 37.63 3.39 12.18 36.55 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 3.76 10.25 31.38 3.16 9.87 34.10 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 1sll_c00 SIALIDASE L user 6 3 # 6 318 ASP C 99 ASP^? 7.14 O2 CIT C 104 595 GLU D 52 GLU.? 13.73 O3 CIT C 104 713 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo 5.64 2.82 38.49 4.59 4.19 37.25 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 4.35 13.73 37.63 3.39 12.18 36.55 -38.82 -73.24 -13.34 -40.85 -73.92 -12.86 coo 3.76 10.25 31.38 3.16 9.87 34.10 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 ULMN 3 1sll_c00 SIALIDASE L user 7 3 # 7 318 ASP D 46 ASP.? 10.10 O7 CIT C 104 595 GLU D 9 GLU.? 12.31 O4 CIT D 103 713 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo 5.64 2.82 38.49 4.59 4.19 37.25 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 4.35 13.73 37.63 3.39 12.18 36.55 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 3.76 10.25 31.38 3.16 9.87 34.10 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 1sll_c00 source 1sll SIALIDASE L : 7 hits 1sll_c00 naa= 3 ULMN 3 1sme_c04 PLASMEPSIN II user 1 3 # 1 A 34 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 37 SER A 51 SER.? 9.93 O6 CIT B 103 A 214 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 51.75 60.57 19.10 52.05 60.90 21.19 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 51.10 65.11 20.73 52.62 63.74 19.42 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 48.59 58.89 25.78 50.13 59.74 24.61 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1sme_c04 PLASMEPSIN II user 2 3 # 2 A 34 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 37 SER C 51 SER.? 10.55 O6 CIT D 103 A 214 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 51.75 60.57 19.10 52.05 60.90 21.19 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 51.10 65.11 20.73 52.62 63.74 19.42 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 48.59 58.89 25.78 50.13 59.74 24.61 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1sme_c04 PLASMEPSIN II user 3 3 # 3 A 34 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 37 SER E 51 SER.? 10.11 C4 CIT F 104 A 214 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 51.75 60.57 19.10 52.05 60.90 21.19 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 51.10 65.11 20.73 52.62 63.74 19.42 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo 48.59 58.89 25.78 50.13 59.74 24.61 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1sme_c04 source 1sme PLASMEPSIN II : 3 hits 1sme_c04 naa= 3 ULMN 3 1ssx_c02 ALPHA-LYTIC PROTEASE user 1 3 # 1 A 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 193 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo 15.02 29.17 19.44 15.63 29.96 17.60 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 19.67 30.58 22.61 18.30 29.87 21.17 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 14.52 29.10 10.01 15.08 29.66 10.19 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 1ssx_c02 ALPHA-LYTIC PROTEASE user 2 3 # 2 A 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 193 GLY B 57 GLY^? 9.92 O7 CIT B 103 coo 15.02 29.17 19.44 15.63 29.96 17.60 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 19.67 30.58 22.61 18.30 29.87 21.17 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 14.52 29.10 10.01 15.08 29.66 10.19 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 ULMN 3 1ssx_c02 ALPHA-LYTIC PROTEASE user 3 3 # 3 A 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 193 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 15.02 29.17 19.44 15.63 29.96 17.60 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 19.67 30.58 22.61 18.30 29.87 21.17 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 14.52 29.10 10.01 15.08 29.66 10.19 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1ssx_c02 ALPHA-LYTIC PROTEASE user 4 3 # 4 A 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 193 GLY C 57 GLY^? 10.09 O1 CIT C 104 coo 15.02 29.17 19.44 15.63 29.96 17.60 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 19.67 30.58 22.61 18.30 29.87 21.17 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 14.52 29.10 10.01 15.08 29.66 10.19 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 ULMN 3 1ssx_c02 ALPHA-LYTIC PROTEASE user 5 3 # 5 A 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 193 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 15.02 29.17 19.44 15.63 29.96 17.60 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 19.67 30.58 22.61 18.30 29.87 21.17 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 14.52 29.10 10.01 15.08 29.66 10.19 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1ssx_c02 ALPHA-LYTIC PROTEASE user 6 3 # 6 A 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 193 GLY D 57 GLY^? 9.79 C2 CIT D 103 coo 15.02 29.17 19.44 15.63 29.96 17.60 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 19.67 30.58 22.61 18.30 29.87 21.17 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 14.52 29.10 10.01 15.08 29.66 10.19 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 ULMN 3 1ssx_c02 ALPHA-LYTIC PROTEASE user 7 3 # 7 A 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 193 GLY E 57 GLY^? 9.68 O2 EDO E 103 coo 15.02 29.17 19.44 15.63 29.96 17.60 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 19.67 30.58 22.61 18.30 29.87 21.17 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 14.52 29.10 10.01 15.08 29.66 10.19 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 ULMN 3 1ssx_c02 ALPHA-LYTIC PROTEASE user 8 3 # 8 A 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 193 GLY F 57 GLY^? 10.08 O2 CIT F 104 coo 15.02 29.17 19.44 15.63 29.96 17.60 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 19.67 30.58 22.61 18.30 29.87 21.17 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 14.52 29.10 10.01 15.08 29.66 10.19 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 ULMN 3 1ssx_c02 ALPHA-LYTIC PROTEASE user 9 3 # 9 A 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 193 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 15.02 29.17 19.44 15.63 29.96 17.60 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 19.67 30.58 22.61 18.30 29.87 21.17 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 14.52 29.10 10.01 15.08 29.66 10.19 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1ssx_c02 source 1ssx ALPHA-LYTIC PROTEASE : 9 hits 1ssx_c02 naa= 3 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 1 3 # 1 A 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 174 ASP A 69 ASP~? 12.13 O2 EDO A 103 A 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 2 3 # 2 A 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 174 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 3 3 # 3 A 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 174 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 4 3 # 4 A 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 174 ASP B 69 ASP~? 11.84 O5 CIT B 103 A 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 5 3 # 5 A 144 HIS B 41 HIS^? 11.37 O1 CIT B 103 A 174 ASP B 27 ASP~? 12.32 O1 CIT B 103 A 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 6 3 # 6 A 144 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 174 ASP C 69 ASP~? 11.49 O6 CIT C 104 A 404 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 7 3 # 7 A 144 HIS C 41 HIS^? 12.16 O1 CIT C 104 A 174 ASP C 27 ASP~? 13.15 O1 CIT C 104 A 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 8 3 # 8 A 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 174 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 9 3 # 9 A 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 174 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 10 3 # 10 A 144 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 174 ASP E 69 ASP~? 11.60 O6 CIT E 104 A 404 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 11 3 # 11 A 144 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 174 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 404 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 12 3 # 12 A 144 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 174 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1ti6_c06 PYROGALLOL HYDROXYTRANSFERASE SMALL user 13 3 # 13 A 144 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 174 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 18.51 -77.38 -39.07 19.76 -78.71 -38.04 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 27.58 -77.64 -39.00 25.78 -78.57 -39.64 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 14.43 -85.16 -40.78 16.47 -83.93 -39.31 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 1ti6_c06 source 1ti6 PYROGALLOL HYDROXYTRANSFERASE SMALL SUBUNIT : 13 hits 1ti6_c06 naa= 3 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 1 3 # 1 C 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 174 ASP A 69 ASP~? 12.13 O2 EDO A 103 C 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 2 3 # 2 C 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s C 174 ASP B 46 ASP.? 11.17 O1 EDO A 103 C 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 3 3 # 3 C 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s C 174 ASP A 46 ASP.? 9.57 O6 CIT B 103 C 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 4 3 # 4 C 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s C 174 ASP B 69 ASP~? 11.84 O5 CIT B 103 C 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 5 3 # 5 C 144 HIS B 41 HIS^? 11.37 O1 CIT B 103 C 174 ASP B 27 ASP~? 12.32 O1 CIT B 103 C 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 6 3 # 6 C 144 HIS C 4 HIS.? -4.06 O2 CIT C 104s C 174 ASP C 69 ASP~? 11.49 O6 CIT C 104 C 404 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 7 3 # 7 C 144 HIS C 41 HIS^? 12.16 O1 CIT C 104 C 174 ASP C 27 ASP~? 13.15 O1 CIT C 104 C 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 8 3 # 8 C 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 174 ASP C 46 ASP.? 10.22 O6 CIT D 103 C 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 9 3 # 9 C 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s C 174 ASP D 69 ASP~? 11.20 O6 CIT D 103 C 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 10 3 # 10 C 144 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 174 ASP E 69 ASP~? 11.60 O6 CIT E 104 C 404 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 11 3 # 11 C 144 HIS E 4 HIS.? -4.01 O2 CIT E 104s C 174 ASP F 46 ASP.? 6.64 O2 EDO F 103 C 404 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 12 3 # 12 C 144 HIS E 41 HIS^? -3.94 C2 EDO E 103s C 174 ASP E 27 ASP~? 4.58 C1 EDO E 103 C 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1ti6_c07 PYROGALLOL HYDROXYTRANSFERASE SMALL user 13 3 # 13 C 144 HIS F 4 HIS.? -4.07 O2 CIT F 104s C 174 ASP E 46 ASP.? 9.98 C4 CIT F 104 C 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo -15.55 89.08 -13.38 -16.05 90.98 -14.11 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -23.98 91.31 -16.16 -21.94 90.86 -16.65 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -8.89 91.06 -18.89 -11.23 91.99 -17.67 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 1ti6_c07 source 1ti6 PYROGALLOL HYDROXYTRANSFERASE SMALL SUBUNIT : 13 hits 1ti6_c07 naa= 3 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 1 3 # 1 E 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s E 174 ASP A 69 ASP~? 12.13 O2 EDO A 103 E 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 2 3 # 2 E 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s E 174 ASP B 46 ASP.? 11.17 O1 EDO A 103 E 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 3 3 # 3 E 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s E 174 ASP A 46 ASP.? 9.57 O6 CIT B 103 E 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 4 3 # 4 E 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s E 174 ASP B 69 ASP~? 11.84 O5 CIT B 103 E 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 5 3 # 5 E 144 HIS B 41 HIS^? 11.37 O1 CIT B 103 E 174 ASP B 27 ASP~? 12.32 O1 CIT B 103 E 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 6 3 # 6 E 144 HIS C 4 HIS.? -4.06 O2 CIT C 104s E 174 ASP C 69 ASP~? 11.49 O6 CIT C 104 E 404 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 7 3 # 7 E 144 HIS C 41 HIS^? 12.16 O1 CIT C 104 E 174 ASP C 27 ASP~? 13.15 O1 CIT C 104 E 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 8 3 # 8 E 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s E 174 ASP C 46 ASP.? 10.22 O6 CIT D 103 E 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 9 3 # 9 E 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s E 174 ASP D 69 ASP~? 11.20 O6 CIT D 103 E 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 10 3 # 10 E 144 HIS E 4 HIS.? -4.01 O2 CIT E 104s E 174 ASP E 69 ASP~? 11.60 O6 CIT E 104 E 404 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 11 3 # 11 E 144 HIS E 4 HIS.? -4.01 O2 CIT E 104s E 174 ASP F 46 ASP.? 6.64 O2 EDO F 103 E 404 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 12 3 # 12 E 144 HIS E 41 HIS^? -3.94 C2 EDO E 103s E 174 ASP E 27 ASP~? 4.58 C1 EDO E 103 E 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1ti6_c08 PYROGALLOL HYDROXYTRANSFERASE SMALL user 13 3 # 13 E 144 HIS F 4 HIS.? -4.07 O2 CIT F 104s E 174 ASP E 46 ASP.? 9.98 C4 CIT F 104 E 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo -7.53-107.59 75.19 -8.14-106.04 76.47 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -3.55-105.39 83.13 -5.21-106.24 82.09 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -16.31-108.78 75.35 -14.20-107.14 76.16 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 1ti6_c08 source 1ti6 PYROGALLOL HYDROXYTRANSFERASE SMALL SUBUNIT : 13 hits 1ti6_c08 naa= 3 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 1 3 # 1 G 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s G 174 ASP A 69 ASP~? 12.13 O2 EDO A 103 G 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 58.10-108.15 40.62 59.57-106.86 41.51 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 2 3 # 2 G 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s G 174 ASP B 46 ASP.? 11.17 O1 EDO A 103 G 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 58.10-108.15 40.62 59.57-106.86 41.51 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 3 3 # 3 G 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s G 174 ASP A 46 ASP.? 9.57 O6 CIT B 103 G 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 58.10-108.15 40.62 59.57-106.86 41.51 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 4 3 # 4 G 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s G 174 ASP B 69 ASP~? 11.84 O5 CIT B 103 G 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 58.10-108.15 40.62 59.57-106.86 41.51 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 5 3 # 5 G 144 HIS B 41 HIS^? 11.37 O1 CIT B 103 G 174 ASP B 27 ASP~? 12.32 O1 CIT B 103 G 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 58.10-108.15 40.62 59.57-106.86 41.51 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 6 3 # 6 G 144 HIS C 4 HIS.? -4.06 O2 CIT C 104s G 174 ASP C 69 ASP~? 11.49 O6 CIT C 104 G 404 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo 60.48-101.16 45.95 60.56-101.20 43.85 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 58.10-108.15 40.62 59.57-106.86 41.51 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 7 3 # 7 G 144 HIS C 41 HIS^? 12.16 O1 CIT C 104 G 174 ASP C 27 ASP~? 13.15 O1 CIT C 104 G 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 58.10-108.15 40.62 59.57-106.86 41.51 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 8 3 # 8 G 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s G 174 ASP C 46 ASP.? 10.22 O6 CIT D 103 G 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 58.10-108.15 40.62 59.57-106.86 41.51 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 9 3 # 9 G 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s G 174 ASP D 69 ASP~? 11.20 O6 CIT D 103 G 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 58.10-108.15 40.62 59.57-106.86 41.51 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 10 3 # 10 G 144 HIS E 4 HIS.? -4.01 O2 CIT E 104s G 174 ASP E 69 ASP~? 11.60 O6 CIT E 104 G 404 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 58.10-108.15 40.62 59.57-106.86 41.51 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 11 3 # 11 G 144 HIS E 41 HIS^? -3.94 C2 EDO E 103s G 174 ASP E 27 ASP~? 4.58 C1 EDO E 103 G 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 58.10-108.15 40.62 59.57-106.86 41.51 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1ti6_c09 PYROGALLOL HYDROXYTRANSFERASE SMALL user 12 3 # 12 G 144 HIS F 4 HIS.? -4.07 O2 CIT F 104s G 174 ASP E 46 ASP.? 9.98 C4 CIT F 104 G 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 60.48-101.16 45.95 60.56-101.20 43.85 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 58.10-108.15 40.62 59.57-106.86 41.51 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 68.57 -97.60 44.49 66.22 -98.53 43.28 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 1ti6_c09 source 1ti6 PYROGALLOL HYDROXYTRANSFERASE SMALL SUBUNIT : 12 hits 1ti6_c09 naa= 3 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 1 3 # 1 I 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s I 174 ASP A 69 ASP~? 12.13 O2 EDO A 103 I 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 2 3 # 2 I 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s I 174 ASP B 46 ASP.? 11.17 O1 EDO A 103 I 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 3 3 # 3 I 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s I 174 ASP A 46 ASP.? 9.57 O6 CIT B 103 I 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 4 3 # 4 I 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s I 174 ASP B 69 ASP~? 11.84 O5 CIT B 103 I 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 5 3 # 5 I 144 HIS B 41 HIS^? 11.37 O1 CIT B 103 I 174 ASP B 27 ASP~? 12.32 O1 CIT B 103 I 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 6 3 # 6 I 144 HIS C 4 HIS.? -4.06 O2 CIT C 104s I 174 ASP C 69 ASP~? 11.49 O6 CIT C 104 I 404 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 7 3 # 7 I 144 HIS C 41 HIS^? 12.16 O1 CIT C 104 I 174 ASP C 27 ASP~? 13.15 O1 CIT C 104 I 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 8 3 # 8 I 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s I 174 ASP C 46 ASP.? 10.22 O6 CIT D 103 I 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 9 3 # 9 I 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s I 174 ASP D 69 ASP~? 11.20 O6 CIT D 103 I 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 10 3 # 10 I 144 HIS E 4 HIS.? -4.01 O2 CIT E 104s I 174 ASP E 69 ASP~? 11.60 O6 CIT E 104 I 404 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 11 3 # 11 I 144 HIS E 41 HIS^? -3.94 C2 EDO E 103s I 174 ASP E 27 ASP~? 4.58 C1 EDO E 103 I 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1ti6_c10 PYROGALLOL HYDROXYTRANSFERASE SMALL user 12 3 # 12 I 144 HIS F 4 HIS.? -4.07 O2 CIT F 104s I 174 ASP E 46 ASP.? 9.98 C4 CIT F 104 I 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo -12.68 -17.50 91.59 -12.79 -19.47 92.31 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -20.27 -21.99 93.95 -18.47 -20.99 94.50 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -5.95 -17.59 97.43 -7.86 -19.17 96.13 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 1ti6_c10 source 1ti6 PYROGALLOL HYDROXYTRANSFERASE SMALL SUBUNIT : 12 hits 1ti6_c10 naa= 3 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 1 3 # 1 K 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s K 174 ASP A 69 ASP~? 12.13 O2 EDO A 103 K 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 102.36 30.86 6.31 102.45 29.08 5.12 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 2 3 # 2 K 144 HIS A 4 HIS.? -4.40 O2 EDO A 103s K 174 ASP B 46 ASP.? 11.17 O1 EDO A 103 K 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 102.36 30.86 6.31 102.45 29.08 5.12 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 3 3 # 3 K 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s K 174 ASP A 46 ASP.? 9.57 O6 CIT B 103 K 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 102.36 30.86 6.31 102.45 29.08 5.12 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 4 3 # 4 K 144 HIS B 4 HIS.? -4.11 O2 CIT B 103s K 174 ASP B 69 ASP~? 11.84 O5 CIT B 103 K 404 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 102.36 30.86 6.31 102.45 29.08 5.12 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 5 3 # 5 K 144 HIS B 41 HIS^? 11.37 O1 CIT B 103 K 174 ASP B 27 ASP~? 12.32 O1 CIT B 103 K 404 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 102.36 30.86 6.31 102.45 29.08 5.12 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 6 3 # 6 K 144 HIS C 4 HIS.? -4.06 O2 CIT C 104s K 174 ASP C 69 ASP~? 11.49 O6 CIT C 104 K 404 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 102.36 30.86 6.31 102.45 29.08 5.12 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 7 3 # 7 K 144 HIS C 41 HIS^? 12.16 O1 CIT C 104 K 174 ASP C 27 ASP~? 13.15 O1 CIT C 104 K 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -48.63 -58.94 -31.36 -49.20 -58.23 -33.25 coo 102.36 30.86 6.31 102.45 29.08 5.12 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 8 3 # 8 K 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s K 174 ASP C 46 ASP.? 10.22 O6 CIT D 103 K 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 102.36 30.86 6.31 102.45 29.08 5.12 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 9 3 # 9 K 144 HIS D 4 HIS.? -4.16 O2 CIT D 103s K 174 ASP D 69 ASP~? 11.20 O6 CIT D 103 K 404 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 102.36 30.86 6.31 102.45 29.08 5.12 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 10 3 # 10 K 144 HIS E 4 HIS.? -4.01 O2 CIT E 104s K 174 ASP E 69 ASP~? 11.60 O6 CIT E 104 K 404 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 102.36 30.86 6.31 102.45 29.08 5.12 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 11 3 # 11 K 144 HIS E 41 HIS^? -3.94 C2 EDO E 103s K 174 ASP E 27 ASP~? 4.58 C1 EDO E 103 K 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 102.36 30.86 6.31 102.45 29.08 5.12 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 1ti6_c11 PYROGALLOL HYDROXYTRANSFERASE SMALL user 12 3 # 12 K 144 HIS F 4 HIS.? -4.07 O2 CIT F 104s K 174 ASP E 46 ASP.? 9.98 C4 CIT F 104 K 404 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 100.18 26.45 -1.32 99.24 26.12 0.53 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 102.36 30.86 6.31 102.45 29.08 5.12 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 99.93 17.48 -0.85 99.14 19.86 0.39 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 1ti6_c11 source 1ti6 PYROGALLOL HYDROXYTRANSFERASE SMALL SUBUNIT : 12 hits 1ti6_c11 naa= 3 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 1 3 # 1 A 250 ALA A 15 ALA~? 15.06 C1 EDO A 103 A 251 GLY A 14 GLY~? 18.08 C2 EDO E 103 A 252 ASP A 17 ASP~? 17.77 C2 EDO E 103 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -7.92 -83.12 -38.44 -6.92 -83.81 -37.59 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 2 3 # 2 A 250 ALA A 92 ALA~? 7.55 O1 EDO A 103 A 251 GLY A 91 GLY~? 10.61 O1 EDO A 103 A 252 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 3 3 # 3 A 250 ALA A 92 ALA~? 7.55 O1 EDO A 103 A 251 GLY A 94 GLY.? 10.50 C1 EDO A 103 A 252 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 4 3 # 4 A 250 ALA B 15 ALA~? 14.11 C4 CIT B 103 A 251 GLY B 14 GLY~? 17.66 C4 CIT B 103 A 252 ASP B 17 ASP~? 19.42 C4 CIT B 103 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -5.10 -93.70 -1.33 -4.68 -94.25 -2.68 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -5.53 -95.57 1.94 -5.32 -95.64 1.14 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -8.70 -93.12 3.11 -9.77 -94.94 3.45 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 5 3 # 5 A 250 ALA B 92 ALA~? 4.16 O3 CIT B 103 A 251 GLY B 91 GLY~? 7.97 O3 CIT B 103 A 252 ASP B 93 ASP~? 9.77 O3 CIT B 103 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 3.29 -89.28 -7.61 2.92 -89.60 -8.27 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 3.85 -90.04 -12.91 5.79 -89.33 -13.36 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 6 3 # 6 A 250 ALA B 92 ALA~? 4.16 O3 CIT B 103 A 251 GLY B 94 GLY.? 8.02 O3 CIT B 103 A 252 ASP B 93 ASP~? 9.77 O3 CIT B 103 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 3.85 -90.04 -12.91 5.79 -89.33 -13.36 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 7 3 # 7 A 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 A 251 GLY C 14 GLY~? 3.87 C1 EDO C 103 A 252 ASP C 17 ASP~? -3.95 O1 EDO C 103s coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 8 3 # 8 A 250 ALA C 92 ALA~? 4.69 O3 CIT C 104 A 251 GLY C 91 GLY~? 8.26 O4 CIT C 104 A 252 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 9 3 # 9 A 250 ALA C 92 ALA~? 4.69 O3 CIT C 104 A 251 GLY C 94 GLY.? 8.41 O3 CIT C 104 A 252 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 10 3 # 10 A 250 ALA D 15 ALA~? 14.37 O4 CIT D 103 A 251 GLY D 14 GLY~? 17.95 O7 CIT D 103 A 252 ASP D 17 ASP~? 19.08 O1 CIT D 103 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -43.98 -63.95 1.87 -42.83 -64.36 0.99 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -44.90 -65.50 5.30 -44.33 -65.47 4.79 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -49.27 -65.18 4.30 -49.35 -67.27 4.77 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 11 3 # 11 A 250 ALA D 92 ALA~? 3.89 O4 CIT D 103 A 251 GLY D 91 GLY~? 7.26 O4 CIT D 103 A 252 ASP D 93 ASP~? 9.04 O4 CIT D 103 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 12 3 # 12 A 250 ALA D 92 ALA~? 3.89 O4 CIT D 103 A 251 GLY D 94 GLY.? 7.85 O4 CIT D 103 A 252 ASP D 93 ASP~? 9.04 O4 CIT D 103 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 13 3 # 13 A 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 A 251 GLY E 14 GLY~? 13.52 O2 EDO C 103 A 252 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 14 3 # 14 A 250 ALA E 92 ALA~? 4.01 O3 CIT E 104 A 251 GLY E 91 GLY~? 5.97 O2 EDO C 103 A 252 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 15 3 # 15 A 250 ALA E 92 ALA~? 4.01 O3 CIT E 104 A 251 GLY E 94 GLY.? 7.76 O3 CIT E 104 A 252 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 16 3 # 16 A 250 ALA F 15 ALA~? 13.96 O3 CIT F 104 A 251 GLY F 14 GLY~? 17.47 O3 CIT F 104 A 252 ASP F 17 ASP~? 19.11 O1 CIT F 104 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -30.55 -73.71 -75.60 -31.05 -72.60 -74.70 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -31.78 -74.33 -79.17 -31.74 -73.80 -78.55 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 17 3 # 17 A 250 ALA F 30 ALA~? 11.84 O2 CIT F 104 A 251 GLY F 28 GLY~? 13.27 O1 CIT F 104 A 252 ASP F 27 ASP~? 14.00 O1 CIT F 104 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -19.58 -90.69 -64.73 -21.00 -90.58 -64.23 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -21.49 -91.20 -70.18 -21.31 -90.68 -69.63 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 18 3 # 18 A 250 ALA F 92 ALA~? 4.20 O4 CIT F 104 A 251 GLY F 91 GLY~? 8.30 O3 CIT F 104 A 252 ASP F 93 ASP~? 9.52 O4 CIT F 104 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -22.80 -67.12 -70.37 -23.31 -66.96 -69.76 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 19 3 # 19 A 250 ALA F 92 ALA~? 4.20 O4 CIT F 104 A 251 GLY F 94 GLY.? 8.80 O3 CIT F 104 A 252 ASP F 93 ASP~? 9.52 O4 CIT F 104 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -26.33 -67.76 -65.92 -25.64 -68.13 -65.72 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 1tz3_c02 source 1tz3 PUTATIVE SUGAR KINASE : 19 hits 1tz3_c02 naa= 3 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 1 3 # 1 B 250 ALA A 15 ALA~? 15.06 C1 EDO A 103 B 251 GLY A 14 GLY~? 18.08 C2 EDO E 103 B 252 ASP A 17 ASP~? 17.77 C2 EDO E 103 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -7.92 -83.12 -38.44 -6.92 -83.81 -37.59 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 2 3 # 2 B 250 ALA A 92 ALA~? 7.55 O1 EDO A 103 B 251 GLY A 91 GLY~? 10.61 O1 EDO A 103 B 252 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 3 3 # 3 B 250 ALA A 92 ALA~? 7.55 O1 EDO A 103 B 251 GLY A 94 GLY.? 10.50 C1 EDO A 103 B 252 ASP A 93 ASP~? 12.48 O1 EDO A 103 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 4 3 # 4 B 250 ALA B 15 ALA~? 14.11 C4 CIT B 103 B 251 GLY B 14 GLY~? 17.66 C4 CIT B 103 B 252 ASP B 17 ASP~? 19.42 C4 CIT B 103 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -5.10 -93.70 -1.33 -4.68 -94.25 -2.68 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -5.53 -95.57 1.94 -5.32 -95.64 1.14 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -8.70 -93.12 3.11 -9.77 -94.94 3.45 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 5 3 # 5 B 250 ALA B 92 ALA~? 4.16 O3 CIT B 103 B 251 GLY B 91 GLY~? 7.97 O3 CIT B 103 B 252 ASP B 93 ASP~? 9.77 O3 CIT B 103 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 3.29 -89.28 -7.61 2.92 -89.60 -8.27 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 3.85 -90.04 -12.91 5.79 -89.33 -13.36 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 6 3 # 6 B 250 ALA B 92 ALA~? 4.16 O3 CIT B 103 B 251 GLY B 94 GLY.? 8.02 O3 CIT B 103 B 252 ASP B 93 ASP~? 9.77 O3 CIT B 103 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 3.85 -90.04 -12.91 5.79 -89.33 -13.36 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 7 3 # 7 B 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 B 251 GLY C 14 GLY~? 3.87 C1 EDO C 103 B 252 ASP C 17 ASP~? -3.95 O1 EDO C 103s coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 8 3 # 8 B 250 ALA C 92 ALA~? 4.69 O3 CIT C 104 B 251 GLY C 91 GLY~? 8.26 O4 CIT C 104 B 252 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 9 3 # 9 B 250 ALA C 92 ALA~? 4.69 O3 CIT C 104 B 251 GLY C 94 GLY.? 8.41 O3 CIT C 104 B 252 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 10 3 # 10 B 250 ALA D 15 ALA~? 14.37 O4 CIT D 103 B 251 GLY D 14 GLY~? 17.95 O7 CIT D 103 B 252 ASP D 17 ASP~? 19.08 O1 CIT D 103 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -43.98 -63.95 1.87 -42.83 -64.36 0.99 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -44.90 -65.50 5.30 -44.33 -65.47 4.79 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -49.27 -65.18 4.30 -49.35 -67.27 4.77 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 11 3 # 11 B 250 ALA D 92 ALA~? 3.89 O4 CIT D 103 B 251 GLY D 91 GLY~? 7.26 O4 CIT D 103 B 252 ASP D 93 ASP~? 9.04 O4 CIT D 103 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 12 3 # 12 B 250 ALA D 92 ALA~? 3.89 O4 CIT D 103 B 251 GLY D 94 GLY.? 7.85 O4 CIT D 103 B 252 ASP D 93 ASP~? 9.04 O4 CIT D 103 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 13 3 # 13 B 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 B 251 GLY E 14 GLY~? 13.52 O2 EDO C 103 B 252 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 14 3 # 14 B 250 ALA E 92 ALA~? 4.01 O3 CIT E 104 B 251 GLY E 91 GLY~? 5.97 O2 EDO C 103 B 252 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 15 3 # 15 B 250 ALA E 92 ALA~? 4.01 O3 CIT E 104 B 251 GLY E 94 GLY.? 7.76 O3 CIT E 104 B 252 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 16 3 # 16 B 250 ALA F 15 ALA~? 13.96 O3 CIT F 104 B 251 GLY F 14 GLY~? 17.47 O3 CIT F 104 B 252 ASP F 17 ASP~? 19.11 O1 CIT F 104 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -30.55 -73.71 -75.60 -31.05 -72.60 -74.70 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -31.78 -74.33 -79.17 -31.74 -73.80 -78.55 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -31.49 -78.63 -78.51 -33.51 -78.78 -79.13 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 17 3 # 17 B 250 ALA F 30 ALA~? 11.84 O2 CIT F 104 B 251 GLY F 28 GLY~? 13.27 O1 CIT F 104 B 252 ASP F 27 ASP~? 14.00 O1 CIT F 104 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -19.58 -90.69 -64.73 -21.00 -90.58 -64.23 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -21.49 -91.20 -70.18 -21.31 -90.68 -69.63 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 18 3 # 18 B 250 ALA F 92 ALA~? 4.20 O4 CIT F 104 B 251 GLY F 91 GLY~? 8.30 O3 CIT F 104 B 252 ASP F 93 ASP~? 9.52 O4 CIT F 104 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -22.80 -67.12 -70.37 -23.31 -66.96 -69.76 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 19 3 # 19 B 250 ALA F 92 ALA~? 4.20 O4 CIT F 104 B 251 GLY F 94 GLY.? 8.80 O3 CIT F 104 B 252 ASP F 93 ASP~? 9.52 O4 CIT F 104 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -26.33 -67.76 -65.92 -25.64 -68.13 -65.72 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 1tz3_c03 source 1tz3 PUTATIVE SUGAR KINASE : 19 hits 1tz3_c03 naa= 3 ULMN 3 1uk7_c00 3.07.01.0009 user 1 3 # 1 A 103 ALA C 72 ALA~? 6.17 O6 CIT C 104 A 224 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 252 HIS C 4 HIS.? -4.06 O2 CIT C 104s coo 10.74 41.88 -3.62 10.55 41.61 -5.11 -48.37 -76.06 -28.58 -48.03 -76.66 -27.22 coo 7.52 49.49 -8.72 7.95 47.43 -8.44 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 9.83 44.81 -9.44 9.32 43.66 -7.77 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 1uk7_c00 source 1uk7 3.07.01.0009 : 1 hits 1uk7_c00 naa= 3 ULMN 3 1uok_c03 OLIGO-1,6-GLUCOSIDASE user 1 3 # 1 199 ASP A 99 ASP^? 8.10 O2 EDO A 103 255 GLU A 101 GLU^? 18.10 O2 EDO A 103 329 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 52.57 37.12 10.17 53.37 35.95 11.75 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 59.16 37.82 13.95 57.63 37.03 15.12 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1uok_c03 OLIGO-1,6-GLUCOSIDASE user 2 3 # 2 199 ASP B 99 ASP^? 7.47 O6 CIT B 103 255 GLU B 101 GLU^? 17.79 O2 CIT B 103 329 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 52.57 37.12 10.17 53.37 35.95 11.75 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 59.16 37.82 13.95 57.63 37.03 15.12 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1uok_c03 OLIGO-1,6-GLUCOSIDASE user 3 3 # 3 199 ASP C 99 ASP^? 7.14 O2 CIT C 104 255 GLU C 101 GLU^? 17.42 O2 CIT C 104 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 52.57 37.12 10.17 53.37 35.95 11.75 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 59.16 37.82 13.95 57.63 37.03 15.12 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1uok_c03 OLIGO-1,6-GLUCOSIDASE user 4 3 # 4 199 ASP D 99 ASP^? 6.89 O6 CIT D 103 255 GLU D 101 GLU^? 17.58 O6 CIT D 103 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 52.57 37.12 10.17 53.37 35.95 11.75 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 59.16 37.82 13.95 57.63 37.03 15.12 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1uok_c03 OLIGO-1,6-GLUCOSIDASE user 5 3 # 5 199 ASP E 99 ASP^? 7.65 C2 CIT E 104 255 GLU E 101 GLU^? 17.69 O2 CIT E 104 329 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 52.57 37.12 10.17 53.37 35.95 11.75 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 59.16 37.82 13.95 57.63 37.03 15.12 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1uok_c03 OLIGO-1,6-GLUCOSIDASE user 6 3 # 6 199 ASP F 99 ASP^? 6.97 O7 CIT F 104 255 GLU F 101 GLU^? 10.35 O2 EDO E 103 329 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 52.57 37.12 10.17 53.37 35.95 11.75 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 59.16 37.82 13.95 57.63 37.03 15.12 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 1uok_c03 source 1uok OLIGO-1,6-GLUCOSIDASE : 6 hits 1uok_c03 naa= 3 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 1 3 # 1 199 ASP A 64 ASP~? 16.37 O2 EDO A 103 218 GLU B 32 GLU~? 16.71 O1 CIT B 103 329 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 70.09 11.71 8.46 70.56 12.89 6.77 -13.30 -70.03 1.72 -15.18 -69.84 2.73 coo 59.16 37.82 13.95 57.63 37.03 15.12 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 2 3 # 2 199 ASP A 69 ASP~? 12.13 O2 EDO A 103 218 GLU B 101 GLU^? 17.79 O2 CIT B 103 329 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 70.09 11.71 8.46 70.56 12.89 6.77 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 59.16 37.82 13.95 57.63 37.03 15.12 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 3 3 # 3 199 ASP A 69 ASP~? 12.13 O2 EDO A 103 218 GLU C 9 GLU.? 12.64 O3 CIT C 104 329 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 70.09 11.71 8.46 70.56 12.89 6.77 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 59.16 37.82 13.95 57.63 37.03 15.12 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 4 3 # 4 199 ASP A 99 ASP^? 8.10 O2 EDO A 103 218 GLU F 101 GLU^? 10.35 O2 EDO E 103 329 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 70.09 11.71 8.46 70.56 12.89 6.77 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 59.16 37.82 13.95 57.63 37.03 15.12 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 5 3 # 5 199 ASP B 69 ASP~? 11.84 O5 CIT B 103 218 GLU A 101 GLU^? 18.10 O2 EDO A 103 329 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 70.09 11.71 8.46 70.56 12.89 6.77 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 59.16 37.82 13.95 57.63 37.03 15.12 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 6 3 # 6 199 ASP B 69 ASP~? 11.84 O5 CIT B 103 218 GLU C 11 GLU.? 13.80 O2 EDO C 103 329 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 70.09 11.71 8.46 70.56 12.89 6.77 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 59.16 37.82 13.95 57.63 37.03 15.12 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 7 3 # 7 199 ASP B 99 ASP^? 7.47 O6 CIT B 103 218 GLU D 52 GLU.? 13.73 O3 CIT C 104 329 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 70.09 11.71 8.46 70.56 12.89 6.77 -38.82 -73.24 -13.34 -40.85 -73.92 -12.86 coo 59.16 37.82 13.95 57.63 37.03 15.12 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 8 3 # 8 199 ASP C 17 ASP~? -3.95 O1 EDO C 103s 218 GLU E 32 GLU~? 15.49 O1 EDO E 103 329 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 70.09 11.71 8.46 70.56 12.89 6.77 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 59.16 37.82 13.95 57.63 37.03 15.12 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 9 3 # 9 199 ASP C 17 ASP~? -3.95 O1 EDO C 103s 218 GLU F 101 GLU^? 10.35 O2 EDO E 103 329 ASP E 93 ASP~? 8.62 O3 CIT E 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 70.09 11.71 8.46 70.56 12.89 6.77 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 59.16 37.82 13.95 57.63 37.03 15.12 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 10 3 # 10 199 ASP C 64 ASP~? 16.62 O2 CIT C 104 218 GLU D 32 GLU~? 17.83 O1 CIT D 103 329 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 70.09 11.71 8.46 70.56 12.89 6.77 -63.28 -49.45 -6.05 -65.42 -49.45 -6.30 coo 59.16 37.82 13.95 57.63 37.03 15.12 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 11 3 # 11 199 ASP C 69 ASP~? 11.49 O6 CIT C 104 218 GLU D 101 GLU^? 17.58 O6 CIT D 103 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 70.09 11.71 8.46 70.56 12.89 6.77 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 59.16 37.82 13.95 57.63 37.03 15.12 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 12 3 # 12 199 ASP C 93 ASP~? 9.74 O3 CIT C 104 218 GLU A 9 GLU.? 14.22 C1 EDO A 103 329 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 70.09 11.71 8.46 70.56 12.89 6.77 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 coo 59.16 37.82 13.95 57.63 37.03 15.12 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 13 3 # 13 199 ASP D 64 ASP~? 16.39 O2 CIT D 103 218 GLU C 32 GLU~? 15.71 O1 CIT C 104 329 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 70.09 11.71 8.46 70.56 12.89 6.77 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 59.16 37.82 13.95 57.63 37.03 15.12 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 14 3 # 14 199 ASP D 69 ASP~? 11.20 O6 CIT D 103 218 GLU C 21 GLU~? 6.35 O1 EDO C 103 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 70.09 11.71 8.46 70.56 12.89 6.77 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 59.16 37.82 13.95 57.63 37.03 15.12 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 15 3 # 15 199 ASP D 69 ASP~? 11.20 O6 CIT D 103 218 GLU C 101 GLU^? 17.42 O2 CIT C 104 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 70.09 11.71 8.46 70.56 12.89 6.77 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 59.16 37.82 13.95 57.63 37.03 15.12 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 16 3 # 16 199 ASP E 17 ASP~? 16.97 O4 CIT C 104 218 GLU C 32 GLU~? 15.71 O1 CIT C 104 329 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 70.09 11.71 8.46 70.56 12.89 6.77 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 59.16 37.82 13.95 57.63 37.03 15.12 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 17 3 # 17 199 ASP E 64 ASP~? 16.37 O2 CIT E 104 218 GLU F 32 GLU~? 16.06 O1 CIT F 104 329 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 70.09 11.71 8.46 70.56 12.89 6.77 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 coo 59.16 37.82 13.95 57.63 37.03 15.12 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 18 3 # 18 199 ASP E 69 ASP~? 11.60 O6 CIT E 104 218 GLU F 101 GLU^? 10.35 O2 EDO E 103 329 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 70.09 11.71 8.46 70.56 12.89 6.77 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 59.16 37.82 13.95 57.63 37.03 15.12 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 19 3 # 19 199 ASP F 64 ASP~? 16.52 O2 EDO E 103 218 GLU E 32 GLU~? 15.49 O1 EDO E 103 329 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 70.09 11.71 8.46 70.56 12.89 6.77 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 59.16 37.82 13.95 57.63 37.03 15.12 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 20 3 # 20 199 ASP F 69 ASP~? 11.68 O6 CIT F 104 218 GLU E 21 GLU~? 9.95 O4 CIT C 104 329 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 70.09 11.71 8.46 70.56 12.89 6.77 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 59.16 37.82 13.95 57.63 37.03 15.12 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 21 3 # 21 199 ASP F 69 ASP~? 11.68 O6 CIT F 104 218 GLU E 101 GLU^? 17.69 O2 CIT E 104 329 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 70.09 11.71 8.46 70.56 12.89 6.77 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 coo 59.16 37.82 13.95 57.63 37.03 15.12 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 22 3 # 22 199 ASP F 99 ASP^? 6.97 O7 CIT F 104 218 GLU A 9 GLU.? 14.22 C1 EDO A 103 329 ASP F 69 ASP~? 11.68 O6 CIT F 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 70.09 11.71 8.46 70.56 12.89 6.77 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 coo 59.16 37.82 13.95 57.63 37.03 15.12 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 1uok_c04 source 1uok OLIGO-1,6-GLUCOSIDASE : 22 hits 1uok_c04 naa= 3 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 1 3 # 1 199 ASP A 64 ASP~? 16.37 O2 EDO A 103 242 GLU D 48 GLU.? -3.37 O7 CIT C 104s 329 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 30.42 34.74 5.00 29.09 35.09 3.38 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 59.16 37.82 13.95 57.63 37.03 15.12 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 2 3 # 2 199 ASP C 69 ASP~? 11.49 O6 CIT C 104 242 GLU A 32 GLU~? 8.29 O4 CIT C 104 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 30.42 34.74 5.00 29.09 35.09 3.38 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 59.16 37.82 13.95 57.63 37.03 15.12 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 3 3 # 3 199 ASP C 69 ASP~? 11.49 O6 CIT C 104 242 GLU E 32 GLU~? 15.49 O1 EDO E 103 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 30.42 34.74 5.00 29.09 35.09 3.38 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 59.16 37.82 13.95 57.63 37.03 15.12 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 4 3 # 4 199 ASP C 69 ASP~? 11.49 O6 CIT C 104 242 GLU E 32 GLU~? 15.49 O1 EDO E 103 329 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 30.42 34.74 5.00 29.09 35.09 3.38 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 coo 59.16 37.82 13.95 57.63 37.03 15.12 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 5 3 # 5 199 ASP C 99 ASP^? 7.14 O2 CIT C 104 242 GLU A 32 GLU~? 8.29 O4 CIT C 104 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 30.42 34.74 5.00 29.09 35.09 3.38 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 coo 59.16 37.82 13.95 57.63 37.03 15.12 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 6 3 # 6 199 ASP C 99 ASP^? 7.14 O2 CIT C 104 242 GLU C 9 GLU.? 12.64 O3 CIT C 104 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 30.42 34.74 5.00 29.09 35.09 3.38 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 59.16 37.82 13.95 57.63 37.03 15.12 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 7 3 # 7 199 ASP C 99 ASP^? 7.14 O2 CIT C 104 242 GLU C 48 GLU.? -2.75 O6 CIT D 103s 329 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 30.42 34.74 5.00 29.09 35.09 3.38 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 59.16 37.82 13.95 57.63 37.03 15.12 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 8 3 # 8 199 ASP D 99 ASP^? 6.89 O6 CIT D 103 242 GLU C 11 GLU.? 13.80 O2 EDO C 103 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 30.42 34.74 5.00 29.09 35.09 3.38 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 59.16 37.82 13.95 57.63 37.03 15.12 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 9 3 # 9 199 ASP D 99 ASP^? 6.89 O6 CIT D 103 242 GLU C 101 GLU^? 17.42 O2 CIT C 104 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 30.42 34.74 5.00 29.09 35.09 3.38 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 59.16 37.82 13.95 57.63 37.03 15.12 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 10 3 # 10 199 ASP D 99 ASP^? 6.89 O6 CIT D 103 242 GLU C 101 GLU^? 17.42 O2 CIT C 104 329 ASP D 69 ASP~? 11.20 O6 CIT D 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 30.42 34.74 5.00 29.09 35.09 3.38 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 59.16 37.82 13.95 57.63 37.03 15.12 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 11 3 # 11 199 ASP D 99 ASP^? 6.89 O6 CIT D 103 242 GLU D 9 GLU.? 12.31 O4 CIT D 103 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 30.42 34.74 5.00 29.09 35.09 3.38 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 59.16 37.82 13.95 57.63 37.03 15.12 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 12 3 # 12 199 ASP D 99 ASP^? 6.89 O6 CIT D 103 242 GLU D 48 GLU.? -3.37 O7 CIT C 104s 329 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 49.16 35.16 15.19 51.08 34.43 15.65 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 30.42 34.74 5.00 29.09 35.09 3.38 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 59.16 37.82 13.95 57.63 37.03 15.12 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 13 3 # 13 199 ASP E 17 ASP~? 16.97 O4 CIT C 104 242 GLU F 101 GLU^? 10.35 O2 EDO E 103 329 ASP C 93 ASP~? 9.74 O3 CIT C 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 30.42 34.74 5.00 29.09 35.09 3.38 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 59.16 37.82 13.95 57.63 37.03 15.12 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 14 3 # 14 199 ASP E 69 ASP~? 11.60 O6 CIT E 104 242 GLU C 32 GLU~? 15.71 O1 CIT C 104 329 ASP E 64 ASP~? 16.37 O2 CIT E 104 coo 49.16 35.16 15.19 51.08 34.43 15.65 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 30.42 34.74 5.00 29.09 35.09 3.38 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 coo 59.16 37.82 13.95 57.63 37.03 15.12 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 1uok_c05 source 1uok OLIGO-1,6-GLUCOSIDASE : 14 hits 1uok_c05 naa= 3 ULMN 3 1v0e_c00 ENDO-ALPHA-SIALIDASE user 1 3 # 1 A 581 GLU B 9 GLU.? 11.84 O3 CIT B 103 A 596 ARG B 53 ARG.? 13.69 O3 CIT B 103 A 647 ARG A 53 ARG.? 15.50 C1 EDO A 103 coo 69.13 32.20 28.58 68.39 32.96 30.44 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 70.89 37.31 29.70 69.54 36.29 32.39 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 coo 66.09 40.54 34.70 66.92 37.69 35.49 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 ULMN 3 1v0e_c00 ENDO-ALPHA-SIALIDASE user 2 3 # 2 A 581 GLU B 11 GLU.? 15.97 O3 CIT B 103 A 596 ARG B 89 ARG.? 13.25 O3 CIT B 103 A 647 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo 69.13 32.20 28.58 68.39 32.96 30.44 0.63 -96.18 -5.96 0.64 -98.22 -6.51 coo 70.89 37.31 29.70 69.54 36.29 32.39 0.32 -96.47 -11.54 1.69 -95.10 -13.99 coo 66.09 40.54 34.70 66.92 37.69 35.49 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1v0e_c00 ENDO-ALPHA-SIALIDASE user 3 3 # 3 A 581 GLU C 11 GLU.? 13.80 O2 EDO C 103 A 596 ARG C 89 ARG.? 16.36 O3 CIT C 104 A 647 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 69.13 32.20 28.58 68.39 32.96 30.44 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 70.89 37.31 29.70 69.54 36.29 32.39 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo 66.09 40.54 34.70 66.92 37.69 35.49 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1v0e_c00 ENDO-ALPHA-SIALIDASE user 4 3 # 4 A 581 GLU D 11 GLU.? 15.90 O4 CIT D 103 A 596 ARG D 89 ARG.? 14.10 O4 CIT D 103 A 647 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 69.13 32.20 28.58 68.39 32.96 30.44 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo 70.89 37.31 29.70 69.54 36.29 32.39 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 coo 66.09 40.54 34.70 66.92 37.69 35.49 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1v0e_c00 ENDO-ALPHA-SIALIDASE user 5 3 # 5 A 581 GLU E 9 GLU.? 7.76 O1 EDO F 103 A 596 ARG E 53 ARG.? 4.89 O1 EDO F 103 A 647 ARG F 53 ARG.? -5.38 O1 EDO F 103s coo 69.13 32.20 28.58 68.39 32.96 30.44 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo 70.89 37.31 29.70 69.54 36.29 32.39 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 66.09 40.54 34.70 66.92 37.69 35.49 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 ULMN 3 1v0e_c00 ENDO-ALPHA-SIALIDASE user 6 3 # 6 A 581 GLU E 11 GLU.? -3.18 O2 EDO C 103s A 596 ARG E 89 ARG.? -3.87 C2 EDO C 103s A 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 69.13 32.20 28.58 68.39 32.96 30.44 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 70.89 37.31 29.70 69.54 36.29 32.39 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo 66.09 40.54 34.70 66.92 37.69 35.49 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c00 ENDO-ALPHA-SIALIDASE user 7 3 # 7 A 581 GLU E 38 GLU^? 8.47 O1 EDO E 103 A 596 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 647 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 69.13 32.20 28.58 68.39 32.96 30.44 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 70.89 37.31 29.70 69.54 36.29 32.39 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 66.09 40.54 34.70 66.92 37.69 35.49 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1v0e_c00 ENDO-ALPHA-SIALIDASE user 8 3 # 8 A 581 GLU F 9 GLU.? 7.31 C2 EDO F 103 A 596 ARG F 53 ARG.? -5.38 O1 EDO F 103s A 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 69.13 32.20 28.58 68.39 32.96 30.44 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 70.89 37.31 29.70 69.54 36.29 32.39 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 coo 66.09 40.54 34.70 66.92 37.69 35.49 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c00 ENDO-ALPHA-SIALIDASE user 9 3 # 9 A 581 GLU F 21 GLU~? 14.58 O1 CIT F 104 A 596 ARG F 18 ARG~? 15.26 O3 CIT F 104 A 647 ARG F 79 ARG~? 14.02 O1 CIT F 104 coo 69.13 32.20 28.58 68.39 32.96 30.44 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 70.89 37.31 29.70 69.54 36.29 32.39 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 coo 66.09 40.54 34.70 66.92 37.69 35.49 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 1v0e_c00 source 1v0e ENDO-ALPHA-SIALIDASE : 9 hits 1v0e_c00 naa= 3 ULMN 3 1v0e_c01 ENDO-ALPHA-SIALIDASE user 1 3 # 1 B 581 GLU B 9 GLU.? 11.84 O3 CIT B 103 B 596 ARG B 53 ARG.? 13.69 O3 CIT B 103 B 647 ARG A 53 ARG.? 15.50 C1 EDO A 103 coo 38.22 57.83 70.36 36.82 56.74 69.18 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 34.24 60.89 68.08 33.31 57.93 67.63 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 coo 31.43 57.38 61.97 31.90 55.58 64.41 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 ULMN 3 1v0e_c01 ENDO-ALPHA-SIALIDASE user 2 3 # 2 B 581 GLU B 11 GLU.? 15.97 O3 CIT B 103 B 596 ARG B 89 ARG.? 13.25 O3 CIT B 103 B 647 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo 38.22 57.83 70.36 36.82 56.74 69.18 0.63 -96.18 -5.96 0.64 -98.22 -6.51 coo 34.24 60.89 68.08 33.31 57.93 67.63 0.32 -96.47 -11.54 1.69 -95.10 -13.99 coo 31.43 57.38 61.97 31.90 55.58 64.41 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1v0e_c01 ENDO-ALPHA-SIALIDASE user 3 3 # 3 B 581 GLU C 11 GLU.? 13.80 O2 EDO C 103 B 596 ARG C 89 ARG.? 16.36 O3 CIT C 104 B 647 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 38.22 57.83 70.36 36.82 56.74 69.18 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 34.24 60.89 68.08 33.31 57.93 67.63 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo 31.43 57.38 61.97 31.90 55.58 64.41 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1v0e_c01 ENDO-ALPHA-SIALIDASE user 4 3 # 4 B 581 GLU D 11 GLU.? 15.90 O4 CIT D 103 B 596 ARG D 89 ARG.? 14.10 O4 CIT D 103 B 647 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 38.22 57.83 70.36 36.82 56.74 69.18 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo 34.24 60.89 68.08 33.31 57.93 67.63 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 coo 31.43 57.38 61.97 31.90 55.58 64.41 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1v0e_c01 ENDO-ALPHA-SIALIDASE user 5 3 # 5 B 581 GLU E 9 GLU.? 7.76 O1 EDO F 103 B 596 ARG E 53 ARG.? 4.89 O1 EDO F 103 B 647 ARG F 53 ARG.? -5.38 O1 EDO F 103s coo 38.22 57.83 70.36 36.82 56.74 69.18 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo 34.24 60.89 68.08 33.31 57.93 67.63 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 31.43 57.38 61.97 31.90 55.58 64.41 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 ULMN 3 1v0e_c01 ENDO-ALPHA-SIALIDASE user 6 3 # 6 B 581 GLU E 11 GLU.? -3.18 O2 EDO C 103s B 596 ARG E 89 ARG.? -3.87 C2 EDO C 103s B 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 38.22 57.83 70.36 36.82 56.74 69.18 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 34.24 60.89 68.08 33.31 57.93 67.63 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo 31.43 57.38 61.97 31.90 55.58 64.41 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c01 ENDO-ALPHA-SIALIDASE user 7 3 # 7 B 581 GLU E 38 GLU^? 8.47 O1 EDO E 103 B 596 ARG E 40 ARG^? -5.36 O2 EDO E 103s B 647 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 38.22 57.83 70.36 36.82 56.74 69.18 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 34.24 60.89 68.08 33.31 57.93 67.63 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 31.43 57.38 61.97 31.90 55.58 64.41 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1v0e_c01 ENDO-ALPHA-SIALIDASE user 8 3 # 8 B 581 GLU F 9 GLU.? 7.31 C2 EDO F 103 B 596 ARG F 53 ARG.? -5.38 O1 EDO F 103s B 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 38.22 57.83 70.36 36.82 56.74 69.18 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 34.24 60.89 68.08 33.31 57.93 67.63 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 coo 31.43 57.38 61.97 31.90 55.58 64.41 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c01 ENDO-ALPHA-SIALIDASE user 9 3 # 9 B 581 GLU F 21 GLU~? 14.58 O1 CIT F 104 B 596 ARG F 18 ARG~? 15.26 O3 CIT F 104 B 647 ARG F 79 ARG~? 14.02 O1 CIT F 104 coo 38.22 57.83 70.36 36.82 56.74 69.18 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 34.24 60.89 68.08 33.31 57.93 67.63 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 coo 31.43 57.38 61.97 31.90 55.58 64.41 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 1v0e_c01 source 1v0e ENDO-ALPHA-SIALIDASE : 9 hits 1v0e_c01 naa= 3 ULMN 3 1v0e_c02 ENDO-ALPHA-SIALIDASE user 1 3 # 1 C 581 GLU B 9 GLU.? 11.84 O3 CIT B 103 C 596 ARG B 53 ARG.? 13.69 O3 CIT B 103 C 647 ARG A 53 ARG.? 15.50 C1 EDO A 103 coo 11.31 31.26 27.00 13.31 30.71 26.58 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 13.44 32.78 22.07 15.56 30.91 23.37 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 coo 21.00 33.35 22.82 19.83 30.82 24.09 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 ULMN 3 1v0e_c02 ENDO-ALPHA-SIALIDASE user 2 3 # 2 C 581 GLU B 11 GLU.? 15.97 O3 CIT B 103 C 596 ARG B 89 ARG.? 13.25 O3 CIT B 103 C 647 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo 11.31 31.26 27.00 13.31 30.71 26.58 0.63 -96.18 -5.96 0.64 -98.22 -6.51 coo 13.44 32.78 22.07 15.56 30.91 23.37 0.32 -96.47 -11.54 1.69 -95.10 -13.99 coo 21.00 33.35 22.82 19.83 30.82 24.09 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1v0e_c02 ENDO-ALPHA-SIALIDASE user 3 3 # 3 C 581 GLU C 11 GLU.? 13.80 O2 EDO C 103 C 596 ARG C 89 ARG.? 16.36 O3 CIT C 104 C 647 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 11.31 31.26 27.00 13.31 30.71 26.58 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 13.44 32.78 22.07 15.56 30.91 23.37 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo 21.00 33.35 22.82 19.83 30.82 24.09 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1v0e_c02 ENDO-ALPHA-SIALIDASE user 4 3 # 4 C 581 GLU D 11 GLU.? 15.90 O4 CIT D 103 C 596 ARG D 89 ARG.? 14.10 O4 CIT D 103 C 647 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 11.31 31.26 27.00 13.31 30.71 26.58 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo 13.44 32.78 22.07 15.56 30.91 23.37 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 coo 21.00 33.35 22.82 19.83 30.82 24.09 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1v0e_c02 ENDO-ALPHA-SIALIDASE user 5 3 # 5 C 581 GLU E 9 GLU.? 7.76 O1 EDO F 103 C 596 ARG E 53 ARG.? 4.89 O1 EDO F 103 C 647 ARG F 53 ARG.? -5.38 O1 EDO F 103s coo 11.31 31.26 27.00 13.31 30.71 26.58 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo 13.44 32.78 22.07 15.56 30.91 23.37 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 21.00 33.35 22.82 19.83 30.82 24.09 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 ULMN 3 1v0e_c02 ENDO-ALPHA-SIALIDASE user 6 3 # 6 C 581 GLU E 11 GLU.? -3.18 O2 EDO C 103s C 596 ARG E 89 ARG.? -3.87 C2 EDO C 103s C 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 11.31 31.26 27.00 13.31 30.71 26.58 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 13.44 32.78 22.07 15.56 30.91 23.37 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo 21.00 33.35 22.82 19.83 30.82 24.09 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c02 ENDO-ALPHA-SIALIDASE user 7 3 # 7 C 581 GLU E 38 GLU^? 8.47 O1 EDO E 103 C 596 ARG E 40 ARG^? -5.36 O2 EDO E 103s C 647 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 11.31 31.26 27.00 13.31 30.71 26.58 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 13.44 32.78 22.07 15.56 30.91 23.37 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 21.00 33.35 22.82 19.83 30.82 24.09 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1v0e_c02 ENDO-ALPHA-SIALIDASE user 8 3 # 8 C 581 GLU F 9 GLU.? 7.31 C2 EDO F 103 C 596 ARG F 53 ARG.? -5.38 O1 EDO F 103s C 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 11.31 31.26 27.00 13.31 30.71 26.58 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 13.44 32.78 22.07 15.56 30.91 23.37 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 coo 21.00 33.35 22.82 19.83 30.82 24.09 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c02 ENDO-ALPHA-SIALIDASE user 9 3 # 9 C 581 GLU F 21 GLU~? 14.58 O1 CIT F 104 C 596 ARG F 18 ARG~? 15.26 O3 CIT F 104 C 647 ARG F 79 ARG~? 14.02 O1 CIT F 104 coo 11.31 31.26 27.00 13.31 30.71 26.58 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 13.44 32.78 22.07 15.56 30.91 23.37 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 coo 21.00 33.35 22.82 19.83 30.82 24.09 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 1v0e_c02 source 1v0e ENDO-ALPHA-SIALIDASE : 9 hits 1v0e_c02 naa= 3 ULMN 3 1v0e_c03 ENDO-ALPHA-SIALIDASE user 1 3 # 1 D 581 GLU B 9 GLU.? 11.84 O3 CIT B 103 D 596 ARG B 53 ARG.? 13.69 O3 CIT B 103 D 647 ARG A 53 ARG.? 15.50 C1 EDO A 103 coo -44.60 -18.05 21.23 -43.91 -19.28 22.81 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo -46.27 -23.29 20.77 -45.12 -23.03 23.65 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 coo -41.59 -27.81 24.72 -42.43 -25.21 26.20 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 ULMN 3 1v0e_c03 ENDO-ALPHA-SIALIDASE user 2 3 # 2 D 581 GLU B 11 GLU.? 15.97 O3 CIT B 103 D 596 ARG B 89 ARG.? 13.25 O3 CIT B 103 D 647 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo -44.60 -18.05 21.23 -43.91 -19.28 22.81 0.63 -96.18 -5.96 0.64 -98.22 -6.51 coo -46.27 -23.29 20.77 -45.12 -23.03 23.65 0.32 -96.47 -11.54 1.69 -95.10 -13.99 coo -41.59 -27.81 24.72 -42.43 -25.21 26.20 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1v0e_c03 ENDO-ALPHA-SIALIDASE user 3 3 # 3 D 581 GLU C 11 GLU.? 13.80 O2 EDO C 103 D 596 ARG C 89 ARG.? 16.36 O3 CIT C 104 D 647 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo -44.60 -18.05 21.23 -43.91 -19.28 22.81 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo -46.27 -23.29 20.77 -45.12 -23.03 23.65 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo -41.59 -27.81 24.72 -42.43 -25.21 26.20 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1v0e_c03 ENDO-ALPHA-SIALIDASE user 4 3 # 4 D 581 GLU D 11 GLU.? 15.90 O4 CIT D 103 D 596 ARG D 89 ARG.? 14.10 O4 CIT D 103 D 647 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo -44.60 -18.05 21.23 -43.91 -19.28 22.81 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo -46.27 -23.29 20.77 -45.12 -23.03 23.65 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 coo -41.59 -27.81 24.72 -42.43 -25.21 26.20 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1v0e_c03 ENDO-ALPHA-SIALIDASE user 5 3 # 5 D 581 GLU E 9 GLU.? 7.76 O1 EDO F 103 D 596 ARG E 53 ARG.? 4.89 O1 EDO F 103 D 647 ARG F 53 ARG.? -5.38 O1 EDO F 103s coo -44.60 -18.05 21.23 -43.91 -19.28 22.81 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo -46.27 -23.29 20.77 -45.12 -23.03 23.65 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo -41.59 -27.81 24.72 -42.43 -25.21 26.20 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 ULMN 3 1v0e_c03 ENDO-ALPHA-SIALIDASE user 6 3 # 6 D 581 GLU E 11 GLU.? -3.18 O2 EDO C 103s D 596 ARG E 89 ARG.? -3.87 C2 EDO C 103s D 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo -44.60 -18.05 21.23 -43.91 -19.28 22.81 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo -46.27 -23.29 20.77 -45.12 -23.03 23.65 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo -41.59 -27.81 24.72 -42.43 -25.21 26.20 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c03 ENDO-ALPHA-SIALIDASE user 7 3 # 7 D 581 GLU E 38 GLU^? 8.47 O1 EDO E 103 D 596 ARG E 40 ARG^? -5.36 O2 EDO E 103s D 647 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo -44.60 -18.05 21.23 -43.91 -19.28 22.81 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo -46.27 -23.29 20.77 -45.12 -23.03 23.65 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -41.59 -27.81 24.72 -42.43 -25.21 26.20 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1v0e_c03 ENDO-ALPHA-SIALIDASE user 8 3 # 8 D 581 GLU F 9 GLU.? 7.31 C2 EDO F 103 D 596 ARG F 53 ARG.? -5.38 O1 EDO F 103s D 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo -44.60 -18.05 21.23 -43.91 -19.28 22.81 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo -46.27 -23.29 20.77 -45.12 -23.03 23.65 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 coo -41.59 -27.81 24.72 -42.43 -25.21 26.20 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c03 ENDO-ALPHA-SIALIDASE user 9 3 # 9 D 581 GLU F 21 GLU~? 14.58 O1 CIT F 104 D 596 ARG F 18 ARG~? 15.26 O3 CIT F 104 D 647 ARG F 79 ARG~? 14.02 O1 CIT F 104 coo -44.60 -18.05 21.23 -43.91 -19.28 22.81 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo -46.27 -23.29 20.77 -45.12 -23.03 23.65 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 coo -41.59 -27.81 24.72 -42.43 -25.21 26.20 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 1v0e_c03 source 1v0e ENDO-ALPHA-SIALIDASE : 9 hits 1v0e_c03 naa= 3 ULMN 3 1v0e_c04 ENDO-ALPHA-SIALIDASE user 1 3 # 1 E 581 GLU B 11 GLU.? 15.97 O3 CIT B 103 E 596 ARG B 89 ARG.? 13.25 O3 CIT B 103 E 647 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo 13.14 -15.80 20.26 11.08 -15.36 20.42 0.63 -96.18 -5.96 0.64 -98.22 -6.51 coo 10.98 -16.04 15.26 8.84 -14.68 17.08 0.32 -96.47 -11.54 1.69 -95.10 -13.99 coo 3.51 -16.91 15.71 4.51 -14.91 17.79 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1v0e_c04 ENDO-ALPHA-SIALIDASE user 2 3 # 2 E 581 GLU C 11 GLU.? 13.80 O2 EDO C 103 E 596 ARG C 89 ARG.? 16.36 O3 CIT C 104 E 647 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 13.14 -15.80 20.26 11.08 -15.36 20.42 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo 10.98 -16.04 15.26 8.84 -14.68 17.08 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo 3.51 -16.91 15.71 4.51 -14.91 17.79 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1v0e_c04 ENDO-ALPHA-SIALIDASE user 3 3 # 3 E 581 GLU D 11 GLU.? 15.90 O4 CIT D 103 E 596 ARG D 89 ARG.? 14.10 O4 CIT D 103 E 647 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 13.14 -15.80 20.26 11.08 -15.36 20.42 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo 10.98 -16.04 15.26 8.84 -14.68 17.08 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 coo 3.51 -16.91 15.71 4.51 -14.91 17.79 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1v0e_c04 ENDO-ALPHA-SIALIDASE user 4 3 # 4 E 581 GLU E 9 GLU.? 7.76 O1 EDO F 103 E 596 ARG E 53 ARG.? 4.89 O1 EDO F 103 E 647 ARG F 53 ARG.? -5.38 O1 EDO F 103s coo 13.14 -15.80 20.26 11.08 -15.36 20.42 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo 10.98 -16.04 15.26 8.84 -14.68 17.08 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo 3.51 -16.91 15.71 4.51 -14.91 17.79 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 ULMN 3 1v0e_c04 ENDO-ALPHA-SIALIDASE user 5 3 # 5 E 581 GLU E 11 GLU.? -3.18 O2 EDO C 103s E 596 ARG E 89 ARG.? -3.87 C2 EDO C 103s E 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 13.14 -15.80 20.26 11.08 -15.36 20.42 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo 10.98 -16.04 15.26 8.84 -14.68 17.08 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo 3.51 -16.91 15.71 4.51 -14.91 17.79 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c04 ENDO-ALPHA-SIALIDASE user 6 3 # 6 E 581 GLU E 38 GLU^? 8.47 O1 EDO E 103 E 596 ARG E 40 ARG^? -5.36 O2 EDO E 103s E 647 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo 13.14 -15.80 20.26 11.08 -15.36 20.42 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo 10.98 -16.04 15.26 8.84 -14.68 17.08 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 3.51 -16.91 15.71 4.51 -14.91 17.79 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1v0e_c04 ENDO-ALPHA-SIALIDASE user 7 3 # 7 E 581 GLU F 21 GLU~? 14.58 O1 CIT F 104 E 596 ARG F 18 ARG~? 15.26 O3 CIT F 104 E 647 ARG F 79 ARG~? 14.02 O1 CIT F 104 coo 13.14 -15.80 20.26 11.08 -15.36 20.42 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo 10.98 -16.04 15.26 8.84 -14.68 17.08 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 coo 3.51 -16.91 15.71 4.51 -14.91 17.79 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 1v0e_c04 source 1v0e ENDO-ALPHA-SIALIDASE : 7 hits 1v0e_c04 naa= 3 ULMN 3 1v0e_c05 ENDO-ALPHA-SIALIDASE user 1 3 # 1 F 581 GLU B 11 GLU.? 15.97 O3 CIT B 103 F 596 ARG B 89 ARG.? 13.25 O3 CIT B 103 F 647 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo -13.62 -54.34 53.96 -12.26 -52.95 53.12 0.63 -96.18 -5.96 0.64 -98.22 -6.51 coo -9.88 -56.64 50.98 -8.81 -53.71 51.30 0.32 -96.47 -11.54 1.69 -95.10 -13.99 coo -6.86 -51.53 46.20 -7.51 -50.44 49.00 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1v0e_c05 ENDO-ALPHA-SIALIDASE user 2 3 # 2 F 581 GLU C 11 GLU.? 13.80 O2 EDO C 103 F 596 ARG C 89 ARG.? 16.36 O3 CIT C 104 F 647 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo -13.62 -54.34 53.96 -12.26 -52.95 53.12 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 coo -9.88 -56.64 50.98 -8.81 -53.71 51.30 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo -6.86 -51.53 46.20 -7.51 -50.44 49.00 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1v0e_c05 ENDO-ALPHA-SIALIDASE user 3 3 # 3 F 581 GLU D 11 GLU.? 15.90 O4 CIT D 103 F 596 ARG D 89 ARG.? 14.10 O4 CIT D 103 F 647 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo -13.62 -54.34 53.96 -12.26 -52.95 53.12 -36.27 -63.51 0.47 -34.79 -65.02 0.31 coo -9.88 -56.64 50.98 -8.81 -53.71 51.30 -33.66 -63.91 -4.16 -31.56 -62.89 -6.20 coo -6.86 -51.53 46.20 -7.51 -50.44 49.00 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1v0e_c05 ENDO-ALPHA-SIALIDASE user 4 3 # 4 F 581 GLU E 9 GLU.? 7.76 O1 EDO F 103 F 596 ARG E 53 ARG.? 4.89 O1 EDO F 103 F 647 ARG F 53 ARG.? -5.38 O1 EDO F 103s coo -13.62 -54.34 53.96 -12.26 -52.95 53.12 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 coo -9.88 -56.64 50.98 -8.81 -53.71 51.30 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 coo -6.86 -51.53 46.20 -7.51 -50.44 49.00 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 ULMN 3 1v0e_c05 ENDO-ALPHA-SIALIDASE user 5 3 # 5 F 581 GLU E 11 GLU.? -3.18 O2 EDO C 103s F 596 ARG E 89 ARG.? -3.87 C2 EDO C 103s F 647 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo -13.62 -54.34 53.96 -12.26 -52.95 53.12 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 coo -9.88 -56.64 50.98 -8.81 -53.71 51.30 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo -6.86 -51.53 46.20 -7.51 -50.44 49.00 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1v0e_c05 ENDO-ALPHA-SIALIDASE user 6 3 # 6 F 581 GLU E 38 GLU^? 8.47 O1 EDO E 103 F 596 ARG E 40 ARG^? -5.36 O2 EDO E 103s F 647 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo -13.62 -54.34 53.96 -12.26 -52.95 53.12 -29.31 -89.59 -49.15 -28.25 -89.30 -51.01 coo -9.88 -56.64 50.98 -8.81 -53.71 51.30 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -6.86 -51.53 46.20 -7.51 -50.44 49.00 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 ULMN 3 1v0e_c05 ENDO-ALPHA-SIALIDASE user 7 3 # 7 F 581 GLU F 21 GLU~? 14.58 O1 CIT F 104 F 596 ARG F 18 ARG~? 15.26 O3 CIT F 104 F 647 ARG F 79 ARG~? 14.02 O1 CIT F 104 coo -13.62 -54.34 53.96 -12.26 -52.95 53.12 -26.20 -82.45 -77.67 -24.96 -81.67 -79.17 coo -9.88 -56.64 50.98 -8.81 -53.71 51.30 -24.74 -77.42 -77.57 -24.14 -77.36 -80.58 coo -6.86 -51.53 46.20 -7.51 -50.44 49.00 -17.17 -82.56 -76.49 -18.18 -82.03 -79.39 1v0e_c05 source 1v0e ENDO-ALPHA-SIALIDASE : 7 hits 1v0e_c05 naa= 3 ULMN 3 1vom_c00 MYOSIN user 1 3 # 1 233 ASN A 44 ASN.? 11.73 O6 CIT B 103 457 GLY A 42 GLY^? 14.43 O2 EDO A 103 459 GLU B 101 GLU^? 17.79 O2 CIT B 103 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -12.08 -75.65 -26.58 -11.94 -76.42 -26.42 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 ULMN 3 1vom_c00 MYOSIN user 2 3 # 2 233 ASN B 44 ASN.? 13.13 O1 EDO A 103 457 GLY B 42 GLY^? 14.02 O1 CIT B 103 459 GLU A 101 GLU^? 18.10 O2 EDO A 103 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -16.95 -88.05 -8.22 -16.29 -87.98 -8.72 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 ULMN 3 1vom_c00 MYOSIN user 3 3 # 3 233 ASN C 44 ASN.? 11.91 O6 CIT D 103 457 GLY C 42 GLY^? 14.18 O1 CIT C 104 459 GLU D 101 GLU^? 17.58 O6 CIT D 103 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -46.70 -55.40 -28.61 -46.31 -55.96 -28.16 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 ULMN 3 1vom_c00 MYOSIN user 4 3 # 4 233 ASN C 90 ASN~? 14.00 O3 CIT C 104 457 GLY E 14 GLY~? 13.52 O2 EDO C 103 459 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 1vom_c00 MYOSIN user 5 3 # 5 233 ASN D 44 ASN.? 12.24 O2 CIT C 104 457 GLY D 42 GLY^? 14.38 C1 CIT D 103 459 GLU C 101 GLU^? 17.42 O2 CIT C 104 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -52.42 -66.59 -9.79 -51.76 -66.17 -10.02 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 ULMN 3 1vom_c00 MYOSIN user 6 3 # 6 233 ASN E 44 ASN.? 11.90 O7 CIT F 104 457 GLY E 42 GLY^? 5.78 O2 EDO E 103 459 GLU F 101 GLU^? 10.35 O2 EDO E 103 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -23.13 -79.15 -45.19 -23.65 -78.62 -45.54 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 ULMN 3 1vom_c00 MYOSIN user 7 3 # 7 233 ASN E 90 ASN~? -4.46 O2 EDO C 103s 457 GLY C 14 GLY~? 3.87 C1 EDO C 103 459 GLU E 11 GLU.? -3.18 O2 EDO C 103s coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 ULMN 3 1vom_c00 MYOSIN user 8 3 # 8 233 ASN F 44 ASN.? 8.45 O2 EDO F 103 457 GLY F 42 GLY^? 14.33 O2 CIT F 104 459 GLU E 101 GLU^? 17.69 O2 CIT E 104 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -33.76 -82.86 -64.67 -33.34 -82.22 -64.40 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -39.46 -85.37 -61.65 -41.47 -85.34 -62.20 1vom_c00 source 1vom MYOSIN : 8 hits 1vom_c00 naa= 3 ULMN 3 1vq1_c00 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 1 3 # 1 A 100 PHE A 47 PHE.? 11.10 O6 CIT B 103 A 197 ASN A 44 ASN.? 11.73 O6 CIT B 103 A 198 PRO A 43 PRO^? 17.15 O2 EDO A 103 coo 5.24 -2.19 28.74 3.83 -0.30 30.29 -2.59 -72.91 -18.03 -4.32 -71.21 -19.43 coo 6.86 -1.03 36.13 5.08 -0.39 35.24 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 3.80 -4.83 39.13 4.75 -4.51 37.10 -8.38 -73.55 -27.31 -9.00 -75.70 -26.82 ULMN 3 1vq1_c00 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 2 3 # 2 A 100 PHE B 47 PHE.? 12.19 O2 EDO A 103 A 197 ASN B 44 ASN.? 13.13 O1 EDO A 103 A 198 PRO B 43 PRO^? 16.74 O1 CIT B 103 coo 5.24 -2.19 28.74 3.83 -0.30 30.29 -21.43 -95.11 -18.48 -22.73 -94.18 -16.16 coo 6.86 -1.03 36.13 5.08 -0.39 35.24 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 3.80 -4.83 39.13 4.75 -4.51 37.10 -18.16 -92.21 -8.38 -16.44 -90.98 -9.14 ULMN 3 1vq1_c00 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 3 3 # 3 A 100 PHE C 47 PHE.? 10.29 O6 CIT D 103 A 197 ASN C 44 ASN.? 11.91 O6 CIT D 103 A 198 PRO C 43 PRO^? 16.83 O1 CIT C 104 coo 5.24 -2.19 28.74 3.83 -0.30 30.29 -44.27 -47.07 -18.55 -45.83 -46.91 -20.85 coo 6.86 -1.03 36.13 5.08 -0.39 35.24 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 3.80 -4.83 39.13 4.75 -4.51 37.10 -44.37 -51.76 -28.68 -44.19 -53.81 -27.76 ULMN 3 1vq1_c00 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 4 3 # 4 A 100 PHE C 47 PHE.? 10.29 O6 CIT D 103 A 197 ASN D -5 ASN.? 16.01 O6 CIT D 103 A 198 PRO C 43 PRO^? 16.83 O1 CIT C 104 coo 5.24 -2.19 28.74 3.83 -0.30 30.29 -44.27 -47.07 -18.55 -45.83 -46.91 -20.85 coo 6.86 -1.03 36.13 5.08 -0.39 35.24 -38.30 -48.37 -26.01 -39.87 -49.66 -25.30 coo 3.80 -4.83 39.13 4.75 -4.51 37.10 -44.37 -51.76 -28.68 -44.19 -53.81 -27.76 ULMN 3 1vq1_c00 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 5 3 # 5 A 100 PHE D 47 PHE.? 11.25 O2 CIT C 104 A 197 ASN D 44 ASN.? 12.24 O2 CIT C 104 A 198 PRO D 43 PRO^? 16.79 C2 CIT D 103 coo 5.24 -2.19 28.74 3.83 -0.30 30.29 -47.67 -75.88 -18.20 -50.04 -75.67 -16.72 coo 6.86 -1.03 36.13 5.08 -0.39 35.24 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 coo 3.80 -4.83 39.13 4.75 -4.51 37.10 -51.31 -70.72 -9.08 -50.24 -68.79 -9.64 ULMN 3 1vq1_c00 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 6 3 # 6 A 100 PHE E 47 PHE.? 10.83 O7 CIT F 104 A 197 ASN E 44 ASN.? 11.90 O7 CIT F 104 A 198 PRO E 43 PRO^? 9.04 O2 EDO E 103 coo 5.24 -2.19 28.74 3.83 -0.30 30.29 -14.13 -76.21 -54.39 -14.06 -77.82 -52.12 coo 6.86 -1.03 36.13 5.08 -0.39 35.24 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 3.80 -4.83 39.13 4.75 -4.51 37.10 -19.31 -77.07 -44.70 -21.34 -76.65 -45.59 ULMN 3 1vq1_c00 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 7 3 # 7 A 100 PHE F 47 PHE.? 11.67 C2 CIT E 104 A 197 ASN F 44 ASN.? 8.45 O2 EDO F 103 A 198 PRO F 43 PRO^? 15.47 O2 EDO F 103 coo 5.24 -2.19 28.74 3.83 -0.30 30.29 -43.32 -78.73 -56.13 -43.26 -81.00 -57.76 coo 6.86 -1.03 36.13 5.08 -0.39 35.24 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 coo 3.80 -4.83 39.13 4.75 -4.51 37.10 -37.87 -81.53 -65.46 -35.92 -80.65 -64.76 1vq1_c00 source 1vq1 N5-GLUTAMINE METHYLTRANSFERASE, HEMK : 7 hits 1vq1_c00 naa= 3 ULMN 3 1vq1_c01 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 1 3 # 1 B 100 PHE A 47 PHE.? 11.10 O6 CIT B 103 B 197 ASN A 44 ASN.? 11.73 O6 CIT B 103 B 198 PRO A 43 PRO^? 17.15 O2 EDO A 103 coo 15.92 -14.38 -0.49 15.85 -16.40 -2.42 -2.59 -72.91 -18.03 -4.32 -71.21 -19.43 coo 21.71 -15.65 -5.30 19.75 -16.44 -5.47 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 21.24 -11.77 -9.43 20.56 -12.14 -7.31 -8.38 -73.55 -27.31 -9.00 -75.70 -26.82 ULMN 3 1vq1_c01 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 2 3 # 2 B 100 PHE B 47 PHE.? 12.19 O2 EDO A 103 B 197 ASN B 44 ASN.? 13.13 O1 EDO A 103 B 198 PRO B 43 PRO^? 16.74 O1 CIT B 103 coo 15.92 -14.38 -0.49 15.85 -16.40 -2.42 -21.43 -95.11 -18.48 -22.73 -94.18 -16.16 coo 21.71 -15.65 -5.30 19.75 -16.44 -5.47 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 21.24 -11.77 -9.43 20.56 -12.14 -7.31 -18.16 -92.21 -8.38 -16.44 -90.98 -9.14 ULMN 3 1vq1_c01 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 3 3 # 3 B 100 PHE C 47 PHE.? 10.29 O6 CIT D 103 B 197 ASN C 44 ASN.? 11.91 O6 CIT D 103 B 198 PRO C 43 PRO^? 16.83 O1 CIT C 104 coo 15.92 -14.38 -0.49 15.85 -16.40 -2.42 -44.27 -47.07 -18.55 -45.83 -46.91 -20.85 coo 21.71 -15.65 -5.30 19.75 -16.44 -5.47 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 21.24 -11.77 -9.43 20.56 -12.14 -7.31 -44.37 -51.76 -28.68 -44.19 -53.81 -27.76 ULMN 3 1vq1_c01 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 4 3 # 4 B 100 PHE D 47 PHE.? 11.25 O2 CIT C 104 B 197 ASN D 44 ASN.? 12.24 O2 CIT C 104 B 198 PRO D 43 PRO^? 16.79 C2 CIT D 103 coo 15.92 -14.38 -0.49 15.85 -16.40 -2.42 -47.67 -75.88 -18.20 -50.04 -75.67 -16.72 coo 21.71 -15.65 -5.30 19.75 -16.44 -5.47 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 coo 21.24 -11.77 -9.43 20.56 -12.14 -7.31 -51.31 -70.72 -9.08 -50.24 -68.79 -9.64 ULMN 3 1vq1_c01 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 5 3 # 5 B 100 PHE E 47 PHE.? 10.83 O7 CIT F 104 B 197 ASN E 44 ASN.? 11.90 O7 CIT F 104 B 198 PRO E 43 PRO^? 9.04 O2 EDO E 103 coo 15.92 -14.38 -0.49 15.85 -16.40 -2.42 -14.13 -76.21 -54.39 -14.06 -77.82 -52.12 coo 21.71 -15.65 -5.30 19.75 -16.44 -5.47 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 21.24 -11.77 -9.43 20.56 -12.14 -7.31 -19.31 -77.07 -44.70 -21.34 -76.65 -45.59 ULMN 3 1vq1_c01 N5-GLUTAMINE METHYLTRANSFERASE, HEMKuser 6 3 # 6 B 100 PHE F 47 PHE.? 11.67 C2 CIT E 104 B 197 ASN F 44 ASN.? 8.45 O2 EDO F 103 B 198 PRO F 43 PRO^? 15.47 O2 EDO F 103 coo 15.92 -14.38 -0.49 15.85 -16.40 -2.42 -43.32 -78.73 -56.13 -43.26 -81.00 -57.76 coo 21.71 -15.65 -5.30 19.75 -16.44 -5.47 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 coo 21.24 -11.77 -9.43 20.56 -12.14 -7.31 -37.87 -81.53 -65.46 -35.92 -80.65 -64.76 1vq1_c01 source 1vq1 N5-GLUTAMINE METHYLTRANSFERASE, HEMK : 6 hits 1vq1_c01 naa= 3 ULMN 3 1vzx_c02 2.04.01.0087 user 1 3 # 1 A 314 TYR A 54 TYR.? 12.54 C1 EDO A 103 A 317 GLU A 9 GLU.? 14.22 C1 EDO A 103 A 365 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 1.77 6.56 57.05 3.05 7.44 59.37 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 3.06 2.85 52.79 4.83 3.89 53.24 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 coo 3.82 17.09 49.56 4.09 14.32 50.84 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1vzx_c02 2.04.01.0087 user 2 3 # 2 A 314 TYR B 54 TYR.? 11.82 O7 CIT B 103 A 317 GLU B 9 GLU.? 11.84 O3 CIT B 103 A 365 ARG A 53 ARG.? 15.50 C1 EDO A 103 coo 1.77 6.56 57.05 3.05 7.44 59.37 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 3.06 2.85 52.79 4.83 3.89 53.24 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 3.82 17.09 49.56 4.09 14.32 50.84 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 ULMN 3 1vzx_c02 2.04.01.0087 user 3 3 # 3 A 314 TYR B 54 TYR.? 11.82 O7 CIT B 103 A 317 GLU B 9 GLU.? 11.84 O3 CIT B 103 A 365 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 1.77 6.56 57.05 3.05 7.44 59.37 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 3.06 2.85 52.79 4.83 3.89 53.24 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 3.82 17.09 49.56 4.09 14.32 50.84 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1vzx_c02 2.04.01.0087 user 4 3 # 4 A 314 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 317 GLU C 9 GLU.? 12.64 O3 CIT C 104 A 365 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 1.77 6.56 57.05 3.05 7.44 59.37 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 3.06 2.85 52.79 4.83 3.89 53.24 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 3.82 17.09 49.56 4.09 14.32 50.84 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1vzx_c02 2.04.01.0087 user 5 3 # 5 A 314 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 317 GLU C 9 GLU.? 12.64 O3 CIT C 104 A 365 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 1.77 6.56 57.05 3.05 7.44 59.37 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 3.06 2.85 52.79 4.83 3.89 53.24 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 3.82 17.09 49.56 4.09 14.32 50.84 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1vzx_c02 2.04.01.0087 user 6 3 # 6 A 314 TYR D 54 TYR.? 11.66 C4 CIT D 103 A 317 GLU D 9 GLU.? 12.31 O4 CIT D 103 A 365 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 1.77 6.56 57.05 3.05 7.44 59.37 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 3.06 2.85 52.79 4.83 3.89 53.24 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 3.82 17.09 49.56 4.09 14.32 50.84 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1vzx_c02 2.04.01.0087 user 7 3 # 7 A 314 TYR F 54 TYR.? 5.10 C2 EDO F 103 A 317 GLU F 9 GLU.? 7.31 C2 EDO F 103 A 365 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 1.77 6.56 57.05 3.05 7.44 59.37 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 3.06 2.85 52.79 4.83 3.89 53.24 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 3.82 17.09 49.56 4.09 14.32 50.84 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 1vzx_c02 source 1vzx 2.04.01.0087 : 7 hits 1vzx_c02 naa= 3 ULMN 3 1vzx_c03 2.04.01.0087 user 1 3 # 1 B1314 TYR A 54 TYR.? 12.54 C1 EDO A 103 B1317 GLU A 9 GLU.? 14.22 C1 EDO A 103 B1365 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1vzx_c03 2.04.01.0087 user 2 3 # 2 B1314 TYR A 54 TYR.? 12.54 C1 EDO A 103 B1317 GLU A 9 GLU.? 14.22 C1 EDO A 103 B1365 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 ULMN 3 1vzx_c03 2.04.01.0087 user 3 3 # 3 B1314 TYR B 54 TYR.? 11.82 O7 CIT B 103 B1317 GLU B 9 GLU.? 11.84 O3 CIT B 103 B1365 ARG A 53 ARG.? 15.50 C1 EDO A 103 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -1.93 -89.29 -24.96 -2.51 -92.29 -24.62 ULMN 3 1vzx_c03 2.04.01.0087 user 4 3 # 4 B1314 TYR B 54 TYR.? 11.82 O7 CIT B 103 B1317 GLU B 9 GLU.? 11.84 O3 CIT B 103 B1365 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1vzx_c03 2.04.01.0087 user 5 3 # 5 B1314 TYR C 54 TYR.? 11.88 O3 CIT C 104 B1317 GLU C 9 GLU.? 12.64 O3 CIT C 104 B1365 ARG C 45 ARG.? 18.33 O6 CIT D 103 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -43.60 -48.74 -25.39 -43.83 -48.42 -28.42 ULMN 3 1vzx_c03 2.04.01.0087 user 6 3 # 6 B1314 TYR C 54 TYR.? 11.88 O3 CIT C 104 B1317 GLU C 9 GLU.? 12.64 O3 CIT C 104 B1365 ARG D 53 ARG.? 12.25 O4 CIT D 103 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -35.35 -64.74 -11.54 -33.97 -62.19 -10.41 ULMN 3 1vzx_c03 2.04.01.0087 user 7 3 # 7 B1314 TYR D 54 TYR.? 11.66 C4 CIT D 103 B1317 GLU D 9 GLU.? 12.31 O4 CIT D 103 B1365 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1vzx_c03 2.04.01.0087 user 8 3 # 8 B1314 TYR D 54 TYR.? 11.66 C4 CIT D 103 B1317 GLU D 9 GLU.? 12.31 O4 CIT D 103 B1365 ARG D 45 ARG.? 18.60 O2 CIT C 104 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -37.48 -64.35 -6.95 -35.58 -63.73 -7.61 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 ULMN 3 1vzx_c03 2.04.01.0087 user 9 3 # 9 B1314 TYR F 54 TYR.? 5.10 C2 EDO F 103 B1317 GLU F 9 GLU.? 7.31 C2 EDO F 103 B1365 ARG E 53 ARG.? 4.89 O1 EDO F 103 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -27.62 -64.57 -53.37 -30.11 -63.08 -54.45 ULMN 3 1vzx_c03 2.04.01.0087 user 10 3 # 10 B1314 TYR F 54 TYR.? 5.10 C2 EDO F 103 B1317 GLU F 9 GLU.? 7.31 C2 EDO F 103 B1365 ARG F 45 ARG.? 16.99 O2 EDO F 103 coo 13.32 10.15 -9.20 12.07 11.36 -11.38 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 12.13 5.84 -5.49 10.31 6.88 -5.76 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 coo 11.24 19.69 -0.67 10.92 17.07 -2.21 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 1vzx_c03 source 1vzx 2.04.01.0087 : 10 hits 1vzx_c03 naa= 3 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 1 3 # 1 A 16 TYR A 3 TYR.? 14.44 O2 EDO A 103 A 40 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 103 LEU A 2 LEU.? 12.09 O2 EDO A 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 7.55 25.51 14.34 9.65 25.73 14.24 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 11.83 18.73 16.99 10.99 19.71 15.26 -23.40 -88.14 -16.22 -23.57 -90.26 -15.78 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 2 3 # 2 A 16 TYR A 54 TYR.? 12.54 C1 EDO A 103 A 40 ASP A 93 ASP~? 12.48 O1 EDO A 103 A 103 LEU A 96 LEU^? 10.34 C1 EDO A 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 7.55 25.51 14.34 9.65 25.73 14.24 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo 11.83 18.73 16.99 10.99 19.71 15.26 -9.29 -89.64 -23.11 -8.75 -89.92 -21.04 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 3 3 # 3 A 16 TYR A 56 TYR^? 12.86 C2 EDO A 103 A 40 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 103 LEU B 100 LEU^? 13.83 O2 EDO A 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo 7.55 25.51 14.34 9.65 25.73 14.24 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 11.83 18.73 16.99 10.99 19.71 15.26 -11.19 -77.10 -21.71 -11.33 -79.05 -22.56 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 4 3 # 4 A 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 40 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 103 LEU A 29 LEU~? 10.48 O2 EDO A 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 7.55 25.51 14.34 9.65 25.73 14.24 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 11.83 18.73 16.99 10.99 19.71 15.26 -26.95 -81.99 -31.30 -27.85 -83.90 -30.83 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 5 3 # 5 A 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 40 ASP A 64 ASP~? 16.37 O2 EDO A 103 A 103 LEU A 68 LEU~? 8.28 O2 EDO A 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 7.55 25.51 14.34 9.65 25.73 14.24 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 11.83 18.73 16.99 10.99 19.71 15.26 -25.35 -90.24 -20.94 -23.22 -90.71 -21.35 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 6 3 # 6 A 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 40 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 103 LEU A 68 LEU~? 8.28 O2 EDO A 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 7.55 25.51 14.34 9.65 25.73 14.24 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 11.83 18.73 16.99 10.99 19.71 15.26 -25.35 -90.24 -20.94 -23.22 -90.71 -21.35 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 7 3 # 7 A 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 40 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 103 LEU A 29 LEU~? 10.48 O2 EDO A 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 7.55 25.51 14.34 9.65 25.73 14.24 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 11.83 18.73 16.99 10.99 19.71 15.26 -26.95 -81.99 -31.30 -27.85 -83.90 -30.83 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 8 3 # 8 A 16 TYR B 3 TYR.? 14.53 O2 CIT B 103 A 40 ASP B 64 ASP~? 16.93 O2 CIT B 103 A 103 LEU B 2 LEU.? 12.07 O2 CIT B 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 7.55 25.51 14.34 9.65 25.73 14.24 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 11.83 18.73 16.99 10.99 19.71 15.26 -10.11 -71.79 -17.26 -8.38 -70.83 -18.16 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 9 3 # 9 A 16 TYR B 54 TYR.? 11.82 O7 CIT B 103 A 40 ASP B 93 ASP~? 9.77 O3 CIT B 103 A 103 LEU B 96 LEU^? 9.68 O7 CIT B 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 7.55 25.51 14.34 9.65 25.73 14.24 3.85 -90.04 -12.91 5.79 -89.33 -13.36 coo 11.83 18.73 16.99 10.99 19.71 15.26 -4.76 -86.79 -16.51 -5.13 -86.53 -18.64 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 10 3 # 10 A 16 TYR B 56 TYR^? 12.51 O1 CIT B 103 A 40 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 103 LEU A 100 LEU^? 13.85 O1 CIT B 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo 7.55 25.51 14.34 9.65 25.73 14.24 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 11.83 18.73 16.99 10.99 19.71 15.26 -17.08 -87.25 -13.38 -14.97 -87.07 -12.96 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 11 3 # 11 A 16 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 40 ASP B 27 ASP~? 12.32 O1 CIT B 103 A 103 LEU B 29 LEU~? 9.72 O1 CIT B 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 7.55 25.51 14.34 9.65 25.73 14.24 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 11.83 18.73 16.99 10.99 19.71 15.26 -10.92 -74.23 -0.54 -9.16 -73.03 -1.02 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 12 3 # 12 A 16 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 40 ASP B 64 ASP~? 16.93 O2 CIT B 103 A 103 LEU B 68 LEU~? 8.47 O2 CIT B 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 7.55 25.51 14.34 9.65 25.73 14.24 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 11.83 18.73 16.99 10.99 19.71 15.26 -6.89 -70.80 -13.14 -5.91 -72.71 -13.57 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 13 3 # 13 A 16 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 40 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 103 LEU B 68 LEU~? 8.47 O2 CIT B 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 7.55 25.51 14.34 9.65 25.73 14.24 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 11.83 18.73 16.99 10.99 19.71 15.26 -6.89 -70.80 -13.14 -5.91 -72.71 -13.57 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 14 3 # 14 A 16 TYR C 3 TYR.? 14.43 O1 CIT C 104 A 40 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 103 LEU C 2 LEU.? 11.85 O2 CIT C 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 coo 7.55 25.51 14.34 9.65 25.73 14.24 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 11.83 18.73 16.99 10.99 19.71 15.26 -53.70 -71.21 -19.02 -53.04 -73.06 -18.04 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 15 3 # 15 A 16 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 40 ASP C 93 ASP~? 9.74 O3 CIT C 104 A 103 LEU C 96 LEU^? 9.85 O3 CIT C 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 7.55 25.51 14.34 9.65 25.73 14.24 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 11.83 18.73 16.99 10.99 19.71 15.26 -39.14 -64.82 -20.28 -39.32 -64.46 -18.13 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 16 3 # 16 A 16 TYR C 56 TYR^? 12.84 O1 CIT C 104 A 40 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 103 LEU D 100 LEU^? 13.70 O1 CIT C 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo 7.55 25.51 14.34 9.65 25.73 14.24 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 11.83 18.73 16.99 10.99 19.71 15.26 -47.31 -55.74 -23.54 -46.04 -57.49 -23.79 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 17 3 # 17 A 16 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 40 ASP C 27 ASP~? 13.15 O1 CIT C 104 A 103 LEU C 29 LEU~? 9.96 O1 CIT C 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 7.55 25.51 14.34 9.65 25.73 14.24 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 11.83 18.73 16.99 10.99 19.71 15.26 -52.67 -69.81 -35.63 -52.40 -71.85 -34.94 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 18 3 # 18 A 16 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 40 ASP C 64 ASP~? 16.62 O2 CIT C 104 A 103 LEU C 68 LEU~? 8.19 O2 CIT C 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 7.55 25.51 14.34 9.65 25.73 14.24 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 11.83 18.73 16.99 10.99 19.71 15.26 -52.21 -74.51 -23.05 -50.26 -73.52 -22.72 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 19 3 # 19 A 16 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 40 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 103 LEU C 68 LEU~? 8.19 O2 CIT C 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 7.55 25.51 14.34 9.65 25.73 14.24 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 11.83 18.73 16.99 10.99 19.71 15.26 -52.21 -74.51 -23.05 -50.26 -73.52 -22.72 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 20 3 # 20 A 16 TYR D -3 TYR.? 15.53 O6 CIT D 103 A 40 ASP D 69 ASP~? 11.20 O6 CIT D 103 A 103 LEU D 2 LEU.? 11.83 O6 CIT D 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 coo 7.55 25.51 14.34 9.65 25.73 14.24 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 11.83 18.73 16.99 10.99 19.71 15.26 -50.75 -50.35 -21.01 -49.33 -48.73 -21.36 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 21 3 # 21 A 16 TYR D 3 TYR.? 14.21 O2 CIT D 103 A 40 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 103 LEU D 2 LEU.? 11.83 O6 CIT D 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 7.55 25.51 14.34 9.65 25.73 14.24 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 11.83 18.73 16.99 10.99 19.71 15.26 -50.75 -50.35 -21.01 -49.33 -48.73 -21.36 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 22 3 # 22 A 16 TYR D 54 TYR.? 11.66 C4 CIT D 103 A 40 ASP D 93 ASP~? 9.04 O4 CIT D 103 A 103 LEU D 96 LEU^? 9.60 C4 CIT D 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 7.55 25.51 14.34 9.65 25.73 14.24 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 11.83 18.73 16.99 10.99 19.71 15.26 -40.15 -59.46 -13.69 -39.38 -59.80 -15.68 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 23 3 # 23 A 16 TYR D 56 TYR^? 12.73 C2 CIT D 103 A 40 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 103 LEU C 100 LEU^? 13.72 O2 CIT D 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 coo 7.55 25.51 14.34 9.65 25.73 14.24 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 11.83 18.73 16.99 10.99 19.71 15.26 -50.61 -66.45 -14.87 -49.30 -65.03 -13.86 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 24 3 # 24 A 16 TYR D 71 TYR~? -4.87 O2 CIT D 103s A 40 ASP D 27 ASP~? 12.70 O1 CIT D 103 A 103 LEU D 29 LEU~? 9.75 O1 CIT D 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 7.55 25.51 14.34 9.65 25.73 14.24 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 11.83 18.73 16.99 10.99 19.71 15.26 -57.68 -51.25 -5.98 -56.83 -49.30 -6.53 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 25 3 # 25 A 16 TYR D 71 TYR~? -4.87 O2 CIT D 103s A 40 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 103 LEU D 68 LEU~? 8.05 O6 CIT D 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 7.55 25.51 14.34 9.65 25.73 14.24 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 11.83 18.73 16.99 10.99 19.71 15.26 -50.69 -47.26 -16.46 -48.95 -48.50 -15.98 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 26 3 # 26 A 16 TYR D 71 TYR~? -4.87 O2 CIT D 103s A 40 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 103 LEU D 68 LEU~? 8.05 O6 CIT D 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 7.55 25.51 14.34 9.65 25.73 14.24 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 11.83 18.73 16.99 10.99 19.71 15.26 -50.69 -47.26 -16.46 -48.95 -48.50 -15.98 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 27 3 # 27 A 16 TYR E 3 TYR.? 13.85 O2 EDO E 103 A 40 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 103 LEU E 2 LEU.? 11.93 O2 CIT E 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 7.55 25.51 14.34 9.65 25.73 14.24 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 11.83 18.73 16.99 10.99 19.71 15.26 -38.80 -84.65 -55.80 -40.65 -84.17 -56.89 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 28 3 # 28 A 16 TYR E 54 TYR.? 6.56 O1 EDO F 103 A 40 ASP E 93 ASP~? 8.62 O3 CIT E 104 A 103 LEU E 96 LEU^? 5.04 C1 EDO F 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 7.55 25.51 14.34 9.65 25.73 14.24 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 11.83 18.73 16.99 10.99 19.71 15.26 -32.10 -70.65 -53.43 -31.78 -70.83 -55.55 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 29 3 # 29 A 16 TYR E 56 TYR^? 8.81 O2 EDO E 103 A 40 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 103 LEU F 100 LEU^? 8.24 O2 EDO E 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo 7.55 25.51 14.34 9.65 25.73 14.24 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 11.83 18.73 16.99 10.99 19.71 15.26 -23.26 -79.30 -50.33 -25.04 -78.05 -50.01 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 30 3 # 30 A 16 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 40 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 103 LEU E 29 LEU~? 10.53 O1 CIT E 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 7.55 25.51 14.34 9.65 25.73 14.24 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 11.83 18.73 16.99 10.99 19.71 15.26 -37.60 -84.97 -38.66 -39.68 -84.53 -39.24 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 31 3 # 31 A 16 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 40 ASP E 64 ASP~? 16.37 O2 CIT E 104 A 103 LEU E 68 LEU~? 8.13 O2 CIT E 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 7.55 25.51 14.34 9.65 25.73 14.24 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 11.83 18.73 16.99 10.99 19.71 15.26 -42.16 -83.41 -51.47 -41.23 -81.44 -51.72 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 32 3 # 32 A 16 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 40 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 103 LEU E 68 LEU~? 8.13 O2 CIT E 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 7.55 25.51 14.34 9.65 25.73 14.24 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 11.83 18.73 16.99 10.99 19.71 15.26 -42.16 -83.41 -51.47 -41.23 -81.44 -51.72 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 33 3 # 33 A 16 TYR F 3 TYR.? 7.56 O2 EDO E 103 A 40 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 103 LEU F 2 LEU.? 11.54 O2 EDO E 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 coo 7.55 25.51 14.34 9.65 25.73 14.24 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 11.83 18.73 16.99 10.99 19.71 15.26 -17.84 -82.79 -52.93 -16.12 -81.66 -52.08 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 34 3 # 34 A 16 TYR F 54 TYR.? 5.10 C2 EDO F 103 A 40 ASP F 93 ASP~? 9.52 O4 CIT F 104 A 103 LEU F 96 LEU^? 6.94 O1 EDO F 103 coo 12.09 16.13 10.57 11.28 18.80 10.73 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 7.55 25.51 14.34 9.65 25.73 14.24 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 coo 11.83 18.73 16.99 10.99 19.71 15.26 -26.37 -71.21 -59.60 -26.77 -70.69 -57.54 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 35 3 # 35 A 16 TYR F 56 TYR^? 13.04 O1 CIT F 104 A 40 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 103 LEU E 100 LEU^? 13.74 O2 CIT F 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 coo 7.55 25.51 14.34 9.65 25.73 14.24 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 11.83 18.73 16.99 10.99 19.71 15.26 -33.88 -81.47 -59.62 -32.42 -80.07 -60.48 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 36 3 # 36 A 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s A 40 ASP F 27 ASP~? 14.00 O1 CIT F 104 A 103 LEU F 29 LEU~? 9.64 O1 CIT F 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 7.55 25.51 14.34 9.65 25.73 14.24 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 11.83 18.73 16.99 10.99 19.71 15.26 -18.08 -88.25 -68.44 -16.23 -87.24 -67.92 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 37 3 # 37 A 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s A 40 ASP F 27 ASP~? 14.00 O1 CIT F 104 A 103 LEU F 36 LEU^? 9.95 O2 CIT F 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 7.55 25.51 14.34 9.65 25.73 14.24 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 11.83 18.73 16.99 10.99 19.71 15.26 -18.40 -89.01 -60.82 -19.96 -87.78 -61.71 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 38 3 # 38 A 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s A 40 ASP F 64 ASP~? 16.52 O2 EDO E 103 A 103 LEU F 68 LEU~? 8.38 O7 CIT F 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 7.55 25.51 14.34 9.65 25.73 14.24 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 11.83 18.73 16.99 10.99 19.71 15.26 -14.42 -82.30 -57.16 -15.55 -80.53 -57.63 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 39 3 # 39 A 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s A 40 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 103 LEU F 68 LEU~? 8.38 O7 CIT F 104 coo 12.09 16.13 10.57 11.28 18.80 10.73 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 7.55 25.51 14.34 9.65 25.73 14.24 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 11.83 18.73 16.99 10.99 19.71 15.26 -14.42 -82.30 -57.16 -15.55 -80.53 -57.63 1vzz_c00 source 1vzz STEROID DELTA-ISOMERASE : 39 hits 1vzz_c00 naa= 3 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 1 3 # 1 B 16 TYR A 3 TYR.? 14.44 O2 EDO A 103 B 40 ASP A 64 ASP~? 16.37 O2 EDO A 103 B 103 LEU A 2 LEU.? 12.09 O2 EDO A 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 coo 9.39 10.77 34.53 11.50 10.63 34.41 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 12.89 17.60 31.13 12.34 16.51 32.90 -23.40 -88.14 -16.22 -23.57 -90.26 -15.78 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 2 3 # 2 B 16 TYR A 54 TYR.? 12.54 C1 EDO A 103 B 40 ASP A 93 ASP~? 12.48 O1 EDO A 103 B 103 LEU A 96 LEU^? 10.34 C1 EDO A 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 9.39 10.77 34.53 11.50 10.63 34.41 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo 12.89 17.60 31.13 12.34 16.51 32.90 -9.29 -89.64 -23.11 -8.75 -89.92 -21.04 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 3 3 # 3 B 16 TYR A 56 TYR^? 12.86 C2 EDO A 103 B 40 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 103 LEU B 100 LEU^? 13.83 O2 EDO A 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo 9.39 10.77 34.53 11.50 10.63 34.41 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 12.89 17.60 31.13 12.34 16.51 32.90 -11.19 -77.10 -21.71 -11.33 -79.05 -22.56 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 4 3 # 4 B 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s B 40 ASP A 27 ASP~? 13.11 O2 EDO A 103 B 103 LEU A 29 LEU~? 10.48 O2 EDO A 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 9.39 10.77 34.53 11.50 10.63 34.41 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 12.89 17.60 31.13 12.34 16.51 32.90 -26.95 -81.99 -31.30 -27.85 -83.90 -30.83 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 5 3 # 5 B 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s B 40 ASP A 64 ASP~? 16.37 O2 EDO A 103 B 103 LEU A 68 LEU~? 8.28 O2 EDO A 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 9.39 10.77 34.53 11.50 10.63 34.41 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 12.89 17.60 31.13 12.34 16.51 32.90 -25.35 -90.24 -20.94 -23.22 -90.71 -21.35 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 6 3 # 6 B 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s B 40 ASP A 99 ASP^? 8.10 O2 EDO A 103 B 103 LEU A 68 LEU~? 8.28 O2 EDO A 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 9.39 10.77 34.53 11.50 10.63 34.41 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 12.89 17.60 31.13 12.34 16.51 32.90 -25.35 -90.24 -20.94 -23.22 -90.71 -21.35 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 7 3 # 7 B 16 TYR A 71 TYR~? -4.90 O2 EDO A 103s B 40 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 103 LEU A 29 LEU~? 10.48 O2 EDO A 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 9.39 10.77 34.53 11.50 10.63 34.41 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 12.89 17.60 31.13 12.34 16.51 32.90 -26.95 -81.99 -31.30 -27.85 -83.90 -30.83 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 8 3 # 8 B 16 TYR B 3 TYR.? 14.53 O2 CIT B 103 B 40 ASP B 64 ASP~? 16.93 O2 CIT B 103 B 103 LEU B 2 LEU.? 12.07 O2 CIT B 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 coo 9.39 10.77 34.53 11.50 10.63 34.41 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 12.89 17.60 31.13 12.34 16.51 32.90 -10.11 -71.79 -17.26 -8.38 -70.83 -18.16 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 9 3 # 9 B 16 TYR B 54 TYR.? 11.82 O7 CIT B 103 B 40 ASP B 93 ASP~? 9.77 O3 CIT B 103 B 103 LEU B 96 LEU^? 9.68 O7 CIT B 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 9.39 10.77 34.53 11.50 10.63 34.41 3.85 -90.04 -12.91 5.79 -89.33 -13.36 coo 12.89 17.60 31.13 12.34 16.51 32.90 -4.76 -86.79 -16.51 -5.13 -86.53 -18.64 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 10 3 # 10 B 16 TYR B 56 TYR^? 12.51 O1 CIT B 103 B 40 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 103 LEU A 100 LEU^? 13.85 O1 CIT B 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo 9.39 10.77 34.53 11.50 10.63 34.41 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo 12.89 17.60 31.13 12.34 16.51 32.90 -17.08 -87.25 -13.38 -14.97 -87.07 -12.96 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 11 3 # 11 B 16 TYR B 71 TYR~? -4.80 O1 CIT B 103s B 40 ASP B 27 ASP~? 12.32 O1 CIT B 103 B 103 LEU B 29 LEU~? 9.72 O1 CIT B 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 9.39 10.77 34.53 11.50 10.63 34.41 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 12.89 17.60 31.13 12.34 16.51 32.90 -10.92 -74.23 -0.54 -9.16 -73.03 -1.02 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 12 3 # 12 B 16 TYR B 71 TYR~? -4.80 O1 CIT B 103s B 40 ASP B 64 ASP~? 16.93 O2 CIT B 103 B 103 LEU B 68 LEU~? 8.47 O2 CIT B 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 9.39 10.77 34.53 11.50 10.63 34.41 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 12.89 17.60 31.13 12.34 16.51 32.90 -6.89 -70.80 -13.14 -5.91 -72.71 -13.57 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 13 3 # 13 B 16 TYR B 71 TYR~? -4.80 O1 CIT B 103s B 40 ASP B 99 ASP^? 7.47 O6 CIT B 103 B 103 LEU B 68 LEU~? 8.47 O2 CIT B 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 9.39 10.77 34.53 11.50 10.63 34.41 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 12.89 17.60 31.13 12.34 16.51 32.90 -6.89 -70.80 -13.14 -5.91 -72.71 -13.57 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 14 3 # 14 B 16 TYR C 3 TYR.? 14.43 O1 CIT C 104 B 40 ASP C 64 ASP~? 16.62 O2 CIT C 104 B 103 LEU C 2 LEU.? 11.85 O2 CIT C 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 coo 9.39 10.77 34.53 11.50 10.63 34.41 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 12.89 17.60 31.13 12.34 16.51 32.90 -53.70 -71.21 -19.02 -53.04 -73.06 -18.04 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 15 3 # 15 B 16 TYR C 54 TYR.? 11.88 O3 CIT C 104 B 40 ASP C 93 ASP~? 9.74 O3 CIT C 104 B 103 LEU C 96 LEU^? 9.85 O3 CIT C 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 9.39 10.77 34.53 11.50 10.63 34.41 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 12.89 17.60 31.13 12.34 16.51 32.90 -39.14 -64.82 -20.28 -39.32 -64.46 -18.13 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 16 3 # 16 B 16 TYR C 56 TYR^? 12.84 O1 CIT C 104 B 40 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 103 LEU D 100 LEU^? 13.70 O1 CIT C 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo 9.39 10.77 34.53 11.50 10.63 34.41 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 12.89 17.60 31.13 12.34 16.51 32.90 -47.31 -55.74 -23.54 -46.04 -57.49 -23.79 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 17 3 # 17 B 16 TYR C 71 TYR~? -4.77 O1 CIT C 104s B 40 ASP C 27 ASP~? 13.15 O1 CIT C 104 B 103 LEU C 29 LEU~? 9.96 O1 CIT C 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 9.39 10.77 34.53 11.50 10.63 34.41 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 12.89 17.60 31.13 12.34 16.51 32.90 -52.67 -69.81 -35.63 -52.40 -71.85 -34.94 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 18 3 # 18 B 16 TYR C 71 TYR~? -4.77 O1 CIT C 104s B 40 ASP C 64 ASP~? 16.62 O2 CIT C 104 B 103 LEU C 68 LEU~? 8.19 O2 CIT C 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 9.39 10.77 34.53 11.50 10.63 34.41 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 12.89 17.60 31.13 12.34 16.51 32.90 -52.21 -74.51 -23.05 -50.26 -73.52 -22.72 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 19 3 # 19 B 16 TYR C 71 TYR~? -4.77 O1 CIT C 104s B 40 ASP C 99 ASP^? 7.14 O2 CIT C 104 B 103 LEU C 68 LEU~? 8.19 O2 CIT C 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 9.39 10.77 34.53 11.50 10.63 34.41 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 12.89 17.60 31.13 12.34 16.51 32.90 -52.21 -74.51 -23.05 -50.26 -73.52 -22.72 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 20 3 # 20 B 16 TYR D -3 TYR.? 15.53 O6 CIT D 103 B 40 ASP D 69 ASP~? 11.20 O6 CIT D 103 B 103 LEU D 2 LEU.? 11.83 O6 CIT D 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 coo 9.39 10.77 34.53 11.50 10.63 34.41 -50.36 -42.24 -14.65 -48.69 -42.23 -15.98 coo 12.89 17.60 31.13 12.34 16.51 32.90 -50.75 -50.35 -21.01 -49.33 -48.73 -21.36 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 21 3 # 21 B 16 TYR D 3 TYR.? 14.21 O2 CIT D 103 B 40 ASP D 64 ASP~? 16.39 O2 CIT D 103 B 103 LEU D 2 LEU.? 11.83 O6 CIT D 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 9.39 10.77 34.53 11.50 10.63 34.41 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 12.89 17.60 31.13 12.34 16.51 32.90 -50.75 -50.35 -21.01 -49.33 -48.73 -21.36 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 22 3 # 22 B 16 TYR D 54 TYR.? 11.66 C4 CIT D 103 B 40 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 103 LEU C 96 LEU^? 9.85 O3 CIT C 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 9.39 10.77 34.53 11.50 10.63 34.41 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 12.89 17.60 31.13 12.34 16.51 32.90 -39.14 -64.82 -20.28 -39.32 -64.46 -18.13 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 23 3 # 23 B 16 TYR D 54 TYR.? 11.66 C4 CIT D 103 B 40 ASP D 93 ASP~? 9.04 O4 CIT D 103 B 103 LEU D 96 LEU^? 9.60 C4 CIT D 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 9.39 10.77 34.53 11.50 10.63 34.41 -33.74 -56.68 -6.93 -32.62 -54.89 -6.89 coo 12.89 17.60 31.13 12.34 16.51 32.90 -40.15 -59.46 -13.69 -39.38 -59.80 -15.68 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 24 3 # 24 B 16 TYR D 56 TYR^? 12.73 C2 CIT D 103 B 40 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 103 LEU C 100 LEU^? 13.72 O2 CIT D 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 coo 9.39 10.77 34.53 11.50 10.63 34.41 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo 12.89 17.60 31.13 12.34 16.51 32.90 -50.61 -66.45 -14.87 -49.30 -65.03 -13.86 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 25 3 # 25 B 16 TYR D 71 TYR~? -4.87 O2 CIT D 103s B 40 ASP D 27 ASP~? 12.70 O1 CIT D 103 B 103 LEU D 29 LEU~? 9.75 O1 CIT D 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 9.39 10.77 34.53 11.50 10.63 34.41 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo 12.89 17.60 31.13 12.34 16.51 32.90 -57.68 -51.25 -5.98 -56.83 -49.30 -6.53 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 26 3 # 26 B 16 TYR D 71 TYR~? -4.87 O2 CIT D 103s B 40 ASP D 64 ASP~? 16.39 O2 CIT D 103 B 103 LEU D 68 LEU~? 8.05 O6 CIT D 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 9.39 10.77 34.53 11.50 10.63 34.41 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 12.89 17.60 31.13 12.34 16.51 32.90 -50.69 -47.26 -16.46 -48.95 -48.50 -15.98 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 27 3 # 27 B 16 TYR D 71 TYR~? -4.87 O2 CIT D 103s B 40 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 103 LEU D 68 LEU~? 8.05 O6 CIT D 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 9.39 10.77 34.53 11.50 10.63 34.41 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 12.89 17.60 31.13 12.34 16.51 32.90 -50.69 -47.26 -16.46 -48.95 -48.50 -15.98 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 28 3 # 28 B 16 TYR E 3 TYR.? 13.85 O2 EDO E 103 B 40 ASP E 64 ASP~? 16.37 O2 CIT E 104 B 103 LEU E 2 LEU.? 11.93 O2 CIT E 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 9.39 10.77 34.53 11.50 10.63 34.41 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 12.89 17.60 31.13 12.34 16.51 32.90 -38.80 -84.65 -55.80 -40.65 -84.17 -56.89 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 29 3 # 29 B 16 TYR E 54 TYR.? 6.56 O1 EDO F 103 B 40 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 103 LEU F 96 LEU^? 6.94 O1 EDO F 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 9.39 10.77 34.53 11.50 10.63 34.41 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 12.89 17.60 31.13 12.34 16.51 32.90 -26.37 -71.21 -59.60 -26.77 -70.69 -57.54 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 30 3 # 30 B 16 TYR E 54 TYR.? 6.56 O1 EDO F 103 B 40 ASP E 93 ASP~? 8.62 O3 CIT E 104 B 103 LEU E 96 LEU^? 5.04 C1 EDO F 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 9.39 10.77 34.53 11.50 10.63 34.41 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo 12.89 17.60 31.13 12.34 16.51 32.90 -32.10 -70.65 -53.43 -31.78 -70.83 -55.55 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 31 3 # 31 B 16 TYR E 56 TYR^? 8.81 O2 EDO E 103 B 40 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 103 LEU F 100 LEU^? 8.24 O2 EDO E 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo 9.39 10.77 34.53 11.50 10.63 34.41 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo 12.89 17.60 31.13 12.34 16.51 32.90 -23.26 -79.30 -50.33 -25.04 -78.05 -50.01 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 32 3 # 32 B 16 TYR E 71 TYR~? -4.78 O2 CIT E 104s B 40 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 103 LEU E 29 LEU~? 10.53 O1 CIT E 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 9.39 10.77 34.53 11.50 10.63 34.41 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 12.89 17.60 31.13 12.34 16.51 32.90 -37.60 -84.97 -38.66 -39.68 -84.53 -39.24 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 33 3 # 33 B 16 TYR E 71 TYR~? -4.78 O2 CIT E 104s B 40 ASP E 64 ASP~? 16.37 O2 CIT E 104 B 103 LEU E 68 LEU~? 8.13 O2 CIT E 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 9.39 10.77 34.53 11.50 10.63 34.41 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo 12.89 17.60 31.13 12.34 16.51 32.90 -42.16 -83.41 -51.47 -41.23 -81.44 -51.72 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 34 3 # 34 B 16 TYR E 71 TYR~? -4.78 O2 CIT E 104s B 40 ASP E 99 ASP^? 7.65 C2 CIT E 104 B 103 LEU E 68 LEU~? 8.13 O2 CIT E 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 9.39 10.77 34.53 11.50 10.63 34.41 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 12.89 17.60 31.13 12.34 16.51 32.90 -42.16 -83.41 -51.47 -41.23 -81.44 -51.72 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 35 3 # 35 B 16 TYR F 3 TYR.? 7.56 O2 EDO E 103 B 40 ASP F 64 ASP~? 16.52 O2 EDO E 103 B 103 LEU F 2 LEU.? 11.54 O2 EDO E 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 coo 9.39 10.77 34.53 11.50 10.63 34.41 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 12.89 17.60 31.13 12.34 16.51 32.90 -17.84 -82.79 -52.93 -16.12 -81.66 -52.08 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 36 3 # 36 B 16 TYR F 54 TYR.? 5.10 C2 EDO F 103 B 40 ASP F 93 ASP~? 9.52 O4 CIT F 104 B 103 LEU F 96 LEU^? 6.94 O1 EDO F 103 coo 14.25 20.09 37.35 13.48 17.40 37.38 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 9.39 10.77 34.53 11.50 10.63 34.41 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 coo 12.89 17.60 31.13 12.34 16.51 32.90 -26.37 -71.21 -59.60 -26.77 -70.69 -57.54 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 37 3 # 37 B 16 TYR F 56 TYR^? 13.04 O1 CIT F 104 B 40 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 103 LEU E 100 LEU^? 13.74 O2 CIT F 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 coo 9.39 10.77 34.53 11.50 10.63 34.41 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo 12.89 17.60 31.13 12.34 16.51 32.90 -33.88 -81.47 -59.62 -32.42 -80.07 -60.48 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 38 3 # 38 B 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s B 40 ASP F 27 ASP~? 14.00 O1 CIT F 104 B 103 LEU F 29 LEU~? 9.64 O1 CIT F 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 9.39 10.77 34.53 11.50 10.63 34.41 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 12.89 17.60 31.13 12.34 16.51 32.90 -18.08 -88.25 -68.44 -16.23 -87.24 -67.92 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 39 3 # 39 B 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s B 40 ASP F 27 ASP~? 14.00 O1 CIT F 104 B 103 LEU F 36 LEU^? 9.95 O2 CIT F 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 9.39 10.77 34.53 11.50 10.63 34.41 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 coo 12.89 17.60 31.13 12.34 16.51 32.90 -18.40 -89.01 -60.82 -19.96 -87.78 -61.71 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 40 3 # 40 B 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s B 40 ASP F 64 ASP~? 16.52 O2 EDO E 103 B 103 LEU F 68 LEU~? 8.38 O7 CIT F 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 9.39 10.77 34.53 11.50 10.63 34.41 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 12.89 17.60 31.13 12.34 16.51 32.90 -14.42 -82.30 -57.16 -15.55 -80.53 -57.63 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 41 3 # 41 B 16 TYR F 71 TYR~? -4.99 O2 CIT F 104s B 40 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 103 LEU F 68 LEU~? 8.38 O7 CIT F 104 coo 14.25 20.09 37.35 13.48 17.40 37.38 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 9.39 10.77 34.53 11.50 10.63 34.41 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 12.89 17.60 31.13 12.34 16.51 32.90 -14.42 -82.30 -57.16 -15.55 -80.53 -57.63 1vzz_c01 source 1vzz STEROID DELTA-ISOMERASE : 41 hits 1vzz_c01 naa= 3 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 1 3 # 1 A 183 GLY A 82 GLY~? 8.30 O1 EDO A 103 B 419 GLY A 81 GLY~? 4.93 C2 EDO A 103 B 420 ALA A 80 ALA~? 7.00 C2 EDO A 103 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -20.19 -86.09 -35.24 -20.75 -85.14 -34.17 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 2 3 # 2 A 183 GLY A 94 GLY.? 10.50 C1 EDO A 103 B 419 GLY A 91 GLY~? 10.61 O1 EDO A 103 B 420 ALA A 92 ALA~? 7.55 O1 EDO A 103 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 3 3 # 3 A 183 GLY B 82 GLY~? 6.34 C4 CIT B 103 B 419 GLY B 81 GLY~? 3.85 C2 CIT B 103 B 420 ALA B 80 ALA~? 6.55 O1 CIT B 103 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 0.09 -82.40 -2.15 -0.72 -82.64 -2.19 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -4.95 -80.68 -0.86 -6.33 -80.07 -1.20 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 4 3 # 4 A 183 GLY C 12 GLY.? 8.94 O2 EDO C 103 B 419 GLY C 14 GLY~? 3.87 C1 EDO C 103 B 420 ALA C 15 ALA~? 8.64 C1 EDO C 103 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -29.72 -59.63 -35.07 -30.25 -59.10 -34.73 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 5 3 # 5 A 183 GLY C 12 GLY.? 8.94 O2 EDO C 103 B 419 GLY E 12 GLY.? 8.67 O2 EDO C 103 B 420 ALA E 15 ALA~? 10.03 O2 EDO C 103 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -29.72 -59.63 -35.07 -30.25 -59.10 -34.73 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -26.84 -62.13 -38.29 -26.35 -62.68 -38.61 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 6 3 # 6 A 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 B 419 GLY C 81 GLY~? -3.48 O5 CIT C 104s B 420 ALA C 80 ALA~? 6.86 O1 CIT C 104 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -44.02 -69.49 -35.47 -45.39 -69.01 -34.93 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 7 3 # 7 A 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 B 419 GLY E 82 GLY~? 5.88 O5 CIT E 104 B 420 ALA E 80 ALA~? 6.56 O1 CIT E 104 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -37.12 -76.28 -38.33 -36.63 -77.60 -38.82 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 8 3 # 8 A 183 GLY C 94 GLY.? 8.41 O3 CIT C 104 B 419 GLY C 91 GLY~? 8.26 O4 CIT C 104 B 420 ALA C 92 ALA~? 4.69 O3 CIT C 104 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 9 3 # 9 A 183 GLY D 82 GLY~? 6.55 O7 CIT D 103 B 419 GLY D 81 GLY~? 3.79 O7 CIT D 103 B 420 ALA D 80 ALA~? 6.01 O1 CIT D 103 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -45.10 -51.83 -0.42 -45.58 -52.48 -0.67 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -50.09 -53.10 -1.75 -51.22 -53.48 -2.77 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 10 3 # 10 A 183 GLY D 94 GLY.? 7.85 O4 CIT D 103 B 419 GLY D 91 GLY~? 7.26 O4 CIT D 103 B 420 ALA D 92 ALA~? 3.89 O4 CIT D 103 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 11 3 # 11 A 183 GLY E 12 GLY.? 8.67 O2 EDO C 103 B 419 GLY C 12 GLY.? 8.94 O2 EDO C 103 B 420 ALA C 15 ALA~? 8.64 C1 EDO C 103 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -26.84 -62.13 -38.29 -26.35 -62.68 -38.61 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -29.72 -59.63 -35.07 -30.25 -59.10 -34.73 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 12 3 # 12 A 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 B 419 GLY C 82 GLY~? 6.29 O5 CIT C 104 B 420 ALA C 80 ALA~? 6.86 O1 CIT C 104 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -44.02 -69.49 -35.47 -45.39 -69.01 -34.93 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 13 3 # 13 A 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 B 419 GLY E 81 GLY~? -3.27 O5 CIT E 104s B 420 ALA E 80 ALA~? 6.56 O1 CIT E 104 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -37.12 -76.28 -38.33 -36.63 -77.60 -38.82 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 14 3 # 14 A 183 GLY E 94 GLY.? 7.76 O3 CIT E 104 B 419 GLY E 91 GLY~? 5.97 O2 EDO C 103 B 420 ALA E 92 ALA~? 4.01 O3 CIT E 104 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 15 3 # 15 A 183 GLY F 82 GLY~? 6.43 O5 CIT F 104 B 419 GLY F 81 GLY~? -3.66 O5 CIT F 104s B 420 ALA F 80 ALA~? 5.70 O1 CIT F 104 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -18.39 -75.04 -72.92 -19.02 -75.49 -72.70 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -19.77 -80.17 -71.91 -20.13 -81.28 -70.95 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 16 3 # 16 A 183 GLY F 94 GLY.? 8.80 O3 CIT F 104 B 419 GLY F 91 GLY~? 8.30 O3 CIT F 104 B 420 ALA F 92 ALA~? 4.20 O4 CIT F 104 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -26.33 -67.76 -65.92 -25.64 -68.13 -65.72 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -22.80 -67.12 -70.37 -23.31 -66.96 -69.76 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 1xny_c00 source 1xny PROPIONYL-COA CARBOXYLASE COMPLEX B SUBUNIT : 16 hits 1xny_c00 naa= 3 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 1 3 # 1 A 420 ALA A 22 ALA~? 8.81 C2 EDO A 103 B 182 GLY A 81 GLY~? 4.93 C2 EDO A 103 B 183 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 coo 41.93-102.35-126.87 41.52-101.89-126.30 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 coo 38.37-101.99-128.11 38.63-102.24-127.37 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 2 3 # 2 A 420 ALA A 22 ALA~? 8.81 C2 EDO A 103 B 182 GLY A 82 GLY~? 8.30 O1 EDO A 103 B 183 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -18.01 -81.73 -35.44 -17.13 -82.87 -35.04 coo 41.93-102.35-126.87 41.52-101.89-126.30 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 coo 38.37-101.99-128.11 38.63-102.24-127.37 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 3 3 # 3 A 420 ALA A 86 ALA~? 12.24 C1 EDO A 103 B 182 GLY A 81 GLY~? 4.93 C2 EDO A 103 B 183 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -11.73 -90.20 -38.44 -12.68 -89.83 -39.60 coo 41.93-102.35-126.87 41.52-101.89-126.30 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 coo 38.37-101.99-128.11 38.63-102.24-127.37 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 4 3 # 4 A 420 ALA A 86 ALA~? 12.24 C1 EDO A 103 B 182 GLY A 94 GLY.? 10.50 C1 EDO A 103 B 183 GLY A 91 GLY~? 10.61 O1 EDO A 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -11.73 -90.20 -38.44 -12.68 -89.83 -39.60 coo 41.93-102.35-126.87 41.52-101.89-126.30 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo 38.37-101.99-128.11 38.63-102.24-127.37 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 5 3 # 5 A 420 ALA A 92 ALA~? 7.55 O1 EDO A 103 B 182 GLY A 81 GLY~? 4.93 C2 EDO A 103 B 183 GLY A 82 GLY~? 8.30 O1 EDO A 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 41.93-102.35-126.87 41.52-101.89-126.30 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 coo 38.37-101.99-128.11 38.63-102.24-127.37 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 6 3 # 6 A 420 ALA A 92 ALA~? 7.55 O1 EDO A 103 B 182 GLY A 82 GLY~? 8.30 O1 EDO A 103 B 183 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -11.26 -94.41 -31.19 -12.27 -95.53 -31.04 coo 41.93-102.35-126.87 41.52-101.89-126.30 -17.68 -90.68 -36.72 -17.50 -89.96 -36.42 coo 38.37-101.99-128.11 38.63-102.24-127.37 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 7 3 # 7 A 420 ALA B 22 ALA~? 8.36 O1 CIT B 103 B 182 GLY B 81 GLY~? 3.85 C2 CIT B 103 B 183 GLY B 82 GLY~? 6.34 C4 CIT B 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -8.49 -83.66 -0.03 -7.52 -84.08 -1.05 coo 41.93-102.35-126.87 41.52-101.89-126.30 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 coo 38.37-101.99-128.11 38.63-102.24-127.37 0.09 -82.40 -2.15 -0.72 -82.64 -2.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 8 3 # 8 A 420 ALA B 22 ALA~? 8.36 O1 CIT B 103 B 182 GLY B 82 GLY~? 6.34 C4 CIT B 103 B 183 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -8.49 -83.66 -0.03 -7.52 -84.08 -1.05 coo 41.93-102.35-126.87 41.52-101.89-126.30 0.09 -82.40 -2.15 -0.72 -82.64 -2.19 coo 38.37-101.99-128.11 38.63-102.24-127.37 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 9 3 # 9 A 420 ALA B 86 ALA~? 9.94 C4 CIT B 103 B 182 GLY B 81 GLY~? 3.85 C2 CIT B 103 B 183 GLY B 82 GLY~? 6.34 C4 CIT B 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 1.15 -88.46 -2.64 1.44 -87.94 -1.23 coo 41.93-102.35-126.87 41.52-101.89-126.30 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 coo 38.37-101.99-128.11 38.63-102.24-127.37 0.09 -82.40 -2.15 -0.72 -82.64 -2.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 10 3 # 10 A 420 ALA B 92 ALA~? 4.16 O3 CIT B 103 B 182 GLY B 81 GLY~? 3.85 C2 CIT B 103 B 183 GLY B 82 GLY~? 6.34 C4 CIT B 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 2.19 -86.50 -9.98 2.87 -85.11 -10.07 coo 41.93-102.35-126.87 41.52-101.89-126.30 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 coo 38.37-101.99-128.11 38.63-102.24-127.37 0.09 -82.40 -2.15 -0.72 -82.64 -2.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 11 3 # 11 A 420 ALA C 15 ALA~? 8.64 C1 EDO C 103 B 182 GLY E 14 GLY~? 13.52 O2 EDO C 103 B 183 GLY E 12 GLY.? 8.67 O2 EDO C 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo 41.93-102.35-126.87 41.52-101.89-126.30 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 coo 38.37-101.99-128.11 38.63-102.24-127.37 -26.84 -62.13 -38.29 -26.35 -62.68 -38.61 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 12 3 # 12 A 420 ALA C 22 ALA~? 8.59 C2 CIT C 104 B 182 GLY C 81 GLY~? -3.48 O5 CIT C 104s B 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -44.35 -64.88 -36.60 -43.33 -65.13 -35.53 coo 41.93-102.35-126.87 41.52-101.89-126.30 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 13 3 # 13 A 420 ALA C 22 ALA~? 8.59 C2 CIT C 104 B 182 GLY C 82 GLY~? 6.29 O5 CIT C 104 B 183 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 38.36-101.47-135.52 39.62-101.29-136.35 -44.35 -64.88 -36.60 -43.33 -65.13 -35.53 coo 41.93-102.35-126.87 41.52-101.89-126.30 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo 38.37-101.99-128.11 38.63-102.24-127.37 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 14 3 # 14 A 420 ALA C 22 ALA~? 8.59 C2 CIT C 104 B 182 GLY C 82 GLY~? 6.29 O5 CIT C 104 B 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -44.35 -64.88 -36.60 -43.33 -65.13 -35.53 coo 41.93-102.35-126.87 41.52-101.89-126.30 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 15 3 # 15 A 420 ALA C 22 ALA~? 8.59 C2 CIT C 104 B 182 GLY E 82 GLY~? 5.88 O5 CIT E 104 B 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -44.35 -64.88 -36.60 -43.33 -65.13 -35.53 coo 41.93-102.35-126.87 41.52-101.89-126.30 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 16 3 # 16 A 420 ALA C 80 ALA~? 6.86 O1 CIT C 104 B 182 GLY E 81 GLY~? -3.27 O5 CIT E 104s B 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -44.02 -69.49 -35.47 -45.39 -69.01 -34.93 coo 41.93-102.35-126.87 41.52-101.89-126.30 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 17 3 # 17 A 420 ALA C 86 ALA~? 9.98 O4 CIT C 104 B 182 GLY C 81 GLY~? -3.48 O5 CIT C 104s B 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 41.93-102.35-126.87 41.52-101.89-126.30 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 18 3 # 18 A 420 ALA C 86 ALA~? 9.98 O4 CIT C 104 B 182 GLY C 94 GLY.? 8.41 O3 CIT C 104 B 183 GLY C 91 GLY~? 8.26 O4 CIT C 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 41.93-102.35-126.87 41.52-101.89-126.30 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 coo 38.37-101.99-128.11 38.63-102.24-127.37 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 19 3 # 19 A 420 ALA C 86 ALA~? 9.98 O4 CIT C 104 B 182 GLY E 12 GLY.? 8.67 O2 EDO C 103 B 183 GLY E 14 GLY~? 13.52 O2 EDO C 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 41.93-102.35-126.87 41.52-101.89-126.30 -26.84 -62.13 -38.29 -26.35 -62.68 -38.61 coo 38.37-101.99-128.11 38.63-102.24-127.37 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 20 3 # 20 A 420 ALA C 86 ALA~? 9.98 O4 CIT C 104 B 182 GLY E 81 GLY~? -3.27 O5 CIT E 104s B 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 41.93-102.35-126.87 41.52-101.89-126.30 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 21 3 # 21 A 420 ALA C 86 ALA~? 9.98 O4 CIT C 104 B 182 GLY E 82 GLY~? 5.88 O5 CIT E 104 B 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 41.93-102.35-126.87 41.52-101.89-126.30 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 22 3 # 22 A 420 ALA C 92 ALA~? 4.69 O3 CIT C 104 B 182 GLY C 81 GLY~? -3.48 O5 CIT C 104s B 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -34.62 -70.50 -26.65 -34.98 -71.98 -26.48 coo 41.93-102.35-126.87 41.52-101.89-126.30 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 23 3 # 23 A 420 ALA D 22 ALA~? 7.88 O1 CIT D 103 B 182 GLY D 81 GLY~? 3.79 O7 CIT D 103 B 183 GLY D 82 GLY~? 6.55 O7 CIT D 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -51.90 -57.58 -1.45 -50.39 -57.48 -1.80 coo 41.93-102.35-126.87 41.52-101.89-126.30 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 coo 38.37-101.99-128.11 38.63-102.24-127.37 -45.10 -51.83 -0.42 -45.58 -52.48 -0.67 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 24 3 # 24 A 420 ALA D 22 ALA~? 7.88 O1 CIT D 103 B 182 GLY D 82 GLY~? 6.55 O7 CIT D 103 B 183 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -51.90 -57.58 -1.45 -50.39 -57.48 -1.80 coo 41.93-102.35-126.87 41.52-101.89-126.30 -45.10 -51.83 -0.42 -45.58 -52.48 -0.67 coo 38.37-101.99-128.11 38.63-102.24-127.37 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 25 3 # 25 A 420 ALA D 86 ALA~? 10.50 O7 CIT D 103 B 182 GLY D 81 GLY~? 3.79 O7 CIT D 103 B 183 GLY D 82 GLY~? 6.55 O7 CIT D 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -41.56 -56.37 1.55 -42.57 -55.96 2.61 coo 41.93-102.35-126.87 41.52-101.89-126.30 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 coo 38.37-101.99-128.11 38.63-102.24-127.37 -45.10 -51.83 -0.42 -45.58 -52.48 -0.67 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 26 3 # 26 A 420 ALA D 86 ALA~? 10.50 O7 CIT D 103 B 182 GLY D 94 GLY.? 7.85 O4 CIT D 103 B 183 GLY D 91 GLY~? 7.26 O4 CIT D 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -41.56 -56.37 1.55 -42.57 -55.96 2.61 coo 41.93-102.35-126.87 41.52-101.89-126.30 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo 38.37-101.99-128.11 38.63-102.24-127.37 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 27 3 # 27 A 420 ALA D 92 ALA~? 3.89 O4 CIT D 103 B 182 GLY D 81 GLY~? 3.79 O7 CIT D 103 B 183 GLY D 82 GLY~? 6.55 O7 CIT D 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -37.94 -54.38 -5.87 -37.79 -52.88 -6.10 coo 41.93-102.35-126.87 41.52-101.89-126.30 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 coo 38.37-101.99-128.11 38.63-102.24-127.37 -45.10 -51.83 -0.42 -45.58 -52.48 -0.67 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 28 3 # 28 A 420 ALA E 15 ALA~? 10.03 O2 EDO C 103 B 182 GLY C 14 GLY~? 3.87 C1 EDO C 103 B 183 GLY C 12 GLY.? 8.94 O2 EDO C 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo 41.93-102.35-126.87 41.52-101.89-126.30 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo 38.37-101.99-128.11 38.63-102.24-127.37 -29.72 -59.63 -35.07 -30.25 -59.10 -34.73 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 29 3 # 29 A 420 ALA E 22 ALA~? 8.49 O1 CIT E 104 B 182 GLY C 82 GLY~? 6.29 O5 CIT C 104 B 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 coo 41.93-102.35-126.87 41.52-101.89-126.30 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 30 3 # 30 A 420 ALA E 22 ALA~? 8.49 O1 CIT E 104 B 182 GLY E 81 GLY~? -3.27 O5 CIT E 104s B 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 coo 41.93-102.35-126.87 41.52-101.89-126.30 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 31 3 # 31 A 420 ALA E 22 ALA~? 8.49 O1 CIT E 104 B 182 GLY E 82 GLY~? 5.88 O5 CIT E 104 B 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 coo 41.93-102.35-126.87 41.52-101.89-126.30 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 32 3 # 32 A 420 ALA E 22 ALA~? 8.49 O1 CIT E 104 B 182 GLY E 82 GLY~? 5.88 O5 CIT E 104 B 183 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 38.36-101.47-135.52 39.62-101.29-136.35 -32.47 -76.71 -37.25 -32.71 -75.57 -38.23 coo 41.93-102.35-126.87 41.52-101.89-126.30 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo 38.37-101.99-128.11 38.63-102.24-127.37 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 33 3 # 33 A 420 ALA E 80 ALA~? 6.56 O1 CIT E 104 B 182 GLY C 81 GLY~? -3.48 O5 CIT C 104s B 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -37.12 -76.28 -38.33 -36.63 -77.60 -38.82 coo 41.93-102.35-126.87 41.52-101.89-126.30 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 34 3 # 34 A 420 ALA E 86 ALA~? 9.46 O2 EDO C 103 B 182 GLY C 12 GLY.? 8.94 O2 EDO C 103 B 183 GLY C 14 GLY~? 3.87 C1 EDO C 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 41.93-102.35-126.87 41.52-101.89-126.30 -29.72 -59.63 -35.07 -30.25 -59.10 -34.73 coo 38.37-101.99-128.11 38.63-102.24-127.37 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 35 3 # 35 A 420 ALA E 86 ALA~? 9.46 O2 EDO C 103 B 182 GLY C 81 GLY~? -3.48 O5 CIT C 104s B 183 GLY C 82 GLY~? 6.29 O5 CIT C 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 41.93-102.35-126.87 41.52-101.89-126.30 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 36 3 # 36 A 420 ALA E 86 ALA~? 9.46 O2 EDO C 103 B 182 GLY C 82 GLY~? 6.29 O5 CIT C 104 B 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 41.93-102.35-126.87 41.52-101.89-126.30 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 37 3 # 37 A 420 ALA E 86 ALA~? 9.46 O2 EDO C 103 B 182 GLY E 81 GLY~? -3.27 O5 CIT E 104s B 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 41.93-102.35-126.87 41.52-101.89-126.30 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 38 3 # 38 A 420 ALA E 86 ALA~? 9.46 O2 EDO C 103 B 182 GLY E 94 GLY.? 7.76 O3 CIT E 104 B 183 GLY E 91 GLY~? 5.97 O2 EDO C 103 coo 38.36-101.47-135.52 39.62-101.29-136.35 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 41.93-102.35-126.87 41.52-101.89-126.30 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo 38.37-101.99-128.11 38.63-102.24-127.37 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 39 3 # 39 A 420 ALA E 92 ALA~? 4.01 O3 CIT E 104 B 182 GLY E 81 GLY~? -3.27 O5 CIT E 104s B 183 GLY E 82 GLY~? 5.88 O5 CIT E 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 41.93-102.35-126.87 41.52-101.89-126.30 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 coo 38.37-101.99-128.11 38.63-102.24-127.37 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 40 3 # 40 A 420 ALA E 92 ALA~? 4.01 O3 CIT E 104 B 182 GLY E 82 GLY~? 5.88 O5 CIT E 104 B 183 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 38.36-101.47-135.52 39.62-101.29-136.35 -38.18 -66.76 -46.70 -39.69 -66.96 -46.85 coo 41.93-102.35-126.87 41.52-101.89-126.30 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo 38.37-101.99-128.11 38.63-102.24-127.37 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 41 3 # 41 A 420 ALA F 22 ALA~? 7.57 O1 CIT F 104 B 182 GLY F 81 GLY~? -3.66 O5 CIT F 104s B 183 GLY F 82 GLY~? 6.43 O5 CIT F 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -24.19 -81.70 -72.40 -24.12 -80.23 -71.87 coo 41.93-102.35-126.87 41.52-101.89-126.30 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 coo 38.37-101.99-128.11 38.63-102.24-127.37 -18.39 -75.04 -72.92 -19.02 -75.49 -72.70 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 42 3 # 42 A 420 ALA F 22 ALA~? 7.57 O1 CIT F 104 B 182 GLY F 82 GLY~? 6.43 O5 CIT F 104 B 183 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 38.36-101.47-135.52 39.62-101.29-136.35 -24.19 -81.70 -72.40 -24.12 -80.23 -71.87 coo 41.93-102.35-126.87 41.52-101.89-126.30 -18.39 -75.04 -72.92 -19.02 -75.49 -72.70 coo 38.37-101.99-128.11 38.63-102.24-127.37 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 43 3 # 43 A 420 ALA F 86 ALA~? 9.86 O3 CIT F 104 B 182 GLY F 81 GLY~? -3.66 O5 CIT F 104s B 183 GLY F 82 GLY~? 6.43 O5 CIT F 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -22.69 -71.22 -74.62 -22.13 -72.06 -75.80 coo 41.93-102.35-126.87 41.52-101.89-126.30 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 coo 38.37-101.99-128.11 38.63-102.24-127.37 -18.39 -75.04 -72.92 -19.02 -75.49 -72.70 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 44 3 # 44 A 420 ALA F 86 ALA~? 9.86 O3 CIT F 104 B 182 GLY F 94 GLY.? 8.80 O3 CIT F 104 B 183 GLY F 91 GLY~? 8.30 O3 CIT F 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -22.69 -71.22 -74.62 -22.13 -72.06 -75.80 coo 41.93-102.35-126.87 41.52-101.89-126.30 -26.33 -67.76 -65.92 -25.64 -68.13 -65.72 coo 38.37-101.99-128.11 38.63-102.24-127.37 -22.80 -67.12 -70.37 -23.31 -66.96 -69.76 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 45 3 # 45 A 420 ALA F 92 ALA~? 4.20 O4 CIT F 104 B 182 GLY F 81 GLY~? -3.66 O5 CIT F 104s B 183 GLY F 82 GLY~? 6.43 O5 CIT F 104 coo 38.36-101.47-135.52 39.62-101.29-136.35 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 41.93-102.35-126.87 41.52-101.89-126.30 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 coo 38.37-101.99-128.11 38.63-102.24-127.37 -18.39 -75.04 -72.92 -19.02 -75.49 -72.70 ULMN 3 1xny_c01 PROPIONYL-COA CARBOXYLASE COMPLEX B user 46 3 # 46 A 420 ALA F 92 ALA~? 4.20 O4 CIT F 104 B 182 GLY F 82 GLY~? 6.43 O5 CIT F 104 B 183 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 38.36-101.47-135.52 39.62-101.29-136.35 -21.26 -68.45 -67.11 -19.74 -68.55 -66.83 coo 41.93-102.35-126.87 41.52-101.89-126.30 -18.39 -75.04 -72.92 -19.02 -75.49 -72.70 coo 38.37-101.99-128.11 38.63-102.24-127.37 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 1xny_c01 source 1xny PROPIONYL-COA CARBOXYLASE COMPLEX B SUBUNIT : 46 hits 1xny_c01 naa= 3 ULMN 3 1xs1_c07 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 B 124 ALA C 86 ALA~? 9.98 O4 CIT C 104 B 126 ARG C 18 ARG~? -3.10 O1 EDO C 103s B 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 2.11 4.00 19.31 3.14 4.86 19.99 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 2.45 5.53 11.28 3.59 7.56 13.29 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo 6.10 2.00 25.24 6.12 1.84 23.13 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c07 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 2 3 # 2 B 124 ALA E 24 ALA~? 10.19 C1 EDO E 103 B 126 ARG A 79 ARG~? -3.92 C2 EDO E 103s B 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 2.11 4.00 19.31 3.14 4.86 19.99 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 coo 2.45 5.53 11.28 3.59 7.56 13.29 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 6.10 2.00 25.24 6.12 1.84 23.13 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c07 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 3 3 # 3 B 124 ALA E 86 ALA~? 9.46 O2 EDO C 103 B 126 ARG E 18 ARG~? 11.85 O4 CIT C 104 B 138 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo 2.11 4.00 19.31 3.14 4.86 19.99 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 2.45 5.53 11.28 3.59 7.56 13.29 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo 6.10 2.00 25.24 6.12 1.84 23.13 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 1xs1_c07 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 3 hits 1xs1_c07 naa= 3 ULMN 3 1xs1_c08 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 C 124 ALA C 86 ALA~? 9.98 O4 CIT C 104 C 126 ARG C 18 ARG~? -3.10 O1 EDO C 103s C 138 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo -4.54 -7.50 19.94 -4.33 -8.73 20.82 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo -3.14 -9.40 12.05 -1.75 -11.23 14.08 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo -8.56 -9.50 25.72 -8.77 -9.47 23.62 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 1xs1_c08 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 2 3 # 2 C 124 ALA C 86 ALA~? 9.98 O4 CIT C 104 C 126 ARG C 18 ARG~? -3.10 O1 EDO C 103s C 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo -4.54 -7.50 19.94 -4.33 -8.73 20.82 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo -3.14 -9.40 12.05 -1.75 -11.23 14.08 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo -8.56 -9.50 25.72 -8.77 -9.47 23.62 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c08 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 3 3 # 3 C 124 ALA E 24 ALA~? 10.19 C1 EDO E 103 C 126 ARG A 79 ARG~? -3.92 C2 EDO E 103s C 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo -4.54 -7.50 19.94 -4.33 -8.73 20.82 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 coo -3.14 -9.40 12.05 -1.75 -11.23 14.08 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo -8.56 -9.50 25.72 -8.77 -9.47 23.62 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c08 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 4 3 # 4 C 124 ALA E 86 ALA~? 9.46 O2 EDO C 103 C 126 ARG E 18 ARG~? 11.85 O4 CIT C 104 C 138 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo -4.54 -7.50 19.94 -4.33 -8.73 20.82 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo -3.14 -9.40 12.05 -1.75 -11.23 14.08 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo -8.56 -9.50 25.72 -8.77 -9.47 23.62 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 1xs1_c08 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 4 hits 1xs1_c08 naa= 3 ULMN 3 1xs1_c09 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 D 124 ALA C 86 ALA~? 9.98 O4 CIT C 104 D 126 ARG C 18 ARG~? -3.10 O1 EDO C 103s D 138 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo 2.08 -1.49 62.94 3.12 -2.39 62.28 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 2.52 -3.11 70.84 3.63 -5.24 68.92 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo 6.23 0.50 57.10 5.93 0.72 59.19 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 1xs1_c09 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 2 3 # 2 D 124 ALA C 86 ALA~? 9.98 O4 CIT C 104 D 126 ARG C 18 ARG~? -3.10 O1 EDO C 103s D 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 2.08 -1.49 62.94 3.12 -2.39 62.28 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo 2.52 -3.11 70.84 3.63 -5.24 68.92 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo 6.23 0.50 57.10 5.93 0.72 59.19 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c09 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 3 3 # 3 D 124 ALA E 24 ALA~? 10.19 C1 EDO E 103 D 126 ARG A 79 ARG~? -3.92 C2 EDO E 103s D 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 2.08 -1.49 62.94 3.12 -2.39 62.28 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 coo 2.52 -3.11 70.84 3.63 -5.24 68.92 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 6.23 0.50 57.10 5.93 0.72 59.19 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c09 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 4 3 # 4 D 124 ALA E 86 ALA~? 9.46 O2 EDO C 103 D 126 ARG E 18 ARG~? 11.85 O4 CIT C 104 D 138 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo 2.08 -1.49 62.94 3.12 -2.39 62.28 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo 2.52 -3.11 70.84 3.63 -5.24 68.92 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo 6.23 0.50 57.10 5.93 0.72 59.19 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 1xs1_c09 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 4 hits 1xs1_c09 naa= 3 ULMN 3 1xs1_c10 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 E 124 ALA C 86 ALA~? 9.98 O4 CIT C 104 E 126 ARG C 18 ARG~? -3.10 O1 EDO C 103s E 138 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo -4.56 10.03 62.36 -4.38 11.31 61.55 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo -3.02 12.00 70.07 -1.94 13.84 67.82 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo -8.67 12.22 56.54 -8.68 12.09 58.65 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 1xs1_c10 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 2 3 # 2 E 124 ALA C 86 ALA~? 9.98 O4 CIT C 104 E 126 ARG C 18 ARG~? -3.10 O1 EDO C 103s E 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo -4.56 10.03 62.36 -4.38 11.31 61.55 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo -3.02 12.00 70.07 -1.94 13.84 67.82 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo -8.67 12.22 56.54 -8.68 12.09 58.65 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c10 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 3 3 # 3 E 124 ALA E 24 ALA~? 10.19 C1 EDO E 103 E 126 ARG A 79 ARG~? -3.92 C2 EDO E 103s E 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo -4.56 10.03 62.36 -4.38 11.31 61.55 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 coo -3.02 12.00 70.07 -1.94 13.84 67.82 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo -8.67 12.22 56.54 -8.68 12.09 58.65 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c10 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 4 3 # 4 E 124 ALA E 86 ALA~? 9.46 O2 EDO C 103 E 126 ARG E 18 ARG~? 11.85 O4 CIT C 104 E 138 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo -4.56 10.03 62.36 -4.38 11.31 61.55 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo -3.02 12.00 70.07 -1.94 13.84 67.82 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo -8.67 12.22 56.54 -8.68 12.09 58.65 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 1xs1_c10 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 4 hits 1xs1_c10 naa= 3 ULMN 3 1xs1_c11 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 F 124 ALA C 86 ALA~? 9.98 O4 CIT C 104 F 126 ARG C 18 ARG~? -3.10 O1 EDO C 103s F 138 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo -11.15 -1.53 62.85 -12.44 -2.03 62.23 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo -13.16 -0.52 70.77 -15.41 -0.40 68.66 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo -11.26 -6.31 57.37 -11.02 -6.31 59.47 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 1xs1_c11 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 2 3 # 2 F 124 ALA C 86 ALA~? 9.98 O4 CIT C 104 F 126 ARG C 18 ARG~? -3.10 O1 EDO C 103s F 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo -11.15 -1.53 62.85 -12.44 -2.03 62.23 -34.14 -68.24 -34.30 -34.26 -68.82 -35.71 coo -13.16 -0.52 70.77 -15.41 -0.40 68.66 -37.03 -63.20 -40.52 -36.73 -60.67 -42.23 coo -11.26 -6.31 57.37 -11.02 -6.31 59.47 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c11 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 3 3 # 3 F 124 ALA E 24 ALA~? 10.19 C1 EDO E 103 F 126 ARG A 79 ARG~? -3.92 C2 EDO E 103s F 138 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo -11.15 -1.53 62.85 -12.44 -2.03 62.23 -30.19 -81.37 -35.63 -29.78 -80.79 -34.30 coo -13.16 -0.52 70.77 -15.41 -0.40 68.66 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo -11.26 -6.31 57.37 -11.02 -6.31 59.47 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 1xs1_c11 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 4 3 # 4 F 124 ALA E 86 ALA~? 9.46 O2 EDO C 103 F 126 ARG E 18 ARG~? 11.85 O4 CIT C 104 F 138 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo -11.15 -1.53 62.85 -12.44 -2.03 62.23 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo -13.16 -0.52 70.77 -15.41 -0.40 68.66 -31.14 -69.48 -33.14 -28.66 -69.19 -31.35 coo -11.26 -6.31 57.37 -11.02 -6.31 59.47 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 1xs1_c11 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 4 hits 1xs1_c11 naa= 3 ULMN 3 1xva_c03 GLYCINE N-METHYLTRANSFERASE user 1 3 # 1 B 137 GLY B 0 GLY.? 18.42 O2 CIT B 103 B 175 ARG A 40 ARG^? 16.77 O2 EDO A 103 B 242 TYR B 3 TYR.? 14.53 O2 CIT B 103 coo 99.45 58.28 3.33 99.57 58.61 4.10 -11.68 -66.89 -21.61 -12.41 -67.26 -21.40 coo 106.37 63.53 0.89 108.02 63.40 -1.62 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 coo 100.93 69.04 4.38 99.52 68.48 2.09 -14.93 -76.07 -18.16 -17.56 -75.13 -18.37 ULMN 3 1xva_c03 GLYCINE N-METHYLTRANSFERASE user 2 3 # 2 B 137 GLY B 42 GLY^? 14.02 O1 CIT B 103 B 175 ARG B 40 ARG^? 17.25 O1 CIT B 103 B 242 TYR A 3 TYR.? 14.44 O2 EDO A 103 coo 99.45 58.28 3.33 99.57 58.61 4.10 -16.95 -88.05 -8.22 -16.29 -87.98 -8.72 coo 106.37 63.53 0.89 108.02 63.40 -1.62 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 100.93 69.04 4.38 99.52 68.48 2.09 -19.78 -82.90 -15.01 -20.82 -80.68 -13.70 ULMN 3 1xva_c03 GLYCINE N-METHYLTRANSFERASE user 3 3 # 3 B 137 GLY C 0 GLY.? 18.38 O2 CIT C 104 B 175 ARG D 40 ARG^? 16.76 O2 CIT D 103 B 242 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo 99.45 58.28 3.33 99.57 58.61 4.10 -58.43 -72.91 -14.46 -58.32 -72.08 -14.62 coo 106.37 63.53 0.89 108.02 63.40 -1.62 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 100.93 69.04 4.38 99.52 68.48 2.09 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1xva_c03 GLYCINE N-METHYLTRANSFERASE user 4 3 # 4 B 137 GLY D 0 GLY.? 18.60 O6 CIT D 103 B 175 ARG C 40 ARG^? 17.96 O1 CIT C 104 B 242 TYR D 3 TYR.? 14.21 O2 CIT D 103 coo 99.45 58.28 3.33 99.57 58.61 4.10 -52.56 -47.08 -27.07 -52.40 -46.76 -26.33 coo 106.37 63.53 0.89 108.02 63.40 -1.62 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 100.93 69.04 4.38 99.52 68.48 2.09 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 ULMN 3 1xva_c03 GLYCINE N-METHYLTRANSFERASE user 5 3 # 5 B 137 GLY D 42 GLY^? 14.38 C1 CIT D 103 B 175 ARG D 40 ARG^? 16.76 O2 CIT D 103 B 242 TYR C 3 TYR.? 14.43 O1 CIT C 104 coo 99.45 58.28 3.33 99.57 58.61 4.10 -52.42 -66.59 -9.79 -51.76 -66.17 -10.02 coo 106.37 63.53 0.89 108.02 63.40 -1.62 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 coo 100.93 69.04 4.38 99.52 68.48 2.09 -53.80 -64.78 -18.50 -56.24 -63.43 -18.40 ULMN 3 1xva_c03 GLYCINE N-METHYLTRANSFERASE user 6 3 # 6 B 137 GLY E 0 GLY.? 18.62 O2 CIT E 104 B 175 ARG F 40 ARG^? 16.45 O2 CIT F 104 B 242 TYR E 3 TYR.? 13.85 O2 EDO E 103 coo 99.45 58.28 3.33 99.57 58.61 4.10 -40.04 -89.68 -60.78 -40.45 -89.11 -60.45 coo 106.37 63.53 0.89 108.02 63.40 -1.62 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 100.93 69.04 4.38 99.52 68.48 2.09 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 ULMN 3 1xva_c03 GLYCINE N-METHYLTRANSFERASE user 7 3 # 7 B 137 GLY F 0 GLY.? 9.67 O2 EDO E 103 B 175 ARG E 40 ARG^? -5.36 O2 EDO E 103s B 242 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 99.45 58.28 3.33 99.57 58.61 4.10 -15.65 -85.40 -47.05 -15.91 -84.76 -47.52 coo 106.37 63.53 0.89 108.02 63.40 -1.62 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 100.93 69.04 4.38 99.52 68.48 2.09 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 1xva_c03 source 1xva GLYCINE N-METHYLTRANSFERASE : 7 hits 1xva_c03 naa= 3 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 1 3 # 1 A 105 ASN A 44 ASN.? 11.73 O6 CIT B 103 A 106 PRO A 43 PRO^? 17.15 O2 EDO A 103 A 108 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 36.18 33.51 20.99 37.11 35.33 20.14 -8.38 -73.55 -27.31 -9.00 -75.70 -26.82 coo 33.01 33.46 15.68 31.96 34.97 17.80 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 2 3 # 2 A 105 ASN A 44 ASN.? 11.73 O6 CIT B 103 A 106 PRO A 55 PRO.? 15.07 C1 EDO A 103 A 108 TYR A 54 TYR.? 12.54 C1 EDO A 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 36.18 33.51 20.99 37.11 35.33 20.14 -4.34 -81.58 -29.52 -4.75 -81.28 -27.35 coo 33.01 33.46 15.68 31.96 34.97 17.80 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 3 3 # 3 A 105 ASN A 44 ASN.? 11.73 O6 CIT B 103 A 106 PRO A 55 PRO.? 15.07 C1 EDO A 103 A 108 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 36.18 33.51 20.99 37.11 35.33 20.14 -4.34 -81.58 -29.52 -4.75 -81.28 -27.35 coo 33.01 33.46 15.68 31.96 34.97 17.80 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 4 3 # 4 A 105 ASN B 44 ASN.? 13.13 O1 EDO A 103 A 106 PRO B 43 PRO^? 16.74 O1 CIT B 103 A 108 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 36.18 33.51 20.99 37.11 35.33 20.14 -18.16 -92.21 -8.38 -16.44 -90.98 -9.14 coo 33.01 33.46 15.68 31.96 34.97 17.80 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 5 3 # 5 A 105 ASN B 44 ASN.? 13.13 O1 EDO A 103 A 106 PRO B 55 PRO.? 14.55 O7 CIT B 103 A 108 TYR B 54 TYR.? 11.82 O7 CIT B 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 36.18 33.51 20.99 37.11 35.33 20.14 -9.50 -94.94 -10.03 -10.73 -93.99 -11.64 coo 33.01 33.46 15.68 31.96 34.97 17.80 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 6 3 # 6 A 105 ASN B 44 ASN.? 13.13 O1 EDO A 103 A 106 PRO B 55 PRO.? 14.55 O7 CIT B 103 A 108 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 36.18 33.51 20.99 37.11 35.33 20.14 -9.50 -94.94 -10.03 -10.73 -93.99 -11.64 coo 33.01 33.46 15.68 31.96 34.97 17.80 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 7 3 # 7 A 105 ASN C 44 ASN.? 11.91 O6 CIT D 103 A 106 PRO C 43 PRO^? 16.83 O1 CIT C 104 A 108 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 34.91 38.94 20.48 33.53 38.20 19.00 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 36.18 33.51 20.99 37.11 35.33 20.14 -44.37 -51.76 -28.68 -44.19 -53.81 -27.76 coo 33.01 33.46 15.68 31.96 34.97 17.80 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 8 3 # 8 A 105 ASN C 44 ASN.? 11.91 O6 CIT D 103 A 106 PRO C 55 PRO.? 15.29 C4 CIT C 104 A 108 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 34.91 38.94 20.48 33.53 38.20 19.00 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 36.18 33.51 20.99 37.11 35.33 20.14 -36.58 -55.92 -26.97 -38.04 -55.79 -25.30 coo 33.01 33.46 15.68 31.96 34.97 17.80 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 9 3 # 9 A 105 ASN C 44 ASN.? 11.91 O6 CIT D 103 A 106 PRO C 55 PRO.? 15.29 C4 CIT C 104 A 108 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 34.91 38.94 20.48 33.53 38.20 19.00 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 36.18 33.51 20.99 37.11 35.33 20.14 -36.58 -55.92 -26.97 -38.04 -55.79 -25.30 coo 33.01 33.46 15.68 31.96 34.97 17.80 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 10 3 # 10 A 105 ASN D 44 ASN.? 12.24 O2 CIT C 104 A 106 PRO D 43 PRO^? 16.79 C2 CIT D 103 A 108 TYR D 56 TYR^? 12.73 C2 CIT D 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 coo 36.18 33.51 20.99 37.11 35.33 20.14 -51.31 -70.72 -9.08 -50.24 -68.79 -9.64 coo 33.01 33.46 15.68 31.96 34.97 17.80 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 11 3 # 11 A 105 ASN D 44 ASN.? 12.24 O2 CIT C 104 A 106 PRO D 55 PRO.? 14.93 C2 CIT D 103 A 108 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 coo 36.18 33.51 20.99 37.11 35.33 20.14 -42.58 -68.38 -6.92 -43.25 -68.18 -9.06 coo 33.01 33.46 15.68 31.96 34.97 17.80 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 12 3 # 12 A 105 ASN D 44 ASN.? 12.24 O2 CIT C 104 A 106 PRO D 55 PRO.? 14.93 C2 CIT D 103 A 108 TYR D 56 TYR^? 12.73 C2 CIT D 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 coo 36.18 33.51 20.99 37.11 35.33 20.14 -42.58 -68.38 -6.92 -43.25 -68.18 -9.06 coo 33.01 33.46 15.68 31.96 34.97 17.80 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 13 3 # 13 A 105 ASN E 44 ASN.? 11.90 O7 CIT F 104 A 106 PRO E 43 PRO^? 9.04 O2 EDO E 103 A 108 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 36.18 33.51 20.99 37.11 35.33 20.14 -19.31 -77.07 -44.70 -21.34 -76.65 -45.59 coo 33.01 33.46 15.68 31.96 34.97 17.80 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 14 3 # 14 A 105 ASN E 44 ASN.? 11.90 O7 CIT F 104 A 106 PRO E 55 PRO.? 13.81 O1 EDO F 103 A 108 TYR E 54 TYR.? 6.56 O1 EDO F 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 36.18 33.51 20.99 37.11 35.33 20.14 -23.56 -68.90 -46.02 -23.20 -70.22 -47.80 coo 33.01 33.46 15.68 31.96 34.97 17.80 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 15 3 # 15 A 105 ASN E 44 ASN.? 11.90 O7 CIT F 104 A 106 PRO E 55 PRO.? 13.81 O1 EDO F 103 A 108 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 36.18 33.51 20.99 37.11 35.33 20.14 -23.56 -68.90 -46.02 -23.20 -70.22 -47.80 coo 33.01 33.46 15.68 31.96 34.97 17.80 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 16 3 # 16 A 105 ASN F 44 ASN.? 8.45 O2 EDO F 103 A 106 PRO F 43 PRO^? 15.47 O2 EDO F 103 A 108 TYR F 56 TYR^? 13.04 O1 CIT F 104 coo 34.91 38.94 20.48 33.53 38.20 19.00 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 coo 36.18 33.51 20.99 37.11 35.33 20.14 -37.87 -81.53 -65.46 -35.92 -80.65 -64.76 coo 33.01 33.46 15.68 31.96 34.97 17.80 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 17 3 # 17 A 105 ASN F 44 ASN.? 8.45 O2 EDO F 103 A 106 PRO F 55 PRO.? 9.55 O2 EDO F 103 A 108 TYR F 54 TYR.? 5.10 C2 EDO F 103 coo 34.91 38.94 20.48 33.53 38.20 19.00 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 coo 36.18 33.51 20.99 37.11 35.33 20.14 -34.96 -72.99 -66.82 -35.16 -73.72 -64.73 coo 33.01 33.46 15.68 31.96 34.97 17.80 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 ULMN 3 2adm_c00 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 18 3 # 18 A 105 ASN F 44 ASN.? 8.45 O2 EDO F 103 A 106 PRO F 55 PRO.? 9.55 O2 EDO F 103 A 108 TYR F 56 TYR^? 13.04 O1 CIT F 104 coo 34.91 38.94 20.48 33.53 38.20 19.00 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 coo 36.18 33.51 20.99 37.11 35.33 20.14 -34.96 -72.99 -66.82 -35.16 -73.72 -64.73 coo 33.01 33.46 15.68 31.96 34.97 17.80 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 2adm_c00 source 2adm ADENINE-N6-DNA-METHYLTRANSFERASE TAQI : 18 hits 2adm_c00 naa= 3 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 1 3 # 1 B 105 ASN A 44 ASN.? 11.73 O6 CIT B 103 B 106 PRO A 43 PRO^? 17.15 O2 EDO A 103 B 108 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 4.66 43.53 47.47 3.74 41.73 46.59 -8.38 -73.55 -27.31 -9.00 -75.70 -26.82 coo 7.86 43.80 42.15 8.87 42.26 44.27 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 2 3 # 2 B 105 ASN A 44 ASN.? 11.73 O6 CIT B 103 B 106 PRO A 55 PRO.? 15.07 C1 EDO A 103 B 108 TYR A 54 TYR.? 12.54 C1 EDO A 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 4.66 43.53 47.47 3.74 41.73 46.59 -4.34 -81.58 -29.52 -4.75 -81.28 -27.35 coo 7.86 43.80 42.15 8.87 42.26 44.27 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 3 3 # 3 B 105 ASN A 44 ASN.? 11.73 O6 CIT B 103 B 106 PRO A 55 PRO.? 15.07 C1 EDO A 103 B 108 TYR A 56 TYR^? 12.86 C2 EDO A 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 4.66 43.53 47.47 3.74 41.73 46.59 -4.34 -81.58 -29.52 -4.75 -81.28 -27.35 coo 7.86 43.80 42.15 8.87 42.26 44.27 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 4 3 # 4 B 105 ASN B 44 ASN.? 13.13 O1 EDO A 103 B 106 PRO B 43 PRO^? 16.74 O1 CIT B 103 B 108 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 4.66 43.53 47.47 3.74 41.73 46.59 -18.16 -92.21 -8.38 -16.44 -90.98 -9.14 coo 7.86 43.80 42.15 8.87 42.26 44.27 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 5 3 # 5 B 105 ASN B 44 ASN.? 13.13 O1 EDO A 103 B 106 PRO B 55 PRO.? 14.55 O7 CIT B 103 B 108 TYR B 54 TYR.? 11.82 O7 CIT B 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 4.66 43.53 47.47 3.74 41.73 46.59 -9.50 -94.94 -10.03 -10.73 -93.99 -11.64 coo 7.86 43.80 42.15 8.87 42.26 44.27 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 6 3 # 6 B 105 ASN B 44 ASN.? 13.13 O1 EDO A 103 B 106 PRO B 55 PRO.? 14.55 O7 CIT B 103 B 108 TYR B 56 TYR^? 12.51 O1 CIT B 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 4.66 43.53 47.47 3.74 41.73 46.59 -9.50 -94.94 -10.03 -10.73 -93.99 -11.64 coo 7.86 43.80 42.15 8.87 42.26 44.27 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 7 3 # 7 B 105 ASN C 44 ASN.? 11.91 O6 CIT D 103 B 106 PRO C 43 PRO^? 16.83 O1 CIT C 104 B 108 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 5.98 38.14 46.94 7.30 38.92 45.46 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 4.66 43.53 47.47 3.74 41.73 46.59 -44.37 -51.76 -28.68 -44.19 -53.81 -27.76 coo 7.86 43.80 42.15 8.87 42.26 44.27 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 8 3 # 8 B 105 ASN C 44 ASN.? 11.91 O6 CIT D 103 B 106 PRO C 55 PRO.? 15.29 C4 CIT C 104 B 108 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 5.98 38.14 46.94 7.30 38.92 45.46 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 4.66 43.53 47.47 3.74 41.73 46.59 -36.58 -55.92 -26.97 -38.04 -55.79 -25.30 coo 7.86 43.80 42.15 8.87 42.26 44.27 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 9 3 # 9 B 105 ASN C 44 ASN.? 11.91 O6 CIT D 103 B 106 PRO C 55 PRO.? 15.29 C4 CIT C 104 B 108 TYR C 56 TYR^? 12.84 O1 CIT C 104 coo 5.98 38.14 46.94 7.30 38.92 45.46 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 4.66 43.53 47.47 3.74 41.73 46.59 -36.58 -55.92 -26.97 -38.04 -55.79 -25.30 coo 7.86 43.80 42.15 8.87 42.26 44.27 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 10 3 # 10 B 105 ASN D 44 ASN.? 12.24 O2 CIT C 104 B 106 PRO D 43 PRO^? 16.79 C2 CIT D 103 B 108 TYR D 56 TYR^? 12.73 C2 CIT D 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 coo 4.66 43.53 47.47 3.74 41.73 46.59 -51.31 -70.72 -9.08 -50.24 -68.79 -9.64 coo 7.86 43.80 42.15 8.87 42.26 44.27 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 11 3 # 11 B 105 ASN D 44 ASN.? 12.24 O2 CIT C 104 B 106 PRO D 55 PRO.? 14.93 C2 CIT D 103 B 108 TYR D 54 TYR.? 11.66 C4 CIT D 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 coo 4.66 43.53 47.47 3.74 41.73 46.59 -42.58 -68.38 -6.92 -43.25 -68.18 -9.06 coo 7.86 43.80 42.15 8.87 42.26 44.27 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 12 3 # 12 B 105 ASN D 44 ASN.? 12.24 O2 CIT C 104 B 106 PRO D 55 PRO.? 14.93 C2 CIT D 103 B 108 TYR D 56 TYR^? 12.73 C2 CIT D 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 coo 4.66 43.53 47.47 3.74 41.73 46.59 -42.58 -68.38 -6.92 -43.25 -68.18 -9.06 coo 7.86 43.80 42.15 8.87 42.26 44.27 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 13 3 # 13 B 105 ASN E 44 ASN.? 11.90 O7 CIT F 104 B 106 PRO E 43 PRO^? 9.04 O2 EDO E 103 B 108 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 4.66 43.53 47.47 3.74 41.73 46.59 -19.31 -77.07 -44.70 -21.34 -76.65 -45.59 coo 7.86 43.80 42.15 8.87 42.26 44.27 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 14 3 # 14 B 105 ASN E 44 ASN.? 11.90 O7 CIT F 104 B 106 PRO E 55 PRO.? 13.81 O1 EDO F 103 B 108 TYR E 54 TYR.? 6.56 O1 EDO F 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 4.66 43.53 47.47 3.74 41.73 46.59 -23.56 -68.90 -46.02 -23.20 -70.22 -47.80 coo 7.86 43.80 42.15 8.87 42.26 44.27 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 15 3 # 15 B 105 ASN E 44 ASN.? 11.90 O7 CIT F 104 B 106 PRO E 55 PRO.? 13.81 O1 EDO F 103 B 108 TYR E 56 TYR^? 8.81 O2 EDO E 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 4.66 43.53 47.47 3.74 41.73 46.59 -23.56 -68.90 -46.02 -23.20 -70.22 -47.80 coo 7.86 43.80 42.15 8.87 42.26 44.27 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 16 3 # 16 B 105 ASN F 44 ASN.? 8.45 O2 EDO F 103 B 106 PRO F 43 PRO^? 15.47 O2 EDO F 103 B 108 TYR F 56 TYR^? 13.04 O1 CIT F 104 coo 5.98 38.14 46.94 7.30 38.92 45.46 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 coo 4.66 43.53 47.47 3.74 41.73 46.59 -37.87 -81.53 -65.46 -35.92 -80.65 -64.76 coo 7.86 43.80 42.15 8.87 42.26 44.27 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 17 3 # 17 B 105 ASN F 44 ASN.? 8.45 O2 EDO F 103 B 106 PRO F 55 PRO.? 9.55 O2 EDO F 103 B 108 TYR F 54 TYR.? 5.10 C2 EDO F 103 coo 5.98 38.14 46.94 7.30 38.92 45.46 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 coo 4.66 43.53 47.47 3.74 41.73 46.59 -34.96 -72.99 -66.82 -35.16 -73.72 -64.73 coo 7.86 43.80 42.15 8.87 42.26 44.27 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 ULMN 3 2adm_c01 ADENINE-N6-DNA-METHYLTRANSFERASE TAQuser 18 3 # 18 B 105 ASN F 44 ASN.? 8.45 O2 EDO F 103 B 106 PRO F 55 PRO.? 9.55 O2 EDO F 103 B 108 TYR F 56 TYR^? 13.04 O1 CIT F 104 coo 5.98 38.14 46.94 7.30 38.92 45.46 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 coo 4.66 43.53 47.47 3.74 41.73 46.59 -34.96 -72.99 -66.82 -35.16 -73.72 -64.73 coo 7.86 43.80 42.15 8.87 42.26 44.27 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 2adm_c01 source 2adm ADENINE-N6-DNA-METHYLTRANSFERASE TAQI : 18 hits 2adm_c01 naa= 3 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 1 3 # 1 B 29 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 50 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 113 GLN A 78 GLN~? 10.77 O1 EDO A 103 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -24.81 -92.50 -33.55 -26.20 -94.06 -34.04 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 2 3 # 2 B 29 HIS B 77 HIS~? -4.07 O1 CIT B 103s B 50 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 113 GLN B 78 GLN~? 5.40 O5 CIT B 103 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -0.37 -74.67 -3.06 0.37 -75.53 -4.88 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 3 3 # 3 B 29 HIS C 77 HIS~? -4.31 O1 CIT C 104s B 50 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 113 GLN C 78 GLN~? 5.88 O5 CIT C 104 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -45.06 -77.16 -33.78 -43.65 -77.62 -32.32 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 4 3 # 4 B 29 HIS D 77 HIS~? -3.79 O1 CIT D 103s B 50 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 113 GLN D 78 GLN~? 9.56 O5 CIT D 103 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -48.77 -45.34 -3.70 -48.95 -43.23 -3.36 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 5 3 # 5 B 29 HIS E 77 HIS~? -4.13 O1 CIT E 104s B 50 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 113 GLN E 78 GLN~? 7.31 O6 CIT E 104 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -44.62 -77.18 -40.55 -46.18 -75.95 -41.22 2ag0_c04 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c04 naa= 3 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 1 3 # 1 B 29 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 50 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 113 GLN A 78 GLN~? 10.77 O1 EDO A 103 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -24.81 -92.50 -33.55 -26.20 -94.06 -34.04 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 2 3 # 2 B 29 HIS B 77 HIS~? -4.07 O1 CIT B 103s B 50 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 113 GLN B 78 GLN~? 5.40 O5 CIT B 103 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -0.37 -74.67 -3.06 0.37 -75.53 -4.88 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 3 3 # 3 B 29 HIS C 77 HIS~? -4.31 O1 CIT C 104s B 50 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 113 GLN C 78 GLN~? 5.88 O5 CIT C 104 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -45.06 -77.16 -33.78 -43.65 -77.62 -32.32 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 4 3 # 4 B 29 HIS D 77 HIS~? -3.79 O1 CIT D 103s B 50 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 113 GLN D 78 GLN~? 9.56 O5 CIT D 103 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -48.77 -45.34 -3.70 -48.95 -43.23 -3.36 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 5 3 # 5 B 29 HIS E 77 HIS~? -4.13 O1 CIT E 104s B 50 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 113 GLN E 78 GLN~? 7.31 O6 CIT E 104 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -44.62 -77.18 -40.55 -46.18 -75.95 -41.22 2ag0_c08 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c08 naa= 3 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 1 3 # 1 A 29 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 50 GLU B 48 GLU.? 3.87 O1 EDO A 103 A 113 GLN A 78 GLN~? 10.77 O1 EDO A 103 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 -24.81 -92.50 -33.55 -26.20 -94.06 -34.04 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 2 3 # 2 A 29 HIS B 77 HIS~? -4.07 O1 CIT B 103s A 50 GLU A 48 GLU.? -2.39 O6 CIT B 103s A 113 GLN B 78 GLN~? 5.40 O5 CIT B 103 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 -0.37 -74.67 -3.06 0.37 -75.53 -4.88 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 3 3 # 3 A 29 HIS C 77 HIS~? -4.31 O1 CIT C 104s A 50 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 113 GLN C 78 GLN~? 5.88 O5 CIT C 104 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 -45.06 -77.16 -33.78 -43.65 -77.62 -32.32 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 4 3 # 4 A 29 HIS D 77 HIS~? -3.79 O1 CIT D 103s A 50 GLU C 48 GLU.? -2.75 O6 CIT D 103s A 113 GLN D 78 GLN~? 9.56 O5 CIT D 103 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 -48.77 -45.34 -3.70 -48.95 -43.23 -3.36 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 5 3 # 5 A 29 HIS E 77 HIS~? -4.13 O1 CIT E 104s A 50 GLU F 48 GLU.? -3.15 C4 CIT E 104s A 113 GLN E 78 GLN~? 7.31 O6 CIT E 104 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 -44.62 -77.18 -40.55 -46.18 -75.95 -41.22 2ag0_c09 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c09 naa= 3 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 1 3 # 1 C 29 HIS A 77 HIS~? -4.41 C2 EDO A 103s C 50 GLU B 48 GLU.? 3.87 O1 EDO A 103 C 113 GLN A 78 GLN~? 10.77 O1 EDO A 103 coo 74.92 8.52 28.42 74.88 6.86 29.70 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 65.25 15.95 28.73 65.73 15.63 30.78 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 70.80 6.73 32.72 71.88 8.55 32.53 -24.81 -92.50 -33.55 -26.20 -94.06 -34.04 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 2 3 # 2 C 29 HIS B 77 HIS~? -4.07 O1 CIT B 103s C 50 GLU A 48 GLU.? -2.39 O6 CIT B 103s C 113 GLN B 78 GLN~? 5.40 O5 CIT B 103 coo 74.92 8.52 28.42 74.88 6.86 29.70 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 65.25 15.95 28.73 65.73 15.63 30.78 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 70.80 6.73 32.72 71.88 8.55 32.53 -0.37 -74.67 -3.06 0.37 -75.53 -4.88 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 3 3 # 3 C 29 HIS C 77 HIS~? -4.31 O1 CIT C 104s C 50 GLU D 48 GLU.? -3.37 O7 CIT C 104s C 113 GLN C 78 GLN~? 5.88 O5 CIT C 104 coo 74.92 8.52 28.42 74.88 6.86 29.70 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 65.25 15.95 28.73 65.73 15.63 30.78 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 70.80 6.73 32.72 71.88 8.55 32.53 -45.06 -77.16 -33.78 -43.65 -77.62 -32.32 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 4 3 # 4 C 29 HIS D 77 HIS~? -3.79 O1 CIT D 103s C 50 GLU C 48 GLU.? -2.75 O6 CIT D 103s C 113 GLN D 78 GLN~? 9.56 O5 CIT D 103 coo 74.92 8.52 28.42 74.88 6.86 29.70 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 65.25 15.95 28.73 65.73 15.63 30.78 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 70.80 6.73 32.72 71.88 8.55 32.53 -48.77 -45.34 -3.70 -48.95 -43.23 -3.36 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 5 3 # 5 C 29 HIS E 77 HIS~? -4.13 O1 CIT E 104s C 50 GLU F 48 GLU.? -3.15 C4 CIT E 104s C 113 GLN E 78 GLN~? 7.31 O6 CIT E 104 coo 74.92 8.52 28.42 74.88 6.86 29.70 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 65.25 15.95 28.73 65.73 15.63 30.78 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 70.80 6.73 32.72 71.88 8.55 32.53 -44.62 -77.18 -40.55 -46.18 -75.95 -41.22 2ag0_c10 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c10 naa= 3 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 1 3 # 1 D 29 HIS A 77 HIS~? -4.41 C2 EDO A 103s D 50 GLU B 48 GLU.? 3.87 O1 EDO A 103 D 113 GLN A 78 GLN~? 10.77 O1 EDO A 103 coo 38.66 11.31 27.15 38.67 12.13 25.22 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 48.72 12.85 33.83 48.36 14.77 32.95 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 42.85 14.77 24.15 41.85 15.11 26.02 -24.81 -92.50 -33.55 -26.20 -94.06 -34.04 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 2 3 # 2 D 29 HIS B 77 HIS~? -4.07 O1 CIT B 103s D 50 GLU A 48 GLU.? -2.39 O6 CIT B 103s D 113 GLN B 78 GLN~? 5.40 O5 CIT B 103 coo 38.66 11.31 27.15 38.67 12.13 25.22 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 48.72 12.85 33.83 48.36 14.77 32.95 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 42.85 14.77 24.15 41.85 15.11 26.02 -0.37 -74.67 -3.06 0.37 -75.53 -4.88 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 3 3 # 3 D 29 HIS C 77 HIS~? -4.31 O1 CIT C 104s D 50 GLU D 48 GLU.? -3.37 O7 CIT C 104s D 113 GLN C 78 GLN~? 5.88 O5 CIT C 104 coo 38.66 11.31 27.15 38.67 12.13 25.22 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 48.72 12.85 33.83 48.36 14.77 32.95 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 42.85 14.77 24.15 41.85 15.11 26.02 -45.06 -77.16 -33.78 -43.65 -77.62 -32.32 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 4 3 # 4 D 29 HIS D 77 HIS~? -3.79 O1 CIT D 103s D 50 GLU C 48 GLU.? -2.75 O6 CIT D 103s D 113 GLN D 78 GLN~? 9.56 O5 CIT D 103 coo 38.66 11.31 27.15 38.67 12.13 25.22 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 48.72 12.85 33.83 48.36 14.77 32.95 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 42.85 14.77 24.15 41.85 15.11 26.02 -48.77 -45.34 -3.70 -48.95 -43.23 -3.36 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 5 3 # 5 D 29 HIS E 77 HIS~? -4.13 O1 CIT E 104s D 50 GLU F 48 GLU.? -3.15 C4 CIT E 104s D 113 GLN E 78 GLN~? 7.31 O6 CIT E 104 coo 38.66 11.31 27.15 38.67 12.13 25.22 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 48.72 12.85 33.83 48.36 14.77 32.95 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 42.85 14.77 24.15 41.85 15.11 26.02 -44.62 -77.18 -40.55 -46.18 -75.95 -41.22 2ag0_c11 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c11 naa= 3 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 1 3 # 1 193 ASP A 64 ASP~? 16.37 O2 EDO A 103 219 GLU A 101 GLU^? 18.10 O2 EDO A 103 294 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 25.84 105.87 9.06 27.86 105.55 8.74 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 33.16 106.80 7.72 33.34 104.87 6.92 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 2 3 # 2 193 ASP A 99 ASP^? 8.10 O2 EDO A 103 219 GLU A 101 GLU^? 18.10 O2 EDO A 103 294 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 25.84 105.87 9.06 27.86 105.55 8.74 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 coo 33.16 106.80 7.72 33.34 104.87 6.92 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 3 3 # 3 193 ASP B 64 ASP~? 16.93 O2 CIT B 103 219 GLU B 101 GLU^? 17.79 O2 CIT B 103 294 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 25.84 105.87 9.06 27.86 105.55 8.74 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 33.16 106.80 7.72 33.34 104.87 6.92 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 4 3 # 4 193 ASP B 99 ASP^? 7.47 O6 CIT B 103 219 GLU B 101 GLU^? 17.79 O2 CIT B 103 294 ASP B 64 ASP~? 16.93 O2 CIT B 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 25.84 105.87 9.06 27.86 105.55 8.74 -9.80 -70.18 -23.04 -8.26 -68.88 -23.69 coo 33.16 106.80 7.72 33.34 104.87 6.92 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 5 3 # 5 193 ASP C 64 ASP~? 16.62 O2 CIT C 104 219 GLU C 101 GLU^? 17.42 O2 CIT C 104 294 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 27.89 102.52 14.98 29.35 101.92 13.57 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 coo 25.84 105.87 9.06 27.86 105.55 8.74 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 33.16 106.80 7.72 33.34 104.87 6.92 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 6 3 # 6 193 ASP C 99 ASP^? 7.14 O2 CIT C 104 219 GLU C 101 GLU^? 17.42 O2 CIT C 104 294 ASP C 64 ASP~? 16.62 O2 CIT C 104 coo 27.89 102.52 14.98 29.35 101.92 13.57 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 25.84 105.87 9.06 27.86 105.55 8.74 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 coo 33.16 106.80 7.72 33.34 104.87 6.92 -58.61 -75.90 -20.03 -59.53 -76.58 -21.83 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 7 3 # 7 193 ASP D 64 ASP~? 16.39 O2 CIT D 103 219 GLU D 101 GLU^? 17.58 O6 CIT D 103 294 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 25.84 105.87 9.06 27.86 105.55 8.74 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 33.16 106.80 7.72 33.34 104.87 6.92 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 8 3 # 8 193 ASP D 99 ASP^? 6.89 O6 CIT D 103 219 GLU D 101 GLU^? 17.58 O6 CIT D 103 294 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 25.84 105.87 9.06 27.86 105.55 8.74 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 coo 33.16 106.80 7.72 33.34 104.87 6.92 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 9 3 # 9 193 ASP F 64 ASP~? 16.52 O2 EDO E 103 219 GLU F 101 GLU^? 10.35 O2 EDO E 103 294 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 27.89 102.52 14.98 29.35 101.92 13.57 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo 25.84 105.87 9.06 27.86 105.55 8.74 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 33.16 106.80 7.72 33.34 104.87 6.92 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 2amg_c02 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 10 3 # 10 193 ASP F 99 ASP^? 6.97 O7 CIT F 104 219 GLU F 101 GLU^? 10.35 O2 EDO E 103 294 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 25.84 105.87 9.06 27.86 105.55 8.74 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 coo 33.16 106.80 7.72 33.34 104.87 6.92 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 2amg_c02 source 2amg 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLASE : 10 hits 2amg_c02 naa= 3 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 1 3 # 1 193 ASP A 64 ASP~? 16.37 O2 EDO A 103 231 ASP C 93 ASP~? 9.74 O3 CIT C 104 294 ASP A 69 ASP~? 12.13 O2 EDO A 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 33.16 106.80 7.72 33.34 104.87 6.92 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 2 3 # 2 193 ASP A 64 ASP~? 16.37 O2 EDO A 103 231 ASP C 93 ASP~? 9.74 O3 CIT C 104 294 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 33.16 106.80 7.72 33.34 104.87 6.92 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 3 3 # 3 193 ASP A 64 ASP~? 16.37 O2 EDO A 103 231 ASP E 27 ASP~? 4.58 C1 EDO E 103 294 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 33.16 106.80 7.72 33.34 104.87 6.92 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 4 3 # 4 193 ASP A 69 ASP~? 12.13 O2 EDO A 103 231 ASP C 93 ASP~? 9.74 O3 CIT C 104 294 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 33.16 106.80 7.72 33.34 104.87 6.92 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 5 3 # 5 193 ASP A 99 ASP^? 8.10 O2 EDO A 103 231 ASP B 27 ASP~? 12.32 O1 CIT B 103 294 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo 33.16 106.80 7.72 33.34 104.87 6.92 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 6 3 # 6 193 ASP A 99 ASP^? 8.10 O2 EDO A 103 231 ASP E 27 ASP~? 4.58 C1 EDO E 103 294 ASP A 64 ASP~? 16.37 O2 EDO A 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 33.16 106.80 7.72 33.34 104.87 6.92 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 7 3 # 7 193 ASP B 64 ASP~? 16.93 O2 CIT B 103 231 ASP C 93 ASP~? 9.74 O3 CIT C 104 294 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 33.16 106.80 7.72 33.34 104.87 6.92 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 8 3 # 8 193 ASP B 64 ASP~? 16.93 O2 CIT B 103 231 ASP E 17 ASP~? 16.97 O4 CIT C 104 294 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 33.16 106.80 7.72 33.34 104.87 6.92 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 9 3 # 9 193 ASP C 93 ASP~? 9.74 O3 CIT C 104 231 ASP A 64 ASP~? 16.37 O2 EDO A 103 294 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 27.89 102.52 14.98 29.35 101.92 13.57 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo 33.16 106.80 7.72 33.34 104.87 6.92 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 10 3 # 10 193 ASP C 93 ASP~? 9.74 O3 CIT C 104 231 ASP A 69 ASP~? 12.13 O2 EDO A 103 294 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 27.89 102.52 14.98 29.35 101.92 13.57 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -28.81 -93.65 -23.22 -27.76 -94.79 -21.78 coo 33.16 106.80 7.72 33.34 104.87 6.92 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 11 3 # 11 193 ASP C 93 ASP~? 9.74 O3 CIT C 104 231 ASP B 64 ASP~? 16.93 O2 CIT B 103 294 ASP E 17 ASP~? 16.97 O4 CIT C 104 coo 27.89 102.52 14.98 29.35 101.92 13.57 -31.09 -69.02 -23.74 -30.42 -70.95 -23.20 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -10.52 -64.96 -16.20 -10.45 -63.85 -14.34 coo 33.16 106.80 7.72 33.34 104.87 6.92 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 12 3 # 12 193 ASP D 99 ASP^? 6.89 O6 CIT D 103 231 ASP C 27 ASP~? 13.15 O1 CIT C 104 294 ASP D 64 ASP~? 16.39 O2 CIT D 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo 33.16 106.80 7.72 33.34 104.87 6.92 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 13 3 # 13 193 ASP F 99 ASP^? 6.97 O7 CIT F 104 231 ASP A 27 ASP~? 13.11 O2 EDO A 103 294 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 33.16 106.80 7.72 33.34 104.87 6.92 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 14 3 # 14 193 ASP F 99 ASP^? 6.97 O7 CIT F 104 231 ASP E 27 ASP~? 4.58 C1 EDO E 103 294 ASP F 64 ASP~? 16.52 O2 EDO E 103 coo 27.89 102.52 14.98 29.35 101.92 13.57 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 33.16 106.80 7.72 33.34 104.87 6.92 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 2amg_c06 source 2amg 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLASE : 14 hits 2amg_c06 naa= 3 ULMN 3 2apr_c04 ACID PROTEINASE (RHIZOPUSPEPSIN) (E.user 1 3 # 1 35 ASP A 46 ASP.? 9.57 O6 CIT B 103 38 SER A 51 SER.? 9.93 O6 CIT B 103 218 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 41.14 58.72 105.19 42.39 59.85 103.92 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo 46.04 57.35 103.96 44.97 58.52 105.78 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo 41.33 60.20 97.63 42.00 60.96 99.49 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 2apr_c04 ACID PROTEINASE (RHIZOPUSPEPSIN) (E.user 2 3 # 2 35 ASP C 46 ASP.? 10.22 O6 CIT D 103 38 SER C 51 SER.? 10.55 O6 CIT D 103 218 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 41.14 58.72 105.19 42.39 59.85 103.92 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo 46.04 57.35 103.96 44.97 58.52 105.78 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo 41.33 60.20 97.63 42.00 60.96 99.49 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 2apr_c04 source 2apr ACID PROTEINASE (RHIZOPUSPEPSIN) (E.C.3.4.23.6: 2 hits 2apr_c04 naa= 3 ULMN 3 2c7v_c08 PTERIDINE REDUCTASE user 1 3 # 1 A 14 ARG A 18 ARG~? 14.68 C2 EDO E 103 A 161 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 174 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 14.43 -13.26 8.40 11.75 -14.25 9.60 -13.40 -85.38 -40.50 -10.48 -85.51 -41.44 coo 3.82 -4.94 15.61 3.37 -6.97 16.02 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 8.61 -7.11 20.41 7.51 -6.92 17.85 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 2c7v_c08 PTERIDINE REDUCTASE user 2 3 # 2 A 14 ARG C 40 ARG^? 17.96 O1 CIT C 104 A 161 ASP D 64 ASP~? 16.39 O2 CIT D 103 A 174 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 14.43 -13.26 8.40 11.75 -14.25 9.60 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 3.82 -4.94 15.61 3.37 -6.97 16.02 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 8.61 -7.11 20.41 7.51 -6.92 17.85 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 2c7v_c08 PTERIDINE REDUCTASE user 3 3 # 3 A 14 ARG C 40 ARG^? 17.96 O1 CIT C 104 A 161 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 174 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 14.43 -13.26 8.40 11.75 -14.25 9.60 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 3.82 -4.94 15.61 3.37 -6.97 16.02 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 8.61 -7.11 20.41 7.51 -6.92 17.85 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 2c7v_c08 PTERIDINE REDUCTASE user 4 3 # 4 A 14 ARG E 45 ARG.? 12.04 O2 EDO E 103 A 161 ASP F 69 ASP~? 11.68 O6 CIT F 104 A 174 TYR F 71 TYR~? -4.99 O2 CIT F 104s coo 14.43 -13.26 8.40 11.75 -14.25 9.60 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 coo 3.82 -4.94 15.61 3.37 -6.97 16.02 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 8.61 -7.11 20.41 7.51 -6.92 17.85 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 ULMN 3 2c7v_c08 PTERIDINE REDUCTASE user 5 3 # 5 A 14 ARG E 79 ARG~? -3.12 O5 CIT C 104s A 161 ASP C 69 ASP~? 11.49 O6 CIT C 104 A 174 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo 14.43 -13.26 8.40 11.75 -14.25 9.60 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo 3.82 -4.94 15.61 3.37 -6.97 16.02 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 8.61 -7.11 20.41 7.51 -6.92 17.85 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 2c7v_c08 source 2c7v PTERIDINE REDUCTASE : 5 hits 2c7v_c08 naa= 3 ULMN 3 2c7v_c09 PTERIDINE REDUCTASE user 1 3 # 1 B 14 ARG A 18 ARG~? 14.68 C2 EDO E 103 B 161 ASP F 99 ASP^? 6.97 O7 CIT F 104 B 174 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo -18.34 17.48 -4.91 -16.98 18.69 -2.39 -13.40 -85.38 -40.50 -10.48 -85.51 -41.44 coo -14.86 10.19 8.14 -14.82 12.31 8.42 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -21.46 12.70 8.53 -19.04 12.30 7.24 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 2c7v_c09 PTERIDINE REDUCTASE user 2 3 # 2 B 14 ARG C 40 ARG^? 17.96 O1 CIT C 104 B 161 ASP D 64 ASP~? 16.39 O2 CIT D 103 B 174 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo -18.34 17.48 -4.91 -16.98 18.69 -2.39 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -14.86 10.19 8.14 -14.82 12.31 8.42 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo -21.46 12.70 8.53 -19.04 12.30 7.24 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 2c7v_c09 PTERIDINE REDUCTASE user 3 3 # 3 B 14 ARG C 40 ARG^? 17.96 O1 CIT C 104 B 161 ASP D 99 ASP^? 6.89 O6 CIT D 103 B 174 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo -18.34 17.48 -4.91 -16.98 18.69 -2.39 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -14.86 10.19 8.14 -14.82 12.31 8.42 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -21.46 12.70 8.53 -19.04 12.30 7.24 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 2c7v_c09 PTERIDINE REDUCTASE user 4 3 # 4 B 14 ARG C 79 ARG~? -3.25 O5 CIT E 104s B 161 ASP E 69 ASP~? 11.60 O6 CIT E 104 B 174 TYR E 71 TYR~? -4.78 O2 CIT E 104s coo -18.34 17.48 -4.91 -16.98 18.69 -2.39 -44.05 -71.70 -41.14 -41.97 -73.26 -42.81 coo -14.86 10.19 8.14 -14.82 12.31 8.42 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -21.46 12.70 8.53 -19.04 12.30 7.24 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 ULMN 3 2c7v_c09 PTERIDINE REDUCTASE user 5 3 # 5 B 14 ARG E 45 ARG.? 12.04 O2 EDO E 103 B 161 ASP F 69 ASP~? 11.68 O6 CIT F 104 B 174 TYR F 71 TYR~? -4.99 O2 CIT F 104s coo -18.34 17.48 -4.91 -16.98 18.69 -2.39 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 coo -14.86 10.19 8.14 -14.82 12.31 8.42 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo -21.46 12.70 8.53 -19.04 12.30 7.24 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 ULMN 3 2c7v_c09 PTERIDINE REDUCTASE user 6 3 # 6 B 14 ARG E 79 ARG~? -3.12 O5 CIT C 104s B 161 ASP C 69 ASP~? 11.49 O6 CIT C 104 B 174 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo -18.34 17.48 -4.91 -16.98 18.69 -2.39 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo -14.86 10.19 8.14 -14.82 12.31 8.42 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -21.46 12.70 8.53 -19.04 12.30 7.24 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 2c7v_c09 source 2c7v PTERIDINE REDUCTASE : 6 hits 2c7v_c09 naa= 3 ULMN 3 2c7v_c10 PTERIDINE REDUCTASE user 1 3 # 1 C 14 ARG A 18 ARG~? 14.68 C2 EDO E 103 C 161 ASP F 99 ASP^? 6.97 O7 CIT F 104 C 174 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo 2.84 19.43 40.34 1.59 20.35 37.65 -13.40 -85.38 -40.50 -10.48 -85.51 -41.44 coo -0.62 11.10 28.05 -0.65 13.15 27.46 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 5.94 13.28 27.17 3.53 13.05 28.58 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 2c7v_c10 PTERIDINE REDUCTASE user 2 3 # 2 C 14 ARG A 45 ARG.? 18.60 O6 CIT B 103 C 161 ASP B 69 ASP~? 11.84 O5 CIT B 103 C 174 TYR B 71 TYR~? -4.80 O1 CIT B 103s coo 2.84 19.43 40.34 1.59 20.35 37.65 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 coo -0.62 11.10 28.05 -0.65 13.15 27.46 -3.36 -67.32 -11.09 -2.69 -67.52 -13.12 coo 5.94 13.28 27.17 3.53 13.05 28.58 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 ULMN 3 2c7v_c10 PTERIDINE REDUCTASE user 3 3 # 3 C 14 ARG C 40 ARG^? 17.96 O1 CIT C 104 C 161 ASP D 64 ASP~? 16.39 O2 CIT D 103 C 174 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 2.84 19.43 40.34 1.59 20.35 37.65 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -0.62 11.10 28.05 -0.65 13.15 27.46 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo 5.94 13.28 27.17 3.53 13.05 28.58 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 2c7v_c10 PTERIDINE REDUCTASE user 4 3 # 4 C 14 ARG C 40 ARG^? 17.96 O1 CIT C 104 C 161 ASP D 99 ASP^? 6.89 O6 CIT D 103 C 174 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo 2.84 19.43 40.34 1.59 20.35 37.65 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -0.62 11.10 28.05 -0.65 13.15 27.46 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 5.94 13.28 27.17 3.53 13.05 28.58 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 2c7v_c10 PTERIDINE REDUCTASE user 5 3 # 5 C 14 ARG D 45 ARG.? 18.60 O2 CIT C 104 C 161 ASP C 69 ASP~? 11.49 O6 CIT C 104 C 174 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo 2.84 19.43 40.34 1.59 20.35 37.65 -49.86 -74.21 -12.21 -51.35 -74.09 -9.50 coo -0.62 11.10 28.05 -0.65 13.15 27.46 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 5.94 13.28 27.17 3.53 13.05 28.58 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 ULMN 3 2c7v_c10 PTERIDINE REDUCTASE user 6 3 # 6 C 14 ARG E 45 ARG.? 12.04 O2 EDO E 103 C 161 ASP F 69 ASP~? 11.68 O6 CIT F 104 C 174 TYR F 71 TYR~? -4.99 O2 CIT F 104s coo 2.84 19.43 40.34 1.59 20.35 37.65 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 coo -0.62 11.10 28.05 -0.65 13.15 27.46 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo 5.94 13.28 27.17 3.53 13.05 28.58 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 ULMN 3 2c7v_c10 PTERIDINE REDUCTASE user 7 3 # 7 C 14 ARG E 79 ARG~? -3.12 O5 CIT C 104s C 161 ASP C 69 ASP~? 11.49 O6 CIT C 104 C 174 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo 2.84 19.43 40.34 1.59 20.35 37.65 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo -0.62 11.10 28.05 -0.65 13.15 27.46 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo 5.94 13.28 27.17 3.53 13.05 28.58 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 ULMN 3 2c7v_c10 PTERIDINE REDUCTASE user 8 3 # 8 C 14 ARG F 45 ARG.? 16.99 O2 EDO F 103 C 161 ASP E 69 ASP~? 11.60 O6 CIT E 104 C 174 TYR E 71 TYR~? -4.78 O2 CIT E 104s coo 2.84 19.43 40.34 1.59 20.35 37.65 -41.57 -80.46 -62.32 -41.29 -81.64 -65.17 coo -0.62 11.10 28.05 -0.65 13.15 27.46 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo 5.94 13.28 27.17 3.53 13.05 28.58 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 2c7v_c10 source 2c7v PTERIDINE REDUCTASE : 8 hits 2c7v_c10 naa= 3 ULMN 3 2c7v_c11 PTERIDINE REDUCTASE user 1 3 # 1 D 14 ARG A 18 ARG~? 14.68 C2 EDO E 103 D 161 ASP F 99 ASP^? 6.97 O7 CIT F 104 D 174 TYR F 3 TYR.? 7.56 O2 EDO E 103 coo -30.56 -11.62 29.88 -27.98 -12.86 28.66 -13.40 -85.38 -40.50 -10.48 -85.51 -41.44 coo -19.83 -4.38 21.99 -19.35 -6.45 21.76 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -24.51 -6.92 17.31 -23.48 -6.50 19.84 -24.15 -84.05 -52.45 -24.99 -86.58 -51.58 ULMN 3 2c7v_c11 PTERIDINE REDUCTASE user 2 3 # 2 D 14 ARG C 40 ARG^? 17.96 O1 CIT C 104 D 161 ASP D 64 ASP~? 16.39 O2 CIT D 103 D 174 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo -30.56 -11.62 29.88 -27.98 -12.86 28.66 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -19.83 -4.38 21.99 -19.35 -6.45 21.76 -54.59 -44.85 -22.25 -55.92 -43.76 -20.99 coo -24.51 -6.92 17.31 -23.48 -6.50 19.84 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 2c7v_c11 PTERIDINE REDUCTASE user 3 3 # 3 D 14 ARG C 40 ARG^? 17.96 O1 CIT C 104 D 161 ASP D 99 ASP^? 6.89 O6 CIT D 103 D 174 TYR D -3 TYR.? 15.53 O6 CIT D 103 coo -30.56 -11.62 29.88 -27.98 -12.86 28.66 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo -19.83 -4.38 21.99 -19.35 -6.45 21.76 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -24.51 -6.92 17.31 -23.48 -6.50 19.84 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 ULMN 3 2c7v_c11 PTERIDINE REDUCTASE user 4 3 # 4 D 14 ARG E 45 ARG.? 12.04 O2 EDO E 103 D 161 ASP F 69 ASP~? 11.68 O6 CIT F 104 D 174 TYR F 71 TYR~? -4.99 O2 CIT F 104s coo -30.56 -11.62 29.88 -27.98 -12.86 28.66 -15.85 -76.39 -48.24 -16.06 -76.51 -45.19 coo -19.83 -4.38 21.99 -19.35 -6.45 21.76 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo -24.51 -6.92 17.31 -23.48 -6.50 19.84 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 ULMN 3 2c7v_c11 PTERIDINE REDUCTASE user 5 3 # 5 D 14 ARG E 79 ARG~? -3.12 O5 CIT C 104s D 161 ASP C 69 ASP~? 11.49 O6 CIT C 104 D 174 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo -30.56 -11.62 29.88 -27.98 -12.86 28.66 -39.47 -76.77 -32.88 -40.70 -74.53 -31.11 coo -19.83 -4.38 21.99 -19.35 -6.45 21.76 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -24.51 -6.92 17.31 -23.48 -6.50 19.84 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 2c7v_c11 source 2c7v PTERIDINE REDUCTASE : 5 hits 2c7v_c11 naa= 3 ULMN 3 2cpu_c01 ALPHA-AMYLASE user 1 3 # 1 A 197 ASP A 27 ASP~? 13.11 O2 EDO A 103 A 233 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 300 ASN C 90 ASN~? 14.00 O3 CIT C 104 coo 12.51 17.07 49.46 12.44 16.89 47.35 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo 6.52 19.14 48.16 7.77 18.42 46.61 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 9.30 22.40 41.76 10.10 20.96 40.36 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 ULMN 3 2cpu_c01 ALPHA-AMYLASE user 2 3 # 2 A 197 ASP C 17 ASP~? -3.95 O1 EDO C 103s A 233 GLU C 21 GLU~? 6.35 O1 EDO C 103 A 300 ASN E 90 ASN~? -4.46 O2 EDO C 103s coo 12.51 17.07 49.46 12.44 16.89 47.35 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo 6.52 19.14 48.16 7.77 18.42 46.61 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 coo 9.30 22.40 41.76 10.10 20.96 40.36 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 ULMN 3 2cpu_c01 ALPHA-AMYLASE user 3 3 # 3 A 197 ASP E 17 ASP~? 16.97 O4 CIT C 104 A 233 GLU E 21 GLU~? 9.95 O4 CIT C 104 A 300 ASN C 90 ASN~? 14.00 O3 CIT C 104 coo 12.51 17.07 49.46 12.44 16.89 47.35 -25.66 -70.40 -33.55 -23.62 -69.78 -33.29 coo 6.52 19.14 48.16 7.77 18.42 46.61 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 coo 9.30 22.40 41.76 10.10 20.96 40.36 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 2cpu_c01 source 2cpu ALPHA-AMYLASE : 3 hits 2cpu_c01 naa= 3 ULMN 3 2esd_c00 1.02.01.0009 user 1 3 # 1 A 154 ASN A 90 ASN~? 16.38 O1 EDO A 103 A 250 ALA A 15 ALA~? 15.06 C1 EDO A 103 A 284 CYH A 88 CYH.? 9.02 C1 EDO A 103 coo -98.31 19.25 26.95 -99.27 21.10 26.57 -4.88 -95.45 -33.14 -2.88 -95.87 -33.61 coo -102.90 29.72 23.02 -103.69 28.50 23.43 -7.92 -83.12 -38.44 -6.92 -83.81 -37.59 coo -98.59 26.45 29.50 -99.24 25.73 26.84 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 ULMN 3 2esd_c00 1.02.01.0009 user 2 3 # 2 A 154 ASN B 90 ASN~? 13.61 O3 CIT B 103 A 250 ALA B 15 ALA~? 14.11 C4 CIT B 103 A 284 CYH B 88 CYH~? 7.91 O3 CIT B 103 coo -98.31 19.25 26.95 -99.27 21.10 26.57 4.74 -92.94 -10.60 5.13 -95.02 -10.92 coo -102.90 29.72 23.02 -103.69 28.50 23.43 -5.10 -93.70 -1.33 -4.68 -94.25 -2.68 coo -98.59 26.45 29.50 -99.24 25.73 26.84 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 ULMN 3 2esd_c00 1.02.01.0009 user 3 3 # 3 A 154 ASN C 90 ASN~? 14.00 O3 CIT C 104 A 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 A 284 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo -98.31 19.25 26.95 -99.27 21.10 26.57 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo -102.90 29.72 23.02 -103.69 28.50 23.43 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo -98.59 26.45 29.50 -99.24 25.73 26.84 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 2esd_c00 1.02.01.0009 user 4 3 # 4 A 154 ASN C 90 ASN~? 14.00 O3 CIT C 104 A 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 A 284 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo -98.31 19.25 26.95 -99.27 21.10 26.57 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo -102.90 29.72 23.02 -103.69 28.50 23.43 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo -98.59 26.45 29.50 -99.24 25.73 26.84 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 2esd_c00 1.02.01.0009 user 5 3 # 5 A 154 ASN D 90 ASN~? 12.97 O4 CIT D 103 A 250 ALA D 15 ALA~? 14.37 O4 CIT D 103 A 284 CYH D 88 CYH.? 7.80 O4 CIT D 103 coo -98.31 19.25 26.95 -99.27 21.10 26.57 -32.84 -58.19 -3.59 -31.15 -59.37 -2.96 coo -102.90 29.72 23.02 -103.69 28.50 23.43 -43.98 -63.95 1.87 -42.83 -64.36 0.99 coo -98.59 26.45 29.50 -99.24 25.73 26.84 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 ULMN 3 2esd_c00 1.02.01.0009 user 6 3 # 6 A 154 ASN E 90 ASN~? -4.46 O2 EDO C 103s A 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 A 284 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo -98.31 19.25 26.95 -99.27 21.10 26.57 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo -102.90 29.72 23.02 -103.69 28.50 23.43 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo -98.59 26.45 29.50 -99.24 25.73 26.84 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 2esd_c00 1.02.01.0009 user 7 3 # 7 A 154 ASN E 90 ASN~? -4.46 O2 EDO C 103s A 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 A 284 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo -98.31 19.25 26.95 -99.27 21.10 26.57 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo -102.90 29.72 23.02 -103.69 28.50 23.43 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo -98.59 26.45 29.50 -99.24 25.73 26.84 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 2esd_c00 1.02.01.0009 user 8 3 # 8 A 154 ASN F 90 ASN~? 14.08 O1 EDO F 103 A 250 ALA F 15 ALA~? 13.96 O3 CIT F 104 A 284 CYH F 88 CYH.? 7.60 O3 CIT F 104 coo -98.31 19.25 26.95 -99.27 21.10 26.57 -25.28 -63.01 -68.95 -26.65 -61.43 -69.45 coo -102.90 29.72 23.02 -103.69 28.50 23.43 -30.55 -73.71 -75.60 -31.05 -72.60 -74.70 coo -98.59 26.45 29.50 -99.24 25.73 26.84 -27.14 -69.89 -70.66 -26.83 -72.10 -69.05 2esd_c00 source 2esd 1.02.01.0009 : 8 hits 2esd_c00 naa= 3 ULMN 3 2esd_c01 1.02.01.0009 user 1 3 # 1 B 154 ASN A 90 ASN~? 16.38 O1 EDO A 103 B 250 ALA A 15 ALA~? 15.06 C1 EDO A 103 B 284 CYH A 88 CYH.? 9.02 C1 EDO A 103 coo -116.62 58.12 2.11 -116.17 56.24 3.01 -4.88 -95.45 -33.14 -2.88 -95.87 -33.61 coo -114.20 47.61 7.65 -114.88 48.80 8.33 -7.92 -83.12 -38.44 -6.92 -83.81 -37.59 coo -118.73 50.90 1.30 -116.61 51.76 2.87 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 ULMN 3 2esd_c01 1.02.01.0009 user 2 3 # 2 B 154 ASN B 90 ASN~? 13.61 O3 CIT B 103 B 250 ALA B 15 ALA~? 14.11 C4 CIT B 103 B 284 CYH B 88 CYH~? 7.91 O3 CIT B 103 coo -116.62 58.12 2.11 -116.17 56.24 3.01 4.74 -92.94 -10.60 5.13 -95.02 -10.92 coo -114.20 47.61 7.65 -114.88 48.80 8.33 -5.10 -93.70 -1.33 -4.68 -94.25 -2.68 coo -118.73 50.90 1.30 -116.61 51.76 2.87 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 ULMN 3 2esd_c01 1.02.01.0009 user 3 3 # 3 B 154 ASN C 90 ASN~? 14.00 O3 CIT C 104 B 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 B 284 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo -116.62 58.12 2.11 -116.17 56.24 3.01 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo -114.20 47.61 7.65 -114.88 48.80 8.33 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo -118.73 50.90 1.30 -116.61 51.76 2.87 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 2esd_c01 1.02.01.0009 user 4 3 # 4 B 154 ASN C 90 ASN~? 14.00 O3 CIT C 104 B 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 B 284 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo -116.62 58.12 2.11 -116.17 56.24 3.01 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo -114.20 47.61 7.65 -114.88 48.80 8.33 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo -118.73 50.90 1.30 -116.61 51.76 2.87 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 2esd_c01 1.02.01.0009 user 5 3 # 5 B 154 ASN D 90 ASN~? 12.97 O4 CIT D 103 B 250 ALA D 15 ALA~? 14.37 O4 CIT D 103 B 284 CYH D 88 CYH.? 7.80 O4 CIT D 103 coo -116.62 58.12 2.11 -116.17 56.24 3.01 -32.84 -58.19 -3.59 -31.15 -59.37 -2.96 coo -114.20 47.61 7.65 -114.88 48.80 8.33 -43.98 -63.95 1.87 -42.83 -64.36 0.99 coo -118.73 50.90 1.30 -116.61 51.76 2.87 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 ULMN 3 2esd_c01 1.02.01.0009 user 6 3 # 6 B 154 ASN E 90 ASN~? -4.46 O2 EDO C 103s B 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 B 284 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo -116.62 58.12 2.11 -116.17 56.24 3.01 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo -114.20 47.61 7.65 -114.88 48.80 8.33 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo -118.73 50.90 1.30 -116.61 51.76 2.87 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 2esd_c01 1.02.01.0009 user 7 3 # 7 B 154 ASN E 90 ASN~? -4.46 O2 EDO C 103s B 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 B 284 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo -116.62 58.12 2.11 -116.17 56.24 3.01 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo -114.20 47.61 7.65 -114.88 48.80 8.33 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo -118.73 50.90 1.30 -116.61 51.76 2.87 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 2esd_c01 1.02.01.0009 user 8 3 # 8 B 154 ASN F 90 ASN~? 14.08 O1 EDO F 103 B 250 ALA F 15 ALA~? 13.96 O3 CIT F 104 B 284 CYH F 88 CYH.? 7.60 O3 CIT F 104 coo -116.62 58.12 2.11 -116.17 56.24 3.01 -25.28 -63.01 -68.95 -26.65 -61.43 -69.45 coo -114.20 47.61 7.65 -114.88 48.80 8.33 -30.55 -73.71 -75.60 -31.05 -72.60 -74.70 coo -118.73 50.90 1.30 -116.61 51.76 2.87 -27.14 -69.89 -70.66 -26.83 -72.10 -69.05 2esd_c01 source 2esd 1.02.01.0009 : 8 hits 2esd_c01 naa= 3 ULMN 3 2esd_c02 1.02.01.0009 user 1 3 # 1 C 154 ASN A 90 ASN~? 16.38 O1 EDO A 103 C 250 ALA A 15 ALA~? 15.06 C1 EDO A 103 C 284 CYH A 88 CYH.? 9.02 C1 EDO A 103 coo -155.36 18.42 28.93 -154.49 20.30 29.39 -4.88 -95.45 -33.14 -2.88 -95.87 -33.61 coo -150.95 29.02 32.87 -150.10 27.86 32.40 -7.92 -83.12 -38.44 -6.92 -83.81 -37.59 coo -155.22 25.64 26.33 -154.78 25.20 29.09 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 ULMN 3 2esd_c02 1.02.01.0009 user 2 3 # 2 C 154 ASN B 90 ASN~? 13.61 O3 CIT B 103 C 250 ALA B 15 ALA~? 14.11 C4 CIT B 103 C 284 CYH B 88 CYH~? 7.91 O3 CIT B 103 coo -155.36 18.42 28.93 -154.49 20.30 29.39 4.74 -92.94 -10.60 5.13 -95.02 -10.92 coo -150.95 29.02 32.87 -150.10 27.86 32.40 -5.10 -93.70 -1.33 -4.68 -94.25 -2.68 coo -155.22 25.64 26.33 -154.78 25.20 29.09 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 ULMN 3 2esd_c02 1.02.01.0009 user 3 3 # 3 C 154 ASN C 90 ASN~? 14.00 O3 CIT C 104 C 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 C 284 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo -155.36 18.42 28.93 -154.49 20.30 29.39 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo -150.95 29.02 32.87 -150.10 27.86 32.40 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo -155.22 25.64 26.33 -154.78 25.20 29.09 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 2esd_c02 1.02.01.0009 user 4 3 # 4 C 154 ASN C 90 ASN~? 14.00 O3 CIT C 104 C 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 C 284 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo -155.36 18.42 28.93 -154.49 20.30 29.39 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo -150.95 29.02 32.87 -150.10 27.86 32.40 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo -155.22 25.64 26.33 -154.78 25.20 29.09 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 2esd_c02 1.02.01.0009 user 5 3 # 5 C 154 ASN D 90 ASN~? 12.97 O4 CIT D 103 C 250 ALA D 15 ALA~? 14.37 O4 CIT D 103 C 284 CYH D 88 CYH.? 7.80 O4 CIT D 103 coo -155.36 18.42 28.93 -154.49 20.30 29.39 -32.84 -58.19 -3.59 -31.15 -59.37 -2.96 coo -150.95 29.02 32.87 -150.10 27.86 32.40 -43.98 -63.95 1.87 -42.83 -64.36 0.99 coo -155.22 25.64 26.33 -154.78 25.20 29.09 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 ULMN 3 2esd_c02 1.02.01.0009 user 6 3 # 6 C 154 ASN E 90 ASN~? -4.46 O2 EDO C 103s C 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 C 284 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo -155.36 18.42 28.93 -154.49 20.30 29.39 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo -150.95 29.02 32.87 -150.10 27.86 32.40 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo -155.22 25.64 26.33 -154.78 25.20 29.09 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 2esd_c02 1.02.01.0009 user 7 3 # 7 C 154 ASN E 90 ASN~? -4.46 O2 EDO C 103s C 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 C 284 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo -155.36 18.42 28.93 -154.49 20.30 29.39 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo -150.95 29.02 32.87 -150.10 27.86 32.40 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo -155.22 25.64 26.33 -154.78 25.20 29.09 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 2esd_c02 1.02.01.0009 user 8 3 # 8 C 154 ASN F 90 ASN~? 14.08 O1 EDO F 103 C 250 ALA F 15 ALA~? 13.96 O3 CIT F 104 C 284 CYH F 88 CYH.? 7.60 O3 CIT F 104 coo -155.36 18.42 28.93 -154.49 20.30 29.39 -25.28 -63.01 -68.95 -26.65 -61.43 -69.45 coo -150.95 29.02 32.87 -150.10 27.86 32.40 -30.55 -73.71 -75.60 -31.05 -72.60 -74.70 coo -155.22 25.64 26.33 -154.78 25.20 29.09 -27.14 -69.89 -70.66 -26.83 -72.10 -69.05 2esd_c02 source 2esd 1.02.01.0009 : 8 hits 2esd_c02 naa= 3 ULMN 3 2esd_c03 1.02.01.0009 user 1 3 # 1 D 154 ASN A 90 ASN~? 16.38 O1 EDO A 103 D 250 ALA A 15 ALA~? 15.06 C1 EDO A 103 D 284 CYH A 88 CYH.? 9.02 C1 EDO A 103 coo -138.05 57.23 54.59 -137.96 55.47 53.43 -4.88 -95.45 -33.14 -2.88 -95.87 -33.61 coo -139.97 46.71 48.80 -139.25 47.90 48.19 -7.92 -83.12 -38.44 -6.92 -83.81 -37.59 coo -135.22 50.13 55.22 -137.25 50.94 53.65 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 ULMN 3 2esd_c03 1.02.01.0009 user 2 3 # 2 D 154 ASN B 90 ASN~? 13.61 O3 CIT B 103 D 250 ALA B 15 ALA~? 14.11 C4 CIT B 103 D 284 CYH B 88 CYH~? 7.91 O3 CIT B 103 coo -138.05 57.23 54.59 -137.96 55.47 53.43 4.74 -92.94 -10.60 5.13 -95.02 -10.92 coo -139.97 46.71 48.80 -139.25 47.90 48.19 -5.10 -93.70 -1.33 -4.68 -94.25 -2.68 coo -135.22 50.13 55.22 -137.25 50.94 53.65 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 ULMN 3 2esd_c03 1.02.01.0009 user 3 3 # 3 D 154 ASN C 90 ASN~? 14.00 O3 CIT C 104 D 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 D 284 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo -138.05 57.23 54.59 -137.96 55.47 53.43 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo -139.97 46.71 48.80 -139.25 47.90 48.19 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo -135.22 50.13 55.22 -137.25 50.94 53.65 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 2esd_c03 1.02.01.0009 user 4 3 # 4 D 154 ASN C 90 ASN~? 14.00 O3 CIT C 104 D 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 D 284 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo -138.05 57.23 54.59 -137.96 55.47 53.43 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo -139.97 46.71 48.80 -139.25 47.90 48.19 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo -135.22 50.13 55.22 -137.25 50.94 53.65 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 2esd_c03 1.02.01.0009 user 5 3 # 5 D 154 ASN D 90 ASN~? 12.97 O4 CIT D 103 D 250 ALA D 15 ALA~? 14.37 O4 CIT D 103 D 284 CYH D 88 CYH.? 7.80 O4 CIT D 103 coo -138.05 57.23 54.59 -137.96 55.47 53.43 -32.84 -58.19 -3.59 -31.15 -59.37 -2.96 coo -139.97 46.71 48.80 -139.25 47.90 48.19 -43.98 -63.95 1.87 -42.83 -64.36 0.99 coo -135.22 50.13 55.22 -137.25 50.94 53.65 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 ULMN 3 2esd_c03 1.02.01.0009 user 6 3 # 6 D 154 ASN E 90 ASN~? -4.46 O2 EDO C 103s D 250 ALA C 15 ALA~? 8.64 C1 EDO C 103 D 284 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo -138.05 57.23 54.59 -137.96 55.47 53.43 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo -139.97 46.71 48.80 -139.25 47.90 48.19 -34.94 -60.08 -35.79 -34.18 -60.15 -34.44 coo -135.22 50.13 55.22 -137.25 50.94 53.65 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 2esd_c03 1.02.01.0009 user 7 3 # 7 D 154 ASN E 90 ASN~? -4.46 O2 EDO C 103s D 250 ALA E 15 ALA~? 10.03 O2 EDO C 103 D 284 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo -138.05 57.23 54.59 -137.96 55.47 53.43 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 coo -139.97 46.71 48.80 -139.25 47.90 48.19 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo -135.22 50.13 55.22 -137.25 50.94 53.65 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 2esd_c03 1.02.01.0009 user 8 3 # 8 D 154 ASN F 90 ASN~? 14.08 O1 EDO F 103 D 250 ALA F 15 ALA~? 13.96 O3 CIT F 104 D 284 CYH F 88 CYH.? 7.60 O3 CIT F 104 coo -138.05 57.23 54.59 -137.96 55.47 53.43 -25.28 -63.01 -68.95 -26.65 -61.43 -69.45 coo -139.97 46.71 48.80 -139.25 47.90 48.19 -30.55 -73.71 -75.60 -31.05 -72.60 -74.70 coo -135.22 50.13 55.22 -137.25 50.94 53.65 -27.14 -69.89 -70.66 -26.83 -72.10 -69.05 2esd_c03 source 2esd 1.02.01.0009 : 8 hits 2esd_c03 naa= 3 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 1 3 # 1 B 185 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 188 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 190 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 2 3 # 2 B 185 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 188 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 190 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 3 3 # 3 B 185 HIS B 74 HIS~? 11.72 O1 CIT B 103 B 188 HIS B 77 HIS~? -4.07 O1 CIT B 103s B 190 TYR B 71 TYR~? -4.80 O1 CIT B 103s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 4 3 # 4 B 185 HIS B 77 HIS~? -4.07 O1 CIT B 103s B 188 HIS B 74 HIS~? 11.72 O1 CIT B 103 B 190 TYR B 71 TYR~? -4.80 O1 CIT B 103s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 5 3 # 5 B 185 HIS C 74 HIS~? 12.10 O1 CIT C 104 B 188 HIS C 77 HIS~? -4.31 O1 CIT C 104s B 190 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 6 3 # 6 B 185 HIS C 77 HIS~? -4.31 O1 CIT C 104s B 188 HIS C 74 HIS~? 12.10 O1 CIT C 104 B 190 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 7 3 # 7 B 185 HIS D 74 HIS~? 11.86 O1 CIT D 103 B 188 HIS D 77 HIS~? -3.79 O1 CIT D 103s B 190 TYR D 71 TYR~? -4.87 O2 CIT D 103s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 8 3 # 8 B 185 HIS D 77 HIS~? -3.79 O1 CIT D 103s B 188 HIS D 74 HIS~? 11.86 O1 CIT D 103 B 190 TYR D 71 TYR~? -4.87 O2 CIT D 103s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 9 3 # 9 B 185 HIS E 74 HIS~? 12.16 O1 CIT E 104 B 188 HIS E 77 HIS~? -4.13 O1 CIT E 104s B 190 TYR E 71 TYR~? -4.78 O2 CIT E 104s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 10 3 # 10 B 185 HIS E 77 HIS~? -4.13 O1 CIT E 104s B 188 HIS E 74 HIS~? 12.16 O1 CIT E 104 B 190 TYR E 71 TYR~? -4.78 O2 CIT E 104s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 11 3 # 11 B 185 HIS F 74 HIS~? 11.52 O1 CIT F 104 B 188 HIS F 77 HIS~? -3.59 O1 CIT F 104s B 190 TYR F 71 TYR~? -4.99 O2 CIT F 104s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 ULMN 3 2hsa_c00 12-OXOPHYTODIENOATE REDUCTASE 3 user 12 3 # 12 B 185 HIS F 77 HIS~? -3.59 O1 CIT F 104s B 188 HIS F 74 HIS~? 11.52 O1 CIT F 104 B 190 TYR F 71 TYR~? -4.99 O2 CIT F 104s coo -2.40 8.56 71.48 -2.16 8.28 69.42 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo -0.71 6.39 65.98 -1.92 4.69 66.21 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 0.03 12.24 67.96 -1.63 12.38 65.68 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 2hsa_c00 source 2hsa 12-OXOPHYTODIENOATE REDUCTASE 3 : 12 hits 2hsa_c00 naa= 3 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 1 3 # 1 A 185 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 188 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 190 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 14.39 1.55 40.83 12.71 2.07 39.67 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 2 3 # 2 A 185 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 188 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 190 TYR A 71 TYR~? -4.90 O2 EDO A 103s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 14.39 1.55 40.83 12.71 2.07 39.67 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 3 3 # 3 A 185 HIS B 74 HIS~? 11.72 O1 CIT B 103 A 188 HIS B 77 HIS~? -4.07 O1 CIT B 103s A 190 TYR B 71 TYR~? -4.80 O1 CIT B 103s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 14.39 1.55 40.83 12.71 2.07 39.67 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 4 3 # 4 A 185 HIS B 77 HIS~? -4.07 O1 CIT B 103s A 188 HIS B 74 HIS~? 11.72 O1 CIT B 103 A 190 TYR B 71 TYR~? -4.80 O1 CIT B 103s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 14.39 1.55 40.83 12.71 2.07 39.67 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 5 3 # 5 A 185 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 188 HIS C 77 HIS~? -4.31 O1 CIT C 104s A 190 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 14.39 1.55 40.83 12.71 2.07 39.67 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 6 3 # 6 A 185 HIS C 77 HIS~? -4.31 O1 CIT C 104s A 188 HIS C 74 HIS~? 12.10 O1 CIT C 104 A 190 TYR C 71 TYR~? -4.77 O1 CIT C 104s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 14.39 1.55 40.83 12.71 2.07 39.67 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 7 3 # 7 A 185 HIS D 74 HIS~? 11.86 O1 CIT D 103 A 188 HIS D 77 HIS~? -3.79 O1 CIT D 103s A 190 TYR D 71 TYR~? -4.87 O2 CIT D 103s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo 14.39 1.55 40.83 12.71 2.07 39.67 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 8 3 # 8 A 185 HIS D 77 HIS~? -3.79 O1 CIT D 103s A 188 HIS D 74 HIS~? 11.86 O1 CIT D 103 A 190 TYR D 71 TYR~? -4.87 O2 CIT D 103s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 14.39 1.55 40.83 12.71 2.07 39.67 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 9 3 # 9 A 185 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 188 HIS E 77 HIS~? -4.13 O1 CIT E 104s A 190 TYR E 71 TYR~? -4.78 O2 CIT E 104s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 14.39 1.55 40.83 12.71 2.07 39.67 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 10 3 # 10 A 185 HIS E 77 HIS~? -4.13 O1 CIT E 104s A 188 HIS E 74 HIS~? 12.16 O1 CIT E 104 A 190 TYR E 71 TYR~? -4.78 O2 CIT E 104s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 14.39 1.55 40.83 12.71 2.07 39.67 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 11 3 # 11 A 185 HIS F 74 HIS~? 11.52 O1 CIT F 104 A 188 HIS F 77 HIS~? -3.59 O1 CIT F 104s A 190 TYR F 71 TYR~? -4.99 O2 CIT F 104s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 14.39 1.55 40.83 12.71 2.07 39.67 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 ULMN 3 2hsa_c01 12-OXOPHYTODIENOATE REDUCTASE 3 user 12 3 # 12 A 185 HIS F 77 HIS~? -3.59 O1 CIT F 104s A 188 HIS F 74 HIS~? 11.52 O1 CIT F 104 A 190 TYR F 71 TYR~? -4.99 O2 CIT F 104s coo 17.28 -0.40 35.65 16.37 -0.39 37.54 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo 14.39 1.55 40.83 12.71 2.07 39.67 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo 19.52 -1.97 40.54 17.56 -3.47 41.92 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 2hsa_c01 source 2hsa 12-OXOPHYTODIENOATE REDUCTASE 3 : 12 hits 2hsa_c01 naa= 3 ULMN 3 2isd_c00 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 1 3 # 1 A 311 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 341 GLU B 48 GLU.? 3.87 O1 EDO A 103 A 356 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 121.00 36.37 19.26 121.57 38.37 19.56 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 125.72 32.70 19.75 124.44 34.16 18.84 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 124.34 41.73 25.55 123.79 42.60 23.72 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 2isd_c00 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 2 3 # 2 A 311 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 341 GLU A 48 GLU.? -2.39 O6 CIT B 103s A 356 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 121.00 36.37 19.26 121.57 38.37 19.56 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 125.72 32.70 19.75 124.44 34.16 18.84 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 124.34 41.73 25.55 123.79 42.60 23.72 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 2isd_c00 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 3 3 # 3 A 311 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 341 GLU D 48 GLU.? -3.37 O7 CIT C 104s A 356 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 121.00 36.37 19.26 121.57 38.37 19.56 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 125.72 32.70 19.75 124.44 34.16 18.84 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 124.34 41.73 25.55 123.79 42.60 23.72 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 2isd_c00 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 4 3 # 4 A 311 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 341 GLU C 48 GLU.? -2.75 O6 CIT D 103s A 356 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 121.00 36.37 19.26 121.57 38.37 19.56 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 125.72 32.70 19.75 124.44 34.16 18.84 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 124.34 41.73 25.55 123.79 42.60 23.72 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 2isd_c00 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 5 3 # 5 A 311 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 341 GLU F 48 GLU.? -3.15 C4 CIT E 104s A 356 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 121.00 36.37 19.26 121.57 38.37 19.56 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 125.72 32.70 19.75 124.44 34.16 18.84 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 124.34 41.73 25.55 123.79 42.60 23.72 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 2isd_c00 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 6 3 # 6 A 311 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 341 GLU E 48 GLU.? -2.93 O7 CIT F 104s A 356 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 121.00 36.37 19.26 121.57 38.37 19.56 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 125.72 32.70 19.75 124.44 34.16 18.84 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 124.34 41.73 25.55 123.79 42.60 23.72 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 2isd_c00 source 2isd PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C, ISO: 6 hits 2isd_c00 naa= 3 ULMN 3 2isd_c01 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 1 3 # 1 B 311 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 341 GLU B 48 GLU.? 3.87 O1 EDO A 103 B 356 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 77.20 37.63 -25.62 77.60 39.62 -25.06 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 79.41 33.66 -21.62 79.55 35.10 -23.14 -18.45 -94.97 -24.16 -18.00 -93.30 -25.45 coo 75.11 43.37 -19.22 76.23 44.10 -20.84 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 2isd_c01 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 2 3 # 2 B 311 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 341 GLU A 48 GLU.? -2.39 O6 CIT B 103s B 356 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 77.20 37.63 -25.62 77.60 39.62 -25.06 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 79.41 33.66 -21.62 79.55 35.10 -23.14 -0.36 -77.14 -13.96 -1.39 -78.11 -12.41 coo 75.11 43.37 -19.22 76.23 44.10 -20.84 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 2isd_c01 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 3 3 # 3 B 311 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 341 GLU D 48 GLU.? -3.37 O7 CIT C 104s B 356 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 77.20 37.63 -25.62 77.60 39.62 -25.06 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 79.41 33.66 -21.62 79.55 35.10 -23.14 -43.06 -74.44 -22.40 -43.15 -73.03 -23.96 coo 75.11 43.37 -19.22 76.23 44.10 -20.84 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 2isd_c01 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 4 3 # 4 B 311 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 341 GLU C 48 GLU.? -2.75 O6 CIT D 103s B 356 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 77.20 37.63 -25.62 77.60 39.62 -25.06 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 79.41 33.66 -21.62 79.55 35.10 -23.14 -42.30 -49.27 -13.16 -43.26 -50.35 -11.60 coo 75.11 43.37 -19.22 76.23 44.10 -20.84 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 2isd_c01 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 5 3 # 5 B 311 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 341 GLU F 48 GLU.? -3.15 C4 CIT E 104s B 356 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 77.20 37.63 -25.62 77.60 39.62 -25.06 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 79.41 33.66 -21.62 79.55 35.10 -23.14 -41.92 -74.47 -51.71 -40.83 -74.34 -49.95 coo 75.11 43.37 -19.22 76.23 44.10 -20.84 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 2isd_c01 PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPuser 6 3 # 6 B 311 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 341 GLU E 48 GLU.? -2.93 O7 CIT F 104s B 356 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 77.20 37.63 -25.62 77.60 39.62 -25.06 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 79.41 33.66 -21.62 79.55 35.10 -23.14 -15.87 -73.80 -60.06 -16.84 -74.41 -61.78 coo 75.11 43.37 -19.22 76.23 44.10 -20.84 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 2isd_c01 source 2isd PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C, ISO: 6 hits 2isd_c01 naa= 3 ULMN 3 2jxr_c04 LIGAND CP-081282 user 1 3 # 1 A 32 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 35 SER A 51 SER.? 9.93 O6 CIT B 103 A 215 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -2.00 -83.54 -20.69 -3.51 -81.70 -20.32 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 2jxr_c04 LIGAND CP-081282 user 2 3 # 2 A 32 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 35 SER B 51 SER.? 11.29 O1 EDO A 103 A 215 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -10.51 -94.26 -19.23 -12.52 -93.00 -18.57 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 2jxr_c04 LIGAND CP-081282 user 3 3 # 3 A 32 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 35 SER C 51 SER.? 10.55 O6 CIT D 103 A 215 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -37.45 -55.70 -17.84 -39.73 -55.02 -18.48 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 2jxr_c04 LIGAND CP-081282 user 4 3 # 4 A 32 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 35 SER D 51 SER.? 10.41 O7 CIT C 104 A 215 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -39.50 -68.75 -15.66 -41.87 -68.85 -16.11 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 2jxr_c04 LIGAND CP-081282 user 5 3 # 5 A 32 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 35 SER E 51 SER.? 10.11 C4 CIT F 104 A 215 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -22.56 -69.18 -55.26 -21.95 -71.51 -54.75 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 ULMN 3 2jxr_c04 LIGAND CP-081282 user 6 3 # 6 A 32 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 35 SER F 51 SER.? -5.94 O2 EDO F 103s A 215 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -36.12 -70.57 -57.89 -36.11 -73.06 -57.76 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 2jxr_c04 source 2jxr LIGAND CP-081282 : 6 hits 2jxr_c04 naa= 3 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 1 3 # 1 A 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 193 GLY A 57 GLY^? 10.14 C1 EDO A 103 coo 14.96 29.22 19.55 15.62 29.93 17.67 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 19.64 30.69 22.61 18.18 29.94 21.25 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 14.54 28.99 9.76 15.06 29.59 10.02 -11.65 -81.44 -25.69 -11.82 -80.71 -25.95 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 2 3 # 2 A 57 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 102 ASP A 99 ASP^? 8.10 O2 EDO A 103 A 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 14.96 29.22 19.55 15.62 29.93 17.67 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 19.64 30.69 22.61 18.18 29.94 21.25 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo 14.54 28.99 9.76 15.06 29.59 10.02 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 3 3 # 3 A 57 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 102 ASP E 27 ASP~? 4.58 C1 EDO E 103 A 193 GLY A 81 GLY~? 4.93 C2 EDO A 103 coo 14.96 29.22 19.55 15.62 29.93 17.67 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 19.64 30.69 22.61 18.18 29.94 21.25 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 14.54 28.99 9.76 15.06 29.59 10.02 -18.67 -89.12 -33.39 -18.68 -88.94 -34.20 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 4 3 # 4 A 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 193 GLY B 57 GLY^? 9.92 O7 CIT B 103 coo 14.96 29.22 19.55 15.62 29.93 17.67 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 19.64 30.69 22.61 18.18 29.94 21.25 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 14.54 28.99 9.76 15.06 29.59 10.02 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 5 3 # 5 A 57 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 102 ASP B 99 ASP^? 7.47 O6 CIT B 103 A 193 GLY B 81 GLY~? 3.85 C2 CIT B 103 coo 14.96 29.22 19.55 15.62 29.93 17.67 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 19.64 30.69 22.61 18.18 29.94 21.25 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo 14.54 28.99 9.76 15.06 29.59 10.02 -2.88 -80.95 -4.07 -2.67 -81.14 -3.34 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 6 3 # 6 A 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 193 GLY C 57 GLY^? 10.09 O1 CIT C 104 coo 14.96 29.22 19.55 15.62 29.93 17.67 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 19.64 30.69 22.61 18.18 29.94 21.25 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 14.54 28.99 9.76 15.06 29.59 10.02 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 7 3 # 7 A 57 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 102 ASP C 99 ASP^? 7.14 O2 CIT C 104 A 193 GLY C 81 GLY~? -3.48 O5 CIT C 104s coo 14.96 29.22 19.55 15.62 29.93 17.67 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 19.64 30.69 22.61 18.18 29.94 21.25 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo 14.54 28.99 9.76 15.06 29.59 10.02 -42.25 -71.08 -32.51 -42.01 -70.90 -33.26 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 8 3 # 8 A 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 193 GLY D 57 GLY^? 9.79 C2 CIT D 103 coo 14.96 29.22 19.55 15.62 29.93 17.67 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 19.64 30.69 22.61 18.18 29.94 21.25 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 14.54 28.99 9.76 15.06 29.59 10.02 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 9 3 # 9 A 57 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 102 ASP D 99 ASP^? 6.89 O6 CIT D 103 A 193 GLY D 81 GLY~? 3.79 O7 CIT D 103 coo 14.96 29.22 19.55 15.62 29.93 17.67 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 19.64 30.69 22.61 18.18 29.94 21.25 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo 14.54 28.99 9.76 15.06 29.59 10.02 -46.98 -52.24 -3.70 -47.09 -52.32 -2.90 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 10 3 # 10 A 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 193 GLY E 57 GLY^? 9.68 O2 EDO E 103 coo 14.96 29.22 19.55 15.62 29.93 17.67 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 19.64 30.69 22.61 18.18 29.94 21.25 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 14.54 28.99 9.76 15.06 29.59 10.02 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 11 3 # 11 A 57 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 102 ASP E 99 ASP^? 7.65 C2 CIT E 104 A 193 GLY E 81 GLY~? -3.27 O5 CIT E 104s coo 14.96 29.22 19.55 15.62 29.93 17.67 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 19.64 30.69 22.61 18.18 29.94 21.25 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo 14.54 28.99 9.76 15.06 29.59 10.02 -38.55 -74.37 -41.34 -38.48 -74.14 -40.58 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 12 3 # 12 A 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 193 GLY F 57 GLY^? 10.08 O2 CIT F 104 coo 14.96 29.22 19.55 15.62 29.93 17.67 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 19.64 30.69 22.61 18.18 29.94 21.25 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 14.54 28.99 9.76 15.06 29.59 10.02 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 ULMN 3 2lpr_c02 ALPHA-LYTIC PROTEASE user 13 3 # 13 A 57 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 102 ASP F 99 ASP^? 6.97 O7 CIT F 104 A 193 GLY F 81 GLY~? -3.66 O5 CIT F 104s coo 14.96 29.22 19.55 15.62 29.93 17.67 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 19.64 30.69 22.61 18.18 29.94 21.25 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo 14.54 28.99 9.76 15.06 29.59 10.02 -18.90 -77.10 -69.77 -18.97 -77.18 -70.57 2lpr_c02 source 2lpr ALPHA-LYTIC PROTEASE : 13 hits 2lpr_c02 naa= 3 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 1 3 # 1 A 12 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 40 LYS A 65 LYS~? 12.23 O2 EDO A 103 A 116 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 18.50 3.53 20.10 16.17 2.61 14.41 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 14.70 6.01 5.61 14.27 7.69 6.78 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 2 3 # 2 A 12 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 40 LYS B 50 LYS.? 6.61 O1 EDO A 103 A 116 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 18.50 3.53 20.10 16.17 2.61 14.41 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo 14.70 6.01 5.61 14.27 7.69 6.78 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 3 3 # 3 A 12 HIS A 77 HIS~? -4.41 C2 EDO A 103s A 40 LYS A 65 LYS~? 12.23 O2 EDO A 103 A 116 HIS A 74 HIS~? 11.00 C1 EDO E 103 coo 12.34 -0.45 10.80 13.53 1.19 11.34 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 18.50 3.53 20.10 16.17 2.61 14.41 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 14.70 6.01 5.61 14.27 7.69 6.78 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 4 3 # 4 A 12 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 40 LYS A 50 LYS.? -4.54 O3 CIT B 103s A 116 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 18.50 3.53 20.10 16.17 2.61 14.41 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo 14.70 6.01 5.61 14.27 7.69 6.78 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 5 3 # 5 A 12 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 40 LYS B 65 LYS~? 11.82 O5 CIT B 103 A 116 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 18.50 3.53 20.10 16.17 2.61 14.41 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 14.70 6.01 5.61 14.27 7.69 6.78 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 6 3 # 6 A 12 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 40 LYS C 65 LYS~? 12.16 O6 CIT C 104 A 116 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 18.50 3.53 20.10 16.17 2.61 14.41 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 14.70 6.01 5.61 14.27 7.69 6.78 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 7 3 # 7 A 12 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 40 LYS D 50 LYS.? -4.40 O3 CIT C 104s A 116 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 18.50 3.53 20.10 16.17 2.61 14.41 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 14.70 6.01 5.61 14.27 7.69 6.78 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 8 3 # 8 A 12 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 40 LYS C 50 LYS.? -4.07 O4 CIT D 103s A 116 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 18.50 3.53 20.10 16.17 2.61 14.41 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo 14.70 6.01 5.61 14.27 7.69 6.78 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 9 3 # 9 A 12 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 40 LYS D 65 LYS~? 11.29 O6 CIT D 103 A 116 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 18.50 3.53 20.10 16.17 2.61 14.41 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 14.70 6.01 5.61 14.27 7.69 6.78 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 10 3 # 10 A 12 HIS D 77 HIS~? -3.79 O1 CIT D 103s A 40 LYS D 65 LYS~? 11.29 O6 CIT D 103 A 116 HIS D 74 HIS~? 11.86 O1 CIT D 103 coo 12.34 -0.45 10.80 13.53 1.19 11.34 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 18.50 3.53 20.10 16.17 2.61 14.41 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 14.70 6.01 5.61 14.27 7.69 6.78 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 11 3 # 11 A 12 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 40 LYS E 65 LYS~? 11.89 O6 CIT E 104 A 116 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 18.50 3.53 20.10 16.17 2.61 14.41 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 14.70 6.01 5.61 14.27 7.69 6.78 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 12 3 # 12 A 12 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 40 LYS F 50 LYS.? -3.77 O3 CIT E 104s A 116 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 18.50 3.53 20.10 16.17 2.61 14.41 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 14.70 6.01 5.61 14.27 7.69 6.78 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 13 3 # 13 A 12 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 40 LYS E 50 LYS.? -4.05 O4 CIT F 104s A 116 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 18.50 3.53 20.10 16.17 2.61 14.41 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo 14.70 6.01 5.61 14.27 7.69 6.78 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 2rnf_c02 RIBONUCLEASE 4 user 14 3 # 14 A 12 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 40 LYS F 65 LYS~? 10.97 O7 CIT F 104 A 116 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 12.34 -0.45 10.80 13.53 1.19 11.34 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 18.50 3.53 20.10 16.17 2.61 14.41 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 14.70 6.01 5.61 14.27 7.69 6.78 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 2rnf_c02 source 2rnf RIBONUCLEASE 4 : 14 hits 2rnf_c02 naa= 3 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 1 3 # 1 B 12 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 40 LYS B 50 LYS.? 6.61 O1 EDO A 103 B 116 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo -6.35 21.42 14.69 -6.06 23.46 15.04 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 2 3 # 2 B 12 HIS A 77 HIS~? -4.41 C2 EDO A 103s B 40 LYS A 65 LYS~? 12.23 O2 EDO A 103 B 116 HIS A 74 HIS~? 11.00 C1 EDO E 103 coo -6.35 21.42 14.69 -6.06 23.46 15.04 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 3 3 # 3 B 12 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 40 LYS A 50 LYS.? -4.54 O3 CIT B 103s B 116 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo -6.35 21.42 14.69 -6.06 23.46 15.04 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -10.61 31.45 9.72 -8.75 26.69 13.45 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 4 3 # 4 B 12 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 40 LYS B 65 LYS~? 11.82 O5 CIT B 103 B 116 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo -6.35 21.42 14.69 -6.06 23.46 15.04 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 5 3 # 5 B 12 HIS B 77 HIS~? -4.07 O1 CIT B 103s B 40 LYS B 65 LYS~? 11.82 O5 CIT B 103 B 116 HIS B 74 HIS~? 11.72 O1 CIT B 103 coo -6.35 21.42 14.69 -6.06 23.46 15.04 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 6 3 # 6 B 12 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 40 LYS C 65 LYS~? 12.16 O6 CIT C 104 B 116 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo -6.35 21.42 14.69 -6.06 23.46 15.04 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 7 3 # 7 B 12 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 40 LYS D 50 LYS.? -4.40 O3 CIT C 104s B 116 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo -6.35 21.42 14.69 -6.06 23.46 15.04 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 8 3 # 8 B 12 HIS C 77 HIS~? -4.31 O1 CIT C 104s B 40 LYS C 65 LYS~? 12.16 O6 CIT C 104 B 116 HIS C 74 HIS~? 12.10 O1 CIT C 104 coo -6.35 21.42 14.69 -6.06 23.46 15.04 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 9 3 # 9 B 12 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 40 LYS C 50 LYS.? -4.07 O4 CIT D 103s B 116 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo -6.35 21.42 14.69 -6.06 23.46 15.04 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 10 3 # 10 B 12 HIS D 77 HIS~? -3.79 O1 CIT D 103s B 40 LYS D 65 LYS~? 11.29 O6 CIT D 103 B 116 HIS D 74 HIS~? 11.86 O1 CIT D 103 coo -6.35 21.42 14.69 -6.06 23.46 15.04 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 11 3 # 11 B 12 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 40 LYS F 50 LYS.? -3.77 O3 CIT E 104s B 116 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo -6.35 21.42 14.69 -6.06 23.46 15.04 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 12 3 # 12 B 12 HIS E 77 HIS~? -4.13 O1 CIT E 104s B 40 LYS E 65 LYS~? 11.89 O6 CIT E 104 B 116 HIS E 74 HIS~? 12.16 O1 CIT E 104 coo -6.35 21.42 14.69 -6.06 23.46 15.04 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 13 3 # 13 B 12 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 40 LYS E 50 LYS.? -4.05 O4 CIT F 104s B 116 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo -6.35 21.42 14.69 -6.06 23.46 15.04 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 14 3 # 14 B 12 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 40 LYS F 65 LYS~? 10.97 O7 CIT F 104 B 116 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo -6.35 21.42 14.69 -6.06 23.46 15.04 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 2rnf_c03 RIBONUCLEASE 4 user 15 3 # 15 B 12 HIS F 77 HIS~? -3.59 O1 CIT F 104s B 40 LYS F 65 LYS~? 10.97 O7 CIT F 104 B 116 HIS F 74 HIS~? 11.52 O1 CIT F 104 coo -6.35 21.42 14.69 -6.06 23.46 15.04 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo -10.61 31.45 9.72 -8.75 26.69 13.45 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo -0.95 25.22 19.68 -0.68 26.73 18.24 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 2rnf_c03 source 2rnf RIBONUCLEASE 4 : 15 hits 2rnf_c03 naa= 3 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 1 3 # 1 141 ASP A 17 ASP~? 17.77 C2 EDO E 103 166 GLY E 57 GLY^? 9.68 O2 EDO E 103 169 GLU E 9 GLU.? 7.76 O1 EDO F 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -10.44 -78.42 -40.78 -9.33 -76.65 -41.22 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 2 3 # 2 141 ASP A 27 ASP~? 13.11 O2 EDO A 103 166 GLY A 14 GLY~? 18.08 C2 EDO E 103 169 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 3 3 # 3 141 ASP A 27 ASP~? 13.11 O2 EDO A 103 166 GLY E 82 GLY~? 5.88 O5 CIT E 104 169 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 4 3 # 4 141 ASP A 46 ASP.? 9.57 O6 CIT B 103 166 GLY B 57 GLY^? 9.92 O7 CIT B 103 169 GLU A 101 GLU^? 18.10 O2 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -22.98 -90.19 -10.74 -24.00 -91.98 -10.21 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 5 3 # 5 141 ASP A 64 ASP~? 16.37 O2 EDO A 103 166 GLY B 57 GLY^? 9.92 O7 CIT B 103 169 GLU B 9 GLU.? 11.84 O3 CIT B 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -30.10 -89.10 -15.37 -31.70 -88.86 -16.74 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -11.79 -87.06 -10.80 -12.42 -87.11 -10.35 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.76 -92.95 -12.91 -2.05 -93.72 -13.89 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 6 3 # 6 141 ASP A 93 ASP~? 12.48 O1 EDO A 103 166 GLY A 14 GLY~? 18.08 C2 EDO E 103 169 GLU F 101 GLU^? 10.35 O2 EDO E 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 7 3 # 7 141 ASP A 93 ASP~? 12.48 O1 EDO A 103 166 GLY B 94 GLY.? 8.02 O3 CIT B 103 169 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -6.86 -96.12 -29.81 -7.57 -98.09 -30.17 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo -16.67 7.89 2.78 -17.65 6.56 1.49 0.63 -96.18 -5.96 0.64 -98.22 -6.51 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 8 3 # 8 141 ASP A 99 ASP^? 8.10 O2 EDO A 103 166 GLY A 91 GLY~? 10.61 O1 EDO A 103 169 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 9 3 # 9 141 ASP A 99 ASP^? 8.10 O2 EDO A 103 166 GLY A 94 GLY.? 10.50 C1 EDO A 103 169 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 10 3 # 10 141 ASP A 99 ASP^? 8.10 O2 EDO A 103 166 GLY B 94 GLY.? 8.02 O3 CIT B 103 169 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo -16.67 7.89 2.78 -17.65 6.56 1.49 0.63 -96.18 -5.96 0.64 -98.22 -6.51 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 11 3 # 11 141 ASP B 27 ASP~? 12.32 O1 CIT B 103 166 GLY B 14 GLY~? 17.66 C4 CIT B 103 169 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -5.53 -95.57 1.94 -5.32 -95.64 1.14 coo -16.67 7.89 2.78 -17.65 6.56 1.49 0.63 -96.18 -5.96 0.64 -98.22 -6.51 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 12 3 # 12 141 ASP B 46 ASP.? 11.17 O1 EDO A 103 166 GLY A 91 GLY~? 10.61 O1 EDO A 103 169 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 13 3 # 13 141 ASP B 93 ASP~? 9.77 O3 CIT B 103 166 GLY A 94 GLY.? 10.50 C1 EDO A 103 169 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 3.85 -90.04 -12.91 5.79 -89.33 -13.36 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 14 3 # 14 141 ASP B 99 ASP^? 7.47 O6 CIT B 103 166 GLY A 94 GLY.? 10.50 C1 EDO A 103 169 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -7.09 -91.43 -29.68 -7.85 -91.66 -29.50 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 15 3 # 15 141 ASP B 99 ASP^? 7.47 O6 CIT B 103 166 GLY B 94 GLY.? 8.02 O3 CIT B 103 169 GLU B 11 GLU.? 15.97 O3 CIT B 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -0.55 -90.47 -11.82 -0.50 -89.64 -11.85 coo -16.67 7.89 2.78 -17.65 6.56 1.49 0.63 -96.18 -5.96 0.64 -98.22 -6.51 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 16 3 # 16 141 ASP C 17 ASP~? -3.95 O1 EDO C 103s 166 GLY C 91 GLY~? 8.26 O4 CIT C 104 169 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -38.40 -57.92 -40.13 -38.13 -55.84 -40.46 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 17 3 # 17 141 ASP C 27 ASP~? 13.15 O1 CIT C 104 166 GLY C 14 GLY~? 3.87 C1 EDO C 103 169 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -33.73 -58.46 -38.99 -33.50 -58.72 -38.29 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 18 3 # 18 141 ASP C 27 ASP~? 13.15 O1 CIT C 104 166 GLY C 82 GLY~? 6.29 O5 CIT C 104 169 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 19 3 # 19 141 ASP C 27 ASP~? 13.15 O1 CIT C 104 166 GLY E 91 GLY~? 5.97 O2 EDO C 103 169 GLU E 11 GLU.? -3.18 O2 EDO C 103s coo 8.28 6.87 1.62 10.08 5.77 1.34 -53.05 -62.70 -36.68 -52.55 -61.06 -35.50 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 20 3 # 20 141 ASP C 46 ASP.? 10.22 O6 CIT D 103 166 GLY D 57 GLY^? 9.79 C2 CIT D 103 169 GLU C 101 GLU^? 17.42 O2 CIT C 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -47.83 -63.08 -10.81 -48.48 -63.46 -10.60 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -54.73 -72.07 -13.37 -54.79 -74.07 -12.73 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 21 3 # 21 141 ASP C 46 ASP.? 10.22 O6 CIT D 103 166 GLY D 91 GLY~? 7.26 O4 CIT D 103 169 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -36.27 -63.51 0.47 -34.79 -65.02 0.31 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 22 3 # 22 141 ASP C 69 ASP~? 11.49 O6 CIT C 104 166 GLY C 82 GLY~? 6.29 O5 CIT C 104 169 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -52.04 -79.48 -24.90 -51.32 -79.68 -22.91 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 23 3 # 23 141 ASP C 99 ASP^? 7.14 O2 CIT C 104 166 GLY C 82 GLY~? 6.29 O5 CIT C 104 169 GLU E 21 GLU~? 9.95 O4 CIT C 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.63 -74.76 -32.54 -30.15 -73.04 -31.40 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 24 3 # 24 141 ASP C 99 ASP^? 7.14 O2 CIT C 104 166 GLY C 91 GLY~? 8.26 O4 CIT C 104 169 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 25 3 # 25 141 ASP C 99 ASP^? 7.14 O2 CIT C 104 166 GLY C 94 GLY.? 8.41 O3 CIT C 104 169 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -33.74 -65.54 -25.16 -34.31 -66.15 -25.05 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 26 3 # 26 141 ASP C 99 ASP^? 7.14 O2 CIT C 104 166 GLY D 94 GLY.? 7.85 O4 CIT D 103 169 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -36.27 -63.51 0.47 -34.79 -65.02 0.31 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 27 3 # 27 141 ASP D 27 ASP~? 12.70 O1 CIT D 103 166 GLY D 14 GLY~? 17.95 O7 CIT D 103 169 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -44.90 -65.50 5.30 -44.33 -65.47 4.79 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -36.27 -63.51 0.47 -34.79 -65.02 0.31 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 28 3 # 28 141 ASP D 46 ASP.? 10.10 O7 CIT C 104 166 GLY C 35 GLY.? 14.42 O1 CIT C 104 169 GLU C 32 GLU~? 15.71 O1 CIT C 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -59.78 -72.68 -26.82 -59.58 -72.16 -27.37 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -57.76 -71.18 -37.96 -56.39 -71.86 -39.44 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 29 3 # 29 141 ASP D 46 ASP.? 10.10 O7 CIT C 104 166 GLY C 57 GLY^? 10.09 O1 CIT C 104 169 GLU D 101 GLU^? 17.58 O6 CIT D 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -43.76 -59.88 -26.01 -44.15 -59.35 -26.49 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -48.80 -49.41 -26.57 -48.02 -47.71 -27.42 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 30 3 # 30 141 ASP D 46 ASP.? 10.10 O7 CIT C 104 166 GLY C 91 GLY~? 8.26 O4 CIT C 104 169 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 31 3 # 31 141 ASP D 99 ASP^? 6.89 O6 CIT D 103 166 GLY D 91 GLY~? 7.26 O4 CIT D 103 169 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -37.22 -56.09 -2.55 -36.90 -56.51 -3.17 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -36.27 -63.51 0.47 -34.79 -65.02 0.31 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 32 3 # 32 141 ASP D 99 ASP^? 6.89 O6 CIT D 103 166 GLY D 94 GLY.? 7.85 O4 CIT D 103 169 GLU D 11 GLU.? 15.90 O4 CIT D 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -37.37 -59.60 -7.12 -37.72 -58.85 -7.30 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -36.27 -63.51 0.47 -34.79 -65.02 0.31 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 33 3 # 33 141 ASP E 27 ASP~? 4.58 C1 EDO E 103 166 GLY C 91 GLY~? 8.26 O4 CIT C 104 169 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -32.10 -69.17 -29.20 -32.06 -68.72 -28.53 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 34 3 # 34 141 ASP E 27 ASP~? 4.58 C1 EDO E 103 166 GLY E 14 GLY~? 13.52 O2 EDO C 103 169 GLU E 11 GLU.? -3.18 O2 EDO C 103s coo 8.28 6.87 1.62 10.08 5.77 1.34 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -25.87 -66.39 -34.48 -25.98 -66.14 -35.23 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 35 3 # 35 141 ASP E 27 ASP~? 4.58 C1 EDO E 103 166 GLY E 82 GLY~? 5.88 O5 CIT E 104 169 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 36 3 # 36 141 ASP E 46 ASP.? 9.98 C4 CIT F 104 166 GLY F 35 GLY.? 14.32 O2 CIT F 104 169 GLU F 32 GLU~? 16.06 O1 CIT F 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -14.95 -90.79 -57.80 -15.39 -90.89 -58.42 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -15.90 -93.43 -68.79 -14.97 -93.32 -70.65 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 37 3 # 37 141 ASP E 64 ASP~? 16.37 O2 CIT E 104 166 GLY F 57 GLY^? 10.08 O2 CIT F 104 169 GLU F 9 GLU.? 7.31 C2 EDO F 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -43.79 -89.73 -55.13 -44.69 -90.60 -53.39 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -30.12 -78.50 -63.24 -30.55 -79.14 -63.52 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -30.57 -68.53 -65.12 -30.13 -66.51 -64.78 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 38 3 # 38 141 ASP E 69 ASP~? 11.60 O6 CIT E 104 166 GLY E 28 GLY~? 10.11 C1 EDO E 103 169 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -33.85 -86.59 -36.02 -34.04 -86.37 -36.75 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 39 3 # 39 141 ASP E 69 ASP~? 11.60 O6 CIT E 104 166 GLY E 82 GLY~? 5.88 O5 CIT E 104 169 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -47.17 -83.15 -49.59 -47.36 -82.34 -51.55 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 40 3 # 40 141 ASP E 93 ASP~? 8.62 O3 CIT E 104 166 GLY C 12 GLY.? 8.94 O2 EDO C 103 169 GLU C 9 GLU.? 12.64 O3 CIT C 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -29.72 -59.63 -35.07 -30.25 -59.10 -34.73 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -32.84 -60.90 -25.08 -31.62 -62.01 -23.74 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 41 3 # 41 141 ASP E 93 ASP~? 8.62 O3 CIT E 104 166 GLY C 82 GLY~? 6.29 O5 CIT C 104 169 GLU A 32 GLU~? 8.29 O4 CIT C 104 coo 8.28 6.87 1.62 10.08 5.77 1.34 -37.09 -63.16 -49.76 -39.19 -62.81 -50.09 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -39.15 -71.79 -34.65 -39.56 -71.08 -34.59 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -32.11 -79.10 -31.27 -33.84 -77.85 -31.06 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 42 3 # 42 141 ASP E 99 ASP^? 7.65 C2 CIT E 104 166 GLY E 82 GLY~? 5.88 O5 CIT E 104 169 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -39.44 -71.36 -39.13 -38.72 -71.78 -39.19 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 43 3 # 43 141 ASP E 99 ASP^? 7.65 C2 CIT E 104 166 GLY E 91 GLY~? 5.97 O2 EDO C 103 169 GLU E 11 GLU.? -3.18 O2 EDO C 103s coo 8.28 6.87 1.62 10.08 5.77 1.34 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 44 3 # 44 141 ASP E 99 ASP^? 7.65 C2 CIT E 104 166 GLY E 94 GLY.? 7.76 O3 CIT E 104 169 GLU E 11 GLU.? -3.18 O2 EDO C 103s coo 8.28 6.87 1.62 10.08 5.77 1.34 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 45 3 # 45 141 ASP F 46 ASP.? 6.64 O2 EDO F 103 166 GLY E 35 GLY.? 14.13 O2 CIT E 104 169 GLU E 32 GLU~? 15.49 O1 EDO E 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -40.51 -91.26 -48.44 -40.06 -91.01 -47.82 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -38.66 -90.13 -37.04 -39.42 -89.20 -35.29 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 46 3 # 46 141 ASP F 46 ASP.? 6.64 O2 EDO F 103 166 GLY E 57 GLY^? 9.68 O2 EDO E 103 169 GLU F 101 GLU^? 10.35 O2 EDO E 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 47 3 # 47 141 ASP F 46 ASP.? 6.64 O2 EDO F 103 166 GLY E 91 GLY~? 5.97 O2 EDO C 103 169 GLU E 11 GLU.? -3.18 O2 EDO C 103s coo 8.28 6.87 1.62 10.08 5.77 1.34 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -36.66 -64.27 -44.28 -36.26 -64.24 -44.99 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 48 3 # 48 141 ASP F 64 ASP~? 16.52 O2 EDO E 103 166 GLY A 91 GLY~? 10.61 O1 EDO A 103 169 GLU A 9 GLU.? 14.22 C1 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -9.28 -93.76 -34.35 -8.79 -93.66 -33.69 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.79 -87.97 -29.16 -3.10 -89.93 -28.80 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 49 3 # 49 141 ASP F 64 ASP~? 16.52 O2 EDO E 103 166 GLY E 57 GLY^? 9.68 O2 EDO E 103 169 GLU E 9 GLU.? 7.76 O1 EDO F 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -12.37 -87.04 -51.85 -11.37 -88.48 -53.09 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -27.44 -75.79 -47.63 -26.88 -76.28 -47.26 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.02 -65.95 -49.27 -29.85 -64.26 -50.27 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 50 3 # 50 141 ASP F 69 ASP~? 11.68 O6 CIT F 104 166 GLY A 14 GLY~? 18.08 C2 EDO E 103 169 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -9.37 -82.12 -58.81 -9.38 -80.73 -57.20 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 51 3 # 51 141 ASP F 93 ASP~? 9.52 O4 CIT F 104 166 GLY E 94 GLY.? 7.76 O3 CIT E 104 169 GLU E 11 GLU.? -3.18 O2 EDO C 103s coo 8.28 6.87 1.62 10.08 5.77 1.34 -23.26 -64.21 -65.54 -21.34 -63.22 -65.56 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 52 3 # 52 141 ASP F 99 ASP^? 6.97 O7 CIT F 104 166 GLY A 14 GLY~? 18.08 C2 EDO E 103 169 GLU A 11 GLU.? 17.04 C1 EDO A 103 coo 8.28 6.87 1.62 10.08 5.77 1.34 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -7.33 -81.36 -41.80 -7.00 -81.88 -41.33 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -3.22 -89.34 -37.21 -2.59 -91.32 -36.67 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 53 3 # 53 141 ASP F 99 ASP^? 6.97 O7 CIT F 104 166 GLY E 94 GLY.? 7.76 O3 CIT E 104 169 GLU E 11 GLU.? -3.18 O2 EDO C 103s coo 8.28 6.87 1.62 10.08 5.77 1.34 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -33.14 -65.45 -48.47 -33.73 -66.07 -48.51 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -29.13 -60.62 -42.01 -30.87 -59.58 -41.34 2tdt_c00 source 2tdt TETRAHYDRODIPICOLINATE N-SUCCINYLTRANSFERASE : 53 hits 2tdt_c00 naa= 3 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 1 3 # 1 A 169 TYR A 56 TYR^? 12.86 C2 EDO A 103 A 172 HIS A 41 HIS^? 12.51 O2 EDO A 103 A 267 ASP A 27 ASP~? 13.11 O2 EDO A 103 coo 26.78 20.44 0.03 28.51 18.26 0.09 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 2 3 # 2 A 169 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 172 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 267 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 26.78 20.44 0.03 28.51 18.26 0.09 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 3 3 # 3 A 169 TYR A 71 TYR~? -4.90 O2 EDO A 103s A 172 HIS A 74 HIS~? 11.00 C1 EDO E 103 A 267 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 26.78 20.44 0.03 28.51 18.26 0.09 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 4 3 # 4 A 169 TYR B 56 TYR^? 12.51 O1 CIT B 103 A 172 HIS B 41 HIS^? 11.37 O1 CIT B 103 A 267 ASP B 27 ASP~? 12.32 O1 CIT B 103 coo 26.78 20.44 0.03 28.51 18.26 0.09 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 5 3 # 5 A 169 TYR B 71 TYR~? -4.80 O1 CIT B 103s A 172 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 267 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 26.78 20.44 0.03 28.51 18.26 0.09 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 6 3 # 6 A 169 TYR C 71 TYR~? -4.77 O1 CIT C 104s A 172 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 267 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 26.78 20.44 0.03 28.51 18.26 0.09 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 7 3 # 7 A 169 TYR D 56 TYR^? 12.73 C2 CIT D 103 A 172 HIS D 41 HIS^? 12.20 O1 CIT D 103 A 267 ASP D 27 ASP~? 12.70 O1 CIT D 103 coo 26.78 20.44 0.03 28.51 18.26 0.09 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 8 3 # 8 A 169 TYR D 71 TYR~? -4.87 O2 CIT D 103s A 172 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 267 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 26.78 20.44 0.03 28.51 18.26 0.09 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 9 3 # 9 A 169 TYR E 56 TYR^? 8.81 O2 EDO E 103 A 172 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 267 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 26.78 20.44 0.03 28.51 18.26 0.09 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 10 3 # 10 A 169 TYR E 71 TYR~? -4.78 O2 CIT E 104s A 172 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 267 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 26.78 20.44 0.03 28.51 18.26 0.09 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 11 3 # 11 A 169 TYR F 56 TYR^? 13.04 O1 CIT F 104 A 172 HIS F 41 HIS^? 12.43 O1 CIT F 104 A 267 ASP F 27 ASP~? 14.00 O1 CIT F 104 coo 26.78 20.44 0.03 28.51 18.26 0.09 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 ULMN 3 2tmd_c00 TRIMETHYLAMINE DEHYDROGENASE user 12 3 # 12 A 169 TYR F 71 TYR~? -4.99 O2 CIT F 104s A 172 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 267 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 26.78 20.44 0.03 28.51 18.26 0.09 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 29.39 14.39 -1.75 31.15 15.06 -2.66 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 33.26 12.70 -5.86 33.92 14.66 -5.47 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 2tmd_c00 source 2tmd TRIMETHYLAMINE DEHYDROGENASE : 12 hits 2tmd_c00 naa= 3 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 1 3 # 1 B 169 TYR A 56 TYR^? 12.86 C2 EDO A 103 B 172 HIS A 41 HIS^? 12.51 O2 EDO A 103 B 267 ASP A 27 ASP~? 13.11 O2 EDO A 103 coo 44.86 1.98 33.27 42.75 1.12 31.67 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 2 3 # 2 B 169 TYR A 71 TYR~? -4.90 O2 EDO A 103s B 172 HIS A 4 HIS.? -4.40 O2 EDO A 103s B 267 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 44.86 1.98 33.27 42.75 1.12 31.67 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 3 3 # 3 B 169 TYR A 71 TYR~? -4.90 O2 EDO A 103s B 172 HIS A 74 HIS~? 11.00 C1 EDO E 103 B 267 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 44.86 1.98 33.27 42.75 1.12 31.67 -25.07 -87.10 -26.35 -22.55 -86.31 -27.06 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 4 3 # 4 B 169 TYR B 56 TYR^? 12.51 O1 CIT B 103 B 172 HIS B 41 HIS^? 11.37 O1 CIT B 103 B 267 ASP B 27 ASP~? 12.32 O1 CIT B 103 coo 44.86 1.98 33.27 42.75 1.12 31.67 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -15.56 -84.10 -5.75 -16.26 -84.15 -3.77 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -16.17 -79.43 -0.27 -16.62 -81.05 -1.56 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 5 3 # 5 B 169 TYR B 71 TYR~? -4.80 O1 CIT B 103s B 172 HIS B 4 HIS.? -4.11 O2 CIT B 103s B 267 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 44.86 1.98 33.27 42.75 1.12 31.67 -7.69 -73.33 -7.58 -7.82 -76.09 -7.52 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 6 3 # 6 B 169 TYR C 71 TYR~? -4.77 O1 CIT C 104s B 172 HIS C 4 HIS.? -4.06 O2 CIT C 104s B 267 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 44.86 1.98 33.27 42.75 1.12 31.67 -51.05 -72.34 -28.88 -49.19 -70.29 -28.96 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 7 3 # 7 B 169 TYR D 56 TYR^? 12.73 C2 CIT D 103 B 172 HIS D 41 HIS^? 12.20 O1 CIT D 103 B 267 ASP D 27 ASP~? 12.70 O1 CIT D 103 coo 44.86 1.98 33.27 42.75 1.12 31.67 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -54.58 -62.55 -8.16 -56.00 -63.02 -6.70 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -59.24 -58.48 -5.66 -58.49 -60.09 -6.78 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 8 3 # 8 B 169 TYR D 71 TYR~? -4.87 O2 CIT D 103s B 172 HIS D 4 HIS.? -4.16 O2 CIT D 103s B 267 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 44.86 1.98 33.27 42.75 1.12 31.67 -52.71 -49.28 -10.92 -51.47 -51.65 -10.06 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 9 3 # 9 B 169 TYR E 56 TYR^? 8.81 O2 EDO E 103 B 172 HIS E 41 HIS^? -3.94 C2 EDO E 103s B 267 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 44.86 1.98 33.27 42.75 1.12 31.67 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 10 3 # 10 B 169 TYR E 71 TYR~? -4.78 O2 CIT E 104s B 172 HIS E 4 HIS.? -4.01 O2 CIT E 104s B 267 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 44.86 1.98 33.27 42.75 1.12 31.67 -39.98 -82.79 -45.67 -37.92 -80.89 -45.44 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 11 3 # 11 B 169 TYR F 56 TYR^? 13.04 O1 CIT F 104 B 172 HIS F 41 HIS^? 12.43 O1 CIT F 104 B 267 ASP F 27 ASP~? 14.00 O1 CIT F 104 coo 44.86 1.98 33.27 42.75 1.12 31.67 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -29.78 -85.01 -66.49 -30.30 -86.26 -68.09 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -25.34 -89.34 -68.46 -26.20 -91.07 -67.68 ULMN 3 2tmd_c01 TRIMETHYLAMINE DEHYDROGENASE user 12 3 # 12 B 169 TYR F 71 TYR~? -4.99 O2 CIT F 104s B 172 HIS F 4 HIS.? -4.07 O2 CIT F 104s B 267 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 44.86 1.98 33.27 42.75 1.12 31.67 -16.33 -83.63 -62.96 -18.63 -82.45 -63.85 coo 40.83 -2.48 29.90 39.16 -2.39 31.17 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 36.38 -5.89 31.55 36.22 -4.28 32.93 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 2tmd_c01 source 2tmd TRIMETHYLAMINE DEHYDROGENASE : 12 hits 2tmd_c01 naa= 3 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 1 3 # 1 A 122 TYR A 54 TYR.? 12.54 C1 EDO A 103 A 214 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 256 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 2 3 # 2 A 122 TYR A 56 TYR^? 12.86 C2 EDO A 103 A 214 ASP A 46 ASP.? 9.57 O6 CIT B 103 A 256 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 3 3 # 3 A 122 TYR B 54 TYR.? 11.82 O7 CIT B 103 A 214 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 256 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 4 3 # 4 A 122 TYR B 56 TYR^? 12.51 O1 CIT B 103 A 214 ASP B 46 ASP.? 11.17 O1 EDO A 103 A 256 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 5 3 # 5 A 122 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 214 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 256 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 6 3 # 6 A 122 TYR C 56 TYR^? 12.84 O1 CIT C 104 A 214 ASP C 46 ASP.? 10.22 O6 CIT D 103 A 256 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 7 3 # 7 A 122 TYR D 54 TYR.? 11.66 C4 CIT D 103 A 214 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 256 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 8 3 # 8 A 122 TYR D 56 TYR^? 12.73 C2 CIT D 103 A 214 ASP D 46 ASP.? 10.10 O7 CIT C 104 A 256 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 9 3 # 9 A 122 TYR E 54 TYR.? 6.56 O1 EDO F 103 A 214 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 256 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 10 3 # 10 A 122 TYR E 56 TYR^? 8.81 O2 EDO E 103 A 214 ASP E 46 ASP.? 9.98 C4 CIT F 104 A 256 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 11 3 # 11 A 122 TYR F 54 TYR.? 5.10 C2 EDO F 103 A 214 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 256 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 12 3 # 12 A 122 TYR F 56 TYR^? 13.04 O1 CIT F 104 A 214 ASP F 46 ASP.? 6.64 O2 EDO F 103 A 256 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 2tpl_c04 source 2tpl TYROSINE PHENOL-LYASE : 12 hits 2tpl_c04 naa= 3 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 1 3 # 1 B 122 TYR A 54 TYR.? 12.54 C1 EDO A 103 B 214 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 256 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 2 3 # 2 B 122 TYR A 56 TYR^? 12.86 C2 EDO A 103 B 214 ASP A 46 ASP.? 9.57 O6 CIT B 103 B 256 LYS B 65 LYS~? 11.82 O5 CIT B 103 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -10.13 -79.04 -29.40 -12.19 -77.21 -29.75 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 3 3 # 3 B 122 TYR B 54 TYR.? 11.82 O7 CIT B 103 B 214 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 256 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 4 3 # 4 B 122 TYR B 56 TYR^? 12.51 O1 CIT B 103 B 214 ASP B 46 ASP.? 11.17 O1 EDO A 103 B 256 LYS A 65 LYS~? 12.23 O2 EDO A 103 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -12.59 -89.99 -7.35 -14.34 -88.50 -5.72 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 5 3 # 5 B 122 TYR C 54 TYR.? 11.88 O3 CIT C 104 B 214 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 256 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 6 3 # 6 B 122 TYR C 56 TYR^? 12.84 O1 CIT C 104 B 214 ASP C 46 ASP.? 10.22 O6 CIT D 103 B 256 LYS D 65 LYS~? 11.29 O6 CIT D 103 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -42.22 -57.30 -29.47 -44.48 -56.93 -30.98 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 7 3 # 7 B 122 TYR D 54 TYR.? 11.66 C4 CIT D 103 B 214 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 256 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 8 3 # 8 B 122 TYR D 56 TYR^? 12.73 C2 CIT D 103 B 214 ASP D 46 ASP.? 10.10 O7 CIT C 104 B 256 LYS C 65 LYS~? 12.16 O6 CIT C 104 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -48.56 -65.73 -7.07 -51.35 -65.50 -6.74 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -43.40 -72.19 -15.23 -41.64 -71.86 -16.31 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 9 3 # 9 B 122 TYR E 54 TYR.? 6.56 O1 EDO F 103 B 214 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 256 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 10 3 # 10 B 122 TYR E 56 TYR^? 8.81 O2 EDO E 103 B 214 ASP E 46 ASP.? 9.98 C4 CIT F 104 B 256 LYS F 65 LYS~? 10.97 O7 CIT F 104 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -24.97 -74.66 -43.96 -24.83 -77.08 -42.62 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 11 3 # 11 B 122 TYR F 54 TYR.? 5.10 C2 EDO F 103 B 214 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 256 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 12 3 # 12 B 122 TYR F 56 TYR^? 13.04 O1 CIT F 104 B 214 ASP F 46 ASP.? 6.64 O2 EDO F 103 B 256 LYS E 65 LYS~? 11.89 O6 CIT E 104 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -32.71 -78.80 -67.08 -32.61 -81.46 -67.71 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -39.53 -74.21 -58.81 -39.25 -72.50 -57.60 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 2tpl_c05 source 2tpl TYROSINE PHENOL-LYASE : 12 hits 2tpl_c05 naa= 3 ULMN 3 3cla_c00 TYPE III CHLORAMPHENICOL ACETYLTRANSuser 1 3 # 1 18 ARG A 79 ARG~? -3.92 C2 EDO E 103s 195 HIS A 74 HIS~? 11.00 C1 EDO E 103 199 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 21.96 2.03 15.24 19.33 1.86 13.55 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 13.48 -0.87 14.56 14.47 -2.14 15.92 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo 17.92 -0.05 18.55 18.90 -0.38 16.73 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 ULMN 3 3cla_c00 TYPE III CHLORAMPHENICOL ACETYLTRANSuser 2 3 # 2 18 ARG A 79 ARG~? -3.92 C2 EDO E 103s 195 HIS E 41 HIS^? -3.94 C2 EDO E 103s 199 ASP E 27 ASP~? 4.58 C1 EDO E 103 coo 21.96 2.03 15.24 19.33 1.86 13.55 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 13.48 -0.87 14.56 14.47 -2.14 15.92 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo 17.92 -0.05 18.55 18.90 -0.38 16.73 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 3cla_c00 source 3cla TYPE III CHLORAMPHENICOL ACETYLTRANSFERASE ( C: 2 hits 3cla_c00 naa= 3 ULMN 3 4mdh_c03 CYTOPLASMIC MALATE DEHYDROGENASE (E.user 1 3 # 1 B 158 ASP E 27 ASP~? 4.58 C1 EDO E 103 B 161 ARG A 79 ARG~? -3.92 C2 EDO E 103s B 186 HIS A 74 HIS~? 11.00 C1 EDO E 103 coo 44.53 16.44 28.54 44.89 18.45 28.77 -30.18 -85.04 -37.85 -28.56 -84.11 -38.91 coo 39.64 19.27 28.15 40.19 21.74 29.94 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 48.32 20.00 31.44 46.45 20.91 31.50 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 4mdh_c03 source 4mdh CYTOPLASMIC MALATE DEHYDROGENASE (E.C.1.1.1.37: 1 hits 4mdh_c03 naa= 3 ULMN 3 5cpa_c01 CARBOXYPEPTIDASE A=ALPHA= (COX) (E.Cuser 1 3 # 1 71 ARG A 79 ARG~? -3.92 C2 EDO E 103s 127 ARG E 40 ARG^? -5.36 O2 EDO E 103s 270 GLU F 101 GLU^? 10.35 O2 EDO E 103 coo -1.14 25.72 1.64 0.76 28.10 1.50 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo 2.87 25.67 -2.58 1.96 27.95 -4.18 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -7.41 30.69 -7.56 -5.96 29.61 -6.39 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 ULMN 3 5cpa_c01 CARBOXYPEPTIDASE A=ALPHA= (COX) (E.Cuser 2 3 # 2 71 ARG E 40 ARG^? -5.36 O2 EDO E 103s 127 ARG A 79 ARG~? -3.92 C2 EDO E 103s 270 GLU F 101 GLU^? 10.35 O2 EDO E 103 coo -1.14 25.72 1.64 0.76 28.10 1.50 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 2.87 25.67 -2.58 1.96 27.95 -4.18 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo -7.41 30.69 -7.56 -5.96 29.61 -6.39 -17.20 -81.34 -47.37 -15.58 -80.55 -46.28 5cpa_c01 source 5cpa CARBOXYPEPTIDASE A=ALPHA= (COX) (E.C.3.4.17.1): 2 hits 5cpa_c01 naa= 3 ULMN 3 5rsa_c01 RIBONUCLEASE A user 1 3 # 1 12 HIS A 4 HIS.? -4.40 O2 EDO A 103s 41 LYS A 65 LYS~? 12.23 O2 EDO A 103 119 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 28.18 18.67 11.43 28.83 17.39 9.89 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 25.33 8.32 6.30 27.86 13.90 7.82 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 33.68 19.99 5.35 34.98 18.36 5.19 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 5rsa_c01 RIBONUCLEASE A user 2 3 # 2 12 HIS A 4 HIS.? -4.40 O2 EDO A 103s 41 LYS B 50 LYS.? 6.61 O1 EDO A 103 119 HIS A 77 HIS~? -4.41 C2 EDO A 103s coo 28.18 18.67 11.43 28.83 17.39 9.89 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 25.33 8.32 6.30 27.86 13.90 7.82 -12.18 -95.61 -22.40 -12.70 -95.25 -27.68 coo 33.68 19.99 5.35 34.98 18.36 5.19 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 ULMN 3 5rsa_c01 RIBONUCLEASE A user 3 3 # 3 12 HIS A 77 HIS~? -4.41 C2 EDO A 103s 41 LYS A 65 LYS~? 12.23 O2 EDO A 103 119 HIS A 74 HIS~? 11.00 C1 EDO E 103 coo 28.18 18.67 11.43 28.83 17.39 9.89 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo 25.33 8.32 6.30 27.86 13.90 7.82 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo 33.68 19.99 5.35 34.98 18.36 5.19 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 ULMN 3 5rsa_c01 RIBONUCLEASE A user 4 3 # 4 12 HIS B 4 HIS.? -4.11 O2 CIT B 103s 41 LYS A 50 LYS.? -4.54 O3 CIT B 103s 119 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 28.18 18.67 11.43 28.83 17.39 9.89 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 25.33 8.32 6.30 27.86 13.90 7.82 0.28 -82.73 -17.71 1.66 -84.44 -13.54 coo 33.68 19.99 5.35 34.98 18.36 5.19 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 5rsa_c01 RIBONUCLEASE A user 5 3 # 5 12 HIS B 4 HIS.? -4.11 O2 CIT B 103s 41 LYS B 65 LYS~? 11.82 O5 CIT B 103 119 HIS B 77 HIS~? -4.07 O1 CIT B 103s coo 28.18 18.67 11.43 28.83 17.39 9.89 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 25.33 8.32 6.30 27.86 13.90 7.82 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 33.68 19.99 5.35 34.98 18.36 5.19 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 ULMN 3 5rsa_c01 RIBONUCLEASE A user 6 3 # 6 12 HIS B 77 HIS~? -4.07 O1 CIT B 103s 41 LYS B 65 LYS~? 11.82 O5 CIT B 103 119 HIS B 74 HIS~? 11.72 O1 CIT B 103 coo 28.18 18.67 11.43 28.83 17.39 9.89 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo 25.33 8.32 6.30 27.86 13.90 7.82 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo 33.68 19.99 5.35 34.98 18.36 5.19 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 ULMN 3 5rsa_c01 RIBONUCLEASE A user 7 3 # 7 12 HIS C 4 HIS.? -4.06 O2 CIT C 104s 41 LYS C 65 LYS~? 12.16 O6 CIT C 104 119 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 28.18 18.67 11.43 28.83 17.39 9.89 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 25.33 8.32 6.30 27.86 13.90 7.82 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 33.68 19.99 5.35 34.98 18.36 5.19 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 5rsa_c01 RIBONUCLEASE A user 8 3 # 8 12 HIS C 4 HIS.? -4.06 O2 CIT C 104s 41 LYS D 50 LYS.? -4.40 O3 CIT C 104s 119 HIS C 77 HIS~? -4.31 O1 CIT C 104s coo 28.18 18.67 11.43 28.83 17.39 9.89 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 25.33 8.32 6.30 27.86 13.90 7.82 -38.68 -71.02 -18.65 -36.67 -71.17 -23.06 coo 33.68 19.99 5.35 34.98 18.36 5.19 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 ULMN 3 5rsa_c01 RIBONUCLEASE A user 9 3 # 9 12 HIS C 77 HIS~? -4.31 O1 CIT C 104s 41 LYS C 65 LYS~? 12.16 O6 CIT C 104 119 HIS C 74 HIS~? 12.10 O1 CIT C 104 coo 28.18 18.67 11.43 28.83 17.39 9.89 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo 25.33 8.32 6.30 27.86 13.90 7.82 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo 33.68 19.99 5.35 34.98 18.36 5.19 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 ULMN 3 5rsa_c01 RIBONUCLEASE A user 10 3 # 10 12 HIS D 4 HIS.? -4.16 O2 CIT D 103s 41 LYS C 50 LYS.? -4.07 O4 CIT D 103s 119 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 28.18 18.67 11.43 28.83 17.39 9.89 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 25.33 8.32 6.30 27.86 13.90 7.82 -37.55 -53.70 -14.59 -37.99 -53.17 -9.73 coo 33.68 19.99 5.35 34.98 18.36 5.19 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 5rsa_c01 RIBONUCLEASE A user 11 3 # 11 12 HIS D 4 HIS.? -4.16 O2 CIT D 103s 41 LYS D 65 LYS~? 11.29 O6 CIT D 103 119 HIS D 77 HIS~? -3.79 O1 CIT D 103s coo 28.18 18.67 11.43 28.83 17.39 9.89 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 25.33 8.32 6.30 27.86 13.90 7.82 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 33.68 19.99 5.35 34.98 18.36 5.19 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 ULMN 3 5rsa_c01 RIBONUCLEASE A user 12 3 # 12 12 HIS D 77 HIS~? -3.79 O1 CIT D 103s 41 LYS D 65 LYS~? 11.29 O6 CIT D 103 119 HIS D 74 HIS~? 11.86 O1 CIT D 103 coo 28.18 18.67 11.43 28.83 17.39 9.89 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo 25.33 8.32 6.30 27.86 13.90 7.82 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo 33.68 19.99 5.35 34.98 18.36 5.19 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 ULMN 3 5rsa_c01 RIBONUCLEASE A user 13 3 # 13 12 HIS E 4 HIS.? -4.01 O2 CIT E 104s 41 LYS E 65 LYS~? 11.89 O6 CIT E 104 119 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 28.18 18.67 11.43 28.83 17.39 9.89 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 25.33 8.32 6.30 27.86 13.90 7.82 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 33.68 19.99 5.35 34.98 18.36 5.19 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 5rsa_c01 RIBONUCLEASE A user 14 3 # 14 12 HIS E 4 HIS.? -4.01 O2 CIT E 104s 41 LYS F 50 LYS.? -3.77 O3 CIT E 104s 119 HIS E 77 HIS~? -4.13 O1 CIT E 104s coo 28.18 18.67 11.43 28.83 17.39 9.89 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 25.33 8.32 6.30 27.86 13.90 7.82 -38.38 -69.86 -54.87 -39.83 -68.71 -49.77 coo 33.68 19.99 5.35 34.98 18.36 5.19 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 ULMN 3 5rsa_c01 RIBONUCLEASE A user 15 3 # 15 12 HIS E 77 HIS~? -4.13 O1 CIT E 104s 41 LYS E 65 LYS~? 11.89 O6 CIT E 104 119 HIS E 74 HIS~? 12.16 O1 CIT E 104 coo 28.18 18.67 11.43 28.83 17.39 9.89 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo 25.33 8.32 6.30 27.86 13.90 7.82 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo 33.68 19.99 5.35 34.98 18.36 5.19 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 ULMN 3 5rsa_c01 RIBONUCLEASE A user 16 3 # 16 12 HIS F 4 HIS.? -4.07 O2 CIT F 104s 41 LYS E 50 LYS.? -4.05 O4 CIT F 104s 119 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 28.18 18.67 11.43 28.83 17.39 9.89 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 25.33 8.32 6.30 27.86 13.90 7.82 -20.28 -69.11 -58.33 -20.00 -69.12 -63.34 coo 33.68 19.99 5.35 34.98 18.36 5.19 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 ULMN 3 5rsa_c01 RIBONUCLEASE A user 17 3 # 17 12 HIS F 4 HIS.? -4.07 O2 CIT F 104s 41 LYS F 65 LYS~? 10.97 O7 CIT F 104 119 HIS F 77 HIS~? -3.59 O1 CIT F 104s coo 28.18 18.67 11.43 28.83 17.39 9.89 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 25.33 8.32 6.30 27.86 13.90 7.82 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo 33.68 19.99 5.35 34.98 18.36 5.19 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 5rsa_c01 source 5rsa RIBONUCLEASE A : 17 hits 5rsa_c01 naa= 3 ULMN 3 1k12_p00 LECTIN user 1 3 # 1 A 52 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 79 ARG A 79 ARG~? -3.92 C2 EDO E 103s A 86 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo -5.53 26.98 5.69 -5.98 25.70 4.09 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -12.15 26.35 6.05 -10.94 27.19 3.35 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 coo -9.59 20.48 4.28 -9.21 22.28 1.82 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 ULMN 3 1k12_p00 LECTIN user 2 3 # 2 A 52 HIS E 41 HIS^? -3.94 C2 EDO E 103s A 79 ARG E 40 ARG^? -5.36 O2 EDO E 103s A 86 ARG A 79 ARG~? -3.92 C2 EDO E 103s coo -5.53 26.98 5.69 -5.98 25.70 4.09 -27.05 -81.07 -42.95 -26.62 -81.74 -41.01 coo -12.15 26.35 6.05 -10.94 27.19 3.35 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo -9.59 20.48 4.28 -9.21 22.28 1.82 -23.36 -86.72 -40.56 -24.74 -84.33 -39.20 1k12_p00 source 1k12 LECTIN : 2 hits 1k12_p00 naa= 3 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 1 1 # 1 A 461 ASN A 44 ASN.? 11.73 O6 CIT B 103 coo 5.80 63.03 55.85 5.52 65.03 56.45 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 2 1 # 2 A 461 ASN A 90 ASN~? 16.38 O1 EDO A 103 coo 5.80 63.03 55.85 5.52 65.03 56.45 -4.88 -95.45 -33.14 -2.88 -95.87 -33.61 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 3 1 # 3 A 461 ASN B 44 ASN.? 13.13 O1 EDO A 103 coo 5.80 63.03 55.85 5.52 65.03 56.45 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 4 1 # 4 A 461 ASN B 90 ASN~? 13.61 O3 CIT B 103 coo 5.80 63.03 55.85 5.52 65.03 56.45 4.74 -92.94 -10.60 5.13 -95.02 -10.92 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 5 1 # 5 A 461 ASN C 44 ASN.? 11.91 O6 CIT D 103 coo 5.80 63.03 55.85 5.52 65.03 56.45 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 6 1 # 6 A 461 ASN C 90 ASN~? 14.00 O3 CIT C 104 coo 5.80 63.03 55.85 5.52 65.03 56.45 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 7 1 # 7 A 461 ASN D -5 ASN.? 16.01 O6 CIT D 103 coo 5.80 63.03 55.85 5.52 65.03 56.45 -38.30 -48.37 -26.01 -39.87 -49.66 -25.30 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 8 1 # 8 A 461 ASN D 44 ASN.? 12.24 O2 CIT C 104 coo 5.80 63.03 55.85 5.52 65.03 56.45 -45.79 -68.74 -12.60 -44.63 -69.00 -14.38 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 9 1 # 9 A 461 ASN D 90 ASN~? 12.97 O4 CIT D 103 coo 5.80 63.03 55.85 5.52 65.03 56.45 -32.84 -58.19 -3.59 -31.15 -59.37 -2.96 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 10 1 # 10 A 461 ASN E 44 ASN.? 11.90 O7 CIT F 104 coo 5.80 63.03 55.85 5.52 65.03 56.45 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 11 1 # 11 A 461 ASN E 90 ASN~? -4.46 O2 EDO C 103s coo 5.80 63.03 55.85 5.52 65.03 56.45 -35.23 -60.67 -47.27 -34.25 -58.85 -47.55 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 12 1 # 12 A 461 ASN F 44 ASN.? 8.45 O2 EDO F 103 coo 5.80 63.03 55.85 5.52 65.03 56.45 -35.95 -76.51 -61.43 -36.28 -75.53 -59.60 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 13 1 # 13 A 461 ASN F 90 ASN~? 14.08 O1 EDO F 103 coo 5.80 63.03 55.85 5.52 65.03 56.45 -25.28 -63.01 -68.95 -26.65 -61.43 -69.45 1kbk_p00 source 1kbk ALPHA-AMYLASE, PANCREATIC : 13 hits 1kbk_p00 naa= 1 ULMN 3 1uy2_p00 ENDO-1,4-BETA-XYLANASE A user 1 3 # 1 A 51 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 108 ASN D -5 ASN.? 16.01 O6 CIT D 103 A 135 ASN C 44 ASN.? 11.91 O6 CIT D 103 coo 17.59 4.66 17.88 15.38 5.96 18.97 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 12.36 16.24 15.27 12.06 14.29 16.05 -38.30 -48.37 -26.01 -39.87 -49.66 -25.30 coo 18.05 11.56 12.71 17.57 10.75 14.60 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 ULMN 3 1uy2_p00 ENDO-1,4-BETA-XYLANASE A user 2 3 # 2 A 51 TYR D -3 TYR.? 15.53 O6 CIT D 103 A 108 ASN C 44 ASN.? 11.91 O6 CIT D 103 A 135 ASN D -5 ASN.? 16.01 O6 CIT D 103 coo 17.59 4.66 17.88 15.38 5.96 18.97 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 coo 12.36 16.24 15.27 12.06 14.29 16.05 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 18.05 11.56 12.71 17.57 10.75 14.60 -38.30 -48.37 -26.01 -39.87 -49.66 -25.30 1uy2_p00 source 1uy2 ENDO-1,4-BETA-XYLANASE A : 2 hits 1uy2_p00 naa= 3 ULMN 3 1uy4_p00 ENDO-1,4-BETA-XYLANASE A user 1 3 # 1 A 51 TYR C 54 TYR.? 11.88 O3 CIT C 104 A 108 ASN D -5 ASN.? 16.01 O6 CIT D 103 A 135 ASN C 44 ASN.? 11.91 O6 CIT D 103 coo 17.50 4.57 17.85 15.28 5.88 18.97 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 12.22 15.98 15.24 11.94 14.05 16.09 -38.30 -48.37 -26.01 -39.87 -49.66 -25.30 coo 17.94 11.43 12.65 17.42 10.61 14.53 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 ULMN 3 1uy4_p00 ENDO-1,4-BETA-XYLANASE A user 2 3 # 2 A 51 TYR D -3 TYR.? 15.53 O6 CIT D 103 A 108 ASN C 44 ASN.? 11.91 O6 CIT D 103 A 135 ASN D -5 ASN.? 16.01 O6 CIT D 103 coo 17.50 4.57 17.85 15.28 5.88 18.97 -47.55 -44.73 -24.06 -50.31 -44.96 -24.07 coo 12.22 15.98 15.24 11.94 14.05 16.09 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 17.94 11.43 12.65 17.42 10.61 14.53 -38.30 -48.37 -26.01 -39.87 -49.66 -25.30 1uy4_p00 source 1uy4 ENDO-1,4-BETA-XYLANASE A : 2 hits 1uy4_p00 naa= 3 ULMN 3 2c3x_p00 ALPHA-AMYLASE G-6 user 1 3 # 1 A 26 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 76 ASN B 44 ASN.? 13.13 O1 EDO A 103 A 81 ASP B 46 ASP.? 11.17 O1 EDO A 103 coo 4.09 43.69 67.89 2.45 42.40 68.10 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 4.75 48.17 75.81 4.99 47.30 77.74 -14.17 -92.08 -13.77 -14.12 -92.41 -15.86 coo 0.57 50.41 73.18 0.46 48.28 73.56 -15.09 -95.32 -17.31 -13.96 -95.71 -19.04 ULMN 3 2c3x_p00 ALPHA-AMYLASE G-6 user 2 3 # 2 A 26 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 76 ASN A 44 ASN.? 11.73 O6 CIT B 103 A 81 ASP A 46 ASP.? 9.57 O6 CIT B 103 coo 4.09 43.69 67.89 2.45 42.40 68.10 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 4.75 48.17 75.81 4.99 47.30 77.74 -6.16 -78.97 -23.82 -5.26 -79.63 -22.02 coo 0.57 50.41 73.18 0.46 48.28 73.56 -1.95 -78.44 -21.25 -0.95 -79.99 -20.20 ULMN 3 2c3x_p00 ALPHA-AMYLASE G-6 user 3 3 # 3 A 26 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 76 ASN C 44 ASN.? 11.91 O6 CIT D 103 A 81 ASP C 46 ASP.? 10.22 O6 CIT D 103 coo 4.09 43.69 67.89 2.45 42.40 68.10 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 4.75 48.17 75.81 4.99 47.30 77.74 -41.65 -54.73 -23.18 -41.30 -54.49 -21.12 coo 0.57 50.41 73.18 0.46 48.28 73.56 -39.78 -51.61 -19.74 -38.72 -52.22 -18.01 ULMN 3 2c3x_p00 ALPHA-AMYLASE G-6 user 4 3 # 4 A 26 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 76 ASN E 44 ASN.? 11.90 O7 CIT F 104 A 81 ASP E 46 ASP.? 9.98 C4 CIT F 104 coo 4.09 43.69 67.89 2.45 42.40 68.10 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 4.75 48.17 75.81 4.99 47.30 77.74 -21.95 -73.76 -50.02 -21.67 -73.31 -52.09 coo 0.57 50.41 73.18 0.46 48.28 73.56 -18.60 -71.82 -53.29 -19.07 -70.50 -54.88 2c3x_p00 source 2c3x ALPHA-AMYLASE G-6 : 4 hits 2c3x_p00 naa= 3 ULMN 4 2cl8_p00 DECTIN-1 user 1 4 # 1 A 145 ARG B 89 ARG.? 13.25 O3 CIT B 103 A 148 SER B 87 SER~? 10.61 C4 CIT B 103 A 152 ALA B 15 ALA~? 14.11 C4 CIT B 103 A 194 GLU B 13 GLU.? 22.42 C4 CIT B 103 coo -29.52 -1.51 -10.80 -29.25 -1.07 -13.87 0.32 -96.47 -11.54 1.69 -95.10 -13.99 coo -35.30 0.90 -4.91 -36.19 -1.20 -5.57 -2.02 -90.62 -3.15 -3.50 -89.66 -1.50 coo -37.81 4.22 -2.30 -36.99 5.43 -2.37 -5.10 -93.70 -1.33 -4.68 -94.25 -2.68 coo -43.25 5.44 -9.45 -44.36 4.89 -7.68 -4.23-100.38 2.35 -5.07-101.78 1.01 ULMN 4 2cl8_p00 DECTIN-1 user 2 4 # 2 A 145 ARG E 89 ARG.? -3.87 C2 EDO C 103s A 148 SER E 87 SER~? 10.44 O7 CIT E 104 A 152 ALA E 15 ALA~? 10.03 O2 EDO C 103 A 194 GLU C 11 GLU.? 13.80 O2 EDO C 103 coo -29.52 -1.51 -10.80 -29.25 -1.07 -13.87 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo -35.30 0.90 -4.91 -36.19 -1.20 -5.57 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 coo -37.81 4.22 -2.30 -36.99 5.43 -2.37 -27.65 -67.17 -37.74 -27.59 -66.33 -38.97 coo -43.25 5.44 -9.45 -44.36 4.89 -7.68 -28.53 -61.63 -31.10 -27.44 -63.52 -31.48 ULMN 4 2cl8_p00 DECTIN-1 user 3 4 # 3 A 145 ARG E 89 ARG.? -3.87 C2 EDO C 103s A 148 SER E 87 SER~? 10.44 O7 CIT E 104 A 152 ALA E 86 ALA~? 9.46 O2 EDO C 103 A 194 GLU C 21 GLU~? 6.35 O1 EDO C 103 coo -29.52 -1.51 -10.80 -29.25 -1.07 -13.87 -29.32 -59.83 -46.42 -30.23 -57.08 -45.24 coo -35.30 0.90 -4.91 -36.19 -1.20 -5.57 -32.17 -67.03 -39.81 -32.05 -69.05 -38.48 coo -37.81 4.22 -2.30 -36.99 5.43 -2.37 -35.91 -66.33 -39.29 -36.49 -66.55 -37.85 coo -43.25 5.44 -9.45 -44.36 4.89 -7.68 -42.63 -61.47 -41.32 -40.73 -61.80 -42.26 2cl8_p00 source 2cl8 DECTIN-1 : 3 hits 2cl8_p00 naa= 4 ULMN 3 1b01_d00 GENE REGULATION/DNA user 1 3 # 1 B 4 ARG B 40 ARG^? 17.25 O1 CIT B 103 B 6 THR B 37 THR^? 15.70 O1 CIT B 103 B 8 THR B 63 THR.? 17.42 O2 CIT B 103 coo 40.52 16.08 100.90 37.97 16.41 102.60 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 36.11 13.64 95.03 34.54 14.86 95.91 -17.76 -70.65 -9.89 -17.86 -69.70 -11.85 coo 32.72 8.05 92.39 31.25 9.11 91.35 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 ULMN 3 1b01_d00 GENE REGULATION/DNA user 2 3 # 2 B 4 ARG B 40 ARG^? 17.25 O1 CIT B 103 B 6 THR B 61 THR^? 13.51 O2 CIT B 103 B 8 THR B 63 THR.? 17.42 O2 CIT B 103 coo 40.52 16.08 100.90 37.97 16.41 102.60 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 coo 36.11 13.64 95.03 34.54 14.86 95.91 -14.77 -73.96 -13.47 -16.75 -74.09 -14.33 coo 32.72 8.05 92.39 31.25 9.11 91.35 -14.04 -67.28 -14.71 -15.31 -65.71 -13.86 ULMN 3 1b01_d00 GENE REGULATION/DNA user 3 3 # 3 B 4 ARG E 40 ARG^? -5.36 O2 EDO E 103s B 6 THR E 61 THR^? 11.76 O1 EDO E 103 B 8 THR E 63 THR.? 15.89 O2 CIT E 104 coo 40.52 16.08 100.90 37.97 16.41 102.60 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 coo 36.11 13.64 95.03 34.54 14.86 95.91 -34.29 -86.98 -51.72 -32.89 -88.23 -52.80 coo 32.72 8.05 92.39 31.25 9.11 91.35 -39.67 -90.87 -53.60 -40.19 -92.33 -52.07 1b01_d00 source 1b01 GENE REGULATION/DNA : 3 hits 1b01_d00 naa= 3 ULMN 4 1cf7_d01 TRANSCRIPTION/DNA user 1 4 # 1 B 118 ASN C 90 ASN~? 14.00 O3 CIT C 104 B 121 ARG C 53 ARG.? 12.90 O3 CIT C 104 B 122 ARG C 89 ARG.? 16.36 O3 CIT C 104 B 124 TYR C 54 TYR.? 11.88 O3 CIT C 104 coo 43.23 33.97 15.91 42.50 32.05 15.39 -28.43 -67.52 -26.32 -26.35 -67.01 -26.21 coo 34.72 34.23 15.94 33.05 32.00 17.31 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 coo 39.23 30.42 19.06 37.28 30.09 16.76 -28.11 -62.04 -25.95 -25.81 -62.98 -24.03 coo 32.79 36.91 20.45 33.09 39.73 20.13 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 ULMN 4 1cf7_d01 TRANSCRIPTION/DNA user 2 4 # 2 B 118 ASN F 90 ASN~? 14.08 O1 EDO F 103 B 121 ARG F 53 ARG.? -5.38 O1 EDO F 103s B 122 ARG F 89 ARG.? 10.30 C2 EDO F 103 B 124 TYR F 54 TYR.? 5.10 C2 EDO F 103 coo 43.23 33.97 15.91 42.50 32.05 15.39 -25.28 -63.01 -68.95 -26.65 -61.43 -69.45 coo 34.72 34.23 15.94 33.05 32.00 17.31 -31.91 -66.07 -61.51 -29.41 -64.23 -61.61 coo 39.23 30.42 19.06 37.28 30.09 16.76 -31.12 -63.92 -68.77 -30.34 -61.79 -66.66 coo 32.79 36.91 20.45 33.09 39.73 20.13 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 1cf7_d01 source 1cf7 TRANSCRIPTION/DNA : 2 hits 1cf7_d01 naa= 4 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 1 3 # 1 I 303 TYR A 54 TYR.? 12.54 C1 EDO A 103 I 306 VAL A 6 VAL.? 5.08 C1 EDO A 103 I 308 VAL A 98 VAL^? 10.78 O2 EDO A 103 coo 26.18 35.24 6.87 24.33 35.18 8.97 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 23.55 29.53 9.81 23.15 27.39 10.24 -14.03 -86.18 -24.20 -15.41 -86.93 -25.76 coo 16.43 30.18 9.35 15.05 30.67 11.01 -14.49 -89.93 -18.69 -13.13 -88.96 -17.28 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 2 3 # 2 I 303 TYR A 54 TYR.? 12.54 C1 EDO A 103 I 306 VAL B 98 VAL^? 10.08 O6 CIT B 103 I 308 VAL B 6 VAL.? -4.77 O7 CIT B 103s coo 26.18 35.24 6.87 24.33 35.18 8.97 -5.69 -85.82 -24.43 -5.64 -88.55 -23.90 coo 23.55 29.53 9.81 23.15 27.39 10.24 -6.59 -80.54 -18.55 -7.74 -81.60 -20.10 coo 16.43 30.18 9.35 15.05 30.67 11.01 -8.11 -83.40 -12.74 -6.87 -82.53 -11.20 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 3 3 # 3 I 303 TYR B 54 TYR.? 11.82 O7 CIT B 103 I 306 VAL A 98 VAL^? 10.78 O2 EDO A 103 I 308 VAL A 6 VAL.? 5.08 C1 EDO A 103 coo 26.18 35.24 6.87 24.33 35.18 8.97 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 23.55 29.53 9.81 23.15 27.39 10.24 -14.49 -89.93 -18.69 -13.13 -88.96 -17.28 coo 16.43 30.18 9.35 15.05 30.67 11.01 -14.03 -86.18 -24.20 -15.41 -86.93 -25.76 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 4 3 # 4 I 303 TYR B 54 TYR.? 11.82 O7 CIT B 103 I 306 VAL B 6 VAL.? -4.77 O7 CIT B 103s I 308 VAL B 98 VAL^? 10.08 O6 CIT B 103 coo 26.18 35.24 6.87 24.33 35.18 8.97 -7.50 -91.25 -15.39 -5.20 -90.61 -16.79 coo 23.55 29.53 9.81 23.15 27.39 10.24 -8.11 -83.40 -12.74 -6.87 -82.53 -11.20 coo 16.43 30.18 9.35 15.05 30.67 11.01 -6.59 -80.54 -18.55 -7.74 -81.60 -20.10 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 5 3 # 5 I 303 TYR C 54 TYR.? 11.88 O3 CIT C 104 I 306 VAL C 6 VAL.? 5.25 O2 CIT C 104 I 308 VAL C 98 VAL^? 10.01 O2 CIT C 104 coo 26.18 35.24 6.87 24.33 35.18 8.97 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 23.55 29.53 9.81 23.15 27.39 10.24 -44.00 -64.86 -23.91 -44.05 -66.46 -25.42 coo 16.43 30.18 9.35 15.05 30.67 11.01 -44.95 -67.54 -18.00 -44.95 -65.90 -16.52 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 6 3 # 6 I 303 TYR C 54 TYR.? 11.88 O3 CIT C 104 I 306 VAL D 98 VAL^? 10.08 O6 CIT D 103 I 308 VAL D 6 VAL.? 4.78 C2 CIT D 103 coo 26.18 35.24 6.87 24.33 35.18 8.97 -37.68 -60.04 -21.64 -36.40 -62.19 -20.44 coo 23.55 29.53 9.81 23.15 27.39 10.24 -43.56 -55.67 -18.17 -43.36 -57.44 -19.52 coo 16.43 30.18 9.35 15.05 30.67 11.01 -45.94 -58.22 -12.52 -46.20 -56.61 -11.06 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 7 3 # 7 I 303 TYR D 54 TYR.? 11.66 C4 CIT D 103 I 306 VAL C 98 VAL^? 10.01 O2 CIT C 104 I 308 VAL C 6 VAL.? 5.25 O2 CIT C 104 coo 26.18 35.24 6.87 24.33 35.18 8.97 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 23.55 29.53 9.81 23.15 27.39 10.24 -44.95 -67.54 -18.00 -44.95 -65.90 -16.52 coo 16.43 30.18 9.35 15.05 30.67 11.01 -44.00 -64.86 -23.91 -44.05 -66.46 -25.42 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 8 3 # 8 I 303 TYR D 54 TYR.? 11.66 C4 CIT D 103 I 306 VAL D 6 VAL.? 4.78 C2 CIT D 103 I 308 VAL D 98 VAL^? 10.08 O6 CIT D 103 coo 26.18 35.24 6.87 24.33 35.18 8.97 -40.38 -64.36 -11.97 -38.28 -62.56 -12.44 coo 23.55 29.53 9.81 23.15 27.39 10.24 -45.94 -58.22 -12.52 -46.20 -56.61 -11.06 coo 16.43 30.18 9.35 15.05 30.67 11.01 -43.56 -55.67 -18.17 -43.36 -57.44 -19.52 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 9 3 # 9 I 303 TYR E 54 TYR.? 6.56 O1 EDO F 103 I 306 VAL E 6 VAL.? -5.01 O2 CIT E 104s I 308 VAL E 98 VAL^? 9.07 O2 EDO F 103 coo 26.18 35.24 6.87 24.33 35.18 8.97 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 23.55 29.53 9.81 23.15 27.39 10.24 -32.31 -75.74 -49.97 -33.95 -75.73 -48.50 coo 16.43 30.18 9.35 15.05 30.67 11.01 -34.98 -76.13 -56.01 -33.27 -75.93 -57.38 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 10 3 # 10 I 303 TYR E 54 TYR.? 6.56 O1 EDO F 103 I 306 VAL F 98 VAL^? 10.00 O7 CIT F 104 I 308 VAL F 6 VAL.? 5.28 O2 CIT F 104 coo 26.18 35.24 6.87 24.33 35.18 8.97 -27.09 -69.50 -51.81 -29.07 -68.22 -53.27 coo 23.55 29.53 9.81 23.15 27.39 10.24 -22.84 -75.20 -55.36 -24.57 -75.00 -54.05 coo 16.43 30.18 9.35 15.05 30.67 11.01 -25.45 -76.97 -61.08 -23.88 -77.08 -62.54 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 11 3 # 11 I 303 TYR F 54 TYR.? 5.10 C2 EDO F 103 I 306 VAL E 98 VAL^? 9.07 O2 EDO F 103 I 308 VAL E 6 VAL.? -5.01 O2 CIT E 104s coo 26.18 35.24 6.87 24.33 35.18 8.97 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 23.55 29.53 9.81 23.15 27.39 10.24 -34.98 -76.13 -56.01 -33.27 -75.93 -57.38 coo 16.43 30.18 9.35 15.05 30.67 11.01 -32.31 -75.74 -49.97 -33.95 -75.73 -48.50 ULMN 3 1cqt_d00 GENE REGULATION/DNA user 12 3 # 12 I 303 TYR F 54 TYR.? 5.10 C2 EDO F 103 I 306 VAL F 6 VAL.? 5.28 O2 CIT F 104 I 308 VAL F 98 VAL^? 10.00 O7 CIT F 104 coo 26.18 35.24 6.87 24.33 35.18 8.97 -31.55 -71.23 -61.22 -29.73 -69.33 -60.34 coo 23.55 29.53 9.81 23.15 27.39 10.24 -25.45 -76.97 -61.08 -23.88 -77.08 -62.54 coo 16.43 30.18 9.35 15.05 30.67 11.01 -22.84 -75.20 -55.36 -24.57 -75.00 -54.05 1cqt_d00 source 1cqt GENE REGULATION/DNA : 12 hits 1cqt_d00 naa= 3 ULMN 3 1emh_d00 HYDROLASE/DNA user 1 3 # 1 A 271 PRO A 43 PRO^? 17.15 O2 EDO A 103 A 272 LEU B 100 LEU^? 13.83 O2 EDO A 103 A 276 ARG A 40 ARG^? 16.77 O2 EDO A 103 coo 16.45 -2.42 17.59 14.58 -2.74 16.47 -8.38 -73.55 -27.31 -9.00 -75.70 -26.82 coo 10.97 0.43 16.73 11.31 2.11 18.06 -11.19 -77.10 -21.71 -11.33 -79.05 -22.56 coo 5.13 -4.12 13.47 2.16 -3.72 14.17 -19.32 -73.92 -22.51 -21.90 -72.78 -21.25 ULMN 3 1emh_d00 HYDROLASE/DNA user 2 3 # 2 A 271 PRO B 43 PRO^? 16.74 O1 CIT B 103 A 272 LEU A 100 LEU^? 13.85 O1 CIT B 103 A 276 ARG B 40 ARG^? 17.25 O1 CIT B 103 coo 16.45 -2.42 17.59 14.58 -2.74 16.47 -18.16 -92.21 -8.38 -16.44 -90.98 -9.14 coo 10.97 0.43 16.73 11.31 2.11 18.06 -17.08 -87.25 -13.38 -14.97 -87.07 -12.96 coo 5.13 -4.12 13.47 2.16 -3.72 14.17 -20.32 -79.74 -8.93 -23.23 -79.07 -9.60 ULMN 3 1emh_d00 HYDROLASE/DNA user 3 3 # 3 A 271 PRO C 10 PRO.? 12.56 C4 CIT C 104 A 272 LEU C 8 LEU.? 8.17 C4 CIT C 104 A 276 ARG C 53 ARG.? 12.90 O3 CIT C 104 coo 16.45 -2.42 17.59 14.58 -2.74 16.47 -36.22 -58.57 -29.82 -34.67 -60.13 -29.45 coo 10.97 0.43 16.73 11.31 2.11 18.06 -39.23 -61.79 -27.77 -40.69 -63.13 -28.70 coo 5.13 -4.12 13.47 2.16 -3.72 14.17 -32.79 -60.68 -20.12 -31.86 -63.57 -19.68 ULMN 3 1emh_d00 HYDROLASE/DNA user 4 3 # 4 A 271 PRO C 43 PRO^? 16.83 O1 CIT C 104 A 272 LEU D 100 LEU^? 13.70 O1 CIT C 104 A 276 ARG C 40 ARG^? 17.96 O1 CIT C 104 coo 16.45 -2.42 17.59 14.58 -2.74 16.47 -44.37 -51.76 -28.68 -44.19 -53.81 -27.76 coo 10.97 0.43 16.73 11.31 2.11 18.06 -47.31 -55.74 -23.54 -46.04 -57.49 -23.79 coo 5.13 -4.12 13.47 2.16 -3.72 14.17 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 ULMN 3 1emh_d00 HYDROLASE/DNA user 5 3 # 5 A 271 PRO D 43 PRO^? 16.79 C2 CIT D 103 A 272 LEU C 100 LEU^? 13.72 O2 CIT D 103 A 276 ARG D 40 ARG^? 16.76 O2 CIT D 103 coo 16.45 -2.42 17.59 14.58 -2.74 16.47 -51.31 -70.72 -9.08 -50.24 -68.79 -9.64 coo 10.97 0.43 16.73 11.31 2.11 18.06 -50.61 -66.45 -14.87 -49.30 -65.03 -13.86 coo 5.13 -4.12 13.47 2.16 -3.72 14.17 -58.50 -62.80 -14.17 -61.19 -61.71 -15.17 ULMN 3 1emh_d00 HYDROLASE/DNA user 6 3 # 6 A 271 PRO E 43 PRO^? 9.04 O2 EDO E 103 A 272 LEU F 100 LEU^? 8.24 O2 EDO E 103 A 276 ARG E 40 ARG^? -5.36 O2 EDO E 103s coo 16.45 -2.42 17.59 14.58 -2.74 16.47 -19.31 -77.07 -44.70 -21.34 -76.65 -45.59 coo 10.97 0.43 16.73 11.31 2.11 18.06 -23.26 -79.30 -50.33 -25.04 -78.05 -50.01 coo 5.13 -4.12 13.47 2.16 -3.72 14.17 -26.02 -87.07 -46.78 -23.66 -88.91 -47.42 ULMN 3 1emh_d00 HYDROLASE/DNA user 7 3 # 7 A 271 PRO F 43 PRO^? 15.47 O2 EDO F 103 A 272 LEU E 100 LEU^? 13.74 O2 CIT F 104 A 276 ARG F 40 ARG^? 16.45 O2 CIT F 104 coo 16.45 -2.42 17.59 14.58 -2.74 16.47 -37.87 -81.53 -65.46 -35.92 -80.65 -64.76 coo 10.97 0.43 16.73 11.31 2.11 18.06 -33.88 -81.47 -59.62 -32.42 -80.07 -60.48 coo 5.13 -4.12 13.47 2.16 -3.72 14.17 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 1emh_d00 source 1emh HYDROLASE/DNA : 7 hits 1emh_d00 naa= 3 ULMN 3 1id3_d00 STRUCTURAL PROTEIN/DNA user 1 3 # 1 E 40 ARG C 40 ARG^? 17.96 O1 CIT C 104 E 41 TYR D 3 TYR.? 14.21 O2 CIT D 103 E 83 ARG A 45 ARG.? 18.60 O6 CIT B 103 coo 41.16 -25.11 -82.73 40.81 -22.13 -82.13 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 40.04 -30.19 -77.46 41.62 -32.14 -76.20 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 33.18 -0.85 -38.14 36.12 -0.03 -38.44 -5.12 -72.35 -24.10 -6.05 -71.09 -26.77 ULMN 3 1id3_d00 STRUCTURAL PROTEIN/DNA user 2 3 # 2 E 40 ARG C 40 ARG^? 17.96 O1 CIT C 104 E 41 TYR D 3 TYR.? 14.21 O2 CIT D 103 E 83 ARG B 45 ARG.? 19.51 O2 EDO A 103 coo 41.16 -25.11 -82.73 40.81 -22.13 -82.13 -54.81 -57.72 -27.86 -56.93 -55.49 -27.28 coo 40.04 -30.19 -77.46 41.62 -32.14 -76.20 -52.22 -56.59 -21.84 -54.67 -57.25 -23.07 coo 33.18 -0.85 -38.14 36.12 -0.03 -38.44 -20.16 -94.56 -11.95 -20.30 -94.61 -8.86 ULMN 3 1id3_d00 STRUCTURAL PROTEIN/DNA user 3 3 # 3 E 40 ARG F 40 ARG^? 16.45 O2 CIT F 104 E 41 TYR E 3 TYR.? 13.85 O2 EDO E 103 E 83 ARG B 53 ARG.? 13.69 O3 CIT B 103 coo 41.16 -25.11 -82.73 40.81 -22.13 -82.13 -30.22 -89.39 -60.91 -29.03 -92.22 -60.60 coo 40.04 -30.19 -77.46 41.62 -32.14 -76.20 -32.38 -85.18 -56.30 -31.27 -87.75 -56.43 coo 33.18 -0.85 -38.14 36.12 -0.03 -38.44 -3.89 -94.19 -17.38 -1.01 -93.51 -18.29 1id3_d00 source 1id3 STRUCTURAL PROTEIN/DNA : 3 hits 1id3_d00 naa= 3 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 1 3 # 1 A 101 VAL A 6 VAL.? 5.08 C1 EDO A 103 A 102 PHE A 58 PHE^? 5.23 O2 EDO A 103 A 169 CYH A 88 CYH.? 9.02 C1 EDO A 103 coo -0.48 2.03 12.21 0.64 0.32 12.97 -14.03 -86.18 -24.20 -15.41 -86.93 -25.76 coo 0.51 5.20 15.97 0.26 4.09 18.50 -16.42 -82.38 -26.61 -17.02 -84.79 -27.84 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -7.87 -88.88 -34.25 -9.47 -87.60 -32.35 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 2 3 # 2 A 101 VAL B 6 VAL.? -4.77 O7 CIT B 103s A 102 PHE B 58 PHE^? -4.80 O1 CIT B 103s A 169 CYH B 88 CYH~? 7.91 O3 CIT B 103 coo -0.48 2.03 12.21 0.64 0.32 12.97 -8.11 -83.40 -12.74 -6.87 -82.53 -11.20 coo 0.51 5.20 15.97 0.26 4.09 18.50 -11.14 -82.54 -8.78 -8.55 -81.62 -8.22 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -1.45 -91.33 -6.89 -3.47 -89.59 -7.60 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 3 3 # 3 A 101 VAL C 6 VAL.? 5.25 O2 CIT C 104 A 102 PHE C 58 PHE^? 5.01 O1 CIT C 104 A 169 CYH C 88 CYH~? 7.95 C4 CIT C 104 coo -0.48 2.03 12.21 0.64 0.32 12.97 -44.00 -64.86 -23.91 -44.05 -66.46 -25.42 coo 0.51 5.20 15.97 0.26 4.09 18.50 -46.77 -63.30 -28.01 -45.69 -65.82 -28.47 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -33.74 -64.43 -30.10 -36.33 -64.14 -29.21 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 4 3 # 4 A 101 VAL D 6 VAL.? 4.78 C2 CIT D 103 A 102 PHE D 58 PHE^? 5.14 O2 CIT D 103 A 169 CYH D 88 CYH.? 7.80 O4 CIT D 103 coo -0.48 2.03 12.21 0.64 0.32 12.97 -45.94 -58.22 -12.52 -46.20 -56.61 -11.06 coo 0.51 5.20 15.97 0.26 4.09 18.50 -50.45 -58.79 -10.29 -49.19 -56.52 -9.21 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -39.77 -60.40 -2.46 -41.70 -60.01 -4.38 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 5 3 # 5 A 101 VAL E 6 VAL.? -5.01 O2 CIT E 104s A 102 PHE E 58 PHE^? 5.04 O2 CIT E 104 A 169 CYH E 88 CYH.? 7.64 O3 CIT E 104 coo -0.48 2.03 12.21 0.64 0.32 12.97 -32.31 -75.74 -49.97 -33.95 -75.73 -48.50 coo 0.51 5.20 15.97 0.26 4.09 18.50 -30.99 -78.83 -46.17 -33.45 -77.60 -45.67 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -32.06 -65.83 -43.44 -31.73 -68.43 -44.38 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 6 3 # 6 A 101 VAL F 6 VAL.? 5.28 O2 CIT F 104 A 102 PHE F 58 PHE^? 5.07 O2 CIT F 104 A 169 CYH F 88 CYH.? 7.60 O3 CIT F 104 coo -0.48 2.03 12.21 0.64 0.32 12.97 -25.45 -76.97 -61.08 -23.88 -77.08 -62.54 coo 0.51 5.20 15.97 0.26 4.09 18.50 -25.99 -81.08 -63.91 -23.68 -79.69 -64.67 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -27.14 -69.89 -70.66 -26.83 -72.10 -69.05 3s57_d00 source 3s57 OXIDOREDUCTASE/DNA : 6 hits 3s57_d00 naa= 3 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 1 3 # 1 C 61 LYS A 65 LYS~? 12.23 O2 EDO A 103 C 90 HIS A 74 HIS~? 11.00 C1 EDO E 103 C 91 GLN A 78 GLN~? 10.77 O1 EDO A 103 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -29.91 -87.09 -31.92 -30.86 -85.64 -33.11 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -24.81 -92.50 -33.55 -26.20 -94.06 -34.04 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 2 3 # 2 C 61 LYS A 65 LYS~? 12.23 O2 EDO A 103 C 90 HIS A 77 HIS~? -4.41 C2 EDO A 103s C 91 GLN A 78 GLN~? 10.77 O1 EDO A 103 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -27.77 -91.77 -17.76 -25.66 -95.74 -20.13 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -23.45 -88.35 -30.37 -21.94 -89.52 -29.52 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -24.81 -92.50 -33.55 -26.20 -94.06 -34.04 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 3 3 # 3 C 61 LYS B 65 LYS~? 11.82 O5 CIT B 103 C 90 HIS B 74 HIS~? 11.72 O1 CIT B 103 C 91 GLN B 78 GLN~? 5.40 O5 CIT B 103 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -6.17 -70.41 -1.18 -7.13 -69.87 0.61 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -0.37 -74.67 -3.06 0.37 -75.53 -4.88 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 4 3 # 4 C 61 LYS B 65 LYS~? 11.82 O5 CIT B 103 C 90 HIS B 77 HIS~? -4.07 O1 CIT B 103s C 91 GLN B 78 GLN~? 5.40 O5 CIT B 103 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -6.80 -67.21 -15.70 -1.99 -68.70 -15.44 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -4.95 -75.61 -4.83 -4.00 -76.59 -6.41 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -0.37 -74.67 -3.06 0.37 -75.53 -4.88 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 5 3 # 5 C 61 LYS C 65 LYS~? 12.16 O6 CIT C 104 C 90 HIS C 74 HIS~? 12.10 O1 CIT C 104 C 91 GLN C 78 GLN~? 5.88 O5 CIT C 104 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -52.01 -75.95 -35.03 -53.03 -75.67 -36.85 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -45.06 -77.16 -33.78 -43.65 -77.62 -32.32 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 6 3 # 6 C 61 LYS C 65 LYS~? 12.16 O6 CIT C 104 C 90 HIS C 77 HIS~? -4.31 O1 CIT C 104s C 91 GLN C 78 GLN~? 5.88 O5 CIT C 104 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -54.48 -76.82 -20.35 -50.27 -79.60 -20.08 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -47.52 -72.84 -31.64 -46.16 -72.52 -30.07 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -45.06 -77.16 -33.78 -43.65 -77.62 -32.32 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 7 3 # 7 C 61 LYS D 65 LYS~? 11.29 O6 CIT D 103 C 90 HIS D 74 HIS~? 11.86 O1 CIT D 103 C 91 GLN D 78 GLN~? 9.56 O5 CIT D 103 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -56.04 -45.50 -5.82 -57.77 -45.68 -4.65 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -48.77 -45.34 -3.70 -48.95 -43.23 -3.36 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 8 3 # 8 C 61 LYS D 65 LYS~? 11.29 O6 CIT D 103 C 90 HIS D 77 HIS~? -3.79 O1 CIT D 103s C 91 GLN D 78 GLN~? 9.56 O5 CIT D 103 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -51.02 -44.74 -19.85 -46.49 -42.75 -17.58 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -50.59 -49.36 -6.99 -48.72 -49.85 -7.78 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -48.77 -45.34 -3.70 -48.95 -43.23 -3.36 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 9 3 # 9 C 61 LYS E 65 LYS~? 11.89 O6 CIT E 104 C 90 HIS E 74 HIS~? 12.16 O1 CIT E 104 C 91 GLN E 78 GLN~? 7.31 O6 CIT E 104 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -43.54 -84.18 -39.56 -43.31 -85.25 -37.77 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -44.62 -77.18 -40.55 -46.18 -75.95 -41.22 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 10 3 # 10 C 61 LYS E 65 LYS~? 11.89 O6 CIT E 104 C 90 HIS E 77 HIS~? -4.13 O1 CIT E 104s C 91 GLN E 78 GLN~? 7.31 O6 CIT E 104 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -44.51 -85.48 -54.41 -46.90 -80.90 -53.83 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -40.46 -79.48 -42.58 -40.09 -77.98 -43.99 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -44.62 -77.18 -40.55 -46.18 -75.95 -41.22 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 11 3 # 11 C 61 LYS F 65 LYS~? 10.97 O7 CIT F 104 C 90 HIS F 74 HIS~? 11.52 O1 CIT F 104 C 91 GLN F 78 GLN~? 8.72 O6 CIT F 104 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -12.33 -86.22 -68.20 -12.34 -87.83 -69.54 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -12.14 -79.10 -69.43 -10.03 -78.76 -69.64 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 12 3 # 12 C 61 LYS F 65 LYS~? 10.97 O7 CIT F 104 C 90 HIS F 77 HIS~? -3.59 O1 CIT F 104s C 91 GLN F 78 GLN~? 8.72 O6 CIT F 104 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -11.98 -83.12 -53.74 -10.66 -77.90 -55.60 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -16.28 -81.16 -66.83 -16.85 -79.41 -65.82 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -12.14 -79.10 -69.43 -10.03 -78.76 -69.64 4hp3_d00 source 4hp3 DNA BINDING PROTEIN/DNA : 12 hits 4hp3_d00 naa= 3 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 1 3 # 1 A 833 VAL A 97 VAL^? 5.91 C1 EDO A 103 A 866 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 881 HIS A 4 HIS.? -4.40 O2 EDO A 103s coo 14.42 17.43 18.29 12.57 16.27 18.27 -13.82 -90.46 -22.44 -15.47 -90.72 -23.78 coo 12.88 23.75 28.18 13.64 25.11 25.83 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 12.85 19.92 23.16 14.49 20.89 24.04 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 2 3 # 2 A 833 VAL A 98 VAL^? 10.78 O2 EDO A 103 A 866 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 881 HIS A 4 HIS.? -4.40 O2 EDO A 103s coo 14.42 17.43 18.29 12.57 16.27 18.27 -14.49 -89.93 -18.69 -13.13 -88.96 -17.28 coo 12.88 23.75 28.18 13.64 25.11 25.83 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 12.85 19.92 23.16 14.49 20.89 24.04 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 3 3 # 3 A 833 VAL B 97 VAL^? 5.04 O6 CIT B 103 A 866 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 881 HIS B 4 HIS.? -4.11 O2 CIT B 103s coo 14.42 17.43 18.29 12.57 16.27 18.27 -4.71 -82.19 -15.63 -3.98 -80.93 -13.97 coo 12.88 23.75 28.18 13.64 25.11 25.83 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 12.85 19.92 23.16 14.49 20.89 24.04 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 4 3 # 4 A 833 VAL B 98 VAL^? 10.08 O6 CIT B 103 A 866 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 881 HIS B 4 HIS.? -4.11 O2 CIT B 103s coo 14.42 17.43 18.29 12.57 16.27 18.27 -6.59 -80.54 -18.55 -7.74 -81.60 -20.10 coo 12.88 23.75 28.18 13.64 25.11 25.83 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 12.85 19.92 23.16 14.49 20.89 24.04 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 5 3 # 5 A 833 VAL C 97 VAL^? -5.06 O7 CIT C 104s A 866 CYH C 60 CYH^? 5.84 O1 CIT C 104 A 881 HIS C 4 HIS.? -4.06 O2 CIT C 104s coo 14.42 17.43 18.29 12.57 16.27 18.27 -42.51 -68.03 -20.96 -43.23 -69.37 -22.52 coo 12.88 23.75 28.18 13.64 25.11 25.83 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 12.85 19.92 23.16 14.49 20.89 24.04 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 6 3 # 6 A 833 VAL C 98 VAL^? 10.01 O2 CIT C 104 A 866 CYH C 60 CYH^? 5.84 O1 CIT C 104 A 881 HIS C 4 HIS.? -4.06 O2 CIT C 104s coo 14.42 17.43 18.29 12.57 16.27 18.27 -44.95 -67.54 -18.00 -44.95 -65.90 -16.52 coo 12.88 23.75 28.18 13.64 25.11 25.83 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 12.85 19.92 23.16 14.49 20.89 24.04 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 7 3 # 7 A 833 VAL D 97 VAL^? 5.40 O6 CIT D 103 A 866 CYH D 60 CYH^? 5.69 O2 CIT D 103 A 881 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 14.42 17.43 18.29 12.57 16.27 18.27 -42.63 -55.58 -14.47 -43.66 -54.04 -13.31 coo 12.88 23.75 28.18 13.64 25.11 25.83 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 12.85 19.92 23.16 14.49 20.89 24.04 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 8 3 # 8 A 833 VAL D 98 VAL^? 10.08 O6 CIT D 103 A 866 CYH D 60 CYH^? 5.69 O2 CIT D 103 A 881 HIS D 4 HIS.? -4.16 O2 CIT D 103s coo 14.42 17.43 18.29 12.57 16.27 18.27 -43.56 -55.67 -18.17 -43.36 -57.44 -19.52 coo 12.88 23.75 28.18 13.64 25.11 25.83 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 12.85 19.92 23.16 14.49 20.89 24.04 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 9 3 # 9 A 833 VAL E 97 VAL^? 5.33 C2 CIT E 104 A 866 CYH E 60 CYH^? 5.61 O2 CIT E 104 A 881 HIS E 4 HIS.? -4.01 O2 CIT E 104s coo 14.42 17.43 18.29 12.57 16.27 18.27 -35.53 -73.89 -52.95 -36.98 -74.49 -51.41 coo 12.88 23.75 28.18 13.64 25.11 25.83 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 12.85 19.92 23.16 14.49 20.89 24.04 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 10 3 # 10 A 833 VAL E 98 VAL^? 9.07 O2 EDO F 103 A 866 CYH E 60 CYH^? 5.61 O2 CIT E 104 A 881 HIS E 4 HIS.? -4.01 O2 CIT E 104s coo 14.42 17.43 18.29 12.57 16.27 18.27 -34.98 -76.13 -56.01 -33.27 -75.93 -57.38 coo 12.88 23.75 28.18 13.64 25.11 25.83 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 12.85 19.92 23.16 14.49 20.89 24.04 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 11 3 # 11 A 833 VAL F 97 VAL^? -5.16 C4 CIT F 104s A 866 CYH F 60 CYH^? 5.70 O2 CIT F 104 A 881 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 14.42 17.43 18.29 12.57 16.27 18.27 -22.57 -73.89 -58.94 -21.05 -74.81 -60.23 coo 12.88 23.75 28.18 13.64 25.11 25.83 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 12.85 19.92 23.16 14.49 20.89 24.04 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 ULMN 3 1hq0_o00 CYTOTOXIC NECROTIZING FACTOR 1 user 12 3 # 12 A 833 VAL F 98 VAL^? 10.00 O7 CIT F 104 A 866 CYH F 60 CYH^? 5.70 O2 CIT F 104 A 881 HIS F 4 HIS.? -4.07 O2 CIT F 104s coo 14.42 17.43 18.29 12.57 16.27 18.27 -22.84 -75.20 -55.36 -24.57 -75.00 -54.05 coo 12.88 23.75 28.18 13.64 25.11 25.83 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 12.85 19.92 23.16 14.49 20.89 24.04 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 1hq0_o00 source 1Hq0 CYTOTOXIC NECROTIZING FACTOR 1 : 12 hits 1hq0_o00 naa= 3 ULMN 3 1ukf_o00 AVIRULENCE PROTEIN AVRPPH3 user 1 3 # 1 A 98 CYH A 60 CYH^? 5.96 O2 EDO A 103 A 212 HIS A 4 HIS.? -4.40 O2 EDO A 103s A 227 ASP A 99 ASP^? 8.10 O2 EDO A 103 coo 32.24 40.70 41.87 34.94 39.83 42.22 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo 35.63 37.64 46.24 33.55 37.41 46.24 -19.82 -87.66 -22.11 -19.37 -89.04 -23.63 coo 30.05 37.79 50.12 31.66 36.75 49.22 -18.90 -91.24 -17.66 -18.99 -91.42 -19.82 ULMN 3 1ukf_o00 AVIRULENCE PROTEIN AVRPPH3 user 2 3 # 2 A 98 CYH B 60 CYH^? 5.88 O1 CIT B 103 A 212 HIS B 4 HIS.? -4.11 O2 CIT B 103s A 227 ASP B 99 ASP^? 7.47 O6 CIT B 103 coo 32.24 40.70 41.87 34.94 39.83 42.22 -13.21 -76.65 -11.34 -11.36 -77.24 -9.40 coo 35.63 37.64 46.24 33.55 37.41 46.24 -8.03 -77.02 -13.14 -6.28 -77.69 -12.17 coo 30.05 37.79 50.12 31.66 36.75 49.22 -6.25 -75.74 -18.43 -5.37 -76.29 -16.56 ULMN 3 1ukf_o00 AVIRULENCE PROTEIN AVRPPH3 user 3 3 # 3 A 98 CYH C 60 CYH^? 5.84 O1 CIT C 104 A 212 HIS C 4 HIS.? -4.06 O2 CIT C 104s A 227 ASP C 99 ASP^? 7.14 O2 CIT C 104 coo 32.24 40.70 41.87 34.94 39.83 42.22 -52.33 -65.92 -25.34 -50.87 -66.80 -27.39 coo 35.63 37.64 46.24 33.55 37.41 46.24 -48.57 -69.23 -23.42 -46.84 -70.10 -24.25 coo 30.05 37.79 50.12 31.66 36.75 49.22 -48.10 -71.15 -17.98 -47.22 -71.52 -19.90 ULMN 3 1ukf_o00 AVIRULENCE PROTEIN AVRPPH3 user 4 3 # 4 A 98 CYH D 60 CYH^? 5.69 O2 CIT D 103 A 212 HIS D 4 HIS.? -4.16 O2 CIT D 103s A 227 ASP D 99 ASP^? 6.89 O6 CIT D 103 coo 32.24 40.70 41.87 34.94 39.83 42.22 -53.57 -55.49 -15.15 -52.62 -54.66 -12.65 coo 35.63 37.64 46.24 33.55 37.41 46.24 -48.69 -53.09 -14.95 -47.44 -52.48 -13.37 coo 30.05 37.79 50.12 31.66 36.75 49.22 -45.56 -51.53 -19.41 -45.45 -51.27 -17.31 ULMN 3 1ukf_o00 AVIRULENCE PROTEIN AVRPPH3 user 5 3 # 5 A 98 CYH E 60 CYH^? 5.61 O2 CIT E 104 A 212 HIS E 4 HIS.? -4.01 O2 CIT E 104s A 227 ASP E 99 ASP^? 7.65 C2 CIT E 104 coo 32.24 40.70 41.87 34.94 39.83 42.22 -33.67 -84.09 -49.32 -34.64 -82.64 -47.26 coo 35.63 37.64 46.24 33.55 37.41 46.24 -36.79 -80.17 -50.97 -37.70 -78.53 -50.03 coo 30.05 37.79 50.12 31.66 36.75 49.22 -38.61 -79.08 -56.42 -38.99 -78.39 -54.42 ULMN 3 1ukf_o00 AVIRULENCE PROTEIN AVRPPH3 user 6 3 # 6 A 98 CYH F 60 CYH^? 5.70 O2 CIT F 104 A 212 HIS F 4 HIS.? -4.07 O2 CIT F 104s A 227 ASP F 99 ASP^? 6.97 O7 CIT F 104 coo 32.24 40.70 41.87 34.94 39.83 42.22 -22.72 -84.87 -59.36 -21.79 -83.84 -61.72 coo 35.63 37.64 46.24 33.55 37.41 46.24 -20.35 -80.15 -58.92 -19.81 -78.86 -60.49 coo 30.05 37.79 50.12 31.66 36.75 49.22 -18.74 -77.42 -54.10 -18.31 -77.25 -56.21 1ukf_o00 source 1UKF AVIRULENCE PROTEIN AVRPPH3 : 6 hits 1ukf_o00 naa= 3 ULMN 3 2ebf_o00 DERMONECROTIC TOXIN user 1 3 # 1 X1165 CYH A 60 CYH^? 5.96 O2 EDO A 103 X1205 HIS A 41 HIS^? 12.51 O2 EDO A 103 X1220 ASP A 27 ASP~? 13.11 O2 EDO A 103 coo -26.56 24.53 92.56 -24.57 23.58 94.36 -21.35 -82.49 -21.79 -21.37 -83.55 -24.24 coo -19.40 30.09 91.63 -20.33 29.86 93.49 -16.59 -76.74 -28.40 -17.31 -75.33 -29.78 coo -21.03 32.79 97.44 -20.59 31.13 96.21 -22.67 -75.83 -31.04 -20.86 -75.49 -29.97 ULMN 3 2ebf_o00 DERMONECROTIC TOXIN user 2 3 # 2